

FRANCHISE DISCLOSURE DOCUMENT

Health Mart Systems, Inc.
a Delaware corporation
www.healthmart.com
www.becomeahealthmart.com
join.healthmart.com
6535 State Hwy 161
Irving, Texas 75039
415-983-8300



We offer franchises for the right to operate a retail pharmacy (“HEALTH MART Drugstore” or “Drugstore”) using the trade names, trademarks, and service marks that we designate, including the trademark HEALTH MART (collectively, “Proprietary Marks”) and the operating and merchandising support services that we describe in this Disclosure Document.

The total initial investment necessary to open and begin operating a HEALTH MART Drugstore ranges from \$2,365 to \$103,865 for franchisees who convert an existing pharmacy business to a HEALTH MART Drugstore (“Open Locations”) and from \$250,865 to \$674,265 for start-up franchisees who do not own an existing pharmacy when they sign the Franchise Agreement (“UnOpened Locations”). The Franchise Agreement does not require that you pay us an initial franchise fee or make payments to us or our affiliates for goods or services before you open and begin operating as a HEALTH MART Drugstore.

This disclosure document summarizes certain provisions of your franchise agreement and other information in plain English. Read this disclosure document and all accompanying agreements carefully. You must receive this disclosure document at least 14 calendar days before you sign a binding agreement with, or make any payment to, the franchisor or an affiliate in connection with the proposed sale. **Note, however, that no governmental agency has verified the information contained in this document.**

The terms of your contract will govern your franchise relationship. Don’t rely on the disclosure document alone to understand your contract. Read all of your contract carefully. Show your contract and this disclosure document to an advisor, like a lawyer or an accountant.

Buying a franchise is a complex investment. The information in this disclosure document can help you make up your mind. More information on franchising, such as “A Consumer’s Guide to Buying a Franchise,” which can help you understand how to use this disclosure document, is available from the Federal Trade Commission. You can contact the FTC at 1-877-FTC-HELP or by writing to the FTC at 600 Pennsylvania Avenue, NW, Washington, D.C. 20580. You can also visit the FTC’s home page at www.ftc.gov for additional information. Call your state agency or visit your public library for other sources of information on franchising.

There may also be laws on franchising in your state. Ask your state agencies about them.

The Issuance Date of this Disclosure Document is June 17, 2022.

▪ How to Use This Franchise Disclosure Document

Here are some questions you may be asking about buying a franchise and tips on how to find more information:

QUESTION	WHERE TO FIND INFORMATION
How much can I earn?	Item 19 may give you information about outlet sales, costs, profits or losses. You should also try to obtain this information from others, like current and former franchisees. You can find their names and contact information in Item 20 or Exhibits L1, L2, and L3.
How much will I need to invest?	Items 5 and 6 list fees you will be paying to the franchisor or at the franchisor's direction. Item 7 lists the initial investment to open. Item 8 describes the suppliers you must use.
Does the franchisor have the financial ability to provide support to my business?	Item 21 or Exhibit M includes financial statements. Review these statements carefully.
Is the franchise system stable, growing, or shrinking?	Item 20 summarizes the recent history of the number of company-owned and franchised outlets.
Will my business be the only HEALTH MART business in my area?	Item 12 and the "territory" provisions in the franchise agreement describe whether the franchisor and other franchisees can compete with you.
Does the franchisor have a troubled legal history?	Items 3 and 4 tell you whether the franchisor or its management have been involved in material litigation or bankruptcy proceedings.
What's it like to be a HEALTH MART franchisee?	Item 20 or Exhibits L1, L2, and L3 list current and former franchisees. You can contact them to ask about their experiences.
What else should I know?	These questions are only a few things you should look for. Review all 23 Items and all Exhibits in this disclosure document to better understand this franchise opportunity. See the table of contents.

What You Need To Know About Franchising *Generally*

Continuing responsibility to pay fees. You may have to pay royalties and other fees even if you are losing money.

Business model can change. The franchise agreement may allow the franchisor to change its manuals and business model without your consent. These changes may require you to make additional investments in your franchise business or may harm your franchise business.

Supplier restrictions. You may have to buy or lease items from the franchisor or a limited group of suppliers the franchisor designates. These items may be more expensive than similar items you could buy on your own.

Operating restrictions. The franchise agreement may prohibit you from operating a similar business during the term of the franchise. There are usually other restrictions. Some examples may include controlling your location, your access to customers, what you sell, how you market, and your hours of operation.

Competition from franchisor. Even if the franchise agreement grants you a territory, the franchisor may have the right to compete with you in your territory.

Renewal. Your franchise agreement may not permit you to renew. Even if it does, you may have to sign a new agreement with different terms and conditions in order to continue to operate your franchise business.

When your franchise ends. The franchise agreement may prohibit you from operating a similar business after your franchise ends even if you still have obligations to your landlord or other creditors.

Some States Require Registration

Your state may have a franchise law, or other law, that requires franchisors to register before offering or selling franchises in the state. Registration does not mean that the state recommends the franchise or has verified the information in this document. To find out if your state has a registration requirement, or to contact your state, use the agency information in Exhibit P.

Your state also may have laws that require special disclosures or amendments be made to your franchise agreement. If so, you should check the State Specific Addenda. See the Table of Contents for the location of the State Specific Addenda.

Special Risks to Consider About *This* Franchise

Certain states require that the following risk(s) be highlighted:

1. **Out-of-State Dispute Resolution.** The franchise agreement requires you to resolve disputes with the franchisor by mediation, arbitration and/or litigation only in Texas. Out-of-state mediation, arbitration, or litigation may force you to accept a less favorable settlement for disputes. It may also cost more to mediate, arbitrate, or litigate with the franchisor in Texas than in your own state.

Certain states may require other risks to be highlighted. Check the “state specific addenda” (if any) to see whether your state requires other risks to be highlighted.

DISCLOSURES REQUIRED BY MICHIGAN LAW

The state of Michigan prohibits certain unfair provisions that are sometimes in franchise documents. If any of the following provisions are in these franchise documents, the provisions are void and cannot be enforced against you.

1. A prohibition on the right of a franchisee to join an association of franchisees.
2. A requirement that a franchisee assent to a release, assignment, novation, waiver or estoppel which deprives a franchisee of rights and protections provided in this act. This shall not preclude a franchisee, after entering into a franchise agreement, from settling any and all claims.
3. A provision that permits a franchisor to terminate a franchise prior to the expiration of its term except for good cause. Good cause shall include the failure of the franchisee to comply with any lawful provision of the franchise agreement and to cure such failure after being given written notice thereof and a reasonable opportunity, which in no event need be more than 30 days, to cure such failure.
4. A provision that permits a franchisor to refuse to renew a franchise without fairly compensating the franchisee by repurchase or other means for the fair market value at the time of expiration of the franchisee's inventory, supplies, equipment, fixtures, and furnishings. Personalized materials which have no value to the franchisor and inventory, supplies, equipment, fixtures, and furnishings not reasonably required in the conduct of the franchise business are not subject to compensation. This subsection applies only if: (i) the term of the franchise is less than five years and (ii) the franchisee is prohibited by the franchise or other agreement from continuing to conduct substantially the same business under another trademark, service mark, trade name, logotype, advertising, or other commercial symbol in the same area subsequent to the expiration of the franchise or the franchisee does not receive at least 6 months advance notice of the franchisor's intent not to renew the franchise.
5. A provision that permits the franchisor to refuse to renew a franchise on terms generally available to other franchisees of the same class or type under similar circumstances. This section does not require a renewal provision.
6. A provision requiring that arbitration or litigation be conducted outside this state. This shall not preclude the franchisee from entering into an agreement, at the time of arbitration, to conduct arbitration at a location outside this state.
7. A provision which permits a franchisor to refuse to permit a transfer of ownership of a franchise, except for good cause. This subdivision does not prevent a franchisor from exercising a right of first refusal to purchase the franchise. Good cause shall include, but is not limited to:
 - a. The failure of the proposed transferee to meet the franchisor's then current reasonable qualifications or standards.
 - b. The fact that the proposed transferee is a competitor of the franchisor or subfranchisor.
 - c. The unwillingness of the proposed transferee to agree in writing to comply with all lawful obligations.
 - d. The failure of the franchisee or proposed transferee to pay any sums owing to the franchisor or to cure any default in the franchise agreement existing at the time of the proposed transfer.
8. A provision that requires the franchisee to resell to the franchisor items that are not uniquely identified with the franchisor. This subdivision does not prohibit a provision that grants to a franchisor a right of first refusal to purchase the assets of a franchise on the same terms and conditions as a bona fide third-party willing and able to purchase those assets, nor does this subdivision prohibit a provision that grants the franchisor the right to acquire the assets of a franchise for the market or appraised value of such

assets if the franchisee has breached the lawful provisions of the franchise agreement and has failed to cure the breach in the manner provided in subdivision (c).

9. A provision which permits the franchisor to directly or indirectly convey, assign, or otherwise transfer its obligations to fulfill contractual obligations to the franchisee unless provision has been made for providing the required contractual services.

10. **The fact that there is a notice of this offering on file with the attorney general does not constitute approval, recommendation, or endorsement by the attorney general.**

11. Michigan law provides that a franchisor whose most recent statements are unaudited and which show a net worth of less than \$100,000 shall, at the request of a franchisee, arrange for the escrow of initial investment and other funds paid by the franchisee or subfranchisor until the obligations to provide real estate, improvements, equipment, inventory, training, or other items included in the franchise offering are fulfilled. At the option of the franchisor, a surety bond may be provided in place of escrow. In the event that an escrow is so established, the escrow agent shall be a financial institution authorized to do business in the State of Michigan. The escrow agent may release to the franchisor those amounts of the escrowed funds applicable to a specific franchisee or subfranchisor upon presentation of an affidavit executed by the franchisee and an affidavit executed by the franchisor stating that the franchisor has fulfilled its obligation to provide real estate, improvements, equipment, inventory, training, or other items. This portion of the Michigan law does not prohibit a partial release of escrowed funds upon receipt of affidavits of partial fulfillment of the franchisor's obligation.

12. Should the prospective franchisee have any questions regarding the notice of this filing with the Attorney General, such questions should be addressed to: Department of the Attorney General; Consumer Protection Division; Antitrust and Franchise Section; PO Box 30213; Lansing, MI 48909; 517-373-7117.

TABLE OF CONTENTS

<u>Item</u>	<u>Page</u>
ITEM 1 THE FRANCHISOR AND ANY PARENTS, PREDECESSORS AND AFFILIATES.....	2
ITEM 2 BUSINESS EXPERIENCE.....	5
ITEM 3 LITIGATION.....	7
ITEM 4 BANKRUPTCY.....	8
ITEM 5 INITIAL FEES.....	8
ITEM 6 OTHER FEES.....	8
ITEM 7 ESTIMATED INITIAL INVESTMENT.....	11
ITEM 8 RESTRICTIONS ON SOURCES OF PRODUCTS AND SERVICES.....	15
ITEM 9 FRANCHISEE’S OBLIGATIONS.....	19
ITEM 10 FINANCING.....	20
ITEM 11 FRANCHISOR’S ASSISTANCE, ADVERTISING, COMPUTER SYSTEMS, AND TRAINING.....	21
ITEM 12 TERRITORY.....	25
ITEM 13 TRADEMARKS.....	26
ITEM 14 PATENTS, COPYRIGHTS AND PROPRIETARY INFORMATION.....	28
ITEM 15 OBLIGATION TO PARTICIPATE IN THE ACTUAL OPERATION OF THE FRANCHISE BUSINESS.....	29
ITEM 16 RESTRICTIONS ON WHAT THE FRANCHISEE MAY SELL.....	29
ITEM 17 RENEWAL, TERMINATION, TRANSFER AND DISPUTE RESOLUTION.....	30
ITEM 18 PUBLIC FIGURES.....	36
ITEM 19 FINANCIAL PERFORMANCE REPRESENTATIONS.....	36
ITEM 20 OUTLETS AND FRANCHISEE INFORMATION.....	37
ITEM 21 FINANCIAL STATEMENTS.....	56
ITEM 22 CONTRACTS.....	56
ITEM 23 RECEIPTS.....	57

Exhibits

A - AGENTS FOR SERVICE OF PROCESS	
B - FRANCHISE AGREEMENT (INCLUDING STATE AMENDMENTS)	
C - EQuIPP SERVICES AGREEMENT FOR PARTICIPATING PHARMACY	
D - BULA AGREEMENT (OPTIONAL)	
E - PHARMACY AND HEALTHCARE SOLUTIONS MASTER SERVICES AGREEMENT, PROVIDER PARTICIPATION ADDENDUM, PROVIDERPAY RECONCILIATION SERVICES ADDENDUM, MCKESSON REIMBURSEMENT ADVANTAGE ADDENDUM (OPTIONAL)	
F - MCKESSON LOCAL MARKETING SUPPORT PLATFORM AGREEMENT (OPTIONAL)	
G - FRANCHISE COMPLIANCE QUESTIONNAIRE	
H - RETAIL VACCINE PROGRAM AGREEMENT (OPTIONAL)	
I - HEALTH MART DIGITAL PORTFOLIO (“HMDP”) PROGRAM (TERMS & CONDITIONS, PRIVACY NOTICE, BUSINESS ASSOCIATE AGREEMENT) (OPTIONAL AS TO PREMIUM SERVICES)	
J - FINANCING DOCUMENTS	
J-1 - MCKESSON CORPORATION SHORT TERM FINANCING DOCUMENTS (OPTIONAL FINANCING) (SECURITY AGREEMENT, GUARANTY, NOTE)	

- J-2 - MCKESSON CORPORATION LONG TERM FINANCING DOCUMENTS (OPTIONAL FINANCING) (SECURITY AGREEMENT, GUARANTY, FORMS OF PROMISSORY NOTE, CERTIFICATE OF INSURANCE; RESOLUTION OF BOARD OF DIRECTORS OF CORPORATE FRANCHISEE, RESOLUTION OF MEMBERS/PARTNERS OF PARTNERSHIP OR LLC FRANCHISEE, LANDLORD WAIVER, LIFE INSURANCE ASSIGNMENT)
- K - FRANCHISE HANDBOOK TABLE OF CONTENTS
- L - INFORMATION ABOUT HMSI FRANCHISEES
- L-1 LIST OF OPERATIONAL FRANCHISEES AS OF MARCH 31, 2022
- L-2 LIST OF NOT YET OPERATIONAL FRANCHISEES AS OF MARCH 31, 2022
- L-3 LIST OF FRANCHISEES WHO HAVE CEASED TO DO BUSINESS UNDER THEIR AGREEMENT OR WHO LEFT THE SYSTEM DURING THE LAST FISCAL YEAR ENDING MARCH 31, 2022
- M - FINANCIAL STATEMENTS
- N - GENERAL RELEASE
- O - STATE-SPECIFIC ADDENDA
- P - LIST OF STATE ADMINISTRATORS
- Q - STATE EFFECTIVE DATES
- R - RECEIPTS

ITEM 1
THE FRANCHISOR AND ANY PARENTS, PREDECESSORS AND AFFILIATES

Terminology

The franchisor is Health Mart Systems, Inc. To simplify the language in this Disclosure Document, the franchisor is referred to by the pronoun “we” or “our” or as “HEALTH MART”. The pronoun “you” or the term “Franchisee” means the person who buys the franchise. When we refer to our “Affiliate” in this Disclosure Document, we mean any other company that we own or which is under common control with us now or in the future. The term “Affiliate” may also include our Parent, McKesson Corporation.

The Franchisor, Our Parent and Affiliates

We were incorporated in the State of Delaware on January 21, 1997. Our principal place of business is 6535 State Hwy 161, Irving, Texas 75039. We conduct business under our corporate name, “Health Mart” and “Health Mart Systems, Inc.” We are a wholly-owned subsidiary of McKesson Corporation, formerly known as McKesson HBOC, Inc. (“Parent” or “McKesson”). A list of our agents for service of process is attached as Exhibit A.

Our Parent was incorporated in the State of Delaware on July 7, 1994, as a wholly-owned subsidiary of McKesson Corporation, a Delaware corporation formed on June 9, 1987 (“Old McKesson”); Old McKesson was subsequently dissolved. Our Parent maintains its principal place of business at 6535 State Hwy 161, Irving, Texas 75039. From an organizational perspective, our Parent includes us within its US pharmaceutical business division.

Our Parent is a “Fortune 100” company and a provider of pharmaceutical and health care products and services to pharmacies, hospitals, and health care networks, directly and through its various subsidiaries. Many of the products, services and programs offered by our Parent and Affiliates are available to you, independent of this franchise offering, because they are available to any qualifying pharmacy. Although you may choose to do business with our Affiliates from time to time, that business is not connected to this franchise offering except as described in this Disclosure Document.

As a part of the franchise offering, our Parent supplies branded and generic prescription drugs and other Merchandise to our franchisees, as described in this Disclosure Document.

Our Affiliate, Strategic Health Alliance II, Inc. (“AccessHealth”), with a principal place of business at 6530 West Campus Oval, Suite 250, New Albany, Ohio 43054, along with American Pharmacy Network Solutions, are members of a joint venture pharmacy services administration organization, or “PSAO,” called Health Mart Atlas, LLC (“Health Mart Atlas”). Health Mart Atlas is a Delaware limited liability company with a principal place of business at 6530 West Campus Oval, Suite 250, New Albany, Ohio 43054. You are not required to belong to a PSAO, but if you do, the PSAO must be approved by us. As of the date of this Disclosure Document, we have approved two PSAOs, including Health Mart Atlas. The Pharmacy and Healthcare Solutions Agreement and Provider Participation Addendum are attached to this Disclosure Document as Exhibit E. To participate in Health Mart Atlas, you must meet eligibility requirements, complete the enrollment process and sign appropriate documents and agreements.

On February 1, 2019, AccessHealth acquired the assets of PPS Data, LLC d/b/a ProviderPay® (“ProviderPay”), a provider of claims reconciliation services for retail pharmacies. ProviderPay offers its services to Health Mart franchisees and to other retail pharmacies that are not part of the Health Mart franchise system. You are not required to use the services of ProviderPay, but if you do, you must complete the enrollment process, and sign appropriate documents and agreements inclusive of the Pharmacy and Healthcare Solutions Agreement and ProviderPay Reconciliation Services Addendum attached to this Disclosure Document as Exhibit E and pay the fee charged by ProviderPay.

AccessHealth also administers the optional McKesson Reimbursement Advantage program, (“MRA”) described in Item 6. If you elect to participate in MRA, you must (i) be a member of the Health Mart Atlas

PSAO and (ii) use the Intelligent Network switching service operated by our Affiliate, McKesson Technologies Inc., through its RelayHealth division (“Relay Health”). Relay Health provides financial and administrative health care solutions for hospitals, physicians, and retail pharmacies. Relay Health maintains a principal place of business at 5995 Windward Parkway, Alpharetta, Georgia 30005.

To participate in MRA, you must complete the enrollment process and sign the appropriate agreements and documents, including the Participation Agreement and Addendum attached to this Disclosure Document as Exhibit E.

Except for a drugstore business that we operate under the Health Mart name at our corporate headquarters in Las Colinas, Texas which is primarily used by our and our Parent's employees (“Headquarters Location”), neither we, our Parent, nor any of the other companies that we identify as an “Affiliate” in this Item 1 have ever owned or operated a drugstore business in the U.S. similar to a HEALTH MART Drugstore, and neither we nor any of our predecessors or Affiliates have ever operated a franchise system in any other line of business in the U.S.

We also offer Health System Retail Services Agreements (“HSRSA”) for the operation of pharmacies under the Health Mart name that are located in hospitals. HSRSA's are only offered under applicable exemptions from state and federal franchise regulations.

Outside of the U.S., one of our Affiliates acquired all of the stock of Medicine Shoppe Canada Inc. in 2012. Medicine Shoppe Canada, Inc. owns a license to award and administer Medicine Shoppe pharmacy franchises in Canada. As a result, since 2012, one of our Affiliates operates a franchise network in Canada as a subfranchisor of the Medicine Shoppe pharmacy franchise system.

In addition to the activities described above, our Parent and Affiliates are engaged in a wide range of business activities in the health care industry in the U.S. and internationally.

The Franchise Offered

We offer franchises for the right to use certain proprietary trademarks (“Proprietary Marks”) and our distinctive and proprietary operating methods and system for establishing and operating Drugstores (the “HEALTH MART System” or “System”). We compile our operational guidance and suggestions, operating methods, policies, procedures, and standards for running your Drugstore on the My Health Mart Web Portal, which includes the Franchise Handbook. You will have access to the My Health Mart Web Portal following execution of the Franchise Agreement. Except for our Headquarters Location, we do not currently operate any retail pharmacies in the U.S. or engage in other business activities at this time.

We offer franchises to persons wanting to start a new retail pharmacy business (“UnOpened Locations”) and persons with existing retail pharmacy businesses interested in converting to a HEALTH MART Drugstore (“Open Locations”). Franchisees of Open Locations and UnOpened Locations will sign the same form of Franchise Agreement (see Exhibit B), which gives you the right to operate your Drugstore at a specific location (“Drugstore Location”) using the Proprietary Marks and the System.

Your Monthly Fees (described in Item 6) entitle you to access a number of core support services that we provide to each Drugstore Location, directly or through various suppliers. These Core Services include operational, management, marketing, features within front end solutions and technical expertise.

Our franchisees currently have access to the following Core Services:

- My Health Mart Web Portal, a proprietary online resource that provides, among other things, information and guidance regarding the practice of pharmacy in broad industry views and through specific location level cooperative analysis, access to various third-party programs, and facilitates your ordering of products from McKesson.
- Health Mart University (HMU), our online training platform for franchisees.

- Health Mart Purchasing Advantage, a program in which we negotiate discount prices and other purchasing terms with various third-party vendors for the benefit of Health Mart franchisees.
- If you elect to sign an agreement with Bula Pharmacy Law Intelligence (“BULA”) in the form of Exhibit D to this Disclosure Document, the BULA Policy and Procedures Module and Regulatory Reference Manual.
- *Pharmacist’s Letter* and *Natural Medicines*, publications of the Therapeutic Research Center, LLC, an independent advisory service on drug therapy and medication management, unaffiliated with us.
- EQuIPP® platform, a program from Pharmacy Quality Solutions (PQS) provides performance data, reporting, measurement, and benchmarking for key quality measures related to patient medication use, available when you sign the EQuIPP Services Agreement for Participating Pharmacy attached to this Disclosure Document as Exhibit C.
- Health Mart Digital Portfolio (Basic service), a HEALTH MART system standard for pharmacies to have a web presence via a landing page to provide consumers with information to locate pharmacies, obtain pharmacy information such as hours and services provided, manage personal profiles and submit for new, refill or transfer prescriptions.
- If you elect to sign the Pharmacy and HealthCare Solutions Master Services Agreement and Provider Participation Addendum, attached to this Disclosure Document as Exhibit E, membership in the Health Mart Atlas PSAO.
- Access to a suite of front-end solutions which align the pharmacy toward consumer needs

We are continually developing and changing the Core Services in order to keep Drugstores relevant to consumers in a highly competitive environment, and the Core Services available to you may change during the term of the Franchise Agreement.

In addition to the Core Services, we may periodically offer certain optional programs for an additional fee. You may elect to participate in any optional program by signing the applicable program agreement or by “opting in” to the program’s terms and conditions via your My Health Mart Web Portal account for your Drugstore. Optional programs that we currently offer are described in Item 6. We may periodically modify or discontinue any of the optional programs that are now in place and add new optional programs, and may charge you for your participation in such optional programs (based on our then-current fees for such optional programs).

Competition

The market for products and services offered by the Drugstores is well established and highly competitive. The products and services will be sold primarily to the general public. You must compete with a variety of stores offering similar products and services, including other national and regional drugstore chains, discount stores, grocery stores, and hospital systems and clinics offering similar products and services, as well as mail-order and locally-owned drugstores and pharmacies. Some of these businesses may offer some or many of their products and services at prices lower than you choose to charge. Their pricing policies could have an adverse impact on your business.

You may also compete for business with other HEALTH MART Drugstores.

Our Parent and other Affiliates with whom you may or will do business may sell the same products or services to pharmacies that are not part of HEALTH MART network. These pharmacies may operate near your Drugstore and directly compete with you.

Industry-Specific Regulations

You are responsible for investigating and complying with all applicable laws, rules, and regulations that govern your Drugstore, including the practice of pharmacy. Retail pharmacies are regulated at the federal,

state, and local levels. You are solely responsible for ensuring that your Drugstore complies with these rules and the numerous other federal laws and regulations that impose obligations and responsibilities upon pharmacies and the practice of pharmacy by individuals.

State pharmacy practice acts will also apply to your Drugstore. These acts vary from state to state but they commonly regulate such things as dispensing drugs, information appearing on prescription drug labels, recordkeeping, continuing education for pharmacists, hours of operation, pharmacy ownership, and drug handling, storage, and disposal.

All states have licensing laws applicable to pharmacists. A licensed pharmacist must at all times operate the pharmacy in your Drugstore. We are not responsible for the practice of pharmacy in your Drugstore, which is solely your responsibility. You should contact the local or state office of your state's Board of Pharmacy for additional information about state laws and regulations that will affect the practice of pharmacy in your Drugstore. State laws may also regulate the delivery of health care testing and wellness services and may require that the Drugstore and the people you employ to perform these services hold additional licenses and qualifications. In addition, many public and private payment plans impose licensing and other types of qualification requirements to receive reimbursement, including recordkeeping requirements. You are solely responsible for investigating, qualifying for, and adhering to these requirements so that you may lawfully offer all of the mandatory programs that we include in the System.

There may be other laws, rules, or regulations applicable to businesses generally which affect your Drugstore. These laws include local licensing, zoning, and permit laws, tax regulations, labor laws, business licensing requirements, the American with Disabilities Act, and laws prohibiting false advertising, among others. Additionally, federal and state laws affecting businesses generally include restrictions against smoking in public places, the public posting of notices regarding health hazards (e.g., tobacco smoke or other carcinogens), fire safety and general emergency preparedness laws, rules regarding the proper use, storage, and disposal of waste, insecticides, and other hazardous materials, and standards regarding employee health and safety.

You are responsible for investigating all laws and regulations that apply to the operation of a pharmacy and complying with those applicable to your Drugstore. Operating your Drugstore in compliance with all applicable laws is a material condition of the Franchise Agreement. We recommend that you consult with your attorney for an explanation of the laws applicable to your Drugstore.

ITEM 2 BUSINESS EXPERIENCE

President Community Pharmacy and Health and Parent Senior Vice President: Nimesh Jhaveri

Nimesh Jhaveri, MBA, RPh, has served as our Community Pharmacy and Health President and as Senior Vice President of our Parent since January 2019. Before joining us, Nimesh worked for Walgreen's for 30 years in a variety of positions with ever-increasing responsibility, with his last position being that of Vice President of Health Services Development. Nimesh is based in Irving, Texas.

Health Mart and Health Mart Atlas President: Eyad Farah

Eyad Farah, B.S. Pharm, MBA, has served as our President and Senior Vice President of our Parent since September 2020. In addition, Eyad also leads McKesson's pharmacy services administrative organization (PSAO), Health Mart Atlas, and the consumer products group. Prior to this role, Eyad served as VP/GM of Health Mart Atlas from July 2016 to August 2020. Eyad joined our Parent in 2010, and has held several positions in Corporate Strategy and Business Development, Marketing, and Product Development. Prior to joining McKesson, Eyad worked at Super-Pharm for 13 years in a variety of positions with progressively growing responsibilities. Eyad is based in New Albany, OH.

Vice President, Treasurer, Director: Holger Landauer

Holger Landauer has served as our Vice President and Treasurer, and as one of our Directors since December 2021, and has held the office of Senior Vice President and Chief Financial Officer at McKesson Pharmaceutical Solutions and Services since December 2021. Since joining our European business in 2005, he has served in various leadership roles of increasing responsibility at the country- and European-level. In November 2020, he was promoted to CFO, Member of the Management Board for McKesson Europe AG. Previously, as Finance and IT Director and member of the German country board, Holger led the McKesson German business into the joint venture with Walgreens Boots Alliance (WBA). Holger is based in Irving, Texas.

Secretary, Corporate Secretary and Assistant General Counsel: Saralisa Brau

Saralisa Brau has served as Secretary since January 2022 and has held the position of Corporate Secretary and Assistant General Counsel of our Parent for that same period of time. Saralisa joined our Parent in August 2017 as Chief Counsel, Antitrust, after serving with the Federal Trade Commission in Washington, D.C. and in private practice. Ms. Brau is based in Washington, D.C.

Vice President, Chief Pharmacy Officer: Nancy Lyons

Nancy Lyons has served as the Vice President, Chief Pharmacy Officer for Health Mart since November 2019. Nancy also served as Senior Manager of Operations for Health Mart from July 2017 to November 2019. Previously, Ms. Lyons served as Director of Continuing Education and Clinical Content for Lebharr-Friedman / Drug Store News, which is based in New York, New York, from November 2014 to July 2017, and as a Scientific Advisor in Global Medical and Scientific Affairs at Roche Diabetes Care from January 2014 to January 2015 in Indianapolis, Indiana. Ms. Lyons also owns a clinical, management consulting and medical writing company, NLCM Consulting, founded in 2013 and based in Indianapolis, Indiana and is an owner and serves as Chief Executive Officer for two small businesses based in Brownsburg, Indiana: Lyons Fire and Safety, founded in May 2011 and D & N Equipment Rental, founded in August 2015. Ms. Lyons is based in Brownsburg, Indiana.

Vice President and General Manager of Pharmacy and Healthcare Solutions: Peter Koo

Peter Koo executes and leads PHS' pharmacy growth by building a leading portfolio of programs and services as the VP/GM Pharmacy Solutions since May 2021. His responsibilities include the Health Mart franchise, McKesson Reimbursement Advantage, ProviderPay and the Consumer Products Group. Prior to his appointment as VP/GM of PHS, Peter held a VP Retail Solutions role within McKesson since 2018. Before McKesson, he served as Senior Vice President of Bartell Drugs from September 2011 until June 2018. He is based out of the McKesson corporate offices in Las Colinas, TX.

Vice President, Retail Operations and Program Management: Charles G. Wilson

Chuck Wilson became the Vice President of Retail Operations and Program Management for Pharmacy and Healthcare Solutions including Health Mart in November 2019. Previously, Mr. Wilson served as the Vice President of Operations for Health Mart from March, 2009 to November 2019. Mr. Wilson works from our offices in Minneapolis, Minnesota.

Vice President, Product Development & Management: Kande Buck-Johnson

Kande Buck-Johnson joined the Community Pharmacy Healthcare unit supporting Health Mart in August 2021 as Vice President of Product Development and Management. Previously, Ms. Buck-Johnson most recently served as VP Customer Operations at Macro Helix based in Atlanta, GA where she performed roles with progressive responsibility across 11 years of service from March 2011 to July 2021. Prior to Macro Helix, Kande was the Pharmacy Director at Anderson Regional Medical Center. Ms. Buck-Johnson is based at our corporate offices in Las Colinas, TX.

Vice President and General Manager of Health Mart Atlas: Crystal Lennartz

Crystal Lennartz has served as the Vice President and General Manager for Health Mart Atlas – McKesson’s Pharmacy Services Administrative Organization (PSAO) – offering industry leading centralized managed care solutions for pharmacies since April 2021. From March 2018 to April 2021, Crystal served as Vice President of Pharmacy Performance for Health Mart Atlas, where she led the team responsible for managing a high-performing pharmacy network across 7,000 independent, small and medium chain pharmacies. Previously, Ms. Lennartz spent six years supporting the Health Mart franchise including serving as Health Mart Chief Pharmacist from April 2016 to March 2018. Crystal is based in Lewis Center, OH.

Vice President, Strategic Planning & Innovation: Melissa Cianciolo

Melissa Cianciolo joined the Community Pharmacy Healthcare unit supporting Health Mart as Vice President of Strategic Planning and Innovation in June 2021. Previously, Ms. Cianciolo was a member of McKesson’s Corporate Strategy & Business Development team from December, 2019 to June 2021, and originally joined McKesson from EY-Parthenon, where she advised Life Science and Consumer & Retail executives on large-scale transformations beginning in July 2017. Melissa is based at our corporate offices in Las Colinas, TX.

Senior Director, Strategic Marketing: Bridget Ahr

Bridget Ahr became Senior Director, Strategic Marketing for Health Mart in April 2020. Previously, she served as Senior Director, Content and Campaign Marketing for our parent from June 2017 to March 2020. She is based in Irving, Texas. From May 2016 to June 2017, Bridget was not otherwise employed. From January 2014 to May 2016, Ms. Ahr was the Director of Marketing for Lauren Engineers and Constructors in Irving, Texas.

ITEM 3 LITIGATION

In re: National Prescription Opiate Litigation, Case No. 1:17-md-02804-DAP (December 8, 2017), U.S. District Court, Northern District of Ohio. Our Parent, along with other pharmaceutical wholesale distributors, pharmaceutical manufacturers, and retail pharmacy chains, has been sued in many cases asserting claims related to distribution of controlled substances. The plaintiffs in these actions have included state attorneys general, county and municipal governments, tribal nations, hospitals, health and welfare funds, third-party payors, and individuals. These actions have been filed in state and federal courts throughout the U.S., and in Puerto Rico and Canada. They seek monetary damages and other forms of relief based on a variety of causes of action, including negligence, public nuisance, unjust enrichment, and civil conspiracy, as well as alleging violations of the Racketeer Influenced and Corrupt Organizations Act (“RICO”), state and federal controlled substances laws, and other statutes.

On July 21, 2021, our Parent and two other national pharmaceutical distributors announced that they had negotiated a comprehensive settlement agreement that would eventually result in the settlement of a substantial majority of opioid lawsuits filed by state and local governmental entities. On February 25, 2022, our Parent announced that it had determined that there was sufficient participation by states and litigating political subdivisions to proceed with the comprehensive settlement. The settlement became effective April 2, 2022. Under that agreement, the three distributors would pay up to approximately \$19.5 billion over 18 years, with up to \$7.4 billion to be paid by our Parent for its 38.1% portion; a minimum of 85% of such payments must be used by state and local governmental entities to remediate the opioid epidemic. Most of the remaining percentage relates to plaintiffs’ attorneys’ fees and costs, and would be payable over a shorter time period.

We remain named as a defendant in approximately 40 of those cases, substantially all of which will be resolved by the comprehensive settlement agreement.

No other litigation is required to be disclosed in this Item.

ITEM 4 BANKRUPTCY

No bankruptcy is required to be disclosed in this Item.

ITEM 5 INITIAL FEES

We do not charge an initial franchise fee. The Franchise Agreement does not require a franchisee to make any payments to us, our Parent, or Affiliates before the Effective Date. Each Drugstore Location is assigned an Effective Date, which corresponds to the date a franchisee begins business as a Health Mart franchisee. The Effective Date is the later of (i) the date that we activate the franchisee's access to the Health Mart System for the Drugstore located at the Drugstore Location; or (ii) the date the Franchise Agreement is fully executed.

A franchisee may, at its option, purchase Merchandise (defined in Item 6) from our Parent before the Effective Date, but it is not required to do so. Interior décor furnishings, aisle markers, and signage are required to be purchased through us and our approved supplier to maintain consistency of the brand's use. Franchisees also may, but are not required to, buy exterior signs, fixtures, accessories and various computer systems from us, our Parent, or another Affiliate. If a franchisee elects to buy any of these items from us, our Parent, or another Affiliate, they may do so, but they are not required to do so before the Effective Date.

ITEM 6 OTHER FEES

TYPE OF FEE⁽¹⁾	AMOUNT⁽¹⁾	DUE DATE	REMARKS
Monthly Fee	\$355 per month (exclusive of taxes)	10th day of each month for the preceding calendar month	Payment of the Monthly Fee begins in the first month following the applicable Effective Date. The Effective Date is the later of (i) the date that we activate the franchisee's access to the Health Mart System for the Drugstore located at the Drugstore Location; or (ii) the date the Franchise Agreement is fully executed. The Monthly Fee includes fees and other amounts charged by third parties and our Affiliates. We may adjust the Monthly Fee from time to time to cover any increase in such fees or other amounts and any changes in the Core Services.
Front End Solutions	\$25 per month	10th day of each month for the preceding calendar month	If you are qualified and elect to participate, we currently offer front end solution(s) as an optional service to such qualified franchisees: monthly in-store merchandising.
Digital Program: Health Mart Digital Portfolio (HMDP)	Currently \$0 for the Basic plan	10th day of each month for the preceding calendar month	If opting to enroll in a plan other than the minimum system standard of the Basic plan (which is required), fees for those

TYPE OF FEE ⁽¹⁾	AMOUNT ⁽¹⁾	DUE DATE	REMARKS
	\$299 per month for the optional Premium service level \$474 for optional Premium Concierge service level		optional escalated service levels will be payable to our Parent. The Digital Program is a HEALTH MART system standard for pharmacies to have a web presence via a landing page to provide consumers with information to locate pharmacies, gain pharmacy information such as hours and services provided, manage personal profiles and submit for new, refill or transfer prescriptions. When activating your participation via the My Health Mart Web Portal, you must agree to the Terms and Conditions, Privacy Notice, and Business Associate Agreement disclosed as Exhibit I.
Merchandise (includes private label and third-party over-the-counter non-prescription drugs and non-drug products and branded and generic prescription drugs)	Then-current prices as published on McKesson Connect; prices may be impacted by whether or not you belong to a particular buying group	Then-current terms as disclosed on McKesson Connect	You must purchase from our Parent no less than the Minimum Purchasing Threshold of branded and generic prescription drugs (currently 50% of your inventory of branded and generic prescription drugs, in the aggregate). All other purchases of Merchandise are at your option.
McKesson Reimbursement Advantage (MRA) Fee	May range from \$200 to \$500 per month based on your claim volume	Monthly	Payable to AccessHealth only if you elect to participate in the McKesson Reimbursement Advantage Program. To participate, you must (i) sign the Pharmacy and Healthcare Solutions Agreement and Provider Participation Addendum (Exhibit E) and belong to the Health Mart Atlas PSAO and (ii) use the Relay Health switching service.
Relay Health Intelligent Network Switching Fees	Varies according to claim volume	10th day of each month	If you elect to participate in the MRA program, you must use Relay Health's Intelligent Network switching service.
Training Fees	Currently, no training fees for mandatory initial	On demand	We may require your managers or employees to complete specific online training classes available through HEALTH MART University ("HMU").

TYPE OF FEE ⁽¹⁾	AMOUNT ⁽¹⁾	DUE DATE	REMARKS
	online training described in Item 11 Fees may vary for optional online training; currently, fees for optional online training classes do not exceed \$2,200 per person per online training course		At this time, attendance at most live or on-demand training classes that we offer is optional and we currently do not impose training fees for live training. For some contracted clinical services and programs, certain courses may be required for participation. The majority of required courses are offered at no cost. We may require future training programs that include additional fees. Eligible franchisees may participate in optional premium courses that are available in HMU at discounted fees from the education provider. Pharmacies may also access structured technician training programs. An entry-level Basic Technician Training program course fee does not exceed \$1,000 per enrolled student. Qualified franchisees may also participate in an accredited technician training program that includes course fees that do not exceed \$2,200 per enrolled student. See Item 11 for more training information.
Taxes on payments that you make to us	Amount of tax	On demand	Due only if any governmental authority charges us, our Affiliates or our Parent a tax on the Monthly Fee or any other fees that you pay, like a gross receipts or similar tax. In that case, we may increase the fee to cover our tax liability. This does not apply to any income taxes that we have to pay.
Retail Vaccine Program	\$250 per year	Within 30 days after invoice; we may withhold program benefits until paid in full.	Payable to us only if you choose to participate by signing the Retail Vaccine Program Agreement attached as Exhibit H. Program duration is 12 months from execution of the Retail Vaccine Program Agreement.
Interest	Lesser of 1.5% per month or maximum rate allowed by law	On demand	If you are late paying us, we can charge you interest.
Costs and Attorney's Fees	Varies	Immediately after notice from us	Due only if we are successful in any legal action that we bring against you or you bring against us in an amount which the court will award.

TYPE OF FEE ⁽¹⁾	AMOUNT ⁽¹⁾	DUE DATE	REMARKS
Indemnification	Will vary under circumstances	Immediately after notice from us	Due only if we suffer losses, incur expenses, or must defend against any claim brought by a third-party against us based on the operation of your Drugstore, your acts or omissions, or those of your employees and agents. You must reimburse us for those losses, expenses, and defense costs.

Notes:

(1) All of the fees described in Item 6 are payable to us or our Affiliates and are non-refundable. We generally impose continuing fees in a uniform manner, but we retain the discretion to alter fees from time to time to cover cost increases and/or changes in services except as otherwise stated in any applicable term sheet or program agreement. Fees for programs generally offered by our Affiliates to all qualified pharmacies (and therefore also available to qualified Health Mart pharmacies), but which are not offered exclusively to Health Mart franchisees or required to operate a franchised Health Mart pharmacy, are not included.

ITEM 7
ESTIMATED INITIAL INVESTMENT
YOUR ESTIMATED INITIAL INVESTMENT

(U) = UnOpened Location
(O) = Open Location

TYPE OF EXPENDITURE	AMOUNT	METHOD OF PAYMENT	WHEN DUE	TO WHOM PAYMENT IS TO BE MADE
Leasehold Improvements ⁽¹⁾	\$0 - \$3,000 (O) \$60,000 - \$115,000 (U)	Lump Sum	As Arranged	Contractor
Exterior Signage ⁽²⁾	\$0 - \$15,000 (O),(U)	Lump Sum When Payment is Due	50% deposit on order, balance due on receipt of invoice	Us or Third-party Suppliers
Interior Decor, Signs, Aisle Markers, and Departmental Signs ⁽³⁾	\$0 - \$5,000 (O),(U)	Lump Sum When Payment is Due	50% deposit on order, balance due on receipt of invoice	Us or Our Parent
Fixtures and Equipment ⁽⁴⁾	\$0 - \$5,000 (O) \$30,000 - \$80,000 (U)	Lump Sum When Payment is Due	50% deposit on order, balance due on receipt of invoice	Our Parent or Third-party Suppliers

TYPE OF EXPENDITURE	AMOUNT	METHOD OF PAYMENT	WHEN DUE	TO WHOM PAYMENT IS TO BE MADE
Inventory including Merchandise ⁽⁵⁾	\$0 (O) \$60,000 - \$110,000 (U)	Lump Sum When Payment is Due	Net 10 days after semi-monthly billing	Our Parent and Third-party Suppliers
Insurance ⁽⁶⁾	\$0 - \$2,500 (O) \$2,000 - \$10,000 (U)	As arranged	Quarterly	Third-party Suppliers
Supplies ⁽⁷⁾	\$200 - \$700 (O), (U)	Lump Sum	As Arranged	Third-party Suppliers
Business Licenses ⁽⁸⁾	\$100 (O) \$350 - \$2,000 (U)	Lump Sum	As Arranged	Licensing Authorities
Utility and Lease Security Deposits ⁽⁹⁾	\$0 (O) \$250 - \$500 (U)	Lump Sum	As Arranged	Utility Companies and other Third-party Suppliers
Computer Hardware and Software ⁽¹⁰⁾	\$0 - \$45,000 (O) \$10,000 - \$45,000 (U)	Lump Sum or Monthly	As Arranged	Third-party Suppliers and our Parent
Monthly Fees (3 months) ⁽¹¹⁾	\$1,065 (O), (U)	Lump Sum	Monthly	Us
Grand Opening and Initial Advertising and Promotion ⁽¹²⁾	\$1,000 - \$1,500 (O) \$0 - \$10,000 (U)	Lump Sum	As Arranged	Third-party Suppliers
Additional Funds (3 months) ⁽¹³⁾	\$0 - \$25,000 (O) \$87,000 - \$280,000 (U)	As you arrange	As you arrange	Miscellaneous
Total ⁽¹⁴⁾	\$2,365 - \$103,865 (O) \$250,865 - \$674,265 (U)			

Notes:

Note 1 (Leasehold Improvements): Leasehold improvements for UnOpened Locations will vary depending on various factors, including the Drugstore Location, size and configuration of the Drugstore, pre-construction costs, and the cost of materials and labor, which may vary based on geography and location. In addition to the impact of local conditions, your costs may vary substantially based on whether the landlord provides tenant improvement allowances. We cannot guaranty that you will be able to negotiate a tenant improvement allowance or other favorable lease terms. There is no “typical” size for a Drugstore. Drugstores currently range in size from 500 to 12,000 square feet. Since all Open Locations will already have a lease for the Drugstore Location, we anticipate that they will have minimal leasehold improvement expenses to convert the existing location to a HEALTH MART Drugstore if the existing location is in good repair.

Note 2 (Exterior Signage): Signage costs will vary according to the type and size of the sign. The low estimate of \$0 assumes that you use only the complimentary essential branding kit that we provide to each franchisee following execution of the Franchise Agreement but excludes the cost of shipping.

Note 3 (Interior Decor): While we do not require these purchases, an UnOpened Location will incur expenses to purchase and install interior decor items, aisle markers, and accessories. All interior signs, decor items, aisle markers, and accessories must be purchased from our Parent and us and our approved supplier. Prices will vary according to the size of your Drugstore and the items that you select.

Note 4 (Fixtures and Equipment): These figures vary based on the size of the Drugstore and whether the existing shelving, checkout counters, and showcases meet our specifications.

Note 5 (Inventory): This amount reflects an UnOpened Location's likely expenses for inventory bought before the Opening Date based on a Drugstore with 1,000 square feet of selling area. Since Open Locations will have existing inventory when they sign the Franchise Agreement, we show no initial inventory purchases for Open Locations. Inventory may include Merchandise purchased from our Parent; however, franchisees have 12 months from the Effective Date of the Franchise Agreement to satisfy the Minimum Purchasing Threshold for such Merchandise.

Note 6 (Insurance): This is an estimate of the range of expenses for the initial period that an UnOpened Location may incur to purchase insurance meeting the coverage requirements that we identify in Item 8. We assume Open Locations will most likely have in place insurance that meets our minimum requirements, but the range includes a \$2,500 allowance for any incremental costs attributable specifically to insurance to become a HEALTH MART Drugstore. Insurance costs may vary substantially depending on various factors, including the geographic location of your Drugstore, your claims history, and the additional policies you may acquire in addition to General Liability and Professional Liability.

Note 7 (Supplies): You will need to purchase stationery, business cards, and other office supplies. Typically, you will purchase quantities that will last longer than the initial period.

Note 8 (Business Licenses): A Drugstore must have certain business licenses and occupancy permits to conduct pharmacy operations. These estimates assume Open Locations already have a licensed pharmacist on staff and have all required licenses and permits required by applicable law. For UnOpened Locations, these costs vary from state to state, as well as from community to community within a particular state, depending on local ordinances.

Note 9 (Utility and Lease Deposits): These estimates assume Open Locations have entered into a lease for the retail pharmacy, have paid utility deposits and a rent security deposit, know their leasing expenses, and incur no incremental expenses for these items when converting to the HEALTH MART System. UnOpened Locations may be required to pay utility deposits, which will vary depending on the location of the Drugstore and your credit history. In addition, UnOpened Locations will pay a lease security deposit equal to one or two months' rent before the Opening Date. The security deposit assumes annual occupancy/lease costs of \$6 to \$15 per square foot. Some landlords will agree to defer the rent commencement date for some time period after you receive possession and while you make leasehold improvements. Depending on the lease terms that you negotiate, payment of rent may start before the Opening Date depending on, among other things, the length of the build-out phase. However, we assume that rent will start on the Opening Date and therefore include rent estimates in the Additional Funds category.

Note 10 (Computer Hardware and Software): As a practical matter, all Drugstores must use a pharmacy management computer system to help with filling prescriptions and recordkeeping related to prescription drugs. At this time, we do not require you to use a particular model or specify minimum requirements for the computer system that you must use to operate your Drugstore other than, if you elect to participate in the MRA program, you must choose a pharmacy management computer system that is compatible with Relay Health's Intelligent Network switching system. We assume that Open Locations already have a suitable pharmacy management system and have no incremental costs for computer hardware and software.

when they convert to the HEALTH MART System. Our Affiliate may make available to you, at your option, comprehensive computer hardware and software packages to use for order and inventory management, pharmacy management, and for front of the Drugstore management (e.g., point-of-sale or POS). The costs of these systems will vary substantially depending on the specific systems, equipment, and method of payment you select. The high estimates for both Open Locations and UnOpened Locations assume that you elect to purchase our computer packages and reflect the cost of using these systems during the initial period.

Note 11 (Monthly Fees): The estimate is for the Monthly Fee for three months.

Note 12 (Grand Opening): We recommend that UnOpened Locations conduct advertising to inform the public of the opening of their HEALTH MART Drugstore. We expect Open Locations will have more modest grand opening costs. We do not require you to purchase any grand opening advertising materials from us or our Affiliates.

Note 13 (Additional Funds): Additional Funds include miscellaneous expenses that you are likely to incur during the initial period. For Open Locations, the initial period is the first three months after you sign the Franchise Agreement; for UnOpened Locations, the initial period is the period of time from the date you sign the Franchise Agreement through the first three months after the Opening Date of your Drugstore (and assumes 12 to 15 weeks to complete leasehold improvements, install fixtures, signs and inventory and complete mandatory training after the Franchise Agreement is signed). Consequently, an UnOpened Location's "initial period" will include a "pre-Opening Date" period plus the first three months after the Opening Date.

Since an Open Location has historical information about its revenue, expenses and cash flow, an Open Location will know if it should budget extra Additional Funds during the initial period. For UnOpened Locations, the Additional Funds category covers expenses during the three months after the Opening Date for rent; telephone service; utilities; salaries and benefits for hourly employees; restocking inventory costs; restocking supplies; workers' compensation; professional fees; licensing fees; and working capital to supplement the cash flow from operating your HEALTH MART Drugstore. The working capital estimate for UnOpened Locations will vary greatly based on a variety of factors including the number of employees that you choose to hire initially and the salary and other benefits you choose to pay them; the extent of your involvement in the day-to-day operations of the Drugstore; your skill, experience, business acumen, and credit-rating; local competition; local economic conditions, and the actual sales levels that you reach during the initial three-month period after the Opening Date. Working capital needs are in addition to cash flow from operations. We cannot estimate your cash flow from operations. The Additional Funds category for Unopened Locations includes an allowance for payroll expenses for opening employees, but does not include any allowance for a draw or salary to the Drugstore's owners during the initial period.

The Additional Funds category for Open Locations and UnOpened Locations excludes (i) fees payable for optional programs in which you choose to enroll or participate in during the initial period; and (ii) payments made to a bank or financing company on any loan that you may obtain to finance initial investment expenses.

Note 14 (Total): The Item 7 ranges reflect our estimate of your initial investment in the Drugstore Location operated under the Franchise Agreement. All figures in Item 7 are estimates only. We cannot guarantee that you will not have additional expenses or other categories of expenses during the initial period. We assume Open Locations will be able to estimate their initial investment expenses based on their historical operating expenses, sales and cash flow. We recommend that UnOpened Locations not plan to draw income from operations during the initial period and plan to have Additional Funds available in reserve, either in cash or through a bank line of credit, to cover unanticipated events during the initial period and beyond. In estimating initial investment expenses, you should allow for inflation, discretionary expenditures, fluctuating interest rates, and other financing costs and local market conditions, all of which are highly variable factors that can result in unexpected increases in costs. You must bear all cost escalations and budget for these contingencies. These Item 7 estimates are based on purchases by franchisees from us, our

Parent, and other Affiliates and on information from our franchisees regarding their initial investment expenses, which we have not verified or audited.

Except as we disclose in Item 10, we do not offer to finance your initial investment. Payments made to us, our Parent, and our Affiliates are not refundable. Whether payments that you make to third parties are refundable depends on your ability to negotiate refund conditions with the third parties. Except as specifically stated, the amounts shown in Item 7 may be subject to increases based on changes in market conditions, inflation, economic conditions, changes in costs from suppliers, changes in our cost of providing goods or services, and future policy changes that we may make.

ITEM 8

RESTRICTIONS ON SOURCES OF PRODUCTS AND SERVICES

Required Purchases

You must purchase at least the required minimum percentage of your entire inventory of branded prescription drugs and generic prescription drugs (“Minimum Purchasing Threshold”) from our Parent (or any other Affiliate we designate) by the applicable Threshold Deadline. The current Minimum Purchasing Threshold is 50% of branded prescription drugs and generic prescription drugs (in the aggregate), and the Threshold Deadline is no later than 12 months from the applicable Effective Date. Minimum percentages may change. You must maintain the Minimum Purchasing Threshold for the remainder of the Franchise Agreement term. We may terminate the Franchise Agreement if you do not attain the Minimum Purchasing Threshold by the Threshold Deadline or maintain the Minimum Purchasing Threshold for the duration of the Franchise Agreement term. We will determine, in our sole discretion, whether or not you meet the Minimum Purchasing Threshold.

You must enter into an agreement, in the form attached to this Disclosure Document as Exhibit C, with Performance Quality Solutions (“PQS”), an independent third-party supplier, to use PQS’s EQuIPP software through the arrangement that we have in place for the Health Mart franchise system. EQuIPP provides performance data, reporting, measurement, and benchmarking for key quality measures related to patient medication use.

Approved Suppliers

You must comply with our standards and specifications for the purchase of all Merchandise (which includes, in addition to branded and generic prescription drugs, private label and third-party over-the-counter non-prescription drugs and non-drug products), signs, supplies, furniture, fixtures, furnishings, decor, equipment, computer systems, and other products and services used or offered for sale at the Drugstore. Our standards and specifications are included in the Franchise Handbook and accessible via the My Health Mart Web Portal.

Currently, our Parent is the only approved supplier of private label over-the-counter non-prescription drugs and other non-drug branded products (“Private Label OTC”). In the future, either our Parent or we may introduce other types of products identified by the Proprietary Marks. We may require you to buy such products from us or our Affiliates and offer them for sale in your Drugstore.

Our Parent and other Affiliates also are approved suppliers (but not the only approved suppliers) of various computer hardware and software systems, including an order and inventory management system, a pharmacy management system, and a front of the store or point of sale management system, as well as a program for interfacing with third-party benefit managers and claims processors. You may choose to purchase, license, or rent (as applicable) the computer hardware and software systems from our Parent or our Affiliates, or you may obtain compatible systems from third parties.

As described in Item 1, you are not required to be a member of a PSAO, but if you join a PSAO, it must be one that we have approved. Currently, we approve two PSAOs, including Health Mart Atlas. If

you elect to participate in the MRA program, you must belong to the Health Mart PSAO and use the Intelligent Network switching services provided by our Affiliate, Relay Health.

Purchases According to Specifications;

Following execution of the Franchise Agreement, we provide all franchisees with an essential branding kit that satisfies our minimum branding requirement; there is no charge for the essential branding kit except for shipping costs. An independent third-party supplier will also offer to sell you exterior signs and interior signs, decor furnishings, aisle markers, and accessories that comply with our specifications. You may purchase approved exterior and interior signs, decor furnishings, aisle markers, and accessories from any approved supplier you choose if the signs, materials, markers, and accessories meet our specifications.

We may, at our option, require that you submit any advertising and promotional materials that you obtain from third parties or prepare on your own for our approval. If we make this request, you must submit the materials to us. We will notify you within 30 days after we receive them of our approval or disapproval. If we do not notify you within 30 days, the materials will be deemed approved.

You must obtain the following types of insurance at no less than the following minimum coverage amounts. We may modify the minimum coverage amounts or require additional types of insurance to meet the specific needs of the particular location or to cover new areas of risk based on our recent experiences or those of our franchisees. We will communicate all changes in writing. Certain programs that we offer or may require in the future may impose additional insurance obligations on your Drugstore, which could result in higher costs.

Certificates of Insurance Required for Participation in the Franchise		
Insurance Type	Minimum Limits	Minimum Coverage
Commercial General Liability (including products liability)	\$1 million per occurrence/ \$3 million annual aggregate	Coverage arising from premises, operations, products and completed operations, personal injury, advertising injury, bodily injury and property damage, including contractual liability
Professional Liability	\$1 million per claim/ \$3 million annual aggregate	Coverage for Drugstore and its employees, as applicable, arising from performance or failure to perform any professional services, including healthcare services under the Franchise Agreement, including errors, omissions, wrongful acts, and negligent acts
Note: The insurance limits required for participation in the franchise can be satisfied through any combination of primary and umbrella/excess insurance, provided the umbrella policy follows form with the primary policy.		

As required by law and recommended for corresponding business needs		
Insurance Type	Minimum Limits	Minimum Coverage
Workers Compensation	Required by applicable law	Scope of coverage as required by applicable law
Commercial Property	As applicable	"All Risks" coverage for inventory, fire, or water damage, with full replacement costs, business interruption, and extra expense coverage
Employers Liability	\$1 million each accident or disease	Coverage for liability for injury to your covered employees
Crime Insurance	\$1 million	Coverage for losses due to fraudulent or dishonest acts committed by your employees acting alone or in collusion with others
Business Auto	\$1 million combined single limit each accident	Coverage for any auto used in performance of duties under the Franchise Agreement for bodily injury and property damage
Network Security/Privacy Liability/Cyber	\$1 million per claim and \$3 million annual aggregate	Coverage arising from liability or losses due to network security, privacy liability, and cyber insurance (first and third-party) liability, wrongful disclosure of data, wrongful disclosure of any business confidential information, personally identifiable information or any personal, or protected health information as defined by HIPAA and HITECH Acts or other applicable law; breach of security, including extortion, unauthorized access to computer(s) or system database(s), identification theft, Web hosting (if applicable), regulatory proceedings, PCI fines and costs, notification costs, and credit monitoring services.

Approval Process for Goods, Services, and Suppliers

You must comply with our standards and specifications for the goods and services that you offer for sale or use in your Drugstore. If we have identified brand requirements, you may purchase and use only approved brands. If we have approved or designated suppliers for any item, you must obtain those items only from the suppliers we have approved or designated. If you wish to use any item that we have not yet evaluated or if you wish to purchase or lease any item from a supplier that we have not yet approved, you must submit a written request for approval to us. You also may be required to submit to us information, specifications and samples to enable us to determine whether the item and/or the supplier complies with our standards and specifications. We also have the right to send representatives to inspect the supplier's facilities and to have samples from the supplier delivered to us or to an independent laboratory we designate for testing. You or the proposed supplier may be required to pay for the cost of the inspection and of the test (including our administrative expenses). We are not required to approve any particular supplier. We will notify you within a reasonable period of time following the date of your request whether you may purchase from the proposed supplier, but we are not obligated to notify you within any specific number of days. We reserve the right to re-inspect supplier facilities and products and to revoke our approval of the

supplier if the supplier fails to continue to meet our standards and specifications. If we revoke our approval of any supplier, you must promptly discontinue using that supplier.

Purchasing Arrangements

We may, but are not obligated to, negotiate discount prices and other types of purchasing programs for the benefit of HEALTH MART franchisees with businesses, organizations, insurance companies, and other third parties under the HEALTH MART Purchasing Advantage Program. Participation in these programs is optional, and we may discontinue these arrangements at any time. Some vendors may pay us revenue based on the aggregate volume of franchisee purchases or per unit engagement. For our fiscal year ending March 31, 2022, payments in the amount of \$22,543 were received from suppliers related to such an arrangement. We may also receive payments from suppliers who sell various promotional items and calendars to our franchisees.

In addition, manufacturers may from time to time offer advertising, display, and promotional allowances to all Drugstores by making payments to our Parent. Our Parent collects and administers the allowances for the benefit of all Drugstores that decide to participate. It applies the allowances to defray any administrative, servicing, and advertising costs and expenses that it incurs on behalf of the participants, and in some programs, also to reduce the cost of the goods sold to the participants.

Our Parent and Affiliates will derive revenue on account of purchases that you make from our Parent and/or Affiliates by purchasing Merchandise or other required items, participating in mandatory programs, and/or choosing to participate in optional programs.

During our fiscal year ending March 31, 2022, our revenue from required franchisee purchases or participation in programs was approximately \$4,000,000, or 12% of our total revenue of approximately \$32,300,000. During this same period, our Parent and all other Affiliates collectively received approximately \$11,600,000,000, in revenue from franchisees (either due to purchases or participation in mandatory and optional programs).

We estimate that your required purchases and leases from us or our Affiliates (including our Parent) will be between 10% to 90% of your cost to establish the Drugstore, and between 50% to 90% of your ongoing costs to operate the Drugstore.

As of the date of this Disclosure Document, there are no purchasing or distribution cooperatives in which you must participate.

All of our officers own stock in our Parent and thereby indirectly hold an interest in the Affiliates of our Parent, which are suppliers of mandatory goods or services.

Other than as described above, we do not provide material benefits to franchisees based upon their purchase of particular products or services or their use of designated or approved suppliers. When determining whether to grant new or additional franchises, we consider many factors, including your compliance with the requirements listed above.

ITEM 9
FRANCHISEE'S OBLIGATIONS

This table lists your principal obligations under the franchise and other agreements. It will help you find more detailed information about your obligations in these agreements and in other items of this Disclosure Document.

OBLIGATION	SECTION IN FRANCHISE AGREEMENT	DISCLOSURE DOCUMENT ITEM
a. Site selection and acquisition/lease	Section 1.2.	Item 11
b. Pre-opening purchases/leases	Sections 6.3., 6.4., 6.5., and 6.6.	Items 5, 8, and 11
c. Site development and other pre-opening requirements	Section 6.	Items 5 and 11
d. Initial and ongoing training	Section 5.	Items 6 and 11
e. Opening	Section 2.1.	Item 11
f. Fees	Section 4.	Items 5, 6, 7, 8, and 11
g. Compliance with standards and policies/Franchise Handbook	Sections 6. and 8.	Items 8, 11, 13, 14, 15, 16, and 17
h. Trademarks and proprietary information	Sections 7., 8., and 9.	Items 13 and 14
i. Restrictions on products/services offered	Section 6.	Items 8 and 16
j. Warranty and customer service requirements	Section 6.	Item 11
k. Territorial development and sales quotas	Not applicable	Item 12
l. Ongoing product/service purchases	Section 6.	Items 6 and 8
m. Maintenance, appearance, and remodeling requirements	Sections 2.2.2. and 6.	Items 8 and 11
n. Insurance	Section 12.	Items 7 and 8
o. Advertising	Section 11.	Items 7, 8, and 11
p. Indemnification	Section 19.	Item 6
q. Owner's participation/management/ staffing	Sections 6.8., 6.9., and 16.2.	Item 15
r. Records and reports	Section 10.	Not applicable
s. Inspections and audits	Section 3.7.	Not applicable
t. Transfer	Section 13.	Item 17
u. Renewal	Not applicable	Item 17

OBLIGATION	SECTION IN FRANCHISE AGREEMENT	DISCLOSURE DOCUMENT ITEM
v. Post-termination obligations	Section 15.	Item 17
w. Non-competition covenants	Section 16.1.	Item 17
x. Dispute resolution	Section 24.	Item 17

ITEM 10 FINANCING

SUMMARY OF FINANCING OFFERED

Item Financed	Source of Financing	Down Payment	Amount Financed	Term (Yrs)	Interest Rate	Monthly Payment	Pre-Payment Penalty	Security Required	Liability Upon Default	Loss of Legal Rights on Default
Initial Inventory	Our Parent	None	Up to 100% of initial purchase for 15 days of projected sales	3-12 month	0%	Varies	None	Blanket UCC/ Security Agreement/ Personal guarantee	Default under Franchise Agreement; acceleration of note	Waiver of notice; confess judgment
Signs, Fixtures and Interior Decor	Our Parent	None	Up to 100% of initial purchase	3-6 month	P+2, with a floor of 7.25%	Varies	None	Blanket UCC/ Security Agreement/ Personal guarantee	Default under Franchise Agreement; acceleration of note	Waiver of notice
Financing Start-Up Costs for a New Store	Our Parent	20%	Amount based on collateral coverage, up to 80% of purchase price	2-7 years	P+2, with a floor of 7.25%	Payable on first of each month	None	Blanket UCC/Security Agreement/ Personal guarantee	Default under Franchise Agreement; acceleration of note	Waiver of notice
Financing for Purchase of an Existing Pharmacy	Our Parent	20%	Amount based on collateral coverage, up to 80% of purchase price	2-7 years	P+2, with a floor of 7.25%	Payable on first of each month	None	Blanket UCC/Security Agreement/ Personal guarantee	Default under Franchise Agreement; acceleration of note	Waiver of notice

For loan terms of under one year, you will sign the short term financing documents that are attached to this Disclosure Document as Exhibit J-1, which include a security agreement, personal guaranty (if you are a business entity) and promissory note.

For loan terms of one year or longer, you will sign the long term financing documents that are attached to this Disclosure Document as Exhibit J-2, which include a security agreement, personal guaranty (if you are

a business entity), promissory note, certificate of insurance, board resolution (if you are a business entity), landlord waiver, and life insurance assignment.

Except as we disclose in the table above, neither we, our Parent, nor any of our Affiliates offer direct or indirect financing, nor do we, our Parent, or our Affiliates guarantee your notes, leases, or other obligations. We make no promise that we, our Parent, or our Affiliates will offer financing to you. The decision to extend the type of financing currently available to franchisees is subject to the sole discretion of our Parent. Among other factors, our Parent will consider your credit history. In individual cases, the actual terms of financing that our Parent may offer may differ from the above terms.

Should we or our Affiliates offer financing, the financing terms may be changed prospectively at any time. The new terms would apply to franchisees that purchase a HEALTH MART franchise after the changes become effective.

ITEM 11 FRANCHISOR'S ASSISTANCE, ADVERTISING, COMPUTER SYSTEMS, AND TRAINING

Except as listed below, we are not required to provide you with any assistance.

Pre-Opening Obligations

Before you open your Drugstore as a HEALTH MART Drugstore or begin operating your existing drugstore as a HEALTH MART Drugstore, we, our Parent, or our Affiliates will:

1. Give you My Health Mart Web Portal access to the Franchise Handbook. (Franchise Agreement, Section 3.1.)
2. At your option, sell you branded prescription drugs, generic prescription drugs and other Merchandise at the then-current prices and terms established by our Parent or other Affiliates. The Threshold Deadline to satisfy the Minimum Purchasing Threshold for branded and generic prescription drugs is 12 months after your Health Mart Drugstore Effective Date. (Franchise Agreement, Sections 3.2 and 6.5.)
3. Give you access to our required and optional online training programs. (Franchise Agreement, Section 5.1.).

Site Selection and Opening

We do not assist you in identifying, evaluating, or selecting any site. We do not require you to obtain our prior approval of your proposed location before you sign a lease. We estimate that the typical length of time between signing the Franchise Agreement and opening your first Drugstore is (i) 3 to 6 weeks for Open Locations and (ii) 12 to 15 weeks for UnOpened Locations. Some factors affecting these time periods may include the current and/or future lay-out of the Drugstore, delivery and installation of fixtures and signs, and delivery of inventory. These estimates do not take into account any construction or remodeling that may have to take place at the Drugstore Location or the time it takes you to negotiate and sign a lease for, or purchase, the site of the Drugstore Location.

Continuing Obligations

During the operation of your Drugstore, we, our Parent, or our Affiliates will:

1. Give you My Health Mart Web Portal access to the Franchise Handbook. (Franchise Agreement, Section 3.1.)
2. Sell you branded prescription drugs, generic prescription drugs and other Merchandise at the then-current prices and terms established by our Parent or other Affiliates. (Franchise Agreement, Section 3.2.)

3. Give you access to our required and optional online training programs and offer additional training as we determine. (Franchise Agreement, Section 5.1.)
4. Provide each Drugstore Location access to the Core Services, which Core Services may be changed, discontinued, terminated, modified, or further developed during the term of the Franchise Agreement. (Franchise Agreement, Section 3.3.)
5. In our discretion, we or our Affiliates may offer Optional Programs upon terms and conditions we or they establish, in which you may elect to participate if you satisfy the eligibility and qualification requirements. (Franchise Agreement, Sections 3.4.) The Optional Programs that are currently offered are described in Item 6.
6. In our discretion, conduct any on-site reviews or consultations that we deem advisable to assess your operation of the Drugstore in compliance with our Standards. (Franchise Agreement, Section 3.6.)

Advertising Programs

We recommend, but do not require, you to conduct a grand opening for the Drugstore Location. The grand opening is designed to publicize the opening or re-branding of the Drugstore located at the Drugstore Location. Any grand opening you conduct will be at your expense, but we may provide resources to assist you in implementing a grand opening program.

We may, in the future, establish a national advertising plan to maximize general public recognition, acceptance, and use of the System (“Advertising Plan”). If we institute an Advertising Plan, we will maintain and administer the Advertising Plan, and we will have the exclusive right to direct the Advertising Plan, including: (a) allocating to the Advertising Plan a portion of the Monthly Fees we receive from franchisees; (b) voluntarily making (and allowing our Affiliates to make) contributions to the Advertising Plan in the amounts, and with the frequency, and timing as that we determine; (c) spending all Advertising Plan revenue for advertising, marketing, and/or promotional purposes during the taxable year within which the revenue is received or carrying forward unspent revenue to future years; (d) maintaining sole discretion over the concepts, materials, and media used in any and all Advertising Plan programs and the placement and allocation of concepts, materials, and media. We do not represent that either we or our Parent or other Affiliates will contribute a minimum amount to the Advertising Plan or that we will establish an Advertising Plan.

If we do establish an Advertising Plan, funds contributed or allocated to the Advertising Plan will be used exclusively to maintain, administer, direct, conduct, and prepare advertising, marketing, merchandizing, public relations, and/or promotional programs and materials and any other activities we believe will enhance the System, including, among other things, the cost of preparing and conducting media advertising campaigns, including print, radio, and television advertising; Internet advertising; direct mail advertising; marketing surveys; employing advertising and/or public relations agencies; purchasing promotional items; and providing promotional and other marketing materials and services to Drugstores operating under the System. We may elect to use Advertising Plan funds to reimburse us or our Affiliates for the actual internal expenses of administering the Advertising Plan. We will not be obligated to make expenditures from the Advertising Plan for or on behalf of any franchisee or to ensure that any particular franchisee benefits directly or pro rata from Advertising Plan expenditures. We will have no obligation to prepare financial reports of the revenue and expenditures of the Advertising Plan or to keep the Advertising Plan revenue segregated in a separate bank account apart from our general funds. Our establishment and/or operation of an Advertising Plan will not impose on us any fiduciary duties or create any fiduciary relationship between you and us.

Any advertising and promotional activities you conduct for your Drugstore must comply with all applicable laws and any standards and requirements that we may specify in the Franchise Handbook or otherwise in writing. At any time, we may ask you to submit your advertising and promotional materials to us (other

than advertising and marketing materials that you purchase from our Marketing Hub). We will notify you within 30 days after we receive your materials of our approval or disapproval; our failure to respond by the end of 30 days will be considered approval to use the materials. Our approval does not mean that the materials comply with applicable law. You remain solely responsible for verifying that the materials comply with all applicable laws. Our right to approve your advertising and promotional materials applies broadly to all materials that you create or have created for you regardless of its format or the media where you intend to place the materials. For example, we may request the right to approve material that you wish to publish promoting your Drugstores or using the HEALTH MART brand on the Internet, including social media networking sites (Twitter, Facebook, YouTube, and comparable consumer-generated media Websites).

We provide local marketing support (“LMS”) for Drugstores through our online Marketing Hub and customer support center which is accessible through the My Health Mart Web Portal. LMS includes multiple marketing programs, and tactics that we make available to franchisees. LMS programs include in-store materials, traditional marketing aids, mailing lists, and digital marketing tools. Currently, all LMS services are delivered by third-party vendors we select. These vendors set their own fees for providing these optional marketing services and display their fees on the Marketing Hub. These vendors may pay us or our Affiliates a portion of the fees that they collect from our franchisees. To participate in the LMS program, you must agree to the terms of use in the McKesson Local Marketing Support Platform Agreement attached as Exhibit F to this Disclosure Document and pay additional fees per for the marketing services that you select. Additionally, if your Drugstore meets our minimum branding standards and you are otherwise a franchisee in good standing, you may be eligible to receive marketing matching funds from us in the amount of up to \$200 per month. Your eligibility to receive and use matching fund credits is in our sole discretion. At this time, access to our Marketing Hub is offered only to HEALTH MART franchisees, but in the future, we may offer the full range of LMS marketing tactics and support services to pharmacies that are not part of the HEALTH MART franchise network.

If any advertising furnished by us, our designee, or a supplier we select or approve contains an actual or suggested retail price for any product or service to be sold at or from your Drugstore, you have no obligation (actual or implied) to follow the price or utilize any of the advertising if the suggested retail price differs from that which you wish to charge.

Our Website, www.healthmart.com, includes an online store locator feature that enables consumers to locate their nearest HEALTH MART Drugstores. Our Digital Portfolio suite of services, which is a required participation for franchisees in our System at the “basic” level and optional to upgrade to Premium or higher service options, provides you with a Webpage template hosted on the www.healthmart.com Website which you may customize with your Drugstore’s Location, operating hours, and additional store-specific services and individual information. If you opt to create a separate Webpage, the store locator feature on our Website will not include an active link to your Webpage. Otherwise, you may not register, attempt to register, obtain any ownership in, or otherwise utilize a Website, domain name, URL, Internet presence, or other electronic communications portal that contains, incorporates, or consists of any of the Proprietary Marks, unless you obtain our prior written approval. We may condition approval of your use of electronic media on the transfer of any and all ownership rights to us, including copyrights.

We do not have an advertising council or committee. If we establish one in the future, any such council or committee will act only in an advisory capacity.

Electronic Cash Register and Computer Programs

As a Health Mart franchisee, you must enter into an agreement with PQS giving you access to its EQuIPP software. EQuIPP is a third-party performance information management platform that provides performance data, reporting, measurement and benchmarking for key quality measures relating to patient medication use. Currently, you are not required to pay a separate fee for the EQuIPP software.

As a practical matter, all Drugstores must use a pharmacy management system to help with the filling of prescriptions and recordkeeping related to the dispensing of prescription drugs. While we do not currently require you to use any particular pharmacy management system, if your Drugstore participates in the MRA program, you must use a pharmacy management system that is compatible with Relay Health's Intelligent Network switch system. We expect that Open Locations will already own a suitable computer system with compatible pharmacy management software. If you are an UnOpened Location, we estimate that the cost to purchase a suitable computer system with compatible pharmacy management software will range between \$10,000 to \$45,000. Your cost will depend in part on the number of workstations and other hardware preferences that you choose. You may purchase computer hardware and software to operate your Drugstore from a supplier of your choice as long as it meets our standards and specifications.

Drugstores also often use a point of sale ("POS") computer system to make the check-out and cash register operations run more smoothly, but at this time we do not require that you purchase or use any particular automation machinery, computer hardware or software (including electronic cash register systems) that perform POS functions.

We may establish and maintain, or contract with third parties to provide, computer software programs, systems, and databases we deem advisable from time to time, in the form and configuration we determine (including all related hardware, "Computer Programs"). You must purchase, license, install, and use, at your sole expense, any and all Computer Programs we require from time to time for use in the operation of the Drugstore, including point-of-sale, pharmacy management systems, performance information management systems, and other computer programs and systems. You must execute the required form of software license agreement for such Computer Programs, which may require you to pay licensing, support, and maintenance fees to us, our Affiliates, or a third party and to obtain upgrades and modifications to such Computer Programs as we require at your expense. We will have independent access to such Computer Programs and may retrieve electronically any information stored in such Computer Programs. We may use the data that you provide or that we collect (including dispensing data, patient data, and other sensitive information) for any lawful purpose even after the Franchise Agreement ends. Among other things, we may use dispensing data, patient data, and other sensitive information to verify your compliance with the Minimum Purchasing Threshold and other obligations under the Franchise Agreement.

Franchise Handbook

The table of contents of our Franchise Handbook, also referred to as the operations manual or toolkit within the My Health Mart Web Portal, is attached to this Disclosure Document as Exhibit K. Since the Franchise Handbook is in electronic format, we estimate that, if printed, the Franchise Handbook would be approximately 870 pages. We may from time to time revise or update the contents of the Franchise Handbook.

Training

Health Mart University (HMU), our online training platform for franchisees, delivers education in multiple ways, including online on-demand training courses, and live webinars. HMU offers training courses for owners, pharmacists, technicians, and other staff designed to enhance pharmacy business, compliance, clinical and operational knowledge through a variety of interactive topics. Currently, both ACPE (Accreditation Council for Pharmacy Education) accredited and non-accredited programs are available. Currently, some optional online courses have a discounted per person enrollment fee of under \$600 per course offered by the content provider. Franchisees may also access other optional, online training courses for technicians to meet certain state or certification requirements through Therapeutic Research Center (TRC), and currently this program has an enrollment fee of under \$1,000 per course. Franchisees that meet the requirements to become approved sites as a part of Health Mart's ASHP/ACPE accredited technician training program may also participate in an optional training program to provide national standards accredited training courses through TRC and at their pharmacy, and the fee to participate in this optional

training course is currently under \$2,200. We may adjust our training fees and impose training fees for online and live training programs that we currently offer without charge.

Within 60 days after signing the Franchise Agreement, you or your designated representative must successfully complete an orientation session with our Health Mart Operations Support Specialists, a teleconference session that we estimate should take approximately 1 hour to complete.

TRAINING PROGRAM

Subject	Hours of Classroom Training	Hours of On-the-Job Training	Location
Health Mart franchise orientation call(s)	Approximately 2.5 hour guided orientation between the primary operator(s) of the pharmacy and our Health Mart Operations support team.	None	Virtual/teleconference

We may occasionally offer live training remotely via Webinar, at regional meetings, or at our annual “IdeaShare” conference. At this time, there is no training fee to attend optional live classes. In the future, we may charge additional fees to attend premium courses such as certificate training programs or workshops. You are responsible for all travel, lodging, and living expenses, including meals, and paying any salary to your managers and employees while they participate in training programs.

Nancy Lyons, Vice President and Chief Pharmacy Officer for our Parent, supervises the creation of training curriculum and the delivery of all training programs to our franchisees. She has held this position since 2017. She has more than 30 years industry experience teaching and supervising the delivery of corporate operations training programs.

ITEM 12 TERRITORY

The Drugstore operated under the Franchise Agreement operates at a specific Drugstore Location.

You will not receive an exclusive territory. You may face competition from other franchisees, from outlets that we own, or from other channels of distribution or competitive brands that we control. While neither we nor our Affiliates currently own any retail pharmacies (except for the Headquarters Location), in the future, we or our Affiliates may do so.

The rights that we grant to you under the Franchise Agreement to operate a Drugstore are non-exclusive. We may establish or operate, or license any other party to establish or operate, a Drugstore under any of the Proprietary Marks, or any other marks whether or not now in use by us or our Affiliates, at any other location, regardless of the proximity to your Drugstore Location and regardless of any impact on the revenue or sales at your Drugstore.

We, and any entity authorized by us, will have the right, at all times, to operate at any location under any other trade names, trademarks, or service marks as we deem appropriate: (a) any type of drugstore, whether full-service, apothecary-style, or otherwise, or (b) a business offering health care services. Nothing prohibits us from acquiring or operating drugstores operating under another name different than the Proprietary Marks which may compete directly with you. We reserve all rights not specifically granted to you under the Franchise Agreement.

If we choose to grant another person the right to locate and operate a Drugstore that is adjacent to or near the vicinity of your Drugstore, the other Drugstore could have an adverse competitive impact on your Drugstore business. Our grant of rights to you offers you no protection from competing Drugstores, no matter how close those Drugstores may be to yours.

As of the date of this Disclosure Document, neither we nor any of our Affiliates have established any other franchises or company-operated outlets under different trade names or trademarks in the United States that sell or lease products or services similar to those which you will offer.

We and our Affiliates reserve the right to offer or sell products and services similar to those you will offer to your customers through alternative channels of distribution. Our Affiliates offer many of the same products and services that they offer to you to other independent retailers, as well as competing chains (including other drugstore chains that operate as franchises) and other businesses that dispense pharmaceuticals, including hospitals and clinics, any of which may operate close to your Drugstore and compete with you for customers.

We and our Affiliates may advertise and promote private label over-the-counter products and third-party brand over-the-counter products via the Internet and may also engage in the wholesale sale of private label over-the-counter and third-party brand over-the-counter products to other businesses that are not part of the HEALTH MART network. We and any entity authorized by us may also accept orders (including orders via the Internet) from, and deliver products and services, including private label over-the-counter products and third-party brand over-the-counter products to customers located anywhere regardless of the proximity of their residence to your Drugstore without paying you any compensation.

We do not offer rights of first refusal or rights to obtain additional locations or territories. If you want the right to operate a second or additional Drugstore, you must enter a separate Franchise Agreement for each Drugstore.

Other franchisees operating under previous forms of franchise agreements may have been granted territories in which we have agreed not to establish another Drugstore. We reserve the right to provide this territorial protection to these and other franchisees on a case-by-case basis.

ITEM 13 TRADEMARKS

The following principal trademarks are registered on the Principal Register of the United States Patent and Trademark Office (“USPTO”) and are included within the scope of the term Proprietary Marks.

NAME	REGISTRATION DATE	REGISTRATION NUMBER
	December 14, 2021	6,590,866
SUNMARK	April 19, 2005	2,941,616
	April 29, 2008	3,417,106
HEALTH MART	August 24, 1993	1,789,774
HEALTH MART	September 14, 1982	1,208,869

Health Mart Systems, Inc. has filed applications with the USPTO to register the trademarks listed below. We do not have federal registrations for the trademarks listed below. Therefore, the trademarks below do not have as many legal benefits and rights as federally registered trademarks. If our right to use one or more of the below trademarks is challenged, you may have to change to alternative trademark(s), which may increase your expenses. Once registered, we intend to renew the registrations and to file all appropriate affidavits at the appropriate times required by law.

NAME	APPLICATION DATE	APPLICATION NUMBER
 Health Mart PHARMACY	August 13, 2020	90/112518
 Health Mart PHARMACY	August 13, 2020	90/111921
HEALTH MART	April 1, 2021	90/619143

Section 8 and 15 affidavits and renewals have been filed for all of the above Proprietary Marks where appropriate.

Our Parent owns the “Sunmark” Proprietary Mark. We own the other Proprietary Marks listed above. We also claim all common law rights in the Proprietary Marks.

There are no presently effective determinations of the USPTO, the trademark trial and appeal board, or the trademark administrator of any state or any court; no pending infringement, opposition or cancellation proceedings; nor any pending material litigation involving the Proprietary Marks that are relevant to your use of them.

There are no agreements currently in effect that significantly limit our rights to use or license the use of the Proprietary Marks in any manner that is material to you.

You may not handle any disputes with third parties concerning the use of our Proprietary Marks. You must promptly notify us of any suspected unauthorized use or infringement of our Proprietary Marks or any challenge to the validity or ownership of our Proprietary Marks. We have the right to direct and control any administrative or alternative dispute resolution proceeding or litigation involving our Proprietary Marks, including any settlement. We have the right, but not the obligation, to take action against uses by others that may constitute infringement of our Proprietary Marks.

We are obligated to defend you against any third-party claim, suit, or demand arising out of your use of our Proprietary Marks. If we determine, however, in our sole discretion, that you have not used our Proprietary Marks in accordance with the Franchise Agreement, the cost of our and your defense, including the cost of any judgment or settlement, will be borne by you. In the event of any litigation relating to your use of our Proprietary Marks, you must execute all documents and do such acts as may, in our opinion, be necessary or useful to carry out our defense or prosecution, including becoming a nominal party to any legal action. Except to the extent that such litigation is the result of your use of our Proprietary Marks in a manner inconsistent with the terms of the Franchise Agreement, we will reimburse you for your out-of-pocket costs of doing such acts.

We do not know of any infringing uses that could materially affect your use of our Proprietary Marks.

We reserve the right to substitute or add different Proprietary Marks for use in identifying the System and the businesses operating under it if we determine that the substitution or addition of different marks would be beneficial to the System. You must implement promptly any substitution or addition of new Proprietary

Marks. You will bear the costs of modifying your signs and advertising materials to conform to our new Proprietary Marks.

We reserve the right to require you to take any action which we, in our reasonable judgment, deem necessary to maintain the quality standards of appearance, product, and service which we have established for our System. These standards must be maintained in order to preserve the integrity and value of our Proprietary Marks. From time to time, we may request that you make substantial expenditures to bring your Drugstore operation and facilities into conformance with our standards.

You must operate and advertise your Drugstore only under the name “HEALTH MART” with only an appropriate prefix that we approve that identifies your particular Drugstore’s independent ownership. You may not use the Proprietary Marks as part of your corporate or legal name or in any manner that suggests or implies that we are responsible for the obligations of your Drugstore or you are our agent. You must register a fictitious business name statement (a.k.a. a DBA or “doing business as” notice) at your expense if state or local laws require you to do so to notify third parties that you do business under the name HEALTH MART.

ITEM 14

PATENTS, COPYRIGHTS, AND PROPRIETARY INFORMATION

We do not own any rights in or to any patents or registered copyrights. We do claim copyright protection and proprietary rights in the original materials used in the System, including our My Health Mart Web Portal, Franchise Handbook, bulletins, correspondence and communications with our franchisees, training, advertising and promotional materials, and other written materials relating to the operation of the Drugstore and the System. You must treat these materials and our other Confidential Information (as defined in the Franchise Agreement) confidentially. We will allow you to use our Confidential Information during the term of the Franchise Agreement, or until we withdraw our permission for its use.

You must agree not to communicate or use our Confidential Information for the benefit of anyone else during the term of the Franchise Agreement. You must also agree not to use our Confidential Information at all after the Franchise Agreement terminates or expires. You can give this Confidential Information only to your employees who need it to operate the Drugstore. If you are an entity, your owners must sign an Owners’ Undertaking in the form of Exhibit D to the Franchise Agreement, which, among other things, binds them to the confidentiality covenants. Your officers, directors, or managers; any Drugstore Manager; and if you are signing the Franchise Agreement as an individual, your spouse, must sign similar covenants in the form of the Principal’s Undertakings, attached as Exhibit E to the Franchise Agreement.

If you develop any new concept, process, or improvement in the operation or promotion of the Drugstore, you must promptly notify us and give us all necessary information about the new process or improvement, without compensation. You agree that any of these concepts, processes, or improvements will become our property, and we may use or disclose them to other franchisees, as we determine appropriate.

There are currently no effective determinations of the Copyright Office (Library of Congress) or any court regarding any of our copyrights, nor are there pending infringement, opposition, or cancellation proceedings, or other pending material litigation involving any of our copyrights that would significantly affect the ownership or use of any of those copyrights. There are no agreements currently in effect which limit our rights to use or license the use of our copyrights.

You may not handle any disputes with third parties concerning the use of our copyrights. You must promptly notify us of any suspected unauthorized use or infringement of our copyrights or any challenge to the validity or ownership of our copyrights. We have the right to direct and control any administrative or alternative dispute resolution proceeding or litigation involving our copyrights, including any settlement. We have the right, but not the obligation, to take action against uses by others that may constitute infringement of our copyrights.

We are obligated to defend you against any third-party claim, suit, or demand arising out of your use of our copyrights. If we determine, however, in our sole discretion, that you have not used our copyrights in accordance with the Franchise Agreement, the cost of our and your defense, including the cost of any judgment or settlement, will be borne by you. In the event of any litigation relating to your use of our copyrights, you must execute all documents and do such acts as may, in our opinion, be necessary or useful to carry out our defense or prosecution, including becoming a nominal party to any legal action. Except to the extent that such litigation is the result of your use of our copyrights in a manner inconsistent with the terms of the Franchise Agreement, we will reimburse you for your out-of-pocket costs of doing such acts.

We do not know of any infringing uses that could materially affect your use of our copyrights.

ITEM 15

OBLIGATION TO PARTICIPATE IN THE ACTUAL OPERATION OF THE FRANCHISE BUSINESS

Either you or a qualified manager you hire must devote full time to the supervision, management, and operation of the Drugstore. If you are an entity, we do not require that your manager have an equity interest in you. If you delegate supervision to a full-time manager, you remain responsible for the manager's performance and compliance with the Franchise Agreement.

You are responsible for ensuring that the Drugstore operates at all times in compliance with all applicable laws. It is your obligation to ensure that your Drugstore is under the supervision of a licensed pharmacist and that all pharmacists that you employ hold proper licenses that are in good standing. At a minimum, you must employ at least one licensed pharmacist at all times.

As a matter of policy, we currently require you or one of your management-level employees to have had managerial experience working in a drugstore or pharmacy before signing the Franchise Agreement. We may change that policy in the future. We may require that you and your managers and employees complete certain mandatory training at your expense when described in Item 11 or the Franchise Handbook as accessible via the My Health Mart Web Portal.

Your Drugstore Manager must sign the Principal's Undertakings attached to the Franchise Agreement as Exhibit E. The Principal's Undertakings includes undertakings to comply with the confidentiality and inter-term non-competition covenant in the Franchise Agreement.

If you are an entity, your owners must sign an Owners' Undertakings in the form of Exhibit D to the Franchise Agreement. The Owners' Undertakings includes undertakings similar to those in the Principal's Undertakings, as well as undertakings to comply with other obligations specific to owners, like undertakings to comply with the transfer restrictions and indemnification obligations in the Franchise Agreement.

ITEM 16

RESTRICTIONS ON WHAT THE FRANCHISEE MAY SELL

A HEALTH MART Drugstore is a retail pharmacy where the majority of the business is the sale of prescription drugs and healthcare related goods and services. All products or services used in or offered for sale at the Drugstore must comply with our Standards and specifications. You are not authorized to conduct retail sales from any location that is not the Drugstore Location.

Our Parent or other Affiliates offer to sell you a broad variety of Merchandise. Currently, you are only required to purchase at least the required minimum percentage of your entire inventory of branded prescription drugs and generic prescription drugs ("Minimum Purchasing Threshold") from our Parent (or any other Affiliate we designate). The current Minimum Purchasing Threshold is 50% of branded prescription drugs and generic prescription drugs (in the aggregate). The minimum percentages may change. You must satisfy the initial Minimum Purchasing Threshold by the applicable Threshold Deadline,

which is 12 months after the Effective Date of the Franchise Agreement for the Drugstore Location. Afterwards, you must maintain the Minimum Purchasing Threshold for the remainder of the Franchise Agreement term.

In the future, we may also require you to participate in certain mandatory programs (including, for example, managed care programs, adherence programs, operating programs, marketing and advertising programs, loyalty programs, customer satisfaction programs, and test programs). Some of these programs may require payment of additional fees to us, our Parent, or other Affiliates. Otherwise, we do not impose specific requirements regarding the goods and services that you must sell at your Drugstore.

We may suggest retail prices, but do not dictate or set the price you will charge for products or services of any kind. You agree to maintain a competitive image and pricing policy for the Drugstore.

Except as described above, we do not restrict the type of goods or services that you may offer, or the customers to whom you may sell.

ITEM 17 RENEWAL, TERMINATION, TRANSFER, AND DISPUTE RESOLUTION

THE FRANCHISE RELATIONSHIP

This table lists important provisions of the franchise and related agreements. You should read these provisions in the agreements attached to this disclosure document.

PROVISION	SECTION IN FRANCHISE AGREEMENT	SUMMARY
a. Length of the franchise term	Section 2.	Begins on the date the Franchise Agreement is fully executed and continues until the Franchise Agreement is terminated by either party.
b. Renewal or extension	Not applicable	Not applicable.
c. Requirements for franchisee to renew or extend	Not applicable	Not applicable.
d. Termination by franchisee	Sections 14.5. and 24.6.	You may terminate the operations of the Drugstore Location operated under the Franchise Agreement for any reason by giving us 60 days advance notice but you must (i) have satisfied all monetary obligations owed by you and your parent, subsidiaries and Affiliates to us and any of our Parent, subsidiaries, or Affiliates, and (ii) have executed a general release, in a form prescribed by us, of any and all claims against us and parent, subsidiaries or Affiliates. The Franchise Agreement includes a mutual limitation of damages if either party terminates the Franchise Agreement based upon the other party's material breach. If you elect to terminate the Franchise Agreement based on our material breach, the maximum damages that you may recover is 24

PROVISION	SECTION IN FRANCHISE AGREEMENT	SUMMARY
		times the average Monthly Fees that you paid to us during the 6 months before the effective date of termination. The limitation on damages does not apply to claims that we have against you for (i) misuse of the Proprietary Marks; or (ii) indemnification under your indemnity obligations in the Franchise Agreement.
e. Termination by franchisor without cause	Section 14.4.	We may terminate the operations of the Drugstore Location operated under the Franchise Agreement without cause upon 60 days prior written notice unless local laws in your state require longer notice or impose other conditions (in which case we will abide by local law) or local laws forbid us to terminate without cause.
f. Termination by franchisor with cause	Section 14.	The Franchise Agreement will terminate automatically upon the occurrence of certain non-curable events of financial default. We may also terminate the Franchise Agreement if you commit a material non-curable default or if you fail to cure a curable default within the required cure period.
g. “Cause” defined—curable defaults	Section 14.3.	Except for the non-curable defaults described below, you have 30 days to cure a default under the Franchise Agreement, including the following: (a) if you fail, refuse or neglect to pay us, our Parent or our other Affiliates for Merchandise or other fees including fees payable for optional programs in which you elect to participate; (b) if you fail to maintain or observe our standards and procedures or maintain substantial compliance with the Franchise Handbook; (c) if you neglect to obtain prior approval from us (except for unauthorized transfers) required under the Franchise Agreement; (d) if you refuse to sign a required software license agreement; or (e) if you use any marks which we believe are confusingly similar to the Proprietary Marks.
h. “Cause” defined—non-curable defaults	Sections 14.1. and 14.2.	Non-curable defaults include financial defaults that result in automatic termination of the Franchise Agreement, including filings in bankruptcy, insolvency or an assignment for the benefit of creditors and the like. Non-curable defaults also include defaults for which we may terminate the Franchise Agreement, like: (a) failure to complete required training; (b) failure to comply with all applicable federal, state, and local laws, rules, and

PROVISION	SECTION IN FRANCHISE AGREEMENT	SUMMARY
		regulations, and to timely obtain and maintain any and all permits, certificates, or licenses necessary for the full and proper operation of the Drugstore; (c) you abandon the operation of the Drugstore, lose the right to occupy the Drugstore Location, or forfeit the right to conduct business in the jurisdiction; (d) you or a Manager loses or has suspended or revoked any license that is required by applicable law to operate the Drugstore including your license to dispense controlled substances; (e) conviction of a felony, certain misdemeanors, a crime involving moral turpitude, or any other crime or offense that we believe is likely to have an adverse effect on the HEALTH MART System, the Proprietary Marks, or our goodwill; (f) if a threat or danger to public health or safety results from the construction, maintenance, or operation of the Drugstore; (g) if any transfer is made without our prior written consent; (h) if an approved transfer is not made within the time provided following death or permanent incapacity; (i) if you fail to comply with the covenants in the Franchise Agreement; (j) if you divulge the contents of the Franchise Handbook or other Confidential Information; (k) if you maintain false books or records; (l) if you misuse any Proprietary Marks; (m) if you commit 3 defaults in any 12 month period, whether cured or not; (n) if you are in default under any other agreement with us, our Parent or any of our Affiliates pertaining to a mandatory program or an optional program; (o) if you fail to attain the Minimum Purchasing Threshold for generic prescription drugs and branded prescription drugs by the applicable deadlines or thereafter fail to maintain the Minimum Purchasing Threshold during the term of the Franchise Agreement; or (p) if a suit to foreclose a lien or mortgage against the Drugstore Location is not dismissed within 30 day or if any real or personal property of the Drugstore is sold after levy. Additionally, your failure to meet plan-based minimum performance criteria set by the government or private party payors allows us to terminate your Franchise Agreement. See additional discussion in <u>Note 1</u> to this Item 17.

PROVISION	SECTION IN FRANCHISE AGREEMENT	SUMMARY
i. Franchisee's obligations on termination/non-renewal	Section 15.	After termination, you must: (a) cease representing yourself as a franchisee or former franchisee; (b) cease using any Confidential Information, confidential methods, procedures or techniques associated with the System, the Proprietary Programs, the Proprietary Marks, and anything else that would cause the public to identify the former Drugstore as an authorized HEALTH MART Drugstore; (c) cancel any assumed name registration which includes any Proprietary Mark; (d) modify the Drugstore Location as necessary to distinguish the appearance from a Drugstore operating as part of the HEALTH MART System; (e) not use any reproduction, counterfeit, copy or colorable imitation of the Proprietary Marks or any mark which, in our opinion, falsely suggests an association with us or the HEALTH MART network; (f) pay all money that you owe to us, our Parent, or any other Affiliates; (g) return all physical copies of records, correspondence, and Confidential Information in your possession to us. You are solely responsible for removing all exterior and interior signs and other property that might associate your pharmacy with the HEALTH MART System. The Franchise Agreement includes a mutual limitation of damages if either party terminates the Franchise Agreement based upon the other party's material breach. If we terminate the Franchise Agreement based on your material breach, the maximum damages that we may recover is 24 times the average Monthly Fees that you paid to us during the 6 months before the effective date of termination. The limitation on damages does not apply to claims that we have against you for (i) misuse of the Proprietary Marks; or (ii) indemnification under your indemnity obligations in the Franchise Agreement.
j. Assignment of contract by franchisor	Section 13.1.	No restrictions on our right to assign.
k. "Transfer" by franchisee—defined	Sections 13.2. and 13.3.	The Franchise Agreement defines certain transactions as constituting an "Event of Transfer" which requires our prior written consent. An Event of Transfer includes a Change of Control (a term that we define in the Franchise Agreement) of a Franchisee that is a business entity; the sale or

PROVISION	SECTION IN FRANCHISE AGREEMENT	SUMMARY
		transfer of any interest in the Franchise Agreement voluntarily or by operation of law; or the sale of substantially all of the assets of the Drugstore. The Franchise Agreement defines certain transactions as constituting a “Qualified Transfer” which require you to notify us immediately and provide us with a written guarantee.
l. Franchisor approval of transfer by franchisee	Sections 13.2. and 13.3.	You may not complete an Event of Transfer without our prior written consent which we will not unreasonably withhold. Our prior consent is not required for one type of Qualified Transfer, specifically: a transaction in which Franchisee is an individual and proposes to transfer all of his or her rights under the Franchise Agreement to a newly-formed business entity and own a controlling interest in the new business entity.
m. Conditions for franchisor approval of transfer	Sections 13.2.	Conditions to obtaining our prior written approval to a proposed Event of Transfer include the following: (a) that all monetary obligations are satisfied; (b) that you are not in default of the Franchise Agreement or any other agreement with us, our Affiliates, your landlord, or other vendors and suppliers; (c) that you sign a general release (see <u>Exhibit N</u>); (d) that you and the transferee enter into a written assignment satisfactory to us which may include a guarantee of performance by the transferee; or we can require that the transferee sign the then-current franchise agreement; (e) that the transferee meet our standards; (f) that the transferee refurbish the Drugstore Location to meet our then-current appearance standards; (g) that you remain liable for all obligations arising before the date of transfer; and (h) that transferee complete training. If the transferee is a business entity, its owners must sign our then-current form of personal guarantee and agree to be jointly and severally liable to us for obligations under the franchise agreement.
n. Franchisor’s right of first refusal to acquire franchisee’s business	Not applicable.	Not applicable.
o. Franchisor’s option to purchase franchisee’s business	Not applicable.	Not applicable.

PROVISION	SECTION IN FRANCHISE AGREEMENT	SUMMARY
p. Death or disability of franchisee	Section 13.5.	We treat your death or permanent incapacity as an Event of Transfer. We allow your estate or personal representative 90 days to obtain our consent to a proposed transferee. We may extend the time period to one year. The Franchise Agreement gives us the option, but does not obligate us, to manage your Drugstore following death or permanent incapacity for 90 days. We may extend this management period for up to a year by mutual agreement. If your heirs or beneficiaries fail to qualify as transferees upon your death, your personal representative, administrator or executor may transfer to someone else who does qualify or may terminate the Franchise Agreement upon 60 days' notice to us.
q. Non-competition covenants during the term of the franchise	Section 16.1.	You may not: (a) divert business from any Drugstore; or (b) own, maintain, operate, engage in, or have any financial or beneficial interest in, advise, assist, or make loans to any Competitive Business, as defined in the Franchise Agreement (subject to state law).
r. Non-competition covenants after the franchise is terminated or expires	Not applicable.	Not applicable.
s. Modification of the agreement	Section 22.	Except those changes we are permitted to make unilaterally, all changes to the Franchise Agreement must be in writing and mutually agreed to by you and us.
t. Integration/merger clause	Section 22.	Only the terms of the Franchise Agreement are binding (subject to state law). Any representations or promises outside of this Disclosure Document and the Franchise Agreement may not be enforceable. Nothing in the Franchise Agreement requires you to waive or disclaim any of the representations that we make in this Disclosure Document.
u. Dispute resolution by arbitration or mediation	Section 24.	Except for actions we may bring to protect our intellectual property or for claims seeking less than \$10,000 in damages, all claims must be submitted first to non-binding mediation. If mediation does not result in settlement of the dispute, either party can commence a lawsuit (subject to state law).

PROVISION	SECTION IN FRANCHISE AGREEMENT	SUMMARY
v. Choice of forum	Section 24.3.	You agree to resolve litigated disputes (excluding requests for injunctive relief or other provisional remedies) only in Texas. See <u>Exhibit R</u> – State-Specific Addenda.
w. Choice of law	Section 24.5.	Texas law governs. See <u>Exhibit O</u> – State-Specific Addenda

Note 1: Plan-based minimum performance criteria are set by third-party payors, public and private employers, union groups, associations, insurance companies, and health maintenance organizations. Performance criteria are based on clinical results. An example of a plan-based minimum performance requirement is the current Star Ratings run by the federal Centers for Medicare & Medicaid Services which focuses on minimum levels of “PDC,” a measure that assesses if a patient has a sufficient supply of medication on hand before the next refill date. The types of plan-based minimum performance measurements and the criteria applied by third-party payors to each measurement change all the time. Each public and private third-party payor publishes its own minimum performance criteria. The duty to meet all plan-based minimum performance criteria articulated by the public and private third-party payors, as these payors, requirements and standards may change, is a constant requirement of the Franchise Agreement as the failure of a HEALTH MART Drugstore to meet plan-based minimum requirements may harm the reputation and goodwill associated with the HEALTH MART brand. The Franchise Handbook identifies the specific performance criteria that we measure and explains information about the performance criteria. We will advise you of any changes in the measured minimum performance criteria through updates to the Franchise Handbook and provide you with a reasonable amount of time, typically 90 days, before we begin measuring performance for any new criteria that we add after you begin operations as a HEALTH MART Drugstore.

ITEM 18 PUBLIC FIGURES

We do not currently use any public figure to promote our franchise, nor is there any public figure who is involved in any respect with the actual management or control of our company.

ITEM 19 FINANCIAL PERFORMANCE REPRESENTATIONS

The FTC’s Franchise Rule permits a franchisor to provide information about the actual or potential financial performance of its franchised and/or franchisor-owned outlets, if there is a reasonable basis for the information, and if the information is included in the Disclosure Document. Financial performance information that differs from that included in Item 19 may be given only if: (1) a franchisor provides the actual records of an existing outlet you are considering buying; or (2) a franchisor supplements the information provided in this Item 19, for example, by providing information about possible performance at a particular location or under particular circumstances.

We do not make any representations about a franchisee’s future financial performance or the past financial performance of company-owned or franchised outlets. We also do not authorize our employees or representatives to make any such representations either orally or in writing. If you are purchasing an existing outlet, however, we may provide you with the actual records of that outlet. If you receive any other financial performance information or projections of your future income, you should report it to our management by

contacting Health Mart Franchise Administration at 6535 State Hwy 161, Irving, Texas 75039, the Federal Trade Commission, and the appropriate state regulatory agencies.

**ITEM 20
OUTLETS AND FRANCHISEE INFORMATION**

**TABLE NO. 1
SYSTEMWIDE OUTLET SUMMARY
FOR FISCAL YEARS ENDING MARCH 31, 2020 - MARCH 31, 2022**

Column 1 Outlet Type	Column 2 Year	Column 3 Outlets At The Start Of The Year	Column 4 Outlets At The End Of The Year	Column 5 Net Change
Franchised	2020	5010	5044	+34
	2021	5044	4935	-109
	2022	4935	4689	-246
Company-Owned	2020	0	0	0
	2021	0	1	1
	2022	1	1	0
Total Outlets	2020	5010	5044	+34
	2021	5044	4936	-108
	2022	4936	4690	-246

Notes:

1. As of March 31, 2022, we had 3 HSRSAs, which are included in the total outlet count.

**TABLE NO. 2
TRANSFERS OF OUTLETS FROM FRANCHISES TO NEW OWNERS
(OTHER THAN THE FRANCHISOR)
FOR FISCAL YEARS ENDING MARCH 31, 2020 - MARCH 31, 2022**

Column 1 State	Column 2 Year	Column 3 Number Of Transfers
Alabama	2020	4
	2021	3
	2022	3

Column 1 State	Column 2 Year	Column 3 Number Of Transfers
Alaska	2020	0
	2021	0
	2022	0
Arizona	2020	1
	2021	0
	2022	0
Arkansas	2020	1
	2021	7
	2022	0
California	2020	7
	2021	5
	2022	14
Colorado	2020	2
	2021	1
	2022	1
Connecticut	2020	1
	2021	0
	2022	1
Delaware	2020	0
	2021	0
	2022	0
Florida	2020	6
	2021	6
	2022	7

Column 1 State	Column 2 Year	Column 3 Number Of Transfers
Georgia	2020	2
	2021	2
	2022	2
Hawaii	2020	0
	2021	0
	2022	0
Idaho	2020	0
	2021	1
	2022	0
Iowa	2020	2
	2021	2
	2022	0
Illinois	2020	4
	2021	3
	2022	4
Indiana	2020	1
	2021	1
	2022	0
Kansas	2020	1
	2021	2
	2022	1
Kentucky	2020	0
	2021	4
	2022	2

Column 1 State	Column 2 Year	Column 3 Number Of Transfers
Louisiana	2020	0
	2021	3
	2022	1
Maryland	2020	1
	2021	0
	2022	1
Massachusetts	2020	0
	2021	0
	2022	1
Michigan	2020	3
	2021	3
	2022	5
Minnesota	2020	1
	2021	0
	2022	0
Mississippi	2020	1
	2021	3
	2022	2
Missouri	2020	1
	2021	3
	2022	2
Montana	2020	0
	2021	1
	2022	2

Column 1 State	Column 2 Year	Column 3 Number Of Transfers
Nebraska	2020	0
	2021	3
	2022	3
Nevada	2020	0
	2021	0
	2022	2
New Hampshire	2020	0
	2021	0
	2022	0
New Jersey	2020	1
	2021	0
	2022	1
New Mexico	2020	0
	2021	0
	2022	0
New York	2020	3
	2021	4
	2022	6
North Carolina	2020	1
	2021	1
	2022	0
North Dakota	2020	0
	2021	0
	2022	0

Column 1 State	Column 2 Year	Column 3 Number Of Transfers
Ohio	2020	1
	2021	2
	2022	4
Oklahoma	2020	3
	2021	5
	2022	1
Oregon	2020	0
	2021	2
	2022	0
Pennsylvania	2020	2
	2021	1
	2022	2
South Carolina	2020	0
	2021	0
	2022	0
South Dakota	2020	2
	2021	1
	2022	0
Tennessee	2020	2
	2021	3
	2022	3
Texas	2020	7
	2021	9
	2022	12

Column 1 State	Column 2 Year	Column 3 Number Of Transfers
Utah	2020	0
	2021	0
	2022	1
Virginia	2020	0
	2021	0
	2022	0
Washington	2020	1
	2021	1
	2022	0
West Virginia	2020	0
	2021	0
	2022	3
Wisconsin	2020	0
	2021	0
	2022	1
Wyoming	2020	1
	2021	0
	2022	0
TOTALS	2020	63
	2021	82
	2022	89

TABLE NO. 3.

**STATUS OF FRANCHISED OUTLETS
FOR FISCAL YEARS ENDING MARCH 31, 2020 - MARCH 31, 2022**

Column 1	Column 2	Column 3	Column 4	Column 5	Column 6	Column 7	Column 8	Column 9
State	Year	Outlets at Start of Year	Outlets Opened	Termina- tions	Non- Renewals	Reacquired by Franchisor	Ceased Operations – Other Reasons	Outlets at End of the Year
Alabama	2020	353	19	20	0	0	5	347
	2021	347	9	14	0	0	10	332
	2022	332	3	20	0	0	1	314
Alaska	2020	5	0	0	0	0	0	5
	2021	5	0	1	0	0	0	4
	2022	4	0	0	0	0	0	4
Arizona	2020	27	3	2	0	0	7	21
	2021	21	5	1	0	0	4	21
	2022	21	0	4	0	0	3	14
Arkansas	2020	93	28	10	0	0	5	106
	2021	106	6	10	0	0	14	88
	2022	88	10	5	0	0	3	90
California	2020	455	107	40	0	0	39	483
	2021	483	82	38	0	0	31	496
	2022	496	51	97	0	0	20	430
Colorado	2020	69	8	7	0	0	1	69
	2021	69	4	20	0	0	1	52
	2022	52	1	5	0	0	2	46

Column 1	Column 2	Column 3	Column 4	Column 5	Column 6	Column 7	Column 8	Column 9
State	Year	Outlets at Start of Year	Outlets Opened	Terminations	Non-Renewals	Reacquired by Franchisor	Ceased Operations – Other Reasons	Outlets at End of the Year
Connecticut	2020	58	4	5	0	0	9	48
	2021	48	3	2	0	0	5	44
	2022	44	10	3	0	0	2	49
Delaware	2020	10	1	0	0	0	0	11
	2021	11	0	0	0	0	0	11
	2022	11	0	1	0	0	0	10
District of Columbia	2020	11	2	0	0	0	0	13
	2021	13	0	0	0	0	2	11
	2022	11	0	1	0	0	0	10
Florida	2020	352	59	32	0	0	29	350
	2021	350	44	20	0	0	16	358
	2022	358	34	32	0	0	7	353
Georgia	2020	223	25	17	0	0	10	221
	2021	221	17	23	0	0	11	204
	2022	204	18	16	0	0	2	204
Guam	2020	0	1	0	0	0	0	1
	2021	1	1	0	0	0	0	2
	2022	2	0	0	0	0	0	2

Column 1 State	Column 2 Year	Column 3 Outlets at Start of Year	Column 4 Outlets Opened	Column 5 Termina- tions	Column 6 Non- Renewals	Column 7 Reacquired by Franchisor	Column 8 Ceased Operations – Other Reasons	Column 9 Outlets at End of the Year
Hawaii	2020	25	2	0	0	0	4	23
	2021	23	2	5	0	0	2	18
	2022	18	2	1	0	0	0	19
Idaho	2020	16	6	2	0	0	0	20
	2021	20	0	0	0	0	0	20
	2022	20	1	2	0	0	0	19
Illinois	2020	139	18	19	0	0	7	131
	2021	131	12	5	0	0	6	132
	2022	132	5	11	0	0	7	119
Indiana	2020	43	12	6	0	0	7	42
	2021	42	7	5	0	0	4	40
	2022	40	4	4	0	0	2	38
Iowa	2020	83	11	8	0	0	8	78
	2021	78	3	2	0	0	4	75
	2022	75	7	3	0	0	1	78
Kansas	2020	85	5	6	0	0	3	81
	2021	81	5	0	0	0	3	83
	2022	83	2	7	0	0	6	72

Column 1 State	Column 2 Year	Column 3 Outlets at Start of Year	Column 4 Outlets Opened	Column 5 Termina- tions	Column 6 Non- Renewals	Column 7 Reacquired by Franchisor	Column 8 Ceased Operations – Other Reasons	Column 9 Outlets at End of the Year
Kentucky	2020	171	18	22	0	0	5	162
	2021	162	8	17	0	0	4	149
	2022	149	11	9	0	0	1	150
Louisiana	2020	70	18	7	0	0	5	76
	2021	76	8	6	0	0	6	72
	2022	72	2	10	0	0	1	63
Maine	2020	7	0	1	0	0	.	6
	2021	6	0	5	0	0	0	1
	2022	1	0	0	0	0	0	1
Mariana Islands	2020	0	0	0	0	0	0	0
	2021	0	2	0	0	0	0	2
	2022	2	0	0	0	0	0	2
Maryland	2020	84	10	12	0	0	4	78
	2021	78	11	4	0	0	6	79
	2022	79	7	5	0	0	4	77
Massachusetts	2020	37	7	3	0	0	3	38
	2021	38	4	4	0	0	4	34
	2022	34	5	1	0	0	1	37

Column 1	Column 2	Column 3	Column 4	Column 5	Column 6	Column 7	Column 8	Column 9
State	Year	Outlets at Start of Year	Outlets Opened	Terminations	Non-Renewals	Reacquired by Franchisor	Ceased Operations – Other Reasons	Outlets at End of the Year
Michigan	2020	289	41	14	0	0	26	290
	2021	290	29	24	0	0	22	273
	2022	273	17	30	0	0	14	246
Minnesota	2020	42	2	2	0	0	16	26
	2021	26	5	8	0	0	2	21
	2022	21	1	2	0	0	0	20
Mississippi	2020	105	18	9	0	0	3	111
	2021	111	5	6	0	0	5	105
	2022	105	3	2	0	0	0	106
Missouri	2020	131	17	6	0	0	0	129
	2021	129	2	29	0	0	6	96
	2022	96	10	4	0	0	0	102
Montana	2020	25	3	1	0	0	2	25
	2021	25	1	7	0	0	1	18
	2022	18	1	2	0	0	0	17
Nebraska	2020	82	17	6	0	0	0	93
	2021	93	12	0	0	0	0	99
	2022	99	14	2	0	0	3	108

Column 1	Column 2	Column 3	Column 4	Column 5	Column 6	Column 7	Column 8	Column 9
State	Year	Outlets at Start of Year	Outlets Opened	Terminations	Non-Renewals	Reacquired by Franchisor	Ceased Operations – Other Reasons	Outlets at End of the Year
Nevada	2020	17	1	1	0	0	2	15
	2021	15	2	1	0	0	0	16
	2022	16	1	3	0	0	0	14
New Hampshire	2020	3	0	0	0	0	0	3
	2021	3	0	1	0	0	0	2
	2022	2	1	0	0	0	0	3
New Jersey	2020	114	15	6	0	0	6	117
	2021	117	12	10	0	0	11	108
	2022	108	12	15	0	0	4	101
New Mexico	2020	15	0	0	0	0	0	15
	2021	15	1	0	0	0	0	16
	2022	16	1	1	0	0	0	16
New York	2020	284	36	23	0	0	27	270
	2021	270	40	17	0	0	11	282
	2022	282	22	36	0	0	6	262
North Carolina	2020	74	9	3	0	0	0	80
	2021	80	16	2	0	0	5	89
	2022	89	2	9	0	0	1	81

Column 1	Column 2	Column 3	Column 4	Column 5	Column 6	Column 7	Column 8	Column 9
State	Year	Outlets at Start of Year	Outlets Opened	Terminations	Non-Renewals	Reacquired by Franchisor	Ceased Operations – Other Reasons	Outlets at End of the Year
North Dakota	2020	37	1	0	0	0	1	37
	2021	37	3	3	0	0	0	37
	2022	37	2	6	0	0	0	33
Ohio	2020	147	13	5	0	0	11	144
	2021	144	5	6	0	0	10	133
	2022	133	15	9	0	0	1	138
Oklahoma	2020	159	14	6	0	0	7	160
	2021	160	18	7	0	0	4	167
	2022	167	9	7	0	0	4	165
Oregon	2020	30	1	3	0	0	3	25
	2021	25	2	2	0	0	3	22
	2022	22	0	1	0	0	1	20
Pennsylvania	2020	116	12	10	0	0	15	103
	2021	103	28	6	0	0	7	118
	2022	118	13	24	0	0	2	105
Rhode Island	2020	11	0	1	0	0	3	7
	2021	7	0	1	0	0	1	5
	2022	5	2	0	0	0	0	7

Column 1 State	Column 2 Year	Column 3 Outlets at Start of Year	Column 4 Outlets Opened	Column 5 Termina- tions	Column 6 Non- Renewals	Column 7 Reacquired by Franchisor	Column 8 Ceased Operations – Other Reasons	Column 9 Outlets at End of the Year
South Carolina	2020	106	13	5	0	0	3	111
	2021	111	7	8	0	0	2	108
	2022	108	4	9	0	0	0	103
South Dakota	2020	37	3	2	0	0	2	36
	2021	36	0	4	0	0	0	32
	2022	32	0	1	0	0	2	29
Tennessee	2020	131	30	14	0	0	2	145
	2021	145	10	3	0	0	5	147
	2022	147	7	11	0	0	4	139
Texas	2020	349	132	31	0	0	45	405
	2021	405	94	33	0	0	25	441
	2022	441	37	48	0	0	14	416
Utah	2020	58	3	7	0	0	5	49
	2021	49	1	5	0	0	3	42
	2022	42	1	6	0	0	0	37
Vermont	2020	3	0	0	0	0	1	2
	2021	2	1	0	0	0	0	3
	2022	3	0	0	0	0	0	3

Column 1	Column 2	Column 3	Column 4	Column 5	Column 6	Column 7	Column 8	Column 9
State	Year	Outlets at Start of Year	Outlets Opened	Terminations	Non-Renewals	Reacquired by Franchisor	Ceased Operations – Other Reasons	Outlets at End of the Year
Virginia	2020	38	4	4	0	0	2	36
	2021	36	6	1	0	0	2	39
	2022	39	2	7	0	0	3	31
Washington	2020	51	6	4	0	0	4	49
	2021	49	4	2	0	0	3	48
	2022	48	6	2	0	0	2	50
West Virginia	2020	37	6	2	0	0	0	41
	2021	41	1	2	0	0	4	36
	2022	36	2	3	0	0	0	35
Wisconsin	2020	91	9	7	0	0	2	91
	2021	91	5	7	0	0	4	85
	2022	85	6	5	0	0	4	82
Wyoming	2020	12	8	1	0	0	0	19
	2021	19	0	0	0	0	0	19
	2022	19	0	0	0	0	0	19
Puerto Rico	2020	0	0	0	0	0	0	0
	2021	0	0	0	0	0	0	0
	2022	0	0	0	0	0	0	0

Column 1 State	Column 2 Year	Column 3 Outlets at Start of Year	Column 4 Outlets Opened	Column 5 Termina- tions	Column 6 Non- Renewals	Column 7 Reacquired by Franchisor	Column 8 Ceased Operations – Other Reasons	Column 9 Outlets at End of the Year
TOTALS	2020	5010	715	329	0	0	352	5044
	2021	5044	543	377	0	0	275	4935
	2022	4935	364	482	0	0	128	4689

Notes:

1. As of March 31, 2022, we had 3 HSRsAs, which are included in the total outlet count.

TABLE NO. 4
STATUS OF COMPANY-OWNED OUTLETS
FOR FISCAL YEARS ENDING MARCH 31, 2020 - MARCH 31, 2022

Column 1 State	Column 2 Year	Column 3 Outlets at Start of the Year	Column 4 Outlets Opened	Column 5 Outlets Reacquired From Franchisee s	Column 6 Outlets Closed	Column 7 Outlets Sold to Franchisee	Column 8 Outlets at End of the Year
Texas	2020	0	0	0	0	0	0
	2021	0	1	0	0	0	1
	2022	1	0	0	0	0	1
TOTALS	2020	0	0	0	0	0	0
	2021	0	1	0	0	0	1
	2022	1	0	0	0	0	1

TABLE NO. 5

**PROJECTED OPENINGS
AS OF FISCAL YEAR ENDING MARCH 31, 2021
(FOR APRIL 1, 2020 TO MARCH 31, 2021)**

Column 1	Column 2	Column 3	Column 4
State	Franchise Agreements Signed but Outlet Not Opened	Projected New Franchised Outlets in Fiscal Year 2022- 2023	Projected New Company-Owned Outlets Openings in Fiscal 2022-2023
ALABAMA	1	7	0
ALASKA	0	0	0
ARIZONA	1	1	0
ARKANSAS	1	5	0
CALIFORNIA	4	23	0
COLORADO	0	1	0
CONNECTICUT	0	1	0
DELAWARE	0	0	0
FLORIDA	3	16	0
GEORGIA	2	10	0
HAWAII	0	0	0
IDAHO	0	0	0
ILLINOIS	0	6	0
INDIANA	0	2	0
IOWA	0	5	0
KANSAS	0	2	0
KENTUCKY	2	6	0
LOUISIANA	0	3	0
MAINE	0	0	0
MARYLAND	1	2	0

Column 1	Column 2	Column 3	Column 4
State	Franchise Agreements Signed but Outlet Not Opened	Projected New Franchised Outlets in Fiscal Year 2022-2023	Projected New Company-Owned Outlets Openings in Fiscal 2022-2023
MASSACHUSETTS	0	3	0
MICHIGAN	0	12	0
MINNESOTA	0	5	0
MISSISSIPPI	0	7	0
MISSOURI	1	7	0
MONTANA	0	0	0
NEBRASKA	0	2	0
NEVADA	0	0	0
NEW HAMPSHIRE	0	0	0
NEW JERSEY	1	6	0
NEW MEXICO	1	1	0
NEW YORK	3	15	0
NORTH CAROLINA	0	5	0
NORTH DAKOTA	0	1	0
OHIO	0	10	0
OKLAHOMA	0	7	0
OREGON	0	2	0
PENNSYLVANIA	0	5	0
RHODE ISLAND	0	1	0
SOUTH CAROLINA	0	6	0
SOUTH DAKOTA	0	1	0
TENNESSEE	0	12	0
TEXAS	6	28	0
UTAH	0	3	0

Column 1	Column 2	Column 3	Column 4
State	Franchise Agreements Signed but Outlet Not Opened	Projected New Franchised Outlets in Fiscal Year 2022-2023	Projected New Company-Owned Outlets Openings in Fiscal 2022-2023
VIRGINIA	0	2	0
WASHINGTON	0	3	0
WEST VIRGINIA	0	2	0
WISCONSIN	0	3	0
WYOMING	0	1	0
TOTALS	27	240	0

The names of all current franchisees and the address and telephone number of each of their Outlets are attached as Exhibit L-1. The names and the address and telephone number of all current franchisees whose outlet is not yet operational as of March 31, 2022, if any, are attached as Exhibit L-2. The name, city, and state, and current business telephone number or if unknown, the last known home telephone number of every franchisee who had an Outlet terminated, cancelled, not renewed, or otherwise voluntarily or involuntarily ceased to do business under the Franchise Agreement during the most recently completed fiscal year or who has not communicated with us within 10 weeks of the Date of Issuance of this Franchise Disclosure Document are attached as Exhibit L-3. If you buy this franchise, your contact information may be disclosed to other buyers when you leave the franchise system.

As of the date of this disclosure document, we are not offering any outlets we control that were previously owned by a franchisee. If we begin to offer any such outlet, specific information about the outlet will be provided to you in a supplement to this disclosure document.

Franchisees in the system have not signed confidentiality clauses that limit their ability to speak openly about their experience with us in the last 3 fiscal years.

There are no known trademark-specific franchisee organizations associated with the system.

ITEM 21 FINANCIAL STATEMENTS

Attached to this Disclosure Document as Exhibit M are our audited financial statements for the fiscal years ended March 31, 2020, March 31, 2021, and March 31, 2022, and the audited consolidated balance sheets of our Parent and its subsidiaries as of March 31, 2022 and 2021, and the related consolidated statements of operations, comprehensive income (loss), stockholders' equity, and cash flows for the fiscal years ended March 31, 2020, March 31, 2021, and March 31, 2022 within Item 8 of our Parent's Form 10-K. Our Parent does not guarantee our obligations to franchisees.

ITEM 22 CONTRACTS

The following agreements are attached as exhibits to this Disclosure Document:

B - FRANCHISE AGREEMENT (INCLUDING STATE AMENDMENTS)

- C - EQuIPP SERVICES AGREEMENT FOR PARTICIPATING PHARMACY
- D - BULA AGREEMENT (OPTIONAL)
- E - PHARMACY AND HEALTHCARE SOLUTIONS MASTER SERVICES AGREEMENT, PROVIDER PARTICIPATION ADDENDUM, PROVIDERPAY RECONCILIATION SERVICES ADDENDUM, MCKESSON REIMBURSEMENT ADVANTAGE ADDENDUM (OPTIONAL)
- F - MCKESSON LOCAL MARKETING SUPPORT PLATFORM AGREEMENT (OPTIONAL)
- G - FRANCHISE COMPLIANCE QUESTIONNAIRE
- H - RETAIL VACCINE PROGRAM AGREEMENT (OPTIONAL)
- I - HEALTH MART DIGITAL PORTFOLIO (“HMDP”) PROGRAM (TERMS & CONDITIONS, PRIVACY NOTICE, BUSINESS ASSOCIATE AGREEMENT) (OPTIONAL AS TO PREMIUM SERVICES)
- J - FINANCING DOCUMENTS
 - J-1 - MCKESSON CORPORATION SHORT TERM FINANCING DOCUMENTS (OPTIONAL FINANCING) (SECURITY AGREEMENT, GUARANTY, NOTE)
 - J-2 - MCKESSON CORPORATION LONG TERM FINANCING DOCUMENTS (OPTIONAL FINANCING) (SECURITY AGREEMENT, GUARANTY, FORMS OF PROMISSORY NOTE, CERTIFICATE OF INSURANCE; RESOLUTION OF BOARD OF DIRECTORS OF CORPORATE FRANCHISEE, RESOLUTION OF MEMBERS/PARTNERS OF PARTNERSHIP OR LLC FRANCHISEE, LANDLORD WAIVER, LIFE INSURANCE ASSIGNMENT)
- N - GENERAL RELEASE
- R - RECEIPTS

ITEM 23 RECEIPTS

The Receipt pages are attached as the last four pages of the Disclosure Document as Exhibit R. Please execute both copies. Retain one copy for your records and return the other to us.

EXHIBIT A
AGENTS FOR SERVICE OF PROCESS

AGENTS FOR SERVICE OF PROCESS

California

State of California
Department of Financial Protection and Innovation
320 W. 4th Street, Suite 750
Los Angeles, California 90013-2344
(213) 576-7500
(866) 275-2677

Hawaii

Hawaii Commissioner of Securities
Department of Commerce and Consumer Affairs
Business Registration Division
State of Hawaii
335 Merchant Street, Room 203
Honolulu, Hawaii 96813

Illinois

Office of Attorney General
State of Illinois
500 South Second Street
Springfield, Illinois 62706

Indiana

Indiana Secretary of State
Franchise Section Indiana
Securities Division
302 West Washington Street, Room E-111
Indianapolis, Indiana 46204

Maryland

Maryland Securities Commissioner
Office of the Attorney General
Securities Division
200 Saint Paul Place
Baltimore, Maryland 21202

Michigan

Michigan Department of Commerce
Corporation & Securities Bureau
G Mennen Williams Building
Franchise Section, 1st Floor
525 West Ottawa Street
Lansing, MI 48913

Minnesota

Minnesota Department of Commerce
Franchise Section
85 7th Place East, Suite 280
Saint Paul, Minnesota 55101-2198

New York

Secretary of State
99 Washington Avenue
Albany, New York 12231

North Dakota

North Dakota Securities Commissioner
600 East Boulevard Avenue
Fifth Floor
Bismarck, North Dakota 58505-0510

Oregon

Department of Consumer and Business
Services
Division of Finance and Corporate
Securities
State of Oregon
Labor & Industries Bldg.
350 Winter Street, NE #410
Salem, Oregon 97310-3881

Rhode Island

Department of Business Regulation
Securities Division
John O. Pastore Complex
1511 Pontiac Avenue, Building 69-1
Cranston, Rhode Island 02920

South Dakota

Franchise Administrator
South Dakota Department of Labor and Regulations
Division of Insurance
Securities Regulation
124 S. Euclid, Suite 104
Pierre, South Dakota 57501

Virginia

State Corporation Commission
Division of Securities and Retail
Franchising
1300 East Main Street, 9th Floor
Richmond, Virginia 23219

Washington

Director of Financial Institutions
Securities Division
State of Washington
150 Israel Rd. SW
Tumwater, Washington 98501

Wisconsin

Wisconsin Department of Financial
Institutions
Division of Securities
345 W. Washington, 4th Floor
Madison, Wisconsin 53703

EXHIBIT B
FRANCHISE AGREEMENT
(INCLUDING STATE AMENDMENTS)



HEALTH MART SYSTEMS, INC.

FRANCHISE AGREEMENT

TABLE OF CONTENTS

Section	Provision	Page
1.	GRANT	1
2.	TERM.....	1
3.	DUTIES OF FRANCHISOR	2
4.	FEES.....	2
5.	TRAINING.....	3
6.	DUTIES OF FRANCHISEE	3
7.	PROPRIETARY MARKS	6
8.	FRANCHISE HANDBOOK.....	8
9.	CONFIDENTIAL INFORMATION.....	8
10.	ACCOUNTING AND RECORDS.....	9
11.	ADVERTISING AND PROMOTION.....	9
12.	INSURANCE.....	10
13.	TRANSFER OF INTEREST.....	11
14.	TERMINATION	13
15.	POST-TERM OBLIGATIONS	14
16.	COVENANTS.....	15
17.	BUSINESS ENTITY FRANCHISEE	16
18.	TAXES AND INDEBTEDNESS.....	16
19.	INDEPENDENT CONTRACTOR AND INDEMNIFICATION.....	16
20.	APPROVALS AND WAIVERS.....	17
21.	NOTICES	18
22.	ENTIRE AGREEMENT	18
23.	SEVERABILITY AND CONSTRUCTION	18
24.	APPLICABLE LAW AND DISPUTE RESOLUTION.....	19
25.	ACKNOWLEDGMENTS.....	20
26.	FRANCHISEE REBATES.....	21
27.	RECEIPT OF MARKETING COMMUNICATIONS.....	21

SCHEDULES

SCHEDULE 1 – DEFINITIONS

SCHEDULE 2 - MCKESSON ONESTOP GENERICS AUTHORIZATION FOR MCKESSON TO
COLLECT CUSTOMER DISPENSING DATA

EXHIBITS

EXHIBIT A - TRADEMARKS

EXHIBIT B - OWNERSHIP OF FRANCHISEE

EXHIBIT C – MINIMUM INSURANCE REQUIREMENTS

EXHIBIT D - OWNER’S UNDERTAKINGS

EXHIBIT E – PRINCIPAL’S UNDERTAKINGS

EXHIBIT F –STATE AMENDMENTS TO FRANCHISE AGREEMENT

**HEALTH MART SYSTEMS, INC.
FRANCHISE AGREEMENT
“DECLARATIONS PAGE”**

“Franchisor”

Health Mart Systems, Inc.
a Delaware Corporation

6535 State Hwy 161
Irving, Texas 75039

“Franchisee”

_____[PRINT NAME]

[If Franchisee is a Business Entity, print state of
formation and type of entity]

[ADDRESS/CITY/STATE/ZIP]

McKesson Act. No. _____

This Declarations Page which incorporates the terms of the Health Mart Systems, Inc. Franchise Agreement (“**Franchise Agreement**”) is made and entered into on _____, by and between Franchisor and Franchisee.

1. Effective Date of Franchise Agreement: _____

2. Franchisee is (check one):

- ☐ Unopened Location
☐ Open Location
☐ Renewal Location

3. Monthly Fee for: \$ _____

4. The Drugstore Location, as defined in Section 1.2, is:

(street address/city/state/zip).

5. As provided in Section 21, all notices to Franchisee shall either be sent to:

Attn: _____ (street address/city/state/zip; fax number; contact person and title)

Owner/Designated Operator email address: _____ (name and email address), or

As trackable message issued to Owner/Designated Operator via My Health Mart Web Portal

[Signature page follows]

IN WITNESS WHEREOF, on the date first above written, Franchisor and Franchisee agree to be bound by the terms of this Declarations Page and the Franchise Agreement.

HEALTH MART SYSTEMS, INC.

FRANCHISEE:

by: _____

[SIGNATURE IF FRANCHISEE IS AN
INDIVIDUAL]

[Printed name]

[Title]

[IF FRANCHISEE IS A BUSINESS ENTITY, PRINT
NAME OF BUSINESS ENTITY]

[Date]

by: _____

[Printed name]

[Title]

[Date]

FOR FRANCHISOR:

This Agreement shall expire upon appropriately executed termination measures by either Franchisor or Franchisee.

**HEALTH MART SYSTEMS, INC.
FRANCHISE AGREEMENT**

WHEREAS, Franchisor, as the result of the expenditure of time, skill, effort, and money, has developed a distinctive and proprietary system for establishing and operating retail drugstores (as further described in Schedule 1, the “**System**”);

WHEREAS, the System is identified by certain trade names, service marks, trademarks, logos, emblems, trade dress and indicia of origin, including, without limitation, the mark “**HEALTH MART**,” as are now designated in Exhibit A to this Agreement and may hereafter be designated by Franchisor in writing for use in connection with the System (the “**Proprietary Marks**”);

WHEREAS, Franchisee desires to operate a retail drugstore under the System and using the Proprietary Marks (as further defined in Schedule 1, the “**Drugstore**”) and to receive the assistance and other benefits provided by Franchisor in connection therewith; and

WHEREAS, Franchisee understands and acknowledges the importance of Franchisor’s high Standards of quality, consistency, appearance, and service and the necessity of operating the Drugstore in conformity with Franchisor’s Standards and specifications.

NOW, THEREFORE, the parties agree as follows:

1. GRANT

1.1. Grant of License. Franchisor grants to Franchisee the right, and Franchisee undertakes the obligation, upon the terms and conditions set forth in this Agreement: (a) to establish and operate a Drugstore in compliance with the System; and (b) to use the Proprietary Marks and the System solely in connection therewith.

1.2. Drugstore Location. The Drugstore shall be operated solely at the location identified on the Declarations Page (the “**Drugstore Location**”). Franchisee is solely responsible for locating, negotiating and acquiring the site to serve as the Drugstore Location. By entering into this Agreement, Franchisor indicates its willingness to award a franchise to operate a Drugstore at the Drugstore Location. However, Franchisor does not represent, warrant or guaranty that Franchisee’s operation of a Drugstore at the Drugstore Location will be successful or profitable. Franchisee

understands and agrees that Franchisor has not been involved in the selection of the Drugstore Location.

1.3. Relocation. During the Term, Franchisee may not relocate the Drugstore Location without Franchisor’s prior written approval. Franchisee must give Franchisor no less than thirty (30) days prior written notice that it wishes to relocate the Drugstore to another location and indicate in its written notice the street address of the new location. Unless Franchisor notifies Franchisee in writing of its disapproval before the end of the thirty (30) day period, Franchisor shall be deemed to have approved the proposed new location, and Franchisor’s approval shall operate to update the Declarations Page to reflect the street address of the proposed new location as the Drugstore Location. The right to relocate does not give Franchisee the right to operate more than one Drugstore under this Agreement during the Term of this Agreement.

1.4. Franchisor’s Reserved Rights. Franchisee acknowledges that the right granted under this Agreement is non-exclusive and that Franchisor and its Affiliates may, without limitation:

1.4.1. Establish or operate, or license another party to establish or operate, a Drugstore under the System and the Proprietary Marks or any other marks at any other location, regardless of proximity to the Drugstore Location and regardless of any impact on the operation of the Drugstore;

1.4.2. Establish or operate, or license another party to establish or operate, any type of drugstore (whether full-service, apothecary-style or otherwise) or any business offering health care services, at any location under any trade names, trademarks or service marks; and

1.4.3. Acquire or operate drugstores operating under a name that is different than the Proprietary Marks, which may compete directly with the Drugstore subject to this Agreement.

2. TERM

The term of this Agreement (the “**Term**”) shall begin on the Effective Date of this Agreement and shall continue until this Agreement is terminated by either party in accordance with the provisions hereof.

3. DUTIES OF FRANCHISOR

3.1. Franchise Handbook. Franchisor will provide Franchisee with online access to the Franchise Handbook. Franchisee may not share its password with any unauthorized person or violate the terms of use set forth in this Agreement or the Franchise Handbook.

3.2. Sale of Merchandise. Franchisor will supply, through McKesson or another of Franchisor's Affiliates or designated third-party suppliers, and Franchisee shall purchase, at Franchisee's expense, a sufficient quantity of Branded Prescription Drugs and Generic Prescription Drugs to enable Franchisee to satisfy the Minimum Purchasing Threshold described in Section 6.5 of this Agreement. Franchisor also may supply other Merchandise through McKesson or another of Franchisor's Affiliates or designated third-party suppliers. All Merchandise (including Branded Prescription Drugs and Generic Prescription Drugs) shall be supplied at then-current prices and on then-current terms and conditions and nothing in this Agreement shall limit or restrict the supplier's right to set prices for Merchandise and to increase those prices during the Term of this Agreement. If any Merchandise purchased from Franchisor, McKesson or Franchisor's other Affiliates is adjudicated to infringe on, or becomes (or in Franchisor's reasonable opinion is likely to become) the subject of any claim, suit, or proceeding arising from or alleging infringement of, any intellectual property right of any third party, then Franchisor, at its own expense, will have a reasonable amount of time either to secure for Franchisee the right to continue using the Merchandise or, if Franchisor determines that continued use is not feasible, to replace or modify the Merchandise to make it non-infringing. The foregoing shall be Franchisee's sole and exclusive remedy.

3.3. Core Services. In addition to providing access to the Franchise Handbook, as provided in Section 3.1, and supplying (or causing its Affiliate to supply) Merchandise in accordance with Section 3.2, Franchisor will provide to Franchisee, in consideration for payment of the then-current Monthly Fee for Core Services, the System's core services, any or all of which may be changed, discontinued, terminated, improved, modified and further developed by Franchisor from time to time (as further defined in Schedule 1, the "**Core Services**").

3.4. Optional Programs. Franchisor or Franchisor's Affiliates may, from time to time, offer various optional programs and services to eligible pharmacies, including, but not limited to, eligible Health Mart pharmacies. If Franchisee satisfies the eligibility and qualification requirements established for any such optional program, Franchisee may participate in the optional program at Franchisee's expense (and based on Franchisor's then-current fees for such optional programs and services) upon the applicable program terms and conditions as may be updated, modified, or discontinued by Franchisor in its sole discretion from time to time.

3.5. Training. Franchisor may provide, in its sole determination, training as set forth in Section 5 of this Agreement.

3.6. Site Visits. Franchisor may conduct such on-site reviews and consultations as it deems advisable to assess Franchisee's operation of the Drugstore in accordance with the Standards.

3.7. Right to Delegate. Franchisee acknowledges and agrees that any duty or obligation of Franchisor may be performed by any Affiliate, designee, employee, or agent of Franchisor, as Franchisor may direct.

3.8. Cooperatives. Franchisor may, from time to time in its discretion, establish purchasing or distribution cooperatives for any of the products or services promoted, offered or sold by Franchisee. If any such cooperatives are established, Franchisee shall participate in them, at Franchisee's expense.

4. FEES

4.1. Initial Fee. Franchisee is not required to pay any initial franchise fee in connection with the execution of this Agreement.

4.2. Monthly Fee. Beginning in the first month following the Effective Date of this Agreement Franchisee shall pay to Franchisor the then-current Monthly Fee together with any applicable taxes (as further defined in Schedule 1, the "**Monthly Fee**"). Monthly Fees shall be paid by the tenth (10th) day of each month, for the preceding calendar month. Franchisor and Franchisee agree that the Monthly Fee is in consideration of Franchisor's award of a franchise to Franchisee. Franchisee acknowledges and agrees that Franchisee's obligation to pay the Monthly Fee described herein shall not be predicated or conditioned upon the validity of any trademark or copyright claimed by Franchisor or attributable to any specific item of intellectual property or service that forms a part of the System.

4.3. Other Fees and Payments. In addition to the Monthly Fee, Franchisee must pay when due (a) all fees for the Optional Programs in which Franchisee participates as set forth in each Term Sheet initialed by Franchisee, and (b) all other fees or amounts described in this Agreement and in any other agreement between Franchisee and Franchisor or its Affiliates. All Monthly Fees and other payments that Franchisee makes to Franchisor, McKesson or Franchisor's other Affiliates are non-refundable.

4.4. Overdue Payments. If any payment is more than fifteen (15) days past due, Franchisee shall pay Franchisor or its Affiliate immediately upon demand, in addition to the overdue amount, interest on such amount from the date it was due until paid, at the rate of 1.5% per month, or if less, the maximum rate permitted by law. Entitlement to such interest shall be in addition to any other remedies Franchisor may have.

4.5. Set-Off. Franchisee has no right to withhold any payment due to Franchisor or its Affiliates on account of any breach or alleged breach of this Agreement and no right to set-off any payments required to be made under this Section 4 against any monetary claim Franchisee may have against Franchisor or its Affiliates.

4.6. Application of Payments. Franchisor reserves the right to apply any monies received from Franchisee to any of Franchisee's obligations, as determined by Franchisor.

4.7. Method of Payment. Upon reasonable written notice from Franchisor to Franchisee, Franchisee agrees to execute all documents necessary to permit Franchisor and its Affiliates to withdraw funds from Franchisee's designated bank account by electronic funds transfer in the amount of the Monthly Fee and any other amounts due under this Agreement at the time such amounts become due and payable. Franchisee further agrees to designate a specific bank account in which Franchisee will maintain sufficient funds to cover all amounts due to Franchisor or its Affiliates for Merchandise and fees payable under this Agreement or any other agreement between Franchisee and Franchisor or its Affiliate.

4.8. Taxes. Each payment to be made to Franchisor shall be made free and clear and without deduction for any Taxes.

5. TRAINING

5.1. Training Programs. At Franchisee's sole expense, Franchisee shall complete, and cause its Manager (or any other of its personnel) to complete, any mandatory training courses that Franchisor may require. For example, and without limitation, Franchisor may require Franchisee and Franchisee's Manager and other employees to complete online training classes in specific subjects available on demand from Franchisor's Website, through audio files, or specific live instructor-led training programs that may be offered by Franchisor.

5.2. Training Costs. Franchisee is solely responsible for paying all training fees and any travel, lodging and living expenses, including meals, for Franchisee or its Manager or employees to complete mandatory or optional training programs. Franchisor will make available an online, searchable library of available on-demand and live training classes and training fees in Health Mart University.

6. DUTIES OF FRANCHISEE

6.1. Compliance with Franchisor's Standards. Franchisee understands and acknowledges the importance of maintaining consistency among all Drugstores operating under the System and of complying with all of Franchisor's Standards relating to the operation of Health Mart Drugstores. To protect the reputation and goodwill of the System and the Proprietary Marks and to maintain high operating Standards and increase the demand for the services and products offered, promoted,

rented and sold by all Health Mart Drugstores, Franchisee agrees, at Franchisee's expense, to comply with Franchisor's Standards, specifications, methods and other requirements set forth in the Franchise Handbook, other written directives that Franchisor may issue from time to time, and any other manuals or materials created or approved for use in the operation of Health Mart Drugstores. Franchisee shall not deviate from such Standards, specifications, methods and requirements without Franchisor's prior written consent.

6.1.1. Franchisee acknowledges that the System may be changed, supplemented, improved, and otherwise modified from time to time, and Franchisee agrees to comply promptly, at Franchisee's sole cost and expense, with each such new or changed Standard, specification, method or requirement. Franchisee understands that its compliance with the changes in the System is a material condition of this Agreement.

6.1.2. Franchisee understands and agrees that Franchisor has no obligation to waive, make any exceptions to, or permit Franchisee to deviate from, the Standards or requirements of the Health Mart System. Any exception or deviation that Franchisor does allow must be stated in writing and executed by Franchisor in order to be enforceable. Franchisee further acknowledges that Franchisor may allow other franchisees to deviate from the Health Mart System in individual cases in the exercise of Franchisor's discretion. Franchisee understands and agrees that it has no right to object to any variances that Franchisor may allow to other franchisees or to itself, McKesson, or other Affiliates of Franchisor, and Franchisee has no claim against Franchisor for not enforcing the Standards of the Health Mart System uniformly.

6.1.3. Franchisor and Franchisee acknowledge that the practice of pharmacy is a profession that must be conducted by licensed pharmacists in compliance with all applicable laws and that it requires the exercise of independent professional judgment. Franchisee and the licensed pharmacists employed by Franchisee are solely responsible for the practice of pharmacy in connection with the operation of the Drugstore and their judgment governs in all matters involving the pharmacy practice. Nothing in Franchisor's Standards or in its administration of the Standards is intended to interfere with the practice of pharmacy by the licensed pharmacists employed by Franchisee. If Franchisee believes that there is a conflict between the Standards and the requirements of the pharmacy practice, Franchisee shall promptly notify Franchisor in writing.

6.2. Legal Compliance. Franchisee shall comply with all applicable federal, state, and local laws, rules, and regulations, and shall timely obtain and maintain any and all permits, certificates, or licenses necessary for the full and proper operation of the Drugstore, including, without limitation, licenses to do business, sales tax permits and all requisite trade, business, occupational or professional licenses necessary for the operation of the Drugstore, including, without limitation, those required for the receipt and sale of

pharmaceuticals. Franchisee understands and agrees that Franchisee shall be solely responsible for compliance with all applicable laws, including, without limitation: (i) any and all requirements governing the practice of pharmacy and all obligations thereunder, including, without limitation, all licensing requirements; (ii) any and all requirements, including regulatory and sub-regulatory guidelines or other issuances, related to participation in federal or state health care programs; (iii) any and all requirements related to the Health Insurance Portability and Accountability Act of 1996, Public Law No. 104-191 (“HIPAA”) and Subtitle D of the Health Information Technology for Economic and Clinical Health Act (the “HITECH Act”); (iv) ensuring that its facilities are in compliance with the Americans with Disabilities Act (as amended, revised or recodified from time to time), (v) ensuring that its facilities, equipment and procedures comply with all applicable rules and regulations of the United States Occupational Safety and Health Association or any similar federal, state or local agency, and (vi) maintaining all records as required by applicable law.

6.3. Signage and Brand Identity. Franchisee must purchase and install all required exterior and interior signs, furniture, fixtures, equipment, supplies and other interior decor furnishings, markers and accessories in accordance with Franchisor’s Standards and specifications at Franchisee’s sole expense on or before the Required Installation Date. The Required Installation Date is no later than ninety (90) days after the Effective Date of this Agreement. Franchisee is solely responsible for obtaining any architectural, engineering and design services required for the construction or finish-out of the Drugstore in compliance with the Standards and specifications prescribed by Franchisor in the Franchise Handbook.

6.3.1. Franchisee shall ensure that all advertising, marketing and promotional materials, signs, decorations, and other items bearing the Proprietary Marks display such Proprietary Marks in the form, color, location, and manner prescribed by Franchisor. If Franchisee desires to purchase an exterior sign bearing the “HEALTH MART” name or other Proprietary Marks from a third-party vendor and not from Franchisor or Franchisor’s Affiliate, Franchisor shall have the right to verify the proper replication of the Proprietary Marks prior to installation and Franchisee may not install such exterior sign without Franchisor’s prior written approval. To obtain Franchisor’s approval, Franchisee must submit a photograph of the proposed sign to Franchisor and, if written notice of disapproval is not received by Franchisee from Franchisor within thirty (30) days from the date that Franchisee receives the photograph, Franchisee may install the exterior sign.

6.3.2. During the Term of this Agreement, Franchisor will provide Franchisee with written notice of any modifications to the current signage, furniture, fixtures, equipment, supplies, decor, furnishings and accessory requirements and specifications. Franchisee shall promptly (and in any event within ninety (90) days from the date of the notice) modify the Drugstore at Franchisee’s sole expense to

comply with any mandatory changes to Franchisor’s Standards and specifications for such items.

6.4. Sourcing. Franchisee agrees to comply with Franchisor’s Standards and specifications for the purchase of all Merchandise, signs, supplies, furniture, fixtures, furnishings, décor, equipment, computer systems, and other products and services used or offered for sale at the Drugstore.

6.4.1. Franchisee acknowledges that such Standards and specifications may include brand requirements. If brand requirements have been identified, Franchisee may purchase and use only approved brands. If Franchisor has approved or designated suppliers (including manufacturers, distributors and other sources) for any item, Franchisee agrees to obtain such items from those approved or designated suppliers. Franchisee’s approved or designated suppliers are those who demonstrate the ability to meet Franchisor’s Standards and specifications, who have been approved in writing by Franchisor and who have not thereafter been disapproved by Franchisor. Franchisee acknowledges and agrees that (a) Franchisor may change the number of approved suppliers at any time, and may designate itself, an Affiliate, or a third party as the exclusive source for any particular item; and (b) Franchisor and its Affiliates may profit from Franchisee’s purchases from designated or approved suppliers and may receive payments, fees, commissions or reimbursements in respect of Franchisee’s purchases (including, without limitation, for products and services Franchisor or its Affiliates provide to Franchisee and from suppliers that Franchisor designates or approves). At its discretion Franchisor may refund such amounts to Franchisee, contribute such amounts to any Advertising Plan established pursuant to Section 11.2, or retain such amounts for its own use in its discretion, notwithstanding any designation by the supplier or otherwise.

6.4.2. If Franchisee wishes to use any item or service that Franchisor has not yet evaluated or if Franchisee wishes to purchase or lease any item from a supplier that Franchisor has not yet approved, Franchisee must submit a written request for approval to Franchisor. Franchisee cannot purchase or lease any such item unless the supplier has been approved in writing by Franchisor. Franchisor is not required to approve any particular supplier. Franchisee may be required to submit information, specifications and samples to Franchisor to enable Franchisor to determine whether the item and/or the supplier complies with Franchisor’s Standards and specifications. Franchisor also has the right to send its representatives to inspect the supplier’s facilities and to have samples from the supplier delivered to Franchisor or to an independent laboratory designated by Franchisor for testing. Franchisee or the proposed supplier may be required to pay for the cost of the inspection and of the test (including Franchisor’s administrative expenses). Franchisor may condition its approval of a supplier on requirements relating to product quality, prices, consistency, reliability, financial capability, labor relations, client relations, frequency of delivery, concentration of purchases, standards of service (including prompt attention to complaints) or other criteria. Franchisor will

notify Franchisee within a reasonable period of time following the date of the request as to whether Franchisee may purchase products from the proposed supplier. Franchisor reserves the right to re-inspect from time to time the facilities and products of any approved supplier and to revoke its approval of the supplier if the supplier fails to continue to meet Franchisor's Standards and specifications. If Franchisor revokes its approval of any supplier, Franchisee agrees to promptly discontinue use of that supplier.

6.5. Minimum Purchasing Threshold. By no later than the applicable "**Threshold Deadline**" (as defined in this Section) and at all times during the Term, Franchisee must purchase from McKesson or from another Affiliate that Franchisor designates, sufficient quantities of Branded Prescription Drugs and Generic Prescription Drugs so that it satisfies the Minimum Purchasing Threshold. The Threshold Deadline is twelve (12) months from the Effective Date of this Agreement. Franchisee shall execute (as "Customer") the McKesson OneStop Generics Authorization for McKesson to Collect Customer Dispensing Data in the form attached at Schedule 2 to this Agreement which, among other things, permits Franchisor to confirm compliance with the Minimum Purchasing Threshold requirements.

6.5.1. All purchases of Merchandise will be at the prices set by the supplier which are in effect when Franchisee places its order and shall be subject to the supplier's then-current purchase and return policies, which may include automatic shipment of new products. Any authorized supplier of Merchandise may increase the prices of Merchandise at any time without prior notice to Franchisee.

6.5.2. Except for the requirement to satisfy the Minimum Purchasing Threshold, Franchisee shall have sole discretion to determine what categories of Merchandise to purchase and whether to purchase Branded Prescription Drugs and Generic Prescription Drugs above the Minimum Purchasing Threshold.

6.5.3. Franchisor acknowledges that Franchisee may offer other products and services that are generally acceptable in independent pharmacies, but Franchisor reserves the right to adopt Standards and specifications for any such other products and services. Franchisee shall cease to use or sell any product or service which has been disapproved by Franchisor.

6.6. Participation in Required System Programs. Franchisee shall, at Franchisee's expense, participate in all mandatory programs prescribed by Franchisor from time to time (including, without limitation, managed care programs, adherence programs, operating programs, marketing and advertising programs, loyalty programs, customer satisfaction programs, and test programs), in the Franchise Handbook or otherwise in writing. Franchisee shall pay any applicable program fees, comply with all terms and conditions of such programs, and execute such agreements relating thereto as Franchisor may require from time to time. Franchisee

understands that participation in any such programs may require that Franchisee execute program-specific agreements, incur expenses and pay additional fees to Franchisor, McKesson or another Affiliate of Franchisor. Franchisee further understands and agrees that any such mandatory programs will be established upon terms and conditions determined by Franchisor in its sole discretion and may be modified, discontinued and/or replaced from time to time by Franchisor.

6.7. Data Requirements. Franchisee shall, to the fullest extent permitted by applicable law, promptly provide to Franchisor any and all dispensing data or other information pertaining to Drugstore operations (including, without limitation, patient information and other sensitive data) that Franchisor may, from time to time, require, at the time and in the manner Franchisor directs. Franchisee agrees that Franchisor may use and disclose all of the data and information that Franchisor captures as a result of Franchisee's participation in the System for as long as Franchisor wishes during and after the Term of this Agreement for any lawful purpose including, without limitation, to verify Franchisee's compliance with this Agreement. In addition, Franchisee agrees to meet or exceed, at all times, all applicable security standards developed by the Payment Card Industry Data Security Standards ("**PCI DSS**") council, or its successor, and other regulations and industry standards applicable to the protection of customer privacy and credit card information, including but not limited to the Fair and Accurate Credit Transaction Act ("**FACTA**") and all other successor or additional laws, and all other data security requirements Franchisor may prescribe.

6.8. Maintenance of Drugstore Premises. Franchisee shall comply with all terms of the lease or sublease of the Drugstore Location and use its best efforts to maintain a good and positive working relationship with the landlord of the Drugstore Location and with neighboring tenants, and shall refrain from any activity which could jeopardize Franchisee's right to occupy the Drugstore Location.

6.8.1. Franchisee shall maintain all equipment, fixtures, leasehold improvements, equipment, supplies and other tangible property located on the premises of the Drugstore Location or used to operate the Drugstore, and all of the products offered for sale at the Drugstore, in good, safe and clean condition and repair and in a manner that ensures employee and consumer safety and that complies with Franchisor's Standards. Franchisee shall take all necessary and appropriate measures to avoid an unsatisfactory safety, sanitation or health rating at any time from any governmental agency or authority, and ensure that any conditions or practices disapproved by any such agency or authority are promptly corrected.

6.8.2. If any deficiencies related to the Drugstore are identified, Franchisee agrees to correct such deficiency within a reasonable time as Franchisor may designate in writing. If Franchisee fails to correct such deficiencies in a manner satisfactory to Franchisor, Franchisor

shall have the right, but not the obligation, to enter the Drugstore Location, without being guilty of trespass, and take such action as is necessary to correct such deficiency and Franchisee shall reimburse Franchisor its reasonable costs and expenses in connection therewith upon demand.

6.9. Management and Staffing. During the Term of this Agreement, except as otherwise approved in writing by Franchisor, Franchisee shall have appointed a Manager who shall devote full time and best efforts to the management and operation of the Drugstore. Franchisee shall also maintain a competent, conscientious, substance-free, trained staff and shall take steps necessary to ensure that its employees promote customer and employee satisfaction; preserve good customer relations; render competent, prompt, courteous, and knowledgeable service; and meet such minimum Standards (including, without limitation, dress codes) as Franchisor may establish from time to time in the Franchise Handbook. Franchisee and its employees shall conduct themselves in a manner that will not detract from the name and goodwill of Franchisor. Franchisee shall be solely responsible for all employment decisions and functions, including, without limitation, those related to hiring, firing, training, wage and hour requirements, insurance and worker's compensation, record keeping, supervision, and discipline of employees.

6.9.1. Franchisee shall at all times staff the Drugstore with such number of employees and operate the Drugstore diligently so as to promote customer and employee satisfaction, promote the sale of product and services which are offered for sale from the Drugstore and maintain a competitive image and pricing policy for the Drugstore.

6.9.2. Franchisee must employ a licensed pharmacist at all times and shall be solely responsible for the practice of pharmacy in the Drugstore, including, without limitation compliance with all laws, regulations and rules applicable to the pharmacy profession.

6.10. Technology. All computer programs and systems used in the operation of the Drugstore, including any pharmacy management computer system, must be compatible with the requirements, Standards and specifications set forth in the Franchise Handbook.

6.10.1. Franchisor may establish and maintain, or contract with third parties to provide, such computer software programs, systems and databases as Franchisor deems advisable from time to time, which may include software programs to assist in accounting, pharmacy automation, customer service, marketing or management functions of the Drugstore, in the form and configuration determined by Franchisor in its sole discretion (including all related hardware, "**Computer Programs**"). Franchisee shall purchase, license, install and use, at its sole expense, any and all such Computer Programs required by Franchisor from time to time for use in the operation of the Drugstore, including point-of-sale, pharmacy management systems, performance information management systems and other computer programs

and systems. Franchisee shall execute the required form of software license agreement for such Computer Programs, which may require Franchisee to pay licensing, support and maintenance fees to Franchisor, its Affiliate or a third party and to obtain upgrades and modifications to such Computer Programs from Franchisor, its Affiliates or a third party at Franchisee's expense and Franchisee must permit Franchisor to access and retrieve electronically any information stored in such Computer Programs.

6.10.2. Franchisor also may make available to Franchisee various automation machinery, computer hardware and software for use in the Drugstore, which Franchisee may elect to purchase. If Franchisee elects to use any optional computer hardware and software that Franchisor makes available, Franchisee must obtain a license to install, use, maintain and upgrade the computer hardware and software at its own expense.

6.11. Notification of Claims. Franchisee shall immediately notify Franchisor in writing of the commencement of any action, suit, or proceeding involving the Drugstore, or of the issuance of any order, writ, injunction, award, or decree of any court, tribunal, agency, or other governmental instrumentality, which may adversely affect the operation or financial condition of the Drugstore.

7. **PROPRIETARY MARKS**

7.1. Franchisor's Representations. Franchisor represents that it will take all steps reasonably necessary to preserve and protect the validity of the Proprietary Marks and Franchisor's right to use and to license others to use the Proprietary Marks.

7.2. Franchisee's Use of the Proprietary Marks. With respect to Franchisee's use of the Proprietary Marks pursuant to this Agreement, Franchisee agrees that:

7.2.1. Franchisee shall use only the Proprietary Marks designated by Franchisor, and shall use them only in the manner authorized and permitted by Franchisor;

7.2.2. Franchisee shall use the Proprietary Marks only for the operation of the Drugstore or in advertising for the Drugstore;

7.2.3. Unless otherwise authorized or required by Franchisor, Franchisee shall operate and advertise the Drugstore under the name "HEALTH MART," with only an appropriate prefix identifying Franchisee as the Drugstore's independent owner operating under a franchise from Franchisor. If required by applicable law, Franchisee shall file certificates of assumed name (e.g., a "d/b/a") with state and/or local agencies. Franchisee shall not use the Proprietary Marks as part of its formal corporate or other legal name unless use is required by applicable law and Franchisee first notifies Franchisor in writing of the requirement under applicable law.

7.2.4. Franchisee shall follow Franchisor's prescribed format for identifying itself as the owner of the Drugstore under a license from Franchisor in conjunction with any use of the Proprietary Marks, including, without limitation, the use thereof on leases, invoices, order forms, receipts, and business stationery, as well as such other uses as Franchisor may designate or approve;

7.2.5. Franchisee's right to use the Proprietary Marks is limited to the uses authorized under this Agreement, and any unauthorized use thereof shall constitute an infringement of Franchisor's rights;

7.2.6. Franchisee shall not use the Proprietary Marks to incur any obligation or indebtedness on behalf of Franchisor;

7.2.7. Franchisee shall not register, attempt to register, obtain any ownership in, or otherwise utilize any Website, domain name, URL, Internet presence or other electronic communications portal which contains, incorporates, or consists of the Proprietary Marks, or any of them, without Franchisor's express written consent, which may be withheld for any or no reason. In the event that Franchisee violates this Section 7.2.7, Franchisee hereby agrees that any such Website, domain name, URL, Internet presence or other electronic communications portal, including any copyrights therein, shall be deemed to be property of Franchisor and Franchisee shall execute any documents or instruments necessary to transfer ownership to Franchisor, without compensation. Such rights are in addition to any rights Franchisor may have under Section 14 of this Agreement. Franchisor may condition approval of Franchisee's use of any such Website, domain name, URL, Internet presence or other electronic communications portal on the transfer of any and all ownership rights therein to Franchisor, including any copyrights therein.

7.2.8. Franchisee shall execute any documents deemed necessary or useful by Franchisor to obtain protection for the Proprietary Marks or to maintain their validity and enforceability; and

7.2.9. Franchisee shall promptly notify Franchisor of: (a) any suspected unauthorized use of the Proprietary Marks, (b) any challenge to the validity of the Proprietary Marks, (c) any challenge to Franchisor's ownership of or right to use and license others to use such Proprietary Marks, and (d) Franchisee's right to use the Proprietary Marks. Franchisee acknowledges that Franchisor has the right to direct and control any administrative proceeding or litigation involving the Proprietary Marks, including any settlement thereof. Franchisor has the right, but not the obligation, to take action against uses by others that may constitute infringement of the Proprietary Marks. Franchisor (and not Franchisee) shall defend Franchisee against any third-party claim, suit, or demand arising out of Franchisee's use of the Proprietary Marks. If Franchisor, in its sole discretion, determines that Franchisee has used the Proprietary Marks in accordance with this Agreement, the cost of such defense, including the cost of

any judgment or settlement, shall be borne by Franchisor. If Franchisor, in its sole discretion, determines that Franchisee has not used the Proprietary Marks in accordance with this Agreement, the cost of such defense, including the cost of any judgment or settlement, shall be borne by Franchisee. In the event of any litigation relating to Franchisee's use of the Proprietary Marks, Franchisee shall execute any and all documents and do such acts as may, in the opinion of Franchisor, be necessary or useful to carry out such defense or prosecution, including, without limitation, becoming a nominal party to any legal action. Except to the extent that such litigation is the result of Franchisee's use of the Proprietary Marks in a manner inconsistent with the terms of this Agreement, Franchisor agrees to reimburse Franchisee for its out-of-pocket costs in performing such acts. For purposes of this Section 7.2.9, the term "**Proprietary Marks**" also shall include any materials for which the Franchisor has a registered copyright or otherwise has claimed copyrights.

7.3. Franchisee's Agreements Regarding the Proprietary Marks. Franchisee expressly understands and acknowledges that:

7.3.1. The Proprietary Marks are valid and serve to identify the System and those who are authorized to operate under the System;

7.3.2. During the Term of this Agreement and after its termination, Franchisee shall not directly or indirectly contest the validity of Franchisor's ownership of, or Franchisor's right to use and to license others to use, the Proprietary Marks;

7.3.3. Franchisee's use of the Proprietary Marks pursuant to this Agreement does not give Franchisee any ownership interest or other interest in or to the Proprietary Marks;

7.3.4. Any and all goodwill arising from Franchisee's use of the Proprietary Marks shall inure solely and exclusively to the benefit of Franchisor, and upon termination of this Agreement, no monetary amount shall be attributable to any goodwill associated with Franchisee's use of the System or the Proprietary Marks;

7.3.5. The right to use the Proprietary Marks granted hereunder to Franchisee is nonexclusive, and Franchisor has and retains the rights, among others: (a) to use the Proprietary Marks itself in connection with marketing, promoting and selling products and services; (b) to grant other licenses for the Proprietary Marks; and (c) to develop and establish other systems using the Proprietary Marks, similar proprietary marks, or any other proprietary marks, and to grant licenses thereto without providing any rights therein to Franchisee; and

7.3.6. Franchisor reserves the right to substitute or add different proprietary marks for use in identifying the System and the businesses operating thereunder.

If Franchisor, in its sole discretion, determines that substitution or addition of different marks as Proprietary Marks will be beneficial to the System. Franchisee shall implement promptly any such substitution or addition of new Proprietary Marks. Franchisee shall bear the costs of conforming to Franchisor's new or substituted Proprietary Marks.

8. FRANCHISE HANDBOOK

8.1. Access and Adherence to the Franchise Handbook. In order to protect the reputation and goodwill of Franchisor and to maintain high standards of operation under the System, Franchisee shall operate the Drugstore in strict accordance with the Standards, methods, policies, and procedures specified by Franchisor in the Franchise Handbook and otherwise in writing, including on the My Health Mart Web Portal, including but not limited to meeting the plan-based minimum performance criteria set by third-party public or private-party payors. Franchisee will receive unique security credentials enabling Franchisee to access Franchisor's private intranet communications system where, among other things, Franchisee will have access to the Franchise Handbook. Franchisee hereby agrees to maintain the secrecy of any security credentials given to Franchisee and ensure that Franchisee's Managers and employees who are authorized to have their own security credentials observe the same terms and conditions as set forth herein.

8.2. Franchise Handbook As Confidential Information. Franchisee shall treat the contents of the Franchise Handbook as Franchisor's Confidential Information and use all reasonable efforts to ensure that the contents remain secret and confidential. Franchisee shall not copy, duplicate, record, or otherwise reproduce or share the foregoing materials, in whole or in part, or otherwise make them available to any unauthorized person. The Franchise Handbook shall remain the sole property of Franchisor. Franchisee agrees not to (a) forward the Franchise Handbook to any unauthorized person; (b) share its security credentials or the contents of the Franchise Handbook with any unauthorized person; or (c) make any electronic or physical copies of the Franchise Handbook except to the limited extent required to efficiently operate the Drugstore and on the condition that the recipient observe the same duties of confidentiality as apply to Franchisee. Upon request from Franchisor, Franchisee must immediately and permanently delete or destroy any extraneous or superseded copies of the Franchise Handbook (including electronic copies) in accordance with Franchisor's instructions. Any violation of the duties of confidentiality by any third party with whom Franchisee is permitted to share access to the Confidential Information shall be deemed to be a violation of this Agreement by Franchisee.

8.3. Revisions to Franchise Handbook. Franchisor may from time to time revise the contents of the Franchise Handbook and Franchisee expressly agrees to comply with each new or changed standard within a reasonable period of time (not to exceed thirty (30) days) specified by Franchisor.

8.4. Current Version of Franchise Handbook Controls. If portions of the Franchise Handbook are furnished in hard-copy written format, Franchisee shall ensure that its copy of the Franchise Handbook is kept current. In the event of any dispute as to the contents of the Franchise Handbook, the terms of the master Franchise Handbook that is digitally maintained or otherwise by Franchisor shall be controlling.

9. CONFIDENTIAL INFORMATION

9.1. Nondisclosure of Confidential Information. Franchisee shall not, during the Term of this Agreement or thereafter, communicate, divulge, or use for the benefit of any other person or legal entity any Confidential Information which may be communicated to Franchisee by Franchisor or of which Franchisee may be apprised by virtue of Franchisee's operation under the terms of this Agreement. In addition, Franchisee shall not use the Confidential Information in any business or capacity other than the operation of the Drugstore in accordance with this Agreement. Franchisee may divulge Confidential Information only to those of its employees who must have access to it in order to operate the Drugstore.

9.2. Confidentiality Restrictions Extend to Franchisee's Personnel. Franchisee represents and warrants that Franchisee and its employees, agents, contractors and any other personnel having access to any Confidential Information of Franchisor, will maintain the confidentiality and secrecy of any Confidential Information that is shared with them and shall be informed of the restrictions against disclosure, use and reproduction of material containing Confidential Information. A violation of the duties of confidentiality by any third party with whom Franchisee is permitted to share Confidential Information shall be deemed to be a violation of this Agreement by Franchisee.

9.3. System Improvements. Franchisee shall notify Franchisor in writing of any change, modification, amendment, or improvement in the System which Franchisee proposes to make ("**Improvement**"), and shall provide to Franchisor such information as Franchisor requests regarding the proposed Improvement. No such Improvement shall be implemented or made without Franchisor's express prior written consent. Franchisee acknowledges and agrees that Franchisor shall have the right, in its discretion, to incorporate the proposed Improvement into the System. Franchisee further agrees that any such Improvement shall become the sole property of Franchisor, and Franchisor shall be the sole owner of all related patents, copyrights, trade secrets and other intellectual property rights. Franchisee and its owners agree to and hereby assign to Franchisor, without compensation, all right, title, and interest therein and waive and/or release all rights of restraint and moral rights therein and thereto. Franchisee further acknowledges and agrees to execute any such documentation, from time to time, as may be required by Franchisor to give effect to this Section. In the event the foregoing provisions of this Section 9.3 are found to be invalid or unenforceable, Franchisee and its Owners hereby grant to Franchisor a worldwide, perpetual, non-exclusive, fully-paid

license for any and all types of use and for an unlimited number of copies, including the right to modify, create derivative works, distribute, sell, transfer, register, encumber, license, rent, loan, lend or lease, use, promote, reproduce and display, in any and all types of media, to use and sublicense the use of the Improvements to the extent such use or sublicense would, absent this agreement, directly or indirectly infringe their rights therein. Franchisee further agrees: (i) to assist Franchisor in, and to execute all necessary documentation for, obtaining and enforcing such rights and (ii) to obtain from any and all of Franchisee's employees and third-party contractors assignments and agreements similar to those set forth herein, in a form specified by or acceptable to Franchisor.

10. ACCOUNTING AND RECORDS

10.1. Recordation and Reporting of Operating Results. All gross revenues, sales tax, and charges collected on behalf of third parties shall be recorded by Franchisee in accordance with applicable laws and the procedures as may be prescribed in the Franchise Handbook, on the computer system, or as Franchisor may specify. Franchisee shall report financial operating results of the Drugstore in the form and manner as Franchisor may require from time to time.

10.2. Books and Records. If requested by Franchisor, Franchisee will prepare, and shall preserve for at least four (4) years from the dates of their preparation, complete and accurate books, records, and accounts in accordance with generally accepted accounting principles and in the form and manner prescribed by Franchisor from time to time in the Franchise Handbook or otherwise in writing.

10.3. Reports. If requested by Franchisor, Franchisee will prepare and submit to Franchisor the following reports, financial statements, and other data:

10.3.1. A report accurately reflecting all gross revenues, accounts payable, accounts receivable, and asset utilization during the preceding calendar month;

10.3.2. Financial statements represented by Franchisee to be true and correct, prepared in accordance with generally accepted accounting principles and showing the results of operations of the Drugstore during the preceding fiscal year;

10.3.3. Copies of Franchisee's state sales tax returns, and the portions of Franchisee's federal and state income tax returns that reflect the operations of the Drugstore; and

10.3.4. Such other forms, reports, records, information, and data as Franchisor may request.

10.3.5. Franchisor shall not communicate or divulge to any other person or legal entity, any report, financial statement, or other data submitted to Franchisor pursuant to Section 10.2 and 10.3 of this Agreement, unless

Franchisor does so: (a) without identifying that such report financial statement, or other data relates to Franchisee or the Drugstore, (b) to the extent required by law, or (c) otherwise with Franchisee's written permission. However, Franchisee acknowledges and agrees that Franchisor may disclose any report, financial statement, or other data submitted to Franchisor to any of Franchisor's Affiliates.

11. ADVERTISING AND PROMOTION

11.1. Grand Opening. Franchisor may provide resources to Franchisee for the implementation of an opening advertising and marketing program and recommends that Franchisee conduct a grand opening, at Franchisee's expense, to publicize the opening or re-branding of Franchisee's Drugstore as a HEALTH MART® Drugstore. Grand opening advertising and marketing activities are designed to promote the opening of the Drugstore under the Proprietary Marks and to familiarize consumers in the general market area of the Drugstore with the HEALTH MART® brand, product line and services.

11.2. Advertising Plan. Franchisor may in the future establish a national advertising plan to maximize general public recognition, acceptance, and use of the System (the "Advertising Plan"). Any such Advertising Plan shall be maintained and administered by Franchisor and Franchisor shall have the exclusive rights to direct the Advertising Plan, including, without limitation, the following:

11.2.1. Franchisor may, in its discretion, periodically allocate to the Advertising Plan a portion of the Monthly Fees received from franchisees and Franchisor or its Affiliates also may make contributions to the Advertising Plan in their sole discretion (including as to the amount, frequency and timing of such contributions). Franchisor does not represent that it or its Affiliates will contribute any minimum amount of funds to the Advertising Plan during any time period.

11.2.2. Franchisor shall have the discretion to spend all Advertising Plan revenue for advertising, marketing and/or promotional purposes during the taxable year within which the revenue is received or to carry-forward unspent revenue to future years.

11.2.3. Franchisor shall have sole discretion over the concepts, materials, and media used in any and all Advertising Plan programs and the placement and allocation thereof. Franchisee agrees and acknowledges that any Advertising Plan established by Franchisor will be intended to maximize general public recognition, acceptance, and use of the System; and that Franchisor will not be obligated, in administering the Advertising Plan, to make expenditures for or on behalf of Franchisee, or to ensure that any particular franchisee benefits directly or pro rata from expenditures by the Advertising Plan.

11.2.4. Any Advertising Plan funds shall be used exclusively to maintain, administer, direct, conduct, and

prepare advertising, marketing, merchandizing, public relations, and/or promotional programs and materials, and any other activities which Franchisor believes will enhance the System, including, among other things, the cost of preparing and conducting media advertising campaigns, including print, radio and television advertising; Internet advertising; direct mail advertising; marketing surveys; employing advertising and/or public relations agencies to assist therein; purchasing promotional items; and providing promotional and other marketing materials and services to Drugstores operating under the System. In addition, Advertising Plan funds may be used to reimburse Franchisor or its Affiliates for the actual internal expenses of administering the Advertising Plan.

11.2.5. Franchisor shall have no obligation to (i) prepare financial reports of the revenue and expenditures of the Advertising Plan, or (ii) keep the Advertising Plan revenue segregated in a separate bank account apart from Franchisor's general funds.

11.2.6. Neither the establishment nor the operation of an Advertising Plan by Franchisor shall be deemed to impose on Franchisor any fiduciary duties or to create between Franchisor and Franchisee any fiduciary relationship.

11.3. Advertising Standards. All advertising and promotional activities that Franchisee chooses to engage in during the Term of this Agreement and all advertising and marketing materials used by Franchisee in any format shall conform to all applicable laws and to the Standards and requirements that Franchisor may specify in the Franchise Handbook or otherwise in writing.

11.3.1. At any time, including prior to any use or dissemination thereof, Franchisor may require that Franchisee submit to Franchisor for Franchisor's approval any advertising, marketing and promotional materials that Franchisee uses or proposes to use, including, without limitation, any and all materials that Franchisee uses as part of its grand opening advertising activities or thereafter during the Term of this Agreement, but excluding materials that Franchisor prepares or furnishes to Franchisee or that Franchisees purchases from Franchisor's Marketing Hub. Advertising furnished by Franchisor or its designee may contain a suggested retail price for any product or service to be sold at or from the Drugstore.

11.3.2. Franchisor shall have thirty (30) days after receiving Franchisee's advertising, marketing and promotional materials in which to review the materials. Franchisor's failure to notify Franchisee within thirty (30) days after receiving Franchisee's materials that Franchisor disapproves Franchisee's use of the materials, shall signify Franchisor's approval and Franchisee may use the materials in the format submitted to Franchisor. Franchisor may withdraw its approval at any time. Franchisee may not use any advertising, marketing or promotional materials that Franchisor has disapproved.

11.3.3. This Section applies to all advertising, marketing and promotional materials, regardless of the format or media, including those appearing in traditional media and on social media Websites (Twitter, Facebook, YouTube, and comparable consumer-generated media Websites), in displays appearing in Franchisee's Drugstore, and in other printed or electronic formats including, without limitation, business forms, stationery, cards, and Internet Websites.

11.4. Advertising Committee. Franchisor shall have the right, in its discretion, to establish a franchisee advertising committee to provide input to Franchisor regarding any or all advertising activities, as determined by Franchisor. Any such committee shall act in an advisory capacity only and shall be formed, organized, and dissolved at the discretion of Franchisor.

12. INSURANCE

12.1. Coverage Requirements. Franchisee shall procure, before the commencement of any operations under this Agreement, and shall maintain in full force and effect at all times during the Term of this Agreement, at Franchisee's expense, insurance policies protecting Franchisee, Franchisor and Franchisor's Affiliates (including their respective officers, directors, shareholders, agents, and employees) against any demand or claim with respect to bodily injury, personal injury, death, or property damage, or any loss, liability, or expense whatsoever arising or occurring upon or in connection with the Drugstore and the Drugstore Location. Such policy or policies shall be written by a carrier with a minimum A.M. Best Rating of A- VII and shall provide at least the types and minimum amounts of coverage specified in Exhibit C, as modified by Franchisor in accordance with Section 12.2. Franchisee is solely responsible for investigating if the types of coverage and minimum coverage amounts required by this Agreement are adequate to cover all risks arising from the operation of the Drugstore and to purchase additional insurance as Franchisee may determine is necessary or advisable based on its own business interests.

12.1.1. Franchisee may satisfy the minimum coverage requirements specified in this Agreement through any combination of primary and umbrella/excess insurance.

12.1.2. All insurance policies except Workers' Compensation and Employer's Liability shall name Franchisor and its Affiliates (including McKesson) as an additional insured. Additionally, Franchisee shall include a "separation of insured" provision or "insured vs. insured carve-back" for additional insureds under all required insurance except Workers Compensation and Employers' Liability with no cross liability or cross suits exclusions.

12.1.3. Franchisee shall cause each insurer of coverage required by this Agreement to endorse each

insurance policy to waive its subrogation rights against Franchisor and its Affiliates.

12.1.4. No required insurance coverage shall be limited or affected by Franchisee's breach of any policy conditions or provisions.

12.1.5. If any required insurance policy is a "claims-made" policy, Franchisee shall keep the policy in force without material alteration for no less than six (6) years immediately following termination of this Agreement. Alternatively, Franchisee shall purchase a six year "tail" policy with prior acts coverage including the same or broader coverage for any claim arising during the Term of this Agreement.

12.2. Changes in Required Coverage. Franchisor may modify the minimum coverage amounts or require additional types of insurance to cover new areas of risk based on the recent experience of other franchisees or as Franchisor reasonably determines, in Franchisor's sole discretion, is appropriate based on prevailing industry standards. Franchisor shall communicate any changes by written notice to Franchisee or through updates to the Franchise Handbook. Franchisee shall have no less than sixty (60) days following receipt of Franchisor's notice to purchase additional insurance to comply with any new coverage requirements.

12.3. No Limitation of Other Obligations. Franchisee's insurance policies shall be independent of any insurance, self-insurance or captive insurance maintained by Franchisor or its Affiliates and Franchisee's obligation to obtain and maintain the policy or policies in the amounts specified in the Franchise Handbook shall not be limited in any way by reason of any insurance which may be maintained by Franchisor. Franchisee's liability shall not be limited to the amount recoverable by insurance and Franchisee's performance of its obligation to maintain insurance shall not relieve it of liability under the indemnity provisions set forth in Section 19.2 of this Agreement. The Commercial General Liability and Business Automobile policies listed in Exhibit C will contain a contractual coverage endorsement insuring Franchisee's performance under such indemnity.

12.4. Evidence of Insurance. On or before the Effective Date of this Agreement, and thereafter at least annually during the Term of this Agreement, within thirty (30) days following Franchisor's written request, Franchisee shall deliver to Franchisor certificates of insurance from the insurance companies underwriting all policies other than Workers Compensation and Employers Liability verifying that Franchisee has in force the proper types and minimum amounts of coverage required by this Agreement. All certificates of insurance shall expressly state that Franchisor shall be notified in writing no less than thirty (30) days' before any material alteration to or cancellation of the coverages evidenced by the most recent certificates of insurance. In addition, if Franchisor requests, Franchisee agrees to deliver to Franchisor a copy of the required insurance policy or policies. Franchisee's failure to provide certificates of insurance to Franchisor upon written

request will not operate to release Franchisee in any manner from any liability arising under this Agreement.

13. **TRANSFER OF INTEREST**

13.1. By Franchisor. Franchisor shall have the absolute right, without limitation, directly or indirectly, voluntarily or by operation of law to sell, transfer or assign its rights under this Agreement or in or to the System or the Proprietary Marks to any person or legal entity of its choosing without prior notice to, or consent of, Franchisee, and the sale, transfer or assignment shall constitute a novation of this Agreement whereby the purchaser shall assume, and be solely responsible for, all obligations of Franchisor under this Agreement from the date of such sale, transfer or assignment. Upon Franchisor's sale, transfer or assignment and purchaser's assumption of Franchisor's obligations, Franchisor shall have no further obligation to Franchisee.

13.2. By Franchisee. Franchisee understands and agrees that the franchise rights awarded by this Agreement are personal to Franchisee and are awarded in reliance upon, among other considerations, the individual or collective character, skill, aptitude, attitude, experience, business ability and financial condition and capacity of Franchisee and, if Franchisee is a Business Entity, that of its officers, directors, shareholders, managers, members, trustees, partners and/or guarantors. Except as provided in Section 13.3 with respect to Qualified Transfers, Franchisee shall not, without Franchisor's prior written consent, directly or indirectly, attempt or complete an Event of Transfer either voluntarily or by operation of law except in accordance with this Agreement. Franchisor agrees not to unreasonably withhold its consent to a proposed Event of Transfer if Franchisee satisfies the conditions set forth in this Section 13.2. Franchisee understands and agrees that Franchisor's consent to an Event of Transfer is not a representation of the fairness of the terms of any contract between Franchisee and a proposed transferee, a guarantee of the Drugstore's or proposed transferee's prospects for success, or a waiver of any claims that Franchisor or Franchisor's Affiliates may have against Franchisee or any personal guarantor. At Franchisor's discretion, Franchisee must satisfy any or all of the following conditions in order to obtain Franchisor's consent to the proposed Event of Transfer. Any attempt to complete an Event of Transfer which fails to comply with the requirements of this Agreement shall be null and void and constitute a material breach of this Agreement.

13.2.1. The proposed transferee (and, if the proposed transferee is a Business Entity, its owners) must demonstrate to Franchisor's satisfaction that it or they meet Franchisor's educational, managerial, financial and business Standards; possess good moral character, business reputation, and credit rating; have the aptitude and ability to operate the Drugstore in compliance with applicable laws (as they may demonstrate through prior related business experience or otherwise), and have adequate financial resources and capital inclusive of its obligations to Franchisee to operate the Drugstore in a fiscally responsible manner.

13.2.2. All of Franchisee's accrued monetary obligations and all other outstanding obligations to Franchisor and its Affiliates must have been satisfied.

13.2.3. Franchisee may not be in default of any provision of this Agreement, any amendment of or successor to this Agreement, or any other agreement between Franchisee and Franchisor or its Affiliates or with Franchisee's landlord, mortgagee, bank, other lenders, employees, suppliers and other third parties.

13.2.4. Franchisee and any Individual transferor shall have executed a general release, in a form satisfactory to Franchisor, of any and all claims against Franchisor and its Affiliates, and their respective officers, directors, shareholders, members, agents, and employees.

13.2.5. The proposed transferee (and, if the proposed transferee is a Business Entity, each of its owners) must agree in writing to assume and discharge all of Franchisee's obligations under this Agreement. Alternatively, Franchisor may, at its option, require the proposed transferee to execute Franchisor's then-current form of franchise agreement. Each of the owners of a proposed transferee that is a Business Entity must execute Franchisor's then-current form of Owner's Undertakings and agree to be personally liable to Franchisor for the obligations set forth therein.

13.2.6. The proposed transferee, at its expense, must commit to refurbish the premises of the Drugstore Location to conform to Franchisor's then-current Standards and specifications, and complete the refurbishing and other requirements within the time specified by Franchisor.

13.2.7. Franchisee and its personal guarantors shall remain liable for Franchisee's obligations to Franchisor arising before the effective date of the Event of Transfer and execute any and all instruments reasonably requested by Franchisor to evidence such liability. Franchisor's consent to an Event of Transfer shall not operate to release Franchisee's owners from obligations arising before the effective date of the Event of Transfer pursuant to the terms of any Owner's Undertakings.

13.2.8. The proposed transferee's manager must complete any mandatory training programs then in effect for managers, at the proposed transferee's expense, upon such terms and conditions as Franchisor may reasonably require.

13.3. Qualified Transfers. A "**Qualified Transfer**" is any transaction in which an individual Franchisee proposes to transfer all of his or her rights under this Agreement to a newly-formed Business Entity that is wholly owned by the individual Franchisee. Franchisee must notify Franchisor immediately of any proposed Qualified Transfer, must provide Franchisor with the written Owner's Undertakings required by this Agreement, and the newly-formed Business Entity must agree in writing to assume and discharge all of Franchisee's obligations under this Agreement and deliver to Franchisor any

and all additional documents which this Agreement requires a Business Entity franchisee to provide to Franchisor.

13.4. Grant of Security Interests. Without Franchisor's prior written consent Franchisee shall not grant a security interest in the Drugstore or in any of the assets of the Drugstore unless the secured party agrees that in the event of any default by Franchisee under any documents related to the security interest, Franchisor shall have the right and option (but not the obligation) to be substituted as obligor to the secured party and to cure any default of Franchisee, and, in the event Franchisor exercises such option, any acceleration of indebtedness due to Franchisee's default shall be void. Franchisee agrees to fully indemnify Franchisor for any and all costs or damages including, without limitation, attorneys' fees, other professional or expert fees, and costs, incurred by Franchisor in curing any default of Franchisee. In no event shall Franchisee agree to grant any security interest or other lien or encumbrance in the System, the Proprietary Marks or any other Confidential Information of Franchisor. Any attempt by Franchisee to grant a security interest in the System, the Proprietary Marks or any other Confidential Information of Franchisor shall constitute a breach of this Agreement and shall be deemed to be void and of no force and effect. Franchisee agrees fully to indemnify Franchisor for any costs or damages including, without limitation, attorneys' fees, other professional or expert fees, and costs, incurred by Franchisor in bringing any action to invalidate or attempt to invalidate any security interest or other lien or encumbrance purported to have been granted in the System, the Proprietary Marks or any other Confidential Information of Franchisor.

13.5. Death or Permanent Incapacity. Upon the death or Permanent Incapacity of any individual Franchisee or any Owner of a Business Entity Franchisee that results in a Change of Control:

13.5.1. The executor, administrator, or personal representative of the deceased or incapacitated person shall transfer his or her interest to a third party approved by Franchisor within ninety (90) days after the date of death or Permanent Incapacity subject to the conditions applicable to an Event of Transfer generally. In the case of transfer by devise or inheritance, if the heirs or beneficiaries of any such person are unable to meet the conditions for obtaining Franchisor's consent to the Event of Transfer, the executor, administrator, or personal representative of the decedent may (i) transfer the decedent's interest to another party approved by Franchisor within a reasonable time, which disposition shall be subject to the conditions applicable to an Event of Transfer generally, or (ii) terminate this Agreement upon sixty (60) days' written notice to Franchisor.

13.5.2. Until the executor, administrator, or personal representative can complete any required Event of Transfer, Franchisor may agree to manage the Drugstore for the account of Franchisee to ensure that the operating Standards of the System are maintained. Any such management services shall be provided pursuant to a mutually agreed upon

management services agreement which shall (among other things) provide for payment to Franchisor of a reasonable management fee and reimbursement for all of its direct costs and expenses in rendering management services. The parties recognize that Franchisor's right to manage the Drugstore is intended to facilitate an orderly transition of ownership with minimal disruption to the Drugstore's continuous operation. However, nothing in this Agreement obligates Franchisor to manage the Drugstore for any period of time regardless of the consequences of its decision or the ability of the executor, administrator, or personal representative to obtain Franchisor's consent to a required Event of Transfer. If Franchisor chooses to manage the Drugstore, Franchisor will only do so for a maximum period of ninety (90) days unless, by mutual agreement of Franchisor and the executor, administrator, or personal representative of the deceased or incapacitated person, the parties extend the management period, but in no event shall the management period be longer than one year from the date of death or Permanent Incapacity. During the time, if any, that Franchisor manages the Drugstore, Franchisor shall periodically discuss the status of the Drugstore's operations and financial results with the executor, administrator, or personal representative and provide suitable current information about the Drugstore's performance as the executor, administrator, or personal representative may reasonably require.

13.6. No Waiver. Franchisor's consent to an Event of Transfer shall not constitute a waiver of any claims that it may have against the transferring party, nor shall it be deemed a waiver of Franchisor's right to demand full compliance with any of the terms of this Agreement.

14. TERMINATION

14.1. Automatic Termination. Franchisee shall be deemed to be in default under this Agreement, and all rights granted to Franchisee herein shall automatically terminate, without notice to Franchisee, (i) if Franchisee shall become insolvent (either by virtue of its having an excess of liabilities over assets or its inability to meet its obligations as they become due), or make a general assignment for the benefit of creditors; (ii) if a petition in bankruptcy is filed by Franchisee or such a petition is filed against and not opposed by Franchisee; (iii) if Franchisee is adjudicated bankrupt or insolvent; (iv) if a bill in equity or other proceeding for the appointment of a receiver of Franchisee or other custodian for Franchisee's business or assets is filed and consented to by Franchisee; (v) if a receiver or other custodian (permanent or temporary) of Franchisee's assets or property, or any part thereof, is appointed by any court of competent jurisdiction; (vi) if proceedings for a composition with creditors under any state or federal law should be instituted by or against Franchisee; (vii) if a final judgment remains unsatisfied or of record for thirty (30) days or longer (unless supersedeas bond is filed); (viii) if Franchisee is dissolved; (ix) if execution is levied against Franchisee's business or property; (x) if suit to foreclose any lien or mortgage against the Drugstore Location or equipment is instituted against Franchisee and not dismissed within thirty (30) days; or (xi) if

the real or personal property of the Drugstore shall be sold after levy thereupon by any sheriff, marshal, or constable.

14.2. Termination by Franchisor on Notice Without Cure. Upon the occurrence of any of the following events of default, Franchisor may, at its option, terminate this Agreement and all rights granted hereunder, without affording Franchisee any opportunity to cure the default, effective immediately upon receipt of notice by Franchisee:

14.2.1. If Franchisee or Franchisee's Manager fails to complete any required training program(s) described in Section 5 hereof to Franchisor's satisfaction;

14.2.2. If Franchisee fails to meet the requirements set forth in Section 6.2;

14.2.3. If Franchisee at any time ceases to operate or otherwise abandons the Drugstore, or loses the right to occupy the Drugstore Location, or otherwise forfeits the right to do or transact business in the jurisdiction where the Drugstore is located;

14.2.4. If Franchisee or Franchisee's Manager ceases to have any required license to operate the Drugstore under the laws of the jurisdiction in which the Drugstore is located;

14.2.5. If Franchisee's right to dispense controlled substances is either suspended or revoked, whether or not Franchisee otherwise has the lawful right to continue operation of the Drugstore under the laws of the jurisdiction in which the Drugstore is located;

14.2.6. If Franchisee or any of Franchisee's Owners is convicted of a felony or a misdemeanor carrying a jail term (but not an infraction), a crime involving moral turpitude, or any other crime or offense that Franchisor believes is reasonably likely to have an adverse effect on the System, the Proprietary Marks, the goodwill associated therewith, or Franchisor's interest therein;

14.2.7. If, in Health Mart's sole good faith judgment, the operation of the Drugstore would result in a threat or danger to public health or safety, or may negatively impact the goodwill of Franchisor or any of Franchisor's Affiliates;

14.2.8. If any purported Event of Transfer of any direct or indirect interest in this Agreement, in Franchisee, or in all or substantially all of the assets of the Drugstore is made to any third party without Franchisor's prior written consent, contrary to the terms of Section 13 hereof;

14.2.9. If an approved Event of Transfer is not effected within the time provided following death or Permanent Incapacity, as required by Section 13.5 hereof;

14.2.10. If Franchisee fails to comply with the covenants in Section 16 hereof or fails to obtain execution

of the Owner's Undertakings attached as Exhibit D by each person who is required to execute it;

14.2.11. If, contrary to the terms of Sections 8 or 9 hereof, Franchisee discloses or divulges the contents of the Franchise Handbook or other Confidential Information;

14.2.12. If Franchisee knowingly maintains false books or records, or knowingly submits any false reports or makes a material misrepresentation to Franchisor;

14.2.13. If Franchisee misuses or makes any unauthorized use of the Proprietary Marks or any other part of the System, fails to adhere to Franchisor's guidelines regarding use and display of Franchisee's name and the Proprietary Marks, contests in any legal proceeding the validity of the Proprietary Marks or Franchisor's ownership of the Proprietary Marks, or otherwise materially impairs the goodwill associated therewith or Franchisor's rights therein;

14.2.14. If Franchisee commits a default subject to Section 14.3 hereof three (3) times or more in any twelve (12) month period, whether or not any such default is cured after notice;

14.2.15. If Franchisee is in default of any other agreement with Franchisor or any of its Affiliates;

14.2.16. If Franchisee fails to meet plan-based minimum performance criteria set by third-party public or private-party payors; or

14.2.17. If Franchisee fails to attain the Minimum Purchasing Threshold by the Threshold Deadline established by this Agreement or, thereafter, fails to maintain the Minimum Purchasing Threshold.

14.3. Termination by Franchisor on Notice with Right to Cure. Except as provided in Sections 14.1 and 14.2 of this Agreement, Franchisee shall have thirty (30) days after its receipt from Franchisor of a written notice of default within which to remedy any default under this Agreement and to provide evidence thereof to Franchisor. Franchisee may avoid termination by immediately initiating a remedy to cure such default and curing it to Franchisor's satisfaction within the thirty (30) day period, and by promptly providing proof thereof to Franchisor. If any such default is not cured within the specified time, or such longer period as applicable law may require, this Agreement shall terminate without further notice to Franchisee, effective immediately upon the expiration of the thirty (30) day period or such longer period as applicable law may require. Franchisee shall be in default pursuant to this Section 14.3 for failure substantially to comply with any of the requirements imposed by this Agreement, as it may from time to time reasonably be supplemented by the Franchise Handbook, or failure to carry out the terms of this Agreement in good faith. Such defaults include, but are not limited to, the following:

14.3.1. If Franchisee fails, refuses, or neglects promptly to pay any monies owing to Franchisor or its Affiliates when due, to fully fund any electronic funds transfers to be made under Section 4.7 hereof;

14.3.2. If Franchisee fails to maintain or observe any of the Standards or procedures prescribed by Franchisor in this Agreement or the Franchise Handbook;

14.3.3. If Franchisee fails, refuses, or neglects to obtain Franchisor's prior written approval or consent as required by this Agreement;

14.3.4. If Franchisee refuses to execute any software license agreement required to be executed pursuant to Section 6.10; or

14.3.5. If Franchisee engages in any business or markets any service or product under a name or mark which, in Franchisor's opinion, is confusingly similar to the Proprietary Marks.

14.4. Termination by Franchisor on Notice Without Cause. In addition to Franchisor's right to terminate for cause in accordance with this Section, Franchisor may terminate this Agreement without cause for any reason or no reason by giving Franchisee sixty (60) days advance written notice unless applicable law expressly forbids termination of a franchise without good cause, in which case this Section shall be of no force or effect.

14.5. Termination by Franchisee. Franchisee may terminate this Agreement by giving Franchisor sixty (60) days advance written notice. In order to exercise its termination right, (i) Franchisee must have satisfied all monetary obligations owed by Franchisee and its Affiliates to Franchisor and any of its Affiliates, and (ii) Franchisee and its Owners must have executed a general release, in a form prescribed by Franchisor, of any and all claims against Franchisor and its Affiliates, and their respective officers, directors, securities holders, agents, and employees.

15. POST-TERM OBLIGATIONS

15.1. Franchisee's Post-Term Obligations. Upon termination of this Agreement, all rights granted hereunder to Franchisee shall terminate immediately and Franchisee shall:

15.1.1. Immediately cease to, and shall not thereafter, directly or indirectly, represent to the public or hold itself out as a present or former franchisee of Franchisor.

15.1.2. Immediately and permanently cease to use, in any manner whatsoever, any Confidential Information, confidential methods, procedures, and techniques associated with the System; the Proprietary Mark "HEALTH MART" and all other Proprietary Marks. In particular, Franchisee shall cease to use, without limitation, all signs, advertising materials, Websites or Web pages, displays,

stationery, forms, products, and any other articles which display the Proprietary Marks. Franchisee agrees not to use any reproduction, counterfeit, copy, or colorable imitation of the Proprietary Marks which, in Franchisor's sole discretion, is likely to cause confusion, mistake, or deception, or which, in Franchisor's sole opinion, is likely to dilute Franchisor's rights in and to the Proprietary Marks. Franchisee further agrees not to utilize any designation of origin or description or representation which, in Franchisor's sole opinion, falsely suggests or represents an association or connection with Franchisor.

15.1.3. Immediately return any physical copies of records, correspondence, and instructions containing Confidential Information, all of which are acknowledged to be the property of Franchisor, and shall retain no copy or record of any of the foregoing, with the exception of Franchisee's copy of this Agreement, any correspondence between the parties, and any of the documents which Franchisee reasonably needs for compliance with any provision of law.

15.1.4. Take such action as may be necessary to cancel any assumed name registration or equivalent registration obtained by Franchisee which contains the mark "HEALTH MART" or any other Proprietary Marks, and furnish Franchisor with evidence satisfactory to Franchisor of compliance with this obligation within five (5) days after termination of this Agreement.

15.1.5. Immediately upon termination of this Agreement, make such modifications or alterations to the premises of the Drugstore Location as may be necessary, in Franchisor's judgment, to distinguish the appearance of the Drugstore Location from that of a Drugstore operating under the System, including such specific changes as Franchisor may reasonably request for that purpose. This includes, for example and without limitation, removing all signs and placards which identify the Drugstore as authorized to do business under the Proprietary Marks.

15.1.6. Promptly pay all sums owing to Franchisor and its Affiliates. In the event of termination for any default of Franchisee, such sums shall include all damages, costs, and expenses, including reasonable attorneys' fees, incurred by Franchisor as a result of the default.

15.2. Termination of Access to System Materials. Upon termination of this Agreement Franchisor shall immediately terminate Franchisee's access to the Franchise Handbook and to all other online databases which are restricted to current Health Mart franchisees or other authorized persons.

16. COVENANTS

16.1. Non-Competition. Franchisee specifically acknowledges that, during the Term of this Agreement, Franchisee and its employees will receive or have access to Franchisor's Confidential Information. Accordingly, Franchisee covenants that during the Term of this Agreement,

except as otherwise approved in writing by Franchisor, Franchisee shall not, directly or indirectly, for itself, or through, on behalf of, or in conjunction with any person or legal entity:

16.1.1. Divert or attempt to divert any present or prospective business or customer of any Drugstore to any Competitor, by direct or indirect inducement or otherwise, or

16.1.2. Do or perform, directly or indirectly, any other act injurious or prejudicial to the goodwill associated with the Proprietary Marks and the System; or

16.1.3. Own, maintain, operate, engage in, or have any financial or beneficial interest in (including any interest in corporations, partnerships, trusts, unincorporated associations, joint ventures or any other legal entity), advise, assist or make loans to, any Competitor located anywhere within (i) the U.S.; (ii) U.S. territories, or (iii) any other country, province, state or geographic area in which Franchisor has used, sought registration of or registered the same or similar Proprietary Marks or operates or licenses others to operate a business under the same or similar Proprietary Marks.

16.2. Undertakings of Owners and Management.

16.2.1. If Franchisee is a Business Entity, Franchisee shall cause each Owner required by Franchisor to execute the Owner's Undertakings that is attached as Exhibit D to this Franchise Agreement. Franchisee understands and agrees that this requirement applies to each person who now owns, or during the term of this Agreement acquires, an interest in the outstanding equity or voting interests of the Business Entity. By executing the Owner's Undertakings, each Owner is personally liable to Franchisor for the obligations specified in such Owner's Undertakings.

16.2.2. The following persons shall execute the Principal's Undertakings set forth in Exhibit E to this Agreement, unless Franchisor otherwise consents in writing: any of Franchisee's officers, directors or managers; any Drugstore Manager; and if Franchisee is an individual, Franchisee's spouse. By executing the Principal's Undertakings, each Principal is personally liable to Franchisor for the obligations specified in such Principal's Undertakings.

16.3. Injunctive Relief. Franchisee acknowledges that any failure to comply with the requirements of this Section will cause Franchisor irreparable injury, for which no adequate remedy at law may be available. Franchisee consents to the issuance of an order of specific performance, temporary restraining order, or preliminary or permanent injunction against violation of the covenants set forth herein without Franchisor having to post bond.

16.4. Franchisee's Representation. Franchisee represents and warrants that neither Franchisee nor any person required to sign a similar covenant pursuant to Section 16.2 is, as of the date of this Agreement, subject to any non-compete,

non-disclosure, non-circumvent, non-solicitation, confidentiality or other agreement which would restrict or limit Franchisee's or any such person's ability to participate in the ownership or operation of the Drugstore. Franchisee further represents and warrants that neither Franchisee nor any person required to sign a similar covenant pursuant to Section 16.2 will be in breach of any such non-compete, non-disclosure, non-circumvention, non-solicitation, confidentiality or other agreement as a result of entering into this Agreement or participating in the ownership or operation of the Drugstore.

16.5. Cooperation with Neighboring Pharmacies. Nothing in this Section 16 shall be deemed to prohibit Franchisee or any of Franchisee's employees from seeking assistance from, or providing assistance to, neighboring pharmacies in connection with short-term product or labor shortages.

17. BUSINESS ENTITY FRANCHISEE

If Franchisee is a Business Entity, Franchisee shall comply with the following requirements: (i) Franchisee's Governing Documents shall at all times authorize the operation of the Drugstore; (ii) copies of Franchisee's Governing Documents shall be promptly furnished to Franchisor; and (iii) Franchisee shall maintain a current list of all owners of record and all beneficial owners of any interest in Franchisee and shall furnish the list to Franchisor upon request. If Franchisee is a corporation, Franchisee shall maintain stop-transfer instructions against the transfer on its records of any equity securities; and each stock certificate of Franchisee shall have conspicuously endorsed upon its face a statement in a form satisfactory to Franchisor that it is held subject to, and that further assignment or transfer thereof is subject to, all restrictions imposed upon assignments by this Agreement.

18. TAXES AND INDEBTEDNESS

18.1. Payment of Taxes and Business Debts. Franchisee shall promptly pay when due all taxes levied or assessed, including, without limitation, unemployment and sales taxes, and all accounts and other indebtedness of every kind incurred by Franchisee in the operation of the Drugstore.

18.2. Bona Fide Disputes. In the event of any bona fide dispute as to Franchisee's liability for taxes assessed or other indebtedness, Franchisee may contest the validity or the amount of the tax or indebtedness in accordance with the procedures of the taxing authority, or applicable law, but in no event shall Franchisee permit a tax sale or seizure by levy or execution or similar writ or warrant, or attachment by a creditor, to occur against the Drugstore Location or its improvements or against any Merchandise in the Drugstore.

19. INDEPENDENT CONTRACTOR AND INDEMNIFICATION

19.1. Independent Contractor. It is understood and agreed by the parties that this Agreement does not create a

fiduciary, special or other similar relationship between them but rather is an arm's-length business relationship; that Franchisee is an independent contractor; and that nothing in this Agreement is intended to constitute either party an agent, legal representative, subsidiary, joint venturer, partner, employer, employee, or servant of the other for any purpose whatsoever.

19.1.1. During the Term of this Agreement, Franchisee shall hold itself out to the public as an independent contractor operating the Drugstore pursuant to a franchise agreement from Franchisor. Franchisee agrees to take such action as may be necessary to do so, including, without limitation, displaying a notice to the public in a conspicuous place inside and outside the Drugstore Location that states that Franchisee is the independent owner of the Drugstore operating under a license from Franchisor. Franchisor may specify the form of the notice.

19.1.2. Nothing in this Agreement authorizes Franchisee or any of its Owners to make any contract, agreement, warranty or representation on behalf of Franchisor or its Affiliates, or to incur any debt or other obligation in the name of Franchisor or its Affiliates, and Franchisor will not assume liability for, or be deemed liable under this Agreement as a result of, any such action, or for any act or omission of Franchisee or any of its Owners or any claim or judgment arising therefrom.

19.1.3. Franchisee shall exercise full and complete control over, and have full responsibility for, its contracts, daily operations, labor relations, employment practices and policies, including but not limited to recruitment, selection, hiring, disciplining, firing, compensation, work rules and schedules of its employees. Neither Franchisor nor its Affiliates exercise any direction or control over the employment policies or employment decisions of Franchisee or its Affiliates. All employees, staff or workers of Franchisee or its Affiliates are solely employees, staff or workers of Franchisee or such Affiliate and are not employees, staff or workers of Franchisor or its Affiliates. Franchisee is responsible for all hiring decisions and solely obligated for any labor claims made by any of its employees, staff or workers against Franchisee and/or Franchisor, and Franchisee agrees to indemnify and hold harmless, to the fullest extent permitted by law, Franchisor from any and all damages, losses or expenses incurred or suffered by Franchisor arising from or in connection with any labor claims that Franchisee's employees, staff or workers may bring against Franchisor. In addition, Franchisee will, and will cause its Affiliates to, ensure that all of their respective employees, staff and workers are covered under all relevant labor laws.

19.2. Indemnification. Franchisee shall, at all times, indemnify, defend and hold harmless to the fullest extent permitted by law Franchisor, its Affiliates, successors and assigns and the respective directors, officers, employees, agents and representatives of each of them (collectively, the "Indemnitees") from and against any and all Losses and Expenses incurred or suffered by them (or any one of them) in

connection with any action, suit, proceeding, claim, demand, investigation or inquiry (made or threatened and formal or informal), or any settlement (whether or not a formal proceeding or action has been instituted) which arises out of or is based upon any of the following whether or not the act, omission or event giving rise to the claim for indemnity is committed by Franchisee or Franchisee's agents, employees, Owners, or representatives, without limitation and without regard to the cause or causes of the acts, omissions, or events or the negligence (whether that negligence is sole, joint, or concurrent, and whether active or passive) or strict liability of Franchisor or any other party or parties arising in connection therewith:

A. Violation, breach, liability or asserted violation of breach of or liability under any contract, federal, state or local law, regulation, rule, order, standard or directive, or of any industry standard;

B. Libel, slander or any other form of defamation.

C. Failure to comply with, violation or breach of any warranty, representation, or obligation in this Agreement;

D. Breach of any material duty under this Agreement including, without limitation, duties pertaining to breach of any privacy, confidentiality or data security obligation in this Agreement;

E. Actual or alleged violations of a third party's intellectual property rights;

F. Claims for personal injury (including death) or damage to property;

G. Claims or liabilities relating to work status, compensation, tax, insurance or benefit matters arising out of Franchisee's arrangements with its employees or independent contractors;

H. Any other acts, errors or omissions, whether actual or alleged, willful or negligent, including, without limitation, in connection with the ownership, construction, renovation, establishment or operation of the Drugstore.

19.2.1. If any Indemnitees are or may be named as a party in any such action, Franchisor may elect (but under no circumstances will be obligated) to undertake the defense and/or settlement thereof. No such undertaking by Franchisor shall, in any manner or form, diminish Franchisee's obligation to indemnify all Indemnitees and to hold each of them harmless.

19.2.2. With respect to any action, suit, proceeding, claim demand, inquiry or investigation, Franchisor may, at any time and without notice, in order to protect persons

or property or the reputation of goodwill of Franchisor or others, order, consent or agree to any settlement or take any remedial or corrective action as Franchisor deems expedient, if, in Franchisor's sole judgment, there are reasonable grounds to believe that: (i) any of the acts or circumstances enumerated in this Section 19.2 have occurred; or (ii) any act, error, or omission of Franchisee may result directly or indirectly in damage, injury or harm to any person or any property. All Losses and Expenses incurred under this Section 19.2.2 shall be chargeable to and paid by Franchisee pursuant to its obligations of indemnity hereunder.

19.2.3. The Indemnitees assume no liability whatsoever for any acts, errors, or omissions of any persons with whom Franchisee may contract or deal regardless of the purpose. Franchisee shall hold harmless and indemnify the Indemnitees (and each of them) for all Losses and Expenses that may arise out of any acts, errors or omissions of such third parties with whom Franchisee may contract. Under no circumstances shall the Indemnitees be required or obligated to seek recovery from third parties or otherwise mitigate their losses in order to maintain a claim against Franchisee. Franchisee agrees that the failure to pursue such recovery or mitigate loss will in no way reduce the amounts recoverable by the Indemnitees from Franchisee.

19.2.4. Any loss or damage suffered by an Indemnitee under this Agreement shall be deemed to be loss or damage suffered by the Franchisor with the intent that the Franchisee shall be liable to the Franchisor rather than to the relevant Indemnitee in respect of that loss or damage. In this regard, the Franchisor shall be entitled to seek and enforce remedies under this Agreement in respect of any breach or default of the Franchisee's obligations under this Agreement and claim damages from the Franchisee in respect of damages suffered by Indemnitees.

20. APPROVALS AND WAIVERS

20.1. Written Approval or Consent Required. Whenever this Agreement requires the prior approval or consent of Franchisor, Franchisee shall make a timely written request to Franchisor therefor. Such approval or consent must be obtained in writing.

20.2. No Warranties. Franchisor makes no warranties or guarantees upon which Franchisee may rely, and assumes no liability or obligation to Franchisee, by providing any waiver, approval, consent, or suggestion to Franchisee in connection with this Agreement, or by reason of any neglect, delay, or denial of any request therefor.

20.3. Waivers. Any waiver granted by Franchisor to Franchisee excusing or reducing any obligation or restriction imposed under this Agreement shall be made in writing and shall be effective upon delivery of such writing by Franchisor to Franchisee or upon such other effective date as specified in the writing. No waiver granted by Franchisor, and no action taken by Franchisor with respect to any third party, shall limit

Franchisor's discretion to take action of any kind, or not to take action, with respect to Franchisee. Any waiver granted by Franchisor to Franchisee shall be without prejudice to any other rights Franchisor may have. No delay or failure of Franchisor to exercise any power reserved to it by this Agreement, or to insist upon strict compliance by Franchisee with any obligation or condition hereunder, and no custom or practice of the parties at variance with the terms hereof, shall constitute a waiver of Franchisor's right to demand exact compliance with any of the terms hereof. Waiver by Franchisor of any particular default of Franchisee shall not affect or impair Franchisor's rights with respect to any subsequent default of the same, similar, or different nature, nor shall any delay, forbearance, or omission of Franchisor to exercise any power or right arising out of any breach or default by Franchisee of any of the terms, provisions, or covenants hereof, affect or impair Franchisor's right to exercise the same, nor shall such constitute a waiver by Franchisor of any right hereunder, or the right to declare any subsequent breach or default and to terminate this Agreement in accordance with its terms. Subsequent acceptance by Franchisor of any payments due it under this Agreement shall not be deemed a waiver by Franchisor of any preceding breach by Franchisee of any terms, covenants, or conditions of this Agreement.

21. NOTICES

Any and all notices required or permitted under this Agreement shall be in writing and shall be personally delivered, sent by registered or certified mail, or sent by overnight courier (such as UPS, FedEx or other similar service) which affords the sender evidence of delivery or attempted delivery, to the respective parties at the following addresses, unless and until a different address has been designated by written notice to the other party:

Notices to Franchisor:

Health Mart Systems, Inc.
6535 State Hwy 161
Irving, Texas 75039
Attn: Health Mart Operations

Notices to Franchisee:

As described on Declarations Page.

Any notice by a means which affords the sender evidence of delivery or attempted delivery shall be deemed to have been given and received at the date and time of receipt or attempted delivery.

Notwithstanding anything to the contrary in this Section 21, Franchisee acknowledges and agrees that, in addition to routine information, invoices and details about System requirements and programs, Franchisor may provide Franchisee with electronic delivery (via email, the Health Mart franchisee web portal or any other electronic means) of any notice required or permitted under this Agreement. Franchisor and Franchisee will

cooperate with each other to adapt new technologies that may be available for the transmission of such information.

22. ENTIRE AGREEMENT

This Agreement, the Declarations Page, the schedules, exhibits and attachments hereto, and the documents referred to herein constitute the entire Agreement between Franchisor and Franchisee concerning the subject matter hereof, and supersede any prior agreements; no other representations having induced Franchisee to execute this Agreement. Nothing in this Agreement, the Declarations Page, the schedules, exhibits or attachments hereto, or the documents referred to herein is intended to disclaim representations which Franchisor has made in the Franchise Disclosure Document which Franchisee acknowledges has been furnished to Franchisee before entering into this Agreement. Except for those permitted to be made unilaterally by Franchisor hereunder, no amendment, change, or variance from this Agreement shall be binding on either party unless mutually agreed to by the parties and executed by their authorized officers or agents in writing.

23. SEVERABILITY AND CONSTRUCTION

23.1. Severability. If, for any reason, any section, part, term, provision, and/or covenant herein is determined to be invalid and contrary to, or in conflict with, any existing or future law or regulation by a tribunal or court of competent jurisdiction, such shall not impair the operation of, or have any other effect upon, such other portions, sections, parts, terms, provisions, and/or covenants of this Agreement as may remain otherwise intelligible or consistent with the original bargain of the parties; and the remaining portions of the Agreement shall continue to be given full force and effect and bind the parties hereto; and said invalid portions, sections, parts, terms, provisions, and/or covenants shall be deemed not to be a part of this Agreement.

23.2. Survival. Any provision or covenant of this Agreement which expressly or by its nature imposes obligations beyond the Term of this Agreement, including, without limitation, Sections 8, 9, 15, 19 and 24, shall survive termination (whether termination is by Franchisor or Franchisee, and regardless of cause).

23.3. No Third-Party Beneficiary. Except as expressly provided to the contrary herein, nothing in this Agreement is intended, nor shall be deemed, to confer upon any person or legal entity other than Franchisee, Franchisor, Franchisor's Affiliates, such of Franchisor's successors and assigns as may be contemplated by Section 13 hereof and the respective officers, directors, shareholders, agents and employees of each of them, any rights or remedies under or by reason of this Agreement.

23.4. Construction of Covenants. Franchisee expressly agrees to be bound by any promise or covenant imposing the maximum duty permitted by law which is subsumed within the terms of any provision, as though it were

separately articulated in and made a part of this Agreement, that may result from striking any portion or portions a tribunal or court of competent jurisdiction may hold to be unreasonable and unenforceable in an unappealed final decision to which Franchisor is a party, or from reducing the scope of any promise or covenant to the extent required to comply with such a tribunal or court order.

23.5. Counterpart Execution. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed an original, but such counterparts together shall constitute one and the same instrument.

24. APPLICABLE LAW AND DISPUTE RESOLUTION

24.1. Mediation. Except as otherwise provided in this Agreement, neither party to this Agreement shall bring an action or proceeding to enforce or interpret any provision of this Agreement, or seeking any legal remedy based upon the relationship created by this Agreement or an alleged breach of this Agreement, until the dispute has been submitted to mediation conducted in accordance with the procedures stated in this Agreement.

24.1.1. The mediation shall be conducted pursuant to the rules of the National Franchise Mediation Program, a dispute resolution program for franchising administered under the auspices of the CPR Institute for Dispute Resolution (the “**Mediation Service**”). Either party may initiate the mediation (the “**Initiating Party**”) by notifying the Mediation Service in writing, with a copy to the other party (the “**Responding Party**”). The notice shall describe with specificity the nature of the dispute and the Initiating Party’s claim for relief. Thereupon, both parties will be obligated to engage in the mediation, which shall be conducted in accordance with the Mediation Service’s then-current rules, except to the extent the rules conflict with this Agreement, in which case this Agreement shall control.

24.1.2. The mediator must be either a practicing attorney with experience in business format franchising or a retired judge.

24.1.3. Except as otherwise provided in this Agreement: (i) the fees and expenses of the Mediation Service, including, without limitation, the mediator’s fee and expenses, shall be shared equally by the parties, and (ii) each party shall bear its own attorney’s fees and other costs incurred in connection with the mediation irrespective of the outcome of the mediation or the mediator’s evaluation of each party’s case.

24.1.4. The mediation conference shall begin as soon as possible with the goal of beginning the mediation within thirty (30) days after selection of the mediator. Regardless of whether Franchisor or Franchisee is the Initiating Party, the mediation shall be conducted at Franchisor’s

headquarters, unless the parties agree upon a mutually acceptable alternative location.

24.1.5. The parties shall participate in good faith in the entire mediation, including the mediation conference, with the intention of resolving the dispute, if at all possible. The parties shall each send at least one representative to the mediation conference who has authority to enter into a binding contract on that party’s behalf and on behalf of all principals of that party who are required by the terms of the parties’ settlement to be personally bound by it. The parties recognize and agree, however, that the mediator’s recommendations and decision shall not be binding on the parties.

24.1.6. If one party breaches this Agreement by refusing to participate in the mediation or not complying with the requirements for conducting the mediation, the non-breaching party may immediately file suit and take such other action to enforce its rights as permitted by law and the breaching party shall be obligated to pay: (i) the mediator’s fees and costs, (ii) the non-breaching party’s reasonable attorneys’ fees and costs incurred in connection with the mediation, and (iii) to the extent permitted by law, the non-breaching party’s reasonable attorneys’ fees and costs incurred in any suit arising out of the same dispute, regardless of whether the non-breaching party is the prevailing party. Additionally, in connection with (iii), the breaching party shall forfeit any right to recover its attorneys’ fees and costs should it prevail in the suit. The parties agree that the foregoing conditions are necessary in order to encourage meaningful mediation as a means for efficiently resolving any disputes that may arise.

24.2. Exceptions to Mediation. The obligation to mediate shall not apply to (i) any disputes, controversies or claims where the monetary relief sought is under \$10,000 or (ii) either party’s application before any court of competent jurisdiction seeking injunctive or other provisional relief (“**Provisional Remedies**”). The party that is seeking Provisional Remedies shall not be required to post bond or comparable security.

24.3. Jurisdiction and Venue. Except as provided in Section 24.2(ii), the parties agree that (i) all disputes arising out of or relating to this Agreement which are not resolved by negotiation or mediation, and (ii) all claims which this Agreement expressly excludes from mediation, shall be brought in the United States District Court for the Northern District of Texas (Dallas Division), or if such court lacks jurisdiction, the District Court for Dallas County, Texas. The parties agree to submit to the jurisdiction of the courts mutually selected by them pursuant to this Section and mutually acknowledge that selecting a forum in which to resolve disputes arising between them is important to promote stability in their relationship. To the fullest extent that it may effectively do so under applicable law, Franchisee waives the defense of an inconvenient forum to the maintenance of an action in the courts identified in this Section and agrees not to commence any action of any kind against Franchisor, Franchisor’s affiliates and their respective

officers, directors, shareholders, limited liability company managers and members, employees and agents or property arising out of or relating to this Agreement except in the courts identified in this Section.

24.4. Waiver of Jury Trial. FRANCHISOR AND FRANCHISEE EACH HEREBY WAIVE THEIR RESPECTIVE RIGHT TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, COUNTERCLAIM OR CROSS-COMPLAINT IN ANY ACTION, PROCEEDING AND/OR HEARING BROUGHT BY EITHER FRANCHISOR OR FRANCHISEE ON ANY MATTER WHATSOEVER ARISING OUT OF, OR IN ANY WAY CONNECTED WITH, THIS AGREEMENT, THE RELATIONSHIP OF THE PARTIES, THE USE OF THE PROPRIETARY MARKS OR ANY CLAIM OF INJURY OR DAMAGE, OR THE ENFORCEMENT OF ANY REMEDY UNDER ANY LAW, STATUTE, REGULATION, EMERGENCY OR OTHERWISE, NOW OR HEREAFTER IN EFFECT, TO THE FULLEST EXTENT PERMITTED UNDER APPLICABLE LAW.

24.5. Governing Law. The parties agree that the laws of the State of Texas shall govern the construction, interpretation, validity and enforcement of this Agreement, without regard to, and without giving effect to, the application of Texas conflict-of-law rules, and shall be applied in any mediation or judicial proceeding to resolve all disputes between them, except to the extent the subject matter of the dispute arises exclusively under federal law, in which event the federal law shall govern. Nothing in this Section is intended by the parties to subject this Agreement to any franchise, business opportunity or similar statute, rule, or regulation of the State of Texas to which it would not otherwise be subject. Franchisee and Franchisor acknowledge and agree that each party's agreement regarding applicable state law set forth in this Section 24 provides each of the parties with the mutual benefit of uniform interpretation of this Agreement and any dispute arising out of this Agreement or the parties' relationship created by this Agreement. Franchisee and Franchisor further acknowledge the receipt and sufficiency of mutual consideration for such benefit, and that each party's agreement regarding applicable state law has been negotiated in good faith and are the part of the benefit of the bargain reflected by this Agreement.

24.6. Damages Waiver and Limitation on Recovery. Except as provided in this Section, Franchisor and Franchisee, on behalf of themselves and their respective Affiliates, directors, officers, shareholders, members, managers, guarantors employees and agents, as applicable, each hereby waive to the fullest extent permitted by law, any right to, or claim for, indirect, special, consequential, punitive or exemplary damages or for lost profits, loss opportunities, or other form of economic damage, whether arising from breach of contract, tort, equity or another legal theory. Furthermore, Franchisor and Franchisee each agree that in the event of a dispute between them arising out of a party's material breach of this Agreement, they and any person claiming rights through them, will be limited to recovering only the actual damages

proven to have been sustained by the party up to a maximum recovery equal to twenty-four (24) times the average Monthly Fee paid to Franchisor during the six (6) months before the effective date of termination. However, the parties agree that the limitations and waivers in this Section do not apply to (i) claims arising out of Franchisee's misuse of the Proprietary Marks; or (ii) claims included in the scope of Franchisee's indemnification obligations pursuant to Section 19 of this Agreement.

24.7. Enforcement Costs. Except as expressly provided in this Agreement, in any action or proceeding brought to enforce any provision of this Agreement or arising out of or in connection with the relationship of the parties hereunder, the prevailing party shall be entitled to recover against the other its reasonable attorneys' fees and court costs in addition to any other relief awarded by the court. As used in this Agreement, the "**prevailing party**" is the party who recovers greater relief in the action.

24.8. Franchisor Right of Entry. If Franchisee fails to initiate and timely complete the alterations described in Section 6.3.2 or Section 15.1.5 as and when required, Franchisee acknowledges and agrees that Franchisor or its designated agents may enter the premises of the Drugstore and adjacent areas at any time, without responsibility for any actual or consequential damages to the property of Franchisee or others, and without liability for trespass or other tort or criminal act, for the purpose of making or causing to be made such changes as may be required, at the expense of Franchisee, including reasonable attorneys' fees incurred by Franchisor.

24.9. Waiver of Collateral Estoppel. The parties agree they should each be able to settle, mediate, litigate or compromise disputes in which they may be, or become, involved with third parties without having the dispute affect their rights and obligations to each other under this Agreement. Franchisor and Franchisee therefore each agree that a decision of a mediator or judge in any proceeding or action in which either Franchisor or Franchisee, but not both of them, is a party shall not prevent the party to the proceeding or action from making the same or similar arguments, or taking the same or similar positions, in any proceeding or action between Franchisor and Franchisee. Franchisor and Franchisee therefore waive the right to assert that principles of collateral estoppel prevent either of them from raising any claim or defense in an action or proceeding between them even if they lost a similar claim or defense in another action or proceeding with a third party.

24.10. Waiver of Class Action Relief. Franchisor and Franchisee agree that any litigation brought by either party against the other will be conducted on an individual, not a class-wide, basis.

25. ACKNOWLEDGMENTS

25.1. Independent Investigation. Franchisee acknowledges that it has conducted an independent

investigation of the business franchised hereunder, and recognizes that the business venture contemplated by this Agreement involves business risks and that its success will be largely dependent upon the ability of Franchisee (or, if Franchisee is a Business Entity, the ability of its Owners and management) as an independent businessperson. Franchisor expressly disclaims the making of, and Franchisee acknowledges that it has not received from Franchisor, any indication, promise, warranty or guarantee, express or implied, as to the potential volume, profits, or success of the business venture contemplated by this Agreement.

25.2. Review of Franchise Agreement and FDD.

Franchisee acknowledges that it has read and understood this Agreement, the attachments hereto, and agreements relating thereto, as well as Franchisor's Franchise Disclosure Document. Franchisee acknowledges that Franchisor has accorded Franchisee ample time and opportunity to consult with advisors of Franchisee's own choosing about the potential benefits and risks of entering into this Agreement and that, in fact, Franchisee has so consulted with professional advisors about such subject matter.

25.3. Reliance on Franchisor.

Franchisee acknowledges and agrees that: (i) the term "Franchisor" as used in this Agreement shall refer only to Health Mart Systems, Inc. and not McKesson or Franchisor's other Affiliates; (ii) Franchisor is not authorized to contract for or on behalf of its parent or any of its other Affiliates; and (iii) this Agreement shall not be deemed to bind or otherwise restrict Franchisor's parent or any of its other Affiliates.

25.4. No Waiver of Statutory Rights.

Nothing in this Agreement is intended to waive any rights Franchisee may have under any applicable federal or state franchise registration or disclosure law.

26. FRANCHISEE REBATES

Franchisee may be entitled to earn rebates on its purchases of pharmaceutical products from McKesson. Any rebate received by Franchisee on its purchases of pharmaceutical products from McKesson is a "discount or other reduction in price" to Franchisee under Section 1128B(b)(3)(A) of the Social Security Act with respect to the purchases made thereunder. To the extent requested to do so or as otherwise required by law or regulation, Franchisee shall fully and accurately disclose any such rebates in any cost or similar reports or claims for reimbursement made to any federal or state health care program or third-party payor.

27. RECEIPT OF MARKETING COMMUNICATIONS

Franchisee consents to receiving marketing calls, emails and/or fax communications from or on behalf of Franchisor, McKesson and/or any McKesson affiliate at the telephone number, cellular phone number, fax number and email address provided by Franchisee as part of Franchisee's

enrollment, participation or inquiry about any Franchisor, McKesson or any McKesson product or service. Franchisee understands that such communications may contain marketing content, program information or updates, or any other communication related to any products, programs or services offered by Franchisor, McKesson or McKesson affiliate. Franchisee further consents to receiving auto-dialed and/or pre-recorded telephone calls, and that such consent is not a condition of purchase or participation in any program. Franchisor will make available to Franchisee an opt-out method by email, phone, fax or other permissible mechanism, by which Franchisee may notify Franchisor or McKesson that Franchisee no longer wishes to receive marketing communications.

SCHEDULE 1

DEFINITIONS

In addition to other terms defined within the body of the Franchise Agreement, the following terms have the meanings given to them below:

“Affiliate” means, with respect to a named person or entity, any person or entity that is controlled by, controlling or under common control with the named person or entity.

“Business Entity” means a corporation, limited liability company, general partnership, limited partnership, trust or other type of legal entity which, under applicable law, may enter into contracts in its own name.

“Change of Control” means a transaction or series of related transactions that result in the sale of all or substantially all of the assets of the Drugstore. If Franchisee is a Business Entity, “Change of Control” also means a transaction or series of related transactions that result in the transfer of a “Controlling Interest” in Franchisee.

“Competitor” means any retail drugstore operating under a trade name or trademark other than “Health Mart”.

“Confidential Information” means information regarding the operational, sales, promotional, and marketing methods and techniques of Franchisor and the System, including, without limitation, business processes, trade secrets, customer lists, knowledge, know-how, Franchisor’s Standards and specifications, the contents of the Franchise Handbook, proprietary Computer Programs, patents applied for concerning the methods of operation of the Drugstore, and any other information, knowledge, know how, techniques, and other data designated by Franchisor as confidential. Confidential Information also includes all dispensing, patient and other sensitive data that Franchisee collects during the course of operating the Drugstore as a Health Mart Drugstore.

“Controlling Interest” means a transfer of (i) 50% or more of the outstanding voting power of Franchisee or an Affiliate of Franchisee, whether voluntarily or by operation of law or due to a merger or consolidation, or (ii) the right to appoint, or cause to be appointed, a majority of Franchisee’s directors, officers or managers.

“Core Services” means services offered by Franchisor to all Health Mart Franchisees, any or all of which may be changed, improved, modified, discontinued, terminated, and further developed by Franchisor from time to time.

“Digital Program or Digital Portfolio” means (intended to be broad to encompass the current scope of what Health Mart Digital Portfolio and My Health Mart Web Portal bring and then leave it open for enhancements or vendor/program name changes in the future) **@ Baker McKenzie please assist in crafting this definition.**

“Drugstore” means the retail pharmacy directly accessible to consumers operated at the Drugstore Location.

“Drugstore Location” means the site occupied by the Drugstore and identified as the Drugstore Location on the Declarations Page.

“Effective Date” means the date shown on the Declarations Page as the Effective Date of this Agreement. The Effective Date is the later of (i) the date that Franchisor activates Franchisee’s access to the System; or (ii) the date this Agreement is fully executed.

“Event of Transfer” means a transaction or series of related transactions that, directly or indirectly, voluntarily or by operation of law: (i) results in the sale, assignment, transfer, pledge, gift, encumbrance or alienation of any interest in this Agreement or the right to use the HEALTH MART System or any portion or components of the System; (ii) involves the offer to sell securities of a Franchisee that is a Business Entity; (iii) results in a Change of Control of Franchisee; or (iv) involves the sale of all or substantially all of the assets of the Drugstore. For purposes of illustration, an Event of Transfer includes, without limitation: (a) an order dissolving the marriage of an individual Franchisee; (b) the issuance of additional equity or voting interests of a Business Entity Franchisee resulting in a Change of Control; (c) a financial restructuring or recapitalization that is secured by a sufficient number of equity or voting interests of a Business Entity such that, if foreclosed upon, would result in a Change of Control; (d) the offering of securities or partnership interests in Franchisee in a public or private offering; (e) the death or Permanent Incapacity of an individual Franchisee or any Owner in a Business Entity Franchisee whose death or Permanent Incapacity would result in a Change of Control; or (f) an agreement to sell, transfer, give away or encumber all or substantially all of the assets of the Drugstore including, without limitation, the right to occupy the Drugstore Location.

“Franchise Handbook” means Franchisor’s confidential Franchise Handbook and referenced as the Toolkit in the My Health Mart Web Portal provided to Franchisees, which may consist of any combination of paper or electronic documents and which Franchisor may modify at any time, containing Franchisor’s mandatory and suggested Standards, specifications and operating procedures and techniques relating to the development and operation of Health Mart Drugstores and Franchisee’s obligations under the Franchise Agreement and covering, without limitation, such subject matter as sales, customer service, marketing, merchandizing, management information systems and enhancements. Notwithstanding the foregoing, nothing in the Franchise Handbook is intended to affect the independent professional judgment of any pharmacist employed at the Drugstore, nor shall it be construed as requiring any such pharmacist to depart from any legal requirements governing the pharmacy practice.

“Governing Documents” means the documents and instruments that create a Business Entity and govern the management and operation of any Business Entity Franchisee, including, without limitation, the following: (i) if Franchisee is a corporation, Franchisee’s Articles of Incorporation or Charter and Bylaws, (ii) if Franchisee is a partnership, Franchisee’s written partnership agreement and any Certificate of Limited Partnership, (iii) if Franchisee is a limited liability company, Franchisees’ Articles of Organization and Operating Agreement, (iv) any amendments to (i)-(iii), and (v) the resolutions of Franchisee’s board of directors, partners, shareholders, members or managers, as applicable, authorizing Franchisee’s execution and performance of this Agreement.

“Losses and Expenses,” as used in Section 19 of the Franchise Agreement, means, without limitation, all obligations, losses, compensatory, exemplary or punitive damages, fines, charges, costs, lost profits, attorneys’ fees, accountants’ fees, expert witness fees, expenses, court costs, settlement amounts, judgments, compensation for damages to Franchisor’s reputation and goodwill, costs of or resulting from delays, financing, costs of advertising material and media time/space, and costs of changing, substituting or replacing the same, and any and all expenses of recall, refunds, compensation, public notices and other such amounts incurred in connection with the matters described.

“Manager” means a fully-trained, licensed Drugstore manager approved by Franchisor. If Franchisee is an individual, Franchisee may be the Manager.

“McKesson” means McKesson Corporation, Franchisor’s parent company.

“Merchandise” means, collectively, the following 4 categories of products:

- (i) HEALTH MART® branded “over the counter” (“**OTC**”) non-prescription drugs and non-drug products identified by any of the Proprietary Marks (collectively, “**Private Label OTC**”);
- (ii) Third Party Brand OTC non-prescription drugs and non-drug products (collectively “**Third Party OTC**”);
- (iii) branded prescription drugs (“**Branded Prescription Drugs**”); and
- (iv) generic prescription drugs (“**Generic Prescription Drugs**”).

“Minimum Purchasing Threshold” means that at least the minimum percentage (as set forth in the Franchise Handbook) of Franchisee’s entire inventory of Branded Prescription Drugs and Generic Prescription Drugs must be purchased in accordance with Section 6.5 of the Franchise Agreement. Currently, at least 50% of Franchisee’s entire inventory of Branded Prescription Drugs and Generic Prescription Drugs (in the aggregate) must satisfy the Minimum Purchasing Threshold.

“Monthly Fee” means the then-current Monthly Fee for Core Services and any applicable taxes. The Monthly Fee includes fees and other amounts charged by third parties and Affiliates of the Franchisor and may be adjusted by Franchisor from time to time to cover any increase in such fees or other amounts and any changes in the Core Services. As of the Effective Date, the Monthly Fee is \$355 (exclusive of taxes).

“Open Location” means a Franchisee whose existing drugstore is renovated to comply with the Standards for a Health Mart Drugstore.

“Permanent Incapacity” means the inability due to medical reasons to devote full time and attention to the administrative and operational activities of the Drugstore that continues for at least one hundred twenty (120) days in the aggregate during any rolling twelve (12) month period during the Term of this Agreement based upon the

examination and findings of a physician who is mutually selected by Franchisor and the personal representative of the person who claims to be permanently incapacitated. A period of incapacity shall be deemed to continue without interruption unless and until the person suffering the incapacity resumes his or her duties on a full time basis for thirty (30) consecutive days.

“Proprietary Marks” has the meaning given to it in the Recitals to the Franchise Agreement.

“Provisional Remedies” means any form of interim relief, including, without limitation, requests for temporary restraining orders, preliminary injunctions, writs of attachment, appointment of a receiver, for claim and delivery, or any other orders which a court may issue when deemed necessary in its sole discretion to preserve the status quo or prevent irreparable injury, including the claim of either party for injunctive relief to preserve the status quo.

“Renewal Location” means a Franchisee that it exercising an option to renew this Agreement in accordance with the terms of its existing Franchise Agreement.

“Standards” means Franchisor’s mandatory and suggested standards for Drugstores operating under the System, including with respect to facilities, services, products, operations, merchandising, customer relations, consistency and appearance, and further including, without limitation, standards for purchasing, offering, promoting and selling new or different products or services or discontinuing the use of specific products or services that Franchisor eliminates from the System, using specified technology systems, or for participating in marketing, merchandising, purchasing or other programs required or offered by Franchisor.

“System” means Franchisor’s distinctive and proprietary system for establishing and operating retail drugstores, the distinguishing characteristics of which include, without limitation, business processes, and other intellectual property; distinctive signage; Standards and specifications for business services, products, supplies, appearance, operations and management control; training and assistance; purchasing programs; advertising, marketing, promotional and sales programs; and other services, all of which may be changed, discontinued, improved, modified and further developed by Franchisor from time to time.

“Taxes” means any present or future taxes, levies, imposts, duties or other charges of whatsoever nature, including any interest or penalties thereon, imposed by any government or political subdivision of such government on or relating to the operation of the Drugstore, the payment of monies, or the exercise of rights granted pursuant to this Agreement, except taxes imposed on or measured by Franchisor’s net income.

“Term” has the meaning given to it in Section 2.

“Threshold Deadline” has the meaning given to it in Section 6.5.

“Unopened Location” means a Franchisee that opens a new drugstore that complies with the Standards for a Health Mart Drugstore.

SCHEDULE 2

**MCKESSON ONESTOP GENERICS AUTHORIZATION FOR MCKESSON TO COLLECT CUSTOMER
DISPENSING DATA**

Schedule 2

McKesson OneStop Generics®

Authorization for McKesson to collect customer dispensing data

As part of our ongoing commitment to improve the McKesson OneStop® Program for our customers, we are inviting you to participate in our efforts to understand how our customers are dispensing prescription drugs. With your partnership and additional support, we can further our commitment to bringing value to our customers with competitive pricing, expert product sourcing and business partnership.



Competitive pricing

Dynamic portfolio pricing focused on highest-volume products



Expert product sourcing

The products you need, when you need them



Business partnership

Customer-specific solutions for a rapidly changing market

Customer authorizes McKesson Corporation to obtain and use data that identifies the prescription drugs purchased and/or dispensed by pharmacies owned or controlled by Customer. Customer acknowledges and understands that obtaining this data will require all electronic claims transactions and cash-pay transactions to be routed through a McKesson-approved network. If applicable, customer acknowledges and agrees that McKesson may disclose information received pursuant to this authorization to Health Mart Systems, Inc. for the purpose of verifying customer's satisfaction of certain terms and conditions of its Health Mart Franchise Agreement.

Customer understands that McKesson Corporation will submit this authorization to its claim switch provider(s), and that its claim switch provider will rely on this authorization.

Customer Information:

Customer Name ("Customer"): _____

Signature: _____

Name of Signatory: _____

Title of Signatory: _____

Date: _____

Pharmacy-Management System: _____

NPI Number: _____

NCPDP Number: _____

McKesson Account Number: _____

Switch Provider(s): _____

Service Election for QS/1 (Redsail) Customers ONLY:

Subscriber hereby requests Redsail Technologies route their claim activity to CMM Intelligent Network (RelayHealth) for the purpose of participation in programs powered by the CMM Intelligent Network (RelayHealth) switch. It is understood that Redsail Technologies will be the primary switch and will continue to bill for switching activity. No additional fee will be incurred for the purpose of claims being routed to CMM Intelligent Network (RelayHealth).

Customer Initials _____

Thank you for helping us improve the OneStop Program.

EXHIBIT A
TRADEMARKS

	Mark	USPTO Registration Date	USPTO Registration No.
1	SUNMARK and design	December 14, 2021	6,590,866
2	SUNMARK	April 19, 2005	2,941,616
3	HEALTH MART and design	April 29, 2008	3,417,106
4	HEALTH MART	August 24, 1993	1,789,774
5	HEALTH MART	September 14, 1982	1,208,869

	Mark	USPTO Application Date	USPTO Application No.
1	HEALTH MART and design (color)	August 13, 2020	90/112518
2	HEALTH MART and design (bw)	August 13, 2020	90/111921
3	HEALTH MART	April 1, 2021	90/619143

Exhibit A

EXHIBIT B

OWNERSHIP OF FRANCHISEE

Name and Address	Type of Interest (i.e., limited partner, general partner, member, or shareholder)	Percentage of Total Ownership Interest

Exhibit B

EXHIBIT C

MINIMUM INSURANCE REQUIREMENTS

Certificates of Insurance Required for Participation in the Franchise		
Insurance Type	Minimum Limits	Minimum Coverage
Commercial General Liability (including products liability)	\$1 million per occurrence/ \$3 million annual aggregate	Coverage arising from premises, operations, products and completed operations, personal injury, advertising injury, bodily injury and property damage, including contractual liability
Professional Liability	\$1 million per claim/ \$3 million annual aggregate	Coverage for Drugstore and its employees, as applicable, arising from performance or failure to perform any professional services, including healthcare services under the Franchise Agreement, including errors, omissions, wrongful acts, and negligent acts
Note: The insurance limits required for participation in the franchise can be satisfied through any combination of primary and umbrella/excess insurance, provided the umbrella policy follows form with the primary policy.		

As required by law and recommended for corresponding business needs		
Insurance Type	Minimum Limits	Minimum Coverage
Workers Compensation	Required by applicable law	Scope of coverage as required by applicable law
Commercial Property	As applicable	"All Risks" coverage for inventory, fire, or water damage, with full replacement costs, business interruption, and extra expense coverage
Employers Liability	\$1 million each accident or disease	Coverage for liability for injury to your covered employees
Crime Insurance	\$1 million	Coverage for losses due to fraudulent or dishonest acts committed by your employees acting alone or in collusion with others
Business Auto	\$1 million combined single limit each accident	Coverage for any auto used in performance of duties under the Franchise Agreement for bodily injury and property damage
Network Security/Privacy Liability/Cyber	\$1M per claim and \$3M annual aggregate	Coverage arising from liability or losses due to network security, privacy liability, and cyber insurance (first and third-party liability, wrongful disclosure of data, wrongful

Exhibit C

		disclosure of any business confidential information, personally identifiable information or any personal, or protected health information as defined by HIPAA and HITECH Acts or other applicable law; breach of security, including extortion, unauthorized access to computer(s) or system database(s), identification theft, Web hosting (if applicable), regulatory proceedings, PCI fines and costs, notification costs, and credit monitoring services.
--	--	---

EXHIBIT D

OWNER'S UNDERTAKINGS

In consideration of, and as an inducement to, Health Mart Systems, Inc. ("**Franchisor**") to enter into that certain Franchise Agreement dated [_____] with _____ ("**Franchisee**"), the undersigned agrees as follows:

1. The undersigned is an Owner of Franchisee. The undersigned acknowledges that the execution of this Owner's Undertakings is in partial consideration for, and a condition to, the granting of the franchise, and that Franchisor would not have entered into the Franchise Agreement without the execution of this Owner's Undertakings.
2. Without limiting any of Franchisee's obligations under the Agreement, the undersigned makes all of the covenants, representations, warranties and agreements set forth in Sections 6.2 (Legal Compliance), 8.2 (Confidentiality of Franchise Handbook), 9 (Confidential Information), 13 (Transfer of Interest), 15.1.1 through 15.1.6 (Post-Term Obligations), 16.1 through 16.3 (Non-Competition and Injunctive Relief), 19.2 (Indemnification) and 24 (Dispute Resolution) of the Agreement and is obligated to perform thereunder. The undersigned has read and understands the meaning of the Sections listed herein.
3. The obligations of Owner are independent of the obligations of Franchisee and a separate action or actions may be brought and prosecuted against Owner, whether or not actions are brought against Franchisee or whether Franchisee is joined in any such action.

IN WITNESS WHEREOF, the undersigned has executed this Owner's Undertakings effective as of _____.

Signature

EXHIBIT E

PRINCIPAL'S UNDERTAKINGS

In consideration of, and as an inducement to, Health Mart Systems, Inc. (“**Franchisor**”) to enter into that certain Franchise Agreement dated [_____] with _____ (“**Franchisee**”), the undersigned agrees as follows:

1. The undersigned is either (i) an officer, director or manager of Franchisee, (ii) the Manager of the Drugstore, or (iii) if Franchisee is an individual, Franchisee’s spouse (each, a “Principal”). The undersigned acknowledges that the execution of this Principal’s Undertakings is in partial consideration for, and a condition to, the granting of the franchise, and that Franchisor would not have entered into the Franchise Agreement without the execution of this Principal’s Undertakings.
2. Without limiting any of Franchisee’s obligations under the Agreement, the undersigned makes all of the covenants, representations, warranties and agreements set forth in Sections 6.2 (Legal Compliance), 8.2 (Confidentiality of Franchise Handbook), 9 (Confidential Information), 15.1.1 through 15.1.3 (Post-Term Obligations), 16.1 and 16.3 (Non-Competition and Injunctive Relief) and 24 (Dispute Resolution) of the Agreement and is obligated to perform thereunder. The undersigned has read and understands the meaning of the Sections listed herein.
3. The obligations of Principal are independent of the obligations of Franchisee and a separate action or actions may be brought and prosecuted against Principal, whether or not actions are brought against Franchisee or whether Franchisee is joined in any such action.

IN WITNESS WHEREOF, the undersigned has executed this Principal’s Undertakings effective as of _____.

Signature

EXHIBIT F
STATE AMENDMENTS TO FRANCHISE AGREEMENT

Exhibit F

**CALIFORNIA AMENDMENT TO HEALTH MART SYSTEMS, INC.
FRANCHISE AGREEMENT**

The Health Mart Systems, Inc. Franchise Agreement between Health Mart Systems, Inc. (“**Franchisor**”) and the undersigned (“**Agreement**”) is hereby amended by the addition of the following language, which will be considered an integral part of the Agreement (“**Amendment**”):

1. The California Department of Financial Protection and Innovation requires that certain provisions contained in franchise documents be amended to be consistent with California law, including the California Franchise Investment Law, CAL. CORP. CODE Section 31000 *et seq.*, and the California Franchise Relations Act, CAL. BUS. & PROF. CODE Section 20000 *et seq.* To the extent that the Agreement contains provisions that are inconsistent with the following, such provisions are hereby amended:

- a. California Business and Professions Code Sections 20000 through 20043 provides rights to Franchisee concerning termination, transfer or non-renewal of a franchise. If the Agreement contains a provision that is inconsistent with California law, California law will control.
- b. The Agreement provides for termination upon bankruptcy. This provision may not be enforceable under federal bankruptcy law (11 U.S.C.A. Sec. 101 *et seq.*).
- c. The Agreement contains a covenant not to compete which extends beyond the termination of the franchise. This provision may not be enforceable under California law.
- d. The Agreement requires application of the laws of the State of Texas. This provision may not be enforceable under California law.

2. Each provision of this Amendment is effective only to the extent that the jurisdictional requirements of the Act, with respect to each such provision, are met independent of this Amendment. This Amendment will have no force or effect if such jurisdictional requirements are not met.

The parties hereto have duly executed and delivered this Amendment to the Agreement on the dates set forth below.

HEALTH MART SYSTEMS, INC.

FRANCHISEE:

by: _____

[Printed name]

[Title]

[Date]

[SIGNATURE IF FRANCHISEE IS AN
INDIVIDUAL]

[IF FRANCHISEE IS A BUSINESS ENTITY, PRINT
NAME OF BUSINESS ENTITY]

by: _____

[Printed name]

[Title]

[Date]

**ILLINOIS AMENDMENT TO HEALTH MART SYSTEMS, INC.
FRANCHISE AGREEMENT**

The Health Mart Systems, Inc. Franchise Agreement between Health Mart Systems, Inc. (“**Franchisor**”) and the undersigned (“**Agreement**”) is hereby amended by the addition of the following language, which will be considered an integral part of the Agreement (“**Amendment**”):

1. The Illinois Attorney General’s Office requires that certain provisions contained in franchise documents be amended to be consistent with Illinois law, including the Franchise Disclosure Act of 1987, 815 ILCS 705/1 *et seq* (“**Act**”). To the extent that the Agreement contains provisions that are inconsistent with the following, such provisions are hereby amended:

a. Paragraphs 705/19 and 705/20 of the Act provide rights to You concerning nonrenewal and termination of this Agreement. If this Agreement contains a provision that is inconsistent with the Act, the Act will control.

b. Any release of claims or acknowledgments of fact contained in the Agreement that would negate or remove from judicial review any statement, misrepresentation, or action that would violate the Act, or a rule or order under the Act, will be void and are hereby deleted with respect to claims under the Act.

c. If the Agreement requires litigation to be conducted in a forum other than the State of Illinois, the requirement is void with respect to claims under the Act.

d. If the Agreement requires that it be governed by a state’s law, other than the state of Illinois, to the extent that such law conflicts with the Act, the Act will control.

e. Section 41 of the Act provides that any condition, stipulation, or provision purporting to bind any person acquiring any franchise to waive compliance with the Act or any other law of Illinois is void.

2. Each provision of this Amendment is effective only to the extent that the jurisdictional requirements of the Act, with respect to each such provision, are met independent of this Amendment. This Amendment will have no force or effect if such jurisdictional requirements are not met.

The parties hereto have duly executed and delivered this Amendment to the Agreement on the dates set forth below.

HEALTH MART SYSTEMS, INC.

FRANCHISEE:

by: _____

[Printed name]

[Title]

[Date]

[SIGNATURE IF FRANCHISEE IS AN
INDIVIDUAL]

[IF FRANCHISEE IS A BUSINESS ENTITY, PRINT
NAME OF BUSINESS ENTITY]

by: _____

[Printed name]

[Title]

[Date]

Exhibit F

**MARYLAND AMENDMENT TO HEALTH MART SYSTEMS, INC.
FRANCHISE AGREEMENT**

The Health Mart Systems, Inc. Franchise Agreement between Health Mart Systems, Inc. (“**Franchisor**”) and the undersigned (“**Agreement**”) is hereby amended by the addition of the following language, which will be considered an integral part of the Agreement (“**Amendment**”):

1. The Maryland Securities Division requires that certain provisions contained in franchise documents be amended to be consistent with Maryland law, including the Maryland Franchise Registration and Disclosure Law, MD. BUS. REG. CODE ANN. §§ 14-201 *et seq.* (2015 Repl. Vol.) (“**Law**”). To the extent that this Agreement contains provisions that are inconsistent with the following, such provisions are hereby amended:

a. Any release required as part of the Agreement or as a condition of the sale, renewal, assignment, or transfer of the franchise will not apply to any liability under the Law.

b. Any acknowledgments or representations of Franchisee made in the Agreement which disclaim the occurrence and/or acknowledge the non-occurrence of acts that would constitute a violation of the Law are not intended to nor will they act as a release, estoppel, or waiver of any liability incurred under the Law.

c. Any requirement that litigation be conducted in a forum other than the State of Maryland will not be interpreted to limit any rights Franchisee may have under the Law to bring suit in the State of Maryland.

d. The limitation on the period of time mediation and/or litigation claims must be brought will not act to reduce the 3-year statute of limitations afforded Franchisee for bringing a claim arising under the Law. Any claims arising under the Law must be brought within 3 years after the grant of the franchise.

2. Each provision of this Amendment is effective only to the extent that the jurisdictional requirements of the Law, with respect to each such provision, are met independent of this Amendment. This Amendment will have no force or effect if such jurisdictional requirements are not met.

The parties hereto have duly executed and delivered this Amendment to the Agreement on the dates set forth below.

HEALTH MART SYSTEMS, INC.

FRANCHISEE:

by: _____

[Printed name]

[Title]

[Date]

[SIGNATURE IF FRANCHISEE IS AN
INDIVIDUAL]

[IF FRANCHISEE IS A BUSINESS ENTITY, PRINT
NAME OF BUSINESS ENTITY]

by: _____

[Printed name]

[Title]

[Date]

**MINNESOTA AMENDMENT TO HEALTH MART SYSTEMS, INC.
FRANCHISE AGREEMENT**

The Health Mart Systems, Inc. Franchise Agreement between Health Mart Systems, Inc. (“**Franchisor**”) and the undersigned (“**Agreement**”) is hereby amended by the addition of the following language, which will be considered an integral part of the Agreement (“**Amendment**”):

1. The Commissioner of Commerce for the State of Minnesota requires that certain provisions contained in franchise documents be amended to be consistent with Minnesota Franchise Act, Minn. Stat. Section 80C.01 *et seq.*, and with the rules and regulations promulgated thereunder (collectively, “**Franchise Act**”). To the extent the Agreement/and or disclosure document contains provisions that are inconsistent with the following, such provisions are hereby amended:

a. The Minnesota Department of Commerce requires that franchisors indemnify Minnesota franchisees against liability to third parties resulting from claims by third parties that the franchisee’s use of the franchisor’s proprietary marks infringes trademark rights of the third party.

b. Minn. Stat. Sec. 80C.14, Subds. 3, 4, and 5 require, except in certain specified cases, that a franchisee be given 90 days notice of termination (with 60 days to cure) and 180 days notice for non-renewal of the franchise agreement. If the Agreement contains a provision that is inconsistent with the Franchise Act, the provisions of the Agreement will be superseded by the Franchise Act’s requirements and will have no force or effect.

c. If Franchisee is required in the Agreement to execute a release of claims or to acknowledge facts that would negate or remove from judicial review any statement, misrepresentation, or action that would violate the Franchise Act, such release will exclude claims arising under the Franchise Act, and such acknowledgments will be void with respect to claims under the Franchise Act.

d. If the Agreement requires that it be governed by the laws of a state other than the state of Minnesota, or if the Agreement requires arbitration or mediation, those provisions will not in any way abrogate or reduce any rights of the franchisee, as provided for in the Franchise Act, including the right to submit matters to the jurisdiction of the courts of Minnesota.

e. Any provision that requires the franchisee to consent to a claims period that differs from the applicable statute of limitations period under Minn. Stat § 80C.17, Subd. 5. may not be enforceable under Minnesota.

2. Minn. Stat. §80C.21 and Minn. Rule 2860.4400J prohibit Franchisor from requiring litigation to be conducted outside Minnesota. In addition, nothing in the disclosure document or Agreement can abrogate or reduce any of Franchisee’s rights as provided for in Minnesota Statutes, Chapter 80C, including Franchisee’s rights to any procedure, forum, or remedies provided for in such law.

3. The Agreement/and or disclosure document is hereby amended to delete all references to liquidated damages (as defined in the Agreement) that are in violation of Minnesota law; provided that no such deletion will excuse the franchisee from liability for actual or other damages, and the formula for liquidated damages in the Agreement/and or disclosure document will be admissible as evidence of actual damages.

4. To the extent required by Minnesota law, the Agreement/and or disclosure document is amended to delete all references to a waiver of jury trial.

5. All sections of the Agreement/and or disclosure document referencing Franchisor’s right to obtain injunctive relief are hereby amended to refer to Franchisor’s right to seek to obtain.

6. Each provision of this Agreement is effective only to the extent that the jurisdictional requirements of Minnesota law applicable to the provision are met independent of this Amendment. This Amendment will have no force or effect if such jurisdictional requirements are not met.

The parties hereto have duly executed and delivered this Amendment to the Agreement on the dates set forth below.

(Signature page is the next page.)

Exhibit F

HEALTH MART SYSTEMS, INC.

FRANCHISEE:

by: _____

[Printed name]

[Title]

[Date]

[SIGNATURE IF FRANCHISEE IS AN
INDIVIDUAL]

[IF FRANCHISEE IS A BUSINESS ENTITY, PRINT
NAME OF BUSINESS ENTITY]

by: _____

[Printed name]

[Title]

[Date]

**NEW YORK AMENDMENT TO HEALTH MART SYSTEMS, INC.
FRANCHISE AGREEMENT**

The Health Mart Systems, Inc. Franchise Agreement between Health Mart Systems, Inc. (“**Franchisor**”) and the undersigned (“**Agreement**”) is hereby amended by the addition of the following language, which will be considered an integral part of the Agreement (“**Amendment**”):

1. The New York Department of Law requires that certain provisions contained in franchise documents be amended to be consistent with New York law, including the General Business Law, Article 33, Sections 680 through 695 (“**Law**”). To the extent that the Agreement contains provisions that are inconsistent with the following, such provisions are hereby amended:

a. If franchisee is required in the Agreement to execute a release of claims or to acknowledge facts that would negate or remove from judicial review any statement, misrepresentation, or action that would violate the Law, regulation, rule, or order under the Law, such release will exclude claims arising under the Law and the regulations promulgated thereunder, and such acknowledgments will be void. It is the intent of this provision that non-waiver provisions of Sections 687.4 and 687.5 of the General Business Law be satisfied.

b. If the Agreement requires that it be governed by the law of a state, other than the state of New York, the choice of law provision will not be considered to waive any rights conferred upon franchisee under the Law.

2. Each provision of this Amendment is effective only to the extent that the jurisdictional requirements of the Law, with respect to each such provision, are met independent of this Amendment. This Amendment will have no force or effect if such jurisdictional requirements are not met.

The parties hereto have duly executed and delivered this Amendment to the Agreement on the dates set forth below.

HEALTH MART SYSTEMS, INC.

FRANCHISEE:

by: _____

[Printed name]

[Title]

[Date]

[SIGNATURE IF FRANCHISEE IS AN
INDIVIDUAL]

[IF FRANCHISEE IS A BUSINESS ENTITY, PRINT
NAME OF BUSINESS ENTITY]

by: _____

[Printed name]

[Title]

[Date]

**NORTH DAKOTA AMENDMENT TO HEALTH MART SYSTEMS, INC.
FRANCHISE AGREEMENT**

The Health Mart Systems, Inc. Franchise Agreement between Health Mart Systems, Inc. (“**Franchisor**”) and the undersigned (“**Agreement**”) is hereby amended by the addition of the following language, which will be considered an integral part of the Agreement (“**Amendment**”):

1. The North Dakota Securities Commissioner requires that certain provisions contained in franchise documents be amended to be consistent with North Dakota law, including the North Dakota Franchise Investment Law, North Dakota Century Code Annotated Chapter 51-19, Sections 51-19-01 through 51-19-17. To the extent that the Agreement contains provisions that are inconsistent with the following, such provisions are hereby amended:

a. If the Franchisee is required in the Agreement to execute a release of claims or to acknowledge facts that would negate or remove from judicial review any statement, misrepresentation or action that would violate the Law, or a rule or order under the Law, such release shall exclude claims arising under the North Dakota Franchise Investment Law, and such acknowledgments shall be void with respect to claims under the Law.

b. Covenants not to compete during the term of and upon termination or expiration of the Agreement are enforceable only under certain conditions according to North Dakota Law. If the Agreement contains a covenant not to compete which is inconsistent with North Dakota Law, the covenant may be unenforceable.

c. If the Agreement requires litigation to be conducted in a forum other than the State of North Dakota, the requirement is void with respect to claims under the North Dakota Franchise Investment Law.

d. If the Agreement requires that it be governed by the law of a state, other than the State of North Dakota, to the extent that such law conflicts with North Dakota Law, North Dakota Law will control.

e. If the Agreement requires mediation or arbitration to be conducted in a forum other than the State of North Dakota, the requirement may be unenforceable under the North Dakota Franchise Investment Law. Arbitration involving a franchise purchased in the State of North Dakota must be held either in a location mutually agreed upon prior to the arbitration or if the parties cannot agree on a location, the location will be determined by the arbitrator.

f. If the Agreement requires payment of a termination penalty, the requirement may be unenforceable under the North Dakota Franchise Investment Law.

g. Any provision that provides that the parties waive their right to a jury trial may not be enforceable under North Dakota law.

h. Any provision that provides that the franchisee consent to a waiver of punitive and exemplary damages may not be enforceable under North Dakota Law.

i. Any provision that requires the franchisee to consent to a claims period that differs from the applicable statute of limitations period under North Dakota Law may not be enforceable under North Dakota Law.

j. If the Agreement requires the franchisee to consent to a limitation of claims, the statute of limitations period under North Dakota law applies.

k. If the Agreement requires the franchisee to pay all costs and expenses incurred by Franchisor in enforcing the agreement, the prevailing party in any enforcement action is entitled to recover all costs and expenses, including attorneys’ fees.

2. Each provision of this Amendment is effective only to the extent that the jurisdictional requirements of the North Dakota Franchise Investment Law, with respect to each such provision, are met independent of this Amendment. This Amendment will have no force or effect if such jurisdictional requirements are not met.

The parties hereto have duly executed and delivered this Amendment to the Agreement on the dates set forth below.

(Signature page is the next page.)

HEALTH MART SYSTEMS, INC.

FRANCHISEE:

by: _____

[Printed name]

[Title]

[Date]

[SIGNATURE IF FRANCHISEE IS AN
INDIVIDUAL]

[IF FRANCHISEE IS A BUSINESS ENTITY, PRINT
NAME OF BUSINESS ENTITY]
by: _____

[Printed name]

[Title]

[Date]

**RHODE ISLAND AMENDMENT TO HEALTH MART SYSTEMS, INC.
FRANCHISE AGREEMENT**

The Health Mart Systems, Inc. Franchise Agreement between Health Mart Systems, Inc. (“**Franchisor**”) and the undersigned (“**Agreement**”) is hereby amended by the addition of the following language, which will be considered an integral part of the Agreement (“**Amendment**”):

1. The Rhode Island Securities Division requires that certain provisions contained in franchise documents be amended to be consistent with Rhode Island law, including the Franchise Investment Act, R.I. Gen. Law. §§ 19-28.1-1 to 19-28.1-34 (“**Act**”). To the extent that this Agreement contains provisions that are inconsistent with the following, such provisions are hereby amended:

a. If the Agreement requires litigation to be conducted in a forum other than the State of Rhode Island, the requirement is void with respect to any claims brought under the Act.

b. If this Agreement requires that it be governed by a state’s law, other than the State of Rhode Island, to the extent that such law conflicts with the Act, such law is void.

c. If the franchisee is required in the Agreement to execute a release of claims or to acknowledge facts that would negate or remove from judicial review any statement, misrepresentation, or action that would violate the Act, or a rule or order under the Act, such release will exclude claims arising under the Act, and such acknowledgments will be void with respect to claims under the Act.

2. Each provision of this Amendment is effective only to the extent that the jurisdictional requirements of the Rhode Island Franchise Investment Act, with respect to each such provision, are met independent of this Amendment. This Amendment will have no force or effect if such jurisdictional requirements are not met.

The parties hereto have duly executed and delivered this Amendment to the Agreement on the dates set forth below.

HEALTH MART SYSTEMS, INC.

FRANCHISEE:

by: _____

[Printed name]

[Title]

[Date]

[SIGNATURE IF FRANCHISEE IS AN
INDIVIDUAL]

[IF FRANCHISEE IS A BUSINESS ENTITY, PRINT
NAME OF BUSINESS ENTITY]

by: _____

[Printed name]

[Title]

[Date]

**WASHINGTON AMENDMENT TO HEALTH MART SYSTEMS, INC.
FRANCHISE AGREEMENT, FRANCHISE COMPLIANCE QUESTIONNAIRE, AND RELATED
AGREEMENTS**

The Health Mart Systems, Inc. Franchise Agreement between Health Mart Systems, Inc. (“**Franchisor**”) and the undersigned (“**Agreement**”) is hereby amended by the addition of the following language, which will be considered an integral part of the Agreement (“**Amendment**”):

1. The Director of the Washington Department of Financial Institutions requires that certain provisions contained in franchise documents be amended to be consistent with Washington law, including the Washington Franchise Investment Protection Act, Wash. Rev. Code §§ 19.100.010 to 19.100.940 (“**Act**”). To the extent that the Agreement contains provisions that are inconsistent with the following, such provisions are hereby amended:

a. In the event of a conflict of laws, the provisions of the Washington Franchise Investment Protection Act, Chapter 19.100 RCW shall prevail.

b. RCW 19.100.180 may supersede the franchise agreement in your relationship with the Franchisor including the areas of termination and renewal of your franchise. There may also be court decisions which may supersede the franchise agreement in your relationship with the franchisor including the areas of termination and renewal of your franchise.

c. In any arbitration or mediation involving a franchise purchased in Washington, the arbitration or mediation site will be either in the state of Washington, or in a place mutually agreed upon at the time of the arbitration or mediation, or as determined by the arbitrator or mediator at the time of arbitration or mediation. In addition, if litigation is not precluded by the franchise agreement, a franchisee may bring an action or proceeding arising out of or in connection with the sale of franchises, or a violation of the Washington Franchise Investment Protection Act, in Washington.

d. A release or waiver of rights executed by a franchisee shall not include rights under the Washington Franchise Investment Protection Act except when executed pursuant to a negotiated settlement after the agreement is in effect and where the parties are represented by independent counsel. Provisions such as those which unreasonably restrict or limit the statute of limitations period for claims under the Act, rights or remedies under the Act such as a right to a jury trial may not be enforceable.

e. Transfer fees are collectable to the extent they reflect Franchisor’s reasonable estimated or actual costs in effecting a transfer.

2. Pursuant to RCW 49.62.020, a noncompetition covenant is void and unenforceable against an employee, including an employee of a franchisee, unless the employee’s earnings from the party seeking enforcement, when annualized, exceed \$100,000 per year (an amount that will be adjusted annually for inflation). In addition, a noncompetition covenant is void and unenforceable against an independent contractor of a franchisee under RCW 49.62.030 unless the independent contractor’s earnings from the party seeking enforcement, when annualized, exceed \$250,000 per year (an amount that will be adjusted annually for inflation). As a result, any provisions contained in the franchise agreement or elsewhere that conflict with these limitations are void and unenforceable in Washington.

3. RCW 49.62.060 prohibits a franchisor from restricting, restraining, or prohibiting a franchisee from (i) soliciting or hiring any employee of a franchisee of the same franchisor or (ii) soliciting or hiring any employee of the franchisor. As a result, any such provisions contained in the franchise agreement or elsewhere are void and unenforceable in Washington.

4. Each provision of this Amendment is effective only to the extent that the jurisdictional requirements of the Rhode Island Franchise Investment Act, with respect to each such provision, are met independent of this Amendment. This Amendment will have no force or effect if such jurisdictional requirements are not met.

The parties hereto have duly executed and delivered this Amendment to the Agreement on the dates set forth below.

HEALTH MART SYSTEMS, INC.

FRANCHISEE:

by: _____

[Printed name]

[Title]

[Date]

[SIGNATURE IF FRANCHISEE IS AN
INDIVIDUAL]

[IF FRANCHISEE IS A BUSINESS ENTITY, PRINT
NAME OF BUSINESS ENTITY]
by: _____

[Printed name]

[Title]

[Date]

EXHIBIT C
EQuIPP AGREEMENT

SCHEDULE 1

STORE LOCATIONS

Note: This Schedule forms a part of the Pharmacy Quality Solutions EQuIPP Services for Participating Pharmacy Agreement, which is attached hereto. For convenience purpose only, this Schedule is being presented first and then the full Agreement follows.

This List of stores identifies

ALL stores that are associated with the Participating Pharmacy

**ALL STORES and NPI/NCPDP #'s MUST BE VERIFIED FOR ACCURACY AND
COMPLETENESS**

[List location name, address contact info, phone, email and any store identifier information]

**EQUIPP SERVICES AGREEMENT
FOR PARTICIPATING PHARMACY**

THIS EQUIPP SERVICES AGREEMENT FOR PARTICIPATING PHARMACY (this “**Agreement**”), consisting of this cover page and the accompanying End User License Agreement inclusive of Terms and Conditions, together with all Exhibits hereto, is entered into by and between Pharmacy Quality Solutions, Inc., a Delaware corporation (“**PQS**”) and the “**Participating Pharmacy**” identified below. Each of the foregoing entities shall be termed a “**Party**” or, collectively, the “**Parties**.”

Participating Pharmacy is a member, franchisee or otherwise has a contractual relationship with one of the following Affiliates of McKesson Corporation (“**McKesson**”): Health Mart Systems, Inc. or Strategic Health Alliance II, Inc. d/b/a AccessHealth and Health Mart Atlas, LLC (McKesson and the Affiliates collectively referred to as “**Customer**”).

McKesson has entered into a separate EQuIPP Services Agreement with PQS (the “**Customer Agreement**”). Pursuant to the terms of the Customer Agreement, PQS agrees to provide Participating Pharmacy with access to EQuIPP (defined in this Agreement) during the term of the Customer Agreement, after Participating Pharmacy has executed this Agreement as long as Participating Pharmacy’s agreement with Customer (the “**Customer Pharmacy Agreement**”) remains in full force and effect and good standing or Participating Pharmacy establishes a similar relationship with another Affiliate as determined by Customer from time to time . The right to access and use EQuIPP (defined below) is subject to all the terms and conditions of this Agreement and the End User License Agreement (“**EULA**”) as amended from time to time. A copy of the EULA in effect as of the Effective Date is attached hereto as Exhibit A. Participating Pharmacy expressly understands and agrees that (i) Participating Pharmacy is solely responsible for analyzing this Agreement and for obtaining any desired legal representation or advice with respect to the terms and conditions of, and Participating Pharmacy’s rights and obligations under, this Agreement, (ii) in entering into the Customer Agreement with PQS, Customer has not acted as Participating Pharmacy’s agent or legal advisor in reviewing or negotiating this Agreement, and (iii) Customer shall have no liability for any claim or loss of Participating Pharmacy or PQS under or arising out of this Agreement. Capitalized terms hereunder shall have the meanings set forth within Section 1 of the Terms and Conditions or within the body of this Agreement.

PARTICIPATING PHARMACY NAME AND ADDRESS			
Participating Pharmacy Name**:			
Address:	City:	State:	Zip Code:
Contact:	Phone:	Email:	
TERM OF AGREEMENT			
This Agreement commences on the Effective Date and the term (“ Term ”) shall continue in effect for the term of the Customer Agreement, unless this Agreement is earlier terminated by either Party as permitted under this Agreement.			

**In the event Participating Pharmacy has multiple store locations, each such location shall be set forth on Schedule 1 attached hereto as modified from time-to-time between the Parties.

By signing below, each Party agrees with all the terms of this Agreement and specifically acknowledges its consent to each and every such term, and both Parties have caused this Agreement to be executed and delivered by their duly authorized officers as of the Effective Date as identified below.

PHARMACY NAME

PHARMACY QUALITY SOLUTIONS, INC.

By:

By:

Signature of Authorized Representative

Signature of Authorized Representative

Print Name of Representative

Print Name of Representative

Print Title of Representative

Print Title of Representative

Date

“**Effective Date**”

EXHIBIT A

END USER LICENSE AGREEMENT

(Last updated March 11, 2022)

BY ACCESSING OR USING EQUIPP.PHARMACYQUALITY.COM DIRECTLY VIA THE INTERNET OR THROUGH A MOBILE APPLICATION (COLLECTIVELY, THE "WEBSITE"), YOU AGREE TO ALL OF THE FOLLOWING TERMS AND CONDITIONS SET FORTH BY PHARMACY QUALITY SOLUTIONS, INC. ("PQS") WHICH FOR PURPOSES OF THIS END USER LICENSE AGREEMENT ("EULA") INCLUDES PQS' THIRD PARTY VENDORS AND AFFILIATES AND THEIR RESPECTIVE AFFILIATES. PQS RESERVES THE RIGHT TO MODIFY THIS EULA AT ANY TIME BY POSTING SUCH MODIFICATIONS TO THE WEBSITE. YOUR CONTINUED ACCESS TO OR USE OF THE WEBSITE AFTER SUCH MODIFICATIONS ARE POSTED, SIGNIFIES YOUR AGREEMENT TO ALL OF THE PROVISIONS OF THE EULA THAT ARE DISPLAYED ON THE WEBSITE ON THE DATE OF SUCH USE.

PQS ENTERS INTO SEPARATE SUBSCRIPTION AGREEMENTS (EACH, A "SUBSCRIPTION AGREEMENT") WITH PARTIES (EACH, A "PQS CUSTOMER") WHO WISH TO OBTAIN A LICENSE TO ACCESS AND USE PQS' EQUIPP® PLATFORM AND SERVICES ("EQUIPP SERVICES" OR "SERVICES"). IN CONNECTION A SUBSCRIPTION AGREEMENT, PQS CUSTOMERS MAY DESIGNATE INDIVIDUAL USERS ("DESIGNATED USERS") SUBJECT TO THE TERMS AND CONDITIONS OF THE SUBSCRIPTION AGREEMENT AND THIS EULA TO ACCESS AND USE OF THE SERVICES. DESIGNATED USERS ARE SOMETIMES REFERRED TO AS "YOU" OR "YOUR".

IF A CONFLICT ARISES BETWEEN THIS EULA AND THE SUBSCRIPTION AGREEMENT IN PLACE BETWEEN PQS AND THE PQS CUSTOMER, THE SUBSCRIPTION AGREEMENT WILL GOVERN YOUR USE OF THE WEBSITE, INCLUDING DATA PROTECTIONS FOR PROTECTED HEALTH INFORMATION ("PHI") AS DEFINED UNDER THE HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT OF 1996 ("HIPAA"). IF YOU ACCESS NON-PUBLICLY AVAILABLE PORTIONS OF THE WEBSITE TO WHICH YOU HAVE BEEN AUTHORIZED ACCESS PURSUANT TO A SUBSCRIPTION AGREEMENT, ADDITIONAL TERMS OF USE MAY APPLY AND WILL CONTROL IN THE EVENT OF CONFLICT WITH THIS EULA.

SCOPE OF LICENSE AND LIMITATIONS

Subject to the terms of this EULA, PQS grants You, solely in your role as a Designated User of a PQS customer organization, a limited, non-exclusive, nontransferable, and revocable license ("License") to use and access the information on the Website. The term of this License (1) shall automatically terminate with the end of the Subscription Agreement with the PQS Customer or termination of your role as a Designated User, (2) can be terminated in accordance with the Subscription Agreement or (3) at any time and for any reason by PQS with or without notice to You for breach of this EULA. Any and all content accessible on the Website (including, for example, and without limitation, performance measurement reports and links to performance improvement tools related to appropriate medication use and pharmacy services, educational materials, scientific content, and PHI) is owned by PQS, its business associates, or third parties. You are authorized to use this information provided on the Website solely for your use in accordance with the Subscription Agreement, and subject to the restriction set forth in this EULA. You may not access or use this information for any other purposes. You may not modify, republish, post, transmit, or distribute any information without the express written consent of PQS. PQS expressly retains all right, title, and interest in and to any proprietary information. Failure to adhere to these provisions could subject you to serious penalties under federal law. Designated Users are authorized to use the Services provided on the Website solely in connection with the EquIPP Services and strictly in accordance with the terms of the Subscription Agreement and this EULA.

UPDATES AND UPGRADES

PQS may from time to time offer or otherwise require PQS Customers, and indirectly, each Designated User, access to an Update or Upgrade.

The Upgrade options may be varied by PQS from-time-to-time or on a continuous basis. If and when the Update or Upgrade is applied to PSQ Customers, and indirectly to Designated Users, the applicable Update or Upgrade will be considered part of the Services and your use of the Upgrade will be subject to this EULA and any other agreement governing use of such Upgrade. If you do not agree to be bound by such superseding agreement, you may not use the Upgrade, and in the event that you are then currently using or have used any Upgrade without agreeing to any superseding agreement, you must cease such use and remove the Upgrade from your Computer and all Licenses to the Upgrade will be considered terminated. PQS reserves the right to discontinue support for all versions of the Software other than the then-current released version or updated Software. To be eligible to use any Software identified as an Upgrade, you must be first licensed and current in your License for the Software eligible for the Upgrade.

For the purposes of this EULA:

“Update” means any patch, bug fix or any other update of the Services delivered to PQS Customers and you pursuant to this EULA and/or a Subscription Agreement; and

“Upgrade” means any new version of the Services delivered to PQS Customers and you pursuant to this EULA and/or a Subscription Agreement.

PRIVACY

Your use of the Website is also governed by our Privacy Policy, which is incorporated into this EULA herein by reference. By using the Website, you indicate that you understand and agree to the practices described in the Privacy Policy. Our privacy policy may be accessed by clicking on the “Privacy Policy” link located within the Website euipp.pharmacyquality.com.

PROTECTED HEALTH INFORMATION

Your organization is a "Covered Entity" under the HIPAA Privacy Standards as defined in Appendix A hereto. In connection with Your use of the Website and the EQuIPP Services, You may upload to the Website, and PQS may need access to “**Protected Health Information**”, “**PHI**” or “**ePHI**” as those terms are defined under HIPAA Privacy Standards (45 C.F.R. Section 160.103) in providing the EQuIPP Services on PQS customer’s behalf. In the event you do access any PHI in connection with your use of the Website or the EQuIPP Services, you shall only utilize such PHI in accordance with minimum necessary standards under HIPAA, and shall maintain and ensure the confidentiality, privacy and security of PHI in accordance with HIPAA Privacy Standards. You and PQS shall be responsible for using appropriate safeguards to maintain and ensure the confidentiality, privacy and security of Protected Information transmitted, in accordance with the standards and requirements as set forth in the HIPAA Business Associate Agreement set forth in Appendix A. Each Designated User with access to PHI via the Website hereby represents and warrants that the organization information that determines access (i.e.

NPI number) provided either to PQS directly by the user, or provided on behalf of the user by a PQS customer organization, is accurate and up-to-date. In the event a Designated User is a Pharmacy or Pharmacy Representative, you shall immediately inform PQS if its organization information (i.e. NPI number) changes.

PQS may use and disclose the PHI of your organizations patients and customers to streamline, calculate and display performance, measure and track progress, and report such performance to health

care insurance providers, without your organization's written authorization. We may share the PHI your organization provides with insurers to assist in their determination of whether performance benchmarks are being met, and whether payments are appropriate. We may also disclose the PHI to health care insurance providers that provide services to your organization and its customers and patients, so that it can improve the quality and efficacy of the health care services your organization provides or for its health care operations. We may also use your PHI to create de-identified data, which no longer identifies your organization's customers or patients, and which may be used or disclosed for analytics, business planning or other purposes.

Certain personal information and PHI may be disclosed to third parties (for example, accrediting bodies for continuing education or entities which provide board certifications) in order to provide the information and services that your organization requests, and may be used by both PQS and third parties to provide that information and/or perform the EQulPP Services. You acknowledge that certain activities may require PQS to share your private information, personal information and/or PHI with the associated third-party accreditor or entity providing board certification. PQS is not responsible for the use of any such information by such third-party accreditor or entity providing board certification, including use by any of the same in a manner not intended when such information is disclosed to them.

PQS may combine, in a non-personally-identifiable format, the information that PQS collects from you with information from other users to create aggregate data, which may be used by us for research purposes or shared with third parties.

PQS may create and use aggregated and/or de-identified data generated or derived from Customer Data or data generated or derived from the use of the Platform by Customer and the Authorized Users, for PQS' business purposes, subject to any applicable legal limitations on the use thereof. Such resulting data is not Customer Data and, as between the Parties, PQS shall own all right, title, and interest in such resulting data. Customer specifically acknowledges and agrees that PQS is permitted to utilize the aggregated and/or de-identified data for such educational, promotional, regulatory, and commercial purposes as PQS may determine in its sole discretion. PQS shall have the right to directly (or through the use of third parties) monitor the operation of the Platform and the use of the Platform by Customer and Authorized Users to provide and improve the Platform, Documentation, and PQS' other products and services, and help ensure compliance with the Agreement by Customer and Authorized Users.

HIPAA COMPLIANCE

You represent and warrant that you will comply with all applicable confidentiality and privacy laws and regulations with respect to Protected Health Information, PHI or ePHI and use of the Services. Without limiting the generality of the foregoing, You are responsible and liable for your use of the Website and Services, including without limitation for using the Services in compliance with HIPAA. You acknowledge that any Protected Health Information, PHI or ePHI that is downloaded to a printer, an Excel file, or otherwise, is outside of the scope of the Services and PQ shall have no responsibility for the use and protection of such Protected Health Information, PHI or ePHI. You agree not to send Protected Health Information, PHI or ePHI to PQS, a PQS Customer, or any authorized party via any unsecured means, including via unsecured (nonencrypted) email. PQS has implemented procedures to verify the identity of users, including multi-factor authentication and two-step verification technical mechanisms, prior to allowing access to Protected Health Information, PHI or ePHI ("Security Controls"). These Security Controls has been implemented to help meet the Person or Entity Authentication section of the HIPAA Security Rule (see 164.312(d)). Opting out of these Security Controls may violate the requirement of the HIPAA Security Rule. IF YOU OPT OUT OF THIS SECURITY CONTROL YOU ARE FULLY RESPONSIBLE FOR THE IMPLICATIONS OF THIS DECISION, INCLUDING THE IMPACT OF NON-COMPLIANCE WITH APPLICABLE LAW.

WEBSITE CONTENT

PQS may provide, through the Website, the following services that include without limitation the following (collectively, "Website Content"): (i) provision of the Website, EQuIPP Services and other online services and Internet sites; (ii) display, performance, provision, and use of: information such as performance reporting, benchmarks, status reports, and other educational, promotional, product, pricing and marketing information ("Information"); (iii) copyrighted works, images, software, audio, data, designs, photographs, text, music, video, graphics, messages, and other such content; and (iv) other Materials, including Our Materials and Third Party Materials

INTELLECTUAL PROPERTY RIGHTS

You acknowledge and agree that, as between the parties, the Services, PQS' Confidential Information disclosed to Customer, and PQS' Confidential Information conceived, reduced to practice, made, acquired, or developed by PQS in connection with the Services, Subscription Agreement or this EULA, or conceived, reduced to practice, made, or developed by PQS prior to execution of the Agreement or separate from PQS' performance of the Agreement, all derivatives of the foregoing (collectively, "PQS Properties"), and all Intellectual Property Rights in the foregoing, are and will remain the sole property of PQS or its licensors, and no rights, title, or interest are granted to you, any PQS Customer, or any third party under a Subscription Agreement or this EULA with respect to the PQS Properties and all Intellectual Property Rights therein other than as expressly set forth in the Agreement. For the purposes of this EULA, Intellectual Property Rights means any and all registered and unregistered rights granted, applied for, or otherwise now or hereafter in existence under or related to any patent, copyright, trademark, trade secret, database protection, or other intellectual property rights laws, and all similar or equivalent rights or forms of protection, in any part of the world.

Other than as expressly permitted in the Agreement, nothing in the Agreement shall be construed to transfer any right, title, or interest to Customer of PQS Properties or any Intellectual Property Rights therein. Customer disclaims all rights to the PQS Properties and any Intellectual Property Rights therein, other than those rights granted in the Agreement, and will assert no claim (copyright, patent, or otherwise) to their use, development, and/or production. Customer may not access, use, resell, sell, license, sublicense, distribute, make available, rent, or lease the PQS Properties or any Intellectual Property Rights therein for any purpose, except as expressly authorized by the Agreement. Customer agrees to respect and not to remove, obliterate, or cancel from view any copyright, trademark, confidentiality or other proprietary notice, mark, or legend appearing on the PQS Properties or output generated by the PQS Properties. Customer shall undertake no action that will interfere with or diminish the Intellectual Property Rights of PQS or its third-party licensors.

PQS owns any input, feedback, and suggestions it provides to PQS (Feedback) and has the full right to exploit such Feedback in any manner and for any purpose, including to improve the Platform and create other products and services, without any compensation to Customer.

FEEDBACK

We encourage you to send us messages, feedback, or data, including, for example, ideas, comments, suggestions, or questions about the Service or any other product or service (collectively, "Feedback"). You agree not to send us any information or ideas that are sensitive or confidential, and you acknowledge that any Feedback we receive from you will not be considered confidential. You grant us a worldwide, royalty-free, exclusive, transferable, sublicensable, perpetual, and irrevocable license to record, use, practice, copy, modify, adapt, create derivative works of, store, host, publish, publicly perform, publicly display, distribute, communicate, and transmit your Feedback in any and all media or distribution methods (now known or later developed), to exercise all Intellectual Property Rights in and to your Feedback. Without limitation and notwithstanding anything to the contrary herein, we will have exclusive ownership of all present and future rights to the Feedback. We will be entitled to use the Feedback for any commercial or other purpose whatsoever (including, for example, developing, improving, producing, providing, or marketing products and services) without compensation to you or any other person sending the Feedback, and we will not be under any obligation to tell you if and how we use the Feedback.

Except as expressly permitted, you may not, modify, copy, reproduce, republish, upload, post, transmit, hyperlink to or from, or distribute in any way any Website Content from the Website, including code and software underlying this Website, nor may you sell, transfer or otherwise use the Website or the Website Content in commerce or for any public or commercial endeavor without PQS's prior and express written consent.

GENERAL USE RULES

By using or accessing the Website or Services, you agree to adhere to the following general use rules. We reserve the right to suspend or terminate your access to the Website, and to refuse any and all current or future access to, or use of, the Website and the Services for violation of any of the following general use rules.

(i) You agree not to use obscene, racist, vulgar, discourteous, indecent or sexually explicit language or images and agree not to post, upload, e-mail, transmit, distribute, or otherwise make available, any such content or materials onto the Website.

(ii) You agree not to post or communicate infringing material or harassing communications or advertisements, and you agree not to post, communicate, upload, e-mail, transmit, distribute, or otherwise make available any material or content that infringes and/or violates any rights of a third party (including its intellectual property, data or other proprietary rights), or any law, regulation or ordinance.

(iii) You agree not to pose any harassing, slanderous, libelous or derogatory information or content, or any advertisements for products or services, "junk mail", spam, chain mail, pyramid schemes, or other form of commercial or illegal solicitation.

(iv) You agree not to harm, or attempt to harm minors in any way by your use or access of the Website or Services.

(v) You agree not to create or use a false identity for the purpose of misleading others.

(vi) You agree not to post or distribute any software or other materials that contain a virus, worm, trojan horse or other harmful or disabling code or component.

(vii) You agree not to interfere with, or disrupt, the operation of the Website and/or the Services, or with servers or networks connected to, or used in connection with the operation of the Website.

(viii) You agree not to disobey any requirements, procedures, policies or regulations established by the owners or operators of any networks, hardware, or software connected to, or used in connection with the operation of the Website, or any requirement that we post on the Website.

(ix) You agree not to engage in any activity or use any device, software or routine that interferes with access to the Website or the proper operation of the Website or the EQUIPP Services.

(x) You agree not to delete or revise any Website Content or information of any other user.

(xi) You agree not to take any action that imposes an unreasonable large load on the Website's infrastructure.

RESTRICTIONS ON USE OF WEBSITE CONTENT, MATERIALS AND MARKS.

Your use of the Website is subject to our and other third party's intellectual property rights. Except as expressly authorized in this EULA, you agree that: (i) You will not reproduce, edit, modify, rent, license, sell, distribute, mirror, republish, download, transmit, or create derivative works from any Materials displayed on, or made available through the Website, or in connection with the Services, in whole or in part, by any means now known or later developed; (ii) You will not attempt to decipher, decompile, disassemble, modify, or reverse engineer any part of the Website or software comprising or in any way making up part of the Website or EQUIPP Services; (iii) You will not copy, post or transmit any Materials that you receive from, access, or retrieve from, the Website or through the Services, to any server, or network of computers; (iv) You will not remove or modify any copyright or trademark notice, or other notice of ownership, displayed on, or affixed to, any Materials, including any copies of the Licensed Materials that you download and/or distribute; and (e) You will not frame the Website within a mark other than that of PQS.

ACTIVITIES WITH THIRD PARTIES ON OR FROM THE WEBSITE

(A) Linking to Third Party Sites from PQS Website

From time to time, PQS may provide links on the Website that will allow you to connect with websites of third parties that are not under our control. PQS is providing these links only as a convenience to you. Further, there may be times while in the Website that you could be directed to sites that are beyond PQS's control. This includes links from other organizations, sponsors or volunteers that may use our logo(s) as part of an EULA with PQS. These other sites may send their own cookies to users, collect data, solicit personal information, or contain information that you may find inappropriate or offensive.

(B) No Warranties

PQS MAKES NO REPRESENTATIONS OR WARRANTIES CONCERNING THE CONTENT OF, OR THE PRIVACY PRACTICES OF, OR THE AVAILABILITY OR QUALITY OF ANY PRODUCTS, MATERIALS OR SERVICES THAT YOU PURCHASE FROM A THIRD PARTY WEBSITE THAT LINKS TO OR FROM ANY PQS WEBSITE EVEN IF WE PROVIDE LINKS TO SUCH SITES ON THE WEBSITE. WE ACCEPT NO RESPONSIBILITY FOR, AND WE EXPRESSLY DISCLAIM ANY WARRANTIES OR LIABILITY RELATING TO, THE ACCURACY, RELEVANCY, COPYRIGHT COMPLIANCE, LEGALITY, OR DECENCY OF MATERIALS DISPLAYED ON, OR CONTAINED IN, WEBSITES LINKED TO, OR TO WHICH YOU ARE DIRECTED FROM, OUR WEBSITE. YOU ACCESS AND USE SUCH WEB SITES, AND THE SERVICES PROVIDED IN CONNECTION THEREWITH, AT YOUR OWN RISK.

(C) No Endorsement

Links to other websites do not imply an endorsement of the materials, products, content, ideas or interactive communications displayed on, or disseminated at or through those websites, nor does the existence of a link to another of our websites imply that the organization or person publishing at that website endorses any of the materials or ideas at our Website. PQS reserves the right to disable links from third party sites to our Website at any time without prior notice.

DISCLOSURE OF AFFILIATIONS

PQS works with a variety of third parties to provide the services available on the Website and to provide links to other websites. These third parties include, for example, accrediting bodies, content providers, technology providers, and suppliers of medical products, information, and services. These entities may supply information that is posted on or accessible through the Website, and, solely in the case of accrediting bodies, may set standards applicable to certain content, but they do not control the content or the operation of the Website.

ACCREDITATION

PQS IS NOT RESPONSIBLE FOR ENSURING THE VALIDITY OF ANY CONTINUING EDUCATION CREDITS; ISSUING NOTIFICATION OF CREDITS OR CERTIFICATION; ENSURING THE SUFFICIENCY OF CREDITS FOR LICENSE RENEWAL; ENSURING PROGRAM CONTENT IS SUFFICIENT TO EARN CONTINUING EDUCATION CREDIT; OR ENSURING THE ACCURACY OR COMPLETENESS OF PERSONAL TRANSCRIPTS.

INFORMATIONAL NATURE OF THE SITE: NO MEDICAL ADVICE

THE INFORMATION ON THE WEBSITE IS INTENDED FOR USE FOR QUALITY REPORTING PURPOSES AND/OR EDUCATION ONLY AND SHOULD NOT BE CONSTRUED AS MEDICAL ADVICE. THIS INFORMATION SHOULD NOT BE USED IN PLACE OF SEEKING PROFESSIONAL MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT BY LICENSED PRACTITIONERS. PQS DOES NOT PRACTICE MEDICINE OR LAW, AND DOES NOT OFFER ANY OTHER PROFESSIONAL ADVICE OR SERVICES. YOU ASSUME FULL RESPONSIBILITY FOR APPROPRIATE USE OF THE INFORMATION AVAILABLE THROUGH THE WEBSITE.

If you think you may have a medical emergency, call your doctor or 911 immediately. PQS does not recommend or endorse any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned on the Website.

SPECIAL ADMONITIONS FOR CHILDREN AND INTERNATIONAL USERS

The Website is designed for adults 18 years of age or older. Users under the age of 18 are not permitted to use the Website. If you are not a U.S. resident, you may access the Website solely at your own risk and are responsible for compliance with local laws and regulations, if applicable.

If you access our Website from outside the United States, be advised that the Website may contain references to Information, Website Content, Materials, Services, products and other information and materials that may not be available, or may be prohibited, in your country. We reserve the right to limit the provision of any of our Website, Website Content, Information, Materials, and any part of the Services to any person, geographic area or jurisdiction we so choose in the exercise of our sole discretion. The Services, or any part thereof, is void where prohibited. You agree to comply with all Applicable Law regarding the use of our Website, Information, Website Content, Materials, and any part of the Services, including any local rules regarding acceptable online conduct. You also specifically agree to comply with all applicable local, state, federal and international laws, regulations, ordinances, rules, codes and orders of all governmental authorities having jurisdiction over you, the applicable PQS Customer, and PQS ("Applicable Law") regarding the transmission of technical data or other information exported from the United States or the country in which you reside.

As a Designated User, your personal information has been disclosed to PQS to facilitate your access to the Website, and as such you consent to the uses of such information described in the Privacy Policy, located at <https://www.equipp.org/content/equipp/EQUIPP.Privacy.pdf>, and acknowledge that such disclosure and use shall be governed by the Applicable Law of the United States and the State of Delaware and not the law of your home country. If you do not agree to the foregoing, please contact PQS via e-mail at support@equipp.org, or the PQS customer for whom you are a designated user, to modify or terminate your access to the Website.

DISCLAIMER OF WARRANTY

THE WEBSITE AND ALL SERVICES, INFORMATION, WEBSITE CONTENT AND MATERIALS MADE AVAILABLE ON OR THROUGH THIS WEBSITE ARE PROVIDED ON AN "AS IS," "WHERE IS," "WITH ALL FAULTS" AND "AS AVAILABLE" BASIS WITHOUT REPRESENTATIONS OR WARRANTIES OF ANY KIND WHATSOEVER, EXPRESS OR IMPLIED. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, PQS EXPRESSLY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, RELATING TO THE WEBSITE, AND ALL SERVICES, INFORMATION, WEBSITE CONTENT AND MATERIALS, INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS. WITHOUT LIMITING THE FOREGOING, PQS MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS, CORRECTNESS, OR TIMELINESS OF THE SERVICES OR WEBSITE CONTENT PROVIDED ON OR THROUGH THE USE OF THE WEBSITE.

WHEN USING THE WEBSITE, INFORMATION WILL BE TRANSMITTED OVER A MEDIUM THAT MAY BE BEYOND PQS'S CONTROL AND JURISDICTION. ACCORDINGLY, PQS DOES NOT ASSUME ANY LIABILITY FOR OR RELATING TO THE DELAY, FAILURE, INTERRUPTION, OR CORRUPTION OF ANY DATA OR OTHER INFORMATION TRANSMITTED IN CONNECTION WITH USE OF THE WEBSITE.

PQS DOES NOT WARRANT THAT THIS WEBSITE OR ANY SERVICES OR INFORMATION MADE AVAILABLE ON OR THROUGH THIS WEBSITE, INCLUDING WITHOUT LIMITATION ANY THIRD-PARTY SOFTWARE, PRODUCTS, ITEMS OR OTHER MATERIALS USED IN CONNECTION WITH THIS WEBSITE, WILL BE TIMELY, SECURE, UNINTERRUPTED OR ERROR FREE, OR THAT DEFECTS WILL BE CORRECTED.

AT ANY TIME AND WITHOUT NOTICE, PQS MAY, FOR ANY REASON WHATSOEVER AND WITHOUT INCURRING ANY LIABILITY OR OBLIGATION TO YOU OR ANY OTHER PARTY, TERMINATE OR SUSPEND THE DISPLAY, OPERATION AND/OR PROVISION OF (A) THE WEBSITE(OR ANY PART THEREOF, INCLUDING ANY CONTENT, INFORMATION, AND/OR MATERIALS); (B) ANY PART OF THE SERVICES; AND/OR (C) YOUR ACCESS TO THE WEBSITE OR ANY PART OF THE SERVICES.

ANY INFORMATION DOWNLOADED OR OTHERWISE OBTAINED THROUGH THE USE OF THE WEBSITE IS DONE AT YOUR OWN DISCRETION AND RISK. YOU SHALL BE SOLELY RESPONSIBLE FOR ANY DAMAGE OR LOSS OF DATA THAT RESULTS FROM THE DOWNLOADING OR USE OF THE INFORMATION AND FOR ANY RESULTS OR LACK OF RESULTS FROM THE USE OF SUCH INFORMATION.

LIMITATION OF LIABILITY

IN NO EVENT AND UNDER NO CIRCUMSTANCES SHALL PQS BE LIABLE FOR ANY CLAIMS, DAMAGES OR LOSSES WHATSOEVER OF ANY KIND, WHETHER DIRECT, INDIRECT, SPECIAL, INCIDENTAL, CONSEQUENTIAL, EXEMPLARY OR PUNITIVE, AND WHETHER ARISING FROM AN ACTION IN CONTRACT, TORT, OR OTHERWISE, RELATED TO OR IN CONNECTION WITH THIS WEBSITE OR ANY SERVICES OR INFORMATION MADE AVAILABLE ON OR THROUGH THIS

WEBSITE, EVEN IF PQS HAS BEEN EXPRESSLY ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, PQS SHALL NOT BE LIABLE FOR ANY CLAIMS OR LOSSES IN CONNECTION WITH ERRORS, OMISSIONS, OR INACCURACIES OF INFORMATIONAL CONTENT, OR ANY DECISION MADE IN RELIANCE ON THE INFORMATION CONTAINED ON OR ACCESSIBLE THROUGH THE WEBSITE.

IF YOU ARE DISSATISFIED WITH ANY ASPECT OF THE WEBSITE AND/OR SERVICES, IF YOU DO NOT AGREE WITH ANY PROVISION OF THIS EULA, OR IF YOU HAVE ANY OTHER DISPUTE OR CLAIM, WITH OR AGAINST PQS WITH RESPECT TO THE EULA OF ANY OF THE WEBSITE OR ANY PART OF THE SERVICES, THEN YOU ACKNOWLEDGE AND AGREE THAT YOUR SOLE AND EXCLUSIVE REMEDY IS TO DISCONTINUE ACCESSING AND/OR USING THE WEBSITE AND/OR THE SERVICES.

SOME JURISDICTIONS DO NOT ALLOW THE EXCLUSION OF CERTAIN WARRANTIES OR THE LIMITATION OR EXCLUSION OF LIABILITY FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES. ACCORDINGLY, SOME OF THE ABOVE LIMITATIONS MAY NOT APPLY TO YOU.

INDEMNITY

AS A DESIGNATED USER FOR A PQS CUSTOMER YOU ARE ENTIRELY RESPONSIBLE FOR MAINTAINING THE CONFIDENTIALITY OF ALL USERNAMES AND PASSWORDS AND ALL ACCOUNTS THAT YOU ESTABLISH IN CONJUNCTION WITH YOUR USE OF OUR WEBSITE OR THE SERVICES ("YOUR ACCOUNTS"). YOU ARE SOLELY RESPONSIBLE FOR ALL ACTIVITIES THAT OCCUR UNDER, OR RELATING TO, YOUR PASSWORDS AND YOUR ACCOUNTS, AND FOR YOUR USE OF ANY OF OUR SITE AND ANY PART OF THE SERVICE.

YOU HEREBY AGREE TO INDEMNIFY, DEFEND, AND HOLD US, AND OUR AFFILIATES, OUR OFFICERS, DIRECTORS, OWNERS, AGENTS, INFORMATION PROVIDERS, LICENSORS, AND LICENSEES (COLLECTIVELY, THE "INDEMNIFIED PARTIES"), HARMLESS FROM AND AGAINST ANY AND ALL LIABILITIES AND COSTS (INCLUDING REASONABLE ATTORNEY'S FEES) INCURRED BY THE INDEMNIFIED PARTIES IN CONNECTION WITH ANY CLAIM ARISING OUT OF, OR RELATING TO: (I) ANY BREACH BY YOU OF THIS EULA; (II) ANY UNAUTHORIZED USE BY YOU OF ANY INFORMATION, WEBSITE CONTENT, MATERIALS, OUR WEBSITE, OR ANY PART OF THE SERVICES; (III) YOUR USE OF OUR WEBSITE AND/OR ANY PART OF THE SERVICES; AND (IV) ALL ACTIVITIES RELATING TO, OR CONDUCTED UNDER, YOUR PASSWORDS AND/OR YOUR ACCOUNTS.

YOU SHALL USE YOUR BEST EFFORTS TO COOPERATE WITH PQS IN THE DEFENSE OF ANY SUCH CLAIM. WE RESERVE THE RIGHT, AT OUR OWN EXPENSE, TO ASSUME THE EXCLUSIVE DEFENSE AND CONTROL OF ANY CLAIM AGAINST YOU OR US THAT IS SUBJECT TO INDEMNIFICATION BY YOU. YOU AGREE THAT IN THE EVENT OF ANY UNAUTHORIZED USE OF OUR WEBSITE, ANY INFORMATION, WEBSITE CONTENT, MATERIALS, AND/OR ANY PART OF THE SERVICES, WE SHALL BE ENTITLED TO OBTAIN AN INJUNCTION PROSCRIBING SUCH UNAUTHORIZED USE, WITHOUT THE NECESSITY TO POST BOND, AND IN ADDITION TO ANY OTHER REMEDIES AVAILABLE AT LAW OR IN EQUITY.

TERMINATION

This EULA may be modified from time to time by PQS, and is effective until we provide notice of termination thereof on our Website. You agree to be bound by EULA as displayed on our Website at the time you use such Website and/or any part of the Services provided in connection therewith. You may not terminate any provision of this EULA. We may terminate your access to our Website, and/or any part of the Services, at any time in our sole discretion, and we reserve the right at any time to discontinue the operation of our Website, and/or the provision of any part of the Services. We may immediately terminate your right to access and/or use any of our Website and/or the Services, without notice, if, in our sole discretion, you fail to comply with any provision of this EULA.

During the term of your access to any Services and at all times thereafter, until the expiration of the applicable statute of limitations, PQS shall have the right, at its sole expense, during normal business hours, to cause an independent, certified public accountant (or, in the case of a non-financial audit, other appropriate auditor) chosen by PQS to inspect such PQS Customer records as PQS deems appropriate for the purposes of verifying the accuracy of any reports and payments delivered under this EULA (which, for clarity, shall include any reports and payments from any sublicensees) and PQS Customer's compliance with the terms hereof; provided that, PQS shall give PQS Customer or any party to this EULA, including any Designated User, reasonable prior written notice (which shall be at least five (5) days) prior to conducting any such audit. Company may require the auditor to sign a customary nondisclosure agreement prior to undertaking any such inspection, and any and all books, records, reports and other documents inspected by such accountant shall be deemed Company's Confidential Information. The accountant shall not disclose to PQS any information other than information relating to the accuracy of reports and payments delivered under this EULA, and any such information delivered to PQS, including in the form of an audit report, shall be deemed PQS Customer's Confidential Information.

INJUNCTIVE RELIEF; CHOICE OF LAW; ENTIRE AGREEMENT; SEVERABILITY; NO WAIVER

You acknowledge and agree that the unauthorized use of our Website, Information, Website Content, Materials, and/or any part of the Services could cause irreparable harm to us and/or organizations or individuals that may be associated with us worldwide. Accordingly, you agree that in the event of any unauthorized use of our Website, any Information, Website Content, Materials, and/or any part of the Service, we shall be entitled to obtain an injunction proscribing such unauthorized use, without the necessity to post bond, and in addition to any other remedies available at law or in equity.

This EULA shall be governed by and interpreted in accordance with laws of the State of Delaware, without giving effect to any conflict of laws provisions. You agree that any action at law or in equity, and/or any claim arising out of or relating to this EULA, our Website, the Services, and/or your access, and/or use, of any of our Website or the Services, shall be filed and litigated only in the state or federal courts located in Durham County, North Carolina. You hereby consent and submit to the exclusive personal jurisdiction of such courts for the purposes of litigating any such action or claim.

This EULA, along with the Privacy Policy incorporated within it by reference, and any applicable Subscription Agreement constitutes the entire agreement between you and PQS with respect to the use of Website, Website Content and EQUIPP Services.

If any provision of this EULA is held by a court of competent jurisdiction to be invalid or unenforceable, then such provision shall be enforced to the maximum extent permissible so as to affect the intent of this EULA, and the remainder of this EULA shall continue in full force and effect.

The failure of PQS to exercise or enforce any right or provision of this EULA will not be deemed a waiver of such right or provision and does not limit our right to future enforcement or remedies.

All of the provisions of this EULA, which by their nature survive the termination of the EULA, shall so survive.

Appendix A: HIPAA BUSINESS ASSOCIATE AGREEMENT

This Business Associate Agreement ("Agreement") is an Appendix to the EULA between You and PQS. Your organization ("Covered Entity") and PQS ("Business Associate") have or are entering into agreements or other documented arrangements (collectively, "Business Arrangement(s)") pursuant to which Business Associate may through its assigned providers perform EQuIPP Services for Covered Entity that require Business Associate to access health information that is protected by state and/or federal law.

1. **Definitions.** All capitalized terms not otherwise defined in this Agreement shall have the meanings set forth in HIPAA, the Privacy Standards, the Security Standards, the HITECH Act, and the Final Omnibus Rule (as defined herein). The Health Information Technology for Economic and Clinical Health Act ("HITECH Act") and its implementing regulations impose new requirements on Business Associates with respect to privacy, security, and breach notification. "Final Omnibus Rule" means those modifications to the HIPAA Rules which were mandated by the HITECH Act., and enacted by the final rule at 78, Fed. Reg. 5566.
2. **Regulatory References.** A reference in this Agreement to a section in HIPAA, the Privacy Standards, the Security Standards, the HITECH ACT, the Final Omnibus Rule or implementing regulations means the section as in effect or as amended, and for which compliance is required.
3. **Business Associate Obligations.** Business Associate may receive from Covered Entity health information that is protected under applicable state and/or federal law, including without limitation, protected health information ("PHI") as defined in the regulations at 45 CFR Parts 160 and 164 (the "Privacy Standards") promulgated pursuant to the Health Insurance Portability and Accountability Act of 1996 ("HIPAA") Other than as expressly permitted herein, Business Associate agrees not to use or disclose (or permit the use or disclosure of) PHI in a manner that would violate the requirements of the Privacy Standards if the PHI were used or disclosed by Covered Entity in the same manner. Business Associate shall use appropriate safeguards to prevent the use or disclosure of PHI other than as expressly permitted under this Agreement or as Required By Law.
4. **Use of PHI.** Business Associate may use PHI received from Covered Entity (i) for the purpose of performing services for Covered Entity as such services are defined in Business Arrangement(s), including the EULA, and the EQuIPP Services Subscriber Agreement, (ii) as necessary for the proper management and administration of the Business Associate or to carry out its legal responsibilities, provided that such uses are permitted under federal and state law, and (iii) to provide data aggregation services relating to the health care operations of the Covered Entity.
5. **Disclosure of PHI.** Business Associate may disclose PHI as necessary to perform its obligations under the Business Arrangement(s) and as permitted by law. If Business Associate discloses PHI received from Covered Entity, or created or received by Business Associate on behalf of Covered Entity, to agents, including a subcontractor (collectively, "Recipients"), Business Associate shall require Recipients to agree to the same restrictions and conditions that apply to the Business Associate under this Agreement. Business Associate shall report to Covered Entity any unauthorized use or disclosure of PHI received from Covered Entity, of which it becomes aware.
6. **Minimum Necessary.** Business Associate shall at all times comply with the "minimum necessary" requirements for use and disclosure of PHI, as defined in the Privacy Standards, Security Standards, HITECH Act, the Final Omnibus Rule, and any implementing regulations. As required by the HITECH Act, the use, disclosure, or, request of PHI, shall be limited to the minimum necessary to accomplish the intended purpose of such use, disclosure, or request. In addition, the entity disclosing the PHI (as opposed to the requester) shall make the minimum necessary determination.

7. Individual Rights Regarding Designated Record Sets. It is not anticipated that Business Associate will maintain a Designated Record Set on behalf of Covered Entity. If Business Associate agrees to maintain a Designated Record Set on behalf of Covered Entity, then Business Associate shall (a) permit an Individual to inspect or obtain a copy of PHI contained in that set about the Individual under conditions and limitations required under 45 CFR § 164.524, and (b) amend PHI maintained by Business Associate as requested by Covered Entity and in accordance with the Privacy Standards set forth at 45 CFR § 164.526.
8. Accounting of Disclosures. Business Associate shall make available to Covered Entity in response to a request from an Individual, information required for an accounting of disclosures of PHI with respect to the Individual, in accordance with 45 CFR § 164.528, incorporating exceptions to such accounting designated under the regulation and any additional requirements imposed by the HITECH Act and its implementing regulations. Such accounting is limited to disclosures that were made in the six (6) years prior to the request and shall not include any disclosures that were made prior to the compliance date of the Privacy Standards. Business Associate shall provide such information necessary to provide an accounting within fifty (50) calendar days of Covered Entity's request. Such accounting must be provided without cost to the Individual if it is the first accounting requested by an Individual within any twelve (12) month period; however, a reasonable, cost-based fee may be charged, for subsequent accountings if Business Associate informs the Covered Entity and the Covered Entity informs the Individual in advance of the fee, and the Individual is afforded an opportunity to withdraw or modify the request. Such accounting shall be provided as long as Business Associate maintains PHI.
9. Withdrawal of Consent or Authorization. Business Associate agrees, if it has notice of revocation, expiration or invalidity of patient consent for the use of PHI, to cease the use and disclosure of any such Individual's PHI except to the extent it has relied on such use or disclosure, or where an exception under the Privacy Standards expressly applies.
10. Records and Audit. Business Associate shall make available to the United States Department of Health and Human Services or its agents, its internal practices, books, and records relating to the use and disclosure of PHI received from, created, or received by Business Associate on behalf of Covered Entity for the purpose of determining Covered Entity's compliance with the Privacy and Security Standards or any other health oversight agency, in a time and manner designated by the Secretary.
11. Notice of Privacy Practices. Covered Entity shall provide to Business Associate its Notice of Privacy Practices ("Notice") when adopted and any amendments thereafter. Business Associate agrees that it will abide by the limitations of any Notice provided to it by Covered Entity of which it has knowledge. The amended Notice shall not affect permitted uses and disclosures on which Business Associate has relied prior to the receipt of such Notice.
12. Term and Termination.
- 12.1 This Agreement shall commence on the Effective Date and shall remain in effect until terminated in accordance with the terms of this Section 12. Any termination shall not affect the respective obligations or rights of the parties arising under this Agreement prior to the effective date of termination, all of which shall continue in accordance with their terms.
- 12.2 Upon Covered Entity's knowledge of a material breach by Business Associate, Covered Entity may end the violation and terminate this Agreement and the corresponding Business Arrangement, provided that:
- (a) Business Associate has been afforded the opportunity to cure the breach; and

- (b) Business Associate does not cure the breach or end the violation within twenty-five (25) calendar days after written notice thereof has been given to Business Associate by Covered Entity.

12.3 If Covered Entity is in violation of any provision of the Privacy Standards, Security Standards, or HITECH Act, the Final Omnibus Rule, or applicable federal or state privacy law, or fails to observe or perform any material covenant or agreement contained in this Agreement for twenty-five (25) calendar days after written notice thereof has been given to Covered Entity by Business Associate, the Business Associate shall have the option to terminate this Agreement, provided all Business Arrangement(s) entered into between the parties, for which this Agreement is required, are also terminated.

12.4 Subject to the survival terms in Section 12.1, this Agreement will automatically terminate without any further action of the parties upon the termination or expiration of ALL Business Arrangement(s) between Covered Entity and Business Associate.

12.5 Upon termination of this Agreement for any reason, Business Associate agrees either to return to Covered Entity or to destroy all PHI received from Covered Entity or otherwise through the performance of services for Covered Entity, that is in the possession or control of Business Associate or its agents. In the case of information for which it is not feasible to "return or destroy," Business Associate shall continue to comply with the covenants in this Agreement with respect to such PHI and shall comply with other applicable state or federal law, which may require a specific period of retention, redaction, or other treatment. Termination of this Agreement shall be cause for Covered Entity to terminate any Business Arrangement.

13. Security of Electronic-PHI. Business Associate will also comply and will require each subcontractor involved in such activity to comply with each applicable requirement of the regulations at 45 CFR Parts 160 and 164 governing the security of EPHI (the "Security Standards"). Business Associate shall, among other requirements:

13.1 Implement administrative, physical and technical safeguards that reasonably and appropriately protect the confidentiality, integrity and availability of such EPHI.

13.2 Ensure that any Recipients, to whom it provides EPHI, agrees to implement reasonable and appropriate safeguards to protect it in accordance with the Security Standards; and

13.3 Business Associate shall report to Covered Entity, without unreasonable delay, any successful Security Incident of which it becomes aware of through its security practices. Security Incidents shall not include inconsequential incidents that occur on a frequent basis such as port scans or "pings," unsuccessful log-on attempts, broadcast attacks on Business Associate's firewall, malware, denials of service or any combination thereof that are detected and neutralized by Business Associate's anti-virus and other defensive software and not allowed past Business Associate's firewall, unless such incident results in unauthorized access, use, destruction, modification or disclosure of PHI.

14. HITECH Act Requirements.

14.1 Standards to Secure Data. The HITECH Act imposes on entities covered by HIPAA and their business associates federal breach notification requirements when "unsecured" PHI is acquired by an unauthorized party. The following requirement shall apply to the extent that Business Associate accesses, maintains, retains, modifies, records, stores, destroys, or otherwise holds, uses, or discloses "unsecured PHI," which is defined in the HITECH Act as not secured through the use of a technology or methodology that renders the information "unusable, unreadable, or indecipherable" to unauthorized individuals. In addition to the notification requirements with respect to EPHI set forth herein above, Business Associate shall notify Covered Entity as soon as possible but not later than 10 days following the discovery of any unauthorized acquisition, access, use or disclosure of such unsecured PHI. Business Associate shall be

considered to have discovered such activity as of the first day on which the unauthorized activity is known or, by exercising reasonable diligence, would have been known to the Business Associate. Such notice shall include identification of each individual whose unsecured PHI has been, or is reasonably believed by the Business Associate to have been accessed, acquired, or disclosed during such unauthorized activity. Covered Entity, at its sole discretion, shall make the determination of whether or not the definition of "Breach" as that term is set forth in the HITECH Act, 45 CFR §164.402 and applicable state law has been met. If Covered Entity determines the unauthorized activity qualifies as a breach that triggers the breach notification requirements, all of the direct costs reasonably associated with sending out notifications of the breach to affected patients, clients, media, and regulatory authorities shall be the responsibility of the Covered Entity.

14.2 The term Breach specifically excludes:

- (i) Any unintentional acquisition, access, or use of PHI by a workforce member or person acting under the authority of a Covered Entity, subcontractor or a Business Associate, if such acquisition, access, or use was made in good faith and within the scope of authority and does not result in further use or disclosure in a manner not permitted under 45 CFR Subpart E.
- (ii) Any inadvertent disclosure by a person who is authorized to access PHI at a Covered Entity, Recipient or Business Associate to another person authorized to access PHI at the same Covered Entity, Recipient or Business Associate, or organized health care arrangement in which the Covered Entity participates, and the information received as a result of such disclosure is not further used or disclosed in a manner not permitted under 45 CFR Subpart E.
- (iii) A disclosure of PHI where a Covered Entity, Recipient or Business Associate has a good faith belief that an unauthorized person to whom the disclosure was made would not reasonably have been able to retain such information.

15. Independent Contractors. Both parties expressly intend that with regard to the provisions of this Agreement, said parties are independent contractors. Further, it is the express intent of the parties hereto that no agent, servant, contractor, or employee assigned by Business Associate to perform the Business Associate obligations described herein shall be deemed an agent, servant, contractor, or employee of Covered Entity.

EXHIBIT D
BULA AGREEMENT (OPTIONAL)

Terms of Use

1. ACCEPTANCE

The following is an agreement ("Agreement") between you and BulaLaw LLC ("Bula", "we", "us", "our").

This Agreement applies to you (i) if you are browsing or using this Site (as defined below), (ii) if you are a subscriber to the Services (a "Subscriber") and (iii) if you are an individual, customer, authorized end user, and/or a Subscriber's authorized end user (each, an "User"). This Agreement supplements and is in addition to any terms and conditions in any end user services agreement entered into by and between Subscriber and Company. In the event of a direct conflict between any term of this Agreement and any term of the end user services agreement, the end user services agreement shall control.

By accessing, browsing and/or using this site ("Site"), you acknowledge that you have read, have understood, and agree to be bound by this Agreement and to comply with all applicable laws and regulations, including U.S. export and re-export control laws and regulations. If you do not agree to these terms, do not use this Site. The material provided on this Site is protected by law, including, but not limited to, United States Copyright Law and international treaties. This Site is controlled and operated by Bula from its offices within the United States. Bula makes no representation that materials in the Site are appropriate or available for use in other locations, and access to them from territories where their contents are illegal is prohibited. Those who choose to access this Site from other locations do so on their own initiative and are responsible for compliance with applicable local laws. Any claim relating to, and the use of, this Site and the materials contained herein is exclusively governed by the laws of Arizona. The state and federal courts located in Phoenix, Arizona, shall have sole jurisdiction over any disputes arising hereunder, and the parties hereby agree to the personal jurisdiction of such courts and irrevocably waive any objection to such venue.

ANY CAUSE OF ACTION OR CLAIM YOU MAY HAVE ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE SITE MUST BE COMMENCED WITHIN ONE (1) YEAR AFTER

THE CAUSE OF ACTION ACCRUES, OTHERWISE, SUCH CAUSE OF ACTION OR CLAIM IS PERMANENTLY BARRED.

2. USE RESTRICTIONS

The copyright in all material provided on this Site is held by Bula. Except as expressly permitted in a writing document signed by an officer of Bula, none of the material may be copied, reproduced, distributed, republished, downloaded, displayed, posted or transmitted in any form or by any means, including, but not limited to, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of Bula or the copyright owner. Permission is granted to you to display, copy, distribute and download the materials on this Site for personal, non-commercial use only, provided you do not modify the materials and that you retain all copyright and other proprietary notices contained in the

materials. This permission terminates automatically if you breach any of these terms. Upon termination, you must immediately destroy any downloaded and printed materials. You also may not, without Bula's permission, "mirror" any material contained on this Site on any other server. Any unauthorized use of any material contained on this Site may violate copyright laws, trademark laws, the laws of privacy and publicity, and communications regulations and statutes.

3. ACCESSING THE SITE, REGISTRATION, ACCOUNTS, AND PASSWORDS

You are responsible for making all arrangements necessary for you to have access to the Site and ensuring that all persons who access the Site through your internet connection are aware of these Terms of Use and comply with them.

To access the Site or some of the resources it offers, you may be asked to provide certain registration details or other information. It is a condition of your use of the Site that all the information you provide on the Site is correct, current, and complete. We may terminate your access to our Site and to the Services if we learn that you have provided us with false or misleading registration data. You agree that all information you provide to register or make a purchase on this Site or otherwise, including but not limited to through the use of any interactive features on the Site, is governed by our [Privacy Policy](#), and you consent to all actions we take with respect to your information consistent with our Privacy Policy.

If you choose, or are provided with, a user name, password, or any other piece of information as part of our security procedures, you must treat such information as confidential, and you must not disclose it to any other person or entity. You also acknowledge that your account is personal to you and agree not to provide any other person with access to this Site or portions of it using your user name, password, or other security information. You are solely responsible for maintaining the confidentiality of your password and account, and you are solely responsible for all use of your password or account, whether authorized by you or not. Bula cannot and will not be liable for any loss or damage arising from your failure to comply with the terms of this Agreement. You agree to notify us immediately of any unauthorized access to or use of your user name or password or any other breach of security. You also agree to ensure that you exit from your account at the end of each session. You should use particular caution when accessing your account from a public or shared computer so that others are not able to view or record your password or other personal information.

We have the right to disable any user name, password, or other identifier, whether chosen by you or provided by us, at any time in our sole discretion for any or no reason, including if, in our opinion, you have violated any provision of this Agreement.

4. PURCHASES AND PAYMENTS

The store connected to this Site is hosted on WooCommerce. They provide us with the online e-commerce platform that allows us to sell our products and services to you. We have no control over WooCommerce's terms of service and encourage you to read them online here: <https://woocommerce.com/terms-conditions/>. A third party payment processor will

process payments through the WooCommerce platform. Your payment will be processed by Stripe, Inc.

You represent and warrant to Company that you will provide current, complete and accurate purchase and account information for all purchases made at our store. You agree to promptly update your account and other information, including your email address and credit card numbers and expiration dates, so that we can complete your transactions and contact you as needed.

We reserve the right to refuse any order you place with us. We may, in our sole discretion, limit or cancel quantities purchased per person, per household or per order. These restrictions may include orders placed by or under the same customer account, the same credit card, and/or orders that use the same billing or shipping address. In the event that we make a change to or cancel an order, we may attempt to notify you by contacting the e-mail, billing address, or phone number provided at the time the order was made. We reserve the right to limit or prohibit orders that, in our sole judgment, appear to be placed by dealers, resellers or distributors.

5. U.S. GOVERNMENT RESTRICTED RIGHTS

The materials on this Site are provided with "RESTRICTED RIGHTS." Use, duplication, or disclosure by the Government is subject to restrictions as set forth in applicable laws and regulations. Use of the materials by the Government constitutes acknowledgment of Bula's proprietary rights in them.

6. INTELLECTUAL PROPERTY

The Site and Services contain proprietary and copyright-protected information. Any unauthorized use of any content contained on the Site or the Services may violate copyright laws, trademark laws, the laws of privacy and publicity, and communications regulations and statutes. You may not modify, publish, transmit, participate in the transfer or sale, create derivative works, or in any way exploit any of the content in whole or in part.

The company name, the terms BULA, BULALAW, BULA INTELLIGENCE, and all related names, logos, product and service names, designs, and slogans are trademarks of Bula or its affiliates or licensors. You must not use such marks without the prior written permission of the Bula. All other names, logos, product and service names, designs, and slogans on this Site are the trademarks of their respective owners. Any questions concerning the use of these Bula's marks or whether a trademark that is not listed above is a trademark of Bula should be referred to Bula at contactus@bulalaw.com.

No right, title, or interest in or to the Site or any content on the Site is transferred to you, and all rights not expressly granted are reserved by Bula. Any use of the Site not expressly permitted by this Agreement is a breach and may violate copyright, trademark, and other laws.

7. CHANGES

Information on this Site may be changed or updated without notice. Bula may also make improvements and/or changes in the products and/or the programs described in this information at any time without notice.

8. AVAILABILITY

Bula reserves the right to withdraw or amend the Site, and any service or material Bula provides on the Site, in Bula's sole discretion without notice. Bula will not be liable if, for any reason, all or any part of the Site is unavailable at any time or for any period. From time to time, Bula may restrict access to some parts of the Site, or the entire Site, to users, including registered users.

Information Bula publishes on this Site may contain references or cross references to products, programs and services that are not announced or available in your country. Such references do not imply that Bula intends to announce such products, programs or services in your country. Consult your local Bula business contact for information regarding the products, programs and services which may be available to you.

9. INFORMATION "AS IS" AND "AS AVAILABLE"

INFORMATION ON THIS SITE MAY CONTAIN TECHNICAL INACCURACIES OR TYPOGRAPHICAL ERRORS. ALL INFORMATION IS PROVIDED BY BULA ON AN "AS IS" AND "AS AVAILABLE" BASIS ONLY. BULA PROVIDES NO REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING THE IMPLIED WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE, MERCHANTABILITY AND NONINFRINGEMENT

10. INDEMNIFICATION

You agree to defend, indemnify, and hold harmless the Bula, its affiliates, licensors, and service providers, and its and their respective officers, directors, employees, contractors, agents, licensors, suppliers, successors, and assigns from and against any claims, liabilities, damages, judgments, awards, losses, costs, expenses, or fees (including reasonable attorneys' fees) arising out of or relating to your violation of this Agreement or your use of the Site, including, but not limited to, any use of the Site's content, services, and products other than as expressly authorized in this Agreement or your use of any information obtained from the Site.

11. LIMITATION OF LIABILITY

UNDER NO CIRCUMSTANCES, INCLUDING, BUT NOT LIMITED TO, NEGLIGENCE, SHALL BULA BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING, BUT NOT LIMITED TO, LOSS OF DATA OR PROFIT, ARISING OUT OF THE USE, OR THE INABILITY TO USE, THE MATERIALS ON THIS SITE, EVEN IF BULA OR AN BULA AUTHORIZED REPRESENTATIVE HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. IF YOUR USE OF MATERIALS FROM THIS SITE RESULTS IN THE NEED FOR SERVICING, REPAIR OR CORRECTION OF EQUIPMENT OR DATA, YOU ASSUME ANY COSTS THEREOF. IN NO EVENT SHALL THE TOTAL LIABILITY OF BULA UNDER THIS AGREEMENT EXCEED FIFTY

DOLLARS (\$50), REGARDLESS OF THE CAUSE OF ACTION, IN TORT, CONTRACT OR OTHERWISE. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL DAMAGES, SO THE ABOVE LIMITATION OR EXCLUSION MAY NOT APPLY TO YOU.

12. BULALAW TRANSMISSIONS

Any material, information or idea you transmit to or post on this Site by any means will be treated as non-confidential and non-proprietary, and may be disseminated or used by Bula or its affiliates for any purpose whatsoever, including, but not limited to, developing, manufacturing and marketing products. Notwithstanding the foregoing, all personal data provided to Bula will be handled in accordance with Bula's Privacy Policy. You are prohibited from posting or transmitting to or from this Site any unlawful, threatening, libelous, defamatory, obscene, scandalous, inflammatory, pornographic, or profane material, or any other material that could give rise to any civil or criminal liability under the law.

13. WAIVER AND SEVERABILITY

No waiver of by Bula of any term or condition set out in this Agreement shall be deemed a further or continuing waiver of such term or condition or a waiver of any other term or condition, and any failure of Bula to assert a right or provision hereunder will not constitute a waiver of such right or provision.

If any provision of this Agreement is held by a court or other tribunal of competent jurisdiction to be invalid, illegal or unenforceable for any reason, such provision shall be eliminated or limited to the minimum extent such that the remaining provisions of the Agreement will continue in full force and effect.

14. REVISIONS

Bula may at any time revise this Agreement by updating this posting. By using this Site, you agree to be bound by any such revisions and should therefore periodically visit this page to determine the then current terms to which you are bound.

15. DIGITAL MILLENNIUM COPYRIGHT ACT ("DMCA") NOTICE.

If the event materials are made available to this Site by third parties not within our control, we are under no obligation to, and do not, scan such content for the inclusion of illegal or impermissible content. However, we respect the copyright interests of others. It is our policy not to permit materials known by us to infringe another party's copyright to remain on the Site. If you believe any materials on the Site infringe a copyright, you should provide us with written notice that at a minimum contains:

1. A physical or electronic signature of a person authorized to act on behalf of the owner of an exclusive right that is allegedly infringed;

2. Identification of the copyrighted work claimed to have been infringed, or, if multiple copyrighted works at a single online site are covered by a single notification, a representative list of such works at that site;
3. Identification of the material that is claimed to be infringing or to be the subject of infringing activity and that is to be removed or access to which is to be disabled, and information reasonably sufficient to permit us to locate the material;
4. Information reasonably sufficient to permit us to contact the complaining party, such as an address, telephone number, and, if available, an electronic mail address at which the complaining party may be contacted;
5. A statement that the complaining party has a good faith belief that use of the material in the manner complained of is not authorized by the copyright owner, its agent, or the law; and
6. A statement that the information in the notification is accurate, and under penalty of perjury, that the complaining party is authorized to act on behalf of the owner of an exclusive right that is allegedly infringed.

All DMCA notices should be sent to our designated agent as follows:

Copyright Administrator Weiss Brown, PLLC

6263 N. Scottsdale Rd, Ste. 340

Scottsdale, AZ 85250 (480) 327-6650

Email: CopyrightAdministrator@WeissBrown.com

It is our policy to terminate relationships regarding content with third parties who repeatedly infringe the copyrights of others.

Confidential and Proprietary. © 2021 Copyright, BulaLaw LLC. All rights reserved. May not be reproduced, copied, transmitted in any form, by any means, electronic, mechanical, photo-copying, recording, or otherwise without prior written permission of BulaLaw LLC.

EXHIBIT E

**PHARMACY AND HEALTHCARE SOLUTIONS MASTER SERVICES AGREEMENT,
PROVIDER PARTICIPATION ADDENDUM, PROVIDERPAY RECONCILIATION SERVICES
ADDENDUM, MCKESSON REIMBURSEMENT ADVANTAGE ADDENDUM**

(OPTIONAL)

**PHARMACY AND HEALTHCARE SOLUTIONS
MASTER SERVICES AGREEMENT**

This Master Services Agreement (this “Agreement”) is made by and between , a wholly owned subsidiary of McKesson Corporation, (“SHA II”) and the SHA II affiliate identified in the applicable Addendum attached hereto or incorporated by reference into this Agreement (collectively “Company”), and _____ (“Provider”). Company, and Provider may be individually referred to as a “Party” and, collectively, the “Parties”.

This Agreement shall be effective as of the date of execution by Company as set forth on the signature page (“Effective Date”).

RECITALS

WHEREAS, Company provides certain services and program offerings to pharmacies;

WHEREAS, Provider is a pharmacy that wishes to participate in one or more of Company Program offerings; and

WHEREAS, Provider desires to participate and Company wishes to provide the services and program offerings under the terms and conditions set forth in this Agreement.

NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained and other good and valuable consideration, it is mutually agreed by and between the Parties as follows:

Article 1: DEFINITIONS

1.1 “Company Policies” means all policies, procedures, standards, manuals, and guidelines established by Company, as may be modified from time to time, that have been provided or made available to Provider. Company Policies may be provided to the Provider electronically through Company’s provider portal(s), or by other means selected by Company.

1.2 “Business Day(s)” means Monday through Friday from 8:00 a.m. to 5:00 p.m. Eastern Standard Time, excluding federal banking holidays.

1.3 “Covered Person” means an individual and their dependents who have elected to receive care from Provider and who are covered by a Payor Plan.

1.4 “Covered Services” means all healthcare services, drugs, products and supplies that Provider is authorized to provide and that are rendered by Provider to a Covered Person entitled to receive coverage from a Payor in accordance with the Covered Person’s Payor Plan.

1.5 “Enrollment Materials” means all documents and information required by Company to be completed and approved prior to participation in any Company program offering.

1.6 “Payor” means any entity or company obligated to a Covered Person to provide reimbursement for Covered Services under a Payor Plan.

1.7 “Payor Plan” means all programs established for the provision of Covered Services to a Covered Person whereby a Payor is obligated to provide coverage for Covered Services.

1.8 “Provider Location(s)” means the service location(s) owned, in whole or part, by an individual or entity that owns Provider.

Article 2: PROVIDER REPRESENTATIONS AND WARRANTIES

2.1 Representations and Warranties. Provider represents and warrants that at all times during the term of this Agreement:

A. Provider, Provider’s owners and the pharmacists and employees employed by Provider (“Provider Parties”) shall comply with i) all Company Policies; ii) all applicable laws, rules and regulations (“Laws”); iii) Payor policies and requirements for reimbursement for Covered Services, where applicable; and iv) all requirements

associated with the practice of pharmacy, including but not limited to (a) state pharmacy board requirements;(b) state and federal Laws regarding operation of pharmacies and purchasing, possession and distribution of controlled substances; (c) state and federal Laws regarding claims and eligibility for payment under any publicly funded plan; (d) state and federal Laws regarding privacy of individually identifiable information of a patient; and (e) Medicare Marketing Guidelines as defined by Centers for Medicare & Medicaid Services;

B. All information set forth in the Enrollment Materials is and shall at all times remain current, true, and accurate and that Provider Parties will participate in and cooperate with all Company, and if applicable Payor enrollment criteria, including credentialing and eligibility requirements to the extent that such requirements apply to Provider; and

C. Provider has all required levels of insurance as set forth in this Agreement. Evidence of satisfaction and/or substantiation of the requirements of this Article 2 shall be provided to Company within three (3) Business Days of Company's request.

Article 3: DUTIES AND OBLIGATIONS OF PROVIDER

3.1 Company Policies. Provider shall comply with and be bound by Company Policies. Provider acknowledges and agrees that updates or revisions to Company Policies may be made from time to time. Such updates or revisions shall be binding on Provider. If Provider determines that the modifications to any Company Policies materially negatively affect the responsibilities or rights of Provider, or Provider otherwise does not agree to adhere to such modifications, then Provider shall have the right to terminate this Agreement in accordance with Section 4.2. Company Policies will be made available online or upon written request by Provider.

3.2 Provider shall provide notice to Company within thirty (30) days of any changes, including but not limited to, changes in Provider's name, ownership, control, authorized individuals, insurance, Provider Location(s), any change to the information provided in the Enrollment Materials including, without limitation, any change to Provider's class of trade information, NCPDP, or CAQH affiliation, or any other credentialing information.

3.3 Provider Location(s). If Provider sells one or more of its Provider Locations, Provider agrees to require the new owner obtain a new NCPDP number for the purchased Provider Location. If the new owner fails to obtain a new NCPDP number for the purchased Provider Location, then Provider agrees to indemnify and hold Company harmless for any and all costs, losses, damages, and liabilities (including, without limitation, reasonable attorneys' fees, expert witness fees, costs of court, and other legal expenses) incurred as a result of a Provider Location having the same NCPDP number following a change in ownership.

3.4 Data Collection and Reporting.

A. Provider agrees to collect and report any data reasonably requested from time to time and in a manner prescribed by Company or any Payor or any government agency (in accordance with applicable Laws, to the extent such data is necessary to comply with the requirements of such agencies as applicable to Provider, Company or Payors). Provider will obtain any Covered Person's consent required in order to authorize Provider to provide access to requested data.

B. Provider agrees that any data collected or obtained by Company, its owners, its owners' parents, or the affiliates and subsidiaries of its owners and its owners' parents (collectively, "Related Parties") by means of Provider's participation under this Agreement or in any program, service or other offering of Related Parties or Payors shall be available to Related Parties for use and disclosure to the fullest extent permitted by applicable law, including, without limitation, in contract negotiations, quality assurance, utilization review, management and monitoring of Payor Agreements, compliance monitoring, internal analyses and any other efforts by Related Parties to enter into or arrange for other programs for the benefit of Provider and Provider Parties. Furthermore, Provider agrees that Company shall be permitted to share any data collected or obtained by Company arising from Provider's participation under this Agreement with any buying group, group purchasing organization or other third-party entity with which Provider is affiliated.

3.5 Monthly Fee. Provider shall pay the fee(s) (the "Fee(s)") outlined in the Enrollment Materials for the services provided under this Agreement. Company may change the Fee(s), from time to time, upon prior notice to Provider. Provider agrees to render payment in full to Company on the applicable due date without making any deductions or adjustments to such payment obligation. If any due date falls on a weekend or holiday, payment is due and payable on the following Business Day. Provider agrees that Company may offset the Fee(s) from amounts

received from third parties through one of Provider's central payment accounts with Company or collect by any other means deemed necessary by Company.

3.6 Credit Terms. If Company offers a credit line to Provider, Provider must qualify for its payment terms based on its individual financial and risk characteristics, subject to review and approval by Company. Provider will maintain a sound financial condition and, at Company's request, shall promptly substantiate its financial condition in writing with audited financial statements and any other supporting information required by Company. Company reserves the right, in its discretion, (a) to change payment terms (including requiring same-day payment or cash on delivery via EFT or ACH); or (b) limit total credit if, (i) Company concludes that there has been a material adverse change in Provider's financial condition or an unsatisfactory payment performance; or (ii) Provider ceases to meet Company's credit requirements or Company determines that Provider is likely to cease meeting such requirements. Upon the occurrence of any event specified in (i) or (ii) above, Company is entitled to suspend or discontinue any services provided under this Agreement.

3.7 Offset Rights. Company may offset any amount owing at any time from Provider (and with respect to any Provider account) to Company (including its Related Parties) against any amounts received and payable at any time by Company to Provider, whether arising under this Agreement or otherwise.

Article 4: TERM AND TERMINATION

4.1 Term. This Agreement shall be effective as of the Effective Date and continue in effect until all addendums to this Agreement ("Addendum(s)") are terminated in accordance with the terms outlined in the applicable Addendum or as outlined in Section 4.2 herein.

4.2 Termination. In the event the Parties desire to terminate participation in any Company program as outlined in the Addendum(s) to this Agreement, the Parties may terminate the Addendum in accordance with the termination provisions outlined in that Addendum without terminating this Agreement. Notwithstanding the previous sentence, this Agreement including the BAA will automatically terminate immediately if all attached Addendums to this Agreement are terminated. Provider may terminate this Agreement and all applicable Addendums as described in Section 3.1 and Section 6.1 of this Agreement related to modification of Company Policies or amendments to this Agreement upon thirty (30) days prior written notice.

Article 5: LIABILITY

5.1 Liability Coverage. Provider, at its sole cost and expense, shall provide and maintain such policies of commercial general liability and professional liability insurance as shall be deemed necessary by Company to insure Provider and its employees against any claim or claims for damages arising by reason of personal injuries, sickness, disease or death, advertising injury, or from injury to or destruction of tangible or intangible property, including loss of use arising therefrom, occasioned, directly or indirectly, in connection with the performance of any service by Provider or any negligent act or omission. The amounts and extent of such insurance coverage and the insurer providing the coverage shall be subject to the approval of Company. In no event shall such insurance coverage be less than \$1,000,000 per occurrence and \$3,000,000 in the aggregate. All policies described above shall be effective no later than the Effective Date of this Agreement and shall remain effective for a period of one (1) year beyond the termination or expiration of this Agreement. Provider shall, on execution of this Agreement and at such times thereafter as Company may request, furnish Company evidence of such insurance either in the form of certificates from the insurer of such insurance or photocopies of the policy itself. Provider's insurer shall agree to notify Company in writing thirty (30) days prior to any modifications, cancellations or terminations or replacements of any such insurance coverage for any reason whatsoever. The insurance companies now or hereafter issuing the foregoing insurance policies shall have an AM Best's Rating of at least A-VII. In no event shall the foregoing coverage limits affect or limit in any manner Provider's liability in connection with the performance of its obligations under this Agreement.

5.2 Indemnity. Provider agrees to indemnify, defend and hold harmless Company, its owners, its owners' parents, and the affiliates and subsidiaries of its owners and its owners' parents, and all of their respective directors, officers and representatives, from and against any and all claims, liabilities, losses, damages, causes of action or injuries, together with costs and expenses, including reasonable attorney's fees, arising out of or resulting from Provider's failure to comply with the obligations set forth herein. The obligation stated herein shall survive expiration or termination of this Agreement.

5.3 Limitation of Liability. Provider acknowledges and agrees that in no event shall Company, its owners, its owners' parents, and the affiliates and subsidiaries of its owners and its owners' parents, or any of their respective officers, directors, employees, subcontractors or representatives, be liable to Provider for any special, indirect, incidental or consequential, punitive or exemplary damages, loss of profits, or loss of goodwill, upon any cause of action even if Company has been notified of the likelihood of such damages occurring. Provider agrees that the sole and exclusive remedy available to Provider shall be limited to the recovery of actual direct damages not in excess of the total member fees actually paid to Company, reduced by any amounts paid, credited or refunded to provider by Company, plus any central pay reimbursement allocable to provider that has been received by Company but not disbursed to provider. The Parties agree that this limitation of liability shall survive and continue in full force and effect despite any failure of an exclusive remedy. Such limitation of liability shall survive expiration or termination of this Agreement.

Article 6: MISCELLANEOUS

6.1 Amendments. Company may modify any provision of this Agreement, including any applicable Addendums or attachments upon thirty (30) days prior written notice to Provider. Provider shall be deemed to have accepted Company's modification if Provider fails to object to such modification, in writing, within the thirty (30) day notice period. If the modifications materially affect the responsibilities or rights of Provider, Provider shall have the right to terminate this Agreement in accordance with Section 4.2. Notwithstanding the foregoing, amendments required by legislative, regulatory or other legal authority, as determined by Company, do not require the consent of Provider and shall be effective immediately upon Provider's receipt of notice of amendment.

6.2 Assignment. This Agreement is intended to secure the services of and be personal to Provider, and shall not be assigned, sublet, delegated, or transferred by Provider without the prior written consent of Company.

6.3 Notice. Any notice required to be given under this Agreement to Company shall be sent to service.HMAtlas@mckesson.com or Strategic Health Alliance II, LLC / Health Mart Atlas, CoverMyMeds Building, 910 John Street, Columbus, OH 43222, unless otherwise notified by Company. Any notice required to be given under this Agreement to Provider shall be sent to the contact information set forth on NCPDP. Notice may be given by (i) hand delivery, (ii) certified mail, return receipt requested, postage prepaid, (iii) by national overnight courier with delivery charges prepaid; (iv) email; or (v) other means specifically permitted under this Agreement. With respect to the preceding sentence, notice shall be deemed to be sufficient and effective immediately when delivered by hand or email, or three (3) days after being mailed or couriered. Additionally, any notice required to be given pursuant to this Agreement, may be given by Company by posting such notice on the network portal(s), and such notice shall be deemed to be sufficient and effective fifteen (15) days following posting of such notice on the network portal(s).

6.4 Confidentiality. Provider shall not disclose to any third party (except as required by agency of the government) any of Company's proprietary business information not available to the general public or obtained by Provider from Company.

To the extent that the Provider records or any other information that Provider discloses to Company pursuant to the terms of this Agreement constitutes Protected Health Information ("PHI") as defined in Section 1 of the Business Associate Agreement Addendum, Provider and Company shall comply with the provisions, which are intended to protect the privacy and provide for the security of PHI in compliance with: (i) the Health Insurance Portability and Accountability Act of 1996, Public Law No. 104-191 ("HIPAA"); (ii) Subtitle D of the Health Information Technology for Economic and Clinical Health Act (the "HITECH Act"), also known as Title XIII of Division A and Title IV of Division B of the American Recovery and Reinvestment Act of 2009, Public Law No. 111-005 ("ARRA"); and (iii) applicable regulations promulgated thereunder by the U.S. Department of Health and Human Services (the "HIPAA Regulations"). In order to satisfy requirements imposed upon Company and Provider under HIPAA, HITECH, ARRA and the HIPAA Regulations, the Business Associate Agreement Addendum is attached to this Agreement and incorporated herein.

6.5 Dispute Resolution. In the event of any dispute arising out of or alleging breach of this Agreement (the "Dispute"), the Parties agree to work together in good faith to resolve the Dispute. If the Parties are unable to resolve the Dispute within sixty (60) days following the date a Party sent written notice of the Dispute to the other Party, the Parties agree that, as a condition precedent to filing suit or otherwise pursuing litigating such Dispute, the Parties shall first participate in a full-day mediation session of the Dispute. If the Parties are unable to agree upon a mediator, the Dispute shall be submitted to mediation administered by the American Arbitration Association under its Commercial Mediation Procedures and using a mediator selected by the AAA. The Parties shall each bear their own attorneys'

fees for such mediation and shall share the cost of mediation equally. The Parties shall cooperate in good faith to complete mediation within thirty (30) days of any party's written request to mediate a Dispute. If, despite the Parties' good faith cooperation, a mediation otherwise required by this Section is not completed within thirty (30) days of a Party's written request to mediate, this condition to filing suit shall be deemed waived and litigation of the Dispute may proceed. Nothing in this Section, however, shall preclude or delay a Party from seeking emergency injunctive relief otherwise allowed by law. In the event a Party obtains injunctive relief in a Dispute subject to this Section, the Parties shall mediate such Dispute as soon as reasonably practicable, but in any event within thirty (30) days of the effective date of such injunctive relief. Notwithstanding the foregoing, Company may elect for disputes involving breach of Section 6.4 to be resolved by a court of competent jurisdiction.

6.6 Severance of Invalid Provisions. If any provision of this Agreement is held to be illegal, invalid or unenforceable under present or future Laws effective during the term hereof, such provision shall be fully severable. This Agreement shall be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a part hereof, and the remaining provision shall remain in full force and effect unaffected by such severance, provided that the invalid provision is not material to the overall purpose and operation of this Agreement.

6.7 Waiver. The waiver by either Party of any breach of any provision of this Agreement or warranty representation herein set forth shall not be construed as a waiver of any subsequent breach of the same or any other provision. The failure to exercise any right hereunder shall not operate as a waiver of such right. All rights and remedies provided herein are cumulative.

6.8 Entire Agreement. This Agreement contains all the terms and conditions agreed on by the Parties hereto regarding the subject matter of this Agreement. Any prior agreements, promises, negotiations or representations, either oral or written, relating to the subject matter of this Agreement not expressly set forth in this Agreement are not of force or effect.

6.9 Independent Relationship. None of the provisions of this Agreement are intended to create nor shall be deemed or construed to create any relationship between Company and Provider other than that of independent entities contracting with each other hereunder solely for the purpose of effecting the provisions of this Agreement. Neither Party is authorized to represent the other for any purpose whatsoever without the prior consent of the other. Company shall not interfere with the right of Provider to exercise professional judgment in the rendering of services, it being understood and agreed that the traditional relationship between the professional and patient will be maintained.

6.10 No Third-Party Benefit. This Agreement is intended for the exclusive benefit of the Parties to this Agreement and their respective successors and assigns. Nothing contained in this Agreement shall be construed as creating any rights or benefits in or to any third party.

6.11 Survival. Termination of this Agreement shall not affect the rights, obligations and liabilities of the Parties arising out of the transactions occurring prior to termination. Additionally, Article 5 shall survive the termination of this Agreement.

6.12 Counterparts. This Agreement may be executed and delivered in one or more counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. A facsimile or other reproduction of this Agreement shall be deemed an original.

6.13 Other Rebates. Provider may be entitled to earn rebates on its purchases of pharmaceutical products from McKesson Corporation ("McKesson"). Any rebate received by Provider on its purchases of pharmaceutical products from McKesson is a "discount or other reduction in price" to Provider under Section 112B(b)(3)(A) of the Social Security Act with respect to the purchases made thereunder. To the extent requested to do so or as otherwise required by law or regulation, Provider shall fully and accurately disclose any such rebates in any cost or similar reports or claims for reimbursement made to any federal or state health care program or third-party Payor.

6.14 Receipt of Marketing Communications. Provider consents to receiving marketing calls, emails, texts and/or fax communications from or on behalf of Company at the telephone number, cellular phone number, fax number and email address provided by Provider in connection with its enrollment or participation in any Company product or service. Provider understands that such communications may contain marketing content, program information or updates, or any other communication related to any products, programs or services offered by Company. Provider further consents to receiving auto-dialed and/or pre-recorded telephone calls, and that such consent is not a condition of purchase or participation in any program. Company will make available to Provider an

opt-out method by email, text, phone, fax, or other permissible mechanism, by which Provider may notify Company that Provider no longer wishes to receive marketing communications.

6.15 Participating Provider Roster; Advertising References to Provider. Provider agrees that Company may use Provider's name, address, telephone number, NCPDP number, CAQH number and any other identifier deemed necessary by Company in any roster of Participating Providers published by Company or Payor. The roster may be inspected by and is intended for the use of prospective and existing Participating Providers and Payors as well as for Company's marketing purposes. Except as specifically set forth herein, both Parties otherwise reserve the right to use and control the use of its name and all symbols, trademarks and service mark (collectively, "Marks") and neither Party shall use the other Party's Marks without the prior written consent of the other Party. In the event of termination of this Agreement, each Party shall immediately discontinue the use of the other Party's name and/or Marks.

IN WITNESS WHEREOF, the Parties have caused their duly authorized agents to execute this Agreement as of the Effective Date.

"SHA II"

Strategic Health Alliance II, Inc. and the SHA II affiliate identified in the applicable Addendum to this Agreement

BY: _____

TITLE: _____

DATE: _____

"Provider"

PROVIDER NAME: _____

NCPDP#: _____

BY: _____

TITLE: _____

DATE: _____

Attachment A

Pharmacy and Healthcare Solutions Services and Participating Provider Location

Provider attests that this Attachment A to the Agreement identifies the Services the Provider will participate in and the Participating Provider Location under this Agreement.

Services

Managed Care Administrative Services

Company may allow Provider to access certain Payor networks for the Managed Care Administrative Services indicated below. Provider acknowledges and agree that it must meet all applicable eligibility and credentialing requirements to participate in the Services or any applicable Payor's network of providers.

_____ Retail PSAO Services

_____ Medical Contracting Services

_____ Specialty PSAO Services (as set forth and identified in the Enrollment Materials)

Reimbursement and Reconciliation Services

_____ McKesson Reimbursement Advantage ("MRA")

_____ ProviderPay

Participating Provider Location

Provider Location Name	Provider NCPDP #

BUSINESS ASSOCIATE AGREEMENT ADDENDUM

This Business Associate Agreement Addendum (“BAA”) is entered into by and between Company and Provider and is effective as of the Effective Date of the Master Services Agreement (the “Underlying Agreement”). “Effective Date” is defined in the Underlying Agreement. Company and Provider may be individually referred to as a “Party” and, collectively, the “Parties” in this BAA.

RECITALS

A. Company is providing services to Provider under the Underlying Agreement, and Provider wishes to disclose certain information to Company pursuant to the terms of such Underlying Agreement, some of which may constitute Protected Health Information (“PHI”) (defined below).

B. Provider and Company intend to protect the privacy and provide for the security of PHI disclosed to Company pursuant to the Underlying Agreement in compliance with (i) the Health Insurance Portability and Accountability Act of 1996, Public Law No. 104-191 (“HIPAA”); (ii) Subtitle D of the Health Information Technology for Economic and Clinical Health Act (the “HITECH Act”), also known as Title XIII of Division A and Title IV of Division B of the American Recovery and Reinvestment Act of 2009, Public Law No. 111-005 ; and (iii) regulations promulgated thereunder by the U.S. Department of Health and Human Services, including the HIPAA Omnibus Final Rule, which amended the HIPAA Privacy and Security Rules (as those terms are defined below) and implemented a number of provisions of the HITECH Act (the “HIPAA Final Rule”), extending certain HIPAA obligations to Company and their subcontractors.

C. The purpose of this BAA is to satisfy certain standards and requirements of HIPAA, the Privacy Rule and the Security Rule (as those terms are defined below), and the HITECH Act, including, but not limited to, Title 45, §§ 164.314(a)(2)(i), 164.502(e) and 164.504(e) of the Code of Federal Regulations (“C.F.R.”).

SECTION 1: DEFINITIONS

“Breach” will have the same meaning given to such term in 45 C.F.R. § 164.402.

“Designated Record Set” will have the same meaning as the term “designated record set” in 45 C.F.R. § 164.501.

“Electronic Protected Health Information” or “Electronic PHI” will have the meaning given to such term under the Privacy Rule and the Security Rule, including, but not limited to, 45 C.F.R. § 160.103, as applied to the information that Company creates, receives, maintains, or transmits from or on behalf of Provider.

“Individual” will have the same meaning as the term “individual” in 45 C.F.R. § 160.103 and will include a person who qualifies as a personal representative in accordance with 45 C.F.R. § 164.502(g).

“Privacy Rule” will mean the Standards for Privacy of Individually Identifiable Health Information at 45 C.F.R. Part 160 and Part 164, Subparts A and E.

“Protected Health Information” or “PHI” will have the same meaning as the term “protected health information” in 45 C.F.R. § 160.103, as applied to the information created, received, maintained, or transmitted by Company from or on behalf of Provider.

“Required by Law” will have the same meaning as the term “required by law” in 45 C.F.R. § 164.103.

“Secretary” will mean the Secretary of the Department of Health and Human Services or his or her designee.

“Security Incident” will have the meaning given to such term in 45 C.F.R. § 164.304.

“Security Rule” will mean the Security Standards at 45 C.F.R. Part 160 and Part 164, Subparts A and C.

“Unsecured PHI” will have the same meaning given to such term under 45 C.F.R. § 164.402, and guidance promulgated thereunder.

Capitalized Terms. Capitalized terms used in this BAA and not otherwise defined herein will have the meanings set forth in the Privacy Rule, the Security Rule, and the HIPAA Final Rule, which definitions are incorporated in this BAA by reference.

SECTION 2: PERMITTED USES AND DISCLOSURES OF PHI

2.1 Uses and Disclosures of PHI Pursuant to the Underlying Agreement. Except as otherwise limited in this BAA, Company may use or disclose PHI to perform functions, activities or services for, or on behalf of, Provider as specified in the Underlying Agreement, provided that such use or disclosure would not violate the Privacy Rule if done by Provider.

2.2 Permitted Uses of PHI by Company. Except as otherwise limited in this BAA, Company may use PHI for the proper management and administration of Company or to carry out the legal responsibilities of Company.

2.3 Permitted Disclosures of PHI by Company. Except as otherwise limited in this BAA, Company may disclose PHI for the proper management and administration of Company, provided that the disclosures are Required by Law, or Company obtains reasonable assurances from the person to whom the information is disclosed that it will remain confidential and will be used or further disclosed only as Required by Law or for the purpose for which it was disclosed to the person (which purpose must be consistent with the limitations imposed upon Company pursuant to this BAA), and that the person agrees to notify Company of any instances of which it is aware in which the confidentiality of the information has been breached. Company may disclose PHI to report violations of law to appropriate federal and state authorities, consistent with 45 C.F.R. § 164.502(j)(1).

2.4 Data Aggregation. Except as otherwise limited in this BAA, Company may use PHI to provide Data Aggregation services for the Health Care Operations of the Provider as permitted by 45 C.F.R. § 164.504(e)(2)(i)(B).

2.5 De-identified Data. Company may de-identify PHI in accordance with the standards set forth in 45 C.F.R. § 164.514(b) and may use or disclose such de-identified data unless prohibited by applicable law.

SECTION 3: OBLIGATIONS OF COMPANY

3.1 Appropriate Safeguards. Company will use appropriate safeguards and will, after the compliance date of the HIPAA Final Rule, comply with the Security Rule with respect to Electronic PHI, to prevent use or disclosure of such information other than as provided for by the Underlying Agreement and this BAA. Except as expressly provided in the Underlying Agreement or this BAA, Company shall not assume any obligations of Provider under the Privacy Rule. To the extent that Company is to carry out any of Provider's obligations under the Privacy Rule as expressly provided in the Underlying Agreement or this BAA, Company will comply with the requirements of the Privacy Rule that apply to Provider in the performance of such obligations.

3.2 Reporting of Improper Use or Disclosure, Security Incident or Breach. Company will report to Provider any use or disclosure of PHI not permitted under this BAA, Breach of Unsecured PHI or any Security Incident, without unreasonable delay, and in any event no more than thirty (30) days following discovery; provided, however, that the Parties acknowledge and agree that this Section constitutes notice by Company to Provider of the ongoing existence and occurrence of attempted but Unsuccessful Security Incidents (as defined below). “Unsuccessful Security Incidents” will include, but not be limited to, pings and other broadcast attacks on Company's firewall, port scans, unsuccessful log-on attempts, denials of service and any combination of the above, so long as no such incident results in unauthorized access, use or disclosure of PHI. Company's notification to Provider of a Breach will include: (i) the identification of each individual whose Unsecured PHI has been, or is reasonably believed by Company to have been, accessed, acquired or disclosed during the Breach; and (ii) any particulars regarding the Breach that Provider would need to include in its notification, as such particulars are identified in 45 C.F.R. § 164.404.

3.3 Company's Agents. In accordance with 45 C.F.R. § 164.502(e)(1)(ii) and 45 C.F.R. § 164.308(b)(2), as applicable, Company will enter into a written agreement with any agent or subcontractor that creates, receives,

maintains or transmits PHI on behalf of Company for services provided to Provider, providing that the agent agrees to restrictions and conditions that are substantially similar to those that apply through this BAA to Company with respect to such PHI.

3.4 Access to PHI. The Parties do not intend for Company to maintain any PHI in a Designated Record Set for Provider. To the extent Company possesses PHI in a Designated Record Set, Company agrees to make such information available to Provider pursuant to 45 C.F.R. § 164.524, within ten (10) Business Days of Company's receipt of a written request from Provider; provided, however, that Company is not required to provide such access where the PHI contained in a Designated Record Set is duplicative of the PHI contained in a Designated Record Set possessed by Provider. If an Individual makes a request for access pursuant to 45 C.F.R. § 164.524 directly to Company, or inquires about his or her right to access, Company will either forward such request to Provider or direct the Individual to Provider.

3.5 Amendment of PHI. The Parties do not intend for Company to maintain any PHI in a Designated Record Set for Provider. To the extent Company possesses PHI in a Designated Record Set, Company agrees to make such information available to Provider for amendment pursuant to 45 C.F.R. § 164.526 within twenty (20) Business Days of Company's receipt of a written request from Provider. If an Individual submits a written request for amendment pursuant to 45 C.F.R. § 164.526 directly to Company, or inquires about his or her right to amendment, Company will either forward such request to Provider or direct the Individual to Provider.

3.6 Documentation of Disclosures. Company agrees to document such disclosures of PHI and information related to such disclosures as would be required for Provider to respond to a request by an Individual for an accounting of disclosures of PHI in accordance with 45 C.F.R. § 164.528. Company will document, at a minimum, the following information ("Disclosure Information"): (a) the date of the disclosure; (b) the name and, if known, the address of the recipient of the PHI; (c) a brief description of the PHI disclosed; (d) the purpose of the disclosure that includes an explanation of the basis for such disclosure; and (e) any additional information required under the HITECH Act and any implementing regulations.

3.7 Accounting of Disclosures. Company agrees to provide to Provider, within twenty (20) Business Days of Company's receipt of a written request from Provider, information collected in accordance with Section 3.6 of this BAA, to permit Provider to respond to a request by an Individual for an accounting of disclosures of PHI in accordance with 45 C.F.R. § 164.528. If an Individual submits a written request for an accounting of disclosures of PHI pursuant to 45 C.F.R. § 164.528 directly to Company, or inquires about his or her right to an accounting, Company will direct the Individual to Provider.

3.8 Governmental Access to Records. Company will make its internal practices, books and records relating to the use and disclosure of PHI received from, or created or received by Company on behalf of, Provider available to the Secretary for purposes of the Secretary determining Provider's compliance with the Privacy Rule and the Security Rule.

3.9 Mitigation. To the extent practicable, Company will cooperate with Provider's efforts to mitigate a harmful effect that is known to Company of a use or disclosure of PHI by Company that is not permitted by this BAA.

3.10 Minimum Necessary. Company will request, use and disclose the minimum amount of PHI necessary to accomplish the purpose of the request, use or disclosure, in accordance with 45 C.F.R. § 164.514(d), and any amendments thereto.

3.11 HIPAA Final Rule Applicability. Company acknowledges that enactment of the HITECH Act, as implemented by the HIPAA Final Rule, amended certain provisions of HIPAA in ways that now directly regulate, or will on future dates directly regulate, Company under the Privacy Rule and Security Rule. Company agrees, as of the compliance date of the HIPAA Final Rule, to comply with applicable requirements imposed under the HIPAA Final Rule, including any amendments thereto.

SECTION 4: OBLIGATIONS OF PROVIDER

4.1 Notice of Privacy Practices. Provider will notify Company of any limitation(s) in its notice of privacy practices in accordance with 45 C.F.R. § 164.520, to the extent that such limitation may affect Company's use or disclosure of PHI. Provider will provide such notice no later than fifteen (15) calendar days prior to the effective date of the limitation.

4.2 Notification of Changes Regarding Individual Permission. Provider will obtain any consent or authorization that may be required by the Privacy Rule, or applicable state law, prior to furnishing Company with PHI. Provider will notify Company of any changes in, or revocation of, permission by an Individual to use or disclose PHI, to the extent that such changes may affect Company's use or disclosure of PHI. Provider will provide such notice no later than fifteen (15) days prior to the effective date of the change.

4.3 Notification of Restrictions to Use or Disclosure of PHI. Provider will notify Company of any restriction to the use or disclosure of PHI that Provider has agreed to in accordance with 45 C.F.R. § 164.522, to the extent that such restriction may affect Company's use or disclosure of PHI. Provider will provide such notice no later than fifteen (15) days prior to the effective date of the restriction. If Company reasonably believes that any restriction agreed to by Provider pursuant to this Section may materially impair Company's ability to perform its obligations under the Underlying Agreement or this BAA, the Parties will mutually agree upon any necessary modification of Company's obligations under such agreements.

4.4 Permissible Requests by Provider. Provider will not request Company to use or disclose PHI in any manner that would not be permissible under the Privacy Rule, the Security Rule or the HITECH Act if done by Provider, except as permitted pursuant to the provisions of Sections 2.2, 2.3, 2.4 and 2.5 of this BAA.

SECTION 5: TERM AND TERMINATION

5.1 Term. The term of this BAA will commence as of the Effective Date, and will terminate when all of the PHI provided by Provider to Company, or created or received by Company on behalf of Provider, is destroyed or returned to Provider. If it is infeasible to return or destroy PHI, Company will extend the protections to such information, in accordance with Section 5.3.

5.2 Termination for Cause. Upon either Party's knowledge of a material breach by the other Party of this BAA, such Party may terminate this BAA immediately if cure is not possible. Otherwise, the non-breaching party will provide written notice to the breaching Party detailing the nature of the breach and providing an opportunity to cure the breach within thirty (30) Business Days. Upon the expiration of such thirty (30) day cure period, the non-breaching Party may terminate this BAA if the breaching party does not cure the breach or if cure is not possible. If termination is not feasible, the non-breaching party may report the breach or violation to the Secretary.

5.3 Effect of Termination.

5.3.1 Except as provided in Section 5.3.2, upon termination of the Underlying Agreement or this BAA for any reason, Company will return or destroy all PHI received from Provider, or created or received by Company on behalf of Provider, at Provider's expense, and will retain no copies of the PHI. This provision will apply to PHI that is in the possession of subcontractors or agents of Company.

5.3.2 If it is infeasible for Company to return or destroy the PHI upon termination of the Underlying Agreement including all applicable Addendums or this BAA, Company will: (a) extend the protections of this BAA to such PHI and (b) limit further uses and disclosures of such PHI to those purposes that make the return or destruction infeasible, for so long as Company maintains such PHI.

SECTION 6: COOPERATION IN INVESTIGATIONS

The Parties acknowledge that certain breaches or violations of this BAA may result in litigation or investigations pursued by federal or state governmental authorities of the United States resulting in civil liability or criminal penalties. Each Party will cooperate in good faith in all respects with the other Party in connection with any request by a federal or state governmental authority for additional information and documents or any governmental investigation, complaint, action or other inquiry.

SECTION 7: SURVIVAL

The respective rights and obligations of Company under Section 5.3 of this BAA will survive the termination of this BAA and the Underlying Agreement.

SECTION 8: AMENDMENT

This BAA may be modified, or any rights under it waived, only by a written document executed by the authorized representatives of both Parties. In addition, if any relevant provision of the Privacy Rule, the Security Rule or the HIPAA Final Rule is amended in a manner that changes the obligations of Company or Provider that are embodied in terms of this BAA, then the Parties agree to negotiate in good faith appropriate non-financial terms or amendments to this BAA to give effect to such revised obligations.

SECTION 9: EFFECT OF BAA

In the event of any inconsistency between the provisions of this BAA and the Underlying Agreement, the provisions of this BAA will control. In the event that a court or regulatory agency with authority over Company or Provider interprets the mandatory provisions of the Privacy Rule, the Security Rule or the HIPAA Final Rule, in a way that is inconsistent with the provisions of this BAA, such interpretation will control. Where provisions of this BAA are different from those mandated in the Privacy Rule, the Security Rule, or the HIPAA Final Rule, but are nonetheless permitted by such rules as interpreted by courts or agencies, the provisions of this BAA will control.

SECTION 10: GENERAL

This BAA is governed by, and will be construed in accordance with, the Laws of the State that govern the Underlying Agreement. Any action relating to this BAA must be commenced within one year after the date upon which the cause of action accrued. Provider will not assign this BAA without the prior written consent of Company, which will not be unreasonably withheld. If any part of a provision of this BAA is found illegal or unenforceable, it will be enforced to the maximum extent permissible, and the legality and enforceability of the remainder of that provision and all other provisions of this BAA will not be affected. All notices relating to the Parties' legal rights and remedies under this BAA will be provided in writing to a Party, will be sent to its address set forth in the Underlying Agreement, or to such other address as may be designated by that Party by notice to the sending Party, and will reference this BAA. Nothing in this BAA will confer any right, remedy, or obligation upon anyone other than Provider and Company. This BAA is the complete and exclusive agreement between the Parties with respect to the subject matter hereof, superseding and replacing all prior agreements, communications, and understandings (written and oral) regarding its subject matter.

PROVIDER PARTICIPATION ADDENDUM

This Provider Participation Addendum to the Agreement between Company and Provider (this “Provider Participation Addendum”) is made by and between Provider and, where applicable and identified on Attachment “A” of the Agreement: 1) Strategic Health Alliance, when contracting on behalf of Atlas Specialty for Specialty Pharmacy Services Administrative Organization (“Specialty PSAO”) services and/or as a McKesson Pharmacist Medical Contracting when contracting for medical services (“Medical Contracting Services”); and/or 2) Health Mart Atlas, when contracting for Retail Pharmacy Services Administrative Organization (“Retail PSAO”) (individually and collectively, “Company”). Company and Provider may be individually referred to as a “Party” and, collectively, the “Parties” in this Provider Participation Addendum.

This Provider Participation Addendum outlines the terms and conditions for Provider’s participation in the Specialty PSAO services, Medical Contracting Services, and/or Retail PSAO services as identified in Attachment “A” (the “Services”) of the Agreement. This Provider Participation Addendum will apply to Atlas Specialty, McKesson Pharmacist Medical Contracting and Health Mart Atlas independently as if Atlas Specialty, McKesson Pharmacist Medical Contracting, and Health Mart Atlas have separately and independently entered into the Agreement with Provider as it relates to the applicable Services under this Provider Participation Addendum. To the extent there is a conflict between the Agreement, any other Addendum to the Agreement, and this Provider Participation Addendum, this Provider Participation Addendum will control with respect to the subject matter described herein.

RECITALS

WHEREAS, Company wishes to create certain networks of pharmacies to provide certain pharmacy or health care services to Covered Person under Plans of various Payors;

WHEREAS, Provider is an entity that wishes to enter into an agreement with Company to participate as a Participating Provider in one or more pharmacy networks established by Company to render Covered Services as set forth in this Provider Participation Addendum; and

WHEREAS, Provider wishes to engage Company as its attorney-in-fact for the purpose of entering into certain plan participation agreements with Payors.

Article 1: DEFINITIONS

The capitalized terms used in this Provider Participation Addendum but not otherwise defined below will have the meaning ascribed to them in the Agreement.

1.1 “Contracted Payor” means a Payor contracted with Company to offer Participating Providers the opportunity to participate in such Payor Plan.

1.2 “Payor Agreement” means an agreement between Company and a Payor whereby the Payor agrees to offer to a Covered Person one or more Payor Plans and Company agrees to make available its network of Participating Providers for the provision of Covered Services. Payor Agreement includes all documents, including reimbursement schedules and Payor Policies and procedures associated with a Payor Plan.

1.3 “Participating Provider” means a provider that has entered into a written agreement with Company to participate in one or more networks established by Company in accordance with all Company Policies and Payor Policies.

1.4 “Participating Provider Location” means Provider Location that has satisfied all criteria for participation in one or more networks of Payors. For purpose of this Provider Participation Addendum, Provider’s Participating Provider Location is listed on Attachment “A” of the Agreement.

1.5 “Payor Policies” means all policies, procedures, standards, manuals, and guidelines established by a Contracted Payor, as may be modified from time to time, that have been provided or made available to Provider by Payor.

1.6 “Pharmacist” means a pharmacist as defined by the laws of the jurisdiction in which Covered Services are provided, and who renders Covered Services as an employee, subcontractor, or Provider.

1.7 “Provider Health Professional” means Pharmacist or Provider Non-Pharmacist Professional. Provider Health Professionals for Medical Contracting Services are listed on Attachment “A” of this Provider Participation Addendum.

1.8 “Provider Non-Pharmacist Professional” means a healthcare professional other than a Pharmacist who is duly authorized under the laws of the jurisdiction in which Covered Services are provided, and who renders Covered Services as an employee or subcontractor of Provider.

Article 2: PROVIDER REPRESENTATIONS AND WARRANTIES

2.1 Representations and Warranties. In addition to the representation and warranties outlined in the Agreement, Provider represents and warrants that at all times during the term of this Provider Participation Addendum:

(a) Provider Parties have not been debarred or excluded from participation in federal or state health care programs and are not the subject of any investigation, hearing or trial that could result in a Provider Party being sanctioned, penalized, or debarred by any state or federal agency;

(b) Provider is authorized to operate and operates as a retail pharmacy in the state in which it conducts business, and is registered with the U.S. Drug Enforcement Agency to receive, store, handle and dispense controlled substances, and is in good standing with respect to such licenses and registrations; and

(c) All Pharmacists employed by Provider are fully licensed as pharmacists in the state in which Provider conducts business and are at all times current and in good standing with respect to such licenses.

Article 3: ADDITIONAL DUTIES AND OBLIGATIONS OF PROVIDER

3.1 Enrollment. Provider and Provider Health Professionals shall meet all applicable credentialing and eligibility requirements and complete the enrollment process including all documents deemed by Company and Contracted Payor to be necessary to make a determination of Provider’s qualifications to participate in one or more networks.

3.2 Notices by Provider. In addition to the notice requirements outlined in the Agreement, Provider shall provide written notice to Company within five (5) Business Days of becoming aware of the occurrence of any disciplinary proceedings by state or federal law enforcement, regulatory agency or licensing board initiated against Provider or any Provider Healthcare Professionals, such notice will include a description of the general nature of such proceedings.

3.3 Maintenance and Access to Records.

(a) Maintenance of Provider Records. Provider shall maintain for at least five (5) years after the date of delivery of Covered Services (or longer if required by applicable law) and readily make available to Company, Payor, and governmental agencies with regulatory authority, Provider and all related administrative records of Covered Person(s) that receive Covered Services, as required by Payor or Company in accordance with this Provider Participation Addendum or pursuant to and as permitted by applicable law.

(b) Access to Provider Records. Subject to applicable disclosure and confidentiality laws, Provider, upon request from Company, Contracted Payor, or any duly designated third party, shall provide access to Provider records, books, and other records of Provider relating to Covered Services provided to Covered Person for purposes of inspection and auditing, and to the cost of Covered Services provided to Covered Person during the term of this Provider Participation Addendum and thereafter for a period of five (5) years or longer if required by applicable law. The provisions of this paragraph shall not operate to waive or limit any restriction on release or disclosure of patient records established in any other provisions of the Agreement or as otherwise required by law.

3.4 Payor Policies. Provider will comply and be bound by Payor Policies. Provider acknowledges and agrees that updates or revisions may be made from time to time to Payor Policies and Plan Summary Documents by Contracted Payor. Such updates or revisions shall be binding on Provider. If Provider determines that the modifications to any Payor Policies or Plan Summary Documents will materially negatively affect the responsibilities or rights of Provider or Provider otherwise does not agree to adhere to such modifications, then Provider may have the right to opt out of the Payor’s network in accordance with Section 5.3 of this Provider Participation Addendum. Provider acknowledges that Company is not responsible for providing Payor Policies or Plan Summary Documents, such Payor Policies or Plan Summary documents may be available online by Payor or upon Provider’s request to Payor.

3.5 Transferability. Provider agrees, on request of the Covered Person or his/her/its Participating Provider, and subject to applicable disclosure and confidentiality laws, to transfer the Provider records of the Covered Person to such other Participating Provider.

Article 4: DUTIES, OBLIGATIONS AND SERVICES OF COMPANY

4.1 Functions. Company shall market to Payors one or more Participating Provider networks consisting of certain Participating Providers. Company shall have the right to establish multiple Participating Provider networks, each with its own criteria for participation.

4.2 Payor Agreements. Company will enter into Payor Agreements that set forth: (a) the criteria for Participating Providers to provide Covered Services to Covered Person under a Payor Plan; (b) the criteria under which a Payor is obligated to make payments to Participating Providers or, if Payor utilizes the Consolidated Reimbursement Program in accordance with Section 7.1 of this Provider Participation Addendum, to Company on behalf of Participating Providers for Covered Services rendered by Participating Providers to Covered Person; (c) a reimbursement methodology for Covered Services provided by Participating Providers; (d) the timing for Payor to make payments to Participating Providers, or Company on behalf of Participating Providers, after receipt of a completed claim form from a Participating Provider; and (e) a process for Participating Provider to appeal payment denials or otherwise substantiate the right of payment in the event payment is withheld or recouped by Payor. Company shall use reasonable efforts to maintain an updated list of Payor Agreements available for participation under each network on its network portal(s) or other means selected by Company. Unless otherwise required by law, Company will provide copies of Payor Agreements upon written request by Provider.

4.3 No Guarantee of Utilization. Provider acknowledges that Company does not warrant or guarantee that Provider will be utilized by a Covered Person within any Payor Plan.

Article 5: ACCEPTANCE OF PAYOR AGREEMENTS AND NETWORK ENROLLMENT

5.1 Appointment of Company as Attorney-in-Fact. Provider hereby constitutes and appoints Company the true, lawful, sole and exclusive attorney for Provider, with full power of substitution, in the name of Provider for the following purposes: (a) to enter into any and all Payor Agreements and contracts in the name of Provider, in accordance with the terms of this Provider Participation Addendum; (b) to collect, receive and manage on Provider's behalf, accounts receivable generated by billings and claims for reimbursement as more fully set forth in Section 7.1 of this Provider Participation Addendum; (c) to take custody of, endorse in the name of Provider, and deposit into Provider's account, any notes, checks, money orders, insurance payments and any other instruments, received in payment of such account receivables for Covered Services or other services provided under or in connection with Payor Agreements; and (d) any purpose agreed to by Company and Provider to administer this Provider Participation Addendum.

5.2 Contract Authority. Subject to Provider's opt-out right set forth in Section 5.3 of this Provider Participation Addendum, Company shall have the authority to enter into prospective Payor Agreements on behalf of Provider for the provision of Covered Services to Covered Person and bind Provider to the terms and conditions set forth therein. Provider agrees to participate in Payor Plans entered into by Company for the network or networks in which Provider is enrolled and shall execute any agreement with a Payor reasonably necessary to implement an agreement between Company and Payor for any Plan from which Provider does not opt-out pursuant to Section 5.3. Provider shall not interfere in any way with any negotiations of or matters related to any existing or potential Payor Agreements between Company and Payors.

5.3 Provider's Right to Opt-Out. Company will provide notice to Provider of any new Payor Agreements. Provider may elect to opt out of participation in any Payor Agreement available within the network within thirty (30) day's written notice following notification by Company of any new Payor Agreements. Provider shall not enjoy the rights conferred, nor be subject to the obligations imposed, by any Payor Agreement from which Provider opts out. Provider acknowledges and agrees that Provider's decision to opt-out of any Payor Agreement may result in additional restrictions upon or exclusions from participation in other Payor Agreements.

5.4 Network Participation

(a) Provider is eligible to participate in those Company networks for which Provider satisfies all participation criteria. Company shall be permitted, but not required, to automatically enroll Provider in all Payor Agreements available under Provider's assigned network, subject to limitations established by Company, Contracted Payors or if applicable, other third parties. Company has the right to restrict participation in certain networks in its sole discretion.

(b) Provider may contract directly with a Payor to participate in any of Payor's Plans not accepted by Company on Provider's behalf.

(c) Upon written notice to Company, Provider may request to change its network affiliation, subject to the terms and conditions set forth in this Provider Participation Addendum. Company shall have the sole discretion as to approving or denying Provider's request.

(d) Provider shall provide a level of service that is consistent with the peer review, utilization review, quality assurance programs, performance standards and other pharmacy requirements and procedures (collectively, "Performance Standards") that may be established by Company and/or a Contracted Payor and disclosed to Provider. Provider understands and agrees that amounts payable to Provider for Covered Pharmacy Services hereunder may be withheld or forfeited to the extent such services fail to meet Performance Standards.

Article 6: PARTICIPATION OF PROVIDER HEALTH PROFESSIONAL AND PARTICIPATING PROVIDER LOCATION

6.1 Participating Provider Location. Provider agrees to render Covered Services only at the Participating Provider Location approved by Company and listed on Attachment "A" of the Agreement. Provider shall notify Company in writing, in at least thirty (30) calendar days prior to any change to Participating Provider Location ownership, business address, email address or business telephone number.

6.2 Termination of Provider Health Professional and/or Participating Provider Location from Company Network. Company may terminate a Provider Health Professional or Participating Provider Location's participation in Company network, without terminating this Provider Participation Addendum, immediately, upon becoming aware of any of the following:

(a) any failure to meet Company and/or Payor credentialing requirements to the extent those requirements apply to Provider, Provider Health Professionals or Participating Provider Location;

(b) the material breach of the Agreement by Provider Health Professional or Participating Provider Location that is not cured by Provider or Provider Health Professional or Participating Provider Location within thirty (30) days after Company provided notice to Provider of the breach;

(c) the suspension, revocation, condition, limitation, qualification, or other material restriction on Provider Health Professional or Participating Provider Location license, certification, and/or permit by any government agency under which Provider Health Professional or Participating Provider Location is authorized to provide Services;

(d) a sanction imposed by any government agency or authority; or

(e) With respect to Provider Health Professionals any criminal charge, related to any health care services or for an indictment, arrest, or conviction for a felony.

Section 7: PROVIDER CHARGES, REIMBURSEMENT PROCEDURE AND BILLINGS

7.1 Provider Reimbursement and Company Recoupment Rights.

(a) Provider acknowledges and agrees that Payors may elect to pay Provider and other Participating Providers directly for Covered Services provided by Provider to Covered Person under Payor's respective Payor Agreement ("Direct Payment"), or to pay Company on behalf of Provider (the "Consolidated Reimbursement Program") for such services. A list of those Payors that have elected to utilize the Consolidated Reimbursement Program will be made available to Provider upon request and is subject to change from time to time.

(b) With respect to funds received by Company under the Consolidated Reimbursement Program, Company will make reasonable efforts to pay Provider within two (2) banking days of Company (i) receiving sufficient funds from Payor for payment of the Covered Services provided under the Payor Agreement (the "Funds"); and (ii) receiving data in a form and substance sufficient to permit Company to pay the Funds properly to the Participating Providers entitled to receipt. In no event shall Company be obligated to pay Provider for any services rendered by Provider if Company has not received monies from Payor sufficient to pay for such services.

(c) Provider acknowledges and agrees that if Provider, either directly or as a result of participation in a network, is or is reasonably anticipated by Company to become subject to a negative charge, recoupment, true-up or other fee or clawback from a Payor, or otherwise has a debit balance for one or more of Participating Provider Locations, Company may, at its option: (i) withhold funds received under the Consolidated Reimbursement Program from future payments to Provider until such time as Provider's balance for all Participating Provider Locations for all Payors is zero dollars or above;

(ii) debit Provider's bank account for the negative amount; or (iii) invoice Provider for such negative amount, which sum will be due and payable with five (5) Business Days following Company's delivery of invoice (collectively, the "Recoupment Rights").

(d) Company shall have the right to debit, withhold or otherwise offset amounts from one Participating Provider Location to satisfy a negative balance of another Participating Provider Location as part of the Consolidated Reimbursement Program set forth in this Section 7.1. Additionally, Company may offset Fees from amounts received under the Consolidated Reimbursement Program or collect such Fees by any other means deemed necessary by Company.

7.2 Contingency Fund. Provider acknowledges and agrees that Company may, in its sole discretion, establish a contingency reserve fund or funds (the "Contingency Fund") that may be used by Company to satisfy any existing or anticipated financial obligation of Company arising from its rights and duties under the Agreement, including without limitation the satisfaction of negative charges, recoupments or fees sought by a Payor for one or more of Company's networks. Provider further agrees that if any Withhold Fund is insufficient to cover the financial obligations of Company, then Provider's proportionate share of the amount of the deficit may be withheld from Provider's next payment or payments in order to satisfy Company's financial obligation.

7.3 Payment in Full. Provider shall accept as payment in full the reimbursement and/or compensation specified in the applicable Payor Plan. Provider agrees that in no event, including, but not limited to non-payment by Payor, Payor insolvency, or breach of the Agreement, shall Provider bill, charge, collect a deposit from, seek compensation, remuneration or reimbursement from, or have any recourse against Covered Person or other persons acting on a Covered Person's behalf for Covered Services provided pursuant to this Provider Participation Addendum and/or a Payor Agreement.

7.4 Co-payments, Coinsurance and Deductibles. Provider is entitled to bill and has the responsibility to collect from a Covered Person any applicable co-payments, coinsurance, or deductibles for Covered Services according to the terms of the applicable Payor Plan or Payor Agreement. Provider understands and agrees that Payor and Company have no responsibility to pay any amount except as described in Section 7.1, and Provider shall bill and collect copayments, deductibles and any other fees that are the Covered Person's responsibility. For services not covered by the Payor Plan or Payor Agreement, Provider may bill Covered Person or other responsible party at a usual and customary charge rate for such services; provided, however, that the provision of, and billing for, such services must be consistent with Payor Policies and permitted by law. Provider agrees to notify Covered Person in advance of providing any uncovered services that the service is not covered by the Plan and that Covered Person will be responsible for all charges.

7.5 Coordination of Benefits. Provider agrees to (a) cooperate with Company and Payor in coordination of benefits; (b) provide Company and Payor-relevant information relating to any other coverage held by Covered Person; and (c) abide by the coordination of benefits, subrogation and duplicate coverage policies and procedures of Company and Payor. Provider consents to the release of Provider information by Company or Payor to other group health plans as is necessary and lawful to accomplish coordination of benefits.

Article 8: CONFIDENTIALITY

8.1 Confidentiality. Provider acknowledges and agrees that all Payor Agreements, Company Policies, Payor Policies, and any other information arising from or relating to the actions of Company in furtherance of the Agreement or its creation, maintenance or operation of one or more networks shall be deemed confidential information ("Confidential Information") and shall not be disclosed without the prior written consent of Company. Any failure of Provider to maintain the confidentiality of Confidential Information shall be deemed a material breach of the Agreement.

Article 9: TERM AND TERMINATION

9.1 Term. This Provider Participation Addendum shall be effective the latter of the Effective Date or the Provider Participation Amendment Effective Date. With respect to Specialty PSAO and Medical Contracting Services, the Provider Participation Addendum will continue for a term of one (1) year ("Initial Term"), and thereafter, unless terminated in accordance with the terms of this Provider Participation Addendum, shall renew automatically for successive renewal terms of one (1) year each ("Renewal Term").

9.2 Termination by Notice. Either Party may terminate this Provider Participation Addendum, with or without cause, by giving at least thirty (30) day's prior written notice to the other Party. With respect to Specialty PSAO and Medical Contracting Services, such termination will become effective at the end of any Initial Term or the applicable Renewal Term.

9.3 Termination by Company. Notwithstanding anything to the contrary in this Provider Participation Addendum, Company may, at its sole option, terminate this Provider Participation Addendum effective immediately upon notice to Provider on any of the following conditions: (a) any failure to provide the required notice outlined in Article 3; (b) breach of any representation and warranty set forth in the Agreement or this Provider Participation Addendum; (c) if Company knows or has reason to believe that Provider is no longer eligible to participate under one or more Payor Agreements or Payor Plans; (d) if performance of or under the Agreement by Company would cause Company to violate or be non-compliant with, or put Company in jeopardy of causing Company to violate or be non-compliant with, any Payor Plan, Payor Agreement, and/or any laws, rules or regulations applicable to the Agreement or services provided by Company to Provider (including without limitation antitrust Laws and Laws related to reimbursement for pharmaceutical products), as determined by Company in its sole discretion; (e) Provider's breach of its confidentiality obligations under the Agreement; or (f) if Company determines in its sole discretion that the continued participation of Provider may negatively impact the goodwill or business of Company, its owners or its owners' parents.

Article 10: AGREEMENT AND SURVIVAL

This Provider Participation Addendum, the Agreement, and the Enrollment Materials contain all terms regarding the subject matter contained herein. All other agreements, promises, negotiations or representations, either oral or written, relating to the subject matter of this Provider Participation Addendum are of no force or effect. Termination of the Agreement or this Provider Participation Addendum shall not affect the rights, obligations and liabilities of the Parties arising out of the transactions occurring prior to termination. Additionally, Sections 7.1 (Provider Reimbursement), 7.2 (Contingency Fund), and 8.1 (Confidentiality) shall survive the termination of the Agreement including, this Provider Participation Addendum.

Appendix 1

Medical Contracting Services Provider Health Professionals

This Appendix 1 applies only to Provider if Provider is participating in the Medical Contracting Services. Provider attests that this Appendix 1 to the Provider Participation Addendum identifies all individual Providers who will participate in Medical Contracting Services under the Agreement.

Provider Health Professionals

To ensure proper set up in the Payor's system for credentialing, if Provider is participating in Medical Contracting Services, please list all Participating Provider Health Professionals for the Participating Provider Location listed in Attachment "A" of the Agreement, as applicable:

***Note:** please check "Add" box to add additional Provider Health Professionals for the Participating Provider Location. You can also attach a list of all Provider Health Professionals & key information for the Participating Provider Location /, as applicable.

Provider Health Professional's Name	CAQH # (if applicable)	Provider Health Professional's NPI #

Appendix 2

State Regulatory Requirements Addendum

This State Regulatory Requirements Addendum (this “Regulatory Addendum”) supplements and is made part of the Provider Participation Addendum between Company and the pharmacy named in the Agreement (“Provider”) that operates a pharmacy location subject to the Agreement in the applicable State outlined below.

In the event of conflict between this Regulatory Addendum and any other attachment or provision of the Agreement, the provisions of this Regulatory Addendum will control with respect to a Provider that operates a pharmacy location subject to the Agreement in the applicable State outlined below or unless otherwise required by law. Company may amend or supplement this Regulatory Addendum as required or requested by the applicable State. Provider agrees that Company is permitted to unilaterally update this Regulatory Addendum to initiate any addition, deletion, or modification required or requested by the applicable State through an amendment to the Agreement.

Unless otherwise defined in this Regulatory Addendum, all capitalized terms shall have the meaning ascribed in the Agreement.

Maryland State Regulatory Requirements

The Maryland Regulatory Requirements outlined in this Addendum apply to an Independent Pharmacy (as defined below) that operate a pharmacy location subject to the Agreement in the State of Maryland.

Section 1: Definitions

For purposes of the Maryland State Regulatory Requirements, the following terms shall have the meaning set forth below:

1.1 “Independent Pharmacy” shall mean a Pharmacy operating within the State of Maryland that is under common ownership with not more than two other pharmacies.

1.2 “Pharmacy Benefits Manager” shall have the meaning stated in Maryland Code § 15-1601.

1.3 “Pharmacy Services Administrative Organization” or (“PSAO”) shall mean an entity that provides a contracted pharmacy with contracting administrative services related to prescription drug benefits.

1.4 “Pharmacy Services Administrative Contract” shall mean a contractual agreement between a PSAO and an Independent Pharmacy under which a PSAO agrees to negotiate with Purchasers or Pharmacy Benefit Managers on behalf of one or more Independent Pharmacies.

1.5 “Purchaser” shall mean the State Employee and Retiree Health and Welfare Benefits Program, an insurer, a nonprofit health services plan, or a health maintenance organization that provides prescription drug coverage or benefits in the State of Maryland.

Section 2: Contracts with Purchasers and Pharmacy Benefit Managers

2.1 PSAO will provide Independent Pharmacy a copy of any contract, amendment, payment schedules or reimbursement rates within five (5) business days after the execution of a contract, or an amendment to a contract, signed on behalf of the Independent Pharmacy by PSAO.

2.2 Independent Pharmacy acknowledges that any contract, amendment, payment schedule or reimbursement rates shared with Independent Pharmacy is confidential and shall not disclose any contract, amendment, payment schedule or reimbursement rates with any third party including any other PSAO.

Section 3: Claims Remittances and Maintenance of Records

3.1 Remittances for claims submitted by a Pharmacy Benefit Manager or Purchaser on behalf of an Independent Pharmacy will be passed by the PSAO to the Independent Pharmacy within a reasonable amount of time but no more than five (5) business days following receipt.

3.2 PSAO shall maintain adequate books and records regarding each Independent Pharmacy that participates with PSAO as follows: 1) in accordance with prudent standards of record keeping; 2) for the duration of the agreement between PSAO and Independent Pharmacy; and 3) for three (3) years after the PSAO ceases to provide PSAO services to the Independent Pharmacy.

Section 4: Ownership; Changes in Ownership; PSAO Participation

4.1 Health Mart Atlas is a limited liability company duly organized under the laws of the State of Delaware. Health Mart Atlas members are Strategic Health Alliance II, Inc d/b/a AccessHealth and American Pharmacy Network Solutions, LLC. Strategic Health Alliance II, Inc. d/b/a AccessHealth is owned by McKesson Corporation, which manufactures, sells, or distributes prescription drugs, biologics, or medical devices.

4.2 PSAO will provide written notice to Independent Pharmacy within five (5) business days of any material change in its ownership or control related to any company, subsidiary, or organization that provides pharmacy services; provides prescription drug or device services; or manufactures, sells, or distributes prescription drugs, biologics, or medical devices

4.3 If PSAO owns or is owned an entity that manufactures, sells, or distributes prescription drugs, biologics or medical devices, PSAO will not require as a condition of entering into Pharmacy Services Administrative Contract that an Independent Pharmacy purchase any drugs, biologics, or medical devices from that entity.

Section 5: Duties of PSAO

5.1 PSAO may not 1) misrepresent pertinent facts or policy provisions that related to an issue in a dispute or an appeal of a decision regarding a dispute; 2) refuse to pay or reimburse an Independent Pharmacy for an arbitrary or capricious reason based on available information; 3) fail to settle a dispute promptly whenever liability is reasonably clear under one part of a policy or contract, in order to influence settlement under other parts of the policy or contract; or 4) fail to act in good faith.

5.2 PSAO may not engage in any activity that is prohibited activity for Pharmacy Benefit Manager under subtitle 16 of the Maryland Code including:

(a) directly or indirectly charge a contracted Independent Pharmacy, or hold a contracted Independent Pharmacy responsible for, a fee or performance-based reimbursement related to the adjudication of a claim or an incentive program.

(b) make or allow any reduction in payment for pharmacy services by a Pharmacy Benefits Manager or purchaser or directly or indirectly reduce a payment for a pharmacy service under a reconciliation process to an effective rate of reimbursement, including generic effective rates, brand effective rates, direct and indirect remuneration fees, or any other reduction or aggregate reduction of payments.

PROVIDERPAY RECONCILIATION SERVICES ADDENDUM

This ProviderPay Reconciliation Services Addendum to the Agreement between Company and Provider (this “ProviderPay Addendum”) is entered into by and between Provider and Strategic Health Alliance II, Inc., d/b/a ProviderPay (“ProviderPay”). Provider and ProviderPay and may be individually referred to as a “Party” and, collectively, the “Parties” in this ProviderPay Addendum.

To the extent there is a conflict between the Agreement and the ProviderPay Addendum, this ProviderPay Addendum will control with respect to the services provided to Provider under this ProviderPay Addendum.

Article 1: DEFINITIONS

The capitalized terms used in this Addendum, but not otherwise defined below, will have the meaning ascribed to them in the Agreement.

1.1 “Account” means any account, designated by Provider to receive debit and credit transactions from ProviderPay in conjunction with Provider’s participation in the ProviderPay Service.

1.2 “ACH” means Automated Clearing House, a method of electronically debiting or crediting deposit accounts.

1.3 “Intellectual Property Right(s)” means any patent, copyright, trademark, program, code, software, trade secret, trade dress, mask work, right of attribution or integrity or other intellectual or industrial property rights or proprietary rights arising under the laws of any jurisdiction (including, without limitation, all claims and causes of action for infringement, misappropriation, or violation thereof and all rights in any registrations and renewals).

1.4 “Legal Process” means any subpoena, order (including, without limitation, an ex parte order), writ (including, without limitation, a writ of attachment, execution, garnishment, or replevin), levy, search warrant, seizure warrant, forfeiture order, receivership order, or similar legal process or proceeding.

1.5 “Lockbox” means a service provided by ProviderPay to receive non-electronic payments from Payors.

1.6 “Login ID” means Provider’s login identifications and passwords in connection with Provider’s use of the ProviderPay Services.

1.7 “Master User” is an individual authorized by Provider to have control and oversight of Provider’s use of the ProviderPay Service. and to grant access to Subordinate Users by issuing a Login ID.

1.8 “ProviderPay Account” means an account set up and owned by ProviderPay for the benefit of the Provider, for ProviderPay to receive and process payments from Payors.

1.9 “ProviderPay Service” means the products and services, including, without limitation, Online Services (as defined below) provided by ProviderPay to Provider for processing and reconciliation activity of claims, remittances, and/or payments received from Payors as described more fully in Section 2 and if offered by Company and selected by Provider, any program services identified as optional on the Enrollment Materials.

1.10 “Subordinate User” means any individual authorized by the Master User to use Online Services on behalf of the Provider.

1.11 “Transfer” means any electronic banking transaction, including a deposit, withdrawal, payment, or advance made electronically.

1.12 “User” means a Master User or Subordinate User authorized to use ProviderPay Services on behalf of the Provider.

Article 2: USE OF THE PROVIDERPAY SERVICES

2.1 Non-transferable Use. For the term of this ProviderPay Addendum, ProviderPay grants Provider a personal, limited, non-exclusive, revocable, non-transferable, and non-sub-licensable right to use the ProviderPay Services pursuant to the terms of this Agreement. ProviderPay may provide certain portions of the ProviderPay Services under license from or other arrangements with third-party licensors or service providers (collectively, “Third-Party Providers”) selected by ProviderPay in its sole discretion. Such Third-Party Providers may provide all or part of the ProviderPay Services or related products or services or provide Provider with access to the ProviderPay Services or related products or services, or their respective licensors. ProviderPay further grants Provider a limited, non-exclusive, personal, non-transferable, royalty-free license, during the term of the ProviderPay Addendum to use the ProviderPay platform solely as part of the ProviderPay

Service in accordance with this Provider Pay Addendum. Provider will comply with any and all additional restrictions on Provider's usage of such ProviderPay Services that ProviderPay may provide to Provider from time to time, or that are otherwise the subject of an agreement between Provider and such Third-Party Providers.

2.2 Proprietary Rights. ProviderPay is providing the ProviderPay Services to Provider only for Provider's own benefit and Account, and only for the purposes, and subject to the terms, of this ProviderPay Addendum. Provider shall not sell, license, distribute, lease, transfer, or provide, directly or indirectly, the ProviderPay Services or any portion of the ProviderPay Services to any third party, except as expressly permitted by this Agreement. Provider acknowledges that all proprietary rights in the ProviderPay Services are owned by ProviderPay, or any applicable Third-Party Providers, and are protected under copyright, trademark, and other intellectual property laws, and other applicable laws. Provider receives no copyrights, other Intellectual Property Rights, or other rights in or to the ProviderPay Services, except those specifically set forth in this ProviderPay Addendum. Provider will protect and not violate those proprietary rights in the ProviderPay Services and honor and comply with ProviderPay's reasonable requests to protect ProviderPay's, and Third-Party Providers' contractual, statutory, and common law rights in the ProviderPay Services. If Provider becomes aware of any violation of any such rights in the ProviderPay Services, Provider will (i) promptly notify ProviderPay in writing; and (ii) to the extent reasonably feasible, use commercially reasonable efforts to cause such violations to cease.

2.3 Access to Online Services. Provider is solely responsible for obtaining access to the online portion of the ProviderPay Services ("Online Services"). Except as otherwise provided in this ProviderPay Addendum, Provider assumes full liability for all User activity and all transactions conducted through the Online Services. ProviderPay will make reasonable efforts to make Online Services generally accessible, with the exception of standard maintenance periods. The Online Services may also not be available if emergency maintenance is required to the system.

2.4 Security of Login ID. Provider is responsible for ensuring the security of Provider's Login ID, and Provider's use of the ProviderPay Services.

2.5 Users. Provider may access the Online Services only through one or more Login IDs. Provider is solely responsible for ensuring that Provider's Login IDs are known to and used by only those Users that Provider authorizes, and for ensuring such Users are properly trained, qualified and supervised. Each User is responsible for keeping the Login ID confidential. At ProviderPay's request, Provider will provide ProviderPay a list of Provider's Users and their respective contact information, and any updates to the list. Provider acknowledges that ProviderPay may deny access to any ProviderPay Service by any User of Provider's Login IDs, that ProviderPay reasonably believes is necessary or appropriate in connection with the Provider's use of the ProviderPay services.

2.6 Termination of Login ID. ProviderPay may terminate, revoke, suspend, modify, or change any or all of Login IDs at any time, without prior notice. Provider will promptly notify ProviderPay, and not allow a User further access to any ProviderPay Service, if any User becomes subject to any criminal, internal or regulatory review, investigation, charge or finding of wrongdoing.

2.7 Liability for Transactions. Notwithstanding any other provision of this ProviderPay Addendum, Provider will be (i) solely responsible for all transactions, acts or omissions of any person using a ProviderPay Service through Provider's Login IDs, whether or not such transactions, acts or omissions were authorized by Provider, and (ii) without limitation of the foregoing or any other provision of this ProviderPay Addendum, bound by the terms of all transactions, acts or omissions placed through any ProviderPay Service using any of Provider's Login IDs. All transactions processed by use of Provider's Login IDs will be deemed to be authorized by Provider and made by an authorized User, whether ProviderPay acknowledges receipt of such transaction. Any access to the ProviderPay Services granted by the Master User to a Subordinate User will be considered by the Parties to be unlimited in amount and scope until the Master User discontinues the permission by changing the Login ID.

2.8 Lost or Stolen Login IDs. If any of Provider's Login IDs have been lost, stolen, or compromised, Provider shall immediately notify ProviderPay in writing, and change the lost, stolen, or compromised Login ID. Following ProviderPay's receipt of such notice, Provider's Login IDs may be cancelled or suspended, but Provider is responsible for any actions taken through the use of such Login IDs before they are cancelled or suspended. ProviderPay has no liability or responsibility arising from or relating to lost, compromised or stolen Login IDs, user identifications or passwords.

2.9 Any software ProviderPay makes available as part of the ProviderPay Services may include encryption methods that are subject to the export and/or import control laws of the United States and other countries. Provider

will cooperate with ProviderPay in complying with any such laws in connection with the Provider's use of the ProviderPay Services.

ARTICLE 3: DUTIES OF PROVIDER

3.1 Payment Returns. If ProviderPay is required at any time to return any portion of any payment received from any Payor or any other funds received from any person or entity, ProviderPay will attempt to collect the funds from the Account through ACH. If funds are not available in the Account, then ProviderPay will notify Provider of any returned amounts, and Provider shall immediately pay to ProviderPay any such amounts without interest or penalty.

3.2 Claim Remittance Address. Provider agrees to assist ProviderPay in instructing Payors selected for the service to submit claim remittances and, if applicable, payments to the Lockbox or the ProviderPay Account.

3.3 Provider Locations. Provider shall submit to ProviderPay a complete list of Provider retail Provider Locations to be included in the ProviderPay Service, together with specific identification detail as requested by ProviderPay.

3.4 Cooperate with ProviderPay. Upon ProviderPay's request, Provider shall:

- a) promptly review and execute Electronic Remittance Advise "ERA" and Explanation of Benefits "EOB" vendor authorization and ERA set-up forms,
- b) promptly review and execute data delivery authorization forms,
- c) schedule appropriate training for designated personnel, and
- d) timely execute the appropriate documents to authorize electronic debiting of the Account for ProviderPay fees.

3.5 Provider's Use of ProviderPay Services. Provider will immediately notify ProviderPay if any of the ProviderPay Services malfunction and/or an error occurs or if Provider otherwise experiences any material malfunction or other connectivity problem that adversely affects Provider's access to or use of any ProviderPay Services. Provider will use the ProviderPay Services and enter into transactions only for the Provider's own benefit and Account and will not use the ProviderPay Services on behalf of any third parties.

3.6 Provider's Proprietary Data. Provider will own all of its proprietary data in any claims, remits and payments processed through the ProviderPay Service. During the term of this ProviderPay Addendum, Provider grants to ProviderPay and its subcontractors a non-revocable, non-transferable, royalty-free license to manipulate, or use any of Provider's data as reasonably necessary for ProviderPay to perform its obligations hereunder. Each of ProviderPay and Provider shall keep and store all such data in a secure environment.

3.7 ACH Rules. Provider agrees to be bound by ACH association rules. These rules provide, among other things, that payments made to Provider are provisional until final settlement is made through a Federal Reserve Bank or payment is otherwise made as provided in Article 4A-403(a) of the Uniform Commercial Code.

Article 4: DUTIES OF PROVIDERPAY

4.1 ProviderPay Services. ProviderPay agrees to provide to Provider in accordance with the terms of this ProviderPay Addendum, certain ProviderPay Services which may be modified from time to time in ProviderPay's sole discretion and will consist of one or more of the following:

- a) post to the ProviderPay Service designated website claims delivered to ProviderPay
- b) receive and post ERAs and EOB from Payors as authorized by Provider receive, process and post actual payments (check or ACH) as authorized by Provider from Payors, and/or Proof of Payment. For purposes of this ProviderPay Addendum, "Proof of Payment" means a copy of an original check from a Payor or an executed certification from Provider in a form acceptable to ProviderPay indicating that Provider received payment from a Payor.
- c) provide Provider's authorized Users with on-line access to reports
- d) during the term of this Provider Pay Addendum, provide online storage and retrieval of Provider data and images for eighteen (18) months after receipt; and
- e) provide Provider with enhancements and upgrades to the extent ProviderPay makes general release of such enhancements and upgrades to ProviderPay users from time to time.

ARTICLE 5: ACCOUNT

5.1 Lockbox Arrangement. Non-electronic payments from Payors obtained pursuant to this ProviderPay Addendum shall be initially processed through the Lockbox, and then forwarded to Provider via ACH Transfer after the funds have been collected from the paying bank. Provider shall not have access to the Lockbox except as may be otherwise provided in this ProviderPay Addendum.

5.2 ProviderPay Account. Provider authorizes ProviderPay to receive and process payments (check or ACH) from Payors and deposit those payments into the ProviderPay Account. Provider hereby authorizes ProviderPay to set up and maintain the ProviderPay Account, and Transfer funds from the ProviderPay Account to the Account. Provider acknowledges and agrees that ProviderPay may deduct any fees, costs, and/or expenses that the Provider owes to ProviderPay from payments that ProviderPay receives from Payors, before Transferring payments to the Account.

5.3 Provider Account. Provider is responsible for setting up and maintaining the Account to receive funds Transfers from ProviderPay. Master User may designate the Account and update information relating to the Account at any time through the ProviderPay website. Any updates made to the Account will go into effect within fifteen (15) Business Days after the Provider updates the information on the ProviderPay website. Provider acknowledges and agrees that ProviderPay may rely on the Account number and other information provided by Provider (including any updates) even if it identifies a financial institution, person, or account other than the one Provider intended.

5.4 Setoff and Automatic Deduction. Provider grants to ProviderPay (i) contractual rights of setoff in addition to any common law rights of set-off in the Lockbox, and the ProviderPay Account, and (ii) rights of setoff, recoupment, and collection with respect to the Account. Provider agrees that ProviderPay may, without notice, setoff against the Lockbox and the ProviderPay Account, and exercise any right of setoff, recoupment, and collection with respect to the Account, any amounts owed by Provider to Payor and/or ProviderPay, including, but not limited to, any fees, charges or other monetary obligations arising under this ProviderPay Addendum. Provider agrees that fees due and payable to a Payor or ProviderPay by Provider will be deducted from the ProviderPay Account as they accrue. Provider agrees that if ProviderPay does not receive payment of an amount credited to the Account or if the payment is reversed, ProviderPay is immediately entitled to set off the amount credited against other funds in the Lockbox and the ProviderPay Account, and exercise any right of setoff, recoupment, and collection with respect to the Account. Provider agrees it has no right to defer payment of such an amount and that it will be liable for ProviderPay's costs to collect any deficit as well as its reasonable attorneys' fees, expert witness fees, costs of court, and other legal expenses), to the extent permitted by law.

5.5 Adjusting Entries. Provider authorizes ProviderPay to make adjusting entries (including debits) to the Lockbox, Provider Pay Account, and the Account to reverse or correct (i) any previous entry (whether by ACH, wire, other electronic, paper item, cash, or other transaction) that was in whole or in part executed without authority or in error by ProviderPay, the Payor, or any third party, or (ii) any discrepancies between actual amounts tendered for deposit and totals or itemizations on any EOBs, ERAs, or Proof of Payment. For purposes of this paragraph, Proof of Payment means a copy of an original check from a Payor or an executed certification from Provider in a form acceptable to ProviderPay indicating that Provider received payment from a Payor.

5.6 Administrative Hold. ProviderPay may at any time place an administrative hold on the funds in the Lockbox, and/or the ProviderPay Account, and/or refuse to make payments and automatic Transfer of funds to the Account: (i) if ProviderPay in its discretion deems such an administrative hold to be appropriate or prudent, or (ii) if ProviderPay is served with or receives any Legal Process purporting to apply to or affect this Agreement including this ProviderPay Addendum, the Lockbox, the ProviderPay Account, or the Account. If ProviderPay is served with, or receives any Legal Process, ProviderPay shall be able to comply with or respond to the Legal Process without liability to Provider. This ability exists notwithstanding the manner or validity of service or delivery, or the validity of the jurisdiction of the court, authority or agency issuing the Legal Process. ProviderPay may place an administrative hold on the funds in the Lockbox and/or the ProviderPay Account, and/or refuse to make payments and automatic Transfer of funds to the Account, and await a final judicial order or determination regarding the Legal Process, or until ProviderPay receives evidence satisfactory to it that the Legal Process has been resolved. ProviderPay will not be liable if account funds are not available to pay items drawn on the Account as a result of ProviderPay's placing an administrative hold on funds in the Lockbox, and/or the ProviderPay Account, and/or refusing to make payments and automatic transfer of funds to the Account for any reason. ProviderPay may deduct any costs and attorney's fees that ProviderPay incurs in responding to any Legal Process.

Article 6: LIABILITY, WARRANTY, DISCLAIMER

6.1 Liability for Failure to Make A Transfer. If ProviderPay does not properly complete a Transfer to or from the Account on time or in the correct amount, ProviderPay will be liable for the actual amount of any losses or

damages, limited to the amount of such Transfer, and any resulting overdraft or service fees (not to exceed the amount of the Transfer), incurred by Provider and resulting directly from such failure, but only to the extent that such losses or damages were caused by the gross negligence or willful misconduct of ProviderPay. ProviderPay will not be liable in the following instances under any circumstances if:

- a) Provider's funds are subject to Legal Process or other encumbrance restricting the Transfer,
- b) Provider's Transfer authorization terminates by operation of law,
- c) Provider fails to comply with the instructions and requirements set forth in this ProviderPay Addendum or the ProviderPay procedures,
- d) ProviderPay has received incomplete or inaccurate information from Provider or a third party involving the Account or Transfer,
- e) ProviderPay reasonably believes that unauthorized use of a password or account has occurred or may be occurring,
- f) Provider defaults under this ProviderPay Addendum or any other agreement between Provider and ProviderPay, or
- g) Provider does not promptly report an incomplete Transfer to ProviderPay.

In no event shall ProviderPay be liable for damages in excess of the amount of the Transfer from which such damages were incurred nor shall it be liable for any incidental, indirect, special, exemplary, punitive, or consequential damages.

6.2 Warranties. Each Party represents and warrants that it has full legal power and authority to enter into this ProviderPay Addendum and that it will comply with all applicable federal, state, and local statutes and regulations, including, without limitation, federal regulations promulgated pursuant to HIPAA. ProviderPay represents and warrants that it will provide the ProviderPay Service in a workmanlike manner consistent with industry standards reasonably applicable to the performance of such service.

6.3 Disclaimer. EXCEPT AS SET FORTH ABOVE, NEITHER PROVIDERPAY NOR ANY SOFTWARE SUPPLIER OR INFORMATION PROVIDER MAKES ANY WARRANTY, EXPRESS OR IMPLIED, TO PROVIDER CONCERNING PROVIDERPAY SERVICES. PROVIDERPAY, ITS SOFTWARE SUPPLIER AND INFORMATION PROVIDER EXPRESSLY DISCLAIM TO THE MAXIMUM EXTENT PERMITTED BY LAW, ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, ORAL OR WRITTEN, INCLUDING, WITHOUT LIMITATION, (i) ANY WARRANTY THAT THE PROVIDERPAY SERVICE IS ERROR-FREE OR WILL OPERATE WITHOUT INTERRUPTION; (ii) ANY AND ALL IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NON-INFRINGEMENT, AND (iii) ANY AND ALL IMPLIED WARRANTIES ARISING FROM STATUTE, COURSE OF DEALING, COURSE OF PERFORMANCE OR USAGE OF TRADE. NO ADVICE, STATEMENT OR INFORMATION GIVEN BY PROVIDERPAY, ITS AFFILIATES, CONTRACTORS OR EMPLOYEES SHALL CREATE OR CHANGE ANY WARRANTY PROVIDED HEREIN.

6.4 Neither ProviderPay nor Provider grants any license to the other except as specifically set forth in this ProviderPay Addendum. Except as expressly set forth under this Section 6, ProviderPay and Provider expressly reserve all of their respective right, title, and interest in and to their respective Intellectual Property Rights. Provider acknowledges and agrees that all right, title and interest in and to the ProviderPay Service, together with all modifications, enhancements, and derivative works, including as configured for Provider, and all Intellectual Property Rights pertaining to the ProviderPay Service are and shall remain owned exclusively by ProviderPay or third-party software providers (or their licensors).

Article 7: TERMINATION; TRANSITION OF SERVICES

7.1 Term. This ProviderPay Addendum shall be effective the latter of the Effective Date or the ProviderPay Amendment Effective Date and continue for a term of one (1) year (the "Initial Term"). Thereafter, unless terminated in accordance with the terms of this ProviderPay Addendum, this ProviderPay Addendum shall renew automatically for successive renewal terms of one (1) year each ("Renewal Term").

7.2 Termination. Either Party may terminate this ProviderPay Addendum, with or without cause, by giving at least thirty (30) days prior written notice to the other Party.

7.3 Transition Assistance Services. If Provider appoints a third party to assume the services, ProviderPay will provide reasonable assistance to that third party, provided that ProviderPay is not obligated to provide trade secrets or other proprietary information to any third party. It is Provider's sole responsibility to work with Payors to reroute payments, remittances, and ERAs. Provider is responsible to continue to pay ProviderPay fees on all remittances processed by ProviderPay.

Article 8: AGREEMENT AND SURVIVAL

This ProviderPay Addendum, the Agreement, and the Enrollment Materials contain all the terms regarding the subject matter herein. Any other agreements, promises, negotiations or representations, either oral or written, relating to the subject matter of this ProviderPay Addendum are of no force or effect. Article 5 and Article 6 of this ProviderPay Addendum, all accrued payment obligations and liabilities under this ProviderPay Addendum, and all provisions of this ProviderPay Addendum that, logically or by their terms should survive termination, shall survive the termination of this ProviderPay Addendum.

MCKESSON REIMBURSEMENT ADVANTAGE ADDENDUM

This McKesson Reimbursement Advantage Addendum to the Agreement between Company and Provider (this "McKesson Reimbursement Services Addendum") is made and entered into by and between Provider and Company. Company and Provider may be individually referred to as a "Party" and, collectively, the "Parties" in this McKesson Reimbursement Services Addendum.

To the extent there is a conflict between the Agreement and this McKesson Reimbursement Services Addendum, the McKesson Reimbursement Services Addendum will control with respect to the subject matter described herein.

Article 1: DEFINITION

The capitalized terms used in this McKesson Reimbursement Services Addendum, but not otherwise defined below, will have the meaning ascribed to them in the Agreement.

"Services" means the McKesson Reimbursement Advantage services of which allows users to access certain features, functions, and services as determined by Company; and if offered by Company and selected by Provider, any program services identified as optional on the Enrollment Materials.

Article 2: DUTIES AND OBLIGATIONS OF PROVIDER

2.1 Provider hereby authorizes any software vendor and network services vendor to direct all of Provider's pharmacy services claims transactions ("Claims") through Company and its subcontractors. Provider shall not use or access any third-party products or services that provide functionality identical or similar to the Services. Provider hereby constitutes and appoints Company the true, lawful, sole, and exclusive attorney for Provider, with full power of substitution, in the name of Provider to (i) resubmit Claims to Payors on Provider's behalf, for billable Covered Services provided by Provider under Payor Agreements, to the extent applicable, and (ii) collect and receive, on Provider's behalf, Provider reimbursements generated by such Claims to the extent applicable to the Services.

2.2 Any data used in, generated by, or pertaining to the Services, including but not limited to data provided by a Payor, by Company or by Provider, and data generated or compiled by a Payor, by Company or by Provider arising out of the Services, shall be considered "Program Data". Provider shall not use any Program Data for any purposes other than those specifically permitted under this McKesson Reimbursement Services Addendum and shall engage in no act or omission that would interfere with, modify, or delay the transmission of any Program Data. Provider shall provide Company with access to and use of all Program Data reasonably required for the provision of the Services, and to the extent that Provider owns such Program Data, Provider hereby grants to Company the non-exclusive, non-transferable, worldwide, perpetual right and license to access and use the Program Data. Provider shall establish and maintain safeguards against the destruction, loss, or alteration of all Program Data within Provider's control, which shall be no less rigorous than those maintained by Provider for its own information of a similar nature.

2.3 Provider is solely responsible for obtaining access to the online portion of the Services. Except as otherwise provided in this McKesson Reimbursement Services Addendum, Provider assumes full liability for all user activity and all transactions conducted by Provider through the online portion of the Services. Provider is responsible for ensuring the security of Provider's login ID, and Provider's use of the Services. Provider may access the online portion of the Services only through one or more login IDs. Provider is solely responsible for ensuring that Provider's login IDs are known to and used by only those users that Provider authorizes, and for ensuring such users are properly trained, qualified, and supervised. Each user is responsible for keeping the login ID confidential. At Company's request, Provider will provide Access Health a list of Provider's users and their respective contact information, and any updates to the list. Provider acknowledges that Company may deny access to the Services by any user of Provider's login IDs, that Company reasonably believes is necessary or appropriate in connection with the Provider's use of the Services. Company may terminate, revoke, suspend, modify, or change any or all of login IDs at any time, without prior notice. Provider will promptly notify Company, and not allow a user further access to the Services, in the event that any user becomes subject to any criminal, internal or regulatory review, investigation, charge or finding of wrongdoing.

Notwithstanding any other provision, Provider will be (i) solely responsible for all transactions, acts or omissions of any person using the Services through Provider's login IDs, whether or not such transactions, acts or omissions were authorized by Provider, and (ii) without limitation of the foregoing or any other provision of this McKesson Reimbursement Services Addendum, bound by the terms of all transactions, acts or omissions placed through the Services using any of Provider's login IDs. All transactions processed by use of Provider's login IDs will be deemed to be authorized by Provider and made by an authorized user, whether Company acknowledges

receipt of such transaction. Any access to the Services granted by Provider to a user will be considered by the Parties to be unlimited in amount and scope until Provider discontinues the permission by changing the login ID.

2.4 Provider shall not disclose the provision of this McKesson Reimbursement Services Addendum, including but not limited to any Fees associated with Customer's participation in the Services.

2.5 Provider shall pay all applicable government taxes and charges related to the sale of the Services. Services usage (if applicable) shall be the amount recorded by Company's computer system.

Article 3: DUTIES AND OBLIGATIONS OF COMPANY

Company reserves the right, without liability to Provider, to suspend, revise, modify, update, or withdraw all or any portion of the Services. In the case of changes that materially affect the responsibilities or rights of Provider, Provider shall have the right to terminate this McKesson Reimbursement Services Addendum upon thirty (30) days prior written notice to Company, such notice to be received by Company no more than thirty (30) days after Company's notice of the applicable changes. Changes required by Payors, or by legislative, regulatory, or other legal authority as determined by the Company, will be effective immediately upon Provider's receipt of notice.

Article 4: INTELLECTUAL PROPERTY

4.1 If Provider receives or accesses any software from Company in connection with the Services, including any related modifications or documentation (collectively, "Software"), Company hereby grants to Provider a limited, nonexclusive, nontransferable, revocable license to use and/or access the Software only in connection with the Services at the Participating Provider Location, subject to this McKesson Reimbursement Services Addendum and any terms of use that Company may post on a Company website, with which any user, including Provider, must comply in order to access and use any particular Software. This license is effective upon delivery and shall continue for the term of this McKesson Reimbursement Services Addendum. The Software shall remain the exclusive property of Company and its licensors. Provider shall not (i) copy, modify, adapt, translate, distribute, lease, loan, sell, sublicense, frame, mirror, create derivative works, reverse engineer, decompile or disassemble the Software; (ii) allow any third party to obtain or use the Software; (iii) use the Software in any manner which would allow the general public or any unauthorized party to access the Software. Provider shall take all reasonable steps to ensure that all user identifications and passwords issued by Company to Provider are kept confidential and shall immediately notify Company in the event that Provider discovers unauthorized disclosure or use thereof. Provider shall be liable for all uses and misuses of user identifications and passwords issued to or for Provider and its employees. The Software shall be considered Company Confidential Information, and Provider shall cease using or accessing, and return or destroy, all Software upon McKesson Reimbursement Services Addendum termination.

4.2 In no event shall Company be required to provide Provider with any equipment or software under this McKesson Reimbursement Services Addendum. Company or its authorized agents shall have the right at any time during regular business hours to audit Provider's use of the Services including applicable equipment, software, Program Data, and related records, to ensure compliance with this McKesson Reimbursement Services Addendum. Notwithstanding any other provision of this Agreement, the Parties shall maintain the confidentiality and privacy of Protected Health Information "PHI" (as defined the Business Associate Addendum) to the extent required by all Laws. If and to the extent Company receives PHI from Provider pursuant to this McKesson Reimbursement Services Addendum, the Parties agree to incorporate the terms and conditions of the Business Associate Addendum.

4.3 Company retains and shall own exclusively all right, title, and interest in and to all intellectual property related to the Services, including without limitation any Program Data not owned by Payors or Covered Persons. To the extent that any materials or intellectual property related to the Services is deemed to be created by Provider, Provider hereby irrevocably transfers, grants, conveys, and assigns exclusively to Company any and all of Provider's right, title, and interest in perpetuity. Provider agrees to cooperate fully with Company and to take any actions reasonably necessary, including, without limitation, the execution of required documents, to give this provision full force and effect.

4.4 Company is providing the Services to Provider only for Provider's own benefit, and only for the purposes, and subject to this Agreement. Provider may not sell, license, distribute, lease, transfer, or provide, directly or indirectly, the Services or any portion of the Services to any third party, except as expressly permitted by this McKesson Reimbursement Services Addendum. Provider acknowledges that all proprietary rights in the Services are owned by Company, or any applicable third parties, and are protected under copyright, trademark, and other intellectual property laws, and other applicable laws. Provider receives no copyrights, other intellectual property rights or other rights in or to the Services, except those specifically set forth

in this McKesson Reimbursement Services Addendum. Provider will protect and not violate those proprietary rights in the Services and honor and comply with Company's reasonable requests to protect Company's, and third parties' contractual, statutory, and common law rights in the Services. If Provider becomes aware of any violation of any such rights in the Services, Provider will (i) promptly notify Company in writing and (ii) to the extent reasonably feasible, use commercially reasonable efforts to cause such violations to cease.

Article 5: WARRANTIES AND INDEMNITIES

5.1 Provider represents, warrants and covenants (i) that it has and will continue to obtain all consents and authorizations necessary to receive the Services, and to provide Company with all Program Data, (ii) that all Program Data and other information provided by Provider to Company for the purposes of obtaining Provider reimbursements is true, complete, and accurate information regarding the Claims.

5.2 Company shall provide the Services in a professional and workmanlike manner. As Provider's sole remedy for breach of this warranty, Company shall use commercially reasonable efforts to correct errors caused solely by Company's employees, agents, or computer systems, provided that Provider gives Company specific written notice of such errors no later than thirty (30) days following Company's provision of the applicable Services.

5.3 Except as expressly provided otherwise in this McKesson Reimbursement Services Addendum, the Services, and Program Data, are provided "AS IS" without warranty of any kind. COMPANY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES, CONDITIONS, REPRESENTATIONS, AND GUARANTEES RELATING IN ANY WAY TO THIS AGREEMENT, WHETHER EXPRESS OR IMPLIED, ARISING BY LAW, CUSTOM, PRIOR ORAL OR WRITTEN STATEMENTS, OR OTHERWISE, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, OR NONINFRINGEMENT. Without limiting the foregoing statement, Company (i) does not warrant that use of or access to the Services or any Software will be uninterrupted or error free, (ii) shall not be responsible for any errors or failures of any systems, software, equipment, or networks other than those within Company's control, and (iii) shall not be liable for any reimbursement or other decisions made by Payors. Provider has no guarantee of receiving any Provider reimbursements for Claims submitted via the Services. Any informational services provided as part of the Services are provided solely for informational purposes and are not intended as a substitute for the professional judgment of the treating practitioner; Covered Persons' medical and treatment decisions are at all times the sole responsibility of the treating practitioner.

5.4 Except to the extent arising solely from Company's gross negligence or willful misconduct, Provider shall defend, indemnify and hold harmless Company, its affiliates, and their officers, directors, employees, shareholders, and agents, and their successors and assigns, from and against any and all claims, actions, suits, liabilities, judgments, losses, damages, costs, charges and expenses (including without limitation attorneys' fees), related to (i) any Program Data or other information provided to Company or Payors by Provider, (ii) Provider's failure to comply with the terms of this McKesson Reimbursement Services Addendum.

Article 6: LIMITATION OF LIABILITY

PROVIDER AGREES THAT THE SOLE AND EXCLUSIVE REMEDY AVAILABLE TO PROVIDER UNDER THIS MCKESSON REIMBURSEMENT SERVICES ADDENDUM SHALL BE THE RECOVERY OF ACTUAL DIRECT DAMAGES NOT IN EXCESS OF ONE (1) MONTH'S AVERAGE FEES ACTUALLY PAID TO COMPANY FOR THE APPLICABLE SERVICES DURING THE TWELVE (12) MONTH PERIOD PRECEDING THE MONTH IN WHICH THE DAMAGE IS ALLEGED TO HAVE OCCURRED (OR, IF THIS MCKESSON REIMBURSEMENT SERVICES ADDENDUM HAS BEEN IN EFFECT FOR A SHORTER PERIOD OF TIME, THEN OVER THE PERIOD OF THE MCKESSON REIMBURSEMENT SERVICES ADDENDUM), REDUCED BY ANY AMOUNTS PAID, CREDITED OR REFUNDED TO PROVIDER BY COMPANY. THIS LIMITATION OF LIABILITY SHALL SURVIVE AND CONTINUE IN FULL FORCE AND EFFECT DESPITE ANY FAILURE OF AN EXCLUSIVE REMEDY.

Article 7: TERM AND TERMINATION

7.1 This McKesson Reimbursement Services Addendum shall be effective on the McKesson Reimbursement Services Addendum Effective Date and continue for a term of one (1) Year (the "Initial Term"). Thereafter, unless terminated in accordance with the terms of this McKesson Reimbursement Services Addendum, this McKesson Reimbursement Services Addendum shall renew automatically for successive renewal terms of one (1) year each ("Renewal Term").

7.2 Either party may terminate this McKesson Reimbursement Services Addendum with or without cause, by giving the other party thirty (30) days prior written notice.

Article 8: AGREEMENT AND SURVIVAL

This McKesson Reimbursement Services Addendum, the Agreement, and the Enrollment Materials contain all the terms regarding the subject matter. Any other agreements, promises, negotiations or representations, either oral or written, relating to the subject matter of this McKesson Reimbursement Services Addendum are of no force or effect. Provisions in this McKesson Reimbursement Services Addendum shall prevail. The following provisions shall survive termination of this McKesson Reimbursement Services Addendum: 2.2, 4.1, 4.3 4.4, 5.4, 5.5, and Article 6.

EXHIBIT F
MCKESSON LOCAL MARKETING SUPPORT PLATFORM AGREEMENT
(OPTIONAL)

MCKESSON LOCAL MARKETING SUPPORT PLATFORM AGREEMENT

THIS MCKESSON LOCAL MARKETING SUPPORT PLATFORM AGREEMENT (this “**Agreement**”) is made by and between McKesson Corporation, a Delaware corporation with its principal office located at 6535 State Hwy 161, Irving, TX 75039 (“**McKesson**”) and you and the legal entity you represent, as identified in the registration information or your McKesson Connect account (“**Pharmacy**”) and is effective as of the date Pharmacy executes this Agreement (the “**Effective Date**”) by clicking its acceptance of this Agreement as set forth below. If you represent more than one legal entity, or the pharmacy locations displayed in your McKesson Connect account are owned by more than one legal entity, then each applicable legal entity and all the pharmacy locations are subject to the requirements of this Agreement (and are included in the definition of “Pharmacy”), unless you indicate otherwise in your registration with McKesson.

McKesson may make available via an internet portal (the “**Marketing Hub**”) certain local marketing support and resources for access or additional purchase by certain pharmacies.

Pharmacy wishes to access the Marketing Hub and McKesson is willing to provide Pharmacy with access to the Marketing Hub subject to the terms of this Agreement.

This Agreement is binding on the individual who indicates his/her acceptance to the terms of this Agreement and the Pharmacy. You and the Pharmacy both represent that the individual providing acceptance and executing this Agreement is authorized by the Pharmacy to do so. Pharmacy is responsible for compliance with the terms of this Agreement and all other acts and omissions by all of its employees, agents, contractors, and representatives, including without limitation all use of the Marketing Hub. A copy of this Agreement will be sent to you via email following its execution.

1. ACCESS AND USE.

1.1 As part of registration and sign-on to the Marketing Hub, Pharmacy will be required to review additional use terms applicable to use of the Marketing Hub (“**Hub Terms**”). In the event Pharmacy does not agree to the Hub Terms, Pharmacy will not be permitted access to the Marketing Hub. Use of the Marketing Hub is also subject to any additional posted terms of use and privacy policy (together with the Hub Terms, the “**Online Terms**”). In the event of a conflict between this Agreement and the Online Terms, this Agreement shall control.

1.2 Subject to the terms and conditions of this Agreement, McKesson grants to Pharmacy during the Term the ability to access and use the Marketing Hub. Pharmacy will be solely responsible for identifying those of its employees and representatives that will have access to the Marketing Hub (“**Authorized Users**”) for the purpose of downloading and/or purchasing (as may be applicable) the local marketing support products and services made available to Pharmacy via the Marketing Hub (“**LMS Resources**”). Neither Pharmacy, nor any of its Authorized Users may share any user ID or password, or otherwise provide access to the Marketing Hub to any third party other than Authorized Users. As set forth above, Pharmacy's Authorized Users may be located in more than one pharmacy facility.

1.3 Certain LMS Resources may be made available at no additional charge to Pharmacy outside the Subscription Fee (if applicable as contemplated below) and certain LMS Resources are subject to payment of the purchase price set forth in the Marketing Hub. In addition, certain LMS Resources and the use and purchase of the same may be subject to additional terms and conditions.

1.4 Certain LMS Resources may permit or require Pharmacy to upload, add or incorporate text, data, images, graphics, or other limited content to templates provided (“**Custom Content**”). **Custom Content may not consist of or include any Protected Health Information as defined by the Health Insurance Portability and Accountability Act of 1996 and its subsequent regulations.** Pharmacy agrees to take all reasonable steps to

ensure that Custom Content and any LMS Resources used by Pharmacy do not contain any Protected Health Information. Pharmacy has the sole responsibility and obligation to ensure and confirm that any Custom Content complies with all applicable local, state, national and international laws, regulations, and ordinances. Pharmacy also has the sole responsibility and obligation to obtain any and all necessary consents and releases to use and upload such Custom Content. McKesson has no obligation to review or monitor Custom Content but reserves the right to do so at any time in its discretion. If requested by McKesson, Pharmacy will provide access to Custom Content. If, at any time, Pharmacy denies McKesson's right to access Custom Content for review or monitoring, Pharmacy acknowledges that such failure shall be deemed a material breach of this Agreement.

1.5 Pharmacy is responsible for maintaining the confidentiality of, and shall not transfer or sell access numbers, passwords, and usernames for use by Pharmacy to access the Marketing Hub. It is the sole responsibility of Pharmacy to conduct communications on the Marketing Hub in accordance with all applicable local, state, and federal laws and regulations, including but not limited to, laws and regulations pertaining to telemarketing, facsimile advertising, commercial e-mail, personal data privacy and export control.

1.6 Pharmacy recognizes that certain LMS Resources may consist of templates for Pharmacy to utilize. Pharmacy acknowledges and agrees that McKesson has no control over the final content, distribution and use of such LMS Resources by Pharmacy. Pharmacy shall be solely responsible for the content, distribution and use of any such materials. In addition, the LMS Resources may include additional services as Pharmacy may elect to utilize and/or pay for. All LMS Resources are merely tools to assist Pharmacy with its marketing efforts; use of the LMS Resources is solely in the discretion and control of Pharmacy, except as otherwise set forth in this Agreement. Pharmacy agrees that Pharmacy and its Authorized Users will perform any and all activities and use any and all LMS Resources in a professional and competent manner and in accordance with trade and industry practice, in compliance with all applicable law including, without limitation the federal anti-kickback law 42 USC 1320a-7b(b) and comparable state law. In no event shall McKesson be held liable for the use or misuse of the LMS Resources by Pharmacy or its Authorized Users.

1.7 Pharmacy acknowledges and agrees that McKesson may use other vendors and subcontractors in providing the Marketing Hub and LMS Resources to Pharmacy ("**Vendors**"). Pharmacy hereby grants permission to McKesson to share Custom Content and other information Pharmacy may provide in connection with utilizing the Marketing Hub to all such subcontractors and vendors for purposes of providing the services contemplated under this Agreement.

2. RESTRICTIONS ON USE OF THE MARKETING HUB.

2.1 The Marketing Hub is subject to modification from time to time at the sole discretion of McKesson or its Vendors, in any manner and for any purpose deemed appropriate by McKesson or its Vendors, including, without limitation, adding, changing, or deleting functionality, increasing operating efficiency, adding, or deleting LMS Resources, and modifying prices and delivery of LMS Resources. Pharmacy shall not, and shall not permit, any third party (including, without limitation, any parent, subsidiary or other affiliate of Pharmacy) to: (i) modify, decompile, disassemble, or reverse engineer the object code for the Marketing Hub; (ii) download any portion of the Marketing Hub, or copy or create derivative works of the Marketing Hub or portions thereof; (iii) license, sublicense, distribute or disclose the Marketing Hub or portions thereof to any third party; or (iv) use the Marketing Hub to provide services for third parties or for any purpose other than for the Pharmacy's own use. In addition to any other remedy available to McKesson, McKesson may restrict or suspend Pharmacy's access to the Marketing Hub in the event of, and for the duration of, any violation by Pharmacy of the prohibitions set forth in this Section.

2.2 Pharmacy agrees not to transmit content that infringes any third party's intellectual property rights or that is unlawful, threatening, abusive, harassing, libelous, deceptive, fraudulent, invasive of another's privacy, vulgar, obscene, or otherwise contains objectionable material of any kind or nature. Pharmacy also warrants to

McKesson that any and all distribution lists utilized by Pharmacy (i) have not been obtained through Internet harvesting methods or any other unlawful electronic collection of addresses or any other public or private source; (ii) have been collected and may be used in accordance with the CAN-SPAM Act of 2003 (CAN-SPAM), the Telephone Consumer Protection Act (TCPA), and other applicable consumer protection laws; and (iii) are complete, accurate and updated for any opt-outs, as applicable and required by law.

2.3 Pharmacy may not post or submit information containing viruses, or any computer programs that result or may result in the damage, interference with or interception or expropriation of this hub, or any related system, software, hardware, data, or other information.

2.4 Pharmacy may upload (i) their own customer lists or (ii) individual information obtained from a third-party vendor to the Marketing Hub for use in connection with LMS Resources so long as Pharmacy has obtained all requisite consumer consents for such disclosure and use. Pharmacy will not upload or use any Protected Health Information as defined under the Health Insurance Portability and Accountability Act (HIPAA) onto or through the Marketing Hub.

2.5 Pharmacy will conduct all marketing and consumer communications in compliance with all applicable laws, including CAN-SPAM and TCPA, and applicable state marketing or advertising laws. In particular, pharmacy will honor all opt out requests in the time period required by law and will only send emails as permitted under CAN-SPAM and text messages as permitted under the TCPA. Pharmacy will not conduct any HIPAA marketing of any kind through Marketing Hub. PHARMACY ACKNOWLEDGES THAT THE ADVERTISING OF GOODS, PRODUCTS OR SERVICES BY THE TRANSMISSION OF UNSOLICITED VOICE MESSAGES, FACSIMILES, E-MAIL, OR TEXT MESSAGES MAY BE IN VIOLATION OF FEDERAL AND STATE LAWS AND REGULATIONS AND MAY SUBJECT THE ADVERTISER TO PENALTIES. Compliance with these laws requires, among other things, that all messages sent by or on behalf of the Pharmacy utilizing LMS Resources, in whatever medium, contain the valid name and required contact information for Pharmacy.

2.6 Pharmacy must adhere to all applicable local, state, and federal laws in accessing and using the Marketing Hub, including but not limited to those laws and regulations regarding:

- i. court ordered publication bans;
- ii. restrictions on publishing, printing, distributing, possessing, selling, advocating, promoting or exposing, obscene or threatening material, child pornography, or hate propaganda;
- iii. restrictions on the use of trademarks or trade names, or any work which is protected by copyright, trade secret, patent, or other intellectual property laws, including software; and
- iv. restrictions on defamation, libel, harm to reputation, invasion of privacy, misuse, or failure to protect personal information, including without limitation HIPAA, violation of secrecy, confidentiality, unfair competition, and other situations which could generate liability.

2.7 Pharmacy and its Authorized Users and all others accessing Pharmacy's Marketing Hub account must comply with all policies, including without limitation the Online Terms.

3. SUPPORT REQUIREMENTS.

3.1 During the Term, Pharmacy may obtain help desk support services for utilizing the Marketing Hub and utilizing and receiving LMS Resources by contacting a Local Marketing Support Team Member at 855-MKTG-HUB M-F 8:30am EST – 7:00pm EST or via email at support@marketinghubsupport.com or via live chat as available by following online links on the Marketing Hub. Support hours may be modified at any time in McKesson's sole discretion.

3.2 McKesson will strive to provide commercially reasonable notice to Pharmacy when the Marketing Hub is or will be unavailable as a result of scheduled maintenance and emergency work. McKesson shall have no liability whatsoever for any unavailability, loss of data or transactions resulting from delays or service interruptions of the Marketing Hub. Pharmacy shall be solely responsible for acquiring and maintaining any hardware, software, and connectivity services, including primary and secondary telecommunication services necessary to access the Internet. McKesson has no obligation to provide access to or use of the Marketing Hub if Pharmacy's hardware, software, or connectivity services are deficient and fail to support the adequate functioning of the Marketing Hub as determined solely by McKesson.

4. OPEN NETWORKS.

4.1 Pharmacy acknowledges and agrees that access to the Marketing Hub shall be made available through the Internet; that information shall be transmitted or accessed over non-dedicated lines and other network systems accessible by third parties ("**Open Networks**") and that it can therefore be lost, corrupted or otherwise damaged; accessed by unauthorized parties, subject to tampering; and may be damaged by a virus or other third-party actions. McKesson does not warrant the accuracy, authenticity, or timeliness of transmissions using Open Networks or the functionality or suitability of any third-party equipment or services used in connection with the transmission of, or access to, information over Open Networks.

4.2 Pharmacy hereby waives, releases, and discharges any and all claims of any kind for loss, damage, or liability that Pharmacy may incur in connection with the use of the Marketing Hub with Open Networks or the transmission of information over Open Networks. Pharmacy agrees to indemnify, defend, and hold McKesson and its affiliates, officers, directors, agents, employees, suppliers, and licensees, harmless from and against any and all losses, costs, damages, and liabilities, including without limitation reasonable attorneys' fees, arising out of or in connection with any claim related to Pharmacy's use of the Marketing Hub with Open Networks or the transmission of information over Open Networks.

4.3 Pharmacy is responsible for the ordering, installation and support, and payment for any additional hardware, software, installation, or other services and fees required to establish connectivity to the Internet and if applicable, process transactions via the Internet. Fees may include, but are not limited to, installation fees, equipment charges, and monthly service fees associated with DSL, cable modem, T1, frame relay, and Internet Service Providers. In the event that Pharmacy has installed hardware or software that conflicts with the operation of the Marketing Hub, Pharmacy will be required to remove such hardware and/or software in order to utilize the Marketing Hub.

5. FEES AND PURCHASE PRICES.

5.1 Subscription Fees. In consideration of the access and services provided by McKesson to Pharmacy under this Agreement, Pharmacy agrees to pay McKesson any applicable subscription and service fees as set forth on the Marketing Hub enrollment page ("**Subscription Fee**"). Access to the Marketing Hub is conditioned upon receipt of Pharmacy's timely payment of the Subscription Fee (if applicable) as further specified on the enrollment page. The Subscription Fee (if applicable) will be invoiced to you by McKesson. McKesson may change any Subscription Fee upon 60 days advanced notice to you.

5.2 LMS Resource Purchase Prices. Certain LMS Resources that you may choose to purchase on the Marketing Hub are subject to additional purchase prices (such additional purchase prices along with the Subscription Fee are collectively the "**Fees**"). Prices remain valid while they are listed and offered on the Marketing Hub. Prices for such LMS Resources may be changed without notice at any time. Item availability may be limited. Items may not be available for immediate delivery. McKesson reserves the right, without

liability or prior notice, to revise or cease to make available any or all items. The price of the items ordered will be the price posted on the Marketing Hub as of the date of the order.

i. All orders must be paid via McKesson invoice. McKesson will issue you an invoice for Pharmacy's purchase, which invoice is subject to the payment terms set forth below.

ii. In addition, if Pharmacy is a part of the Health Mart Systems, Inc. ("**Health Mart**") pharmacy franchise, it may be eligible to use available matching funds from Health Mart to pay for certain LMS Resources. If applicable to Pharmacy, Pharmacy agrees that information on its available matching funds may be made available to McKesson's Vendor to allow the processing of any order using matching funds. Whether matching funds are available for any particular LMS Resources will be in McKesson's discretion and a more detailed description of Pharmacy's eligibility for matching funds can be found in the Health Mart Operations Manual.

5.3 Fees under this Agreement are exclusive of all taxes. Pharmacy agrees to be responsible for and pay when invoiced or otherwise due any and all state and local sales, use, or other such tax that may be assessed or charged in connection with the performance of the Agreement, excluding any federal, state, or local taxes based on McKesson's net income. Pharmacy hereby agrees to indemnify and hold McKesson harmless against any interest or penalty assessed in any way arising from the failure of Pharmacy to pay any such tax.

5.4 Payment Terms. Pharmacy agrees to pay all Fees and applicable taxes in accordance with the payment terms and conditions contained in its supply agreement or other arrangement with McKesson for the order and purchase of pharmaceutical and other products. All Fees due from Pharmacy shall be paid to McKesson without any right of set-off or deduction. All Fees are non-refundable, and you will not be entitled to a refund of any monthly Fees in any event unless expressly set forth in this Agreement. Disputes as to the accuracy of an invoice or any Fee charged must be presented in writing to McKesson by Pharmacy within 45 days of the date of invoice or date such Fee is charged, or such Fees shall be deemed undisputed. McKesson shall be entitled to recover its costs and expenses incurred in collecting any Fees due including reasonable attorneys' fees. All payment obligations will survive termination of this Agreement. In addition to any other remedy available, McKesson may restrict or suspend Pharmacy's use and access to the Marketing Hub, and LMS Resources until such past due Fees plus any interest (if applicable) are paid, without notice to Pharmacy.

6. COMPLIANCE AND WARRANTIES.

6.1 Pharmacy shall be solely responsible for the integrity of the Custom Content and for complying and requiring all Authorized Users using the Marketing Hub and LMS Resources to comply with the terms set forth in this Agreement. McKesson has no liability for any acts or omissions by Pharmacy or its Authorized Users, including without limitation any misuse of the Marketing Hub or LMS Resources. Pharmacy will use commercially reasonable security measures for protecting the confidentiality of its usernames and passwords to access the Marketing Hub.

6.2 Pharmacy represents and warrants to McKesson that it will utilize the Marketing Hub, the LMS Resources and any related services in compliance with all laws, ordinances, and governmental regulatory rules and regulations, whether federal, state, local and international, applicable to its business, including but not limited to HIPAA, CAN-SPAM, TCPA, and other federal and state healthcare and consumer marketing laws. In the event Pharmacy utilizes the LMS Resources to disseminate advertising offering the availability of goods or products or services, Pharmacy specifically warrants to McKesson: (i) that it will undertake all required actions necessary to comply with applicable federal and state, "Do Not Call" and telemarketing registration statutes and regulations; and (ii) Pharmacy will not utilize the LMS Resources in a manner which results in a violation of any applicable laws or regulations. THE FINAL DECISION ABOUT ANY ASPECT OF USE OF LMS RESOURCES OR THE MARKETING HUB UNDERTAKEN BY THE PHARMACY OR ITS AUTHORIZED USERS IS THE SOLE AND EXCLUSIVE RESPONSIBILITY OF PHARMACY.

6.3 Pharmacy represents, warrants and covenants that: (i) its registration and the related information provided during registration is true, accurate and complete in all material respects; (ii) Pharmacy has the authority to enter into this Agreement; (iii) Pharmacy is a bona fide pharmacy in business under the appropriate state and/or federal laws and regulations and hold all necessary licenses required to operate lawfully; (iv) Pharmacy will use the Marketing Hub only for lawful purposes; (v) Pharmacy is the rightful owner of all Custom Content, or otherwise has the lawful right, license or consent to use the Custom Content, and (vi) such Custom Content does not infringe upon any third party intellectual property or other right.

6.4 Pharmacy further warrants and covenants that: (i) it will not interfere with or disrupt McKesson's or its Vendors' security measures; (ii) it will not interfere with or disrupt networks connected to the Marketing Hub, and it will comply with all regulations, policies and procedures of such networks, including any Open Networks; (iii) it will comply with United States law regarding the transmission of technical data exported from the United States and all applicable laws and regulations regarding use of consumer data; and (iv) it may not make copies of any aspect of the Marketing Hub, except as maybe expressly permitted by this Agreement, and in no event for purposes of distribution to the public by sale or other transfer of ownership, or by rental, lease or lending.

6.5 Pharmacy further acknowledges, notwithstanding confidentiality provisions hereof, that McKesson may disclose usage information about Pharmacy's orders, Custom Content, and enrollment in the Marketing Hub to satisfy any law, regulation, government agency request, court order, subpoena, or other legal process.

7. **CONFIDENTIALITY.** Each party (the "**Discloser**") may disclose to the other party (the "**Recipient**") certain non-public information relating to the Discloser's business, including technical and non-technical proprietary and confidential information, marketing, financial, personnel, planning, and other information that is marked confidential, or which the Recipient should reasonably know to be confidential given the nature of the information and the circumstance of disclosure even if it is not identified as "Confidential Information" ("**Confidential Information**"). Confidential Information of each party will also include the terms of the Agreement, but not the existence and general nature of the Agreement. Confidential Information will not include any information: (i) lawfully obtained or created by the Recipient independently of, and without use of, Discloser's Confidential Information and without breach of any obligation of confidence; (ii) that is in or enters the public domain without breach of any obligation of confidence by the parties hereto; (iii) was known to or contained in the records of the Recipient from a source other than the Discloser at the time of disclosure by the Discloser to the Recipient; (iv) becomes known to the Recipient from a source other than the Discloser without breach of the Agreement by the Recipient; or (v) was disclosed pursuant to court order or as otherwise compelled by law, after reasonable advance written notice to the Discloser. Except as expressly permitted by the Agreement, the Recipient will:

7.1 not disclose Discloser's Confidential Information except: (i) to the employees or contractors of the Recipient to the extent that they need to know that Confidential Information for the purpose of performing the Recipient's obligations under the Agreement, and who are bound by confidentiality terms with respect to that Confidential Information no less restrictive than those contained in this Section; or (ii) as required to be disclosed by law, to the extent required to comply with that legal obligation, provided that the Recipient will promptly notify the Discloser of such obligation unless prohibited by law;

7.2 use the Discloser's Confidential Information only for the purpose of performing Recipient's obligations under the Agreement; and

7.3 use all reasonable care in handling and securing the Discloser's Confidential Information and employ all reasonable data security measures that the Recipient ordinarily uses with respect to its own proprietary information of similar nature and importance. Upon the written request of the Discloser, the Recipient will return to the Discloser, and destroy and/or erase all of the Discloser's Confidential Information in tangible form, upon the expiration or

termination of the Agreement and the Recipient will promptly certify in writing to the Discloser that it has done so. The obligations in this Section will survive termination of the Agreement.

8. INTELLECTUAL PROPERTY RIGHTS.

8.1 The Marketing Hub and LMS Resources, and any modifications or copies thereof, shall at all times remain the exclusive property and proprietary material of McKesson or its licensors and protected by copyright and/or trade secret law and no ownership rights are transferred by the Agreement. McKesson and its third-party licensors, as appropriate, shall retain all right, title and interest in and to the Marketing Hub, all versions, enhancements, and modifications thereto, all McKesson's Confidential Information, and any intellectual property rights related to the foregoing. Pharmacy shall protect the Marketing Hub and LMS Resources against any disclosure to any third parties without McKesson's prior written permission.

8.2 Any Custom Content used in connection with or incorporated into LMS Resources shall remain Pharmacy's sole and exclusive property. However, Pharmacy's submission of Custom Content affects a non-exclusive, royalty-free, fully-paid up, worldwide right and license for McKesson and its vendors to display, reproduce, use, distribute, and modify the form of such Custom Content to the extent reasonably necessary for McKesson and its vendors to provide Pharmacy with the LMS Resources Pharmacy requests.

9. TERM AND TERMINATION. Except as may otherwise be agreed by the parties, the term of this Agreement shall be for a period of 1 year following the Effective Date ("**Initial Term**") and shall automatically renew for successive 1 year periods (each a "**Renewal Term**" and collectively, the "**Term**"), unless either party gives written notice of termination to the other party at least 30 days prior to the expiration date of the Initial Term or any Renewal Term, or the Agreement is terminated as otherwise provided herein. A party may terminate this Agreement immediately upon written notice to the other party if the other party: (i) materially breaches this Agreement and fails to remedy or fails to commence reasonable efforts to remedy, that breach within 10 days (but with respect to Pharmacy's payment obligations 5 days) after receiving notice of the breach; (ii) infringes the intellectual property rights of the non-breaching party and fails to remedy that breach within 10 days after receiving notice of the breach; (iii) materially breaches this Agreement in a manner that cannot be remedied; or (iv) commences dissolution proceedings or ceases to operate in the ordinary course of business. **IN ADDITION, MCKESSON MAY TERMINATE THIS AGREEMENT IMMEDIATELY, WITHOUT LIABILITY TO PHARMACY, UPON WRITTEN NOTICE TO PHARMACY IF APPROPRIATE TELECOMMUNICATIONS / CONNECTIVITY SERVICES CANNOT BE REASONABLY OBTAINED BY PHARMACY OR PHARMACY CEASES TO BE A DISTRIBUTION CUSTOMER OF MCKESSON OR IN THE EVENT THAT MCKESSON IS NO LONGER ABLE TO PROVIDE THE SERVICE TO PHARMACY.**

10. EFFECT OF TERMINATION.

10.1 Upon the termination of this Agreement for any reason (i) all license, and access rights granted to Pharmacy shall automatically and immediately cease and (ii) Pharmacy shall, at McKesson's option, return or destroy all of McKesson's Confidential Information within 72 hours of such termination. Termination of this Agreement shall not terminate any rights or obligations accruing prior to termination including, but not limited to, Pharmacy's obligation to pay all Fees incurred by Pharmacy up to and including the date of termination. All provisions concerning Intellectual Property, Confidentiality, Limitation of Liability, Disclaimer/No Warranty, and Indemnification, shall survive termination of this Agreement or any reason.

10.2 In the event of termination of this Agreement for any reason, Pharmacy shall remain liable for all outstanding Fees invoiced prior to the date of termination including, without limitation the Subscription Fees due for the remainder of the Term and McKesson shall not pro rate or refund any such Fees. Notwithstanding the foregoing, if Pharmacy cancels this Agreement within 30 days after McKesson issues an invoice for Subscription

Fees for any Renewal Term and assuming Pharmacy owes no other Fees to McKesson, Pharmacy may terminate this Agreement and McKesson will refund the Subscription Fees for such Renewal Term.

11. DISCLAIMER; NO WARRANTY.

11.1 THE MARKETING HUB, LMS RESOURCES AND RELATED SERVICES LICENSED AND PROVIDED HEREUNDER ARE LICENSED AND PROVIDED "AS-IS," "WHERE IS" AND "WITH ALL FAULTS," WITHOUT ANY WARRANTIES OF ANY KIND. MCKESSON, ON BEHALF OF ITSELF AND ITS AFFILIATES, LICENSORS AND VENDORS, DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ALL IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, NON-INFRINGEMENT, AND THOSE ARISING FROM A COURSE OF DEALING OR USAGE OF TRADE. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, NEITHER MCKESSON, ITS AFFILIATES, NOR ITS VENDORS MAKES ANY REPRESENTATION, WARRANTY OR CONDITION THAT THE MARKETING HUB WILL BE AVAILABLE AT ANY GIVEN TIME, THAT IT WILL OPERATE UNINTERRUPTED OR ERROR-FREE, THAT DEFECTS WILL BE CORRECTED OR THAT YOU WILL BE ABLE TO USE THE MARKETING HUB CORRECTLY. NEITHER MCKESSON NOR ANY OF ITS LICENSORS OR VENDORS, MAKES ANY REPRESENTATION OR WARRANTY AS TO THE ACCURACY OR COMPLETENESS OF LMS RESOURCES, MARKETING HUB, OR RELATED SERVICES PROVIDED TO PHARMACY. NEITHER MCKESSON NOR ANY OF ITS LICENSORS OR VENDORS, MAKES ANY REPRESENTATION OR WARRANTY AS TO THE RESULTS YOU WILL ACHIEVE BY PHARMACY'S USE OF LMS RESOURCES, MARKETING HUB, OR RELATED SERVICES PROVIDED TO PHARMACY.

11.2 PHARMACY IS SOLELY RESPONSIBLE FOR INDEPENDENTLY VERIFYING THE ACCURACY OF ALL DATA AND MATERIALS PROVIDED TO PHARMACY; FOR VERIFYING THE OWNERSHIP OF CUSTOM CONTENT; AND ASSURING THAT ITS USES AND DISCLOSURES OF CUSTOM CONTENT COMPLY WITH HIPAA AND OTHER APPLICABLE FEDERAL AND STATE PRIVACY AND SECURITY LAWS AND REGULATIONS AND ALL APPLICABLE STATE AND FEDERAL ADVERTISING AND MARKETING LAWS, INCLUDING CAN-SPAM AND THE TCPA.

11.3 MCKESSON AND ITS AFFILIATES EXPRESSLY DISCLAIM ANY AND ALL LIABILITY TO THIRD PARTIES, SPECIFICALLY INCLUDING, WITHOUT LIMITATION, PHARMACY BENEFIT MANAGERS, PAYORS, PRESCRIBERS AND PATIENTS. PHARMACY ASSUMES SOLE RESPONSIBILITY FOR ITS USE OF THE SOFTWARE, SERVICES, AND MATERIALS, INCLUDING ANY RELIANCE OR DECISIONS MADE BASED ON THE SAME.

12. INDEMNIFICATION. Pharmacy acknowledges and agrees that it is the final responsible party with respect to use of the Marketing Hub and any LMS Resources. Notwithstanding anything to the contrary contained in this Agreement, Pharmacy assumes the risk of liability for, and agrees, at its sole expense, to indemnify, defend and hold harmless McKesson, its affiliates, its agents, and their respective affiliates and its and their directors, officers and employees ("Indemnitees"), from and against any and all liabilities, losses, damages, claims and expenses (including legal expenses) arising out of or relating to, directly or indirectly, Pharmacy's participation, exercise, use, and disclosure of the Marketing Hub, LMS Resources and any related services or otherwise arising under or related to the Marketing Hub, including without limitation, any and all claims which are threatened or brought against Indemnitees, arising out of or relating to: (i) any act or omission of Pharmacy related to the use and distribution of the Marketing Hub or LMS Resources; (ii) Pharmacy's non-compliance with any federal, state or local laws or regulations; (iii) Pharmacy's business, including without limitation, any injury related to the conduct of Pharmacy's pharmacy operations; (iv) any breach of Pharmacy's representations and warranties as set forth in Section 6; or (iv) any Custom Content. This indemnity will survive the termination of the Agreement.

13. LIMITATION OF LIABILITY.

13.1 NEITHER MCKESSON NOR ITS AFFILIATES, NOR THEIR LICENSORS OR VENDORS SHALL HAVE LIABILITY OF ANY KIND, TO PHARMACY OR ANY THIRD PARTY, ARISING OUT OF OR RELATED TO PHARMACY'S USE OR MISUSE OF THE MARKETING HUB, LMS RESOURCES OR ANY RELATED SERVICES. IN NO EVENT SHALL

MCKESSON OR ITS AFFILIATES OR VENDORS BE LIABLE FOR ANY LOSSES OR DAMAGES OF ANY KIND INCLUDING, WITHOUT LIMITATION, FOR LOST USE, BUSINESS, PROFITS, OR REVENUE, COST OF PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES, OR ANY OTHER DIRECT, SPECIAL, INDIRECT, CONSEQUENTIAL, RELIANCE, INCIDENTAL, EXEMPLARY, OR PUNITIVE DAMAGES HOWEVER CAUSED AND UNDER ANY THEORY OF LIABILITY. THE FOREGOING LIMITATIONS SHALL APPLY REGARDLESS OF WHETHER MCKESSON OR ITS AFFILIATES OR THEIR LICENSORS OR VENDORS HAVE BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, NOTWITHSTANDING THE FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY AND REGARDLESS OF WHETHER SUCH DAMAGES ARISE OUT OF THIRD-PARTY CLAIMS AGAINST PHARMACY.

13.2 THE LMS RESOURCES ARE TO BE USED FOR INFORMATIONAL PURPOSES ONLY. YOU ACKNOWLEDGE THAT THE MARKETING HUB, CONTENT AND LMS MATERIALS ARE IN NO CASE TO BE USED AS A SUBSTITUTE FOR PROFESSIONAL MEDICAL ADVICE NOR IS IT INTENDED TO BE RELIED UPON BY ANY PERSON OR ENTITY, INCLUDING ANY CONSUMER, FOR PURPOSES OF MEDICAL DIAGNOSIS OR TREATMENT. MCKESSON, ITS AFFILIATES AND ITS VENDORS SHALL USE COMMERCIALY REASONABLE EFFORTS TO ENSURE THE ACCURACY OF THE LMS RESOURCES, BUT NEITHER MCKESSON, ITS AFFILIATES, NOR ITS VENDORS GUARANTEES THE SEQUENCE, ACCURACY, OR COMPLETENESS OF THE CONTENT AND SHALL NOT BE LIABLE IN ANY WAY TO PHARMACY, ITS CONSUMERS, OR ANYONE ELSE TO WHOM THE LMS RESOURCES MAY BE FURNISHED FOR ANY DELAYS, INACCURACIES, UNAVAILABILITY, ERRORS OR OMISSIONS IN THE SAME. USE OF THE LMS RESOURCES IS SOLELY AT PHARMACY'S OWN RISK AND SOLE DISCRETION.

14. ASSIGNMENT. Pharmacy may not assign this Agreement, in whole or in part, to any third party without the prior written consent of McKesson. For purposes of the Agreement, an assignment includes any assignment or transfer due to merger, sale, or other operation of law of Pharmacy or any Pharmacy Facility. Nothing in the Agreement shall confer upon any person other than the parties and their respective successors or assigns, any rights, remedies, obligations, or liabilities whatsoever.

15. INDEPENDENT CONTRACTORS. The relationship between McKesson and Pharmacy is that of independent contractors, and nothing contained herein shall be construed to: (i) give either party the power to control the activities of the other; (ii) constitute the parties as partners, joint venturers or co-owners; or (iii) allow a party to act as the agent for the other or to otherwise create or assume any obligation on behalf of the other party for any purpose whatsoever, except as contemplated by this Agreement.

16. GOVERNING LAW AND INJUNCTIVE RELIEF. The Agreement is governed by and construed in accordance with the laws of the State of Delaware, without regard to conflict of law principles. The federal and state courts within the State of Delaware shall have proper and exclusive jurisdiction and venue to adjudicate any dispute arising from or related to the subject matter of this Agreement. No action arising out of this Agreement, regardless of form, other than collection of outstanding payment obligations, may be brought by either party more than 1 year after the cause of action accrued. The prevailing party in any litigation or proceeding brought pursuant to this Agreement shall be entitled to recover all reasonable costs and expenses, including its attorneys' fees and court costs. Pharmacy acknowledges that the extent of damages in the event of the breach of Section 1, 2, 6, 7, 8 or 10 would be difficult or impossible to ascertain, and that there will be available no adequate remedy at law in the event of any such breach. Pharmacy therefore agrees that if it breaches any of Section 1, 2, 6, 7, 8 or 10, McKesson will be entitled to injunctive or other equitable relief, in addition to any other relief to which it may be entitled, without posting of a bond, proof of damages or other similar requirement.

17. FORCE MAJEURE. Except for Pharmacy's payment obligations, neither party shall be liable for failure to meet its obligations under the Agreement to the extent that such failure is caused by matters which are beyond the reasonable control of such party, including, without limitation, failure of electronic equipment or communication

lines, severe weather, natural disasters, strikes or labor problems, acts of God, acts of terrorism, acts of war, or acts of government.

18. NOTICES. All notices under this Agreement shall be in writing. Both emails and faxes shall be considered written notices. If notices are delivered via mail, they shall be sent by overnight delivery service or certified mail return receipt requested, if to McKesson, to the address specified in the first paragraph (to the attention of its Law Department) or if to Pharmacy, to the address specified by Pharmacy in the registration process or to such other address as may be specified by such party in writing in accordance with this Section. Email or fax notices sent to Pharmacy shall be sent to the address or fax number McKesson has on file for Pharmacy. Email or fax notices sent to McKesson shall be sent to the address or fax number as specified by McKesson in writing.

19. ELECTRONIC SIGNATURE. This Agreement may be executed electronically, in compliance with the provisions of the federal Electronic Signatures in Global and National Commerce Act ("E-SIGN" Act, 15 U.S.C. § 7001 et seq.), the Uniform Electronic Transactions Act or any applicable successor statutes or regulations then in effect that control the manner and means by which a person is bound to a written agreement.

20. AFFIRMATION OF FRANCHISE AGREEMENT. If Pharmacy is a member of the Health Mart pharmacy franchise, nothing in this Agreement is intended to amend the terms and conditions of the Franchise Agreement between Health Mart and Pharmacy, which the parties affirm is in full force and effect.

21. MISCELLANEOUS. This Agreement, together with the Online Terms, constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior oral or written proposals or communications. This Agreement may not be modified, supplemented, qualified, or interpreted by any trade usage or prior course of dealing not made a part of the contract by its express terms. The invalidity or unenforceability of any provision herein shall not affect the validity of this Agreement as a whole and any such provision should be enforced, and reconstructed, if need be, to apply to the maximum extent allowable. The failure of McKesson to enforce at any time any of the provisions herein, to exercise any election or option provided herein or to require at any time the performance of any of the provisions herein will not be construed as a waiver of such provisions. Each party executes the Agreement by its duly authorized representative. Pharmacy warrants that Pharmacy's entry into, and performance of this Agreement has been authorized by all necessary company action, and upon its execution by Pharmacy, this Agreement shall constitute the valid and binding obligation of Pharmacy, enforceable according to its terms.

22. By signing this Agreement, Pharmacy acknowledges and agrees that it has carefully read, and fully understands all of the terms and conditions of this Agreement, and enters into this Agreement freely, knowingly, and without coercion, intending to be legally bound thereby.

EXHIBIT G
FRANCHISE COMPLIANCE QUESTIONNAIRE

FRANCHISE COMPLIANCE QUESTIONNAIRE

As you know, Health Mart Systems, Inc. (“we”, “us” or “Franchisor”) and you are preparing to enter into a Franchise Agreement for the operation of a Drugstore. You must execute this Declaration to confirm no statement or promise has been made to you by our representatives that we do not authorize or you believe is untrue, inaccurate or misleading. We also want to confirm you understand the terms of the agreements you will sign.

- I have received and personally reviewed the Franchise Disclosure Document (the “FDD”) and each exhibit the FDD identifies as being attached to it presented by Franchisor.
- I understand all of the information contained in the Franchise Agreement.
- I received the FDD together with a copy of all proposed agreements relating to the sale of a Drugstore at least the longer of (i) 14 calendar days, or (ii) ten (10) business days before I executed this document and before I paid any consideration in connection with this franchise.
- I electronically acknowledged receipt of the FDD.
- I understand all of the information contained in the FDD.
- I have had the opportunity to discuss the benefits and risks of operating a Drugstore with an attorney, accountant or other professional advisor, and I understand those benefits and risks.
- I understand each of the following: (i) Franchisor retains the right to modify the HEALTH MART® System; (ii) the HEALTH MART® System may evolve and change over time; (iii) an investment in a Drugstore involves business risks; and (iv) the success of my Drugstore depends primarily upon my business ability and personal efforts as well as competition from other businesses, the location that I chose for my Drugstore and other economic and business factors.
- No employee or other person speaking on behalf of Franchisor made any statement or promise concerning the revenues or profits that I will or am likely to earn from owning and operating a Drugstore or that my Drugstore may generate.
- No employee or other person speaking on behalf of Franchisor made any statement or promise regarding the amount of money I may earn in operating a Drugstore.
- No employee or other person speaking on behalf of Franchisor made any statement or promise regarding the costs I may incur in operating a Drugstore other than disclosures appearing in the FDD.
- No employee or other person speaking on behalf of Franchisor made any statement or promise concerning the likelihood of success I should or might expect to achieve from operating a Drugstore.
- No employee or other person speaking on behalf of Franchisor made any statement, promise or agreement concerning the advertising, marketing, training, support services or assistance I will or may receive that is contrary to, or different from, the information contained in the FDD.
- No employee or other person speaking on behalf of Franchisor made any statement, promise or agreement concerning the anticipated income, earnings or growth of Franchisor or any Drugstore.

- I understand my answers are important to Franchisor and Franchisor will rely on them in deciding whether or not to enter into a Franchise Agreement with me.

By signing this Declaration, I represent that I have responded truthfully based upon my personal knowledge and belief.

Dated: _____, _____

APPLICANT

EXHIBIT H
RETAIL VACCINE PROGRAM AGREEMENT
(OPTIONAL)

EXHIBIT H

Vaccine Starter Kit Program Agreement

This Vaccine Starter Kit Program Agreement (“Agreement”) is entered into by and between Health Mart Systems, Inc. (“Health Mart”) and **you and the legal entity you represent**, as identified in the registration information on your Health Mart Connect account (“Pharmacy”) and is effective as of the date Pharmacy executes this Agreement (the “Effective Date”) by clicking its acceptance of this Agreement as set forth below. If you represent more than one legal entity, or the pharmacy locations displayed in your Health Mart Connect account are owned by more than one legal entity, then each applicable legal entity and all the pharmacy locations are subject to the requirements of this Agreement (and are included in the definition of “Pharmacy”), unless you indicate otherwise in your registration with Health Mart. Pharmacy and Health Mart are referred to hereinafter collectively as the “Parties” or individually as a “Party.”

RECITALS

WHEREAS, Health Mart desires to offer Pharmacy certain services related to Pharmacy’s establishment of a vaccine program.

WHEREAS, Pharmacy desires to access and use such services.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:

1. **Vaccine Starter Kit Program** (“Program”): Health Mart agrees to provide the Program to Pharmacy in support of Pharmacy’s operation of a vaccine program. Health Mart shall provide the Program for a period of six (6) months from the date Pharmacy signs this Agreement. The Program shall include the following:
 - a. Health Mart will provide Pharmacy with documents and materials relating to establishing a vaccine program and with access to third party materials, such as those prepared by Electronic Billing Services (EBS), and Stericycle (“Program Materials”). The Program Materials may cover topics such as vaccine and immunization administration, pharmacy workflow, and customizable marketing materials.
 - b. There will be a monthly outbound phone call conducted by a Health Mart vaccine representative which will last for a minimum of thirty (30) minutes. This call will cover different topics pertinent to establishing a vaccine program.
 - c. Health Mart will deliver reasonable administrative follow-up support to Pharmacy, including emails and mailings, after each monthly phone call related Pharmacy’s vaccine program.
 - d. Pharmacy will have access via phone or email to the vaccine representative at any time during the program.

2. Eligible Pharmacies:

- a. To be eligible for participation in the Program, Pharmacy is required to be a Health Mart franchisee in good standing.
- b. All Pharmacy and pharmacist licenses must be current and valid. Pharmacy must operate in compliance with all applicable laws.
- c. Pharmacy must not be excluded from federal health care programs or otherwise ineligible to provide immunization and/or vaccination services for any reason.

3. Fees:

- a. For the provision of the Program, Health Mart will charge Pharmacy a one-time payment of \$250 ("Fee").
- b. The Fee must be paid via Health Mart invoice. Health Mart will issue Pharmacy an invoice for Pharmacy's use of the Program, which invoice must be paid within thirty (30) days. Pharmacy will be required to pay any applicable taxes associated with the Fee.
- c. Health Mart has no obligation to provide the Program to Pharmacy in the event the Fee is not paid.

4. Disclaimer; Limited Liability:

- a. Pharmacy acknowledges and agrees that Health Mart is not responsible for, not liable for, not in control of, nor otherwise able to influence or direct any of the vaccine services provided to patients by Pharmacy nor in any way responsible for how Pharmacy uses the Program. Health Mart is not licensed to practice pharmacy and is not advising Pharmacy in any respect regarding the practice of pharmacy. Health Mart, under the Program, is merely providing its franchisees with administrative support and access to BULA Content that Pharmacy may use, in its sole discretion and professional judgment, in establishing its vaccine program.

5. Representations and Warranties:

- a. Pharmacy represents and warrants to Health Mart that it will utilize the Program, and any related services in compliance with all applicable laws and regulations. THE FINAL DECISION ABOUT ANY ASPECT OF USE OF THE PROGRAM IS THE SOLE RESPONSIBILITY OF PHARMACY.
- b. Pharmacy represents, warrants and covenants that: (i) its registration and the related information provided during registration is true, accurate and complete in all material respects; (ii) Pharmacy has the authority to enter into this agreement; and (iii) Pharmacy is a bona fide pharmacy in business under the appropriate state and/or federal laws and regulations and holds all necessary licenses required to operate lawfully.

- c. Pharmacy agrees that Pharmacy will perform its services in a professional and competent manner and in accordance with trade and industry practice, in compliance with all applicable law including, without limitation the federal anti-kickback law 42 USC 1320a-7b(b) and comparable state law. In no event shall Health Mart be held liable for the use or misuse of the Program by Pharmacy.

6. Indemnification: Pharmacy acknowledges and agrees that it is the final responsible party with respect to Pharmacy's use of the Program. Pharmacy assumes the risk of liability for, and agrees, at its sole expense, to indemnify, defend and hold harmless Health Mart, its affiliates, its agents, and their respective affiliates and its and their directors, officers and employees ("**Indemnitees**"), from and against any and all liabilities, losses, damages, claims and expenses (including legal expenses) arising out of or relating to, directly or indirectly, Pharmacy's participation, exercise, use, and disclosure of the Program and its provision of immunization and/or vaccination services, including without limitation, any and all claims that are threatened or brought against Indemnitees, arising out of or relating to: (i) any act or omission of Pharmacy related to the use of the Program, (ii) Pharmacy's non-compliance with any federal, state or local laws or regulations; or (iii) any breach of Pharmacy's representations and warranties as set forth in the Agreement or this agreement. This indemnity will survive the termination of the agreement.

7. Miscellaneous:

- a. This agreement is binding on the individual who indicates his/her acceptance to the terms of this agreement and the Pharmacy. Pharmacy represents that the individual providing acceptance and executing this agreement is authorized by the Pharmacy to do so. Pharmacy is responsible for compliance with the terms of this agreement and all other acts and omissions by all of its employees, agents, contractors, and representatives. A copy of this agreement will be sent to Pharmacy via email following its execution.
- b. By signing this agreement, Pharmacy acknowledges and agrees that it has carefully read, and fully understands all of the terms and conditions of this agreement, and enters into this agreement freely, knowingly, and without coercion, intending to be legally bound thereby.
- c. Venue for any disputes arising hereunder shall be in federal court in Dallas County, Texas

EXHIBIT I

**HEALTH MART DIGITAL PORTFOLIO (TERMS & CONDITIONS, PRIVACY NOTICE,
BUSINESS ASSOCIATE AGREEMENT)**

Terms & Conditions, Privacy Policy and Business Associate Agreement

Health Mart Digital Portfolio (“HMDP”)

Terms & Conditions

Effective Date - August 26th, 2021

The HMDP website and mobile app is provided by Health Mart Systems, Inc. (“**Health Mart**”) and its Business Associates, as part of your Health Mart franchise program.

The HMDP is operated by Health Mart in conjunction with a Business Partner (Prescribe Wellness). The HMDP is being offered to help Health Mart pharmacies attract new patients by providing a consistent online experience for consumers that provides information and services that patients are expecting in today’s digital world. It will give Health Mart pharmacies the ability to be found through a store landing page via the store locator on Healthmart.com. It will provide patients and users with general store information (location, phone, services, hours) that they are looking for and give them the ability to track prescriptions, order refills and pharmacy related services (“**Services**”) at their local Health Mart pharmacy via the HMDP. Health Mart franchisees can also enroll in a fee-based premium offering of the HMDP and be able to customize their store website.

Use of the mobile app is subject to the applicable End User Agreement. Your enrollment and access to the HMDP is subject to your agreement with all the HMDP Terms & Conditions of use as set forth below (including the HMDP Privacy Policy and Business Associate Addendum). These HMDP Terms & Conditions together with our Privacy Policy and Business Associate Addendum constitute the agreement between you and Health Mart regarding use of the HMDP (“**Agreement**”).

SCOPE

These HMDP Terms & Conditions of use applies only to the HMDP that consists of the following websites:

- my.healthmart.com
- pharmacy.healthmart.com
- mypharmacy.healthmart.com
- pharmacystores.healthmart.com

The HMDP mobile App is available for download on Google Play or the Apple AppStore.

These HMDP Terms & Conditions of use of the HMDP are conditional upon you completing the steps required to setup your store website and mobile app for your patients to access and use your store information presented to them.

Health Mart retains the right both to refuse your registration and to terminate these HMDP Terms & Conditions of use at its sole discretion upon notice to you.

If you do not wish to utilize the HMDP, please do not enroll in the HMDP program. By agreeing to the HMDP Terms & Conditions of use you acknowledge that Health Mart may use other business associates, vendors, and subcontractors in providing the services contemplated hereunder.

By agreeing to these HMDP Terms & Conditions of use of the HMDP, which you will do by electronically checking a box to indicate your acceptance of the terms contained herein, you acknowledge and agree that you have carefully read, and fully understand all of the terms and conditions of HMDP’s Terms & Conditions of use of the HMDP, and enter into this HMDP Terms & Conditions of use HMDP on behalf of the legal entity you represent freely, knowingly, and without coercion, intending to be legally bound thereby.

The HMDP is an enhanced digital experience for pharmacies and patients. The HMDP landing page is a store webpage that presents patient facing store information contained within my.healthmart.com, store profile or any other platform where store information is shared with Health Mart. This information can be presented via the store locator, store listing and a webpage including information such as - store name, address, phone number, fax number, store services and other public information. On the HMDP landing page patients can request prescription transfers from other pharmacies or send prescription refill requests via fax to the pharmacy.

For the HMDP you hereby acknowledge and agree that, the prescriptions filled at the pharmacy by your patients who use the HMDP (“**Consumers**”) will display patient and prescription information to each Consumer when the Consumer accesses the HMDP.

You authorize Health Mart, and their designees, including their business associates, vendors, and subcontractors to use and disclose all necessary pharmacy and patient data, including but not limited to personal health information to allow the HMDP Services to be provided to the pharmacy and patients (the “**Delivered Data**”) (collectively, the “**Authorization**”). You represent and warrant that you have obtained, or will obtain, to the extent necessary, all patient authorizations in order to send the Delivered Data to Health Mart.

You shall promptly advise Health Mart in writing of the existence of any restrictions upon the use or disclosure of any Delivered Data. All Delivered Data shall be used by Health Mart pursuant to this Agreement (including the Business Associate Addendum). We shall be permitted to use the Delivered Data for the uses set forth in the Agreement and shall have the right to de-identify Delivered Data as set forth in the Agreement. You hereby acknowledge and agree that the HMDP may provide educational tools and other resources for Consumers, including adherence tools, based on the prescription drugs Consumers are taking.

The HMDP may provide the functionality to allow Consumers to manage multiple user profiles and thus manage the prescriptions for third-party individuals, such as minor children or other dependents. To the extent this feature is enabled, and your Consumers choose to use it, you hereby agree to such functionality and agree to take all necessary steps needed to support such functionality.

You must provide accurate, truthful, and complete contact information and other information about your business, or such other registration application as Health Mart may direct you to use in order to apply for access to the HMDP. You must advise Health Mart of any changes to such information as soon as is reasonably possible. From time to time, Health Mart may modify, in its sole discretion, the information required from you for your application for registration. Upon such a modification by Health Mart and notice to you, you must provide the additional or updated information to Health Mart within a reasonable period of time, as requested.

LICENSE AND RESTRICTIONS

Patient and user access to the HMDP will require patients and users to register to use and access the HMDP, which registration will be subject to an online agreement with Health Mart governing the use and access of the HMDP, including without limitation any customized content or platform. Use of and access to any customized content and platform will also be subject to any specific terms and policies, including without limitation to the HMDP Terms & Conditions of use, Privacy Policy and Business Associate Addendum. Health Mart and its business associates, vendors reserve the right to terminate or suspend access to the HMDP and/or the customized content by you or by any patient or users without notice in the event Health Mart reasonably believes a violation of any applicable agreement or policies has occurred. You may not send unsolicited messages (e.g. spam) through the HMDP, or post or submit information containing viruses, or any computer programs that result or may result in the damage, interference with or interception or expropriation of the HMDP, or any related system, software, hardware, data or other information.

You may not collect or use any contact or other information of any individual or patient that is not affiliated with a pharmacy that may be contained on or available through the HMDP for any purposes other than as expressly permitted in this Agreement.

You may not use any robot, spider or other automatic device or manual process to monitor or copy the HMDP web pages or any content contained on or available through the HMDP, including without limitation the content.

You may not copy, market, distribute, export, translate, reverse engineer, transmit, merge, modify, transfer, adapt, loan, rent, lease, assign, share, redistribute, host, hyper-link to, frame, store, or permit access to all or part of the HMDP or your customized content by any person other than your authorized employees and representatives or your registered patient, as applicable. Health Mart retains the right, but is not obligated, to store and monitor any activity and content on any system operated by Health Mart, including without limitation the HMDP, and the right to disclose such activity and content to third parties, including without limitation law enforcement officers.

You must adhere to all applicable local, state, and federal laws in accessing and using the HMDP, including but not limited to those laws and regulations regarding:

- court ordered publication bans;
- restrictions on publishing, printing, distributing, possessing, selling, advocating, promoting or exposing, obscene or threatening material, child pornography, or hate propaganda;
- restrictions on the use of trademarks or trade names, or any work which is protected by copyright, trade secret, patent or other intellectual property laws, including software; and
- restrictions on defamation, libel, harm to reputation, invasion of privacy, misuse or failure to protect personal information, including without limitation the Health Insurance Portability and Accountability Act (HIPAA), violation of secrecy, confidentiality, unfair competition and other situations which could generate liability.

You and your employees and representatives must comply with all HMDP access policies, including without limitation the HMDP's Terms & Conditions of use, Privacy Policy, Business Associate Addendum, and, to the extent you use the mobile app component of HMDP.

OWNERSHIP

The HMDP may consist of software, graphics, images, text, data or other materials, all of which are proprietary to Health Mart, its affiliates or its business associate or vendors and which are protected by copyright, trademark and other intellectual property laws. You may not directly or indirectly use, reproduce or display any trademarks associated with the HMDP unless otherwise expressly permitted pursuant to a written license agreement between you and Health Mart. Health Mart has the right to terminate this Agreement immediately upon notice of misappropriation of any trademarks associated with the HMDP. You acquire no right, title or interest in the HMDP or any copyrighted works, trademarks or any other intellectual property, or any individual software, graphics, images, text, data or other materials components, except the limited license granted above. You must maintain the confidential nature of all Confidential Information, defined below, during the term of this Agreement and at all times after the termination of this Agreement and may not use such Confidential Information for your benefit (except as expressly permitted under this Agreement), or for the benefit of any third party. You must exercise the same degree of care and protection with respect to the Confidential Information as used to maintain the confidentiality of your information that you deem confidential. You will use at least a reasonable degree of care and protection and will only disclose the Confidential Information to your employees on a need-to-know basis. **"Confidential Information"** includes, without limitation, the HMDP and any other Health Mart information regarded as confidential and proprietary by Health Mart or its business associate or vendors that is reasonably protected as such, regardless of whether such information is identified as confidential or proprietary in writing. Notwithstanding the above, nothing in this Agreement restricts your right to disclose or use any information that you can reasonably document (i) was already known to you at the time of Health Mart's disclosure to you, as evidenced by written documents in your possession, without an obligation of confidentiality, (ii) was generally available to the public or becomes publicly known through no wrongful act by you, (iii) was received by you from a third party who had a legal right to provide it to you, or (iv) was developed by you independently of the Confidential Information you receive from Health Mart. In the event you are required to disclose Confidential Information pursuant to a valid request from a court of competent jurisdiction, you must notify Health Mart in a timely manner before providing any Confidential Information in order to enable Health Mart to seek an appropriate protective order and

cooperate with Health Mart in seeking to obtain such an order. Any such disclosure must be limited to the specific information required and you must use reasonable efforts to obtain confidential treatment of any Confidential Information required to be disclosed. Your obligations as to Confidential Information shall continue until such time as such Confidential Information is no longer maintained as confidential by Health Mart.

DISCLAIMERS & LIMITATIONS

Neither Health Mart nor its business associate or vendors are a party to, nor is Health Mart or its business associate or vendors otherwise involved in, any transactions entered into by you and any consumer, even if such transaction occurs via the customized content. Furthermore, neither Health Mart nor its business associate or vendors shall be liable for any dispute that arises between you and any Consumer or third party.

THE CONTENT ON THE HMDP IS TO BE USED FOR INFORMATIONAL PURPOSES ONLY. YOU ACKNOWLEDGE THAT THE CONTENT IS IN NO CASE TO BE USED AS A SUBSTITUTE FOR PROFESSIONAL MEDICAL ADVICE NOR IS IT INTENDED TO BE RELIED UPON BY ANY PERSON OR ENTITY, INCLUDING ANY CONSUMER, FOR PURPOSES OF MEDICAL DIAGNOSIS OR TREATMENT. HEALTH MART OR ITS BUSINESS ASSOCIATE OR VENDORS SHALL USE COMMERCIALY REASONABLE EFFORTS TO ENSURE THE ACCURACY OF THE CONTENT, BUT NEITHER HEALTH MART, ITS AFFILIATES, NOR ITS BUSINESS ASSOCIATE OR VENDORS GUARANTEES THE SEQUENCE, ACCURACY, OR COMPLETENESS OF THE CONTENT AND SHALL NOT BE LIABLE IN ANY WAY TO YOU, YOUR CONSUMERS, OR ANYONE ELSE TO WHOM THE CONTENT MAY BE FURNISHED, FOR ANY DELAYS, INACCURACIES, UNAVAILABILITY, ERRORS OR OMISSIONS IN THE CONTENT. SUCH CONTENT IS RELIED UPON AT YOUR OWN RISK AND SOLE DISCRETION.

Neither Health Mart, its affiliates, nor its business associate or vendors shall have any liability for any claim based upon the use or combination of the HMDP with other information or content not provided by or approved by Health Mart or its business associate or vendors or for the use of any release other than a current, unaltered release of the HMDP. You will have no right or authority, at any time, to make any representation or commitment on behalf of Health Mart, its affiliates or its business associate or vendors, or to make any representations or warranties, guarantees or commitments to any third party, including any Consumer, with respect to the HMDP, except as expressly authorized by Health Mart or its business associate or vendors in writing.

THE HMDP, AND ANY CONTENT AND SERVICES PROVIDED, AND ANY RESPONSES, MATERIALS OR INFORMATION PROVIDED, RECEIVED, ACCESSED, PROCESSED, UPLOADED OR DOWNLOADED ON, THROUGH, TO OR FROM THE WEBSITE, AND ACCESS TO THE SAME, ARE PROVIDED "AS IS," "WHERE IS," AND "WITH ALL FAULTS" AND WITHOUT ANY WARRANTIES, REPRESENTATIONS OR CONDITIONS OF ANY KIND, WHETHER EXPRESS, IMPLIED, STATUTORY OR OTHERWISE INCLUDING ANY REPRESENTATIONS, WARRANTIES OR CONDITIONS OF MERCHANTABLE QUALITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, NON-INFRINGEMENT, OR THOSE ARISING FROM A COURSE OF DEALING OR USAGE OF TRADE. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, NEITHER HEALTH MART, ITS AFFILIATES, NOR ITS BUSINESS ASSOCIATE OR VENDORS MAKES ANY REPRESENTATION, WARRANTY OR CONDITION THAT THE HMDP WILL BE AVAILABLE AT ANY GIVEN TIME, THAT IT WILL OPERATE UNINTERRUPTED OR ERROR-FREE, THAT DEFECTS WILL BE CORRECTED OR THAT YOU WILL BE ABLE TO USE THE HMDP CORRECTLY.

Health Mart will strive to provide you with notice of any patient and users requests or preferences related to the patient and user's data as it relates to use of the HMDP and Services. However, you are solely responsible for ensuring that your use of Consumer data is lawful, including without limitation any data that you may otherwise have or collect outside the scope of the HMDP.

LIMITATION OF LIABILITY

IN NO EVENT SHALL HEALTH MART, ITS BUSINESS ASSOCIATE OR VENDORS, SUPPLIERS, AFFILIATES, OR THEIR RESPECTIVE DIRECTORS, OFFICERS, EMPLOYEES OR AGENTS, BE LIABLE TO YOU, OR ANY CONSUMER, OR ANY OTHER THIRD PARTY, FOR PROCUREMENT OF SUBSTITUTE PRODUCTS OR SERVICES OR FOR ANY PUNITIVE, EXEMPLARY, AGGRAVATED, ECONOMIC, SPECIAL, INDIRECT, DIRECT, OR CONSEQUENTIAL DAMAGES, OF ANY KIND OR NATURE WHATSOEVER, INCLUDING WITHOUT LIMITATION, (i) INJURY TO PERSONS, ANY LOSS OF PROFITS, REVENUE, BUSINESS, INFORMATION, DATA, BUSINESS INTERRUPTION OR LOSS OF EXPECTED SAVINGS, OR (ii) ANY DAMAGES WHATSOEVER RELATING TO YOUR USE OF HMDP (INCLUDING CONTENT AND SERVICES), CUSTOM CONTENT, OR INTERRUPTION, DELAYS, ERRORS, OMISSIONS, OR PENALTIES IN ANY WAY RELATED TO THIS AGREEMENT, THE HMDP, REGARDLESS OF THE CAUSE OF ACTION IT ARISES FROM, INCLUDING BUT NOT LIMITED TO, BREACH OF CONTRACT, WARRANTY, TORT, DELAYS, INCONVENIENCE, NEGLIGENCE, STRICT LIABILITY, PERFORMANCE OR NON-PERFORMANCE UNDER THIS AGREEMENT, OR OTHERWISE, EVEN IF HEALTH MART, ITS BUSINESS ASSOCIATE OR VENDORS, SUPPLIERS OR AFFILIATES HAVE BEEN ADVISED AS TO THE POSSIBILITY OF THOSE DAMAGES OR IF SUCH LOSSES OR DAMAGES WERE OTHERWISE REASONABLY FORESEEABLE.

IN ANY EVENT, THE MAXIMUM TOTAL AGGREGATE LIABILITY OF HEALTH MART, ITS BUSINESS ASSOCIATE OR VENDORS, SUPPLIERS OR AFFILIATES, AND THEIR RESPECTIVE DIRECTORS, OFFICERS, EMPLOYEES AND AGENTS, FOR ANY CLAIM OR DAMAGE WHATSOEVER, INCLUDING WITHOUT LIMITATION, CLAIMS FOR BREACH OF CONTRACT, MISREPRESENTATION, OR OTHER TORTS (INCLUDING, NEGLIGENCE OR STRICT LIABILITY) OR OTHERWISE, ARISING DIRECTLY OR INDIRECTLY, SHALL NOT TO EXCEED TEN THOUSAND DOLLARS (\$10,000), WHICH SHALL BE YOUR SOLE REMEDY EVEN IT IF SHOULD FAIL OF ITS ESSENTIAL PURPOSE.

You understand that these limitations form a part of the basis of the bargain in allowing you to use the HMDP.

YOUR COSTS

YOU ARE RESPONSIBLE FOR YOUR OWN COMPUTER HARDWARE AND SOFTWARE AND CONNECTION TO THE INTERNET FOR ACCESS TO THE HMDP AND THE FEES SET FORTH BELOW.

PAYMENT

Access to the HMDP is conditioned upon receipt of your HMDP Registration and for Premium Services, your timely payment of the Set-Up Charges as further specified in the HMDP pricing sheet, if applicable. All required and applicable fees will be invoiced to you by Health Mart or its business associates. Health Mart or its business associates may change such charges and fees upon sixty (60) days' advanced notice to you. All fees are non-refundable, and you will not be entitled to a refund of any monthly fees in any event.

REPRESENTATIONS & COVENANTS

YOU REPRESENT, WARRANT AND COVENANT THAT: (I) YOUR REGISTRATION ON THE HMDP ENROLLMENT FORM AND THE RELATED INFORMATION YOU PROVIDE ON YOUR APPLICATION IS TRUE, ACCURATE AND COMPLETE IN ALL MATERIAL RESPECTS; (II) YOU HAVE THE AUTHORITY TO ENTER INTO THIS AGREEMENT; (III) YOU ARE A BONA FIDE PHARMACY IN BUSINESS UNDER THE APPROPRIATE STATE AND/OR FEDERAL LAWS AND REGULATIONS AND HOLD ALL NECESSARY LICENSES REQUIRED TO OPERATE LAWFULLY; (IV) YOU WILL USE THE HMDP ONLY FOR LAWFUL PURPOSES AND IN ACCORDANCE WITH ALL LOCAL, STATE, FEDERAL, AND INTERNATIONAL LAWS, REGULATIONS AND ORDINANCES, INCLUDING WITHOUT LIMITATION HIPAA; (V) YOU ARE THE RIGHTFUL OWNER OF ALL CUSTOM CONTENT, OR OTHERWISE HAVE THE LAWFUL RIGHT, LICENSE

OR CONSENT TO USE THE CUSTOM CONTENT ON THE CUSTOMIZED HMDP, AND (VI) SUCH CUSTOM CONTENT DOES NOT INFRINGE UPON ANY THIRD PARTY INTELLECTUAL PROPERTY OR OTHER RIGHT.

YOU FURTHER WARRANT AND COVENANT THAT (1) YOU WILL NOT INTERFERE WITH A THIRD PARTY'S USE AND ENJOYMENT OF THE HMDP; (2) YOU WILL NOT INTERFERE WITH OR DISRUPT HEALTH MART'S OR ITS BUSINESS ASSOCIATE OR VENDORS' SECURITY MEASURES; (3) YOU WILL NOT INTERFERE WITH OR DISRUPT NETWORKS CONNECTED TO THE HMDP, AND WILL COMPLY WITH ALL REGULATIONS, POLICIES AND PROCEDURES OF SUCH NETWORKS; (4) YOU WILL COMPLY WITH UNITED STATES LAW REGARDING THE TRANSMISSION OF TECHNICAL DATA EXPORTED FROM THE UNITED STATES AND ALL APPLICABLE LAWS AND REGULATIONS REGARDING USE OF CONSUMER DATA; (5) YOU MAY NOT CREATE ANY DERIVATIVE WORKS BASED ON, OR IN ANY OTHER MANNER DUPLICATE, PRINT, REPRODUCE, OR MAKE COPIES OF ANY ASPECT OF THE HMDP, INCLUDING THE WEB PAGES, OR ANY UNDERLYING SOFTWARE RELATED TO THE HMDP, EXCEPT AS MAYBE EXPRESSLY PERMITTED BY THIS AGREEMENT, AND IN NO EVENT FOR PURPOSES OF DISTRIBUTION TO THE PUBLIC BY SALE, ASSIGNMENT OR OTHER TRANSFER OF OWNERSHIP, OR BY RENTAL, LEASE OR LENDING; (6) YOU MAY NOT DECOMPILE, DISASSEMBLE, TRANSLATE, OR OTHERWISE REVERSE-ENGINEER THE HMDP OR ANY PART OF THE HMDP; (7) OBTAIN OR USE THE SOURCE CODE FOR THE HMDP IN WHOLE OR IN PART; AND, (8) YOU MAY NOT PERFORM PUBLICLY OR PUBLICLY DISPLAY ANY ASPECT OF THE HMDP OR ANY UNDERLYING SOFTWARE RELATED TO THE HMDP, EXCEPT AS PERMITTED ON A CUSTOMIZED HMDP.

INDEMNITY

You are solely responsible for the access to, selection and use of the HMDP and all items, statements or other content transmitted, posted, received or created using your Key(s), even if transmitted, posted, received or created by someone else. You unconditionally agree to defend, indemnify and hold harmless Health Mart, its business associate or vendors and affiliates, and their respective directors, officers, employees and agents, from and against any and all damages, losses, claims, liabilities, costs and expenses (including reasonable legal fees and costs) arising, made, suffered, awarded against or incurred, directly or indirectly, by any of them from or in connection with: (i) your breach of this Agreement or any of your representations, warranties or covenants in this Agreement; (ii) your, or your employee's or representative's, use, misuse or operation of the HMDP; (iii) any use or misuse of the Key(s); (iv) any transaction entered into between you and a Consumer; (v) your violation of any applicable law, including without limitation any privacy or data security law or regulation, (vi) your use or misuse of any Consumer data, and (vii) any claims or allegations that your Custom Content infringes upon any third party's intellectual property or other proprietary rights. Notwithstanding the foregoing, Health Mart, its business associate or vendors and affiliates reserve the right to participate reasonably in the defense of any such claim subject to your indemnification obligation.

SEVERABILITY

Any provision of this Agreement that is illegal, invalid or unenforceable in any jurisdiction will, as to that jurisdiction, be ineffective to the extent of such illegality, invalidity or unenforceability and will be modified to the minimum extent necessary to make such provision legal, valid and enforceable while maintaining the intentions of the parties. Should such modification prove to be impractical or impermissible, the offending provision will be severed from the balance of this Agreement, without affecting the remaining provisions of this Agreement or affecting the legality, validity or enforceability of such provision in any other jurisdiction.

FORCE MAJEURE

Health Mart has no obligation to perform under this Agreement to the extent and for the period that Health Mart is prevented from doing so by any cause beyond its reasonable control, including the inability to use or the failure of any third party telecommunications carrier or other services.

TERMINATION

This Agreement commences as of the date that you submit your application for registration to access and use the HMDP and agree to this Agreement and will continue until otherwise terminated under this Agreement. This Agreement may be terminated without cause by either party upon thirty (30) days' prior written notice. This Agreement will automatically terminate, regardless of Term, in the event your franchise relationship with Health Mart terminates.

Without limiting any other rights or remedies available to Health Mart under this Agreement, at law or in equity, this Agreement shall immediately terminate if any of the following occurs:

- Bankruptcy or insolvency proceedings are taken by or against you or if a receiver, trustee or other similar person is appointed over your assets;
- After receiving notice in writing from Health Mart, you fail to immediately observe or perform any of your obligations under this Agreement; or
- You do not complete the registration process accurately or your request is not accepted by Health Mart for any reason.

ENTIRE AGREEMENT

These HMDP Terms & Conditions, the HMDP's posted Privacy Policy and the Business Associate Addendum constitute the entire agreement between the parties with respect to the access to and use of the HMDP, and supersede all prior written or oral negotiations, agreements, representations and other communications between the parties with respect to the HMDP, provided that the parties acknowledge they are subject to other agreements covering different subjects areas, including the Health Mart Franchise agreement, and such agreements shall remain in effect.

ASSIGNMENT OF AGREEMENT

You may not assign this Agreement without the prior written consent of Health Mart. Health Mart may assign this Agreement without your prior written consent. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns.

INDEPENDENT CONTRACTORS

The parties acknowledge that each is an independent contractor, and neither is the agent, representative, partner, fiduciary or trustee of the other party and neither party has the authority to act as or represent itself as an agent of the other party.

GOVERNING LAW

This Agreement shall be governed by and construed in accordance with the laws of the State of Texas and the federal laws of the United States, without regard to conflicts of laws principles. This Agreement and access to the HMDP shall be deemed to have been performed and occurred in the State of Texas and the courts of that State shall have exclusive jurisdiction to entertain any action arising under this Agreement. You hereby irrevocably submit to the exclusive jurisdiction and venue of the state courts of the State of Texas, located in Dallas County, and the federal courts located in Dallas County and waive any objections as to personal jurisdiction, venue and forum nonconveniens.

NOTICES

If to Health Mart Franchise:

Any notice, demand or other communication required or permitted to be given or made under this Agreement given to Health Mart franchises must be in writing and will be sufficiently given, made and deemed received if delivered by (i) electronic mail ("e-mail") to your current e-mail address reflected in your HMDP registration; or (ii) sent by courier or prepaid registered mail at the applicable address set forth in your contact information submitted by you on your request to access the HMDP or if to Health Mart.

If to Health Mart:

Any notice, demand or other communication required or permitted to be given or made under this Agreement given to Health Mart must be in writing and will be sufficiently given, made and deemed received if delivered sent by courier or prepaid registered mail at the applicable address forth below for

Health Mart.

Health Mart Systems, Inc.
6535 N. State Highway 161
Irving, TX 75039

with a copy to:

McKesson Corporation, Legal Department
6535 N. State Highway 161
Irving, TX 75039

INTERPRETATION

The division of this Agreement into Sections and the insertion of headings are for convenience or reference only and shall not affect the construction or interpretation of the Agreement. Unless the context otherwise requires, words using the singular include the plural and vice versa, and words importing gender includes all genders. When used in this Agreement, the word “including” (or includes) means “including (or includes) without limitation.” Any reference in this Agreement to a “person” will be deemed to include an individual, corporation, partnership, trust, unincorporated organization, government and the heirs, executors, administrators or other legal representation of an individual.

AMENDMENT AND WAIVER OF THIS AGREEMENT

Health Mart reserves the right to modify the Agreement upon thirty (30) days’ prior written notice to you via email or posting upon your login or access to the HMDP.

**Health Mart Digital Portfolio (“HMDP”)
Privacy Notice
Effective Date – August 25th, 2021**

At McKesson (“**McKesson**” or “**we**”), we value the trust that our customers place in us to appropriately use and protect personal information. This Health Mart Digital Portfolio Privacy Notice informs visitors and regular users of McKesson’s Health Mart Digital Portfolio about how McKesson may collect, use, and share personal information and how it is protected. We want you to be clear how we’re using personal information and the ways in which we protect this information. By using this website, you accept the privacy practices presented in this Privacy Notice. We encourage you to read this Privacy Notice in full to understand our privacy practices before using this website or submitting any personal information.

SCOPE

This Privacy Notice applies only to the HMDP website and mobile app.

- <https://my.healthmart.com/HealthMartDigitalPortfolio/home.htm>
- web.prescribewellness.com

McKesson affiliates and subsidiaries may have separate websites, subdomains, and applications through other web, mobile, cloud or SaaS platforms which are not subject to this Privacy Notice. Additionally, McKesson business partners, ad networks and other third parties may have their own websites and services with separate privacy practices. We encourage you to read the privacy notices of all websites and applications that you visit and understand their privacy practices.

PERSONAL INFORMATION WE COLLECT

When you use this website, we may collect personal information about you. Personal information is any information accessed, collected, or used by McKesson that identifies an individual, or can reasonably be used to identify an individual, whether directly or indirectly. The personal information we may collect includes, but is not limited to:

- First name, last name
- Licenses and certifications
- Date of birth, photographs, videos
- Business address, telephone numbers, and electronic mail addresses
- Occupation/title
- User ID and password
- Marketing preference such as text message or email notification and frequency, Geo-location/GPS information, device identification number/serial number (such as for mobile phone, tablet, or computer), device/User activity (such as login-logout info, sites/pages visited, # of visits, click stream, navigation, beacon signal hits, errors, crash rate, or other user activities)

TRACKING TECHNOLOGIES WE USE

We use various technologies to collect personal information about visitors to our websites and/or users of our applications. These technologies include but are not limited to the following:

- Web server logs
 - As is true of most websites and applications, we gather certain information automatically and store it in log files. This information may include IP addresses, browser type, internet service provider, referring/exit pages, operating system, date/time stamp and/or clickstream data.
- Geo-location Services
 - When you enable a location-based service, we may collect information about your location with HMDP. Your browser or other device may use various technologies to determine location, such as sensor data from your device that may provide information on nearby Wi-Fi access points and cell towers.
- Other Tracking Technologies
 - We also use local storage such as HTML5 to collect and store content information and preferences. Third parties who we partner with to provide certain features on our site or to display advertising use local storage such as HTML5 to collect and store information. Various browsers may offer their own management tools for removing HTML5 local storage.

HOW WE RESPOND TO “DO NOT TRACK” SIGNALS

Some web browsers have a “Do Not Track” feature. This feature allows you to tell websites you visit that you do not want to have your online activity tracked over time and across websites. These features are not yet uniform across browsers and not broadly supported. This site is not currently set up to respond to those signals.

HOW WE USE THE PERSONAL INFORMATION COLLECTED

We may use the personal information we collect for purposes such as, but not limited to:

- Customer and troubleshooting support,
- Assist in finding a Health Mart pharmacy close to the patient, and
- Further develop products and services.

HOW WE SHARE PERSONAL INFORMATION COLLECTED

McKesson does not sell personal information about you to third parties.

McKesson may also need to share information with companies, organizations, or individuals outside of McKesson if we have a good faith belief that access, use, preservation, or disclosure of that information is reasonably necessary to:

- Meet applicable laws, regulations, legal processes, or enforceable governmental requests;
- Enforce applicable Terms of Service, including investigation of potential violations;
- Detect, prevent, or otherwise address fraud, security, or technical issues;
- Protect against harm to the rights, property or safety of our users, McKesson, or the public as required or permitted by law; or
- Engage in a merger, acquisition, reorganization, or sale of all or a portion of McKesson assets.

YOUR CHOICE

Where appropriate or legally required, we will describe how your information that we collect through HMDP will be used and will provide choices about whether to allow us to engage in that use. To exercise your choice, you may contact us to correct, update, amend or request deletion of your personal information through the HMDP customer service contact listed on the HMDP website.

Where permitted, or with your prior consent where required by law, we will use your name and email address to send the Health Mart newsletter to you. You may choose to stop receiving our newsletter or marketing emails by following the unsubscribe instructions included in these emails.

ACCESS TO PERSONAL INFORMATION

Some McKesson websites allow you to directly view, edit, or delete information about you through your profile settings. If this option is not available, you can update information about you through the HMDP customer service contact listed on the HMDP website.

RETENTION

We will retain your personal information for as long as your account is active, as reasonably useful for commercial purposes, and as necessary to comply with our legal obligations, resolve disputes and enforce our agreements.

HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT (“HIPAA”)

As a key provider of services and technology to the healthcare industry, McKesson has implemented programs to address the privacy and security requirements of HIPAA.

To the extent that we are functioning as a HIPAA covered entity, a Notice of Privacy Practices will be provided to you or made available to you.

CHILDREN’S PRIVACY

This HMDP site and/or application/portal is not intended for any user under the age of 13, and we do not knowingly collect personal information from children under the age of 13. We request that children under the age of 13 not submit any personal information through the HMDP site and/or app/portal.

HOW WE PROTECT YOUR INFORMATION

McKesson has established appropriate physical, electronic and administrative safeguards to protect the information we collect from or about our users. We restrict access to personal information to McKesson employees, contractors and agents who need to know that information to process it for us, and who are subject to confidentiality obligations.

Any sensitive personal information (e.g., credit / debit card number) will be transmitted in an encrypted form using SSL encryption. Notwithstanding our security safeguards, it is impossible to guarantee 100% security in all circumstances. If you have any questions about security or have reason to believe that your

interaction with us is no longer secure (for example, you feel that the security of any account you might have with us has been compromised), you must immediately notify us of the problem by contacting McKesson at Privacy@McKesson.com.

CHANGES TO THIS PRIVACY NOTICE

We may periodically update this Privacy Notice to describe new features, products or services we offer and how it may affect our use of personal information about you and your controls. We will not apply changes to this Privacy Notice retroactively to personal information we have previously collected. Since we may update this Privacy Notice, we recommend that you check the current version available from time to time located on <https://my.healthmart.com/Healthmartdigitalpharmacy/home.htm>. If we make changes to this Privacy Notice, we will update the “**Effective Date**” at the beginning of the Privacy Notice.

CONTACT INFORMATION

If you have questions or concerns about this Privacy Notice, our information handling practices, or any other aspect of privacy and security of your personal information, please contact us at: Privacy@McKesson.com.

You may also write to us at:
McKesson Corporation
ATTN: Privacy Officer (Privacy Notice)
Health Mart Systems, Inc.
2 National Data Plaza NE, 3rd Floor
Atlanta, GA 30329

Health Mart Digital Portfolio Business Associate Addendum Effective Date - August 25th, 2021

This Business Associate Addendum (“**Addendum**”) is entered into by and between Health Mart Systems, Inc. (“**Health Mart**” or “**Business Associate**”) and the Covered Entity named in the Health Mart Digital Portfolio (“**HMDP**”) Agreement (“**Pharmacy**”) and is effective as of the Effective Date indicated below. Health Mart and Pharmacy may be individually referred to as a “**Party**” and, collectively, the “**Parties**” in this Addendum.

RECITALS

- A. Health Mart provides the use of the HMDP and other tools and services to Pharmacy pursuant to the HMDP Terms & Conditions together with our Privacy Policy and this Business Associate Addendum between you and Health Mart regarding use of the HMDP or other agreements between the parties as may be amended from time to time (collectively, “**Agreement**”).
- B. The Pharmacy wishes to disclose certain information to Health Mart pursuant to the Agreement, some of which may constitute Protected Health Information (“**PHI**”) as defined below.
- C. The Pharmacy and Health Mart intend to protect the privacy and provide for the security of PHI disclosed to Health Mart pursuant to the Agreement in compliance with the HIPAA Regulations.

SECTION 1: DEFINITIONS

“**Breach**” will have the same meaning given to such term in 45 C.F.R. § 164.402.

“**Designated Record Set**” will have the same meaning as the term “designated record set” in 45 C.F.R. § 164.501.

“**Electronic Protected Health Information**” or “**Electronic PHI**” will have the meaning given to such term under the Privacy Rule and the Security Rule, including, but not limited to, 45 C.F.R. § 160.103, as applied to the information that MSH creates, receives, maintains or transmits from or on behalf of Practice.

“HIPAA Regulations” means the Privacy Rule, the Security Rule and the HIPAA Final Rule, as each is defined herein, and may be amended from time to time

“Individual” will have the same meaning as the term “individual” in 45 C.F.R. § 160.103 and will include a person who qualifies as a personal representative in accordance with 45 C.F.R. § 164.502(g).

“Privacy Rule” will mean the Standards for Privacy of Individually Identifiable Health Information at 45 C.F.R. Part 160 and Part 164, Subparts A and E.

“Protected Health Information” or **“PHI”** will have the same meaning as the term “protected health information” in 45 C.F.R. § 160.103, as applied to the information created, received, maintained or transmitted by MSH from or on behalf of the Practice.

“Required by Law” will have the same meaning as the term “required by law” in 45 C.F.R. § 164.103.

“Secretary” will mean the Secretary of the Department of Health and Human Services or his or her designee.

“Security Incident” will have the meaning given to such term in 45 C.F.R. § 164.304.

“Security Rule” will mean the Security Standards at 45 C.F.R. Part 160 and Part 164, Subparts A and C.

“Unsecured PHI” will have the same meaning given to such term under 45 C.F.R. § 164.402, and guidance promulgated thereunder.

Capitalized Terms. Capitalized terms used in this Addendum and not otherwise defined herein will have the meanings set forth in the HIPAA Regulations, which definitions are incorporated in this Addendum by reference.

SECTION 2: PERMITTED USES AND DISCLOSURES OF PHI

2.1 Uses and Disclosures of PHI Pursuant to the Agreement. Health Mart may use or disclose PHI to perform functions, activities, or services for, or on behalf of, Customer as specified in the Agreement, provided that such use or disclosure would not violate the Privacy Rule if done by Customer.

2.2 Permitted Uses of PHI by Health Mart. Health Mart may use PHI for its proper management and administration of Business Associate or to carry out its legal responsibilities.

2.3 Permitted Disclosures of PHI by Health Mart. Health Mart may disclose PHI for its proper management and administration, provided that the disclosures are Required by Law. Health Mart may disclose PHI to report violations of law to appropriate federal and state authorities, consistent with 45 C.F.R. § 164.502(j)(1).

2.4 Data Aggregation. Health Mart may use PHI to provide Data Aggregation services for the Health Care Operations of the Pharmacy as permitted by 45 C.F.R. § 164.504(e)(2)(i)(B).

2.5 De-identified Data. Health Mart may de-identify PHI in accordance with the standards set forth in 45 C.F.R. § 164.514(b) and may use or disclose such de-identified data unless prohibited by applicable law.

2.6 HIPAA Authorization. Health Mart may use PHI to solicit patient HIPAA authorizations in accordance with the standards set forth in 45 C.F.R. § 164.508.

SECTION 3: OBLIGATIONS OF HEALTH MART

3.1 Appropriate Safeguards. Health Mart will use appropriate safeguards and will comply with the Security Rule with respect to Electronic PHI, to prevent use or disclosure of such information other than as provided for by the Agreement and this Addendum. Except as expressly provided in the Agreement, Health Mart will not assume any obligations of the Pharmacy under the Privacy Rule. To the extent that Health Mart is to carry out any of the Pharmacy’s obligations under the Privacy Rule as expressly provided in the Agreement and this Addendum, Health Mart will comply with the requirements of the Privacy Rule that apply to the Pharmacy in the performance of such obligations.

3.2 Reporting of Improper Use or Disclosure, Security Incident or Breach. Health Mart will report to the Pharmacy any use or disclosure of PHI not permitted under the Agreement or by this Addendum, Breach of Unsecured PHI or any Security Incident, without unreasonable delay; provided, however, that the Parties

acknowledge and agree that this Section constitutes notice by Health Mart to the Pharmacy of the ongoing existence and occurrence of attempted but Unsuccessful Security Incidents (as defined below). “**Unsuccessful Security Incidents**” will include, but not be limited to, pings and other broadcast attacks on Health Mart’s firewall, port scans, unsuccessful log-on attempts, denials of service and any combination of the above, so long as no such incident results in unauthorized access, use or disclosure of PHI.

3.3 Health Mart’s Agents. As applicable, Health Mart will enter into a written agreement with any agent or subcontractor that creates, receives, maintains or transmits PHI on behalf of Health Mart for services provided to Pharmacy, providing that the agent agrees to restrictions and conditions that are substantially similar to those that apply through this Addendum to Health Mart with respect to such PHI.

3.4 Access to PHI. The Parties do not intend for Health Mart to maintain any PHI in a Designated Record Set for the Pharmacy. To the extent Health Mart possesses PHI in a Designated Record Set, Health Mart agrees to make such information available to Pharmacy pursuant to 45 C.F.R. § 164.524, within a reasonable time of Health Mart’s receipt of a written request from Pharmacy; provided, however, that Health Mart is not required to provide such access where the PHI contained in a Designated Record Set is duplicative of the PHI contained in a Designated Record Set possessed by Pharmacy. If an Individual makes a request for access pursuant to 45 C.F.R. § 164.524 directly to Health Mart, or inquires about his or her right to access, Health Mart will either forward such request to Pharmacy or direct the Individual to Pharmacy.

3.5 Amendment of PHI. The Parties do not intend for Health Mart to maintain any PHI in a Designated Record Set for the Pharmacy. To the extent Health Mart possesses PHI in a Designated Record Set, Health Mart agrees to make such information available to Pharmacy for amendment pursuant to 45 C.F.R. § 164.526 within a reasonable timeframe but no less than twenty (20) days of Health Mart’s receipt of a written request from Pharmacy. If an Individual submits a written request for amendment pursuant to 45 C.F.R. § 164.526 directly to Health Mart, or inquires about his or her right to amendment, Health Mart will either forward such request to Pharmacy or direct the Individual to Pharmacy.

3.6 Documentation of Disclosures. Health Mart agrees to document such disclosures of PHI and information related to such disclosures as would be required for the Pharmacy to respond to a request by an Individual for an accounting of disclosures of PHI in accordance with 45 C.F.R. § 164.528. Health Mart will document, at a minimum, the following information (“**Disclosure Information**”): (a) the date of the disclosure; (b) the name and, if known, the address of the recipient of the PHI; (c) a brief description of the PHI disclosed; (d) the purpose of the disclosure that includes an explanation of the basis for such disclosure; and (e) any additional information required under the HITECH Act and any implementing regulations.

3.7 Accounting of Disclosures. Health Mart agrees to provide to the Pharmacy, within twenty (20) business days of Health Mart’s receipt of a written request from Customer, information collected in accordance with Section 3.5 of this Addendum, to permit the Pharmacy to respond to a request by an Individual for an accounting of disclosures of PHI in accordance with 45 C.F.R. § 164.528. If an Individual submits a written request for an accounting of disclosures of PHI pursuant to 45 C.F.R. § 164.528 directly to Health Mart, or inquires about his or her right to an accounting, Health Mart will direct the Individual to the Pharmacy.

3.8 Governmental Access to Records. Health Mart will make its internal practices, books and records relating to the use and disclosure of PHI received from, or created or received by Health Mart on behalf of, the Pharmacy available to the Secretary for purposes of the Secretary determining the Pharmacy’s compliance with the Privacy Rule and the Security Rule.

3.9 Mitigation. To the extent practicable, Health Mart will cooperate with the Pharmacy’s efforts to mitigate a harmful effect that is known to Health Mart of a use or disclosure of PHI by Health Mart that is not permitted by this Addendum.

3.10 Minimum Necessary. Health Mart will request, use and disclose the minimum amount of PHI necessary to accomplish the purpose of the request, use or disclosure, in accordance with 45 C.F.R. § 164.514(d), and any amendments thereto.

SECTION 4: OBLIGATIONS OF PHARMACY

4.1 Notice of Privacy Practices. The Pharmacy will cease using HMDP if any limitation(s) in its Notice of Privacy Practices affect Health Mart's use or disclosure of PHI.

4.2 Individual Permission. The Pharmacy will obtain any consent or authorization that may be required by the Privacy Rule, or applicable state law, prior to the patient accessing the HMDP application(s).

4.3 Permissible Requests by Pharmacy. The Pharmacy will not request Health Mart to use or disclose PHI in any manner that would not be permissible under the HIPAA Regulations if done by Pharmacy, except as permitted pursuant to the provisions of Sections 2.2, 2.3, 2.4 and 2.5 of this Addendum.

SECTION 5: TERM AND TERMINATION

5.1 Term. The term of this Addendum will commence as of the Effective Date of the Agreement, and will terminate when the Pharmacy ceases using the HMDP, and all of the PHI provided by the Pharmacy to Health Mart, or created or received by Health Mart on behalf of the Pharmacy, is destroyed or returned to the Pharmacy. If it is infeasible to return or destroy PHI, Health Mart will extend the protections to such information, in accordance with Section 5.3.

5.2 Termination. Health Mart may suspend or discontinue providing the HMDP to Pharmacy without notice or cause. Health Mart may pursue any other remedy legally available if Pharmacy fails to comply with any of the obligations hereunder.

5.3 Effect of Termination.

5.3.1 Except as provided in Section 5.3.2, upon termination of the Agreement or this Addendum for any reason, Health Mart will return or destroy all PHI received from the Pharmacy, or created or received by Health Mart on behalf of the Pharmacy, at the Pharmacy's expense, and will retain no copies of the PHI.

5.3.2 If it is infeasible for Health Mart to return or destroy the PHI upon termination of the Agreement or this Addendum, Health Mart will: (a) extend the protections of this Addendum to such PHI and (b) limit further uses and disclosures of such PHI to those purposes that make the return or destruction infeasible, for so long as Health Mart maintains such PHI.

SECTION 6: COOPERATION IN INVESTIGATIONS

The Parties acknowledge that certain breaches or violations of this Addendum may result in litigation or investigations pursued by federal or state governmental authorities of the United States resulting in civil liability or criminal penalties. Each Party will cooperate in good faith in all respects with the other Party in connection with any request by a federal or state governmental authority for additional information and documents or any governmental investigation, complaint, action or other inquiry.

SECTION 7: SURVIVAL

The respective rights and obligations of Health Mart under Section 5.3 of this Addendum will survive the termination of this Addendum.

SECTION 8: AMENDMENT

This Addendum is subject to the Agreement only. The Addendum may be changed from time to time without notice. Continued use of the HMDP following any change constitutes acceptance of the change, and this Addendum.

SECTION 9: EFFECT OF ADDENDUM

In the event of any inconsistency between the provisions of this Addendum and the Agreement, the provisions of this Addendum will control. In the event that a court or regulatory agency with authority over Health Mart or Pharmacy interprets the mandatory provisions of the HIPAA Regulations, in a way that is inconsistent with the provisions of this Addendum, such interpretation will control.

SECTION 10: LIMITATION OF LIABILITY

Under this Addendum, Health Mart's liability shall be limited to (1) any fines levied against the Pharmacy by a federal or state agency due to a breach of PHI caused by Health Mart or (2) the actual costs of notifying affected individuals in the event of breach of PHI caused by Health Mart. In no event shall Health Mart or its affiliated parties be liable for any damages, costs or expenses including but not limited to special, indirect, incidental, or consequential damages of any kind whatsoever (including, without limitation, attorneys' fees) in any way due to, resulting from, or arising in connection with use of the HMDP and materials or use of a third-party website.

SECTION 11: COMPLETE AGREEMENT

This Addendum along with the Agreement constitutes the entire agreement governing the use of the HMDP. This Addendum is the complete, final, and exclusive embodiment of the agreement between the parties with regard to this subject matter and supersedes any prior oral discussions or written communications and agreements

SECTION 12: AUTHORITY TO AGREE

By agreeing to this Addendum and using the HMDP, you warrant and agree that you are authorized to agree to these terms on behalf of the Pharmacy.

By checking on the checkbox, you agree to the Health Mart Digital Portfolio Terms & Conditions.

By checking on the checkbox, you agree to the Health Mart Digital Portfolio Privacy Policy.

By checking on the checkbox, you agree to the Health Mart Digital Portfolio Business Associate Agreement.

EXHIBIT J-1

**MCKESSON CORPORATION SHORT TERM FINANCING DOCUMENTS
(SECURITY AGREEMENT, GUARANTY, NOTE)**

(OPTIONAL FINANCING)

McKESSON

Security Agreement

McKesson Corporation, for itself and as agent for its affiliates (including D&K Healthcare Resources LLC)

The undersigned debtor(s) (individually or collectively, "Debtor") hereby grants to McKesson Corporation, a Delaware corporation, and any of its affiliates with which Debtor has an account, including, without limitation, D & K Healthcare Resources LLC (McKesson Corporation and any such affiliates, individually or collectively, the "Secured Party"), a security interest in Debtor's property described in attached Exhibit A, both now owned and hereafter acquired, together with all attachments, replacements, substitutions, additions and accessions, and all cash and non-cash proceeds thereof, all collectively referred to as "Collateral." All items of Collateral shall remain personal property, not become part of any real estate regardless of the manner of affixation and be kept at the locations listed in Exhibit A.

This security interest is granted to secure timely and full payment and performance of all present and future obligations of Debtor to Secured Party (all collectively referred to as the Obligations), including, without limitation, all promissory notes, direct loans, or sales on credit. This security interest shall continue in effect irrespective of any retaking and redelivery of Collateral to Debtor until all Obligations are fully paid in cash. Each of McKesson Corporation and/or D & K Healthcare Resources LLC and/or their affiliates may be extending credit to the Debtor from time to time, and therefore this security interest is granted to McKesson Corporation, to D & K Healthcare Resources LLC, and to their affiliates, and McKesson Corporation shall act as agent for its affiliates (including D & K Healthcare Resources LLC) with respect to such security interest, as applicable from time to time.

Debtor's Covenants, Representations, Warranties: Debtor represents and warrants and, so long as any Obligation is owed by Debtor, covenants as follows:

1. All information supplied and statements made by Debtor in any financial statement or application for credit prior to this Agreement are true and correct.
2. Debtor owns the Collateral; and except for the security interest granted hereby and any previously granted security interests disclosed to Secured Party by Debtor in writing, the Collateral will be kept free from all liens and encumbrances.
3. Debtor will maintain and repair the Collateral, keeping it free from unreasonable waste, deterioration or depreciation.
4. Debtor will insure and maintain insurance to protect the Collateral against all loss, damage, or destruction due to fire, theft, and other casualty loss, for the full insurable value plus such other insurance as Secured Party may specify. All such policies relating to the Collateral shall contain an endorsement showing the loss payable to Secured Party or its assignee as their respective interests may appear. Debtor shall furnish evidence of such insurance to Secured Party at least annually. All risk of loss, damage, or destruction of Collateral shall at all times be on Debtor.
5. Debtor shall furnish to Secured Party or its designee financial statements, prepared by its accountants in accordance with generally accepted accounting principles on a basis consistently applied, as follows: monthly statements due 45 days after month-end; reviewed, fiscal-year-end statements due 120 days after the year-end closing.
6. Debtor shall also make available to Secured Party, upon request, (i) Debtor's books of account and records for inspection, examination, abstracting and copying, and (ii) all of Debtor's Collateral and other property (or evidence thereof) for inspection and inventorying.
7. Debtor shall inform Secured Party immediately on the occurrence of any materially adverse change in Debtor's financial condition.
8. Debtor will defend at its own cost any action, proceeding or claim affecting the Collateral.
9. Debtor will pay when due all taxes, assessments, liens or encumbrances, license fees and any other public or private charges levied or assessed against the Collateral or this Agreement or any accompanying note.
10. Debtor's stockholders' capital, capital surplus and retained earnings minus all of its assets which would be classified as intangible assets in accordance with GAAP shall at all times be a positive number.
11. The proceeds of any and all loans and other extensions of credit by Secured Party shall be used for business purposes in connection with the operation of a pharmacy, and not for personal, family or household purposes.
12. Debtor shall execute and deliver any and all documents relating to this transaction, in form satisfactory to Secured Party, to perfect and maintain the security interest granted herein. Debtor hereby authorizes Secured Party to file UCC financing statements without Debtor's signature.
13. Debtor's chief executive office is located at the address specified on Exhibit A. Debtor shall not change its chief executive office or its state of incorporation without giving Secured Party prior written notice of such change.
14. Without written consent from Secured Party, Debtor will not:
 - a. move the Collateral from the locations shown in Exhibit A or change its name or its form or place of business;
 - b. liquidate or merge or consolidate with or into any other corporation;
 - c. assign, cancel, terminate, encumber or otherwise dispose of any existing leases for Debtor's business premises;
 - d. create or assume any indebtedness, except accounts payable and other liabilities incurred in the ordinary course of business;

- e. declare or pay any dividends or make any return or distribution of cash or property to or among its shareholders except for taxes due under their subchapter S tax election;
- f. reduce the value of the collateral classified as inventory by more than 10% from the amount owned by Debtor at ____/____/____ or to less than \$_____ (whichever is greater) even in the ordinary course of business.

Default: Any one of the following events shall constitute a default by Debtor hereunder:

1. Failure of Debtor to pay when due any of the Obligations.
2. Failure of Debtor to perform and observe any of the terms, conditions, covenants, obligations, and warranties contained in this Agreement, any supply agreement, or any other agreement between Debtor and Secured Party or any of Secured Party's affiliates.
3. Any of Debtor's representations shall be untrue.
4. Secured Party reasonably determines that the Collateral is inadequate to protect Secured Party's interest or that there has occurred or there reasonably may occur a materially adverse change in Debtor's ability to meet any of the Obligations, and Debtor fails to cure the deficiency upon 30 days' notice.
5. Voluntary or (if not dismissed within 60 days) involuntary filing of proceedings under federal or state bankruptcy statutes, or an assignment for the benefit of creditors, or an appointment of a receiver or trustee over Debtor's business.
6. Any guarantor of any of the Obligations shall fail to perform or observe any term, covenant or agreement contained in the guaranty of such guarantor or in any other document signed by such guarantor in connection with such guaranty; or any guaranty or any other document executed by a guarantor in connection with a guaranty shall for any reason be revoked or invalidated, or otherwise cease to be in full force and effect.
7. This Agreement, together with any financing statements or any other document executed in connection herewith, shall cease to create a valid and perfected first priority lien in any of the Collateral purported to be covered hereby.

Remedies:

1. In the event of default, Secured Party shall have all of the rights and remedies of a Secured Party under the Uniform Commercial Code, and any other applicable law, together with the rights and remedies specified hereunder.
2. At the election of Secured Party, after the occurrence of any default, the entire unpaid amount of the Obligations, together with interest accrued thereon, shall become immediately due and payable.
3. Secured Party may demand possession of the Collateral in which case Debtor shall immediately deliver the Collateral to Secured Party at Debtor's expense. Upon taking of the Collateral, Secured Party has the right to sell, lease, or otherwise dispose of it in any commercially reasonable manner pursuant to the provisions of the UCC.
4. Unless otherwise provided by law, any requirement of reasonable notice of sale of the Collateral by Secured Party shall be met if such notice is mailed, postage prepaid, to Debtor at the primary place of business at least five days before the time of the sale or disposition.
5. Debtor shall pay Secured Party all of its expenses of taking, holding, preparing for sale and the like, including reasonable attorney's fees and other legal expenses.
6. With respect to accounts included in the Collateral, Secured Party may and Debtor shall, when requested by Secured Party, notify the account debtors of the security interest created hereunder and the assignment to Secured Party, and authorize the account debtor to make all payments directly to Secured Party. Secured Party may alone, or in conjunction with Debtor, take any and all action necessary to collect the accounts, and in so doing, may have all of Debtor's mail delivered to Secured Party by notifying the postal authorities or may open and dispose of mail addressed to Debtor and execute, sign, and endorse negotiable and other instruments for the payment of money or other evidences of payment, on behalf of and in the name of Debtor, for all of which this shall be deemed a sufficient power of attorney.
7. Failure of Secured Party to exercise any right under this Agreement or any promissory note secured hereby shall not be construed as a waiver of any default.

Other Provisions:

1. This Agreement shall be deemed to constitute a purchase money security interest in any and all Collateral purchased by Debtor either directly from Secured Party (thereby securing payment of the purchase price) or from a third party using proceeds of loans or advances made by Secured Party (thereby securing repayment of such loans or advances).
2. Any provisions hereof contrary to, prohibited by or invalid under applicable laws or regulations shall be inapplicable and deemed omitted herefrom, but shall not invalidate the remaining provisions hereof.
3. This Agreement constitutes the complete understanding between the parties. This Agreement may only be modified or canceled by a written agreement between the parties and signed by the party against whom the modification or cancellation is sought to be enforced.
4. The term "Secured Party" shall include any assignee or successor of Secured Party or any holder of a promissory note or other evidence of the obligations secured hereby. After assignment of this Agreement, Secured Party shall not be the assignee's agent for any purpose.

5. This Agreement shall be binding upon, and shall inure to the benefit of, the respective heirs, executors, successors and assigns of the parties hereto.

6. This Agreement shall be governed by and construed in accordance with the laws of the State of California.

Dated: _____

Secured Party: McKesson Corporation, for itself and as agent for its affiliates (including D&K Healthcare Resources LLC)

By: _____
(Signature)

Title: _____

Print Name: _____

Debtor: _____
(Company Name)

By: _____
(Signature)

Title: _____

Print Name: _____

Debtor: _____
(Company Name)

By: _____
(Signature)

Title: _____

Print Name: _____

Debtor: : _____
(Company Name)

By: _____
(Signature)

Title: _____

Print Name: _____

EXHIBIT A
to
Security Agreement

Debtor: _____

Secured Party: McKesson Corporation, for itself and as agent for its affiliates (including D&K Healthcare Resources LLC) Description of Collateral:

All personal property of Debtor, wherever located, including but not limited to all "accounts," "general intangibles," "chattel paper," "documents," "proceeds of letters of credit," "instruments," "investment property," "deposit accounts," "inventory," "fixtures" and "equipment," and all "proceeds" of the foregoing, whether now owned or hereafter acquired, as such terms are defined in Division 9 of the California Uniform Commercial Code in effect on the date hereof. Without limiting the foregoing, the Collateral includes:

1. All present and future accounts, contract rights and general intangibles, including all cash, accounts receivable, insurance proceeds and all right, title, and interest in and to prescription files.

2. All present and future inventory held for resale or lease including, without limiting the generality of the foregoing: all drugs (prescription stock & proprietaries), toiletries, cosmetics, and disposable medical supply items.

durable medical equipment and supplies inventory including items involving respiratory aids, home convalescent aids, and nutritional therapy.

3. All present and future equipment, fixtures and property used by Debtor in its business including, without limiting the generality of the foregoing, all display cases, gondolas, paneling, shelving, sinks, cabinets, furniture, signs, typewriters, cash registers, computers, safes and fountain and refrigeration equipment.

Location of Collateral:

(The listing of locations of the collateral is intended to assist Secured Party in determining where to find the collateral and shall not limit in any way the identity of the collateral. The grant of a security interest in the collateral pertains to collateral wherever located.)

Location of Debtor's Chief Executive Office:

McKESSON
Individual Guaranty

McKesson Corporation and its affiliates, including D&K Healthcare Resources LLC

To: McKesson Corporation

We request McKesson Corporation and its affiliates, including D & K Healthcare Resources LLC, (collectively "you") to extend credit, to make loans or other advances to or otherwise to do business with

Company (Legal & Trade Style Names)

City

State

(called "Debtor"). To induce you to do so, we jointly and severally guarantee to you that Debtor will fully and promptly perform and pay all its present and future obligations to you, whether direct or indirect, joint or several, absolute or contingent, secured or unsecured, matured or unmatured, and whether originally contracted with you or otherwise acquired by you. This guaranty applies to all the Debtor's obligations to you, even if such obligations are invalid or unenforceable against the Debtor for any reason and even if any security for such obligations is insufficient, invalid, unenforceable or not perfected. This guaranty is an absolute and unconditional guaranty of payment. It is a continuing guaranty and covers any future extensions of credit by you to Debtor. This guaranty is a guaranty of payment when due and not merely of collectibility after judgment or other action against Debtor.

We agree, without your first having to proceed against Debtor or any security held by you, to pay on demand (a) all sums due and to become due to you from Debtor and (b) all losses, costs, attorney's fees or expenses which may be suffered by you by reason of Debtor's default on its obligations or our default under this guaranty. We agree to pay on demand any deficiency resulting from a sale of security held by you even if the sale is made without notice to us. Our obligations under this guaranty are independent of and separate from the obligations of Debtor. Upon the occurrence and during the continuance of any default by Debtor, you can sue any one or more of us separately from Debtor, whether or not you sue Debtor in such lawsuit and whether or not you sue Debtor in a separate lawsuit. If you proceed with any course of action under this guaranty or against Debtor, that choice shall not preclude you from taking any other course of action.

This guaranty shall not be affected by the termination or change in the relationship between any of us and Debtor. Each of us assumes all responsibility for keeping informed of (a) Debtor's financial condition and assets, (b) all other circumstances bearing upon the risk of nonpayment of Debtor's obligations to you and (c) the nature, scope and extent of the risks which we assume and incur under this guaranty. We agree that you shall have no duty to advise any of us of information known to you regarding such circumstances or risks. We waive notice of your acceptance of this guaranty and of presentment, demand, protest and notice of non-payment or protest as to any note or obligation signed, accepted, endorsed or assigned to you by Debtor. We also waive any other demands and notices required by law. We also waive all set-offs and counterclaims.

You may at any time, without our consent, without notice to any of us and without affecting or impairing our obligation under this guaranty, do any of the following: (a) renew, modify (including any increase or decrease in the rate of interest), or extend any obligations of Debtor, or co-guarantors (whether hereunder or under a separate agreement) or of any other party at any time directly or contingently liable for the payment of any of Debtor's obligations; (b) enter into additional extensions of credit to Debtor; (c) accept partial payments of Debtor's obligations; (d) settle, release (by operation of law or otherwise), compound, compromise, collect or liquidate any of Debtor's obligations and the security therefor in any manner; (e) consent to the transfer of security; or (f) bid and purchase at any sale of security.

If at any time performance and payment of Debtor's obligations is rescinded or reduced in amount, or if you must return any payments received from Debtor, this guaranty shall be reinstated as to each of us for the amount so reduced or returned.

This guaranty constitutes the complete understanding between you and us. This guaranty may be modified only in writing signed by the party against whom the modification is sought to be enforced. To be binding against you, any modification must be signed by your Vice President-Credit or a higher officer. Any of us may terminate this guaranty only by sending notice to you at One Post Street, San Francisco, CA 94104, Attn: Vice President-Credit by registered mail naming a termination date not less than 90 days after your receipt of such notice. No termination shall be effective as to any of us who has not given such notice. Any termination shall not affect any transaction or credit extended prior to the effective date of termination, and any renewals, extensions or amendments thereof.

We represent that this guaranty has been duly authorized by all necessary corporate action and that its delivery to you does not violate any contracts binding upon any of us. This guaranty shall bind our respective heirs, executors, successors and assigns, and shall inure to your successors and assigns. We waive notice of any assignment of this guaranty by you. This guaranty shall be governed by, and construed in accordance with, the laws of the State of California.

We agree to pay on demand all of your costs and expenses and the fees and disbursements of your counsel (including allocated costs of internal counsel) in connection with (a) the enforcement or attempted enforcement, or preservation of any rights or interests under, this guaranty and (b) any out-of-court workout or other refinancing or restructuring or any bankruptcy case concerning Debtor or us.

The failure of any one of us to sign this guaranty, or the unenforceability of this guaranty against any of us, shall not affect the obligations of the rest of us under this guaranty. All of our obligations under this guaranty are joint and several.

Executed this _____ day of _____, 20____ at _____
city, state

Signature _____ Print Name _____ Social Security # _____

Signature _____ Print Name _____ Social Security # _____

Signature _____ Print Name _____ Social Security # _____

Witness _____ Print Name _____

Promissory Note (Fixed-Rate Monthly Installment Note)

Principal \$ _____

Date _____

For value received, the undersigned "Debtor" promises to pay to McKesson Corporation, a Delaware corporation ("McKesson"), or order, installments as set forth below, the principal sum of _____ dollars. Debtor agrees to pay interest on the unpaid principal sum from the date hereof until paid in full at a rate of _____% per year, calculated monthly on the principal outstanding at the close of business on the last calendar day of each month. All interest shall be computed on the basis of the actual number of days elapsed over a 360-day year. Interest shall be billed separately by McKesson and shall be due on the day of each month.

Principal shall be payable in _____ consecutive monthly installments of \$ _____ each, made on the _____ day of each month, commencing _____, 20_____, and a final installment of \$ _____ on _____, 20_____, at which time any remaining principal and all unpaid accrued interest hereunder shall be due and payable.

In addition to any interest on overdue amounts, Debtor shall pay a late charge equal to 18% per year of each installment delinquent 10 days or more until the delinquency is paid.

Debtor may prepay this Note in whole or in part at any time, without premium or penalty. Each prepayment shall be accompanied by payment of all interest accrued on the amount of such prepayment. Partial prepayments shall be applied to the principal portion of the unpaid installments in reverse chronological order, beginning with the final installment and working backwards until principal has been paid in full. In no event shall a partial prepayment otherwise excuse or delay the due date of any installment of principal or interest. If Debtor desires to prepay in full, Debtor shall request a pay-out figure from McKesson.

Debtor shall make each payment under this Note in immediately available funds, unconditionally in full without set-off, counterclaim or other defense, on the day when due to McKesson by means of pre-authorized electronic debits by McKesson against an account of Debtor at a bank reasonably acceptable to McKesson, or by such other means as may be acceptable to McKesson. Each payment received hereunder shall be applied first to accrued interest and the balance, if any, to the principal.

☐ This note is secured by a Security Agreement dated _____ by and between Debtor and McKesson as secured party.

Failure of Debtor to pay any Note installment within 10 days after written notice to Debtor that the installment is overdue or any default under any Security Agreement constitutes a default under this Note. The holder hereof shall be entitled upon any default under this Note to demand payment of the unpaid principal balance and all accrued interest thereon by written notice to Debtor. Debtor agrees to pay any and all collection costs and reasonable attorney's fees incurred by McKesson in connection herewith.

Except as expressly provided in this Note, Debtor waives presentment, protest, notice of every kind including demand, intent to accelerate maturity, and acceleration of maturity, set-offs and counterclaims and expressly agrees that this Note, or any payment thereunder, may be extended from time to time without in any way affecting the liability of the Debtor thereof.

This Note shall be governed by and construed in accordance with the laws of the State of California. Any provisions hereof contrary to, prohibited by, or invalid under applicable laws or regulations shall be inapplicable and deemed omitted herefrom, but shall not invalidate the remaining provisions hereof. This Note shall bind Debtor's successors and assigns.

Debtor: _____
Full legal name of entity

By: _____
Signature

Print Name

EXHIBIT J-2

**MCKESSON CORPORATION LONG TERM FINANCING DOCUMENTS
(SECURITY AGREEMENT, GUARANTY, FORMS OF PROMISSORY NOTE, CERTIFICATE
OF INSURANCE, RESOLUTION OF BOARD OF DIRECTORS OF CORPORATE
FRANCHISEE, RESOLUTION OF MEMBERS/PARTNERS OF PARTNERSHIP OR LLC
FRANCHISEE, LANDLORD WAIVER, LIFE INSURANCE ASSIGNMENT)
(OPTIONAL FINANCING)**

McKESSON

Individual Guaranty

McKesson Corporation

To: McKesson Corporation

We request McKesson Corporation and its affiliates (collectively "you") to extend credit, to make loans or other advances to or otherwise to do business with

company (legal & trade style names)

city

state

(called "Debtor"). To induce you to do so, we jointly and severally guarantee to you that Debtor will fully and promptly perform and pay all its present and future obligations to you, whether direct or indirect, joint or several, absolute or contingent, secured or unsecured, matured or unmatured, and whether originally contracted with you or otherwise acquired by you. This guaranty applies to all the Debtor's obligations to you, even if such obligations are invalid or unenforceable against the Debtor for any reason and even if any security for such obligations is insufficient, invalid, unenforceable or not perfected. This guaranty is an absolute and unconditional guaranty of payment. It is a continuing guaranty and covers any future extensions of credit by you to Debtor. This guaranty is a guaranty of payment when due and not merely of collectibility after judgment or other action against Debtor.

We agree, without your first having to proceed against Debtor or any security held by you, to pay on demand (a) all sums due and to become due to you from Debtor and (b) all losses, costs, attorney's fees or expenses which may be suffered by you by reason of Debtor's default on its obligations or our default under this guaranty. We agree to pay on demand any deficiency resulting from a sale of security held by you even if the sale is made without notice to us. Our obligations under this guaranty are independent of and separate from the obligations of Debtor. Upon the occurrence and during the continuance of any default by Debtor, you can sue any one or more of us separately from Debtor, whether or not you sue Debtor in such lawsuit and whether or not you sue Debtor in a separate lawsuit. If you proceed with any course of action under this guaranty or against Debtor, that choice shall not preclude you from taking any other course of action.

This guaranty shall not be affected by the termination or change in the relationship between any of us and Debtor. Each of us assumes all responsibility for keeping informed of (a) Debtor's financial condition and assets, (b) all other circumstances bearing upon the risk of nonpayment of Debtor's obligations to you and (c) the nature, scope and extent of the risks which we assume and incur under this guaranty. We agree that you shall have no duty to advise any of us of information known to you regarding such circumstances or risks. We waive notice of your acceptance of this guaranty and of presentment, demand, protest and notice of non-payment or protest as to any note or obligation signed, accepted, endorsed or assigned to you by Debtor. We also waive any other demands and notices required by law. We also waive all set-offs and counterclaims.

You may at any time, without our consent, without notice to any of us and without affecting or impairing our obligation under this guaranty, do any of the following: (a) renew, modify (including any increase or decrease in the rate of interest), or extend any obligations of Debtor, of co-guarantors (whether hereunder or under a separate agreement) or of any other party at any time directly or contingently liable for the payment of any of Debtor's obligations; (b) enter into additional extensions of credit to Debtor; (c) accept partial payments of Debtor's obligations; (d) settle, release (by operation of law or otherwise), compound, compromise, collect or liquidate any of Debtor's obligations and the security therefor in any manner; (e) consent to the transfer of security; or (f) bid and purchase at any sale of security.

If at any time performance and payment of Debtor's obligations is rescinded or reduced in amount, or if you must return any payments received from Debtor, this guaranty shall be reinstated as to each of us for the amount so reduced or returned.

This guaranty constitutes the complete understanding between you and us. This guaranty may be modified only in writing signed by the party against whom the modification is sought to be enforced. To be binding against you, any modification must be signed by your Vice President-Financial Services or a higher officer. Any of us may terminate this guaranty only by sending notice to you at One Post Street, San Francisco, CA 94104, Attn: Vice President-Financial Services by registered mail naming a termination date not less than 90 days after your receipt of such notice. No termination shall be effective as to any of us who has not given such notice. Any termination shall not affect any transaction or credit extended prior to the effective date of termination, and any renewals, extensions or amendments thereof.

We represent that this guaranty has been duly authorized by all necessary corporate action and that its delivery to you does not violate any contracts binding upon any of us. This guaranty shall bind our respective heirs, executors, successors and assigns, and shall inure to your successors and assigns. We waive notice of any assignment of this guaranty by you. This guaranty shall be governed by, and construed in accordance with, the laws of the State of California.

We agree to pay on demand all of your costs and expenses and the fees and disbursements of your counsel (including allocated costs of internal counsel) in connection with (a) the enforcement or attempted enforcement, or preservation of any rights or interests under, this guaranty and (b) any out-of-court workout or other refinancing or restructuring or any bankruptcy case concerning Debtor or us.

(continued on reverse)

The failure of any one of us to sign this guaranty, or the unenforceability of this guaranty against any of us, shall not affect the obligations of the rest of us under this guaranty. All of our obligations under this guaranty are joint and several.

Executed this ____ day of _____, 200 ____ at

city, state

signature

print name

signature

print name

signature

print name

witness

print name

McKESSON
Security Agreement
McKesson Corporation

The undersigned debtor(s) (individually or collectively, "Debtor") hereby grants to McKesson Corporation, a Delaware Corporation ("Secured Party"), a security interest in Debtor's property described in attached Exhibit A, both now owned and hereafter acquired, together with all attachments, replacements, substitutions, additions and accessions, and all cash and non-cash proceeds thereof, all collectively referred to as "Collateral." All items of Collateral shall remain personal property, not become part of any real estate regardless of the manner of affixation and be kept at the locations listed in Exhibit A.

This security interest is granted to secure timely and full payment and performance of all present and future obligations of Debtor to Secured Party (all collectively referred to as the Obligations), including, without limitation, all promissory notes, direct loans, or sales on credit. This security interest shall continue in effect irrespective of any retaking and redelivery of Collateral to Debtor until all Obligations are fully paid in cash.

Debtor's Covenants, Representations, Warranties: Debtor represents and warrants and, so long as any Obligation is owed by Debtor, covenants as follows:

1. All information supplied and statements made by Debtor in any financial statement or application for credit prior to this Agreement are true and correct.
2. Debtor owns the Collateral; and except for the security interest granted hereby and any previously granted security interests disclosed to Secured Party by Debtor in writing, the Collateral will be kept free from all liens and encumbrances.
3. Debtor will maintain and repair the Collateral, keeping it free from unreasonable waste, deterioration or depreciation.
4. Debtor will insure and maintain insurance to protect the Collateral against all loss, damage, or destruction due to fire, theft, and other casualty loss, for the full insurable value plus such other insurance as Secured Party may specify. All such policies relating to the Collateral shall contain an endorsement showing the loss payable to Secured Party or its assignee as their respective interests may appear. Debtor shall furnish evidence of such insurance to Secured Party at least annually. All risk of loss, damage, or destruction of Collateral shall at all times be on Debtor.
5. Debtor shall furnish to Secured Party or its designee financial statements, prepared by its accountants in accordance with generally accepted accounting principles on a basis consistently applied, as follows: monthly statements due 45 days after month-end; reviewed, fiscal-year-end statements due 120 days after the year-end closing.
6. Debtor shall also make available to Secured Party, upon request, (i) Debtor's books of account and records for inspection, examination, abstracting and copying, and (ii) all of Debtor's Collateral and other property (or evidence thereof) for inspection and inventorying.
7. Debtor shall inform Secured Party immediately on the occurrence of any materially adverse change in Debtor's financial condition.
8. Debtor will defend at its own cost any action, proceeding or claim affecting the Collateral.
9. Debtor will pay when due all taxes, assessments, liens or encumbrances, license fees and any other public or private charges levied or assessed against the Collateral or this Agreement or any accompanying note.
10. Debtor's stockholders' capital, capital surplus and retained earnings minus all of its assets which would be classified as intangible assets in accordance with GAAP shall at all times be a positive number.
11. The proceeds of any and all loans and other extensions of credit by Secured Party shall be used for business purposes in connection with the operation of a pharmacy, and not for personal, family or household purposes.
12. Debtor shall execute and deliver any and all documents relating to this transaction, in form satisfactory to Secured Party, to perfect and maintain the security interest granted herein. Debtor hereby authorizes Secured Party to file UCC financing statements without Debtor's signature.
13. Debtor's chief executive office is located at the address specified on Exhibit A. Debtor shall not change its chief executive office or its state of incorporation without giving Secured Party prior written notice of such change.
14. Without written consent from Secured Party, Debtor will not:
 - a. move the Collateral from the locations shown in Exhibit A or change its name or its form or place of business;
 - b. liquidate or merge or consolidate with or into any other corporation;
 - c. assign, cancel, terminate, encumber or otherwise dispose of any existing leases for Debtor's business premises;
 - d. create or assume any indebtedness, except accounts payable and other liabilities incurred in the ordinary course of business;
 - e. declare or pay any dividends or make any return or distribution of cash or property to or among its shareholders except for taxes due under their subchapter S tax election;

- f. reduce the value of the collateral classified as inventory by more than 10% from the amount owned by Debtor at
_____/_____/_____ or to less than \$ _____ (whichever is greater) even in the ordinary course of business.

Default: Any one of the following events shall constitute a default by Debtor hereunder:

1. Failure of Debtor to pay when due any of the Obligations.
2. Failure of Debtor to perform and observe any of the terms, conditions, covenants, obligations, and warranties contained in this Agreement, any supply agreement, or any other agreement between Debtor and Secured Party.
3. Any of Debtor's representations shall be untrue.
4. Secured Party reasonably determines that the Collateral is inadequate to protect Secured Party's interest or that there has occurred or there reasonably may occur a materially adverse change in Debtor's ability to meet any of the Obligations, and Debtor fails to cure the deficiency upon 30 days' notice.
5. Voluntary or (if not dismissed within 60 days) involuntary filing of proceedings under federal or state bankruptcy statutes, or an assignment for the benefit of creditors, or an appointment of a receiver or trustee over Debtor's business.
6. Any guarantor of any of the Obligations shall fail to perform or observe any term, covenant or agreement contained in the guaranty of such guarantor or in any other document signed by such guarantor in connection with such guaranty; or any guaranty or any other document executed by a guarantor in connection with a guaranty shall for any reason be revoked or invalidated, or otherwise cease to be in full force and effect.
7. This Agreement, together with any financing statements or any other document executed in connection herewith, shall cease to create a valid and perfected first priority lien in any of the Collateral purported to be covered hereby.

Remedies:

1. In the event of default, Secured Party shall have all of the rights and remedies of a Secured Party under the Uniform Commercial Code, and any other applicable law, together with the rights and remedies specified hereunder.
2. At the election of Secured Party, after the occurrence of any default, the entire unpaid amount of the Obligations, together with interest accrued thereon, shall become immediately due and payable.
3. Secured Party may demand possession of the Collateral in which case Debtor shall immediately deliver the Collateral to Secured Party at Debtor's expense. Upon taking of the Collateral, Secured Party has the right to sell, lease, or otherwise dispose of it in any commercially reasonable manner pursuant to the provisions of the UCC.
4. Unless otherwise provided by law, any requirement of reasonable notice of sale of the Collateral by Secured Party shall be met if such notice is mailed, postage prepaid, to Debtor at the primary place of business at least five days before the time of the sale or disposition.
5. Debtor shall pay Secured Party all of its expenses of taking, holding, preparing for sale and the like, including reasonable attorney's fees and other legal expenses.
6. With respect to accounts included in the Collateral, Secured Party may and Debtor shall, when requested by Secured Party, notify the account debtors of the security interest created hereunder and the assignment to Secured Party, and authorize the account debtor to make all payments directly to Secured Party. Secured Party may alone, or in conjunction with Debtor, take any and all action necessary to collect the accounts, and in so doing, may have all of Debtor's mail delivered to Secured Party by notifying the postal authorities or may open and dispose of mail addressed to Debtor and execute, sign, and endorse negotiable and other instruments for the payment of money or other evidences of payment, on behalf of and in the name of Debtor, for all of which this shall be deemed a sufficient power of attorney.
7. Failure of Secured Party to exercise any right under this Agreement or any promissory note secured hereby shall not be construed as a waiver of any default.

Other Provisions:

1. This Agreement shall be deemed to constitute a purchase money security interest in any and all Collateral purchased by Debtor either directly from Secured Party (thereby securing payment of the purchase price) or from a third party using proceeds of loans or advances made by Secured Party (thereby securing repayment of such loans or advances).
2. Any provisions hereof contrary to, prohibited by or invalid under applicable laws or regulations shall be inapplicable and deemed omitted herefrom, but shall not invalidate the remaining provisions hereof.
3. This Agreement constitutes the complete understanding between the parties. This Agreement may only be modified or canceled by a written agreement between the parties and signed by the party against whom the modification or cancellation is sought to be enforced.
4. The term "Secured Party" shall include any assignee of Secured Party or any holder of a promissory note or other evidence of the obligations secured hereby. After assignment of this Agreement, Secured Party shall not be the assignee's agent for any purpose.
5. This Agreement shall be binding upon, and shall inure to the benefit of, the respective heirs, executors, successors and assigns of the parties hereto.

6. This Agreement shall be governed by and construed in accordance with the laws of the State of California.

Dated: _____

Secured Party: **McKesson Corporation**

By: _____ Title: _____

Debtor:

By: _____ Title: _____

Debtor:

By: _____ Title: _____

Debtor:

By: _____ Title: _____

EXHIBIT A
to
Security Agreement

Debtor: _____

Secured Party: **McKesson Corporation**

Description of Collateral:

All personal property of Debtor, wherever located, including but not limited to all "accounts," "general intangibles," "chattel paper," "documents," "proceeds of letters of credit," "instruments," "investment property," "deposit accounts," "inventory," "fixtures" and "equipment," and all "proceeds" of the foregoing, whether now owned or hereafter acquired, as such terms are defined in Division 9 of the California Uniform Commercial Code in effect on the date hereof. Without limiting the foregoing, the Collateral includes:

1. All present and future accounts, contract rights and general intangibles, including all cash, accounts receivable, insurance proceeds and all right, title, and interest in and to prescription files.
2. All present and future inventory held for resale or lease including, without limiting the generality of the foregoing:
 - all drugs (prescription stock & proprietaries), toiletries, cosmetics, and disposable medical supply items.
 - durable medical equipment and supplies inventory including items involving respiratory aids, home convalescent aids, and nutritional therapy.
3. All present and future equipment, fixtures and property used by Debtor in its business including, without limiting the generality of the foregoing, all display cases, gondolas, paneling, shelving, sinks, cabinets, furniture, signs, typewriters, cash registers, computers, safes and fountain and refrigeration equipment.

Location of Collateral:

(The listing of locations of the collateral is intended to assist McKESSON in determining where to file financing statements and shall not limit in any way the identity of the collateral. The grant of a security interest in the collateral pertains to collateral wherever located.)

Location of Debtor's Chief Executive Office:

State of Debtor's Incorporation:

MCKESSON CORPORATION

Negotiable Promissory Note (Variable-Rate / Secured)

Principal \$ _____

Date _____

City & State _____

1. **Principal and Interest.** For value received, the undersigned "Debtor" promises to pay to McKesson Corporation, a Delaware corporation ("McKesson"), or order, in installments as set forth below, the *principal* sum of _____ dollars, together with interest on the unpaid principal sum from the date hereof until paid in full at a variable rate equal to the sum of (i) the highest rate of interest published in The Wall Street Journal as constituting the "prime rate" or "base rate" in such publications Table of Money Rates on such date, plus (ii) 2.00% (such sum, the "Interest Rate"); provided, however, at no time shall the Interest Rate hereunder be less than 7.25%. Interest will be billed prior to the due date on the basis of the Interest Rate(s) in effect up to the date of billing and any adjustment required due to a rate change between the billing and due date will be added to or subtracted from the next succeeding billing. All interest shall be computed on the basis of a 360-day year and counting the actual number of days elapsed.

2. **Payment.** Principal shall be payable in _____ consecutive monthly installments of \$ _____ each, together with interest thereon calculated as provided above, made on the first day of each month, commencing , 20 __, and a final installment of \$ _____ on _____, 20 __, at which time any remaining principal and all unpaid accrued interest hereunder shall be due and payable; provided that the full amount of principal and interest shall be due and payable upon the occurrence of any default hereunder or under the Security Agreement (as defined below) and acceleration of the maturity of this Note in accordance with Section 5, below. In addition to any interest on overdue amounts, Debtor shall pay a late charge equal to 1.50% per month of each installment delinquent ten days or more until the delinquency is paid. Debtor shall make each payment under this Note in immediately available funds, unconditionally in full without set-off, counterclaim or other defense, on the day when due to McKesson by means of pre-authorized electronic debits by McKesson against an account of Debtor at a bank reasonably acceptable to McKesson, or by such other means as may be acceptable to McKesson. Each payment received hereunder shall be applied first to accrued interest and the balance, if any, to the principal.

3. **Prepayment.** Debtor may prepay this Note in whole or in part at any time, without premium or penalty. Each prepayment shall be accompanied by payment of all interest accrued on the amount of such prepayment. Partial prepayments shall be applied to the principal portion of the unpaid installments in reverse chronological order, beginning with the final installment and working backwards until principal has been paid in full. In no event shall a partial prepayment otherwise excuse or delay the due date of any installment of principal or interest. If Debtor desires to prepay in full, Debtor shall request a pay-off figure from McKesson.

4. **SECURITY AGREEMENT.** THE OBLIGATIONS UNDER THIS NOTE ARE SECURED BY A SECURITY AGREEMENT OF EVEN DATE HERewith, BETWEEN DEBTOR AND MCKESSON AS SECURED PARTY, AS SUCH SECURITY AGREEMENT MAY BE AMENDED, RESTATED, SUPPLEMENTED OR OTHERWISE MODIFIED FROM TIME TO TIME (THE "SECURITY AGREEMENT").

5. **Default.** Failure of Debtor to pay any Note installment within 10 days after written notice to Debtor that the installment is overdue or any default under the Security Agreement constitutes a default under this Note. The holder hereof shall be entitled upon any default under this Note to demand payment of the unpaid principal balance and all accrued interest thereon by written notice to Debtor. Debtor agrees to pay any and all collection costs and reasonable attorney's fees incurred by McKesson in connection herewith.

6. **Maximum Rate of Interest.** In no event shall the actual amount of interest paid hereunder exceed the legally permissible rate of interest and if the Interest Rate is deemed to be in excess of the legally permissible rate of interest any such excess shall first be applied as a repayment of principal.

7. **Waivers.** Except as expressly provided in this Note, Debtor waives presentment, protest, notice of every kind including demand, intent to accelerate maturity, and acceleration of maturity, set-offs and counterclaims and expressly agrees that this Note, or any payment thereunder, may be extended from time to time without in any way affecting the liability of the Debtor thereof.

8. **Successors and Assigns.** This Note may not be assigned by the Debtor without McKesson's prior written consent. Subject to the foregoing, the rights and benefits of the Debtor and McKesson shall be binding upon and benefit their respective successors, assigns and transferees.

9. **Governing Law.** This Note shall be governed by and construed in accordance with the laws of the State of California. Any provisions hereof contrary to, prohibited by, or invalid under applicable laws or regulations shall be inapplicable and deemed omitted here from, but shall not invalidate the remaining provisions hereof.

[Debtor]_____

By_____Title_____

Negotiable Promissory Note (Variable-Rate Note)**McKesson Corporation**

Principal \$ _____

Date _____

City & State _____

For value received, the undersigned "Debtor" promises to pay to McKesson Corporation, a Delaware corporation ("McKesson"), or order, in installments as set forth below, the *principal* sum of

_____ dollars. Debtor agrees to pay interest on the unpaid principal sum from the date hereof until paid in full at a rate of ____% per year above the "Reference Rate" announced from time to time by Bank of America NT&SA in San Francisco, California. Interest will be billed prior to the due date on the basis of the Reference Rate in effect up to the date of billing and any adjustment required due to a rate change between the billing and due date will be added to or subtracted from the next succeeding billing. All interest shall be computed on the basis of a 360-day year and counting the actual number of days elapsed.

Principal shall be payable in _____ consecutive monthly installments of \$ _____ each, made on the first day of each month, commencing _____, 20____, and a final installment of \$ _____ on _____, 20____, at which time any remaining principal and all unpaid accrued interest hereunder shall be due and payable; provided that the full amount of principal and interest shall be due and payable if Debtor ceases to use McKesson as its primary supplier of pharmaceuticals, health and beauty care products, and durable medical equipment and supplies.

Debtor has delivered to McKesson a promissory note dated _____, 20____ in the amount of \$ _____ (the "Prior Note") which was secured by a security agreement dated _____, 20____ and which may have been partially repaid. This Note represents a restructuring of the terms of the Prior Note. This Note is issued not in payment of the debt evidenced by the Prior Note but as evidence of the prior debt as restructured. This Note shall be secured by the original security agreement, as amended from time to time, and all other collateral delivered by Debtor to McKesson as security for the payment of the Prior Note.

In addition to any interest on overdue amounts, Debtor shall pay a late charge equal to 1.50% per month of each installment delinquent 10 days or more until the delinquency is paid.

Debtor may prepay this Note in whole or in part at any time, without premium or penalty. Each prepayment shall be accompanied by payment of all interest accrued on the amount of such prepayment. Partial prepayments shall be applied to the principal portion of the unpaid installments in reverse chronological order, beginning with the final installment and working backwards until principal has been paid in full. In no event shall a partial prepayment otherwise excuse or delay the due date of any installment of principal or interest. If Debtor desires to prepay in full, Debtor shall request a pay-out figure from McKesson.

Debtor shall make each payment under this Note in immediately available funds, unconditionally in full without set-off, counterclaim or other defense, on the day when due to McKesson by means of pre-authorized electronic debits by McKesson against an account of Debtor at a bank reasonably acceptable to McKesson, or by such other means as may be acceptable to McKesson. Each payment received hereunder shall be applied first to accrued interest and the balance, if any, to the principal.

This Note is secured by a Security Agreement of even date by and between Debtor and McKesson as secured party. This Note shall bind Debtor's successors and assigns.

Failure of Debtor to pay any Note installment within 10 days after written notice to Debtor that the installment is overdue or any default under the Security Agreement constitutes a default under this Note. The holder hereof shall be entitled upon any default under this Note to demand payment of the unpaid principal balance and all accrued interest thereon by written notice to Debtor.

Debtor agrees to pay any and all collection costs and reasonable attorney's fees incurred by McKesson in connection herewith.

Except as expressly provided in this Note, Debtor waives presentment, protest, notice of every kind including demand, intent to accelerate maturity, and acceleration of maturity, set-offs and counterclaims and expressly agrees that this Note, or any payment thereunder, may be extended from time to time without in any way affecting the liability of the Debtor thereof.

This Note shall be governed by and construed in accordance with the laws of the State of California. Any provisions hereof contrary to, prohibited by, or invalid under applicable laws or regulations shall be inapplicable and deemed omitted herefrom, but shall not invalidate the remaining provisions hereof.

[Debtor] _____

By _____ Title _____

McKESSON

Negotiable Promissory Note (Variable-Rate Note)

McKesson Corporation

Principal \$ _____

Date _____

City & State _____

For value received, the undersigned "Debtor" promises to pay to McKesson Corporation, a Delaware corporation ("McKesson"), or order, in installments as set forth below, the *principal* sum of

_____ dollars. Debtor agrees to pay interest on the unpaid principal sum from the date hereof until paid in full at a rate of _____% per year above the "Reference Rate" announced from time to time by Bank of America NT&SA in San Francisco, California. Interest will be billed prior to the due date on the basis of the Reference Rate in effect up to the date of billing and any adjustment required due to a rate change between the billing and due date will be added to or subtracted from the next succeeding billing. All interest shall be computed on the basis of a 360-day year and counting the actual number of days elapsed.

Principal shall be payable in _____ consecutive monthly installments of \$ _____ each, made on the first day of each month, commencing _____, 20____, and a final installment of \$ _____ on _____, 20____, at which time any remaining principal and all unpaid accrued interest hereunder shall be due and payable; provided that the full amount of principal and interest shall be due and payable if Debtor ceases to use McKesson as its primary supplier of pharmaceuticals, health and beauty care products, and durable medical equipment and supplies.

Debtor has delivered to McKesson a promissory note dated _____, 20____ in the amount of \$ _____ (the "Prior Note") which was secured by a security agreement dated _____, 20____ and which may have been partially repaid. This Note represents an additional debt of \$ _____ of Debtor added to the balance of the Prior Note. This Note is issued not in payment of the debt evidenced by the Prior Note but as evidence of the prior debt as increased. This Note shall be secured by the original security agreement, as amended from time to time, and all other collateral delivered by Debtor to McKesson as security for the payment of the Prior Note.

In addition to any interest on overdue amounts, Debtor shall pay a late charge equal to 1.50% per month of each installment delinquent 10 days or more until the delinquency is paid.

Debtor may prepay this Note in whole or in part at any time, without premium or penalty. Each prepayment shall be accompanied by payment of all interest accrued on the amount of such prepayment. Partial prepayments shall be applied to the principal portion of the unpaid installments in reverse chronological order, beginning with the final installment and working backwards until principal has been paid in full. In no event shall a partial prepayment otherwise excuse or delay the due date of any installment of principal or interest. If Debtor desires to prepay in full, Debtor shall request a pay-out figure from McKesson.

Debtor shall make each payment under this Note in immediately available funds, unconditionally in full without set-off, counterclaim or other defense, on the day when due to McKesson by means of pre-authorized electronic debits by McKesson against an account of Debtor at a bank reasonably acceptable to McKesson, or by such other means as may be acceptable to McKesson. Each payment received hereunder shall be applied first to accrued interest and the balance, if any, to the principal.

This Note is secured by a Security Agreement of even date by and between Debtor and McKesson as secured party. This Note shall bind Debtor's successors and assigns.

Failure of Debtor to pay any Note installment within 10 days after written notice to Debtor that the installment is overdue or any default under the Security Agreement constitutes a default under this Note. The holder hereof shall be entitled upon any default under this Note to demand payment of the unpaid principal balance and all accrued interest thereon by written notice to Debtor.

Debtor agrees to pay any and all collection costs and reasonable attorney's fees incurred by McKesson in connection herewith.

Except as expressly provided in this Note, Debtor waives presentment, protest, notice of every kind including demand, intent to accelerate maturity, and acceleration of maturity, set-offs and counterclaims and expressly agrees that this Note, or any payment thereunder, may be extended from time to time without in any way affecting the liability of the Debtor thereof.

This Note shall be governed by and construed in accordance with the laws of the State of California. Any provisions hereof contrary to, prohibited by, or invalid under applicable laws or regulations shall be inapplicable and deemed omitted here from, but shall not invalidate the remaining provisions hereof.

[Debtor] _____

By _____ Title _____

McKESSON

Negotiable Promissory Note (Variable-Rate Note)

McKesson Corporation

Principal \$ _____

Date _____

City & State _____

For value received, the undersigned "Debtor" promises to pay to McKesson Corporation, a Delaware corporation ("McKesson"), or order, in installments as set forth below, the *principal* sum of _____

_____ dollars. Debtor agrees to pay interest on the unpaid principal sum from the date hereof until paid in full at a rate of _____% per year above the "Reference Rate" announced from time to time by Bank of America NT&SA in San Francisco, California. Interest will be billed prior to the due date on the basis of the Reference Rate in effect up to the date of billing and any adjustment required due to a rate change between the billing and due date will be added to or subtracted from the next succeeding billing. All interest shall be computed on the basis of a 360-day year and counting the actual number of days elapsed.

Principal shall be payable in _____ consecutive monthly installments of \$ _____ each, made on the first day of each month, commencing _____, 20 __, and a final installment of \$ _____ on _____, 20 __, at which time any remaining principal and all unpaid accrued interest hereunder shall be due and payable; provided that the full amount of principal and interest shall be due and payable if Debtor ceases to use McKesson as its primary supplier of pharmaceuticals, health and beauty care products, and durable medical equipment and supplies.

Debtor has delivered to McKesson a promissory note dated _____, 20 __ in the amount of \$ _____ (the "Prior Note") which was secured by a security agreement dated _____, 20 __ and which may have been partially repaid. This Note represents an additional debt of \$ _____ of Debtor and a restructuring of the terms of the Prior Note as increased. This Note is issued not in payment of the debt evidenced by the Prior Note but as evidence of the prior debt as increased and restructured. This Note shall be secured by the original security agreement, as amended from time to time, and all other collateral delivered by Debtor to McKesson as security for the payment of the Prior Note.

In addition to any interest on overdue amounts, Debtor shall pay a late charge equal to 1.50% per month of each installment delinquent 10 days or more until the delinquency is paid.

Debtor may prepay this Note in whole or in part at any time, without premium or penalty. Each prepayment shall be accompanied by payment of all interest accrued on the amount of such prepayment. Partial prepayments shall be applied to the principal portion of the unpaid installments in reverse chronological order, beginning with the final installment and working backwards until principal has been paid in full. In no event shall a partial prepayment otherwise excuse or delay the due date of any installment of principal or interest. If Debtor desires to prepay in full, Debtor shall request a pay-out figure from McKesson.

Debtor shall make each payment under this Note in immediately available funds, unconditionally in full without set-off, counterclaim or other defense, on the day when due to McKesson by means of pre-authorized electronic debits by McKesson against an account of Debtor at a bank reasonably acceptable to McKesson, or by such other means as may be acceptable to McKesson. Each payment received hereunder shall be applied first to accrued interest and the balance, if any, to the principal.

This Note is secured by a Security Agreement of even date by and between Debtor and McKesson as secured party. This Note shall bind Debtor's successors and assigns.

Failure of Debtor to pay any Note installment within 10 days after written notice to Debtor that the installment is overdue or any default under the Security Agreement constitutes a default under this Note. The holder hereof shall be entitled upon any default under this Note to demand payment of the unpaid principal balance and all accrued interest thereon by written notice to Debtor.

Debtor agrees to pay any and all collection costs and reasonable attorney's fees incurred by McKesson in connection herewith.

Except as expressly provided in this Note, Debtor waives presentment, protest, notice of every kind including demand, intent to accelerate maturity, and acceleration of maturity, set-offs and counterclaims and expressly agrees that this Note, or any payment thereunder, may be extended from time to time without in any way affecting the liability of the Debtor thereof.

This Note shall be governed by and construed in accordance with the laws of the State of California. Any provisions hereof contrary to, prohibited by, or invalid under applicable laws or regulations shall be inapplicable and deemed omitted here from, but shall not invalidate the remaining provisions hereof.

[Debtor] _____

By _____ Title _____

To: _____

Gentlemen:

We are presently obligated to McKesson Corporation under a Security Agreement in connection with financing of certain assets briefly described below.

It will be appreciated if you would fill out, execute, and mail the Certificate of Insurance appearing below.

Your courtesy in issuing and forwarding the requested instrument at your earliest convenience will be appreciated.

Insured

By: _____

Title

Date: _____

CERTIFICATE OF INSURANCE

Reference: Policy# _____ Expiring: _____ Amount \$ _____

With _____

(Name and Address of Insurance Company)

This is to certify that the insurer named herein has issued to the insured named herein the above referenced insurance policy which insures against loss or damage by fire, lightning and the usual supplemental extended coverages. The said policy is hereby extended to cover the interests of McKesson Corporation at:

(local address)

In the event of any material change in or cancellation of said policy, notice thereof will be mailed to McKesson Corporation 10 days in advance of such change or cancellation.

Name and address of Insured: _____

Location and Description
of Insured Property

Name and address
of issuing company

Issued by: _____ Date of Issue: _____

(Authorized Representative)

McKESSON

Resolution of Board of Directors

McKesson Corporation

Name of Corporation

I, _____, hereby certify that I am the duly elected Secretary and official custodian of certain records including the charter, by-laws and the minutes of the meetings of the Board of Directors of the above named corporation which is duly organized and existing under the laws of the State of _____, and that the following is a true, accurate and complete transcript of resolutions contained in the minute book of the Corporation, duly adopted at a meeting of the Board of Directors of said Corporation duly held on the ____ day of _____, 20 ____, at which meeting there was present and acting throughout a quorum authorized to transact the business hereinafter described, and that the proceedings of said meeting were in accordance with the charter and by-laws of said Corporation, and that said resolutions have not been amended or revoked and are in full force and effect.

Whereas, this Corporation is indebted to McKesson Corporation, its divisions, subsidiaries and affiliates (collectively, "McKesson"), and may from time to time be indebted to McKesson, for loans made, goods sold and/or services rendered to this corporation by McKesson;

Whereas, McKesson has requested that this corporation grant to McKesson a security interest(s) in any or all of the assets of this corporation to secure the aforesaid indebtedness;

Whereas, it is to the best interest and advantage of this corporation to grant such security interest(s) to McKesson;

Now, therefore, be it resolved, that each of the officers of this corporation named below, or his duly elected successor in office, is hereby authorized and empowered on behalf of this corporation to:

Execute and deliver to McKesson, all notes, instruments, and agreements required by McKesson to evidence present and/or future indebtedness owing. Such notes, instruments, and agreements shall be in the form required by McKesson and may include any charges and interest, and may be payable on demand or in installments as such officer may agree to by his signature thereon;

Do any and all acts required from time to time by McKesson to execute and deliver all instruments and agreements to secure the aforesaid indebtedness and to grant to McKesson and its assigns a security interest in any or all present and future assets of this corporation, including, without limiting the generality of the foregoing, inventory held for resale or lease; equipment, fixtures and property used by Debtor in its business; accounts, contract rights and general intangibles, including all cash, accounts receivable, insurance proceeds (as used in the Security Agreement "accounts"); and all right, title, and interest in and to prescription files; and in the proceeds and products of the foregoing.

Do all further acts and things, as McKesson or the officer(s) deem necessary or proper in connection with the aforesaid indebtedness and the collateral securing said indebtedness, and that the doing of any such acts or things and the execution of any such instruments, agreements and documents shall be considered for all purposes as full and conclusive proof that the same was deemed necessary and proper by the officer(s) doing or executing the same, and all such acts, instruments, documents and agreements shall be binding on this corporation;

Resolved, that the officers referred to in the foregoing resolutions are as follows:

_____, President
_____, Vice President
_____, Treasurer
_____, Secretary

Resolved, that McKesson and any assignee of McKesson are authorized to rely upon the aforesaid resolutions until receipt of written notice of any change.

In witness hereof, I have hereunto set my hand and affixed the seal of said Corporation this ____ day of _____, 20 ____.

By _____

Secretary

(Corporate Seal)

Consent of Stockholders

The undersigned, being the legal and beneficial owners and holders of all of the issued and outstanding capital stock of

,

do hereby in all respects approve, confirm and ratify all of the matters and actions authorized in the foregoing resolutions of the Board of Directors of said Corporation.

Stockholder	Stock Owned
By _____	_____ %
By _____	_____ %
By _____	_____ %
By _____	_____ %

McKESSON

Resolution of Members/Partners

McKesson Corporation

Name of Limited Liability Company or Partnership ("Company")

[\[insert name and specify whether it is an LLC or a partnership\]](#)

Whereas, this Company is indebted to McKesson Corporation, its divisions, subsidiaries and affiliates (collectively, "McKesson"), and may from time to time be indebted to McKesson, for loans made, goods sold and/or services rendered to this Company by McKesson;

Whereas, McKesson has requested that this Company grant to McKesson a security interest(s) in any or all of the assets of this Company to secure the aforesaid indebtedness;

Whereas, it is to the best interest and advantage of this Company to grant such security interest(s) to McKesson;

Now, therefore, be it resolved, that each of the managers of this Company named below is hereby authorized and empowered on behalf of this Company to:

Execute and deliver to McKesson all notes, instruments, and agreements required by McKesson to evidence present and/or future indebtedness owing. Such notes, instruments, and agreements shall be in the form required by McKesson and may include any charges and interest, and may be payable on demand or in installments as such manager may agree to by his or her signature thereon;

Do any and all acts required from time to time by McKesson to execute and deliver all instruments and agreements to secure the aforesaid indebtedness and to grant to McKesson and its assigns a security interest in any or all present and future assets of this Company, including, without limiting the generality of the foregoing, inventory held for resale or lease; equipment, fixtures and property used by this Company in its business; accounts, contract rights and general intangibles, including all cash, accounts receivable, and insurance proceeds; and all right, title, and interest in and to prescription files; and the proceeds and products of the foregoing;

Do all further acts and things, as McKesson or the manager deem necessary or proper in connection with the aforesaid indebtedness and the collateral securing said indebtedness, and that the doing of any such acts or things and the execution of any such instruments, agreements and documents shall be considered for all purposes as full and conclusive proof that the same was deemed necessary and proper by the manager doing or executing the same, and all such acts, instruments, documents and agreements shall be binding on this Company; and

Resolved, that the managers referred to in the foregoing resolutions are as follows:

_____ (signature)	_____ (print or type name)
_____ (signature)	_____ (print or type name)
_____ (signature)	_____ (print or type name)
_____ (signature)	_____ (print or type name)

Resolved, that McKesson and any assignee of McKesson are authorized to rely upon the aforesaid resolutions until receipt of written notice of any change.

The undersigned, being all of the members or partners and holders of all of the membership or partnership interest in the Company, do hereby in all respects adopt, approve, confirm and consent to all of the matters and actions authorized in the foregoing resolutions.

Member/Partner Signature	Percentage Interest	Print Name
_____	_____ %	_____
_____	_____ %	_____
_____	_____ %	_____
_____	_____ %	_____

McKESSON
McKesson Corporation

LANDLORD'S WAIVER AND CONSENT (Plans 88, 96)

To: McKesson Corporation, Secured Party

In consideration of the loan to be made by the above-named secured party to

_____ to be secured in whole or in part

Debtor

by a security agreement covering the following described personal property:

1. All present and future accounts, contract rights and general intangibles, including all cash, accounts receivable, insurance proceeds (as used in the Security Agreement "accounts"), and all right, title, and interest in and to prescription files.
2. All present and future inventory held for resale or lease including, without limiting the generality of the foregoing:
 - all drugs (prescription stock & proprietaries), toiletries, cosmetics, and disposable medical supply items.
 - durable medical equipment and supplies inventory including items involving respiratory aids, home convalescent aids, and nutritional therapy.
3. All present and future equipment, fixtures and property used by Debtor in its business including, without limiting the generality of the foregoing, all display cases, gondolas, paneling, shelving, sinks, cabinets, furniture, signs, typewriters, cash registers, computers, safes, and fountain and refrigeration equipment.

hereinafter referred to as "collateral", now located or to be located at:

(address of location of collateral, including city, state and zip)

(hereinafter called the "premises"), the undersigned landlord of the premises by these presents consents to aid installation and does waive and relinquish to the secured party all right of levy for rent and all claims and demands of every kind against the collateral, this waiver to continue until full compliance by the debtor with all the terms and conditions of the security agreement and with any extensions or renewals thereof. The undersigned agrees that the collateral shall not become part of the freehold and may be repossessed by the secured party at any time.

WITNESS the hand and seal of the undersigned landlord,

***NOTARY ACKNOWLEDGEMENT

Date_____

(ON BACK) REQUIRED***

Landlord_____

By_____

Title_____

If corporation, have signed by president, vice -
president, or treasurer. If owner or partner, state which.

To: _____

Gentlemen:

Please refer to life insurance policy # _____

Now in force/to be written for me in the amount of \$ _____

covering _____

at _____

Please make a collateral assignment (loss payable clause) in favor of McKesson Corporation "as interest may appear"
and send a copy to McKesson Corporation,

attention _____,

_____.

Sincerely,

By _____

EXHIBIT K
FRANCHISE HANDBOOK TABLE OF CONTENTS

EXHIBIT K

FRANCHISE HANDBOOK TABLE OF CONTENTS

HEALTH MART FRANCHISE HANDBOOK

TABLE OF CONTENTS

I. Clinical Services (184 pages)

- Nutrient Depletion
- Medication Therapy Management
- Prescriptive Authority
- Health Screenings and Testing Services
- Disease States
- Medication Synchronization

II. Controlled Substance Resources (69 pages)

- Rules, Regulations & News
- Practices for Dispensing
- Patient Care
- Disposal
- Combating Opioid Misuse

III. Diabetes Care (140 pages)

- Get Started
- Help Patients Know Their Prediabetes Risk
- Billing for Diabetes Products and Services
- Front End Support

IV. Education and Training (31 pages)

- Health Mart University
- Quality and Performance

- Technician Training
- Smart Retailing Newsletter
- Optional Services
- Tools and Resources

V. Forms (3 pages)

VI. Front End (6 pages)

- Store Extras
- Store Development and Design

VII. Franchise Requirements and Resources (22 pages)

- What's Required
- Programs
- Resources

VIII. HIV AIDS Resources (39 pages)

- Learn about the PrEP Program in FAQs-Not for Patient Distribution
- How to Enroll
- Training for Ready, Set, PrEP
- Find Your Store in the Pharmacy Locator
- Marketing

IX. Managed Care (13 pages)

- Medicare
- Coupon Programs
- Insurance Marketplace Resources
- Pharmacy Services Administration Organizations (PSAO)

X. Marketing (152 pages)

- Local Marketing Support
- Matching Funds Policy
- Optional Services

- Resources

XI. myHealthMart Resource Guide (22 pages)

- Module 1
- Module 2
- Module 3
- Module 4
- Module 5
- Module 6

XII. Operations (63 pages)

- Business Opportunities
- Common Practices
- Product Restrictions
- Monthly Calendar
- Disaster Recovery

XIII. Performance and Quality (92 pages)

- Why Performance and Quality Matter
- Improve Performance and Quality
- Tools and Resources
- Prescriber Partnerships

XIV. Products and Supplies (3 pages)

- Discounts
- Supplies
- Generics

XV. Regulatory Resources (30 pages)

- USP <800>
- Bula Intelligence Tool
- REMS
- Federal Topics

XVI. Reports (1 page)

TOTAL PAGES - 870

EXHIBIT L-1

LIST OF OPERATIONAL FRANCHISEES AS OF MARCH 31, 2022

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
BERNIES PHARMACY	Teresa Hall	4100 LAKE OTIS PKWY 200	ANCHORAGE	AK	99508	907-5622138
WHALE TAIL PHARMACY	JULIE MCDONALD	333 COLD STGE RD STE 103	CRAIG	AK	99921	907-8265750
MEDICAL CENTER FAIRBANKS	GERLAD BROWN	1867 AIRPORT ROAD #105	FAIRBANKS	AK	99701	907-4522328
PETERSBURG RX (BOX) ELINK	Cate Kowalski	215 N NORDIC DR	PETERSBURG	AK	99833	907-7723265
MIKES DISCOUNT PHCY BIR	Mike Pitzing	201 KIRKLAND ST	ABBEVILLE	AL	36310	334-5852288
BROOKLERE PHARMACY NO 102	Anthony Brooklere	3633 GRAY AVENUE	ADAMSVILLE	AL	35005	205-6741400
ADDISON DISCOUNT PHARMACY	David Godbee	30910 HIGHWAY 278 POB 180	ADDISON	AL	35540	256-7476342
BLAIR PHARMACY	Daniel Blair	81 WEATHERLY CLB DR STE A	ALABASTER	AL	35007	205-3583470
BROOKLERE PHARMACY HM 301	Johnny Brooklere	205 BUCK CREEK PLAZA	ALABASTER	AL	35007	205-6641200
ALBERTVILLE DISCOUNT PHCY	Brett Hulan	422 NORTH BROAD ST	ALBERTVILLE	AL	35950	256-8781515
FOODLAND DISCOUNT PHCY	Rodney Crowell	313 E SAND MTN DRIVE	ALBERTVILLE	AL	35950	256-8786930
BRINDLEY'S FAMILY PHCY	Steve Brindley	209 SAND MOUNTAIN DR E	ALBERTVILLE	AL	35950	256-8782111
CARLISLE DRUG COMPANY	Daniel Champion	839 AIRPORT DRIVE #101	ALEXANDER CITY	AL	35010	256-3290900
JACKSON DISCOUNT DRUGS	Dion James	1974 CHEROKEE RD	ALEXANDER CITY	AL	35010	256-2342538
MEDICINE EXPRESS FAM PHCY	Sherry Tremelling	1144 AIRPORT DR.	ALEXANDER CITY	AL	35010	256-2158014
DOWNEY DRUG ALEXANDR HM	Paul Graham	658 VALLEY CUB DR	ALEXANDRIA	AL	36250	256-8204540
GENTRY DRUGS	Phil Gentry	551 MEMORIAL PKWY E	ALICEVILLE	AL	35442	205-3736688
ANDERSON PHARMACY HM	Gabriel Argo	7101 ETOWAH ST	ALTOONA	AL	35952	205-5896557
SNEAD DISCOUNT PHARMACY	John Gentry	87458 US HWY 278-E POB510	ALTOONA	AL	35952	205-4667990
MALLETTE DRUG CO HM	Tavia Tillman	837 S THREE NOTCH STPO327	ANDALUSIA	AL	36420	334-2221141
DOWNEY DRUGS HM	Johnnie Ellis	2427 HWY 202	ANNISTON	AL	36201	256-2379426
HIGHLAND HEALTH SYSTEMS	Kevin Blanchet	331 EAST 8TH ST	ANNISTON	AL	36202	256-2363403
LATHAMS DRUG HM	Steve Parrish	178 SOUTH MAIN ST	ARAB	AL	35016	256-5864132
PARKWAY PHARMACY HM	Terry Bennett	606 BRINDLEE MTN PKWY NOR	ARAB	AL	35016	256-5864120
JONES DISCOUNT PHCY HM	Tiffany Jones - Elrod	1036 N BRINDLEE MTN PKWY	ARAB	AL	35016	256-5863179
JONES DRUG HM	Nick Holland	30508 ARDMORE AVENUE	ARDMORE	AL	35739	256-4232155

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
CENTRAL PHARMACY WESTSIDE	FADI NUSEIBEH	4801 W SAGINAW HWY	LANSING	MI	48917	517-8334629
CENTRAL PHCY-MT. HOPE	FADI NUSEIBEH	1001 E MOUNT HOPE AVE	LANSING	MI	48910	517-3160711
CENTRAL PHCY MLK	FADI NUSEIBEH	3500 S MARTIN LUTHER KING JR BLVD	LANSING	MI	48910	517-5745015
CENTRAL PHCY-PATIENT CARE	Fadi Nuseibeh	3955 PATIENT CAREWAY	LANSING	MI	48911	517-3931000
QUALITY MED RX	Jon Sanford	1601 E MICHIGAN AVE	LANSING	MI	48912	517-8991680
MED CARE PHCY	AYAD SALEM	28500 SOUTHFIELD RD #300	LATHRUP VILLAGE	MI	48076	248-5599901
SOUTHFIELD PHARMACY LLC	David Yoon	26237 SOUTHFIELD	LATHRUP VILLAGE	MI	48076	248-7284960
LENOX COMMUNITY PHY	CHRISTOPHER HANAI	36267 26 MILE ROAD #1	LENOX	MI	48048	586-6486703
CET PHARMACY SERVICE	Abdul Chudry	25880 W OUTER DR	LINCOLN PARK	MI	48146	734-5024293
GET WELL PHARMACY	Kassem Kleit	1770 FORT STREET	LINCOLN PARK	MI	48146	734-9272878
PHARMOR LINCOLN PK.	NABEEL ALBADANY	4150 DIX HWY	LINCOLN PARK	MI	48146	313-3823802
FAMILY CARE PHARMACY	SAM ATTO	3782 FORT STREET	LINCOLN PARK	MI	48146	313-3819200
MEDPULSE PHARMACY LLC	Ankush Sharma	37595 W 7 MILE ROAD	LIVONIA	MI	48152	734-7447174
LIVONIA FAMILY PHCY	Arjun Ajbani	15983 MIDDLEBELT	LIVONIA	MI	48154	734-7447636
MERRIMAN PHARMACY	Fadi Nuseibeh	31320 5 MILE RD	LIVONIA	MI	48154	734-4273430
TOP CARE PHCY HM	Miriam Hamadi	27493 SIX MILE ROAD	LIVONIA	MI	48152	734-7621500
LIVONIA PHARMACY	ROSAIAH KAVURI	17888 FARMINGTON RD	LIVONIA	MI	48152	734-7448110
THE PHARMACY SHOP	JEFF CHEHAB	28411 DEQUINDRE ROAD	MADISON HEIGHTS	MI	48071	248-5915555
PUTVIN DRUG HM	MARK ROHDE	211 S CEDAR STREET	MANISTIQUE	MI	49854	906-3415494
MEDICINE TREE PHARMACY	Krish Kandagatla	56109 VILLAGE CENTER CIR	MATTAWAN	MI	49071	269-6686801
MELVINDALE PHARMACY HM	Ali Elhasan	18287 ALLEN ROAD	MELVINDALE	MI	48122	313-3860889
MEMPHIS DRUGS	Hussein Smidi	80850 MAIN STREET	MEMPHIS	MI	48041	810-3922424
PUTVIN DRUG STORE HM	Jeff DeFrancisco	119 ELM STREET	MUNISING	MI	49862	906-3872248
MAPLE VALLEY PHCY	Fadi Nuseibeh	219 MAIN ST	NASHVILLE	MI	49073	517-6154700
NEWBERRY HOMETOWN PHCY	DAVID DEMERSE	7344 STATE HWY M-123	NEWBERRY	MI	49868	906-2939900
NEWPORT PHARMACY	Abraham Berro	7825 N DIXIE HWY STE 105	NEWPORT	MI	48166	734-8721490

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
THE DRUG STORE ASHLAND HM	Jana Wheeler	83871 HIGHWAY 9	ASHLAND	AL	36251	256-3543784
ASHLAND PHARMACY INC HM	Michelle Phillips	83074 HWY 9 P.O. BOX 487	ASHLAND	AL	36251	256-3542166
ASHVILLE DRUGS, INC	Curt Eddy	35767 US HWY 231	ASHVILLE	AL	35953	205-5947088
EASTSIDE PHY&COMPOUNDING	Billy Cannon	1406 LINDSAY LANE S STE A	ATHENS	AL	35613	256-2337070
HOMETOWN PHCYOFLIMESTONE	BILLY CANNON	100 HWY 31 STE H	ATHENS	AL	35611	256-2328448
LIMESTONE DRUG HM	Chandler Willingham	200 W MARKET ST BOX 709	ATHENS	AL	35612	256-2323811
WESTSIDE JIFFY PHARMACY	Charles Hill	1204 W MARKET ST	ATHENS	AL	35611	800-5555555
ATHENS CREEKSIDE DRUGS	Mark Jackson	605 HWY 31 S SUITE D	ATHENS	AL	35611	256-2328274
ATHENS PHARMACY	PHILLIP PRESLEY	705 WEST MARKET	ATHENS	AL	35611	256-2322242
BUY RITE DRUGS 10	PAULA NORMAN	400 MEDICAL PARK DRIVE	ATMORE	AL	36502	251-3687378
RICKS DISCOUNT PHCY HM	Rick Bearden	1433 3RD ST SW	ATTALLA	AL	35954	256-5385850
OUR HOME PHARMACY HM	Craig Hyatt	2320 MOORES MILL RD	AUBURN	AL	36830	334-8878780
THE DRUG STORE	Lisa Leonard	464 N. DEAN RD	AUBURN	AL	36830	334-8214493
BERRY DISCOUNT APOTHECARY	CHRIS CANNON	31 DEPOT STREET	BERRY	AL	35546	205-6894777
EASTERN VALLEY DRUG HM	Charles Prickett	1310 EASTERN VALLEY RD	BESSEMER	AL	35020	205-4255258
FMS #3 RX HM	Patrick Devereux	1817 13TH AVE N	BESSEMER	AL	35020	205-4243194
HINKLE PHARMACY HM	Taner Hinkle	1090 9TH AVE SW	BESSEMER	AL	35022	205-4253039
ROCK CREEK PHCY	Teri Wade	6817 WARRIOR RIVER RD	BESSEMER	AL	35023	205-4978777
HOMETOWN PHCY SERVICES	Tim Mullins	519 WEST TOWN PLAZA	BESSEMER	AL	35020	205-4261922
BIRMINGHAM APOTHECARY	Ankit Patel	1032 SOUTH 20TH STREET	BIRMINGHAM	AL	35205	205-2514248
MILLS PHCY AT PARKWAY	BEETINA LONG	9709 PARKWAY EAST SUITE F	BIRMINGHAM	AL	35215	205-4539889
MILLS PHY AT WOODLAWN	BEETINA LONG	6501 1ST AVE NORTH	BIRMINGHAM	AL	35206	205-5917800
CITIZEN EXPRESS PHARMACY	Delmous Vance	1513 5TH AVE N	BIRMINGHAM	AL	35203	205-3238374
GIBSON DISCOUNT PHCY HM	James George	1133 LOMB AVE SW	BIRMINGHAM	AL	35211	205-7874692
LIBERTY PHARMACY	Jim Parekh	3735 CORP WOODS DR ST 101	BIRMINGHAM	AL	35242	205-9779290
VACCA DISCOUNT DRUG CO	John Vacca	7633 Georgia Road S.	BIRMINGHAM	AL	35212	205-9563300

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
KEYSTONE SPCLTY CARE PHCY	Hala Bazzi-Lang	46325 W 12 MILE RD STE 150	NOVI	MI	48377	248-2673004
ARBOR LANE PHCY-FOX RUN	OSAMA FAKIH	41100 FOX RUN ROAD	NOVI	MI	48377	248-6688778
OAK PARK RX	Linda Askar	24651 COOLIDGE HWY	OAK PARK	MI	48237	800-5555555
GOOD HEALTH PHCY HM	Wissam Beydoun	15300 W NINE MILE RD - STE 2	OAK PARK	MI	48237	248-5410600
MERCURY DRUGS	YASMINE Abdelhamed	22150 COOLIDGE HWY	OAK PARK	MI	48237	248-5453600
VILLAGE CARE PHARMACY	ajaykumar gajera	427 W MAIN STREET	OWOSSO	MI	48867	800-5555555
CENTRAL PHCY- OWOSSO	DAVID LARNER	111 N. WASHINGTON ST	OWOSSO	MI	48867	989-7251344
MEDICINE ROOM	CRAIG CROWE	72 S. WASHINGTON STE 207	OXFORD	MI	48371	248-6287990
CENTRAL PHCY_PERRY LLC	DAVID LARNER	150 S. MAIN ST	PERRY	MI	48872	517-6258640
PONTIAC GENERAL HSPTL PHY	Mansoor Khan	461 W HURON ST STE 111	PONTIAC	MI	48341	248-8590020
POTTERVILLE PHCY	Fadi Nuseibeh	121 E LANSING RD	POTTERVILLE	MI	48876	517-6459800
ARBOR LANE #3	OSAMA FAKIH	24224 JOY ROAD #103	REDFORD	MI	48239	313-5324000
REMUS PHARMACY HM	Jim Horton	144 WEST WHEATLAND	REMUS	MI	49340	989-9673360
MY RX PHARMACY LLC	Mohamed Nasser	17013 FORT ST STE 100	RIVERVIEW	MI	48193	734-2883750
THERA SCRIPT	HASSAN ABBASI	455 BARCLAY CIRCLE DR.#C2	ROCHESTER HILLS	MI	48307	248-2891376
WELLPOINTE PHARMACY	JOHN MITCHELL	1701 S. BOULEVARD #105	ROCHESTER HILLS	MI	48307	248-8529355
ROCHESTER HILLS PHARMACY	JOHN MITCHELL	6700 N. ROCHESTER RD #101	ROCHESTER HILLS	MI	48306	248-6011178
SAGINAW DISCOUNT PHARMACY	Ganesh Patel	3085 HALLMARK CT STE 3	SAGINAW	MI	48603	989-4017600
HEALTHCENTER PHARMACY	MUSTAFA HAIDAR	21600 HARPER AVE, STE 300	SAINT CLAIR SHORES	MI	48080	586-4214003
LAKEWOOD-MADHAV PHCY	Srinivas Sanikommu	24800 HARPER AVE STE 2	SAINT CLAIR SHORES	MI	48080	586-3592326
ARFSTROM PHARMACY	Jeanine Lacross	415 ASHMUN STREET	SAULT STE MARIE	MI	49783	906-6329661
SAULT COMMUNITY PHARMACY	Jeanine LaCross	560 GOVENOR OSBORN BLVD	SAULT STE MARIE	MI	49783	906-6322122
PHARMASCRIP OF SHELBY	Mike Mustapha	50505 SCHOENHERR RD	SHELBY TOWNSHIP	MI	48315	586-8030800
CADILA PHARMACY	HITESH UPADHYAY	23832 SOUTHFIELD RD	SOUTHFIELD	MI	48075	248-5579333
MAJESTIC PHARMACY	MOOMEN FARA	25861 LAHSER RD	SOUTHFIELD	MI	48033	248-9488800
SOUTHFIELD SCRIPTS	SOUZAN TARRAF	17330 NORTHLAND PARK CT	SOUTHFIELD	MI	48075	248-6219149

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
VILLAGE DRUG CO.	Matt Zauchin	300 CARLOW LANE STE 116	BIRMINGHAM	AL	35242	205-4105528
RITCHS PHARMACY HM	Ralph Sorrell	2714 CAHABA RD	BIRMINGHAM	AL	35223	205-8711141
TYNERS PHARMACY HM	Randy Tyner	5616 CHALKVILLE ROAD	BIRMINGHAM	AL	35235	205-8563784
MEDHELP RX	Robert Bryant	4600 HWY 280, STE 102	BIRMINGHAM	AL	35242	205-2538776
LAKESHORE PHARMACY I HM	Robert Bryant III	ONE LAKESHORE DR STE 102	BIRMINGHAM	AL	35209	205-9458081
PEDS RX PHCY SOLUTIONS	SAM BLAKEMORE	1600 SEVENTH AVE SOUTH	BIRMINGHAM	AL	35233	205-9838727
BLOUNTSVILLE PHARMACY	Olivia Butler	69005 MAIN STREET	BLOUNTSVILLE	AL	35031	800-5555555
CLARK'S PHARMACY	B.J. JONES	241 BILLY DYAR BLVD	BOAZ	AL	35957	256-8401100
BOAZ DISC DRUGS HM	Dale Johnson	10460 AL HWY 168, STE 1	BOAZ	AL	35957	256-5936546
COTTRELL'S HOMETOWN PHCY	Danny Cottrell	305 FOREST AVE	BREWTON	AL	36426	800-5555555
MEDICAL CENTER PHARMACY B	DANNY COTTRELL	1121 BELLEVILLE AVE	BREWTON	AL	36426	251-8675454
MILLS PHCY AT BROOKWOOD	BEETINA LONG	16114 HWY 216 SUITE A	BROOKWOOD	AL	35444	205-5561600
MR DISCOUNT DRUGS BUTLER	Greg Manley	604 E. PUSHMATAHA STREET	BUTLER	AL	36904	205-4592990
WILLARDS MEDICAL ARTS	Willard McDonald	313 EAST PUSHMATAHA ST	BUTLER	AL	36904	205-4593710
COWART DRUG COMPANY	KACIE WHITE	8320 HIGHWAY 31	CALERA	AL	35040	205-6681723
WHITAKER DRUGS LLC	Chip Whitaker	20 CAMDEN BYPASS	CAMDEN	AL	36726	334-4561589
CARROLLTON DRUGS HM	David Handley	25700 HWY 17	CARROLLTON	AL	35447	205-3672476
ALACO DISCOUNT PHCY # 6	Donnie George	1490 CHESNUT BYPASS	CENTRE	AL	35960	256-9278539
DEANS DRUGS, INC HM	Tracy Bishop	699 CEDAR BLUFF RD	CENTRE	AL	35960	256-9275569
J & S DRUGS HM	Seth Young	1130 WALNUT ST	CENTREVILLE	AL	35042	205-9264821
SNIDER'S DISCOUNT PHCY	Doug Snider	15582 HWY 280	CHELSEA	AL	35043	205-6783899
OPEN HANDS INC	Jeff Honea II	16688 HIGHWAY 280	CHELSEA	AL	35043	205-6787755
PEOPLES DRUGS HM	Tracy Wix	8260 HWY 72 WEST	CHEROKEE	AL	35616	256-3596242
MEDICAL VILLAGE PHARMACY	Steve Ladas	426 S. CRAFT HWY	CHICKASAW	AL	36611	251-4564172
CITRONELLE DRUG CO HM	Robert Jeffus	19240 MOBILE ST	CITRONELLE	AL	36522	251-8665522
CHANDLER DRUG	Brad Jackson	914 7TH ST SOUTH	CLANTON	AL	35045	205-7558009
WRIGHT DRUG AND GIFT HM	Butch Deneke	206 7TH STREET SOUTH	CLANTON	AL	35045	205-7553350

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
PHARMOR PHCY - GREENFIELD	Zaki Siddiqui	15627 W 9 MILE RD	SOUTHFIELD	MI	48075	248-8096024
BELAVISTA DRUGS	Jihad Beydoun	15830 FORT ST STE #5	SOUTHGATE	MI	48195	734-2821940
PRIME CARE PHARMACY	Rabih Sibai	3 HERITAGE DR # 3	SOUTHGATE	MI	48195	734-3241290
COLLIE DRUG	Sami Shimoon	21728 HARPER AVE	ST CLAIR SHORES	MI	48080	586-7766122
PLUM RX PHARMACY	Jasmin Shamoun	39880 VAN DYKE AVE	STERLING HEIGHTS	MI	48313	248-6133237
INFINITY PHARMACY	Jihad Beydoun	36909 SCHOENHERR STE 300	STERLING HEIGHTS	MI	48312	800-5555555
CANAL PHARMACY #2	KANU PATEL	2405 E FOURTEEN MILE RD	STERLING HEIGHTS	MI	48310	586-4393550
BLUESTONE PHARMACY	majdi alhusseini	13469 E 14 MILE RD	STERLING HEIGHTS	MI	48312	313-4450058
CAREMONT PHARMACY	MARK KASHAT	44344 DEQUINDRE-STE #120	STERLING HEIGHTS	MI	48314	586-3236400
GET WELL PHARMACY	Rene Qarana	3900 18 MILE RD	STERLING HEIGHTS	MI	48314	586-2759970
TRUE RX	Talal Hubaishi	38300 VAN DYKE AVE STE 102	STERLING HEIGHTS	MI	48312	586-2750422
MED MART PHARMACY 1	Ali Berry	25850 EUREKA RD	TAYLOR	MI	48180	313-2832000
MAXCARE RX PHARMACY	Diana Kabbani	7847 TELEGRAPH RD	TAYLOR	MI	48180	734-5781189
PHARMAX PHARMACY	Fadi Nuseibeh	10501 TELEGRAPH RD STE 105	TAYLOR	MI	48180	313-5743434
WELLNESS HEALTH MART PHCY	MAHER SALAMEH	11780 TELEGRAPH RD STE 110	TAYLOR	MI	48180	734-9213971
PIONEER MEDICAL PHCY	MIKE AHEER	12701 TELEGRAPH RD	TAYLOR	MI	48180	734-2508858
PHARMOR PHARMACY TAYLOR	Nabeel Albadany	14625 TELEGRAPH RD STE B	TAYLOR	MI	48180	734-7207355
TRENTON PHARMACY	Hilmi Algohaim	2674 W JEFFERSON AV 200	TRENTON	MI	48183	734-3073344
MED INDEX PHCY	ANIL GUNTUPALLI	1639 BIG BEAVER RD #101	TROY	MI	48083	248-5280888
WELLNESS PHY & COMPOUND	Gassan Asadi	215 E BIG BEAVER RD #500	TROY	MI	48083	248-8176770
UNASOURCE PHARMACY	JOHN MITCHELL	4600 INVESTMENT DR #100	TROY	MI	48098	248-3120037
TROY CITY PHARMACY	MADAN AHEER	1903 E WATTLES RD	TROY	MI	48085	248-6889224
PHARMACARE DRUGS 1 INC	Ali Nasser	6048 RAWSONVILLE RD	VAN BUREN TWP	MI	48111	734-8790995
TRUEWELLNESS PHARMACY	Michael Sleiman	10824 BELLEVILLE RD	VAN BUREN TWP	MI	48111	734-3918549
WAKEFIELD PHARMACY HM	Kathy Rocco	408 SUNDAY LAKE STREET	WAKEFIELD	MI	49968	906-2295966
VILLAGE PHARMACY	ALEXANDER SIOMKA	6213 CHICAGO - STE#200	WARREN	MI	48092	586-7517979
RYAN PHARMACY HM	Auday Maki	23421 RYAN ROAD	WARREN	MI	48091	586-7550040

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
CLEVELAND DISCOUNT PHA HM	Kim Larue	36321 STATE HWY 79 STE 2	CLEVELAND	AL	35049	205-2748000
COLLINSVILLE DRUGS	Brandon Boswell	588 S VALLEY AVE	COLLINSVILLE	AL	35961	256-5242981
CORDOVA DRUG HM	Ken Glover	430 SCHOOL ST	CORDOVA	AL	35550	205-4837811
CROSSVILLE DRUGS INC HM	ALAN GARDNER	15192 UNIT 2 AL HWY 68	CROSSVILLE	AL	35962	256-5287124
KILPATRICK PHARMACY	BJ Jones	415 COUNTY ROAD 179	CROSSVILLE	AL	35962	256-5611500
GRAND POINTE PHCY	ANGELA VEAL	2045 2ND AVE N,W,	CULLMAN	AL	35058	256-7371330
GOOD HOPE PHARMACY	KIAH BROWN	1167 COUNTY RD 437	CULLMAN	AL	35055	256-8415958
HOSPITAL DISC PHCY WEST	Kiah Brown	1201 4TH ST SW	CULLMAN	AL	35055	256-7347658
SPECIALTY PHARMACY	Kiah Brown	2104 ALABAMA HWY 157 SPEC	CULLMAN	AL	35058	256-7343146
HOSP DISC PHCY CENTRAL	Kiah Brown	209 4TH AVE NE	CULLMAN	AL	35055	256--734-60
MCSWAINS PHARMACY	Nicole Robertson	1910 MAIN AVE SW	CULLMAN	AL	35055	256-7341662
HERITAGE PHARMACY HM	Rita Freeman	1701 MAIN AVE SW STE C	CULLMAN	AL	35055	256-7373773
MEDICAL ARTS APOTHECARY	SUSAN ADKISON	124 7TH ST SW HEALTH CENT	CULLMAN	AL	35055	256-7344933
CULLMAN DISCOUNT PHCY	Tom Ploppert	1407 2ND AVE SW	CULLMAN	AL	35055	256-7344251
JIMS PHARMACY AT THE LAKE	JIM CLANTON	6378 HWY 49 S	DADEVILLE	AL	36853	256-3733439
CENTER DGS OF DALEVILLE	STACY BOUCHER	181 HWY 84 WEST	DALEVILLE	AL	36322	334-5984242
ADAMS DRUGS-PINE LEVEL	Chris Phung	2175 B HIGHWAY 31 N	DEATSVILLE	AL	36022	334-3519550
LAKE PHARMACY HM	Robert Golden	95 LIGHTWOOD RD HWY 23	DEATSVILLE	AL	36022	334-5692112
PAY-LESS PHARMACY HM	BLAKE GOWEN	1206 7TH ST SE	DECATUR	AL	35601	256-3535011
WESTMEADE PHARMACY HM	David Duncan	2104 DANVILLE RD SW	DECATUR	AL	35601	256-3558211
PAY-LESS PHCY EXP #2	Jeff Camp	1517 WEST MOULTON STREET	DECATUR	AL	35601	256-3551815
PAYLESS PHCY EXPRESS HM	Steve Harris	2122 DANVILLE ROAD, SW	DECATUR	AL	35601	256-3517006
BENDALL'S PHARMACY INC	Tim Douthit	1316-A STRATFORD RD SE	DECATUR	AL	35601	256-3532021
BOONE'S PHCY HM	Raymond Boone	951 US HWY 80 W	DEMOPOLIS	AL	36732	334-2898989
KEN GLOVER DRUG HM	Ken Glover	27 MIDWAY PLAZA HWY 78 E	DORA	AL	35062	205-6489918
NORTHCUTT DRUG CO HM	Glenn Northcutt	1774 WEST MAIN	DOTHAN	AL	36301	334-7939538
CIRCLE PHARMACY	JASON SCOTT	2021 ALEXANDER DR	DOTHAN	AL	36301	334-7922717

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
CARERX SPECIALTY PHARMACY	Clyde Furuta	13201 STEPHENS RD STE#G	WARREN	MI	48089	734-6564082
HANAN PHARMACY LLC	Farah Darwiche	4600 E 14 MILE RD - SUITE 2	WARREN	MI	48092	586-9995951
HEALTH POINTE PHARMACY	Joe Naim	26000 HOOVER RD #107	WARREN	MI	48089	586-8595588
RYANS RX PHARMACY	Khaled Hussain	29230 RYAN RD STE B	WARREN	MI	48092	586-4137188
YOURX PHARMACY	LENA SAFADI	29134 RYAN ROAD	WARREN	MI	48092	586-3935232
COMMUNITY RX PHCY	MAHBUBUR MOTLIB	27124 DEQUINDRE RD	WARREN	MI	48092	586-9202225
3 BROTHERS PHARMACY	Omar Odeh	25656 SCHOENHERR RD SUITE B	WARREN	MI	48089	313-4430948
STAR PHARMACY	Shah Bhuiyan	24831 RYAN RD	WARREN	MI	48091	800-5555555
GREATER CARE PHARMACY	Yunus Wasel	24800 HOOVER RD STE B	WARREN	MI	48089	586-4865008
NCA PHARMACY	SHATHA MATTI	7362 HIGHLAND RD	WATERFORD	MI	48327	248-4616509
ONE STOP PHARMACY LLC	Delphine Akene	33950 VAN BORN RD	WAYNE	MI	48184	734-7272000
BMC PHCY W BLOOMFIELD	Heather Thomas	6900 ORCHARD LAKE RD STE 104	WEST BLOOMFIELD	MI	48322	248-8555505
LAKES DISCOUNT PHARMACY	Hussein Elsaghir	2300 HAGGERTY RD STE 1070	WEST BLOOMFIELD	MI	48323	248-6681212
H & A HEALTH PHARMACY	Hilmi Algohaim	1207 S WAYNE RD	WESTLAND	MI	48186	313-8708870
R K PHARMACY	KHODR BAZZI	181 N. WAYNE RD	WESTLAND	MI	48185	800-5555555
PLATINUM LIFE PHARMACY	Regina Amadi	30785 ANN ARBOR TRL	WESTLAND	MI	48185	734-3303262
PITKIN DRUG CO INC	Ryan Breigel	101 W COLBY ST	WHITEHALL	MI	49461	231-8935495
CENTRAL PHCY-WILLIAMSTON	Fadi Nuseibeh	129 S PUTNAM ST	WILLIAMSTON	MI	48895	517-9925101
HANNAHVILLE IHC PHCY SPEC	Kenneth Meshigaud	W365 US 2 & 41 STE 600	WILSON	MI	49896	906-7232560
GREAT LAKES PHCY LLC	Ani Pathak	3247 BIDDLE AVE STE A	WYANDOTTE	MI	48192	734-2845100
APOLLO PHCY OF WYANDOTTE	Chetan Patel	2000 EUREKA RD	WYANDOTTE	MI	48192	800-5555555
WYANDOTTE PHARMACY	NEHA PATEL	375 EUREKA RD STE A	WYANDOTTE	MI	48192	734-7200929
RIVERWOOD AITKIN PHCY	Spencer Page	171 RED OAK DR	AITKIN	MN	56431	218-4294344
BARNESVILLE DRUG	MICHELLE HOPPE	117 FRONT ST S	BARNESVILLE	MN	56514	218-3542131
HUGOS FAMILY PHARMACY CRO	Scott Van Camp	1310 UNIVERSITY AVENUE	CROOKSTON	MN	56716	218-2813174
HUGOS FAMILY PHARMACY E G	Scott Van Camp	224 14TH STREET NE	EAST GRAND FORKS	MN	56721	218-7730611
ELY COMMUNITY PHCY THE	Beth Hartshorn	328 WEST CONAN STREET	ELY	MN	55731	218-3658788

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
DOCTORS CENTER PHARMACY	MICHAEL STRINGER	4119 WEST MAIN ST	DOTHAN	AL	36305	334-7931316
MIKES SOUTHSIDE PHCY BIR	Mike Pitzing	1006 S OATES ST	DOTHAN	AL	36301	334-7943174
BOWEN PHARMACY	Tina Stringer	110 HEALTHEAST DRIVE	DOTHAN	AL	36303	334-7944211
HARRISON DRUG HM	Rex Harrison	25372 HIGHWAY 195 BOX 505	DOUBLE SPRINGS	AL	35553	205-4898806
ECLECTIC FAMILY PHARMACY	Teresa Lett	575 CLAUD ROAD, STE 2000	ECLECTIC	AL	36024	334-5412522
ELBERTA PHARMACY INC HM	Tonja Lowery	24980 STATE ST PO DR 670	ELBERTA	AL	36530	251-9868115
SALEM PHARMACY	Mark Jackson	28730 AL HWY 99 STE A	ELKMONT	AL	35620	256-2161820
BRYARS-WARREN DRUG CO	JEREMY WILLETTE	112 NORTH MAIN ST	ENTERPRISE	AL	36330	334-3472506
CENTER DRUGS ENTERPRISE	Jeremy Willette	607A BOLL WEEVIL CIR	ENTERPRISE	AL	36330	334-3474242
HOLLEY PHARMACY	JOHN HOLLEY	612 N MAIN ST STE A	ENTERPRISE	AL	36330	334-3930086
BUY RITE DRUGS #14	Tracy Alligood	146 E BROAD ST	EUFAULA	AL	36027	334-6873591
BUY RITE DRUGS #13	Tracy Alligood	542 S EUFAULA	EUFAULA	AL	36027	334-6870021
MILLS PHARMACY AT EUTAW	Beetina Long	306 MORROW AVE	EUTAW	AL	35462	205-3720500
QUALITY DISC DRUGS	ROBERT HAGER	4109 EVA ROAD PO BOX 98	EVA	AL	35621	256-7967131
FAIRHOPE PHCY HM	Betty Barnhill	398 FAIRHOPE AVE PO BX512	FAIRHOPE	AL	36532	251-9288822
FAYETTE DOWNTOWN PHCY	Katie Wakefield	101 TEMPLE AVE S	FAYETTE	AL	35555	205-9324513
FLOMATON MED CTR PHCY	CHARELS COTTRELL	174 HWY 113	FLOMATON	AL	36441	251-2960004
NORTHGATE PHARMACY HM	CHAD CHAD	3522 CLOVERDALE RD	FLORENCE	AL	35633	256-7661224
ST FLORIAN PHARMACY	Derek Ray	4395 CO RD 47	FLORENCE	AL	35630	256-7650123
MEDICAL CTR PHY FLORENCE	Kenneth Aday	1751 VETERANS DRIVE #105	FLORENCE	AL	35630	256-7700778
FLORENCE XPRESS PHARMACY	Tom Ploppert	2908 MALL RD	FLORENCE	AL	35630	256-9624251
C AND H DISCOUNT DRUG HM	RICHARD HAMMON	1916 GAULT AVE N NO STORE	FORT PAYNE	AL	35967	256-8452004
C AND H DISC DRUG HM	RICHARD HAMMON	1702 GLENN BLVD SW	FORT PAYNE	AL	35967	256-8450242
FRISCO CITY PHARMACY HM	Desak Hicks	3749 BOWDEN ST	FRISCO CITY	AL	36445	251-2672111
FYFFE PHCY HM	Brandon Rains	44 BLACKWELL ST	FYFFE	AL	35971	256-6232944
JERRYS DISCOUNT PHCY HM	Jerry Rogers	300 WALL STREET	GADSDEN	AL	35904	256-5471221

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
RIVERWOOD GARRISON CLINIC	Spencer Page	27278 STATE HIGHWAY 18	GARRISON	MN	56450	320-5253401
BARON'S PHARMACY	Craig Baron	1120 E 34TH STREET	HIBBING	MN	55746	218-2634922
BARON'S PHARMACY MESABA	Craig Baron	3605 MAYFAIR AVE	HIBBING	MN	55746	218-2634922
CITY DRUG HM	GARY ANDERSON	314 3RD ST	INTERNATIONAL FALLS	MN	56649	218-2833423
JUBA PHARMACY	Ahmed Adayib	1926 CHICAGO AVE S	MINNEAPOLIS	MN	55404	816-3775388
CEDAR PHARMACY	Ahmed Mussa	417 CEDAR AVE S	MINNEAPOLIS	MN	55454	612-8143271
HIKMA PHARMACY	OMAR BIHI	615 CEDAR AVE	MINNEAPOLIS	MN	55454	612-3153678
MEDICAL PHCY-MOORHEAD IPC	Sheila Nudell	101 11TH ST SO	MOORHEAD	MN	56560	218-2337365
MED PHCY MOORHEAD AZOOL	Shelia Nudell	950 40TH AVE S	MOORHEAD	MN	56560	218-3594007
BOIS FORTE PHARMACY	Lynette Tahtinen	5219 SAINT JOHN DR	ORR	MN	55771	218-7570230
WEST SEVENTH PHARMACY	Jeff Johnson	1106 WEST 7TH ST	SAINT PAUL	MN	55102	651-2281493
COMO PHARMACY	PAO KUE	217 COMO AVE STE 107	ST PAUL	MN	55103	651-4870044
HUGOS FAMILY PHARMACY THI	Scott Van Camp	215 PENNINGTON AVENUE	THIEF RIVER FALLS	MN	56701	218-6818556
VERMILLION PUBLIC PHCY	Lynette Tahtinen	1613 FARM RD S	TOWER	MN	55790	218-7532180
WARREN PHARMACY, INC - MN	Vern Borowicz	103 W. JOHNSON AVE	WARREN	MN	56762	218-7455481
SINKS PHARMACY 100 HM	Sandy Mitchell	206D S ALVARADO POB 934	BELLE	MO	65013	573-8593100
EVANS DRUG BOLIVAR	Kevin McCullough	703 E COLLEGE ST	BOLIVAR	MO	65613	417-3265208
SINKS PHARMACY BOURBON	Amy Mitchell	124 N OLD HWY 66	BOURBON	MO	65441	573-7323256
COUNTY MARKET #397	CHRISTOPHER NIEMANN	1106 BUSINESS HWY 61 S	BOWLING GREEN	MO	63334	573-3243383
BOWLING GREEN PHARMACY	Shari Black	8 N COURT STREET	BOWLING GREEN	MO	63334	573-3242112
GREEN HILLS PHARMACY HM	David Gardner	712 SOUTH MAIN	BROOKFIELD	MO	64628	660-2582122
BRUNSWICK FAMILY PHCY	Tony Clark	807 E BROADWAY ST SUITE B	BRUNSWICK	MO	65236	660-5482118
EVANS DRUG BUFFALO	Kevin McCullough	315 S ASH ST	BUFFALO	MO	65622	417-3452321
LAKE REGIONAL PHY CMC EDI	MICHAEL HENZE	1930-C N BUSINESS ROUTE 5	CAMDENTON	MO	65020	573-3462300
CAMERON FAMILY PHCY #191	JILL SAUNDERS	1303 N WALNUT	CAMERON	MO	64429	816-6322201
COUNTY MARKET PHCY #409	Art Awerkamp	1805 ELM STREET	CANTON	MO	63435	573-2880355

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
HUGHS PHARMACY HM	Mary Tucker	100 MED CTR DR STE 102	GADSDEN	AL	35903	256-4927407
CORNERSTONE PHARMACY HM	Scott Godfrey	851 GOODYEAR AVE	GADSDEN	AL	35903	256-4565850
MILLS PHCY AT GARDENDALE	Beetina Long	439 FIELDSTOWN RD #145	GARDENDALE	AL	35071	205-6318989
J & J DRUGS	Steve Hill	1318 MAIN ST	GARDENDALE	AL	35071	205-6318731
GILSTRAP DRUGS HM	Michael Booth	1008 W MAPLE AVE	GENEVA	AL	36340	334-6842272
CENTER DRUG COMPANY	PAULA NORMAN	702 W MAPLE AVE	GENEVA	AL	36340	334-6849408
HOMETOWN PHARMACY HM	Cole Floyd	69 WEST MAIN ST	GILBERTOWN	AL	36908	251-8432400
ALACO DISCOUNT PHCY # 7	Amanda Divine	544 MAIN ST W	GLENCOE	AL	35905	256-4924900
GOODWATER PHARMACY HM	Brad Collins	21338 AL HWY 9 PO BX 48	GOODWATER	AL	35072	256-8396361
GRAND BAY PHARMACY	DANNY COTTRELL	12475 US HWY 90	GRAND BAY	AL	36541	281-865555
BOONE'S PHARMACY	RAYMOND BOONE	850 D TUSCALOOSA ST	GREENSBORO	AL	36744	334-6247151
CITY DRUG GROVE HILL	Richard Boone	123 JACKSON STREET	GROVE HILL	AL	36451	251-2753416
MCGUIRE DRUG HM	Ralph Christopher	141 12TH AVE W. PO BX 520	GUIN	AL	35563	205-4683402
ISLAND DRUG & GIFTS HM	James Willis	3645 GULF SHORES PKWY 107	GULF SHORES	AL	36542	251-9671100
BUNCH PHARMACY HM	Buddy Bunch	1800 HENRY ST	GUNTERSVILLE	AL	35976	256-5825700
HARALSON DRUGS CO INC	Steve Murphee	1941 PATTERSON STREET	GUNTERSVILLE	AL	35976	256-5823661
MAJORS DISCOUNTS DRUGS	Donna Majors	1025 HIGHWAY 13 NORTH	HALEYVILLE	AL	35565	205-4864534
ROBERT'S HOMETOWN PHCY	Robert Ellis	2415 11TH AVE SUITE A	HALEYVILLE	AL	35565	205-4864663
HANCEVILLE DRUG CO	Benjamin B Burkhart	101 COMMERCIAL STREET SE	HANCEVILLE	AL	35077	256-3524110
BLUE AND GRAY DRUGS HM	Chris Henderson	804 MAIN ST N.E BOX 288	HANCEVILLE	AL	35077	256-3524371
HERITAGE PHCY OFDODGECITY	RITA FREEMAN	561 AL HWY 69 SOUTH	HANCEVILLE	AL	35077	256-2873333
GILCHRIST PHARMACY #2	Mike Preuitt	615 MYNATT ST STE F	HARTSELLE	AL	35640	256-7730050
GILCHRIST PHARMACY INC	Mike Previtt	404 SPARKMAN ST NW	HARTSELLE	AL	35640	256-7731999
SUR SAV PHARMACY HM	Mazen Newahid	6046 HWY 53	HARVEST	AL	35749	256-8589677
HAYDEN PHARMACY HM	Jennifer Metcalf	4086 STATE HWY 160	HAYDEN	AL	35079	205-5901515
FOSTER DRUG CO	John Carpenter	12 LAFAYETTE ST	HAYNEVILLE	AL	36040	334-5482125

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
MEDICENTER PHARMACY	Eric Schreiber	465 S MOUNT AUBURN RD	CAPE GIRARDEAU	MO	63703	573-6515250
BROADWAY PHARMACY	Kevin Wood	710 BROADWAY ST	CAPE GIRARDEAU	MO	63701	573-3358207
PARK PHARMACY	Kevin Wood	37 DOCTORS PARK #2	CAPE GIRARDEAU	MO	63703	573-3344432
HEALING ARTS & SPEC PHCY	Sarah Mirgaux	3250 GORDONVILLE RD - 101	CAPE GIRARDEAU	MO	63703	573-3390999
CEDAR HILL DRUG	Michelle Eberhart	7032 STATE ROUTE BB	CEDAR HILL	MO	63016	636-2743111
ST LUKES HOSP PHCY CF	ROBERT NGUYEN	224 S WOODSMILL RD STE 350S	CHESTERFIELD	MO	63017	314-2056023
THE MEDICAL ARTS PHARMACY	BROCK SMITH	7710 CARONDELET STE 125	CLAYTON	MO	63105	314-8620333
NEXTRX	Neal Head	2909 FALLING LEAF LN	COLUMBIA	MO	65201	800-5555555
TOWNE PHARMACY	AMY MITCHELL	200 N. FRANKLIN	CUBA	MO	65453	573-8857212
WESTLAND PHARMACY HM	Michelle Eberhart	2020 ROCK RD	DE SOTO	MO	63020	636-3371761
PARKLAND APOTHECARY, LLC	Lisa Umfleet	1131 N DESLOGE DR	DESLOGE	MO	63601	573-4316677
SUPER SAVER PHARMACY	Phillip Wilkins	100 H & S DRIVE	DONIPHAN	MO	63935	573-9965220
EVANS DRUGS - ELDO	KEVIN MCCULLOUGH	209 E. HWY 54	EL DORADO SPRINGS	MO	64744	417-8763313
LAKE REG PHCY- ELDON	David Halsell	416-B SOUTH MAPLE ST.	ELDON	MO	65026	573-5572231
PARKLAND RX FARM	Lisa Umfleet	806 VALLEY CREEK DR	FARMINGTON	MO	63640	573-7471191
SAM'S HM #3 EDI	Christian Tadrus	300 N CHURCH PO BOX 509	FAYETTE	MO	65248	660-2482275
PRESCRIPTIONS PLUS	Lisa Umfleet	348 FESTUS CENTRE DR	FESTUS	MO	63028	636-9332224
PARKLAND RX FRED	LISA UMFLEET	1025 HWY 72 BYPASS	FREDERICKTOWN	MO	63645	573-7836000
COURT SQUARE PHARMACY	Craig Atkins	512 W 3RD ST	GAINESVILLE	MO	65655	417-6792650
MAIN STREET MEDICAL PHCY	Nicole Neal	403 S MAIN STREET	GALLATIN	MO	64640	660-6637979
MEDLEY PHARMACY GERALD	Sandy Mitchell	733 W SPRINGFIELD RD	GERALD	MO	63037	573-7645980
PARKLAND RX GREEN	Lisa Umfleet	137 FRONT STREET	GREENVILLE	MO	63944	618-7031295
MAXWELL PHARMACY, INC	Matthew Maxwell	200 SOUTH 9TH STREET	HANNIBAL	MO	63401	573-7193530
BERLENER DRUG STORE HM	Frank Meyer	119 BAVARIAN HILLS BLVD	HERMANN	MO	65041	573-4862612
HILLSBORO DRUG HM	Michelle Eberhart	10666 HIGHWAY 21	HILLSBORO	MO	63050	636-7973468
SMITHWAY PHARMACY	Missy Smith	100 W TILDEN ST	HUMANSVILLE	MO	65674	417-7541501

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
HAZEL GREEN PHARMACY HM	Chandler Willingham	13574 HWY 231-431 N STE B	HAZEL GREEN	AL	35750	256-8130150
MIKE'S PHCY OF HEADLAND	MIKE PITZING	202 HOLMAN DR	HEADLAND	AL	36345	334-6933324
CLEBURNE PHARMACY	FRANK TANT	875 ROSS ST	HEFLIN	AL	36264	256-4632197
CAMP DRUGS	Kevin Camp	18294 BROAD ST	HENAGAR	AL	35978	256-6575187
HOKES BLUFF DRUG SHOPPE	Candace West	5702 US HWY 278	HOKES BLUFF	AL	35903	256-4941918
MURPHY'S PHARMACY HM	Jason Spencer	11069 US HIGHWAY 278 E	HOLLY POND	AL	35083	256-7964449
HOMEWOOD PHARMACY	Ryan Hamilton	940 OXMOOR ROAD	HOMEWOOD	AL	35209	205-871900
MILLS SPECIALTY CENT FILL	BEETINA LONG	2400 MOUNTAIN DRIVE	HOOVER	AL	35226	205-8719007
MILLS PHCY AT BLUFF PARK	Beetina Long	2148 TYLER RD #100	HOOVER	AL	35226	205-8239500
GREEN VALLEY DRUG CO INC	Bill Box	1915 HOOVER COURT	HOOVER	AL	35226	205-8221151
ROSS BRIDGE PHARMACY	Patrick Devereux	3601 MARKET ST STE 104	HOOVER	AL	35226	205-4261883
DOUGLAS DISCOUNT PHARM HM	Jim Gann Jr.	9461 HIGHWAY 75	HORTON	AL	35980	256-5931750
WELDON PHARMACY HM	Diane Cashatt	1280 HUEYTOWN RD	HUEYTOWN	AL	35023	205-4912805
PHARMACY XPRESS HM	Nathan Antonio	2910 ALLISON BON MEM #112	HUEYTOWN	AL	35023	205-7444480
SPARKMAN PHCY FRANKLIN	Farzan Isfahani	807 FRANKLIN ST. SE	HUNTSVILLE	AL	35801	256-4299821
HEALTHMART PHARMACY	FARZAN ISFAHANI	2015 SPARKMAN DR NW	HUNTSVILLE	AL	35810	256-7157475
SPARKMAN PHCY WELLSTONE	FARZAN ISFAHANI	4040 MEMORIAL PARKWAY	HUNTSVILLE	AL	35802	256-7056499
CHASE PHARMACY INC HM	Rick Sansom	2700 B WINCHESTER RD	HUNTSVILLE	AL	35811	256-8511345
IDER DISCOUNT DRUGS	RODNEY WILLIAMS	10705 ALABAMA HIGHWAY 75	IDER	AL	35981	256-6575151
BAYOU PHARMACY	DANNY COTTRELL	12855 PADGETT SWITCH ROAD	IRVINGTON	AL	36544	251-8247979
MACS DRUGS HM	Randy Guy	201 COMMERCE ST PO BOX426	JACKSON	AL	36545	251-2463616
CROW DRUG HM	Jay Colvin	1430 PELHAM ROAD S	JACKSONVILLE	AL	36265	256-4357931
PROFESSIONAL PHARMACY	Jake Barnett	2001 AIRPORT ROAD NORTH	JASPER	AL	35504	205-2214564
SAM GLOVER DRUGS HM	Ken Glover	408 W 18TH ST	JASPER	AL	35501	205-3871481
GLOVER DRUG URGENT CARE	Ken Glover	2708 OLD HWY 78	JASPER	AL	35501	205-3871800
AFTER HOURS RX INC HM	Mark George	1800 BIRMINGHAM AVE	JASPER	AL	35501	205-3877811

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
SINKS PHARMACY IBERIA	AMY MITCHELL	2322 HIGHWAY 17	IBERIA	MO	65486	573-7932050
STADIUM PHARMACY	Vikranth Anneboina	4811 S. ARROWHEAD DR.	INDEPENDENCE	MO	64055	816-3564600
PARKLAND RX IRONTON	LISA UMFLEET	1500 HIGHWAY 21	IRONTON	MO	63650	573-5466000
MEDICENTER PHARMACY HM	Stephen Sommer	200 W. WASHINGTON ST	JACKSON	MO	63755	573-2431303
JEFFERSON CITY MED GRP PH	Melissa Astin	1241 WEST STADIUM BLVD	JEFFERSON CITY	MO	65109	573-5567780
SPALITTO'S PHARMACY	Pete Spalitto	3801 INDEPENDENCE AVE	KANSAS CITY	MO	64124	816-2314717
CORNERSTONE KENNETT	KENNY HARRISON	123 1ST STREET	KENNETT	MO	63857	573-8889094
KIRKSVILLE PHARMACY	Jessica Buchheit	1611 S BALTIMORE ST STE B	KIRKSVILLE	MO	63501	660-9567010
LAKE REGIONAL PHCY LO EDI	MICHAEL HENZE	1870 BAGNELL DAM BLVD	LAKE OZARK	MO	65049	573-9646200
LAKE REGIONAL PHY-LAURIE	MICHAEL HENZE	156-D MISSOURI BLVD	LAURIE	MO	65038	573-3747522
ADVOCATES FOR A HLTHY COM	K Brooks Miller	860 LYNN ST	LEBANON	MO	65536	417-3440062
LEES SUMMIT PHARMACY	Jamie Morales	1198 NE DOUGLAS ST	LEES SUMMIT	MO	64086	816-6075152
RINNE PHARMACY	Jeremy Rinne	100 DEER LICK ST	LICKING	MO	65542	573-6742995
EVANS DRUGS LOCKWOOD, LLC	Kevin McCullough	725 MAIN ST	LOCKWOOD	MO	65682	417-2324721
FAMILY DRUG TF2	Shari Black	301 GEORGIA ST	LOUISIANA	MO	63353	573-7544551
MARCELINE PHARMCY	BILL KOCH	1509 NORTH MISSOURI AVE	MARCELINE	MO	64658	660-3762700
RANDOLPH DRUG STORE EDI	Kenton Randolph	301 S POLK POB 235	MAYSVILLE	MO	64469	816-4492700
MILAN U SAVE	HALEY WETER	111 E 2ND STREET	MILAN	MO	63556	660-2653779
SAM'S HM #1 EDI	Chris Tadrus	300 N MORLEY PO BOX 957	MOBERLY	MO	65270	660-2630909
SAM'S HM #2 EDI	Christian Tadrus	530 E 24 HIGHWAY	MOBERLY	MO	65270	660-2636710
FAMILY PHCY MONTGOME HM	Jack Holtman	806 NORTH STURGEON	MONTGOMERY CITY	MO	63361	573-5642273
EVANS DRUG NEVADA	Kevin McCullough	1407 W AUSTIN BLVD	NEVADA	MO	64772	417-6673953
PRATT'S REXALL DRUGS HM	Craig Willimann	100 DWAYNE VONBEHREN DRIV	NEW HAVEN	MO	63068	573-2373321
LAKE REGINL PHY OBMP EDI	MICHAEL HENZE	1057 B MEDICAL PARK DR	OSAGE BEACH	MO	65065	573-3022700
EVANS DRUGS - OSCEOLA	Kevin McCullough	675 THIRD STREET	OSCEOLA	MO	64776	417-6462301
MEDLEY PHARMACY HM	Sandy Mitchell	601 E HIGHWAY 28	OWENSVILLE	MO	65066	573-4373440

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
ENGLISH PLAZA PHCY RX	Neil Evans	1640 HWY 78 EAST	JASPER	AL	35501	205-2213090
KILLEN CORNER DRUG STORE	Bennie Maharrey	1621 HWY 72 PO BOX 99	KILLEN	AL	35645	256-7572166
LOWES PHARMACY HM	Brent Fuller	339 9TH AVE S.W.	LAFAYETTE	AL	36862	334-8647781
MILLS PHARMACY AT LEEDS	Beetina Long	8420 1ST AVE	LEEDS	AL	35094	205-6995195
PATTERSON PHARMACY	JOHN PATTERSON	7513 PARKWAY DRIVE	LEEDS	AL	35094	205-6995113
LEIGHTON PHARMACY	Grace Askins	2230 RAILROAD STREET	LEIGHTON	AL	35646	256-4466527
LEXINGTON DISCOUNT DRUG	Callie Sinyard	11601 HWY 101	LEXINGTON	AL	35648	406-2295550
LINCOLN PHARMACY HM	Ron Strickland	99 MAGNOLIA S BOX 200	LINCOLN	AL	35096	205-7637759
LITTLE DRUG COMPANY HM	Richard Boone	310 SOUTH MAIN STREET	LINDEN	AL	36748	334-2954270
LOCUST FORK PHARMACY HM	Johnny Cleveland	29984 STATE HWY79 STE 600	LOCUST FORK	AL	35097	205-6802222
LOXLEY DISC PHCY HM	Robert Barnhill	2140 E RELHAM DR/PO BX217	LOXLEY	AL	36551	251-9645332
FOSTER DRUG CO OF LUVERNE	Alan Carpenter	1554 S FOREST AVE	LUVERNE	AL	36049	334-3356553
B AND B DISCOUNT DRUGS	Bobbie Bowers	98 SOUTH FOREST AVENUE	LUVERNE	AL	36049	334-3353758
MADISON PHARMACY	FARZAN ISFAHANI	8498 MADISON BLVD A	MADISON	AL	35758	256-3251139
SURE SAVE PHARMACY	MAZEN NUWAYHID	30694 HWY 72 SUITE A	MADISON	AL	35756	256-2306200
MAPLESVILLE PHAR	TIM GIBBS	9081 AL HWY 22 PO BOX 145	MAPLESVILLE	AL	36750	334-3662425
COLLEGE CITY DRUG HM	Bradford Sturgis	304 WASHINGTON ST	MARION	AL	36756	800-8489692
MILLS PHCY AT MCCALLA	BEETINA LONG	4750 EASTERN VALLEY RD	MC CALLA	AL	35111	205-4771007
CURREN PHARMACY	MARCY CURREN	22586 HWY 216	MC CALLA	AL	35111	205-4777797
MILLS PHCY AT MIDFIELD	BEETINA LONG	30 A PHILLIPS DR	MIDFIELD	AL	35228	205-9257000
ADAMS DRUGS- MILLBROOK	Chris Phung	185 ASHTON PLAZA ST	MILLBROOK	AL	36054	334-3863501
SPRING VIEW DRUGS HM	James Davis	4810 MAIN ST PO BOX 722	MILLBROOK	AL	36054	334-2856705
JOE GOLDEN	SUMMER WILSON	13532 HWY 96 EAST	MILLPORT	AL	35576	205-6623817
DEUEL DRUG STORE	CHUCK DEUEL JR	2710 SPRINGHILL AVE	MOBILE	AL	36607	251-4787607
DAWES POINT PHARMACY	DANNY COTTRELL	8650 COTTAGE HILL RD #101	MOBILE	AL	36695	251-6079800
THREE NOTCH PHARMACY	DANNY COTTRELL	4880 LAKELAND DR, STE F	MOBILE	AL	36619	251-6610066

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
COUNTY MARKET PHCY #375	Art Awerkamp	1208 S MAIN	PALMYRA	MO	63461	573-7690343
PARIS PHARMACY HM	Jason Dodge	223 NORTH MAIN ST	PARIS	MO	65275	660-3274514
HEALTHCARE PHARMACY	Terry Hyde	628 OLD ST MARYS RD	PERRYVILLE	MO	63775	573-5472517
PARKLAND RX PIED	Lisa Umfleet	420 PIEDMONT AVE	PIEDMONT	MO	63957	573-2234235
ST FRANCIS POPLAR BLUFF	Maryann Reese	ST FRANCIS POPLAR BLUFF	POPLAR BLUFF	MO	63901	573-7787190
AUSTIN PLAZA PHARMACY	Terry Hyde	410 E HIGH ST STE A	POTOSI	MO	63664	573-4382349
STONER DRUG # 2	Chris Roup	315 SO MAIN ST	ROCKPORT	MO	64482	660-7442433
SINKS PHARMACY SELECT LLC	Sandra Mitchell	1024 S BISHOP AVENUE	ROLLA	MO	65401	573-3649616
SINKS PHARMACY HM	Sandy Mitchell	1375B E 10TH ST	ROLLA	MO	65401	573-3649616
SINKS PHARMACY SOUTH HM	Sandy Mitchell	1100B S BISHOP AVE	ROLLA	MO	65401	573-3084899
SINK'S PHARMACY ST CLAIR	Amy Mitchell	1435 N. MAIN ST	SAINT CLAIR	MO	63077	636-6298085
FOREST CITY HEALTHMART	Frank Meyer	125 N. JEFFERSON	SAINT JAMES	MO	65559	573-2655400
WINKELMANN SONS DRG CO	DAN WINKELMANN JR	3300 MERAMEC ST	SAINT LOUIS	MO	63118	314-3533300
WEST PINE PHARMACY HM	Devin Dalpoas	4401 W PINE BLVD	SAINT LOUIS	MO	63108	314-5331081
GOLDSMITH PHARMACY	Stephen Sommer	777 S. NEW BALLAS RD.	SAINT LOUIS	MO	63141	314-4325020
EXCEL PHARMACY	Raj Jhala	505 SALT LICK RD	SAINT PETERS	MO	63376	636-2786561
SINKS PHARMACY	Amy Mitchell	1204 EAST HIGHWAY 32	SALEM	MO	65560	573-7294091
MOSER PHARMACY EDI	HERSHEL MOSER	900 S MAIN	SALEM	MO	65560	573-7293300
SEMO DRUG	Brandon Michael	102 W COMMERCIAL ST	SENATH	MO	63876	800-5555555
RANDYS RX	RANDY ACKMAN	1012 NORTH MAIN	SIKESTON	MO	63801	573-4710285
SIKESTON MEDICENTER PHCY	STEPHEN SOMMER	507 NORTH MAIN ST	SIKESTON	MO	63801	573-4714401
MEDICENTER PHARMACY	Eric Schreiber	1474 N BOONVILLE AVE	SPRINGFIELD	MO	65802	417-8691866
FOREST CITY MEDICAL CTR	Frank Meyer	1000 B N. JEFFERSON	ST JAMES	MO	65559	573-2652525
OLIVE STREET PHARMACY	IRINA SHLAFSHTEYN	10420 OLD OLIVE ST RD	ST LOUIS	MO	63141	314-7365555
JUNIPER PHARMACY	Steven Ortiz	522 N NEW BALLAS STE 206	ST LOUIS	MO	63141	314-4991227
TJ PHARMACY	Tuan Le	3900 S GRAND BLVD	ST LOUIS	MO	63118	314-8750121

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
SKYLAND DRUG INC HM	Robert Dobbs	3968 GOVT BLVD	MOBILE	AL	36693	251-6660176
MONTEVALLO DRUG RX HM	Nicole Heaton	3990 HWY 25	MONTEVALL O	AL	35115	205-6651261
ADAMS DRUGS-PERRY HILL	Chris Phung	1633 PERRY HILL RD	MONTGOME RY	AL	36106	334-3868813
ADAMS DRUGS-EAST	Chris Phung	35 MITCHELL DR	MONTGOME RY	AL	36109	334-2720802
ADAMS DRUGS-TAYLOR ROAD	Chris Phung	7200 COPPERFIELD DR STE A	MONTGOME RY	AL	36117	334-3869370
ADAMS DRUGS-CENTRAL	Chris Phung	934 ADAMS AVE	MONTGOME RY	AL	36104	334-2643496
ADAMS DRUGS-SOUTH	Chris Phung	3016 MCGEHEE RD	MONTGOME RY	AL	36111	334-2811671
ADAMS DRUGS-VAUGHN ROAD	Chris Phung	8193 VAUGHN ROAD	MONTGOME RY	AL	36116	334-2774800
ADAMS DRUGS-CHANTILLY	Chris Phung	9168 EASTCHASE PKWY	MONTGOME RY	AL	36117	334-3867068
ADAMS DRUG MED ON TIME	Chris Phung	37 MITCHELL DR	MONTGOME RY	AL	36109	334-2885532
CITY DRUG, LLC	Michael Sigmon	11 DEXTER AVE	MONTGOME RY	AL	36104	334-2636144
PARKWAY PHCY OF MOODY	TUCKER MALONE	1021 CROSSROADS PLAZA	MOODY	AL	35004	205-6401881
MOULTRIE PHCY @ CADDO	Ben Moultrie	22747 AL HWY 24 EAST LAWR	MOULTON	AL	35650	256-9050030
MOULTRIE PHY LNGTWN	Ben Moultrie	20332 AL HIGHWAY 33	MOULTON	AL	35650	256-9744900
LOGAN PHARMACY	DARRELL THRASHER	15190 COURT ST STE A	MOULTON	AL	35650	256-9741770
STEVES DISCOUNT DRUGS	STEVE MCLEMORE	11809 AL HWY 157 SUITE A	MOULTON	AL	35650	256-9747663
KC DRUG	KIMBERLY CREWS	40870 HWY 69 STE D	MOUNDEVILLE	AL	35474	205-3718755
CRESTLINE PHARMACY	Matt Leach	60 CHURCH ST	MOUNTAIN BRK	AL	35213	205-8710317
DALTON PHARMACY	DARRELL THRASHER	1110 EAST 6TH ST	MUSCLE SHOALS	AL	35661	256-9785102
FORD CITY PHARMACY	Ken Aday	14490 COUNTY LINE RD #B	MUSCLE SHOALS	AL	35661	256-6274858
AVALON DISCOUNT DRUG HM	Mark Ray	2400 AVALON AVE BOX 2409	MUSCLE SHOALS	AL	35661	256-3141001
JACKSON APOTHECARY	Brad Jackson	12755 HIGHWAY 22 E	NEW SITE	AL	36256	256-3923448
TUSCALOOSA DRUG NORTH	BRIAN SWEATT	13620 HWY 43 N STE A	NORTHPORT	AL	35475	205-4096410
NORTHSIDE DRUG	Chris Cannon	19039 HWY 43 N STE D	NORTHPORT	AL	35475	205-3307704
ODENVILLE PHARMACY HM	Curt Eddy	140 COUNCIL DRIVE	ODENVILLE	AL	35120	205-6296303
MARGARET PHARMACY	MARK ROSS	145 JEFF WILSON DRIVE	ODENVILLE	AL	35120	205-3191999

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
GREENE PHARMACY HM	David Greene	128 WEST MAIN ST	STEELE	MO	63877	573-6954533
STEELVILLE DRUG MEDLEY	AMY MITCHELL	503 W MAIN	STEELVILLE	MO	65565	573-7752900
EVANS DRUGS - STOCKTON	KEVIN MCCULLOUGH	19 PUBLIC SQ	STOCKTON	MO	65785	417-2763128
SINKS PHARMACY SULLIVAN	Amy Mitchell	153 E SPRINGFIELD RD	SULLIVAN	MO	63080	573-4684777
EVANS DRUG SUNRISE BEACH	Kevin McCullough	13655 N STATE HWY 5	SUNRISE BEACH	MO	65079	573-3728305
SWEET SPRINGS PHCY HM	William Koch	401 S LOCUST	SWEET SPRINGS	MO	65351	660-3356300
BECKWITH PHARMACY	MARK BECKWITH	107 A NORTH LINCOLN DRIVE	TROY	MO	63379	636-5288462
VAN BUREN DRUG HM	Rita Barnes	406 MAIN ST PO BOX 361	VAN BUREN	MO	63965	573-3238159
COUNTY MARKET PHCY #392	CHRIS NIEMANN	1555 US 54 WEST	VANDALIA	MO	63382	573-5942136
SINKS PHARMACY HM	Sandy Mitchell	606 HIGHWAY 63 S	VIENNA	MO	65582	573-4226400
SINKS PHARMACY	AMY MITCHELL	1000 GW LANE STE 105	WAYNESVILLE	MO	65583	800-5555555
WEBSTER PHARMACY	STEVE ZIELINSKI	608 E LOCKWOOD AVE	WEBSTER GROVES	MO	63119	314-9621065
GOOD GRACES PHARMACY	Brandon Gregory	857 E MAIN ST #3	WILLOW SPRINGS	MO	65793	417-8550428
CHCC OUTPATIENT PHY	Esther Muna	1 LOWER NAVY HILL ROAD	SAIPAN	MP	96950	670-2331150
BRABU PHARMACY	Theodore Parker	101 AKARI CH PALE ARNOLD	SAIPAN	MP	96950	670-2332669
CORNER DRUG COMPANY	Jimmy O'Brian	802 EARL FRYE BLVD	AMORY	MS	38821	662-2565920
MEDICAL ARTS PHARMACY HM	FRED EDMONDSON	735 SOUTH 4TH STREET	BALDWYN	MS	38824	662-3655036
HOUSTON DISCOUNT PHY INC	Joseph Collins	110 E MAIN ST	BALDWYN	MS	38824	662-3658261
BALDWYN L AND L PHCY	Libby Kirkpatrick	1025 NORTH RIDGE RD	BALDWYN	MS	38824	662-3659975
NEWPOINTE PHCY # 2 HM	Robert Carr	4295 HWY 42	BASSFIELD	MS	39421	601-9436913
MAGNOLIA DRUG COMPANY	Sheree Moorman	131 HIGHWAY 51 N	BATESVILLE	MS	38606	662-4581717
MIDTOWN PHCY AND GIFTS	Tom Turfitt	620 BLUE MEADOW RD	BAY ST LOUIS	MS	39520	228-4675574
BEAUMONT DRUGS	ROCKY MCGARITY	881 HWY 198	BEAUMONT	MS	39423	601-7843313
BELMONT PHARMACY	BILL WEATHERFORD	338 2ND STREET	BELMONT	MS	38827	662-4549902
SQ PHCY GIFTS OF BELMONT	Thomas Spradling	85 MAIN ST	BELMONT	MS	38827	662-2317234
A & A INFUSION SPECIALTY	Drake Collins	124 E JACKSON ST	BELZONI	MS	39038	662-3320177

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
ALACO DISCOUNT PHARMACY 4	Tommy Morgan	27550 STATE HIGHWAY 75 STE 107	ONEONTA	AL	35121	205-2742194
OPELIKA MEDICAL ARTS PHAR	Dennis Miller	121 20TH ST. BLDG. 1	OPELIKA	AL	36801	334-7455756
THOMAS PHARMACY INC HM	Roger Burnett	1713 PERPPERILL PKWY	OPELIKA	AL	36801	334-7453632
BEAUREGARD DRUGS	TUCKER SIMMONS	7667 AL HWY 51	OPELIKA	AL	36804	334-3649993
BUY RITE DRUGS 2	PAULA NORMAN	591 S UNION STREET	OZARK	AL	36360	334-7748505
BUY RITE DRUGS #15	Tracy Alligood	1301 E ANDREWS AVE	OZARK	AL	36360	229-4354571
GROSS DRUG CO INC	Tammy Hadder	6456 AL HWY 269	PARRISH	AL	35580	205-6869945
NEIL'S PHARMACY	NEIL DAMRON	1573 CAHABA VALLEY RD	PELHAM	AL	35124	205-9885023
MAINSTREET DRUGS INC	CURT EDDY	2319 COGSWELL AVE STE 400	PELL CITY	AL	35125	205-3384903
NORTHSIDE APOTHECARY	Jeff Preuss	74 PLAZA DR	PELL CITY	AL	35125	205-8147272
PELL CITY PHARMACY HM	Tucker Malone	1027 MARTIN ST S, #13	PELL CITY	AL	35128	205-3386080
U SAVE IT PHARMACY 18	PAULA NORMAN	1108 13TH STREET	PHENIX CITY	AL	36867	334-2988390
PHIL CAMPBELL DRUG HM	Tamara Yancey	2962 HWY 237	PHIL CAMPBELL	AL	35581	205-9934123
ALACO DISCOUNT PHCY #5	Jenny Williamson	702 HWY 278 BYPASS E	PIEDMONT	AL	36272	256-4477779
MILLS PHCY AT PINSON	BEETINA LONG	6662 HWY 75 STE 118	PINSON	AL	35126	205-6803737
CARROLL TOTAL CARE PHA HM	Greg Carroll	6767 OLD SPRINGVILLE ROAD	PINSON	AL	35126	205-6805557
MILLS PHY @PLEASANT GROVE	BEETINA LONG	847 A PARK RD	PLEASANT GROVE	AL	35127	205-7440447
ADAMS DRUGS - PRATTVILLE	Chris Phung	103 S MEMORIAL DR	PRATTVILLE	AL	36067	334-3585353
SUPER BEE PHARMACY HM	Debbie Adams	3354 RAINBOW DRIVE	RAINBOW CITY	AL	35906	256-4422592
HAYMON DRUGS	Brad Haymon	128 W MAIN ST	RAINSVILLE	AL	35986	256-6384142
RAINSVILLE DRUGS BIR HM	STACY SHARP-GILES	503 MAIN ST W POBOX 1370	RAINSVILLE	AL	35986	256-6382255
RED BAY PHARMACY	Bill Weatherford	925 4TH ST NW	RED BAY	AL	35582	256-3564044
REDMONT PHARMACY	JC JR	1102 4TH ST NW POB 1487	RED BAY	AL	35582	256-3569000
H&W APOTHECARY	Wendie Jennings	211 1ST STREET	REFORM	AL	35481	205-3160077
EMERGING HOME CARE PHARMA	Tommy Wood	3868 HIGHWAY 431 BOX 899	ROANOKE	AL	36274	334-8637511
LEE DRUG STORE	Donna Brown	18530 FLORIDA ST	ROBERTSDALE	AL	36567	251-9477378

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
POLKS DRUGS 8	JOE FLYNT	1845 POPPS FERRY RD	BILOXI	MS	39532	228-2070505
COX BLYTHE DRUGS	Audra Armistead	122 W COLLEGE ST	BOONEVILLE	MS	38829	662-7285732
DAVIDSON PHARMACY, LLC	Lauren Davidson Null	203A N 2ND ST	BOONEVILLE	MS	38829	800-5555555
POLKS DISCOUNT DRUGS 4	DAVID TULLAR	1866 SPILLWAY RD	BRANDON	MS	39047	601-9924466
POLKS CROSSGATE DISDRUG 1	DAVIS WILSON	335 CROSSGATES BLVD	BRANDON	MS	39042	601-8258660
POLKS DISCOUNT DRUGS 7	DENNIS SMITH	1031 STAR RD	BRANDON	MS	39042	601-8254507
POLKS DISCOUNT DRUGS 6	CHRIS BENTON	7264 SIWELL RD	BYRAM	MS	39272	601-3718662
CALEDONIA PHARMACY	Blair Thompson	741 MAIN STREET	CALEDONIA	MS	39740	662-3564000
CHANDLER DRUG HM	JR Denton	131 PUBLIC SQUARE	CALHOUN CITY	MS	38916	662-6285331
CANTON DISCOUNT DRUG HM	Jason Strung	726 EAST PEACE ST	CANTON	MS	39046	601-8593827
WESTGATE DRUGS	Douglas Smith	1015 LEE DR	CLARKSDALE	MS	38614	662-6277858
HAIRE DRUG CENTER HM	Eddie Ellis	549 MEDICAL DR	CLARKSDALE	MS	38614	662-6242526
HENDERSON DRUGS	William E. Poff	2021 HOSPITAL DR	CLARKSDALE	MS	38614	662-6246591
CLARKSDALE PHARMACY	William Eric Poff	425 DESOTO AVENUE	CLARKSDALE	MS	38614	662-6270100
PARKWAY PHARMACY	ALLEN MILEY	134 E NORTHSIDE DR	CLINTON	MS	39056	601-9248935
COLDWATER PHARMCY HM	Steve Perkins	421 CENTRAL AVE/PO BX 309	COLDWATER	MS	38618	662-6227441
SAV ON DRUGS HM	DEBORAH MCDANIEL	345 BROAD ST	COLUMBIA	MS	39429	601-7366321
MEDICAL PLAZA ON HARPER	RICK QUINN	1425 SOUTH HARPER RD	CORINTH	MS	38834	662-2866337
MEDICAL PLAZA PHARMACY HM	RICK QUINN	111 ALCORN DRIVE	CORINTH	MS	38834	662-2866991
JONES COUNTY DRUG INC	JAY SCOGGIN	407 HILL ST	ELLISVILLE	MS	39437	601-4773030
POLKS FLORENCE DISDRUG 2	KENNY WILLOUGHBY	101 49 PLACE	FLORENCE	MS	39073	601-8458610
FRENCH'S PHCY OF FOREST	DAVID FRENCH	512 AIRPORT RD	FOREST	MS	39074	601-4691418
A & A RETAIL	ROBERT STOKES	2044 HIGHWAY 1 SOUTH	GREENVILLE	MS	38701	662-3320177
A&A INFUSION & SPCLTY 2	Robert Stokes	1430 S MAIN ST	GREENVILLE	MS	38701	662-3320177
A&A INFUSION & SPCLTY 3	Robert Stokes	423 MCALLISTER ST	GREENVILLE	MS	38701	662-3320177
GREENWOOD DOWNTOWN DRUGS	GUY PHILLIPS	105 CARROLLON AVE	GREENWOOD	MS	38930	662-4534401

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
ROGERSVILLE PHARMACY	Jason Humphreys	16135 HWY 72 W	ROGERSVILLE	AL	35652	256-4447777
BARNETT DRUGS HM	Jeff Thompson	1661 LEE ST / PO BOX 70	ROGERSVILLE	AL	35652	256-2475451
CROSSROADS PHARMACY	Ken Aday	2800 HIGHWAY 101	ROGERSVILLE	AL	35652	256-2475833
FOODLAND RX SCOTTSBORO	David Kinsley	1402 COUNTY PARK RD STE 1	SCOTTSBORO	AL	35769	256-2591011
SCOTTSBORO FAMILY PHARMAC	JEFF HILL	201 VETERANS DR	SCOTTSBORO	AL	35768	256-2599300
SECTION PHARMACY INC HM	Monica Payne	5295 TAMMY LITTLE DR	SECTION	AL	35771	256-2287179
SWIFT DRUG CO INC	BUDDY SWIFT	217 BROAD ST PO BOX 735	SELMA	AL	36701	334-8744651
PILCHER MCBRYDE DRUG CO	JIM CREECH	101 BROAD ST	SELMA	AL	36701	334-8757208
BROWN DRUG COMPANY	TIM GIBBS	1631 BROAD ST	SELMA	AL	36701	800-8489692
DALLAS AVENUE PHARMACY	TIM GIBBS	1402 WEST DALLAS AVE	SELMA	AL	36701	334-8723255
MED CENTER PHARMACY	TIM GIBBS	101 SAMUEL O MOSELEY DRIVE	SELMA	AL	36701	334-8749495
CARTER DRUG COMPANY INCHM	TIM WILLIAMSON	133 BROAD STREET	SELMA	AL	36702	334-8757223
SEMMES PHARMACY	DANNY COTTRELL	8985 MOFFETT ROAD	SEMMES	AL	36575	251-6457979
MEDICAL CENTER PHARMACY	MIKE SIGMON	507 NORTH COLUMBIA A	SHEFFIELD	AL	35660	256-3814311
U SAVE IT PHARMACY 17	PAULA NORMAN	2463 LEE RD 430	SMITHS STATION	AL	36877	334-2971505
SULLIGENT DRUG	Jonathan Beasley	55314 HWY 17 STE D	SULLIGENT	AL	35586	205-6980107
BROOKLERE PHARMACY #104	ANTHONY BROOKLERE	385 BRYAN RD STE 200	SUMITON	AL	35148	205-6486059
FT WILLIAMS PHARMACY HM	Chad Lightsey	401 W. FT WILLIAMS ST.	SYLACAUGA	AL	35150	256-2072007
MARBLE CITY PHCY HM	Danny Johnson	264 W FORT WILLIAMS	SYLACAUGA	AL	35150	256-2454446
SYLACAUGA PHARMACY	Hang Dinh	1244 TALLADEGA HIGHWAY	SYLACAUGA	AL	35150	205-9944666
SYLVANIA PHCY HM	RODNEY WILLIAMS	14 INDUSTRIAL LANE	SYLVANIA	AL	35988	256-6386070
EXPRESS PHCY- TALLADEGA	Mark Walker	320 W BATTLE ST	TALLADEGA	AL	35160	256-3621120
THE APOTHECARY, INC HM	CECELIA SMITH	1405 GILMER AVE	TALLASSEE	AL	36078	334-2833120
HERREN HILL PHARMACY HM	Robert Herren	24 HERREN HILL ROAD	TALLASSEE	AL	36078	334-2528800
KESSLERS PHARMACY HM	Mike Burns	1152 EAST LAKE BLVD	TARRANT	AL	35217	205-8416421
CONWELLS PHARMACY HM	Frank Conwell	10835 DAUPHIN ISLAND PKWY	THEODORE	AL	36590	251-9730805
THORSBY DRUGS	CHRISTA HAYES	4 MINNESOTA AVE	THORSBY	AL	35171	205-6883784

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
FIRST HEALTH-SMO HM	Frank Marascalco	1300 SUNSET DRIVE C	GRENADA	MS	38901	662-2260666
VALUE DRUG MART	Nga Nguyen	2709 25TH AVE C&D	GULFPORT	MS	39501	228-3575353
HOMETOWN PHARMACY	Brent Thompson	40518 OLD HIGHWAY 45 S	HAMILTON	MS	39746	662-3197946
NEWPOINTE PHARMACY HM	Karl Slyvest	6555 US HWY 98W. SUITE 6	HATTIESBURG	MS	39402	601-4503345
FUNDERBURK'S PHCY HM	Cheryl Suddoth	134 WEST COMMERCE	HERNANDO	MS	38632	662-4295337
IUKA DISCOUNT DRUGS	Lee Griffin	1411 W QUITMAN ST	IUKA	MS	38852	662-4239039
BARNETT APOTHECARY HM	STEVE BARNETT	606 BATTLEGROUND DR	IUKA	MS	38852	662-4239994
NORTHTOWN PHARMACY	ANDREW CLARK	6220 OLD CANTON RD	JACKSON	MS	39211	601-6654694
PICKLES DRUG STORE HM	Rob Pickle	100 N JACKSON ST	KOSCIUSKO	MS	39090	662-2891112
QUINN PHARMACY HM	Clayton Johnson	3160 AUDOBON DRIVE NORTH	LAUREL	MS	39440	601-4280688
READ DISCOUNT DRUGS	Paul Read	PO BOX 8111	LAUREL	MS	39441	601-4263238
HODGES PHARMACY	Wayne Hodges	411 ST FRANCIS ST	LEAKESVILLE	MS	39451	601-3942602
A&A INFUSION & SPCLTY	Robert Stokes	125 E 3RD ST	LELAND	MS	38756	662-3320177
PEOPLES DRUG STORE LEXING	Guy Phillips	102 COURT SQ	LEXINGTON	MS	39095	662-8342721
JITNEY PHARMACY LEXINGTON	Nick King	334 DEPOT STREET	LEXINGTON	MS	39095	662-8343378
LIBERTY DRUG HM	Ronnie Blalock	110 MAIN STREET	LIBERTY	MS	39645	601-6578051
TABOR DRUGS	Thomas Cefalu	16575 W MAIN ST	LOUISVILLE	MS	39339	662-7735363
EDWARDS DISCOUNT DRUG	Rocky McGarity	103 W FRONTAGE RD STE A	LUCEDALE	MS	39452	601-9474941
MACON CITY DRUG	BILL BELL	2939 JEFFERSON PO BOX 424	MACON	MS	39341	662-7265143
BRICK CITY DRUGS	John Hegi	159 FOUNTAINS BLVD	MADISON	MS	39110	769-2311400
MANTACHIE PHARMACY	Katlyn Spralding	3309 HWY 371 N	MANTACHIE	MS	38855	662-3223901
SONSHINE PHCY MANTACHIE	Susan Willis	2745 HIGHWAY 371 N	MANTACHIE	MS	38855	662-2825757
QUITMAN DRUG COMPANY HM	Don Haynes	1026 MARTIN LUTHER KING	MARKS	MS	38646	662-3263505
SONSHINE PHARMACY	Susan Willis	712 HWY 371	MOOREVILLE	MS	38857	662-2318360
FRENCH'S PHARMACY HM	David French	365 SOUTH 4TH STREET	MORTON	MS	39117	601-7328821
SONSHINE PHCY NETTLETON	Susan Willis	7230 HWY 45 N	NETTLETON	MS	38858	662-9630171
NEW ALBANY PHY&SOLUTIONS	Michael Warren	140 FAIRFIELD DR	NEW ALBANY	MS	38652	662-5397777

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
TRINITY DISCOUNT DRUGS	BEN MOULTRIE	1380 OLD HWY 24	TRINITY	AL	35673	256-3503365
BYRD DRUG CO INC HM	Joe Watson	81 N COURT SQ	TROY	AL	36081	334-5660100
TRUSSVILLE TOTALCAREHMLLC	Greg Carroll	115 N CHALKVILLE ROAD	TRUSSVILLE	AL	35173	205-6553455
ARGO PHARMACY, LLC	JOHNNY CLEVELAND	247 US HWY 11	TRUSSVILLE	AL	35173	205-4672223
NELMS PHARMACY	WILLIAM NELMS	115 WATTERSON PRKWY #105	TRUSSVILLE	AL	35173	205-6556133
TUSCALOOSA DRUGS 5PTS	BRIAN SWEAT	4301 VETERANS MEMORIAL PKWY	TUSCALOOSA	AL	35404	205-4699669
TUSCALOOSA CAPSTONE DRUG	BRIAN SWEATT	1236 MCFARLAND BLVD N E	TUSCALOOSA	AL	35406	205-4699669
JANN'S PHARMACY	JANN SIDES	1825 MCFARLAND BLVD N 200	TUSCALOOSA	AL	35406	205-7522045
SPECIALTY PHCY OF SHOALS	BRANDI KENNEDY	1404 E AVALON AVE	TUSCUMBIA	AL	35674	256-3891358
BIG BEAR DISCOUNT DRUGS	Trae Nelms	203 WEST LEE STREET	TUSKEGEE	AL	36083	334-7276563
UNION SPRINGS PHARMA HM	David Stewart	204 PRAIRIE ST N PO BX311	UNION SPRINGS	AL	36089	334-7382320
UNION DRUGS	TIM GIBBS	117 WATER ST	UNIONTOWN	AL	36786	334-6282241
VALLEY PHARMACY HM	ANGELA MOORE	4103 20TH AVE	VALLEY	AL	36854	334-7562037
HOODS PHARMACY HM	John Hood	4500 20TH AVENUE	VALLEY	AL	36854	334-7563219
FAIRFAX DRUG COMPANY	Steve Sharp	89 TRAMMELL BLOCK	VALLEY	AL	36854	334-7562305
VALLEY GRANDE	TIM GIBBS	7171 AL HWY 22 NORTH	VALLEY GRANDE	AL	36701	334-8752271
BEASLEY'S PHARMACY	Jonathan Beasley	170 5TH ST SW	VERNON	AL	35592	800-5555555
DURHAM PHCY HM	Sam Durham	44984 HWY 17 PO BOX 509	VERNON	AL	35592	205-6959612
GENTRY PHCY HM	Clint Gentry	3100 BLUE LAKE DR	VESTAVIA	AL	35243	205-9701983
CAHABA PHARMACY HM	Jim Parekh	3135 CAHABA HEIGHTS RD STE 101	VESTAVIA	AL	35243	205-9779299
ROCKY RIDGE DRUG	Keri Bates Bates	3346 MORGAN DR	VESTAVIA HILLS	AL	35216	205-2597100
MILLS PHCY AT CORNER	BEETINA LONG	10107 CORNER SCHOOL RD	WARRIOR	AL	35180	205-6473900
SHIPPS DISCOUNT PHCY HM	Jennifer Metcalf	88 WHITE OAK TRAIL	WARRIOR	AL	35180	205-5901100
CLEBURNE PHARMACY WEDOWEE	Frank Tant	1290 MAIN STREET S	WEDOWEE	AL	36278	256-3572315
ADAMS DRUGS- WETUMPKA	Adams Drugs	5268 US HWY 231	WETUMPKA	AL	36092	334-5675136
ROCKY'S DRUG & MERCANTILE	Rocky McGarity	13170 MOFFETT RD	WILMER	AL	36587	251-6454000

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
POLK'S DRUGS #9	JESSE MURPHY	6008 WASHINGTON AVE	OCEAN SPRINGS	MS	39564	228-2151020
NORTH HALSTEAD LLC	STEVEN CARTER	998 NORTH HALSTEAD RD	OCEAN SPRINGS	MS	39564	228-2151911
MIKE'S PHARMACY	Steven Perkins	9065 SANDIDGE CENTER CV	OLIVE BRANCH	MS	38654	662-8928448
CHANEY'S PHARMACY HM	Brent Smith	501 BRAMLETT	OXFORD	MS	38655	662-2347221
OXFORD RX	Mary John White	821 N LAMAR BLVD	OXFORD	MS	38655	662-6078794
HEALTHPLUS PHARMACY	VISHAL BAROT	238 SOUTH PEARSON RD	PEARL	MS	39208	601-9144848
RHODES-ROBBY DRUGS HM	Justin Rhodes	114 BROOKS/RAILROAD AV	PELAHATCHIE	MS	39145	601-8548252
PETAL DRUG CO INC	KATHRYN PARKER	201 OLD RICHTON RD.	PETAL	MS	39465	601-5453141
RODGERS FAM PHCY POS HM	Kim Rodgers	130 W CENTRAL AVE	PETAL	MS	39465	601-5828351
HOSPITAL DISCOUNT DRUG HM	Dan Stone	919 HOLLAND AVE	PHILADELPHIA	MS	39350	601-6562621
MONTGOMERY DRUG E-LINK HM	James Randle	349 HWY 15N	PONTOTOC	MS	38863	662-4895555
ANDERSON DRUGS HM	Stephen Anderson	5796 US HWY 11/PO BOX 407	PURVIS	MS	39475	601-7945525
HAMMACK DRUG	KIM CHANCELLOR	101 A WEST DONALD STREET	QUITMAN	MS	39355	601-7763711
POLKS DISCOUNT DRUGS 5	RONNIE SKELTON	1201 HWY 49 SOUTH STE 2	RICHLAND	MS	39218	601-9328609
STRICKLANDS CASH AND SAVE	Warren Strickland	703 FRONT ST N POB 1619	RICHTON	MS	39476	601-7886332
SAVER EXPRESS PHARMACY	Daniel Rowland	1051 HIGHLAND COLONY PKWY STE C	RIDGELAND	MS	39157	601-3688907
CHOICE PHARMACY	Erin Martinez	396 HWY 51 N STE B	RIDGELAND	MS	39157	769-3004906
SMITH DRUG HM	Trevor Williams	90 MAIN ST/ PO BX 138	RIENZI	MS	38865	662-4625357
DEEP DELTA DRUGS	Charlie Darden	56 S FOURTH ST	ROLLING FORK	MS	39159	662-8736006
ROLLING FORK DRUG CO	Guy Phillips	20917 US HWY 61	ROLLING FORK	MS	39159	662-8734723
SALTILLO PHARMACY	Lee Griffin	2698 HWY 145	SALTILLO	MS	38866	662-2692781
R AND D PHARMACY HM	Donnie O'Neal	23457 CENTRAL DRIVE STE A	SAUCIER	MS	39574	228-8321898
COMMUNITY DISCOUNT PHCY	Mollie Spencer	100 N FRONT ST	SENATOBIA	MS	38668	662-5625268
MAY'S PHARMACY HM	Sam McNulty	4385 HWY 51 SOUTH	SENATOBIA	MS	38668	662-5628550
SHELBY DRUG CO HM	Glen Neal	1211 BROADWAY OLD HWY 61S	SHELBY	MS	38774	662-3987487
SHERMAN DRUGS HM	Lindy McManus	670 HIGHWAY 178 STE 1	SHERMAN	MS	38869	662-8448880

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
WAKEFIELD PHARMACY	KATIE WAKEFIELD	145 STATE HWY 253 ST STE C	WINFIELD	AL	35594	205-4874199
ODEN SHIREY DRUG CO HM	Robin Lindsey	970 U.S. HWY 43 PO B 220	WINFIELD	AL	35594	205-4876700
WOODSTOCK DRUG HM	David Rocker	28891 HWY 5 PO BOX 280	WOODSTOCK	AL	35188	205-9389221
#29 ALLCARE	Dean Sikes	521 MAIN STREET	ARKADELPHIA	AR	71923	870-4039400
#32 ALLCARE PHCY ALF	Dean Sikes	515 MAIN STREET	ARKADELPHIA	AR	71923	870-2465553
HEALTH-WAY SAV-ON DRUGS	Blenda McVey	1903 W DEWITT HENRY DR	BEEBE	AR	72012	501-8826471
CORNERSTONE BELLA VISTA	Jim Graham	1 MERCY WAY STE 50	BELLA VISTA	AR	72714	479-8766200
WEST SIDE PHARMACY	Kenny Harrison	620 WEST SOUTH ST STE C	BENTON	AR	72015	501-7783151
POYNOR DRUG	Matt Willmott	408 PUBLIC SQUARE	BERRYVILLE	AR	72616	870-4232737
ROSE PHARMACY	JOHN ROSE	1003 NORTH 6TH ST	BLYTHEVILLE	AR	72315	870-7624545
WINNINGHAM PHARMACY	Justin Piker	232 W MAIN ST	BRADFORD	AR	72020	501-3442763
THE PHARMACY AT BROOKLAND	Mike Barkley	406A HONEYSUCKLE	BROOKLAND	AR	72417	870-2069920
CORNERSTONE PHCY BRYANT	Ben Ramsey	2203 N REYNOLDS RD	BRYANT	AR	72022	501-4818964
BRYANT FAMILY PHCY	CHARLIE TUCKER	3801 HIGHWAY 5 NORTH	BRYANT	AR	72022	501-8472880
HAWKINS RX	Layne Hawkins	902 CENTRAL BLVD	BULL SHOALS	AR	72619	870-4457188
CAMDEN DRUG HM	BETSY TUBERVILLE	1005 WASHINGTON	CAMDEN	AR	71701	870-8369303
MORRISON'S PHARMACY HM	Bill Morrison	1286 HIGHWAY 4 BY-PASS	CAMDEN	AR	71701	870-8368132
MORRISONS CLINIC PHARMACY	Bill Morrison	353 CASH ROAD	CAMDEN	AR	71701	870-8362727
CARAWAY DRUG	Brad Hamilton	106 W STATE ST	CARAWAY	AR	72419	870-3512697
WALLING DRUG	Jennifer Walling	316 N MAIN ST STE A	CAVE CITY	AR	72521	870-2320450
ECONO-MED PHARMACY	Greta Ishmael	1 CHOCTAW CENTER	CHEROKEE VILLAGE	AR	72529	870-8564696
CLINTON DRUG	Michael Butler	2526 HIGHWAY 65 S STE 101	CLINTON	AR	72031	501-7458414
SAV-ON DRUGS HM	David Baker	1014 HARKRIDER	CONWAY	AR	72032	501-3276777
CONWAY MEDICAL PARK PHCY	James Thomas	650 UNITED DR STE 110	CONWAY	AR	72032	501-3586212
CORNERSTONE CONWAY	JOHN WIRGES	815 HOGAN LANE STE 10	CONWAY	AR	72034	501-3283282
HARRIS DRUG & GIFTS, LLC	Renee Logan	205 DEQUEEN AVE.	DE QUEEN	AR	71832	870-5843555
DUMAS FAMILY PHARMACY	Cheryl Stimson	301 HWY 65 SOUTH	DUMAS	AR	71639	800-5555555

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
GATLIN'S PHARMACY	Bart Doran	18 1ST AVE	TISHOMINGO	MS	38873	662-4386605
TUNICA PHARMACY HM	Eric Poff	1181 MAIN STREET	TUNICA	MS	38676	662-3631431
RXS TUPELO	DOUGLAS WRIGHT JR	2801 WEST MAIN STE A	TUPELO	MS	38801	662-6206400
PAKMEDS PHARMACY	Robin Jackson	5060 RAYMOND AVENUE	TUPELO	MS	38801	800-5555555
HELPING HAND FAMILY PHCY	Michael Jones	1670 HWY 61 NORTH	VICKSBURG	MS	39183	601-6316837
DUNCANS PHARMACY INC HM	Jim Jackson	28271 HWY 15 PO BOX 220	WALNUT	MS	38683	662-2234727
LAB DISCOUNT DRUGS HM	Abe Hutto	923 WAYNE STREET	WAYNESBORO	MS	39367	601-7354444
BONNER DISCOUNT DRUGS	Jerry Bonner	1017 AZALEA DRIVE	WAYNESBORO	MS	39367	601-7352141
ROSE DRUG HM	Andrew Williams	595 COMMERCE STREET	WEST POINT	MS	39773	662-4943341
POINT CITY DRUGS	BLAIR THOMPSON	7683 HWY 45 ALT BLVD	WEST POINT	MS	39773	662-4950008
HOMETOWN FAMILY PHCY INC	Brett Thames	930 HALL ST STE H	WIGGINS	MS	39577	691--528-12
COUNTY DISCOUNT DRUG	Robert Parker	820 HALL ST	WIGGINS	MS	39577	601-9284482
HAMMOND'S PHARMACY HM	Gay Hammond	212 NORTH APPLGATE	WINONA	MS	38967	662-2838802
KARTS OF WINONA PHARM INC	Sanjeev Kumar	603 MIDDLETON RD	WINONA	MS	38967	662-5085014
WEBB'S PHARMACY	Nick King	216 SOUTH MAIN ST	YAZOO CITY	MS	39194	662-7463253
VANJONS PHARMACY	Wade E. Ward	320 E FIFTEENTH ST	YAZOO CITY	MS	39194	662-7463562
BAKER DRUG	Alyse Webber	103 S MAIN STREET	BAKER	MT	59313	406-7782214
PHARM406	Kyle Austin	1410 38TH ST W	BILLINGS	MT	59102	406-7176100
PRICE RITE BOZEMAN HM	Randy Harrington	910 N 7TH AVE	BOZEMAN	MT	59715	406-5870608
CHOTEAU DRUG	Faye Persinger	102 MAIN AVE N	CHOTEAU	MT	59422	406-4662700
DAHL MEMORIAL HC COM PHCY	Michelle Mehling	215 SANDY ST	EKALAKA	MT	59324	406-7758896
FAIRFIELD DRUG HM	Jill Tex	407 CENTRAL, PO BOX 247	FAIRFIELD	MT	59436	406-4672336
YELLOWSTONE PHY OF FORSTH	Leanna Schwend	1025 MAIN ST	FORSYTH	MT	59327	406-3462134
WESTERN DRUG-GLASGOW INC	FRED COMPTON	537-539 2ND AVE SOUTH	GLASGOW	MT	59230	406-2284308
PUBLIC DRUG	Jessica Cardwell	324 CENTRAL AVENUE	GREAT FALLS	MT	59401	406-4531497
406 CLINIC PHARMACY	Eric Shields	1315 WYOMING ST STE B	MISSOULA	MT	59801	406-5414060
SAVMOR DRUG I HM	Nancy Trenary	1610 S 3RD WEST STE 100	MISSOULA	MT	59801	406-7216017

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
SAMA CLINIC PHARMACY	Amy Webb	600 S TIMBERLANE DR #101	EL DORADO	AR	71730	870-6393929
HIGHLANDS ONCOLOGY GROUP	Jeff Hunnicutt	3232 N NORTH HILLS BLVD	FAYETTEVILLE	AR	72703	479-6951199
PRICE HARRIS PHARMACY	LAURA HARRIS	313 ARKANSAS STREET	FORREST CITY	AR	72335	870-6337474
#34 ALLCARE PHARMACY	Dean Sikes	3409 WHEELER AVENUE	FORT SMITH	AR	72901	479-7637890
COLEMAN PHARMACY	Michael Butler	3610 GRAND AVENUE	FORT SMITH	AR	72904	479-7835171
GOSNELL DRUGS	Brandon Michael	134 BEVILL AVE	GOSNELL	AR	72315	870-7519242
CORNERSTONE PHARMACY HM	Kenny Harrison	8470 EDMONT ROAD	GREERS FERRY	AR	72067	501-8256265
SAM ALEXANDER PHARMACY	Tara Willmott	127 N MAIN STREET	HARRISON	AR	72601	870-7416511
HARRISON FAMILY PHARMACY	Ray Harrison	2323 HIGHWAY 229	HASKELL	AR	72015	501-7946338
HOT SPRINGS PHARMACY	ADUSTON SPIVEY	1210 AIRPORT RD	HOT SPRINGS	AR	71913	501-7602444
FOUNTAIN LAKE FAMILY PHCY	Michael Butler	4517 PARK AVENUE	HOT SPRINGS	AR	71901	501-5473400
VILLAGE HEALTHMART #1	MICHAEL BUTLER	4440 N HIGHWAY 7	HOT SPRINGS VILLAGE	AR	71909	501-9220777
CORNERSTONE JACKSONVILLE	Kenny Harrison	315 S JAMES ST	JACKSONVILLE	AR	72076	501-9826979
ALLCARE PHARMACY #15	Dean Sikes	1903 GRANT AVE, STE I & J	JONESBORO	AR	72401	870-2450207
CAMP'S MEDICAL PHARMACY	Donna Camp	4109 E JOHNSON AVE STE A	JONESBORO	AR	72405	870-9105550
STONE'S PHARMACY	Eric Hadley	417 E MATTHEWS AVE	JONESBORO	AR	72401	870-9355538
WEST END ASSOCIATES	Krystal Soo	619 W NETTLETON AVE	JONESBORO	AR	72401	870-9324742
SOUTHERN PHY AR JONESBORO	kyle lomax	3001 APACHE DR	JONESBORO	AR	72401	870-9721751
PARKER ROAD SPCLTY PHCY	Mike Soo	1109 W. PARKER RD	JONESBORO	AR	72404	870-9356400
SOO'S DRUG STORE	Tyler Soo	2822 E NETTLETON AVE	JONESBORO	AR	72401	870-9326930
SOUTHRN PHY AR LEACHVILLE	Kyle Lomax	109 S MAIN ST	LEACHVILLE	AR	72438	870-5396831
SOUTHERN PHY AR LEPANTO	Kyle Lomax	730 GREENWOOD AVE STE A	LEPANTO	AR	72354	870-4752617
CORNERSTONE PHARMACY HM	Aubrey Harton	16115 ST VINCENT STE120	LITTLE ROCK	AR	72223	501-8212300
MEDIC PHARMACY #1 INC	Becky Loux	5901 W 12TH	LITTLE ROCK	AR	72204	501-6643907
CORNERSTONE PHARMACY HM	Brittany Marsh	4220 RODNEY PARHAM	LITTLE ROCK	AR	72212	501-2232224
ARCH STREET PHARMACY HM	CHARLIE TUCKER	11200 ARCH STREET PIKE	LITTLE ROCK	AR	72206	501-2617181
#31 ALLCARE PHARMACY	Dean Sikes	10620 COLONEL GLENN RD	LITTLE ROCK	AR	72204	501-2178886

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
PLAINS DRUG HM	Andi Holmes	214 RAILROAD STREET	PLAINS	MT	59859	406-8263552
RR HLTH CARE SOLUTIONS	Cory Adams	63802 US HIGHWAY 93 STE B	RONAN	MT	59864	406-6765600
FAMILY HEALTH PHARMACY HM	Shiree Dupuis-Ryan	63307 HWY 93 SOUTH	RONAN	MT	59864	406-6762111
SEELEY SWAN PHARMACY HM	Karen Dove	3027 HWY 83	SEELEY LAKE	MT	59868	406-6778989
MINERAL PHARMACY	Andrea Holmes	207 RIVER STREET	SUPERIOR	MT	59872	406-8224681
THOMPSON FALLS FAMILY PHY	Justin Holmes	1221 MAIN ST	THOMPSON FALLS	MT	59873	406-8274349
MEDICAL PHY OF ALBEMARLE	MARK RICHARD	320 YADKIN STREET	ALBEMARLE	NC	28001	704-9829179
MEDICAL PHCY OF UWHARRIE	MARK RICHARDS	1420 US HWY 52 N	ALBEMARLE	NC	28001	704-5509906
APPALACHIAN SPECIALTY PHY	Jason Graessle	932 HENDERONVILLE RD #106	ASHEVILLE	NC	28803	828-2224269
ASHEVILLE COMPOUNDING PHY	John Clark	760 MERRIMON AVENUE	ASHEVILLE	NC	28804	828-2558757
PINNACLE APOTHECARY	Jonathan Snipes	24 SARDIS RD STE A	ASHEVILLE	NC	28806	803-4296922
ASHEVILLE MOUNTAIN PHCY	Paul Wolfe	1272 TUNNEL ROAD STE 20	ASHEVILLE	NC	28805	828-5750723
ROAN MT PHCY BAKERSVILLE	Jordan Baker	604 S HIGHWAY 226	BAKERSVILLE	NC	28705	828-4479419
BELMONT'S DRUG STORE HM	Matt Morgan	403 EAST CATAWBA ST	BELMONT	NC	28012	704-8299897
GORDON FAMILY PHARMACY	Jeff Gordon	518 S BROAD ST	BREVARD	NC	28712	828-8776111
BRYSON CITY PHCY INC HM	Mike Spina	200 VALLEY VILLAGE SHOP	BRYSON CITY	NC	28713	828-4881705
PRESCRIPTION PAD BRNSVILE	Anthony Randolph	730 E MAIN ST	BURNSVILLE	NC	28714	828-6783914
CAROLINA MOUNTAIN PHCY	JARED MATTSON	7 PISGAH HWY	CANDLER	NC	28715	828-6336700
501 PHARMACY	Greg Vassie	69 KNOX WAY STE 110	CHAPEL HILL	NC	27516	984-9990501
AVALON PHARMACY	Divyeshkumar Patel	8401 MEDICAL PLAZA DR 120	CHARLOTTE	NC	28262	980-5800080
WALKER'S DRUG STORE	KAVEL (KEVIL) BHATHELA	4390 COLWICK RD	CHARLOTTE	NC	28211	704-3643444
CAROLINA PHY ARBORETUM	VIC PATEL	8035 PROVIDENCE RD # 300	CHARLOTTE	NC	28277	704-9094700
HOUSER DRUG COMPANY HM	Tim Moss	302 EAST MAIN STREET	CHERRYVILLE	NC	28021	704-4356011
CLINTON DRUG CO	AMANDA BRYAN	307 BEAMAN STREET	CLINTON	NC	28328	910-5928444
MATTHEWS HM	Jimmy Matthews	408 N E BOULEVARD	CLINTON	NC	28328	910-5923122
BOWMAN DRUG CO HEALTHMART	Don Beam	126 FIRST AVENUE SOUTH	CONOVER	NC	28613	828-4641354
MEDICAL VILLAGE PHARMACY	Kelly Cross	815 FAIRGROVE CHURCH RD SE	CONOVER	NC	28613	828-3224505

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
PARKWEST PHARMACY	Gwendolyn Paige Herzig	904 AUTUMN ROAD	LITTLE ROCK	AR	72211	501-2243499
RHEA DRUG STORE HM	Joe Searcy	2801 KAVANAUGH	LITTLE ROCK	AR	72205	501-6634131
BLANDFORD PHARMACY INC.	KEITH SHOLES	5 ST. VINCENT CIR STE#110	LITTLE ROCK	AR	72205	501-6644466
KAVANAUGH RX PHCY	KENNY HARRISON	5008 E KAVANAUGH	LITTLE ROCK	AR	72207	501-6643844
CORNERSTONE OTTER CREEK	KENNY HARRISON	10320 STAGECOACH RD	LITTLE ROCK	AR	72210	501-4551900
CORNERSTONE PHARMACY MAIN	KENNY HARRISON	1701 MAIN ST	LITTLE ROCK	AR	72206	501-2465451
VILLAGE HEALTHMART#2	MICHAEL BUTLER	24615 HIGHWAY 5	LONSDALE	AR	72087	501-9220909
MALVERN FAMILY PHARMACY	Michael Butler	902 MARTIN LUTHER KING BL	MALVERN	AR	72104	501-7327950
COMMUNITY CARE PHCY	Shelyn Davis	1606 MARTIN LUTHER KING BLVD	MALVERN	AR	72104	501-2291446
DELTA DRUG HM APCI	Matthew Jackson	257 S HWY 18	MANILA	AR	72442	870-5613113
THE LOCAL PHARM	Andrew Benson	924 STATE HIGHWAY 77	MARION	AR	72364	800-5555555
SOUTHERN PHY AR MARK TREE	Kyle Lomax	203 NEWSOME DR STE A	MARKED TREE	AR	72365	870-3582135
MARMADUKE FAMILY PHCY	David Eddington	11901 US 49 N	MARMADUKE	AR	72443	870-5972911
SOUTHERN PHY AR MONETTE	Kyle Lomax	214 W DREW AVE	MONETTE	AR	72447	870-4862111
POWER PHARMACY INC HM	Cheryl Power	1310 SOUTH 4TH STREET	NASHVILLE	AR	71852	870-8451413
DARLING MED-SAVE	Jamie Darling	1303 MCLAIN ST	NEWPORT	AR	72112	870-5235888
CORNERSTONE JFK	KENNY HARRISON	5328 JOHN F KENNEDY BLVD	NORTH LITTLE ROCK	AR	72116	501-2465035
BAKER DRUG INC HM	Kenny Harrison	4307 E BROADWAY ST	NORTH LITTLE ROCK	AR	72117	501-9453264
CORNERSTONE PHCY LAKEWOOD	KENNY HARRISON	2609 MCCAIN BLVD	NORTH LITTLE ROCK	AR	72116	501-3531984
MEDICINE MAN JFK	Terry Perkins	5308 JFK BLVD STE 3	NORTH LITTLE ROCK	AR	72116	501-9407517
MEDICINE MAN SPRINGHILL	Terry Perkins	3201 SPRINGHILL DR STE 110	NORTH LITTLE ROCK	AR	72117	501-9407517
MEDICINE MAN MAIN ST.	Terry Perkins	2520 MAIN ST	NORTH LITTLE ROCK	AR	72114	501-9407517
THE PILL PEDDLER PHCY	Stephanie Rapert	1740 S US HIGHWAY 61	OSCEOLA	AR	72370	870-5630777
FUTRELL PHARMACY INC HM	J MARK FUTRELL	115 EAST BROADWAY	POCAHONTAS	AR	72455	870-8925615
#23B ALLCARE PHARMACY	Dean Sikes	216 SOUTH 13TH ST STE B	ROGERS	AR	72758	877-4209400
HIGHLANDS PHARMACY	Jeff Hunnicutt	808 S 52ND ST	ROGERS	AR	72758	479-8781818
STOTTS DRUG STORE INC HM	Nancy Showalter	103 W ARCH	SEARCY	AR	72143	501-2682536

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
EDEN DRUG INC HM	PETE CROUCH	103 W STADIUM DRIVE	EDEN	NC	27288	336-6274854
MEDICINE BOX FORESTCIT HM	Sheila Sheehan	664 SOUTH BROADWAY	FOREST CITY	NC	28043	828-2451696
SMART PHARMACY LLC	JACOB REICHE	60 GEORGIA ROAD	FRANKLIN	NC	28734	828-3693784
TIPTON COMPOUNDING PHCY	Jamie Leigh Tipton	175 E MAIN ST STE A	FRANKLIN	NC	28734	828-5248900
U SAVE IT PHCY-FRANKLIN	PAULA NORMAN	20 FRANKLIN PLAZA DRIVE	FRANKLIN	NC	28734	828-5240156
BEAM & PUTNAM INC	Roger Putnam	701 WEST FRANKLIN BLVD	GASTONIA	NC	28052	704-8679611
GRANITE DRUG CENTER	Bryan Huffstetler	21 FALLS AVE	GRANITE FALLS	NC	28630	828-3962144
MEDICAL ARTS PHARMACY	Charles White	253 RUIN CREEK RD	HENDERSON	NC	27536	800-5555555
MEDICAL CENTER HICKORY	Bill Means	126 NORTH CENTER STREET	HICKORY	NC	28601	828-3227717
LONG VIEW DRUG	Justin Austin	2637 1ST AVE SW	HICKORY	NC	28602	828-3247948
BETHLEHEM PHARMACY HM	Mark Richards	9471 NC HIGHWAY 127	HICKORY	NC	28601	828-4958258
NOLANS FAMILY PHARMACY	Fiona Cole	2513 EASTCHESTER DR #119	HIGH POINT	NC	27265	832-3611491
HILLSBOROUGH PHARMACY	Greg Vassie	110 BOONE SQUARE ST #29	HILLSBOROUGH	NC	27278	919-2451212
INDIAN TRAIL PHARMACY	DONALD BEAM	106 INDIAN TRAIL RD SOUTH	INDIAN TRAIL	NC	28079	704-8217617
KM PHARMACY HEALTHMART	David Dellinger	1106 SHELBY ROAD	KINGS MOUNTAIN	NC	28086	704-7391698
KNIGHTDALE PHARMACY	SEGMIA TOHNYA	6602 KNIGHTDALE BLVD STE 120	KNIGHTDALE	NC	27545	919-2951112
CAJAH MOUNTAIN DISC/SERV	ARCHIE DAVIS	2006 CONNELLY SPRINGS RD	LENOIR	NC	28645	828-7268632
FOOTHILLS PHARMACY HM	James Roberson	202-A HARPER AVE NW	LENOIR	NC	28645	828-7546453
LEWISVILLE DRUG PHCY	Keith Vance	6715 SHALLOWFORD RD	LEWISVILLE	NC	27023	336-9460220
COMMUNITY PHCY LINCOLNTON	MARK RICHARDS	626 CENTER DRIVE	LINCOLNTON	NC	28092	704-7352556
MEDICAL PHCY OF LOCUST	MARK RICHARDS	236 MARKET ST STE 100	LOCUST	NC	28097	704-8883784
PRESCRIPTION PAD MARION	Anthony Randolph	1211 N MAIN ST	MARION	NC	28752	828-6599727
MADISON PHCY AND GIFTS	Cynthia Niles	4401 US HWY 25 70	MARSHALL	NC	28753	828-6491632
GIANT GENIE PHCY MATTHEWS	Austin Wise	2925 SENNA DR STE 100	MATTHEWS	NC	28105	704-8140154
GPS PHARMACY	Julya Friedman	163 S TRADE ST STE A	MATTHEWS	NC	28105	980-2452028
MILLERS CREEK PHCY HM	Herman Osborne	2924 N NC HWY 16	MILLERS CREEK	NC	28651	336-8383145
JONES DRUGS INC HM	Randy Epley	208 AVERY AVE	MORGANTON	NC	28655	828-4371565

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
SEARCY MEDICAL CTR PHCY	Todd Mcleod	2900 HAWKINS DR STE 100	SEARCY	AR	72143	501-2683311
BRIAN'S PHARMACY	BRIAN KOESY	4201 E KIEHL	SHERWOOD	AR	72120	501-9202400
HIGHLANDS ONC PHCY PRKWY	Jeff Hunnicutt	3901 PARKWAY CIRCLE	SPRINGDALE	AR	72762	479-8781939
WESTSIDE FAMILY PHCY HM	Jon Ragan	3819 WEST SUNSET	SPRINGDALE	AR	72762	479-7563232
BEARD DRUG CO INC HM	Eddie Beard	614 SOUTH LINCOLN AVENUE	STAR CITY	AR	71667	870-6284277
COKER HAMPTON DRUG	James Bethea	218 S MAIN ST	STUTT GART	AR	72160	870-6732691
CSI PHARMACY	James Sheets	1201 EAST 35TH STREET	TEXARKANA	AR	71854	870-7743666
COLLEGE HILL DRUG	MICHAEL BUTLER	100 EAST STREET	TEXARKANA	AR	71854	870-7726969
THE DAILY DOSE PHARMACY	Leigh Anne Ross	421 HIGHWAY 463 N	TRUMANN	AR	72472	870-7090566
BARLOW PHARMACIES, INC	Kelly Barlow	1515 FAYETTEVILLE RD	VAN BUREN	AR	72956	479-4747171
ECONO-MED OF WALNUT RIDGE	Greta Ishmael	1045 W MAIN STREET STE B	WALNUT RIDGE	AR	72476	870-8564696
WYNNE MED PHY CROSS CNTY	Leslie Johnson	718 SOUTH FALLS BLVD	WYNNE	AR	72396	870-2388531
RIVERSIDE PHARMACY	Sathish Cariappa	2410 HIGHWAY 95	BULLHEAD CITY	AZ	86442	928-2194700
HAND IN HAND PHARMACY	Ji Young Kim	1940 W CHANDLER BLVD #3	CHANDLER	AZ	85224	480-5347537
MEDMETRICS PHARMACY	TAYLOR FROILAND	1075 W QUEEN CREEK RD STE 2	CHANDLER	AZ	85248	480-8833800
SAROUJA GILBERT PHARMACY	SAM ALNAJJAR	3570 S VAL VISTA DR#108	GILBERT	AZ	85297	480-8870244
THE APOTHECARY SHOP	Tony Liska	1840 MESQUITE AVE, SUITE E	LAKE HAVASU CITY	AZ	86403	928-8550106
NOWRX-MESA	Carey Breese	2452 W BIRCHWOOD AVE #106	MESA	AZ	85202	480-5973580
ON THE GO PHARMACY	Chris Quintana	15830 N 35TH AVE SUITE #3	PHOENIX	AZ	85053	602-6075094
METIER PHARMACY	J RANDLE HOUSE	3511 E INDIAN SCHOOL	PHOENIX	AZ	85018	602-8996960
PHOENIX PHARMACY	VITTELIAN FORBES	1701 E THOMAS RD #105	PHOENIX	AZ	85016	602-2376677
AVE MARIA PHARMACY	PATRICK MCNERNEY	1945 COMMERCE CTR CR STE C	PRESCOTT	AZ	86301	928-7728674
RIO RICO PHARMACY HM	Joe Coil	1131 W FRONTAGE RD	RIO RICO	AZ	85648	520-7613338
MIXTURES PHARMACY SCOTTSD	Lori Allen	6590 N SCOTTSDALE RD, #140	SCOTTSDALE	AZ	85253	480-4000649
SIERRA PHCY AND COMP LAB	Elizabeth Davie	2085 E FRY BLVD	SIERRA VISTA	AZ	85635	520-4590705
CALLS COMMUNITY PHARMACY	Jordan Call	985 S MAIN ST	SNOWFLAKE	AZ	85937	928-4571115

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
WALLYS PHARMACY	Lin Hamilton	933 ROCKFORD ST STE 5	MOUNT AIRY	NC	27030	336-7899089
MOUNT AIRY DRUG HM	Mark Richards	725 W. INDEPENDENCE BLVD	MOUNT AIRY	NC	27030	336-7865506
GATES PHARMACY	Neil Elden	364 N SOUTH STREET	MOUNT AIRY	NC	27030	336-7895050
TRENT EAST PHARMACY HM	Nathan DAUGHTRY	937 HWY 70 EAST	NEW BERN	NC	28560	252-6386500
BRAME HUIE PHARMACY	Cathy Huie	1920 W PARK DRIVE	NORTH WILKESBORO	NC	28659	336-8388988
BLUE RIDGE PHCY MIDTOWN	Kim Koontz	306 WILKESBORO AVENUE	NORTH WILKESBORO	NC	28659	336-8383782
BLUE RIDGE PHCY NO PARKHM	Mark Huffman	23 A SPARTA ROAD	NORTH WILKESBORO	NC	28659	336-6677272
PINEHURST MED CLINIC PHCY	BRANDON ENFINGER	15 REGIONAL DRIVE 2ND FLR	PINEHURST	NC	28374	910-2353404
PINEVILLE PHARMACY	KISHAN Patel	311 S POLK ST STE 80	PINEVILLE	NC	28134	704-9647366
RALEIGH NEUROLOGY	RICK CHAPMAN	1540 SUNDAY DRIVE	RALEIGH	NC	27607	919-3254275
OAKRIDGE PHARMACY	Varun Patel	2406 BLUE RIDGE RD #180	RALEIGH	NC	27607	800-5555555
REIDSVILLE PHCY HM	Andy Gaster	924 SOUTH SCALES ST	REIDSVILLE	NC	27320	336-3429175
DRUGCO EXPRESS #5	Neal White	1096 EAST 10TH STREET	ROANOKE RAPIDS	NC	27870	800-5555555
DRUGCO DISCOUNT PHY #6	Neal White	270 SMITH CHURCH ROAD	ROANOKE RAPIDS	NC	27870	800-5555555
ROBBINSVILLE PHARMACY	Mike Spinn	238 RODNEY ORR BYPASS	ROBBINSVILLE	NC	28771	828-4792273
COMMUNITY PHCY ROXBORO	Robert Morgan	719 NORTH MAIN STREET	ROXBORO	NC	27573	336-5999293
MEDICINE BOX/RUTHERFORDHM	Laura Hodge	200 CHARLOTTE ROAD	RUTHERFORD TON	NC	28139	828-2877117
COMMUNITY PHARMACY HM	Debra Griffin	1194 WYKE ROAD	SHELBY	NC	28150	704-4821904
LOWRY DRUG	Fred Wilson Lowry Jr	750 HARTNESS RD	STATESVILLE	NC	28677	704-8732247
SOUTHSIDE DRUG HM	Ken Chapman	430 WESTERN AVE	STATESVILLE	NC	28677	704-8737612
MARK'S HEALTHMART PHCY	Maqbool Adam	836 ASHEVILLE HWY	SYLVA	NC	28779	828-6315547
DAMERON DRUG STORE/SERXXX	David Dameron	100 SO MAIN STREET	TABOR CITY	NC	28463	910-6533089
DRUGCO DISCOUNT PHY #7	Neal White	1507 N. MAIN STREET	TARBORO	NC	27886	800-5555555
PEOPLES DRUG STORE HM	Phil Icard	255 NC HWY 16 SOUTH	TAYLORSVILLE	NC	28681	828-6322271
TOWN & COUNTRY DRUG HM	Phillip Sprinkle	53 EAST MAIN AVENUE	TAYLORSVILLE	NC	28681	828-6322278
COMMUNITY PHCY TIMBERLAKE	Sara Biever	413 HELENA MORIAH ROAD	TIMBERLAKE	NC	27583	336-3641053

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
MAIN PHARMACY	John Au	103 N GARFIELD AVE STE D	ALHAMBRA	CA	91801	626-5761219
GOLDEN HEALTH PHARMACY	Kelly Guo	88 S PALM AVE	ALHAMBRA	CA	91801	626-9405002
WEBSTER'S PHARMACY	MICHAEL MILLER	2450 NORTH LAKE AVE	ALTADENA	CA	91001	626-7971163
LAST FRONTIER PHARMACY	Kevin Kramer	1111 N. NAGLE ST. #RP101	ALTURAS	CA	96101	530-7088850
ROCCO PHARMACY	Brandy Ta	1491 E LA PALMA STE A	ANAHEIM	CA	92805	714-6037972
SANTA MARIA PHARMACY2	Marcos Soliman	1224 S BROOKHURST ST	ANAHEIM	CA	92804	714-5567788
TRUE CARE PHARMACY	Michelle Nguyen	421 N. BROOKHURST ST. #123	ANAHEIM	CA	92801	714-5988939
THE PHARMACY	NANCY PAI	3055 W. ORANGE 108	ANAHEIM	CA	92804	714-9954161
BLAST PHARMACY	Ranny Tawfik	1807 W KATELLA AVE STE 206	ANAHEIM	CA	92804	714-7337978
PACIFIC OAK COMP PHCY	John Kong	12 N 1ST AVE	ARCADIA	CA	91006	626-3488930
BARNES ARCATA FAM DRUG HM	Sherri Sumner	1080 G ST	ARCATA	CA	95521	707-8222496
MEADOWMONT PHARMACY	PATRICK CROSBY	2182 HIGHWAY 4	ARNOLD	CA	95223	209-7951155
BEST CARE PHARMACY HM	Pashmina Patel	1051 E. GRAND AVE.	ARROYO GRANDE	CA	93420	805-4811961
KOAM PHARMACY HM	Kwang Kim	18102 S. PIONEER BLVD 101	ARTESIA	CA	90701	562-4023636
FAMILY MEDICAL PHARMACY	Susan Ham	18009 NORWALK BLVD	ARTESIA	CA	90701	562-4020500
GREATER PLACER PHARMACY	HUYQUANG LE	3133 PROFESSIONAL DR #17	AUBURN	CA	95603	530-8858582
LEO'S CATALINA DRUG STORE	Bryce Noll	401 CRESCENT AVE	AVALON	CA	90704	310-5100189
PHAST PHARMACY	Ayman Mohamed	1121 W COLUMBUS ST	BAKERSFIELD	CA	93301	661-5786500
ACCESS SPECIALTY PHCY	Ebram Tawdrous	5555 BUSINESS PARK S STE 230	BAKERSFIELD	CA	93309	661-4893500
DOWNTOWN PHARMACY	JASWINDER KAUR	2700 F STREET STE 200	BAKERSFIELD	CA	93301	661-3225700
SOUTHWEST PHARMACY	Jaswinder Kaur	3400 PANAMA LN STE L	BAKERSFIELD	CA	93313	661-8375700
LEE'S BPMC PHARMACY SS	RANDY LEE	4570 CALIFORNIA AVE #110	BAKERSFIELD	CA	93309	661-6331100
CAREPHARM PHARMACY	VINCENT DANG	4700 PANAMA LANE STE 116	BAKERSFIELD	CA	93313	661-8367557
HEALTH MART BELL GARDENS	Jeanie Son	7625 EASTERN AVE STE C	BELL GARDENS	CA	90201	323-7733800
FAMILY PHY BVRLY HILLS	DAVID NEWMAN	8314 WILSHIRE BLVD	BEVERLY HILLS	CA	90211	323-6534070
GARFIELD PHARMACY	Eddie Yadidi	9400 BRIGHTON WAY	BEVERLY HILLS	CA	90210	310-2740144

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
COMMUNITY PHARMACY VALE	MARK RICHARDS	9576 NC HIGHWAY 10 WEST	VALE	NC	28168	704-4620226
MARK'S HEALTHMART PHCY	Christy Kirkpatrick	97 KENT LANE	WAYNESVILLE	NC	28786	828-2466191
PRESCRIPTION PAD OF WEAVE	Andy Stoker	3 N MAIN STREET	WEAVERVILLE	NC	28787	828-4847800
PEOPLE'S DRUG	Bradley Eller	423 E 2ND ST	WEST JEFFERSON	NC	28694	336-2469990
CHEROKEE PHARMACY	MICHAEL SPINN	664 CHEROKEE CROSSING	WHITTIER	NC	28789	828-4972273
WINTER PARK DISCOUNT DRUG	Nirav Patel	5220 WRIGHTSVILLE AVE	WILMINGTO N	NC	28403	910-7912346
SUNSET PARK PHARMACY	Nirav Patel	2059 CAROLINA BEACH RD	WILMINGTO N	NC	28401	910-7620695
BEULAH DRUG	Wyatt Martenson	147 WEST MAIN STREET	BEULAH	ND	58523	701-8735215
CHURCHILL PHARMACY HM	Dan Churchill	1190 W TURNPIKE AVE STE2	BISMARCK	ND	58501	701-2240339
MAYO PHARMACY	Kevin Martian	303 NORTH 4TH ST	BISMARCK	ND	58501	701-2232425
BOTTINEAU PHARMACY	MATT PAULSON	505 MAIN STREET	BOTTINEAU	ND	58318	701-2282291
BOTTINEAU CLINIC PHARMACY	MATT PAULSON	314 OHMER STREET	BOTTINEAU	ND	58318	701-2282220
CARRINGTON DRUG HM	Matt Paulson	415 MAIN	CARRINGTON	ND	58421	701-6522521
CENTRAL PHCY CARRINGTON	Shane Wendel	990 MAIN ST	CARRINGTON	ND	58421	701-6522651
COOPERSTOWN DRUG	MATT PAULSON	901 BURREL AVE SE PO BOX 627	COOPERSTO WN	ND	58425	701-7972414
CLINIC PHARMACY D HM	Becky Fletshock	1001 7TH ST NE	DEVILS LAKE	ND	58301	701-6624427
ND PHARMACY INC #748	Robert Treitline	1761 3RD AVENUE W # B	DICKINSON	ND	58601	701-2254434
ND PHARMACY WEST	Robert Treitline	1283 ROUGHRIDER BLVD	DICKINSON	ND	58601	701-4830724
EDGELEY PHARMACY	DAN CHURCHILL	509 MAIN STREET	EDGELEY	ND	58433	701-4932810
PRAIRIE PHARMACY	Kelly Hart	4731 13TH AVE SW	FARGO	ND	58103	701-3730325
MEDICAL PHARMACY SOUTH	LANA KIRSCHENMANN	4151 45TH ST SO	FARGO	ND	58104	701-2828075
PROSPERITY HEALTH PHARMAC	Virginia Howe	5180 PROSPERITY WAY # 106	FARGO	ND	58104	701-8663920
GLEN ULLIN PHARMACY	DAN CHURCHILL	113 S MAIN ST	GLEN ULLIN	ND	58631	701-3483303
WALLS MEDICINE CENTER HM	Dennis Johnson	708 S WASHINGTON	GRAND FORKS	ND	58201	701-7460497
WALLS HEALTHMART PHARMACY	Dennis Johnson	4440 SOWASHINGTON ST 101D	GRAND FORKS	ND	58201	701-7322900
EMBRACE PHARMACY	Samantha Buck	2424 32ND AVE S STE 101B	GRAND FORKS	ND	58201	701-7571552

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
WILSHIRE MEDICAL PHARMACY	ELLIOT WINESTOCK	8920 WILSHIRE BLVD #108	BEVERLY HILLS	CA	90211	310-6570750
PHARMACY 90210	SEAN SOROUDI	9735 WILSHIRE BLVD #110	BEVERLY HILLS	CA	90212	310-7772000
DWAYNES FRIENDLY PHARMACY	Dwayne Wilson	644 WEST LINE STREET	BISHOP	CA	93514	760-8722522
BLYTHE MART PHARMACY	James Lee	301 W HOBSON WAY	BLYTHE	CA	92225	760-9223511
BESTCARE PHARMACY	Evelyn Yoon	5317 BEACH BLVD	BUENA PARK	CA	90621	714-6707979
EARTH VILLAGE PHARMACY	JANICE JANG	5161 BEACH BLVD STE C	BUENA PARK	CA	90621	714-2289212
BETTER CARE RX PHARMACY	Donovan Wallace	4128 W BURBANK BLVD	BURBANK	CA	91505	818-5000079
LANDMARK SPLTY PHARMACY	Marine Zatikian	1208 W MAGNOLIA BLVD	BURBANK	CA	91506	818-2600010
NOWRX-BURLINGAME	Cary Breese	800 BURLWAY	BURLINGAME	CA	94010	650-5045127
CAMDEN PHARMACY	Thuan Vo	3189 S BASCOM AVE	CAMPBELL	CA	95008	408-3710111
NEW CARE PHARMACY	Karine Melkonyan	8346 TOPANGA CANYON BLVD	CANOGA PARK	CA	91304	888-4057565
PRICE RITE PHARMACY	CHRISTINE CHIU	6010 HIDDEN VALLEY RD #135	CARLSBAD	CA	92011	760-8938331
CARLSBAD NEIGHBRHD PHCY	Cuong Duong	2626 EL CAMINO REAL #A	CARLSBAD	CA	92008	760-9940900
CERRITOS MEDICAL PHCY	Nancy Cha	13325 E. ARTESIA BLVD.	CERRITOS	CA	90703	562-9265900
ST MARY PHARMACY	Beshoy Gerges	9917 TOPANGA CANYON BLVD	CHATSWORTH	CA	91311	818-9604521
WELLPHARMA RX PHARMACY	Natalie Haroutunian	21102 DEVONSHIRE ST	CHATSWORTH	CA	91311	747-2240091
SANTA FE PHARMACY	MARIAN MIKHAIL	12916 CENTRAL AVE	CHINO	CA	91710	909-3429181
K'S PHARMACY	Robert Kim	12582 CENTRAL AVE	CHINO	CA	91710	909-5917429
CHINOCARE PHARMACY	Sohil Patel	13085 CENTRAL AVE, SUITE #2	CHINO	CA	91710	909-9278323
CALICARE PHARMACY	Viraj Patel	12144 CENTRAL AVE STE B	CHINO	CA	91710	909-9963861
LIVE WELL PHARMACY	Jake Chuang	15871 POMONA RINCON RD STE 110	CHINO HILLS	CA	91709	909-3252211
SUNRISE PHARMACY	Leon Davydov	1637 THIRD AVE STE A	CHULA VISTA	CA	91911	619-9349999
CLAREMONT PHARMACY	NIKKI HO	358 S INDIAN HILL BLVD	CLAREMONT	CA	91711	909-9297228
EXCEL SPECIALTY PHARMACY	Deola Edema	604 N MAGNOLIA AVE STE105	CLOVIS	CA	93611	559-3751241
LA BOTICA PHARMACY HM	Chandra Patel	49281 GRAPEFRUIT BLVD #2	COACHELLA	CA	92236	760-2963468
YOSEMITE DRUG	Katie Bass	35300 HWY 41 STE 101	COARSEGOLD	CA	93614	559-6922479
BROTHERHOOD PHARMACY	Yonghyun Kim	1040 S MT VERNON AVE #E	COLTON	CA	92324	909-2224884

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
HILLSBORO REXALL DRUG HM	Shane Wendel	13 NORTH MAIN STREET	HILLSBORO	ND	58045	701-6365231
LAKOTA DRUG	MATT PAULSON	117 NORTH MAIN STREET	LAKOTA	ND	58344	701-2472781
LANGDON DRUG HM	Lyle Lutman	805 3RD ST	LANGDON	ND	58249	701-2563330
LARIMORE DRUG	Matt Paulson	203 TOWNER AVE	LARIMORE	ND	58251	701-3432461
CENTRAL PHCY NEW ROCKFORD	Shane Wendel	4 NORTH 8TH	NEW ROCKFORD	ND	58356	701-9475313
NEW SALEM PHARMACY	DAN CHURCHILL	509 ASH AVE BOX H	NEW SALEM	ND	58563	701-8437563
NORTHWOOD DRUG	Matt Paulson	10 N MAIN ST	NORTHWOOD	ND	58267	701-5875271
STEELE DRUG	Dan Churchill	101 W BROADWAY BOX 498	STEELE	ND	58482	701-4752521
CENTRAL AVENUE PHCY HM	DOREEN SAYLER	323 NO CENTRAL AVE #101	VALLEY CITY	ND	58072	701-8455280
CORNER DRUG D HM	Lee Ann Folden	619 DAKOTA AVE	WAHPETON	ND	58075	701-6426223
BARRETT PHARMACY HM	Jeff Dobbs	145 N MAIN STREET	WATFORD	ND	58854	701-8423311
MEDICAL PHARMACY SHEYENNE	Sheila Nudell	2050 SHEYENNE ST	WEST FARGO	ND	58078	218-2337365
PRESCRIPTION SHOP W FARGO	Tim Holland	1210 SHEYENNE ST	WEST FARGO	ND	58078	701-2824665
ND PHARMACY #1 ACH HM	Robert Treitline	20 EAST 26TH STREET	WILLISTON	ND	58801	701-5724181
LAKE CREST PHARMACY	Anita Ruse	620 MAIN ST STE B	ADAMS	NE	68301	402-9887145
ONE2ONE AINSWORTH LLC	Brad Bowdino	255 N MAIN ST	AINSWORTH	NE	69210	402-3871403
GOOD LIFE HM	Angie Svoboda	124 SOUTH 4TH STREET	ALBION	NE	68620	402-3953353
DAVES PHARMACY ALLIANCE	Dave Randolph	223 BOX BUTTE AVENUE	ALLIANCE	NE	69301	308-7624811
HAYS PHARMACY	Paul Fulmer	706 WEST MAIN ST	ALMA	NE	68920	308-9282022
CODY'S U-SAVE PHARMACY HM	CODY KUSZAK	2220 J STREET	AUBURN	NE	68305	402-2744186
STONER DRUG	Colby Haynes	2115 14TH STREET STE 201	AUBURN	NE	68305	402-2740220
JIM'S U-SAVE HM	Jim McHargue	219 Q STREET	AURORA	NE	68818	402-6943187
DEINES PHARMACY	Mitch Deines	910 COURT ST	BEATRICE	NE	68310	402-2234779
BENKELMAN PHARMACY	JAMIE HANES	509 CHIEF STREET	BENKELMAN	NE	69021	308-4232759
HEALTHMART PHARMACY-15817	Mike Aksamit	15817 CW HADAN DRIVE	BENNINGTON	NE	68007	402-9325556
HEALTHMART PHARMACY-238	Mike Aksamit	238 SOUTH 8TH STREET	BLAIR	NE	68008	402-4269066
BLOOMFIELD PHCY	John Nagengast	105 S BROADWAY SUITE 1	BLOOMFIELD	NE	68718	402-3734411

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
DAVISON DRUG HM	Frank Davison	640 MARKET STREET	COLUSA	CA	95932	530-4582188
WEST ALONDRA MED PHCY SS	Bharatsinh Zala	1410 WEST ALONDRA	COMPTON	CA	90220	310-6318674
COMPTON COMMUNITY PHCY HM	Chetna Resham	555 W COMPTON BLVD #102	COMPTON	CA	90220	310-5372337
OAK GROVE PHARMACY	NASSER ABOUKHALIL	785 OAK GROVE RD-G2	CONCORD	CA	94518	925-6811823
COOL VILLAGE PHARMACY	Chuck Rydell	5020 ELLINGHOUSE DR #E	COOL	CA	95614	530-8891427
R & M DRUG	AHLET HII	1115 WHITLEY AVE	CORCORAN	CA	93212	559-9922138
OLD TIME DRUGS/TIN RX	Christina Garcia	1322 SOLANO	CORNING	CA	96021	530-8240800
CORONA VALLEY PHARMACY	Chandra Patel	2079 COMPTON AVE. STE 105	CORONA	CA	92881	951-3653434
CORONA SPECIALTY PHCY	Diane Ahn	1280 CORONA POINTE CT 114	CORONA	CA	92879	951-2781008
CARE-MORE PHARMACY	Farnoosh Fathi	720 SOUTH RAMONA AVE, SUITE 102	CORONA	CA	92879	951-6834300
MAIN STREET PHARMACY	MARIA KAW	823 S MAIN ST STE 102	CORONA	CA	92882	951-2793125
CARE-PRO PHARMACY	NITAL PATEL	1307 W. SIXTH ST. STE 107	CORONA	CA	92882	951-4964408
JC NEIGHBORHOOD PHCY	RAMY MASSOUD	770 MAGNOLIA AVE #1-G	CORONA	CA	92879	951-5318041
TAP PHARMACY	Tiffany Norwood	601 W 6TH ST	CORONA	CA	92882	951-4061521
CDM DRUGS	LALEH TAHERI	2865 EAST COAST HWY #150	CORONA DEL MAR	CA	92625	949-6447575
MESA VERDE PHARMACY	Genevieve Benjamin	1525 MESA VERDE DR E #101	COSTA MESA	CA	92626	714-8843574
CITRUS VALLEY PHARMACY	Chad Nour	457 S CITRUS AVE	COVINA	CA	91723	626-2614400
ALTO CULVER RETAIL	Brian Meewes	6065 BRISTOL PARKWAY #100	CULVER CITY	CA	90230	617-9535935
JADE PHARMACY 2	An Nguyen	10133 S DE ANZA	CUPERTINO	CA	95014	559-7651325
CHERRY PHARMACY CUTLER	Wenbo Liu-cutler	40657 RD 128	CUTLER	CA	93615	559-3900023
CARE 4 U PHARMACY	HARMINDER BAJAJ	901 CAMPUS DRIVE STE 206	DALY CITY	CA	94015	650-3020345
HOT SPRINGS PHARMACY	MARKO FAM	13313 PALM DR STE A	DESERT HOT SPRINGS	CA	92240	760-2512222
AURORA PHARMACY	Li Yin	404 S PROSPECTORS UNIT C	DIAMOND BAR	CA	91765	909-9990988
DIAMOND PHARMACY	Min Jin Lee	21337 COLD SPRING LN	DIAMOND BAR	CA	91765	909-3232211
COMPLETE CARE CMPNDG PHCY	Nancy Pham	315 S. DIAMOND BAR BLV #D	DIAMOND BAR	CA	91765	909-8616900
DINUBA PHARMACY	EMAD MORCOS	172 N L STREET	DINUBA	CA	93618	559-7254525
MEDELLA PHARMACY 1	JOSEPH GIRGIS	8610 FIRESTONE BLVD	DOWNEY	CA	90241	310-9932363

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
RON'S PHARMACY	RONALD KARMAZIN	537 WEST GAGE/POB 307	BLUE HILL	NE	68930	402-7563811
VARNEY HM	MARGE TRYTHALL	744 SOUTH E ST/PO BOX 70	BROKEN BOW	NE	68822	308-8722852
SEVEN VALLEYS HEALTH MART	Marg Trythall	200 E PACIFIC	CALLAWAY	NE	68825	308-8362219
CORNER DRUG	Fadi Tanbouza	401 G STREET	CENTRAL CITY	NE	68826	308-9462205
TRAV'S USAVE PHCY	Travis Kuchar	1414 16TH STREET	CENTRAL CITY	NE	68826	308-9463859
PETERSEN DRUG	Drew Petersen	302 MAIN ST	CHADRON	NE	69337	308-4322400
SUPER SAVER PHCY #18	Mark Griffin	3318 23RD ST	COLUMBUS	NE	68601	402-5633349
TOOLEY DRUG HM	Tim Tooley	2615 13TH STREET	COLUMBUS	NE	68601	402-5647205
TOOLEY CLINIC PHCY HM	Tim Tooley	4306 38TH STREET	COLUMBUS	NE	68601	402-5628627
SERVICE DRUG HM	Paul McGinnis	133 E 8TH ST	COZAD	NE	69130	308-7842238
FRONTIER FAMILY PHARMACY	TYLER STURGEON	312 W 8TH ST	COZAD	NE	69130	308-7843500
PETERSEN DRUG	Drew Petersen	202 MAIN ST	CRAWFORD	NE	69339	308-6654138
KEN'S U-SAVE PHARMACY HM	Ken Marvin	1302 LINDEN AVENUE	CRETE	NE	68333	402-8263784
CURTIS DISCOUNT PHARMACY	Dan Kreis	115 CENTER AVE	CURTIS	NE	69025	308-5551212
SAV-RX PHCY @ A&A DRUG	Christy Piti	1612 N BELL STREET	FREMONT	NE	68025	402-7217634
KUBAT PHARMACY FREMONT	Steve Bullock	350 W 23RD ST STE E	FREMONT	NE	68025	402-7274044
REIMER PHARMACY	NIKOLAS REIMER	312 BROADWAY ST	FULLERTON	NE	68638	308-5362641
GERING PHARMACY HM	Chris Bosche	1400 TENTH STREET	GERING	NE	69341	308-4362181
LAMBERT'S FAMILY PHARMACY	Abbey Lambert	814 1ST ST	GIBBON	NE	68840	308-4685210
STOCKMEN'S DRUG	Mike Cookston	116 N MAIN ST	GORDON	NE	69343	308-2821114
GOTHENBURG DISCOUNT PHCY	DAN KREIS	902 AVENUE D	GOTHENBURG	NE	69138	308-5377155
SUPER SAVER PHARMACY #28	Mark Griffin	710 STATE ST	GRAND ISLAND	NE	68801	308-3980940
U-SAVE PHARMACY HM	Mark Miller	3224 W 13TH ST.	GRAND ISLAND	NE	68803	308-3849010
U-SAVE PHARMACY 4TH STREE	MIKE HAMIK	423 W 4TH ST	GRAND ISLAND	NE	68801	308-3847372
U-SAVE PHARMACY HM	Scott Weyers	2105 S LOCUST ST	GRAND ISLAND	NE	68801	308-3823784
GRANT PHARMACY	JASON BURKE	218 CENTRAL AVE	GRANT	NE	69140	308-3524511
USAVE PHARMACY	MIKE HAMIK	611 N HWY 6	GRETN	NE	68028	402-3325990

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
CAREMORE PHCY EASTVALE	Divesh Patel	13394 LIMONITE AVE STE 120	EASTVALE	CA	92880	951-4446768
FAMILY PHARMACY CENTER	Aziz Abualia	220 WEST MAIN ST	EL CAJON	CA	92020	760-5476527
NUDOS PHARMACY	Bijan Sabouri	455 N MAGNOLIA AVE	EL CAJON	CA	92020	619-4420303
LMD SAN DIEGO PHARMACY	Ghassan Azeez	330 S MAGNOLIA AVE 102	EL CAJON	CA	92020	800-5555555
BETTER LIFE PHARMACY	Nadim Dib	528 E MAIN ST	EL CAJON	CA	92020	619-6050000
PREFERRED PHARMACY HM	Bhavik Patel	1601 N IMPERIAL AVE STE B	EL CENTRO	CA	92243	760-5924650
DESERT PHARMACY	John Teague	1560 S IMPERIAL AVE	EL CENTRO	CA	92243	760-7917685
EL CENTRO PHARMACY	SANGATI PATER	325 WAKE AVE	EL CENTRO	CA	92243	760-5924542
LAKESIDE PHARMACY	Anna Liu	9109 LAGUNA MAIN SUITE125	ELK GROVE	CA	95758	800-5555555
LAGUNA PHARMACY	Hao Hoang	8112 SHELTON RD STE 300	ELK GROVE	CA	95758	916-6849922
ACCESS MYRX PHARMACY	Linh Tran	9632 EMERALD OAK DR STE G	ELK GROVE	CA	95624	916-4790615
CENTRAL CARE PHARMACY	Sahak Vartkessian	16260 VENTURA BLVD	ENCINO	CA	91436	818-3861888
MADISON VILLAGE PHARMACY	Parmjit Banes	6716 MADISON AVE STE 11	FAIR OAKS	CA	95628	916-9037949
MAYERS PHARMACY	Louis Ward	43471 HWY 299E	FALL RIVER MILLS	CA	96028	530-3367519
SIERRA VISTA PHARMACY	Feby Salem	650 E VISALIA RD	FARMERSVILL E	CA	93223	559-5948602
RINGS PHARMACY	Tom Renner	362 MAIN ST. / PO 577	FERNDALE	CA	95536	707-7864511
COMPLETE CARE PHARMACY	Daniel S Fuchs	1050 IRON POINT RD	FOLSOM	CA	95630	208-3086495
ST HELEN'S MEDICAL PHCY	Yu Seong Chang	17577 ARROW BLVD STE 101	FONTANA	CA	92335	909-4289842
GREEN'S FORTUNA PHCY HM	Robert Johnson	1058 MAIN ST	FORTUNA	CA	95540	707-7253040
ONE PHARMACY	Jenny Dang	18049 MAGNOLIA ST	FOUNTAIN VALLEY	CA	92708	714-5879786
JADE PHARMACY	An Nguyen	34460 FREMONT BLVD STE B	FREMONT	CA	94555	510-7924742
PROSCRIPTS PHARMACY	Gevork Yaralyan	7462 N FRESNO ST	FRESNO	CA	93720	559-7538180
FULLERTON MEDICAL PHCY	INSEEK HAM	1401 S. BROOKHURST RD	FULLERTON	CA	92833	714-9924908
BE WELL PHARMACY	Lilian Lee	105 N LAWRENCE AVE	FULLERTON	CA	92832	714-4499300
FULLERTON EXPRESS PHCY	Samah Ibrahim	105 W BASTANCHURY RD STE D	FULLERTON	CA	92835	714-5007727
CAL PHARMACY	ANDY NGO	9746 WESTMINSTER AVE #D4	GARDEN GROVE	CA	92844	714-6361881
WESTMED PHARMACY	Binh Mac	8342 GARDEN GROVE BLVD #2	GARDEN GROVE	CA	92844	714-8676707

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
RUSS'S MARKET PHARMACY #7	Mark Griffin	611 N BURLINGTON AVE	HASTINGS	NE	68901	402-4638503
CROSIER PARK PHARMACY HM	Scott Kirkegaard	405 EAST 14TH STREET	HASTINGS	NE	68901	402-4624600
THAYER COUNTY PHARMACY	Michael Logsdon	428 LINCOLN AVE	HEBRON	NE	68370	402-7686319
DAVES PHCY HEMINGFORD	Dave Randolph	508 NIOBRARA	HEMINGFOR D	NE	69348	308-4875212
HENDERSON PHARMACY HM	DONALD NORRIS	1060 NORTH MAIN STREET	HENDERSON	NE	68371	402-7234475
MEADOWLARK PHARMACY	Jonathon Lamarque	520 PRAIRIE VIEW LANE	HICKMAN	NE	68372	402-7920006
FULMER PHARMACY	Paul Fulmer	1317 HILL STREET	HOLDREGE	NE	68949	308-9954401
ADAMS DRUG	JIM AND JAMIE HANES	513 BROADWAY	IMPERIAL	NE	69033	308-8824949
ABC DRUG HM	Amy Brandt	2123 CENTRAL AVE	KEARNEY	NE	68847	308-2372175
U-SAVE PHARMACY KEARNEY	Kimberly Hamik	3611 2ND AVE	KEARNEY	NE	68847	308-4551555
HAEBERLES GRAND CENTRAL	Mark Griffin	7 W 25TH ST	KEARNEY	NE	68847	308-2372545
BEMIS DRUG	Grant Kinn	129 S CHESTNUT ST	KIMBALL	NE	69145	308-2353936
MAIN ST APOTHECARY HM	Christina Patefield	201 E 2ND ST	LAUREL	NE	68745	402-2563511
USAVE PHARMACY	TRAVIS MALOLEY	603 N. WASHINGTON	LEXINGTON	NE	68850	308-3246325
LINCOLN PHARMACY	Faheem Rashidi	3300 A ST STE 100	LINCOLN	NE	68510	402-7708261
STOCKWELL PHARMACY	LEE SCHMIT	3811 S 27TH ST	LINCOLN	NE	68502	402-4238588
SUPER SAVER PHCY #9	Mark Griffin	2662 CORNHUSKER HWY	LINCOLN	NE	68521	402-4667775
RUSS'S PHARMACY #1	Mark Griffin	1709 WASHINGTON ST	LINCOLN	NE	68502	402-4742102
SUPER SAVER PHARMACY #4	Mark Griffin	233 N 48TH ST	LINCOLN	NE	68504	402-4648822
RUSS'S PHARMACY #15	Mark Griffin	130 N 66TH ST	LINCOLN	NE	68505	402-4668111
RUSS'S PHARMACY #21	Mark Griffin	1550 S CODDINGTON AVE	LINCOLN	NE	68522	402-4358241
SUPER SAVER PHCY #17	Mark Griffin	2525 PINE LAKE RD	LINCOLN	NE	68512	402-4208269
SUPER SAVER PHARMACY #11	Mark Griffin	5460 S 56TH ST	LINCOLN	NE	68516	402-4230870
SUPER SAVER #27	Mark Griffin	840 FALLBROOK BLVD	LINCOLN	NE	68521	402-4388870
ALIVATION PHARMACY	Matt Duffy	8550 CUTHILLS CIRCLE	LINCOLN	NE	68526	402-4766060
BLAKES PHARMACY	Kitran Geise	213 MAIN ST	LOUISVILLE	NE	68037	402-2343025
U-SAVE PHCY AND MED SUPP	Angela Langan	902 N HIGHWAY 83	MC COOK	NE	69001	308-3455670

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
DSK PHARMACY	Jasmine Lee	9580 GARDEN GROVE BLV 108	GARDEN GROVE	CA	92844	714-5376619
NEXT DOOR PHARMACY	JILA MOKHTARE	9922 KATELLA AVE STE P	GARDEN GROVE	CA	92840	949-3028457
PHARMACY PLUS	Kwang Hwang	9914 GARDEN GROVE BLVD	GARDEN GROVE	CA	92844	714-9563830
GILBERT DRUGS	Mark Choi	9240 GARDEN GROVE BLVD #20	GARDEN GROVE	CA	92844	714-6388230
WELLCARE PHARMACY	Raymond Nguyen	9972 WESTMINSTER AVE#100	GARDEN GROVE	CA	92844	714-6947381
WELLNESS PHARMACY	Emad Mahmoud	14133 S VERMONT AVE	GARDENA	CA	90247	951-7074500
COMFORT CARE PHARMACY	Aram Kavoukjian	478 W COLORADO ST	GLENDALE	CA	91204	818-2477000
HARVARD FAMILY PHARMACY	EVELINA MKHITARIAN	145 S GLENDALE AVE	GLENDALE	CA	91205	818-6620700
JEWEL CITY PHARMACY	Gary John Gevorkian	800 S CNTRL AV SUITE 101A	GLENDALE	CA	91204	800-5555555
FIRST STOP PHARMACY	Karolina Khlebnikova	1577 E CHEVY CHASE DR STE 130	GLENDALE	CA	91206	818-4845455
LA CARE PHARMACY	Lilit Hakobyan	721 E BROADWAY BLVD	GLENDALE	CA	91205	818-3964818
HYE PHARMACY INC #4 HM	Peter Taglyan	1200 S CENTRAL AVENUE	GLENDALE	CA	91204	818-2407152
DELTA DRUGS II INC	Rita Avakian	437 FERNANDO CT	GLENDALE	CA	91204	818-3092884
TRINITY PHARMACY	JOHN KOLTA	1335 S GRAND AVE	GLENDORA	CA	91740	626-3352700
HEALTHRX SPECIALTY PHCY	Mai Thai	1844 E ROUTE 66	GLENDORA	CA	91740	626-3354777
KNOLLWOOD PHARMACY HM	Mil Tossoun	16911 SAN FERNANDO MISSION BLVD	GRANADA HILLS	CA	91344	818-3638107
DRUGS R US	Nazik Vardanyan	16229 DEVONSHIRE ST	GRANADA HILLS	CA	91344	818-3600206
GROVELAND PHARMACY	PATRICK CROSBY	18638 MAIN ST, PO BOX 809	GROVELAND	CA	95321	209-9625211
STARS PHARMACY	SAMI BORAIE	830 GUADALUPE ST	GUADALUPE	CA	93434	805-2190771
HALF MOON BAY PHARMACY	Andrew Lai	40 STONE PINE RD	HALF MOON BAY	CA	94019	650-7265542
GRAND AVENUE PHCY	MARGO SOBOL	4455 W. 117TH ST.101	HAWTHORNE	CA	90250	310-6493774
NOWRX HAYWARD	Cary Breese	29233 PACIFIC	HAYWARD	CA	94544	510-3277000
PLEASANT CARE PHARMACY	Chau Phan	1652 B STREET	HAYWARD	CA	94541	510-2009984
MISSION PHARMACY HM	Jennifer Tam	22138 MISSION BLVD	HAYWARD	CA	94541	510-5818540
TENNYSON PHARMACY	WING CHENG	589 W TENNYSON RD	HAYWARD	CA	94544	510-2660800
ICARE PHARMACY 2	Pam Duong	920 SUNNYSLOPE RD	HOLLISTER	CA	95023	831-2657733
PARKERS PHARMACY	Anuj Shukla	102 W 5TH ST	HOLTVILLE	CA	92250	760-3562826

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
FARRELLS PHARMACY	Patrick Farrell	120 WEST B ST	MCCOOK	NE	69001	308-3451781
USAVE PHARMACY MILFORD	Mark Vogt	610 FIRST ST	MILFORD	NE	68405	402-5789734
PEDLEY DRUG HM	Jeffrey Hanson	419 NORTH COLORADO	MINDEN	NE	68959	308-8322815
MOSER'S U-SAVE PHARMACY	Robert Moser	1821 S. 11TH ST	NEBRASKA CITY	NE	68410	402-8733397
WANEK PHARMACY	DANELLE CHARF	410 MAINE STREET	NELIGH	NE	68756	402-8875426
HILLTOP DRUGS ETC.	Mark Vogt	108 W 11TH STREET	NELIGH	NE	68756	402-8875551
KUBAT HEALTH CARE NORFOLK	Anthony Schmid	120 N 27TH ST STE 100	NORFOLK	NE	68701	402-3713444
VITAL CARE OF NORFOLK INC	Joshua Blood	120 N 27TH ST STE 200	NORFOLK	NE	68701	402-3713444
U-SAVE PHARMACY HM	Patrick Hammond	1001 WEST BENJAMIN AVENUE	NORFOLK	NE	68701	402-3798728
U SAVE PAVILION PHY	BILL SNODGRASS	611 W FRANCIS ST STE 130	NORTH PLATTE	NE	69101	308-2216993
RX EXPRESS PHARMACY	Brian Wilson	402 N JEFFERS ST	NORTH PLATTE	NE	69101	308-5327010
WESTFIELD PHCY HM	Kim Riley	1845 WEST A	NORTH PLATTE	NE	69101	308-5325539
U-SAVE PHARMACY	Travis Covey	211 WEST LEOTA	NORTH PLATTE	NE	69101	308-5320310
CORNER DRUG HM	Richard Mulder	301 N OAKLAND AVE	OAKLAND	NE	68045	402-6855883
U-SAVE PHARMACY HM	Brian Wilson	23 N SPRUCE ST	OGALLALA	NE	69153	308-2842242
NE ORTHOPEDIC HOSP RTL	ANNA MCCASLIN	2808 S 143RD PLZ	OMAHA	NE	68144	402-6093301
TOWER PHARMACY EXPRESS #7	BRUCE GOLDBERG	349 N 78TH STREET	OMAHA	NE	68114	402-9328709
EDS REXALL DRUG	Jason Enders	2701 SO 10TH ST	OMAHA	NE	68108	402-3421731
KUBAT PHARMACY SOUTH	Steve Bullock	2401 N STREET	OMAHA	NE	68107	402-7314333
KUBAT PHARMACY	Steve Bullock	4924 CENTER ST	OMAHA	NE	68106	402-5588888
GOOD LIFE DISCT PHARM HM	Angie Svoboda	125 SOUTH 16TH STREET	ORD	NE	68862	308-7283295
TOOLEYS OSCEOLA PHCY	TIM TOOLEY	415 HAWKEYE ST	OSCEOLA	NE	68651	402-7478994
THE OSMOND PHARMACY	Scott Taylor	322 STATE STREET	OSMOND	NE	68765	402-7483708
PLAINVIEW FAMILY PHARMACY	Ashley Dendinger	103 S MAIN ST	PLAINVIEW	NE	68769	402-5824202
KELLER PHARMACY	CHRIS KELLER	101 W 3RD ST P.O. BOX 365	PONCA	NE	68770	402-7552216
SVANDA PHARMACY HM	GEOFFREY WRIGHT	314 GRAND AVENUE	RAVENNA	NE	68869	308-4523672
BREHM DRUG	Jeff Platek	608 HOWARD AVE	SAINT PAUL	NE	68873	308-7544611

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
QUINN'S APOTHECARY PHCY	SUJIN JEUN	18502 BEACH BLVD STE 116	HUNTINGTON BEACH	CA	92648	714-9160593
BELLA TERRA PHARMACY	TramAnh Ton	16121 BEACH BLVD STE A	HUNTINGTON BEACH	CA	92647	949-2202554
BEACH PROFESSIONAL PHCY	YOON HEE CHANG	17742 BEACH BLVD STE 100	HUNTINGTON BEACH	CA	92647	714-8484447
SAN MARTIN PHARMACY	YOUSEF BAHD	2699 E FLORENCE AVE	HUNTINGTON PARK	CA	90255	323-5826078
IDYLLWILD PHARMACY	George Baslious	54391 VILLAGE CENTER DR #6	IDYLLWILD	CA	92549	951-6592135
ALTO IRVINE RETAIL	Brian Meewes	9213 RESEARCH DR	IRVINE	CA	92618	510-3310230
NOWRX-IRVINE	Cary Breese	1641 KAISER AVE	IRVINE	CA	92614	650-3865761
VALUE RX PHARMACY	Huong "Hana" Tran	22 ODYSSEY #135	IRVINE	CA	92618	949-3871133
JURUPA VALLEY PHARMACY	SANTOSH PATEL	7830-7832 LIMONATE AVE	JURUPA VALLEY	CA	92509	951-3322235
HILLS PHARMACY	Eduard Ikan	2906 1/2 FOOTHILL BLVD	LA CRESCENTA	CA	91214	818-3309675
RANCHO PHARMACY	Fatima Hamade	3835 AVOCADO BLVD STE 100	LA MESA	CA	91941	619-3037771
4 FRONT PHARMACY	Justus Benjamin	7200 PARKWAY DR. STE. 104	LA MESA	CA	91942	619-3033574
WORLD PHARMACY	Leonid Davydov	7339 EL CAJON BLVD STE L	LA MESA	CA	91942	619-3038800
VILLAGE ROSE PHARMACY	LORELEI NGUYEN	7773 UNIVERSITY AVE	LA MESA	CA	91942	619-7411344
LA PALMA TOWERS	ANDREA PARK	5451 LA PALMA AVE #17	LA PALMA	CA	90623	714-5227791
HONEY PHARMACY	Lauren Min	7002 MOODY ST UNIT 106	LA PALMA	CA	90623	562-4032332
GRACE COMMUNITY PHARMACY	SUN KIM	4881 LA PALMA AVENUE	LA PALMA	CA	90623	562-8600586
LOTUS RX	Thao Vo	7851 WALKER ST STE 102	LA PALMA	CA	90623	714-7358859
C & A PHARMACEUTICALS	CHRIS DOWNING	31852 COAST HWY STE 103	LAGUNA BEACH	CA	92651	949-4990885
ABC PHARMACY LAGUNA	Megan Chan	23141 MOULTON PKWY	LAGUNA HILLS	CA	92653	949-9169990
SEENA PHARMACY	MICHAEL PARSI	24731 ALICIA PARKWAY #B	LAGUNA HILLS	CA	92653	949-4629700
ADVANCED PHCY SOLUTIONS	Sam Lee	26611 CABOT RD STE B	LAGUNA HILLS	CA	92653	949-3487900
PHARMACY OF THE WOODS	TERRY BLASINGAME	28200 ST HWY 189 STE #N-150	LAKE ARROWHEAD	CA	92352	909-3363999
DELTA DRUGS	Rita Avakian	2497 E LAKESHORE DR STE B	LAKE ELSINORE	CA	92530	951-2452325
ZANE PHARMACY	Amr Elsayed	23653 EL TORO RD	LAKE FOREST	CA	92630	949-5867780
LINK PHARMACY	Yitong Lin	22942 RIDGE ROUTE DR 104	LAKE FOREST	CA	92630	949-2155899
LEO'S LAKESIDE PHARMACY	Ramesh Rakholia	9943 MAINE AVE	LAKESIDE	CA	92040	619-4431013

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
COMM PHCY AT REG WEST	John Mentgen	3911 AVENUE B STE M200	SCOTTSBLUFF	NE	69361	308-6301900
MUERI DRUG	MIKE MUERI	544 SEWARD ST	SEWARD	NE	68434	402-6433332
YUNGDAHL'S APOTHECARY	MARSHA YUNGDAHL	309 COMMERCIAL ST G	STROMSBURG	NE	68666	402-7642827
SUPERIOR PHARMACY HM	Lane Hawley	348 N CENTRAL POBOX 308	SUPERIOR	NE	68978	402-8794234
SYRACUSE T&COUNTRY HM	Rhonda Stinson	1710 POPLAR ST	SYRACUSE	NE	68446	402-2692001
CHIEF DRUG	Colby Haynes	123 S 3RD STREET	TECUMSEH	NE	68450	402-3353375
HASSELBALCH PHARMACY	Mike Wendt	143 S 3RD ST	TECUMSEH	NE	68450	402-3353303
TILDEN PHARMACY	DANELLE CHARF	103 EAST 2ND ST	TILDEN	NE	68781	402-3685385
HEART CITY DRUG	Bradley Bowdino	110 N MAIN STREET	VALENTINE	NE	69201	402-3765959
URBAN CLINIC PHARMACY	JULIA URBAN	1760 COUNTY ROAD J	WAHOO	NE	68066	402-4431630
U-SAVE PHARMACY WAVERLY	Nicole King	13851 GUILDFORD ST STE D	WAVERLY	NE	68462	402-7860225
U-SAVE PHARMACY HM	Mark Patefield	216 EAST 7TH STREET	WAYNE	NE	68787	402-3752922
TOM'S REXALL DRUG STORE	Jon Einfalt	124 N MAIN ST	WEST POINT	NE	68788	402-3722108
CHARLIE'S U-SAVE PHCY HM	Charlie Moore	2029 LINCOLN AVE	YORK	NE	68467	402-3624429
COLONIAL VILLAGE HM	Marc Fournier	54 PARK AVE	CONTOOCOON	NH	03229	603-7464600
FIRST COLONY CORP	Glenn Perreault	82 NEWPORT RD	NEW LONDON	NH	03257	603-5267525
VALLEY INDEPENDENT PHCY	Janice Spinney	3631 WHITE MOUNTAIN HWY	NORTH CONWAY	NH	03860	603-7305432
QUICK MED PHARMACY	VIK BHATT	1221 MAIN STREET	ASBURY PARK	NJ	07712	732-6927986
HOME DRUG STORE	VISHAL SOOD	814 MAIN STREET	ASBURY PARK	NJ	07712	732-7743400
BROADWAY HEALTH RX	Ashraf Ashamalla	974 BROADWAY	BAYONNE	NJ	07002	201-4712400
BAYONNE PHARMACY	Ashraf Ashamalla	651 BROADWAY	BAYONNE	NJ	07002	201-3391200
ULTRACARE HEALTHMART PHY	JAY PATEL	557 BROADWAY	BAYONNE	NJ	07002	201-4558200
LIBERTY PHARMACY	Shadi Gad	265 BROADWAY	BAYONNE	NJ	07002	201-4367000
MEDBOX SPECIALTY PHCY	Charulatta Brahmbhatt	14 FRANKLIN ST #102	BELLEVILLE	NJ	07109	+18-0055555
CAMDEN PHARMACY	Umesh Patel	537 MARKET ST	CAMDEN	NJ	08102	856-3617735
ROSVOLD PHARMACY	Thomas Stehr	2702 ROUTE 130 N	CINNAMINSON	NJ	08077	856-8294877
CUREMED PHARMACY	GHADA ABUKUWAIK	353 CROOKS AVENUE	CLIFTON	NJ	07011	862-2259432

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
HOWARD DRUGS	HAE ROH	20141 S. PIONEER BLVD	LAKEWOOD	CA	90715	562-8665795
JOHNS SHOP RITE PHARMACY	Mike Halim	4333 SOUTH ST	LAKEWOOD	CA	90712	562-6160056
LINCOLN PHARMACY	Henry Le	831 STERLING PKWY STE 120	LINCOLN	CA	95648	916-2093618
YOUNGS PAYLESS PHCY HM	John Hunnell	18980 N HWY 88	LOCKEFORD	CA	95237	209-7273762
FAIRMONT PHARMACY	Beatle Tran	1121 W VINE STREET SUITE 13	LODI	CA	95240	209-6258633
LOMA LINDA HEALTH PHCY	SUE PARK	11382 MOUNTAIN VW AVE A2	LOMA LINDA	CA	92354	909-7963780
LOMA LINDA PHARMACY	Viraj Patel	25620 BARTON RD	LOMA LINDA	CA	92354	909-7968308
ATLANTIC DRUGS	Amit Thakkar	4233 ATLANTIC AVE	LONG BEACH	CA	90807	562-9127940
GAGE PHARMACY	Attef Girgis	5735 ATLANTIC AVE	LONG BEACH	CA	90805	562-4238437
VERMILLION'S DRUG #3	CHIRAG PATEL	1942 E ANAHEIM ST	LONG BEACH	CA	90813	562-5910549
DOUGLAS PARK PHARMACY	JOSEPH CHERIAN	3828 SCHAUFEL AVE #260	LONG BEACH	CA	90808	562-3534723
FAMILY PHARMACY SS	Rakesh Patel	1400 ATLANTIC AVENUE	LONG BEACH	CA	90813	562-5914417
COMPOUND CENTRAL PHARMACY	Tuan Nguyen	5032 KATELLA AVE	LOS ALAMITOS	CA	90720	562-4312308
NOFEL PHARMACY	Abdul Nofel	215 UNIT A E 7TH ST	LOS ANGELES	CA	90014	213-6239171
WESTSIDE MEDICAL PHARMACY	Ali Gandji	11968 WILSHIRE BLVD	LOS ANGELES	CA	90025	310-441200
YORK DISCOUNT PHARMACY	Ana Chlasyan	5821 YORK BLVD	LOS ANGELES	CA	90042	323-3028090
SUN DRUG PHARMA INC	Ani Ghaplanyan	1803 N HILLHURST AVE	LOS ANGELES	CA	90027	323-6638017
LG PHARMACY HM	Ani Grigorian	5400 HOLLYWOOD BLVD #A	LOS ANGELES	CA	90027	323-6646664
TFC PHARMACY	Bella Grigoryan	4914 1/2 W SLAUSON AVE	LOS ANGELES	CA	90056	323-3484205
MARIPOSA PHARMACY	BILL PARK	2970 W OLYMPIC BLVD SUITE 104	LOS ANGELES	CA	90006	213-3655067
WILSHIRE LA JOLLA PHCY	CHERYL CHE	6360 WILSHIRE BLVD	LOS ANGELES	CA	90048	323-6586611
XPRS RX PHARMACY	Daniel Yagoubian	11205 1/4 NATIONAL BLVD	LOS ANGELES	CA	90064	818-8023712
CAL MED PHARMACY	EDDIE CHUNG	1414 S. GRAND AVE #101	LOS ANGELES	CA	90015	213-7464677
KORYO PHARMACY	HEE KIM	2727 W. OLYMPIC BLVD 103	LOS ANGELES	CA	90006	213-7386970
GARFIELD PRESCRIPTION	Hyo Soo Lee	3756 SANTA ROSALIA DR.	LOS ANGELES	CA	90008	323-2955585
STOCKER RX PHARMACY F	HYOSOO LEE	3750 SANTA ROSALIA DR. #1	LOS ANGELES	CA	90008	323-2953194

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
LAKEVIEW PHARMACY	Mustafa Faraj	244 LAKEVIEW AVE	CLIFTON	NJ	07011	973-5100250
JERUSALEM PHARMACY	Younis Rasheed	1414 MAIN AVE	CLIFTON	NJ	07011	973-3406200
COLONIA NATURAL PHARMACY	SVETISBAV MILIC	515 INMAN AVE	COLONIA	NJ	07067	732-3813400
DELRAN PHARMACY	JOSEPH JESUELE JR	88 HARTFORD RD STE A	DELRAN	NJ	08075	856-7645400
RAY PHARMACY	MAHENDRA PATEL	187 NORTH AVE	DUNELLEN	NJ	08812	732-9681481
WINDSOR PHARMACY	CHINMAY ARYA	722 RT 18	EAST BRUNSWICK	NJ	08816	732-2573784
OASIS PHARMACY	Sejal Patel	237 PLAINFIELD AVENUE	EDISON	NJ	08817	732-5431320
MORRIS AVENUE PHARMACY	IRA ZARESTKA	333 MORRIS AVENUE	ELIZABETH	NJ	07208	908-3535200
TAKE CARE PHARMACY	SABINA SEBASTIAN	182A ELMORA AVE	ELIZABETH	NJ	07202	908-3515768
HARRY'S PHARMACY	Harry Patel	1776 N OLDEN AVE	EWING	NJ	08638	609-2514500
FANWOOD PHARMACY	MITUL PATEL	246 SOUTH AVE UNIT 104	FANWOOD	NJ	07023	908-6806936
FARMINGDALE DRUGS INC	Hemal Makadia	73 MAIN ST	FARMINGDALE	NJ	07727	732-9389051
STAR PHARMACY	Kyong Yu	1400 ANDERSON AVE UNIT #7	FORT LEE	NJ	07024	201-2248877
BERGEN CARE PHCY INC	Tae Park	1622 PARKER AVE #1A	FORT LEE	NJ	07024	201-4614646
ULTRA CARE PHARMACY FP	JAY PATEL	3191 ROUTE 27 STORE #3	FRANKLIN PARK	NJ	08823	732-7986076
GLEN RIDGE PHCY & SURG	Hina Patel	855 BLOOMFIELD AVENUE	GLEN RIDGE	NJ	07028	973-7435900
HACKENSACK PHARMACY	DOUG CABALLERO	441 PASSAIC STREET	HACKENSACK	NJ	07601	201-4881230
SKYLANDS FAMILY PHARMACY	Umesh Patel	198B MOUNTAIN AVE	HACKETTSTOWN	NJ	07840	908-8523784
FIRST AID RX	Arthur Aylaroff	397 HALEDON AVE #102	HALEDON	NJ	07508	862-2377222
BELMONT PHARMACY	Bassam Mustafa	364 BELMONT AVENUE	HALEDON	NJ	07508	973-4578850
BELL WORKS PHARMACY	David Metzger	101 CRAWFORDS CORNER RD STE 116C	HOLMDEL	NJ	07733	732-2854064
SOMA PHARMACY	Gurdine Soma	3420 HIGHWAY 9	HOWELL	NJ	07731	732-9879969
LYONS PHARMACY	Ankur Barot	471-79 LYONS AVE	IRVINGTON	NJ	07111	973-9266496
ALL WELLNESS PHARMACY	LENNY ZBARSKY	180 N COUNTY LINE RD	JACKSON	NJ	08527	732-9874209
VERONA PHARMACY	ASHRAF ASHAMALLA	739 COMMUNIPAAW AVE #A	JERSEY CITY	NJ	07304	201-9469501
ULTRA CARE PHARMACY JC	JAY PATEL	568 WESTSIDE AVE	JERSEY CITY	NJ	07304	201-4339777

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
SAMSUNG CARE PHARMACY	INAE OH	2717 W OLYMPIC BLVD #105	LOS ANGELES	CA	90006	213-2632039
VERNON CENTRAL BOTICA PHY	Isaac Lee	4375 S. CENTRAL AVENUE	LOS ANGELES	CA	90011	323-2318992
WESTSIDE PHARMACY	Jack Pirooz	11504 SANTA MONICA BLVD	LOS ANGELES	CA	90025	310-4790200
PACIFIC DRUGS	JAMES PAI	1047 NORTH STATE STREET	LOS ANGELES	CA	90033	323-2260237
KEY DRUGS	JAMES PAI	770 S. VERMONT	LOS ANGELES	CA	90005	213-3832211
KT PLAZA PHARMACY	JAMIE PARK	928 S WESTERN AVE STE 110	LOS ANGELES	CA	90006	213-3820212
SYD'S PHARMACY	Jonathan Friedman	7111 BEVERLY BLVD	LOS ANGELES	CA	90036	323-9338571
PARK MESA PHARMACY	Joseph Cherian	4314 W SLAUSON AVE STE# 1	LOS ANGELES	CA	90043	323-3783323
NANOOM PHARMACY	Kyungsig Michelle Choi	866 S WESTMORELAND AVE STE 101B	LOS ANGELES	CA	90005	213-4595800
ONE PHARMACY	Kyungsig Michelle Choi	4301 S FIGUEROA ST STE E	LOS ANGELES	CA	90037	213-4595900
ELITE CARE PHARMACY	Lusik Davtjan	5101 SANTA MONICA BLVD STE 6	LOS ANGELES	CA	90029	323-4269990
OLIVE HILL PHARMACY	Mi Sook Cho	255 SOUTH HILL ST 217	LOS ANGELES	CA	90012	213-6802000
MOTHER'S CARE PHARMACY	MIA BANG	3500 W. 6TH ST. #120	LOS ANGELES	CA	90020	213-7393030
SILOAM PHARMACY	MICHELLE NA	2528 WEST OLYMPIC BLVD102	LOS ANGELES	CA	90006	213-3820700
MOTHER'S PHCY & NUTRITION	Mihwa Bang	2120 W 8TH. STE 103	LOS ANGELES	CA	90057	213-2632143
HANMI PHARMACY INC	NAM Hong	325 1/2 S WESTERN AVE	LOS ANGELES	CA	90020	626-4221271
NORMANDY PHARMACY	Nancy Cha	3003 W OLYMPIC BLVD #101	LOS ANGELES	CA	90006	213-3863001
HYE PHARMACY, INC SS HM	Peter Taglayan	5236 SANTA MONICA BLVD	LOS ANGELES	CA	90029	323-6617152
OLIVE BRANCH PHARMACY	Reda Alhoussayni	2070 S. CENTRAL AVE.	LOS ANGELES	CA	90011	213-5364888
OLIVE BRANCH PHCY	Reda Alhoussayni	2811 S SAN PEDRO ST	LOS ANGELES	CA	90011	323-4322131
R AND D PHARMACY	Roselyn Roque	1905 HILLHURST AVE	LOS ANGELES	CA	90027	323-5733439
GRAND AVE PHARMACY	SAM CHUNG	1400 S. GRAND AVE. 100	LOS ANGELES	CA	90015	213-7464114
LEE'S DISCOUNT DRUG SS	Sang Lee	2732 WEST OLYMPIC BLVD	LOS ANGELES	CA	90006	213-3826391
ALEXANDER PHARMACY #1	Soheil Attar	1084 N WESTERN AVE	LOS ANGELES	CA	90029	323-4671084
DISCOUNT MEDICAL PHARMACY	Sorin Kazangian	2716 GRIFFITH PARK BLVD	LOS ANGELES	CA	90027	323-6618366
MID-WEST MEDICAL PHARMACY	Tom Shafa	8733 BEVERLY BLVD	LOS ANGELES	CA	90048	310-6571635

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
EXCEL PHARMACY	JOANN BHATIA	612 PAVONIA AVE	JERSEY CITY	NJ	07306	201-2395800
THE PRESCRIPTION SHOPPE	JOANN BHATIA	550 NEWARK AVE SUITE 101	JERSEY CITY	NJ	07306	201-3600600
WISDOM PHARMACY	Raj Patel	2717 JOHN F KENNEDY BLVD	JERSEY CITY	NJ	07306	201-6304619
CONCORD PHARMACY	Remon Endrawes	317 MARTIN LUTHER KING JR	JERSEY CITY	NJ	07305	201-9209806
VITALIS PHARMACY	Remon Endrawes	3495 KENNEDY BLVD	JERSEY CITY	NJ	07307	201-2221800
VALERY'S PHARMACY LLC.	Valerie Ortiz	2983 JOHN F KENNEDY BLVD	JERSEY CITY	NJ	07306	201-9842180
JEFFERSON PHARMACY	Carlos Almanza	706 RTE 15 SOUTH STE 104	LAKE HOPATCONG	NJ	07849	973-6632560
KINGS PHARMACY DEPARTMENT	Avi King	152 JAMES ST	LAKEWOOD	NJ	08701	732-7194920
MADISON PHARMACY	Moses Werzberger	400 MADISON AVE	LAKEWOOD	NJ	08701	732-3704200
WESTGATE PHARMACY	Moses Werzberger	112 HILLSIDE BLVD	LAKEWOOD	NJ	08701	732-3702500
REFUAH PHARMACY	Moses Werzberger	911 EAST COUNTY LINE RD	LAKEWOOD	NJ	08701	732-9429987
PENLAR PHARMACY	Kaushal Patel	160 LAWRENCEVILLE PENN RD	LAWRENCEVILLE	NJ	08648	609-8952619
BIENESTAR PCY & WELNES CT	Gladys Duenas	799 S. EMERSON AVE	LINDENWOLD	NJ	08021	856-8057991
DIAMOND PHARMACY	Calos Almanza	444 OCEAN BLVD N	LONG BRANCH	NJ	07740	201-8035838
HEALTHVIA PHARMACY	Yesha Patel	300 E GREENTREE RD STE 8	MARLTON	NJ	08053	856-9838700
MEDFORD PHARAMCY	Richard Kress	639 STOKES RD #101	MEDFORD	NJ	08055	609-6546884
QUAKERBRIDGE PHARMACY	Glenn Sudnick	94 FLOCK ROAD	MERCERVILLE	NJ	08619	609-5871850
BARRYS MONTVILLE PHCY	Amit Patel	185 CHANGEBRIDGE RD	MONTVILLE	NJ	07045	973-3356688
BARON II DRUG & SURGICAL	LUIS MEDINA	91 MOONACHIE ROAD	MOONACHIE	NJ	07074	201-6411110
MOUNT ARLINGTON PHARMACY	Amul Patel	181 HOWARD BLVD	MOUNT ARLINGTON	NJ	07856	973-6013617
ULTRACARE PHARMACY NB	JAY PATEL	272 GEORGE STREET	NEW BRUNSWICK	NJ	08901	732-5431568
NEW BRUNSWICK PHCY & SURG	SHILPA PATEL	159 FRENCH STREET	NEW BRUNSWICK	NJ	08901	732-4181100
PREMIER HEALTH PHCY	Amit Patel	393 CENTRAL AVE	NEWARK	NJ	07103	973-9913870
KAYES DRUG STORE	Andy Barot	1069 BERGEN ST	NEWARK	NJ	07112	973-9264100
NEWARK COMMUNITY PHARMACY	JOHN MEO	751 BROADWAY	NEWARK	NJ	07104	973-4812400
MICHAELS PHARMACY	Michael Kaldas	287 SOUTH ORANGE AVENUE	NEWARK	NJ	07103	973-5585940

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
NOUBARS EL ADOBE PHCY II	Vartan Gevorkian	2010 WILSHIRE BLVD #2010F	LOS ANGELES	CA	90057	213-4133999
WATTS PROF PHCY HM	Walter Provost	9909 SO COMPTON AVE	LOS ANGELES	CA	90002	323-5643218
LITTLE TOKYO PHARMACY	William Kim	402 E 2ND ST	LOS ANGELES	CA	90012	213-6804011
PLAZA WEST PHARMACY	Yelena Goldin	8540 S SEPULVEDA BLVD#102	LOS ANGELES	CA	90045	310-6456422
BOTICA DEL SOL	Yousef Bahdi	2331 CESAR CHAVEZ AVE	LOS ANGELES	CA	90033	323-2607531
LOS ANGELES PHARMACY	Moshe Lalehzari	8628 W PICO BLVD	LOS ANGELES PHARMACY	CA	90035	800-5555555
SORCI HLTHCARE PHARMACY	MIKE SORCI	15714 LOS GATOS BLVD STE A	LOS GATOS	CA	95032	408-3564747
LATIMERS PHARMACY	Christina Garcia	7885 HIGHWAY 99E	LOS MOLINOS	CA	96055	530-3842330
LYNWOOD COMMUNITY PHCY	Jitesh Zala	3737 MLK JR BLVD STE 101	LYNWOOD	CA	90262	310-4382616
GREAT RX PHARMACY	HETAL PATEL	26930 CHERRY HILLS BLVD	MENIFEE	CA	92586	951-6797988
NEW HOPE PHARMACY	Valerie Nguyen	29798 HAUN ROAD #100	MENIFEE	CA	92586	714-4480357
RUMI PHARMACY	Kaveh Samadi	23162 LOS ALISOS BLVD STE102A	MISSION VIEJO	CA	92691	949-4572246
FLORIDA AVE PRESCRIPT HM	Elaine George-Pardini	1541 FLORIDA AVE, STE P	MODESTO	CA	95350	209-5767277
BEVERLY PLAZA RX INC	MAIS MELIKIAN	101 E BEVRLY BLVD STE 101	MONTEBELLO	CA	90640	323-7257155
MONTECITO RX	Lara Hove	1498 E VALLEY RD	MONTECITO	CA	93108	805-9692284
HONEST PHARMACY	Mei Tang	210 N GARFIELD AVE 101	MONTEREY PARK	CA	91754	909-9968809
MTR PARK PROF PHARAMCY	Sri Nainala	850 S ATLANTIC BLVD STE 100	MONTEREY PARK	CA	91754	626-3089227
GALEN RX PHARMACY	Anna Cunningham	4111 OCEAN VIEW BLVD	MONTROSE	CA	91020	818-6968585
LIFETIME PHARMACY	Ada VanDyke	23080 ALESSANDRO BLVD #212	MORENO VALLEY	CA	92553	951-6567171
MORRO BAY DRUG AND GIFT	Sumanta Paul	600 MORRO BAY BLVD STE B	MORRO BAY	CA	93442	805-7038613
CAMINO PHARMACY	Carol Luc	701 E EL CAMINO REAL	MOUNTAIN VIEW	CA	94040	650-9347699
NOWRX-MOUNTAIN VIEW	CARY BREESE	2224 OLD MIDDLEFIELD WAY STE J	MOUNTAIN VIEW	CA	94043	650-3865761
BALBOA PHARMACY	Jeff Ford	716 E BALBOA BLVD	NEWPORT BEACH	CA	92661	949-6735370
HILL PHARMACY	KYUSANG LEE	1441 AVOCADO AVE. #101	NEWPORT BEACH	CA	92660	949-6406564
MARINER'S PHARMACY	YUNG KO	320 SUPERIOR AVE ST. 120	NEWPORT BEACH	CA	92663	949-6457200
METRO PHARMACY	Albert Zakaryan	8660 WOODLEY AVE STE 101B	NORTH HILLS	CA	91343	818-8911904

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
GUARDY'S PHARMACY HM	Paul Hsu	403-409 BLOOMFIELD AVENUE	NEWARK	NJ	07107	973-4822648
APOLLO PHARMACY	Yogeshkumar Brahmbhatt	130 SUMMER AVE	NEWARK	NJ	07104	973-3506155
BROADWAY PHARMACY	Avelino Avelenda	7211 BROADWAY	NORTH BERGEN	NJ	07047	201-7669300
QUICK AID PHARMACY	Ahab Ayad	505 MILLTOWN RD	NORTH BRUNSWICK	NJ	08902	732-2472333
US PHARMACY LAB	David Yoon	220 LIVINGSTON ST	NORTHVALE	NJ	07647	201-3229090
BURGESS CHEMISTS 2	DANIEL ALBIZATI	559 FRANKLIN AVE	NUTLEY	NJ	07110	973-2350909
ADLERS OAK PARK PHARMACY	Kam Patel	67 MONMOUTH ROAD	OAKHURST	NJ	07755	732-2294200
WE CARE PHARMACY	Jignesh Patel	3317 SUNSET AVE	OCEAN	NJ	07712	732-4935100
TEXAS ROAD PHARMACY	Jaime Silverman	1181-1183 ENGLISHTOWN RD	OLD BRIDGE	NJ	08857	732-7231101
PARK RIDGE PHARMACY	Amgad Wassef	40 PARK AVE ST 5	PARK RIDGE	NJ	07656	201-5542200
LAKESHORE PHARMACY	Joann Bhatia	299 PARSIPPANY RD	PARSIPPANY	NJ	07054	862-7015808
LA NUEVA MERCEDES PHCY	Ankur Barot	500 RIVER ST	PATERSON	NJ	07524	973-2792800
MORT JACOBS PHARMACY	JANICE DEHOMBRE	506 PARK AVENUE	PATERSON	NJ	07504	973-2794600
FABIO'S PHARMACY	NESTOR JAIME	88 MARKET STREET	PATERSON	NJ	07505	862-2573300
PARK AVE DRUGS	Nidal Hozien	107 PARK AVE	PATERSON	NJ	07501	973-9288888
CITY RX PHARMACY	ZUBAER MALIK	7 WEST BROADWAY	PATERSON	NJ	07505	973-2470786
SMITH PHARMACY	AARTI SHAH	91 SMITH STREET	PERTH AMBOY	NJ	08861	732-6616625
ST JOSEPH PHARMACY	Harshil Patel	758 MEMORIAL PKWY	PHILLIPSBURG	NJ	08865	908-4540777
STELTON PHARMACY	AMY BUCH	179 STELTON ROAD	PISCATAWAY	NJ	08854	732-4248080
PLAINSBORO PHARMACY	YOUSRY MACKSOD	9 SCHALKS ROAD	PLAINSBORO	NJ	08536	609-7500101
SANTE INTEGRATIVE PHCY	Chris Castagna	200 NASSAU ST	PRINCETON	NJ	08542	609-9218822
LIVEWELL PHARMACY	Dar Patel	477 ROUTE 10 E UNIT 13	RANDOLPH	NJ	07869	973-7759818
RED BANK FAMILY PHCY	KAMESH PATEL	141 BROAD STREET	RED BANK	NJ	07701	732-5309460
INVICTUS PHARMACY	Alan Oustaev	60 ESSEX STREET STE 105	ROCHELLE PARK	NJ	07662	201-8807000
RUMSON PHARMACY NJ LLC	AMIT PATEL	22 WEST RIVER ROAD #100	RUMSON	NJ	07760	732-8421234
RUTHERFORD PHARMACY	Zubaer Malik	62 PARK AVE	RUTHERFORD	NJ	07070	201-8066000

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
ELITE CLINICAL CARE PHCY	Christine Gabrielyan	9103 SEPULVEDA BLVD	NORTH HILLS	CA	91343	818-9706804
THE QR PHARMACY	Irina Shevchenko	11507 OXNARD ST #2	NORTH HOLLYWOOD	CA	91606	818-9274321
EL CAMINO PHARMACY	Janice Chang	10940 VICTORY BLVD	NORTH HOLLYWOOD	CA	91606	818-7634334
HYE PHARMACY #3 HM	Peter Taglyan	12509 VICTORY BLVD	NORTH HOLLYWOOD	CA	91606	818-7660100
ST MARY PHARMACY	Beshoy Gerges	8254 WHITE OAK AVE, UNIT #4	NORTHRIDGE	CA	91325	818-9758004
CLINICARE PHARMACY	DIANA AROUCHANOVA	9245 RESEDA BLVD	NORTHRIDGE	CA	91324	818-7277234
RELIABLE REXALL PHCYSS HM	Stan Goldenberg	18350 ROSCOE BLVD #102	NORTHRIDGE	CA	91325	818-8857722
PIONEER PHARMACY	KIHO PAI	15917 PIONEER BLVD	NORWALK	CA	90650	562-4026972
BRADFORD PHARMACY	Alfred Lau	445 8TH STREET	OAKLAND	CA	94607	510-4511388
WELLSPRING PHARMACY	Andrew Beyers	4184 PIEDMONT AVE STE C	OAKLAND	CA	94611	510-4281559
NICHOLS HILL PRESCRIP HM	Benjamin Yuh	2844 SUMMIT STREET	OAKLAND	CA	94609	510-8938841
ACCESS PHARMACY	Daniel Torbati	2693 FRUITVALE AVE	OAKLAND	CA	94601	800-5555555
NEW OAKLAND PHARMACY #2	Jennifer Tam	388 9TH STREET #108	OAKLAND	CA	94607	510-7633282
NEW OAKLAND PHCY #1 HM	Jennifer Tam	333 NINTH STREET	OAKLAND	CA	94607	510-6280368
NEW OAKLAND-LAKE MERRITT	KAM TAM	250 EAST 18TH ST 3RD FL	OAKLAND	CA	94606	510-6280878
CHILDREN'S CLINIC	KAM TAM	747 52ND STREET	OAKLAND	CA	94609	510-4283166
OAKLAND CLINIC	KAM TAM	5220 CLAREMONT AVE	OAKLAND	CA	94618	510-4284088
OCEANSIDE PHARMACY	TARUN WADHWA	3601 VISTA WAY SUITE 103	OCEANSIDE	CA	92056	310-9720372
OJAI VILLAGE PHARMACY	Kingsley Labrosse	202 E. OJAI AVE	OJAI	CA	93023	805-6467272
ORANGE EXPRESS PHARMACY	GEORGE IBRAHIM	1233 N TUSTIN ST	ORANGE	CA	92867	714-2881720
PALISADES COMP PHCY	SEAN SOROUDI	540 PALISADES DR	PACIFIC PALISADES	CA	90272	310-4544848
CORNERSTONE PHARMACY	Greg Collins	39575 WASHINGTON ST #103	PALM DESERT	CA	92211	760-6414796
PV DRUGSTORE	Victor Bordbar	2325 PALOS VERDES WST 220	PALOS VERDES ESTATES	CA	90274	424-3272990
SANTA MARIA PHARMACY LTC	Michael Soliman	16444 PARAMOUNT BLVD #101	PARAMOUNT	CA	90723	562-2323732
ST. LUKE'S PROF PHARMACY	MAT JUNG	2554 E.WASHINGTON #B	PASADENA	CA	91107	626-7917595
MINTWOOD PHARMACY	Milad Tossoun	455 N LAKE AVE	PASADENA	CA	91101	626-3142945

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
SOUTH ORANGE DRUGS	Doug Caballero	73 S ORANGE AVE	SOUTH ORANGE	NJ	07079	973-8215414
DURHAM PHARMACY LLC	SEJAL PATEL	124 DURHAM AVENUE UNIT 6	SOUTH PLAINFIELD	NJ	07080	908-5488224
HOMETOWN PHCY	Timothy Murphy	1805 RTE 206 UNIT 9 RED LION PLAZA	SOUTHAMPTON	NJ	08088	609-8595633
SPOTSWOOD PHARMACY	Amr Hillal	14 SNOWHILL ST	SPOTSWOOD	NJ	08884	732-9556060
VILLAGE DRUG	JESSICA DELLARAGIONE	1201 SYCAMORE AVE SUITE 110	TINTON FALLS	NJ	07724	732-5427455
CONTIGO PHARMACY	Ashish Vora	3510 BERGENLINE AVE	UNION CITY	NJ	07087	201-5009366
FARMACIA SAN JOSE	RAUL MAZON	149 48TH STREET	UNION CITY	NJ	07087	201-8641809
LOYALTY PHARMACY	Safia Ahmad	3605 BERGENLINE AVE	UNION CITY	NJ	07087	201-9720172
PARK AVE PHARMACY	SYED HUSSAINI	3712 PARK AVE	WEEHAWKEN	NJ	07086	201-5529500
MULKAY DRUGS	BEVERLY MULKAY	6601 BROADWAY AVE	WEST NEW YORK	NJ	07093	201-8544900
GILMORE PHARMACY	ILEANA DOMINGUEZ	6000 PARK AVE	WEST NEW YORK	NJ	07093	201-8685005
TOWN PHARMACY	VIVEK BHATT	4911 BERGENLINE AVE	WEST NEW YORK	NJ	07093	201-7661900
MEDICOS PHARMACY	Syed Hussaini	741 NORTHFIELD AVE STE199	WEST ORANGE	NJ	07052	973-3241000
ALAMOGORDO COMPHY	Allan Yeh	1003 EAST 10TH ST	ALAMOGORDO	NM	88310	575-2230795
VICTORS REGENT PHARMACY	JOHN CASTILLO	1643 ISLETA BLVD SW	ALBUQUERQUE	NM	87105	505-8771620
JOHNS PHARMACY	John Ma	9134 CENTRAL AVE SE	ALBUQUERQUE	NM	87123	505-3409769
MEDICINE CHEST PHARMACY	KEN CORAZZA	1123 CANDELARIA RD NW	ALBUQUERQUE	NM	87107	505-3442335
DURAN CENTRAL PHARMACY	MONA GHATTAS	1815 CENTRAL AVE NW	ALBUQUERQUE	NM	87104	505-2474141
LOWELLS PHCY	LOWELL IRBY	612 N 13TH ST	ARTESIA	NM	88210	575-7466681
PHARMACY PLUS	GEORGE SANDOVAL	407 HWY 550 W	BERNALILLO	NM	87004	505-8672336
CITY DRUG HM	Lori Montoya	7 MAIN STREET	CLAYTON	NM	88415	575-3749121
ONE CARE INFUSION PHCY	Mohannad Rashid	907 W COAL AVE	GALLUP	NM	87301	505-7264155
TRUST PHARMACY	EUGENE GUTIERREZ	1000 E ROOSEVELT AVE	GRANTS	NM	87020	505-2873913
PHARMACY 575	Mark Poling-hobbs	305 E SANGER #600	HOBBS	NM	88240	575-2638042
DEL REY PHARMACY	Kenneth Okwunwanne	3291 DEL REY BLVD #3	LAS CRUCES	NM	88012	915-2619713
HEALTHCARE PHARMACY	YAZID ATIEH	3865 E LOHMAN AVE STE 2	LAS CRUCES	NM	88011	575-9151538

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
ROBINSONS PHARMACY	Dennis Thomas	359 MAIN STREET	PLACERVILLE	CA	95667	530-6223186
SAN JOAQUIN DRUG	Katie BASS	9215 E HIGHWAY 140	PLANADA	CA	95365	209-3821291
PLAYA PHARMACY HM	Joseph Chehade	8131 W. MANCHESTER AVE.	PLAYA DEL REY	CA	90293	310-8234500
NOWRX-PLEASANTON	Cary Breese	7067 COMMERCE CIR.	PLEASANTON	CA	94588	650-3865761
ARTESIA MEDICAL PHARMACY	DAVID LIM	160 E ARTESIA ST STE 135	POMONA	CA	91767	909-6230551
PHILLIPS RANCH PHARMACY 2	JOANNE EVANS	3040& 3042 W. TEMPLE AV	POMONA	CA	91766	909-7668330
ORANGE GROVE PHARMACY	JOYCE LIM	1770N ORANGE GROVE STE110	POMONA	CA	91767	909-6236429
HOLT PHARMACY	TONY HA	1101 E. HOLT AVE. #F	POMONA	CA	91767	909-6201011
RINALDI PHARMACY	Narine Demirchyan	11237 TAMPA AVE	PORTER RANCH	CA	91326	818-4889350
PORTERVILLE PHARMACY	John Mikhael	406 W PUTNAM AVE	PORTERVILLE	CA	93257	559-7934410
PORTERVILLE PHARMACY 2	John Mikhael	1270 W HENDERSON AVE	PORTERVILLE	CA	93257	559-6151560
PORTOLA VILLAGE PHARMACY	Lindsey Compton	157 COMMERCIAL ST	PORTOLA	CA	96122	530-8324218
SIERRA PHARMACY HM	Pradeep Amin	8661 BASELINE RD	RANCHO CUCAMONGA	CA	91730	909-9899800
GREEN VALLEY PHARMACY	Walter Wong	8237 ROCHESTER AVE, SUITE 120	RANCHO CUCAMONGA	CA	91730	909-9800999
ROSE PHARMACY RM	Peter Chu	35400 BOB HOPE DRIVE, SUITE 207	RANCHO MIRAGE	CA	92270	760-8326287
CAJON PHARMACY	KHALID MAHFOUZ	232 CAJON ST. STE. A	REDLANDS	CA	92373	909-7924922
BRAND NEW PHARMACY	Shams Gerges	1819 W REDLANDS BLVD 101	REDLANDS	CA	92373	909-3355400
PILL BOX DRUG HM	Patrick Hwang	165 PALOS VERDES BLVD.	REDONDO BEACH	CA	90277	310-3789487
REEDLEY PRO-SCRIPT PHCY	JUAN FONSECA	1045 G STREET	REEDLEY	CA	93654	559-7437113
MEGA PHARMACY INC.	Elvira Zakaryan	17705 SATICOY STREET	RESEDA	CA	91335	818-9758142
VICTORY PLAZA PHARMACY	Steve Rad	18515 VICTORY BLVD	RESEDA	CA	91335	818-6008283
DELTA PHARMACY	CARL FINK	407 N. MAIN ST	RIO VISTA	CA	94571	707-3742498
ICAREMORE PHCY	Bhavesh Pansara	9493 GARFIELD ST	RIVERSIDE	CA	92503	951-2997100
EMPIRE PHARMACY	KHALID ALI	1340 MASSACHUSETTS AVE	RIVERSIDE	CA	92507	951-5308800
ARLINGTON PRESCRIPTION PH	Mohammed Salman	8990 GARFIELD ST #12	RIVERSIDE	CA	92503	951-6885232
RIVERWALK PHARMACY	Tapan Patel	4234 RIVERWALK PKWY #130	RIVERSIDE	CA	92505	951-3523030

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
PLAZA DRUGS	ELROY ARAGON	178 BRIDGE ST	LAS VEGAS	NM	87701	505-4255221
KELLY'S PHARMACY	Dale Kemper	312 N CALIFORNIA ST	SOCORRO	NM	87801	575-8352125
WELLBORN PHARMACY HM	Brian Wilson	315 SO 2ND BOX 985	TUCUMCARI	NM	88401	575-4612784
JOLLY/SILVER STATE ALAMO	Andrew Bleak	414 BROADWAY STREET	ALAMO	NV	89001	775-7253515
SILVER STATE DRUG	Andrew Bleak	800 NORTH SPRING STREET	CALIENTE	NV	89008	775-7263771
SUNRISE MEDICAL PHARMACY	BRENDAN LY	3131 LA CANADA ST. STE201	LAS VEGAS	NV	89169	702-7322334
ALTO LAS VEGAS RETAIL	Brian Meewes	600 PILOT RD STE A	LAS VEGAS	NV	89119	702-7014608
TRUE CARE PHARMACY #3	CHETANKUMAR PATEL	2208 S NELLIS BLVD #5A	LAS VEGAS	NV	89104	702-7018943
LIFECARE PHARMACY	Cletus Amadi	3050 E DESERT INN RD STE 124	LAS VEGAS	NV	89121	702-6972105
OK'CARE PHARMACY	JOHN OKOYE	4845 S RAINBOW BLVD #403	LAS VEGAS	NV	89103	702-5389388
VESPER SPECIALTY PHARMACY	Joshua Koroghli	4225 S EASTERN AVE STE 16	LAS VEGAS	NV	89119	702-3334377
TRUE CARE PHARMACY HM	Lalu Patel	3525 S FORT APACHE RD 165	LAS VEGAS	NV	89147	702-2332010
LA PHARMACY	Lizette Perez Flores	4180 S RAINBOW BLVD SUITE 808	LAS VEGAS	NV	89103	702-7223707
SANTA MARIA PHARMACY	Michael Soliman	3827 E SUNSET RD STE L	LAS VEGAS	NV	89120	702-4740268
GREENBAY SPECIALTY PHCY	Parag Patel	3483 S EASTERN AVE STE 100	LAS VEGAS	NV	89169	725-2543210
TANGO PHARMACY	Robenson Apibo-Tango	4090 W CRAIG RD STE 101	NORTH LAS VEGAS	NV	89032	214-8861077
VALLEY PHARMACY	AMAR CHANDALURI	5055 SUN VALLEY BLVD #210	SUN VALLEY	NV	89433	775-2000945
RIVERFRONT PHARMACY	Harsh Patel	2490 RIVERFRONT CTR	AMSTERDAM	NY	12010	518-8430500
30TH AVENUE PHARMACY	Areej Abdullah	35-06 30TH AVE	ASTORIA	NY	11103	718-7778544
PHARMACHOICE	Mansour Mansour	25-78 STEINWAY STREET	ASTORIA	NY	11103	718-7286070
PHARMACARE	Mansour Mansour	21-09A 31ST STREET	ASTORIA	NY	11105	347-8480455
ASTOR PHARMACY CORP	MARIA RIOS	35-18 DITMARS BLVD	ASTORIA	NY	11105	718-9329800
HEALTH HUB PHARMACY	Moisey Zargarov	3029 STEINWAY ST	ASTORIA	NY	11103	+18-0055555
AVENUE CHEMISTS	Stellamaria Vitakos	4501 30TH AVE	ASTORIA	NY	11103	718-5451010
CLINIX PLUS PHARMACY	Nabeel Ashfaq	1655 GRAND AVE	BALDWIN	NY	11510	516-4422046
HEALTH MART PHARMACY	DEMETRIS PAVLOU	5 CANDLEWOOD RD	BAYSHORE	NY	11706	631-3004670

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
WATSONS PHCY & HOME HLTH	KANNY LIU	8622 GARVEY AVE, STE 102	ROSEMEAD	CA	91770	626-2802223
GOLDEN PAYLESS PHARMACY	KEJING GUO	3109 DEL MAR AVE	ROSEMEAD	CA	91770	949-3024258
REMEDY RX	PUJA KHANA	1420 E ROSEVILLE PKWY #130	ROSEVILLE	CA	95661	916-7401600
URS PHARMACY	John Yu	19115 COLIMA RD STE 107	ROWLAND HEIGHT	CA	91748	305-3930525
EASTLAND PHARMACY	DANIELLE KIM	18339A E COLIMA ROAD	ROWLAND HEIGHTS	CA	91748	626-8101056
NEW LIFE PHARMACY	INSEON CHUNG	1722 DESIRE AVE. 103	ROWLAND HEIGHTS	CA	91748	626-8393000
WELLNESS PHARMACY	Harpreet Gill	5880 STOCKTON BLVD. SUITE C	SACRAMENT O	CA	95824	800-5555555
CAPITAL CITY PHARMACY	Mitesh Patel	500 UNIVERSITY AVE #110	SACRAMENT O	CA	95825	916-4523454
MERCY PLAZA PHARMACY	Seajal Jivan	3941 J ST STE 130	SACRAMENT O	CA	95819	916-6427900
TEN ACRES PHARMACY	Sonya Frausto	2930 FREEPORT BLVD	SACRAMENT O	CA	95818	916-7302859
ELK GROVE PHARMACY 2	ThyTu Luu	8701 CENTER PKWY #150	SACRAMENT O	CA	95823	916-4026817
SAN ANDREAS PHARMACY	PATRICK CROSBY	45 EAST CHARLES ST STE C	SAN ANDREAS	CA	95249	209-6945516
LOMA LINDA UNIV PHCY	Alan Connelly	250 SOUTH G ST	SAN BERNARDINO	CA	92410	909-7712990
HIGHLAND COMMUNITY PHCY	PREMAL PATEL	1470 E HIGHLAND AVE #A	SAN BERNARDINO	CA	92404	909-9077915
RADIANCE PHY	Rajesh Gupta	1823 COMMERCENTER WEST	SAN BERNARDINO	CA	92408	909-5702339
ALTO PHARMACY SAN DIEGO	Ajay Khatri	4240 KEARNY MESA RD #107	SAN DIEGO	CA	92111	800-8745881
PROACTIVE CARE PHARMACY	Anh Pham	7345 LINDA VISTA RD STE E	SAN DIEGO	CA	92111	858-4054675
REMEDY	April Segal	320 W CEDAR ST STE 103	SAN DIEGO	CA	92101	619-9155862
GOOD MORNING PHCY	HaeSun Cho	7655 CLAIREMONT MESA BLVD	SAN DIEGO	CA	92111	858-2681660
REGENTS PHARMACY	John Han	6255 UNIVERSITY AVE #A1	SAN DIEGO	CA	92115	858-3578737
PURE CARE PHARMACY	Mina Said	5550 CARMEL MOUNTAIN RD	SAN DIEGO	CA	92130	858-9256149
PROVISION PHARMACY	Mitesh Patel	4428 GLACIER AE	SAN DIEGO	CA	92120	619-4663246
PHILLIP PHARMACY	PHOUNG NGUYEN	5507 EL CAJON BLVD STE E	SAN DIEGO	CA	92115	619-4589660
VIET PHCY & MED. SUPPLIES	PHUONG NGUYEN	4616 EL CAJON BLVD ST. 6	SAN DIEGO	CA	92115	619-5638212
ALVARADO COMMUNITY PHCY	RAMESH RAKHOLIA	6367 ALVARADO CT STE 109	SAN DIEGO	CA	92120	619-2877697
PARADISE HILLS PHARMACY	SOJI AKANWO	2366 REO DR	SAN DIEGO	CA	92139	619-4703710

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
BELLE HARBOR	RICHARD LONGO	449 BEACH 129TH STREET	BELLE HARBOR	NY	11694	718-6340001
PHAMCO DRUGS	KHALID CHAUDHARY	248-15 UNION TURNPIKE	BELLEROSE	NY	11426	718-7495807
PRECISON PHARMACY	RICHARD LONGO	2640 MERRICK RD	BELLMORE	NY	11710	516-7854774
PHARMACY AT BLASDELL	Joanne Haefner	4233 LAKE AVE	BLASDELL	NY	14219	716-2428608
TRUECARE PHARMACY	SRI POPURI	995 ROUTE 22	BREWSTER	NY	10509	845-2792931
ROSE DRUG STORE	ABU IDDRISS	262 E. BURNSIDE AVE	BRONX	NY	10457	718-2941470
BENJAMINS PHARMACY & SURG	BENJAMIN YUNUS	987-989 ALLERTON AVE	BRONX	NY	10469	718-4059111
JOSEPH KRAMER INC	BURT KRAMER	309 ST ANNS AVE	BRONX	NY	10454	718-9931488
EXCEL PHARMACY	German Jaime	2701 WILLIAMSBRIDGE RD	BRONX	NY	10469	973-5726901
CUSTOM RX INC	German Jamie	979 LEGGETT AVE	BRONX	NY	10455	347-5914470
IMPERIAL PHARMACY INC	Gilles de Tosellet	3050 CORLEAR AVENUE	BRONX	NY	10463	718-5810019
ISABELS PHARMACY INC	Igor Alayev	338 E GUN HILL RD	BRONX	NY	10467	718-6554005
DRUGBOX PHARMACY	Johnny Arias	500-5 BAYCHESTER AVE	BRONX	NY	10475	718-8727662
LIFE STAR PHARMACY	Jose Solano	1215 JEROME AVE	BRONX	NY	10452	+18-0055555
LEROY PHARMACY II HM	Kalpesh Shah	239 E 198TH ST	BRONX	NY	10458	718-2207600
CEDRA PHARMACY INC	MAZEN KARNABY	3027 3RD AVENUE	BRONX	NY	10455	917-4737788
PILGRIM PHARMACY HM	Michael Macioci	2941 WESTCHESTER AVENUE	BRONX	NY	10461	718-8280498
HUNTS POINT PHARMACY	Muhammad Shaid	2799 3RD AVE	BRONX	NY	10455	718-4011249
SECURITY DRUGS	NATWAR GEVARIA	3419 BOSTON ROAD	BRONX	NY	10469	718-6546974
PARKCHESTER PHARMACY	Nazer Ahmed	1663 METROPOLITAN AVE	BRONX	NY	10462	347-3989006
LIVEWELL PHARMACY	Niurka Vasquez	1432 E GUN HILL RD	BRONX	NY	10469	347-8438562
1ST AID PHARMACY	RAFAEL PEREZ	23 W. FORDHAM ROAD	BRONX	NY	10468	718-4503555
DJ DRUGS	Roman Shamalov	3721 RIVERDALE AVE	BRONX	NY	10463	718-5496709
ELDER PHARMACY	SANJIV SHETH	1527 WESTCHESTER AVE	BRONX	NY	10472	718-8422777
ADEE PHARMACY	Stephen Colabella	1427 E GUN HILL RD	BRONX	NY	10469	718-3791954
WECARE RX PLUS	Syed Ali	2405 WESTCHESTER AVE	BRONX	NY	10461	718-6845070

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
VERTEXRX PHARMACY	Angel Samvalian	11273 LAUREL CANYON BLVD STE 4	SAN FERNANDO	CA	91340	818-6389652
ABSOLUTE CARE PHCY	Boris Ana Mekinian	541 N MACLAY AVE 104	SAN FERNANDO	CA	91340	818-3650422
ALTO SAN FRAN RETAIL	Brian Meews	1400 TENNESSEE ST. UNIT 2	SAN FRANCISCO	CA	94107	818-5846487
TIN RX/CASTRO SF	Christina Garcia	2175 MARKET ST UNIT 122	SAN FRANCISCO	CA	94114	628-8959508
CLAY MEDICAL PHARMACY	GARLAND NG	929 CLAY STREET	SAN FRANCISCO	CA	94108	415-9565456
PARNASSUS HEIGHTS PHCY HM	Robert Dudum	350 PARNASSUS AVE #100	SAN FRANCISCO	CA	94117	415-5649191
SUTTER PROFESSIONAL PHCY	TERRY CHU	2300 SUTTER STREET #101	SAN FRANCISCO	CA	94115	415-5673223
VIEWPOINT/QUICKFILL PHARM	Laurie Potash-Bresnick	209 W LAS TUNAS DR	SAN GABRIEL	CA	91776	626-9437820
LION PHARMACY	An MAI	2857 SENTER ROAD STE A	SAN JOSE	CA	95111	408-7843921
BAY RX INC	An Nguyen	1661 BURDETTE DR STE AB	SAN JOSE	CA	95121	408-6228531
ALUM ROCK PHARMACY	AN NGUYEN	1855 ALUM ROCK AVE STE A	SAN JOSE	CA	95116	408-2541551
NOWRX- SAN JOSE	CARY Breese	1310 TULLY RD STE 101	SAN JOSE	CA	95122	650-3865761
LEXANN PHARMACY INC	JEREMY LAI	1569 LEXANN AVE #104	SAN JOSE	CA	95121	408-5289079
EVERGREEN PHARMACY II	KEVIN DANG	2365 QUIMBY RD #150	SAN JOSE	CA	95122	408-3910700
EVERGREEN PHARMACY	Kevin Dang	2690 SOUTH WHITE RD #200A	SAN JOSE	CA	95148	408-2700670
VIET TOWN PHARMACY	Khoa Pham	999 STORY ROAD UNIT 9024	SAN JOSE	CA	95122	408-7282407
ALTO PHARMACY SAN JOSE	Mattieu Gamache-Asselin	2360 QUME DR STE A	SAN JOSE	CA	95131	800-8745881
KC PHARMACY	Nhuong Le	2060 ABORN RD #150B	SAN JOSE	CA	95121	408-4004755
ICARE PHARMACY	Pam Duong	1727-B BERRYESSA RD	SAN JOSE	CA	95133	408-9267691
SAN JOSE PHARMACY	Phi Nguyen	200 JOSE FIGUERES AVE#235	SAN JOSE	CA	95116	408-2548884
PANDIA PHARMACY	Susana Craig	1900 CAMDEN AVE 101	SAN JOSE	CA	95124	650-4370561
TAN PHARMACY	Tan Nguyen	2611 SENTER RD STE 100	SAN JOSE	CA	95111	408-6804360
KING PHARMAC & DME HM	TIFFANY THU LAME	2323 MONTPELIER DR STE D	SAN JOSE	CA	95116	408-3470193
CREEKSIDE PHARMACY	Tiffany Tran	1863 ALUM ROCK AVE STE A	SAN JOSE	CA	95116	408-9296029
OC PHARMACY	Anthony D'Alessandro	31654 RANCHO VIEJO RD	SAN JUAN CAPISTRANO	CA	92675	415-6865587
SAN MARCOS PHARMACY	TARUN WADHWA	631-A S RANCHI SANTA FE RD	SAN MARCOS	CA	92078	760-7980898

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
KING RAJ PHARMACY	Tualasi Malla	58 EAST KINGSBRIDGE RD	BRONX	NY	10468	718-5848371
J&J PHARMACY	ZUNILBA LAMORENA	332 EAST 188TH ST	BRONX	NY	10458	718-3672000
FRANKLIN & CARROLL DRUGS	Ahmad Irgan	886 FRANKLIN AVE	BROOKLYN	NY	11225	718-2211838
CHEMIX PHARMACY	Albert Mavashev	5909 18TH AVE	BROOKLYN	NY	11204	718-4444000
FAMILY CARE NY PHCY	Ali Zeeshan	170 AVENUE U	BROOKLYN	NY	11223	718-9460101
TABLET RX	Amer Abdilahman	122 BAY RIDGE AVE	BROOKLYN	NY	11220	347-4975585
FULTON 1ST PHARMACY	AMJAD HUSSEIN	1185 FULTON ST	BROOKLYN	NY	11216	718-4849100
GRISTEDES PHARMACY #0544	ANGELA PENGOS	101 CLARK STREET	BROOKLYN	NY	11201	718-8349003
GLOBE PHARMACY	BRETT COHEN	405 86TH STREET	BROOKLYN	NY	11209	718-7452233
DOOR TO DOOR PHARMACY	Chinedu Maurice Agbasionwe	259 TROY AVE	BROOKLYN	NY	11213	718-4847400
FILL HERE RX	CHRIS BRAVO	2116 ROCKAWAY PKWY	BROOKLYN	NY	11236	718-9688600
THE MEDICINE CHEST	Efraim Halberstan	4407 15TH AVE	BROOKLYN	NY	11219	718-6334246
SHIMONS PHARMACY	Ersel Kohanteb	115 LEE AV	BROOKLYN	NY	11211	718-3840234
VLS PHARMACY	GOPESH PATEL	4402 5TH AVE	BROOKLYN	NY	11220	718-8541384
SAM PHARMACY	Hosam Elsayyad	210 PARKSIDE AVE	BROOKLYN	NY	11226	718-5136657
AVK RX INC	IRINA ARONOVA	3904 CHURCH AVE	BROOKLYN	NY	11203	718-4849810
MOISHES PHARMACY CORP	Irina Kanevskaya	4508 13TH AVE	BROOKLYN	NY	11219	917-9716453
MEDPACK LLC	Israel Grunwald	5923 STRICKLAND AVENUE	BROOKLYN	NY	11234	347-5061000
C&J WELLNESS PHARMACY	Jean Romelus	1425 BROADWAY	BROOKLYN	NY	11221	718-4430591
BROADWAY PHARMACY HM	Jogy Abraham	1226 BROADWAY	BROOKLYN	NY	11221	718-4431331
MARINO PHARMACY	John Alessandri	167 WYKOFF AVE	BROOKLYN	NY	11237	718-4973104
FAMILY PHARMACY HM	Kamram Mustala	1101 FLATBUSH AVE	BROOKLYN	NY	11226	718-7032440
PHAMCO DRUGS	KHALID CHAUDHARY	376 UTICA AVE	BROOKLYN	NY	11213	718-7788750
STELLA'S PHARMACY	Lavanya Akula	8722 GLENWOOD ROAD	BROOKLYN	NY	11236	718-2728450
SPENCER DRUG	LINDA MACH	5702 SEVENTH AVENUE	BROOKLYN	NY	11220	718-4393852
BRIDGE PHARMACY	Maria Georgakopoulos	8912 3RD AVE	BROOKLYN	NY	11209	718-8361400

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
TED'S VILLAGE PHCY HM	Steve Pham	29 WEST 25TH AVE	SAN MATEO	CA	94403	650-3491373
OC COMMUNITY PHARMACY	Arman Nazaryan	809 SOUTH MAIN UNIT C	SANTA ANA	CA	92701	714-8843331
MEDCARE FAMILY PHARMACY	David Donner	1710 S MAIN ST #109-1B	SANTA ANA	CA	92707	714-9537538
HAPPY CARE PHARMACY	Khanh Vo	120 SOUTH HARBOR BLVD SUITE B	SANTA ANA	CA	92704	714-7604485
CAREJOY PHARMACY	Lan Nguyen	2708 WESTMINSTER AVE 120	SANTA ANA	CA	92706	657-2184166
ALLCARE PHARMACY #3	Loc Tran	1106 E 17TH ST STE B	SANTA ANA	CA	92701	714-5509303
MIRACLE CARE PHARMACY	Siamak Tehrani	24355 LYONS AVE #110	SANTA CLARITA	CA	91321	661-2222221
JDX PHARMACY HM	Chhitu Patel	1504 SOUTH BROADWAY	SANTA MARIA	CA	93454	805-9221747
GOLDEN WELLNESS RX PHCY	AMANDA PARHAMI	1230 MONTANA AVE. STE 106	SANTA MONICA	CA	90403	310-4513322
2222 PRESCRIPTION PHCY	HOMAYOON KHORSANDI	2222 SANTA MONICA BLVD STE 103	SANTA MONICA	CA	90404	310-4535557
SMC PHARMACY	Matt Sesto	1908 SANTA MONICA BLVD #4	SANTA MONICA	CA	90404	310-3159999
CENTRAL PHARMACY HM	Sharon Steer	2008 WILSHIRE BLVD	SANTA MONICA	CA	90403	310-3953294
ALL CARE PHARMACY	Jay Rakholia	8790 CUYAMACA ST STE B	SANTEE	CA	92071	619-4490908
PALCO PHCY RX	DANIEL BYWATER	113 MAIN SUITE D/PO 157	SCOTIA	CA	95565	800-8489692
SELMA PHARMACY	Sammy Dous	2132 HIGH ST	SELMA	CA	93662	559-3189646
MICHAELS PHARMACY	Babak Kohanteb	4955 VAN NUYS BLVD	SHERMAN OAKS	CA	91403	818-9050669
MULTICARE PHARMACY	MARGO SOBOL	4849 VAN NUYS BLVD 101A	SHERMAN OAKS	CA	91403	818-4619600
HOME CARE PHARMACY	Jason Miles	1687 ERRINGER RD #101	SIMI VALLEY	CA	93065	805-5279600
TAHOE VALLEY PHARMACY	DOUG MUNDY	2074 LAKE TAHOE BL. #1	SOUTH LAKE TAHOE	CA	96150	530-5410870
HAMMER LANE PHARMACY	Amir Khan	2339 W HAMMER LN STE J	STOCKTON	CA	95209	209-4777100
ORGLIFE RX & COMPOUNDING	Lena Badalyan	12038 VENTURA BLVD STE A	STUDIO CITY	CA	91604	800-5555555
STANFRED DRUGS HM	Elizabeth Lara	8031 VINELAND AVENUE	SUN VALLEY	CA	91352	818-7673737
RXBOUTIQUE PHARMACY	Edita Martirosyan	18425 BURBANK BLVD # 414	TARZANA	CA	91356	310-3306455
DYNAMED PHARMACY	Joseph Cherian	19618 VENTURA BLVD	TARZANA	CA	91356	818-5930528
FIRSTCARE PHARMACY	Matt Sesto	18555 VENTURA BLVD STE A	TARZANA	CA	91356	818-2131000
TARZANA WELLNESS PHCY	Sarah Simpson	18840 VENTURA BLVD STE 120	TARZANA	CA	91356	818-6008800
ARCHANGEL MICHAEL PHCY	MARY GALEY	31754 TEMECULA PKWY STE D	TEMECULA	CA	92592	951-3027733

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
ST MARIE INC	Mary Hana	7211 5TH AVE	BROOKLYN	NY	11209	347-5606866
ALAFIYA PHARMACY	Mohamed Alawlaqi	7820 5TH AVE	BROOKLYN	NY	11209	917-8870963
AMERICARE PHARMACY	Mohamed Elsayed	8114 5TH AVE	BROOKLYN	NY	11209	929-3735578
PHARMACY EXPRESS	Mohammad Iqbal	1081 RUTLAND RD	BROOKLYN	NY	11212	718-4934199
EXCEL DRUGS	MOHAN MANNE	42 THOMAS S BOYLAND ST	BROOKLYN	NY	11233	718-4531003
RAFIEH PHARMACY	Moshe Fekete	70 LEE AVENUE	BROOKLYN	NY	11211	718-3870021
APNI PHARMACY CORP	Muhammad Shahbaz	211 NEPTUNE AVE	BROOKLYN	NY	11235	718-9757885
LIVE GOOD PHARMACY	Ngozi Abgasiomwe	1025 NOSTRAND AVE	BROOKLYN	NY	11225	718-2219300
FRONTLINE PHCY AND SURG	Ngozi Abgasiomwe	2610 ATLANTIC AVE	BROOKLYN	NY	11207	718-4009144
GENA CARE PHARMACY	NGOZI AGBASIONWE	173 CHAUNCEY STREET	BROOKLYN	NY	11233	718-4847166
SURE DRUGS	Rathna veeramachanni	312 RALPH AVE	BROOKLYN	NY	11233	718-7446800
KINGS PARK SLOPE HM	Ron Del Gaudio	357 FLATBUSH AVE	BROOKLYN	NY	11238	718-2303535
KINGS DRUG & SURGICAL HM	Ron Del Gaudio	492 CLARKSON AVE	BROOKLYN	NY	11203	718-3633300
COMPLETE CARE RX	Sara Amer	723 NOSTRAND AVE	BROOKLYN	NY	11216	347-6273303
LIBERTY CHEMISTS	Sarah Zafarani	1501 NEWKIRK AVE	BROOKLYN	NY	11226	718-6765995
SOS PHARMACY	SERGEY SEMENOV	1201 AVENUE Z	BROOKLYN	NY	11235	917-9334000
OXFORD PHARMACY	Sherif Atef	264 FLAT BUSH AVE	BROOKLYN	NY	11217	929-2980369
QUICK CARE PHARMACY	Shlomo Chaya	2314 CONEY ISLAND AVE	BROOKLYN	NY	11223	718-3755700
TREE OF LIFE RX	Simho Aronov	2472 CONEY ISLAND AVE	BROOKLYN	NY	11223	718-3360900
16TH AVE PHARMACY	Solomon Gulyamov	4605 16TH AVE	BROOKLYN	NY	11204	718-6868000
PHAMCO DRUGS	TARIQUE CHAUDHARY	802 NOSTRAND AVE	BROOKLYN	NY	11216	718-6042585
CLINICMED PHARMACY	Udoka Okekeozo	1801 PITKIN AVE	BROOKLYN	NY	11212	718-4847470
PHARMA HOLDING INC	Victoria Finkel	572 BEDFORD AVE	BROOKLYN	NY	11249	718-3847334
BUFFALO PHCY RTL HM	Alec Gillies	1479 KENSINGTON AVE	BUFFALO	NY	14215	716-8327742
DISCOUNT PHARMACY	HASSAN MANA	429 WILLIAM ST	BUFFALO	NY	14204	716-8523000
PHARMACY AT MATTINA	Joanne Haefner	300 NIAGARA ST	BUFFALO	NY	14201	716-2428600
VITAL PHARMACY	Joseph Bellavia	301 CONNECTICUT ST	BUFFALO	NY	14213	716-9234603

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number	Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
VAIL RANCH PHARMACY	Nilesh Vaghani	32675 TEMECULA PKWY STE B	TEMECULA	CA	92592	951-3038300	URBAN HEALTH PHCY INC	Uzair Ahmed	564 NIAGARA ST BLDG 2	BUFFALO	NY	14201	716-3300908
EVERGREEN RX PHARMACY	YVONNE TONGOC	40963 WINCHESTER RD.	TEMECULA	CA	92591	951-2969074	MILEX DRUG-PSSNY-C HM	Robert Begert	3130 MAIN ST.	CALEDONIA	NY	14423	585-5386140
WEST COAST RX	Arthur Gyanjyan	375 ROLLING OAKS DR STE 150	THOUSAND OAKS	CA	91361	805-3710700	REFRESH PHARMACY	Terry Wong	5700 W GENESEE ST STE 106	CAMILLUS	NY	13031	519-5758104
THREE RIVERS DRUG	DAVID STANLEY	40893 SIERRA DR PO BX 415	THREE RIVERS	CA	93271	559-5614217	GREENE MEDICAL ARTS PHCY	srinivas velesetty	159 JEFFERSON HEIGHTS	CATSKILL	NY	12414	518-9431715
BC PHARMACY	Bernadette Caloza	10628 RIVERSIDE DR #2	TOLUCA LAKE	CA	91602	818-4529001	TILE PHCY-PSSNY PS HM	Joseph Rutowski	1029-31 CLEVELAND DR	CHEEKTOWA GA	NY	14225	716-6324888
VM PHARMACY	Elena Tumasyn	23451 MADISON STREET #100	TORRANCE	CA	90505	310-3780005	LONG ISLAND APOTHECARY	Brian Zone	6216 JERICHO TPKE	COMMACK	NY	11725	631-4869172
CONCIERGE PHARMACY	Matt Sesto	23215 HAWTHORNE BLVD #B	TORRANCE	CA	90505	310-2994999	GEROULD'S PHCY 4	FRANK STEED	98 W. PULTENEY ST.	CORNING	NY	14830	607-9363233
GRANT LINE PHARMACY	Beatle Tran	2160 W GRANT LINE RD #205	TRACY	CA	95377	209-8322999	SALBARO DRUGS	Mirvice Ahmed	10607 CORONA AVE	CORONA	NY	11368	718-6995099
CHERRY STREET PHCY	Kartikeya Jha	1028 N CHERRY ST	TULARE	CA	93274	559-2342112	CORONA CHEMISTS	Tania Rizzo	105-12 NORTHERN BLVD	CORONA	NY	11368	347-5071126
TIN RX AT THE TOWER INC	Christina Garcia	1801 COLORADO AVE STE 300	TURLOCK	CA	95382	209-8508818	CROSS RIVER PHARMACY	Stuart Feldman	20 N SALEM RD	CROSS RIVER	NY	10518	914-7633152
CURA PHARMACY	Gopal Sojitra	17400 IRVINE BLVD STE P	TUSTIN	CA	92780	714-5052872	SAVE MOR DRUGS HM	Yogi K	175 SOUTH RIVERSIDE AVE	CROTON ON HUDSON	NY	10520	914-2712900
TWAIN HARTE PHARMACY	Patrick Crosby	22629 TWAIN HARTE DR STE D	TWAIN HARTE	CA	95383	209-5863225	CUBA PHARMACY HM	Rick Wonderling	2 CENTER STREET	CUBA	NY	14727	585-9683111
NEW PHARMACY 2	MAHER MICHAEL	72724 29 ALMS HWY STE 104	TWENTYNINE PALMS	CA	92277	760-3672000	P&G PHCY/COUNTY LINE PHCY	steven weinberg	1111 RTE 110	E FARMINGDALE	NY	11735	631-2496400
NEW TIB VSQZ HLTH CT HM	Jennifer Tam	33255 9TH STREET	UNION CITY	CA	94587	510-4898088	LARWOOD PHARMACY	John Rutowski	597 OAKWOOD AVE	EAST AURORA	NY	14052	716-6521360
T.H.E. PHARMACY	NAJY ABIFADEL	360 E 7TH STREET STE F	UPLAND	CA	91786	909-9466411	SULTANA/LIGHTHOUSE PHCY	Tarique Chaudhary	747 MONTAUK HIGHWAY	EAST PATCHOGUE	NY	11772	631-6542444
SUNRISE PHARMACY INC	Kim Pham	51 WELLNESS WAY STE 110	VALLEY SPRINGS	CA	95252	209-5849088	VALUE DRUGS EASTCHESTER	Sarit Roy	1 TUCKAHOE AVE	EASTCHESTER	NY	10709	914-7715640
CANYON PHCY/101 PHARMACY	Erry Astourian	12117 MAGNOLIA BLVD	VALLEY VILLAGE	CA	91607	818-9274249	CYS ELMA PHARMACY HM	Joseph Rutowski	2317 BOWEN ROAD	ELMA	NY	14059	716-6523920
GO TO PHARMACY	Gevorg Keroglyan	5961 LAUREL CANYON AVE #2	VALLEY VILLAGE	CA	91607	818-8507010	ELMWAY PHARMACY	Phoebe Tse	82-45 BROADWAY	ELMHURST	NY	11373	718-8032288
LOVVIT PHARMACY	Manvel Khacheryan	12504 MAGNOLIA BLVD	VALLEY VILLAGE	CA	91607	323-9870315	ELMHURST PHCY & HOME INFU	Silvia Segarra	81-06 BAXTER AVENUE	ELMHURST	NY	11373	718-5072299
HEALTHY WAY PHARMACY	Alis Arabyan	7223 BALBOA BLVD	VAN NUYS	CA	91406	818-9979420	99 PHARMACY INC	Ting Chen	74-02 GRAND AVE UNIT A	ELMHURST	NY	11373	718-5003699
APOLLO PHARMA SERVICES	Anna Bogdanyan	16104 HART ST	VAN NUYS	CA	91406	818-2571457	GEROULD'S PHCY 1	FRANK STEED	130 S. MAIN STREET	ELMIRA	NY	14904	607-7333669
SHERMAN WAY PHARMACY	ARNOLD NIKOGOSYAN	15333 SHERMAN WAY UNIT C	VAN NUYS	CA	91406	818-4538380	GEROULD'S PHCY 2	FRANK STEED	215 HOFFMAN ST	ELMIRA	NY	14905	607-7320597
NOWRX VAN NUYS	Cary Breese	16517 ARMINTA ST	VAN NUYS	CA	91406	818-6466000	BAKERS DRUGS & SURGICAL	Khaled Ali	500A ELMONT RD	ELMONT	NY	11003	516-4444800
PRIORITY CARE PHARMACY	HAROUT KAZANCHYEN	5902 VAN NUYS BLVD.	VAN NUYS	CA	91401	818-5088665	CORNER DRUG - PSSNY HM	Patrick Magee	101 WEST MAIN ST	ENDICOTT	NY	13760	607-7850431
PRIME LIBERTY PHARMACY	Hasmik Gevshenian	7335 VAN NUYS BLVD #107	VAN NUYS	CA	91405	818-4653515	FILLMORE PHCY-PSSNY HM	Brian Loucks	10560 RT 19	FILLMORE	NY	14735	585-5672228
CIRCLE A PHARMACY	Honey Hakimirad	7449 WOODLEY AVE	VAN NUYS	CA	91406	424-2028650	LEAVITT PHARMACY INC	Alex Shen	35-19 LEAVITT ST #S1	FLUSHING	NY	11354	718-4451888

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
NOVA LUXE PHARMACY	Noune Aramyan	13756 VICTORY BLVD	VAN NUYS	CA	91401	818-8092382
HYE PHARMACY #2 HM	Peter Taglyan	13745 VICTORY BLVD	VAN NUYS	CA	91401	818-7827152
MESA CARE PHARMACY	Souheil Attar	7218 VAN NUYS BLVD STE B	VAN NUYS	CA	91405	818-7856049
HEALTHY CARE PHARMACY	Tereza Buniatyan	6405 VAN NUYS BLVD	VAN NUYS	CA	91401	818-6163488
KING PLAZA PHARMACY	Vahagh Kagramanyan	7227 VAN NUYS BLVD	VAN NUYS	CA	91405	818-7366638
SUPER DISCOUNT PHARMACY	YELENA SLYUSARANSKAYA	14618 VICTORY BLVD UNIT B	VAN NUYS	CA	91411	818-3768316
MARVEL PHARMACY	Yevgeniya Gabriyelova	15246 SATICOY ST	VAN NUYS	CA	91405	818-8060208
VISTA CARE PHARMACY	AMIR RAO	12351 MARIPOSA RD #11	VICTORVILLE	CA	92395	760-8437000
R & M DRUG VISALIA	Ahlet Hii	3833 W CALDWELL AVE, SUITE B	VISALIA	CA	93277	559-3657861
VISALIA PHARMACY	Hany Mansour	444 NORTHWEST 3RD AVE	VISALIA	CA	93291	559-6679292
MEDRX PHCY/COMPOUNDING	Hashem Heiati	1031 E. VISTA WAY	VISTA	CA	92084	760-7247125
ROYAL PHARMACY	Abdoali Shahdawala	1839A YGNACIO VALLEY RD	WALNUT CREEK	CA	94598	510-5579183
BETTER VALUE PHARMACY	BonJun Koo	2707 E VALLEY BLVD #100	WEST COVINA	CA	91792	626-9604723
EASYCARE PHARMACY	Matt Sesto	7320 WOODLAKE AVE #100	WEST HILLS	CA	91307	818-9271000
MEDCENTA PHARMACY	Payam Ghorbani	6401 PLATT AVE STE 4	WEST HILLS	CA	91307	818-9145049
CEDARMAK PHARMACY	Mak Bagheri	8737 BEVERLY BLVD #102	WEST HOLLYWOOD	CA	90048	424-3037860
CIENEGA PHARMACY	Mike Rabia	7360 ST MONCA BVD STE 101	WEST HOLLYWOOD	CA	90046	310-3609969
JEFFERSON PHARMACY	THYE PHAM	1029 JEFFERSON BLVD	WEST SACRAMENT O	CA	95691	916-3712022
CAPITOL PHARMACY HM	Tom Bui	1250 HARBOR BLVD STE 600	WEST SACRAMENT O	CA	95691	916-6174321
PRIMECARE PHARMACY	Matt Sesto	32144 AGOURA RD STE 101	WESTLAKE VILLAGE	CA	91361	818-9641000
BT PHARMACY	BAO TRAN	14262 BEACH BLVD	WESTMINSTER	CA	92683	714-6225992
BOLSA MEDICAL ARTS PHCY	Peter Lee	15262 GOLDENWEST ST	WESTMINSTER	CA	92683	714-8972541
WHITTIER INTER PHCY HM	James Nam	12291 E WASHINGTONBLV101	WHITTIER	CA	90606	562-9454166
FOUCH AND SON PHCY HM	Julia Davison	692 E ST	WILLIAMS	CA	95987	530-4735350
WILLOWS PHARMACY HM	Tejas Patel	226 NORTH BUTTE STREET	WILLOWS	CA	95988	530-9347744

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
NORTHERN PHARMACY	Dosung Jung	164-16 NORTHERN BLVD	FLUSHING	NY	11358	718-4452470
123 PHARMACY	Jing Yao	3712 PRINCE STREET F14	FLUSHING	NY	11354	718-9711690
AVONORA PHARMACY	STANLEY ARONOV	149-01 UNION TURNPIKE	FLUSHING	NY	11367	718-9693300
MAPLE PARK PHARMACY	Weiquan Liang	4260 KISSENA BLVD FL 1	FLUSHING	NY	11355	914-8298273
BARTHOLOMEW'S PHCY PSSNY	RANDALL BUCHANAN	2 ELM STREET	FRANKLINVILLE	NY	14737	716-6763350
179 ATLANTIC INC DBAKI HM	Scott Buda	29 ATLANTIC AVE	FREEPORT	NY	11520	516-3774050
MYRTLE MEDS INC	Ben Davidov	7617 MYRTLE AVE	GLENDALE	NY	11385	718-6503526
CENTRAL NEIGHBORHOOD RX	Joseph Natanov	6743 CENTRAL AVE	GLENDALE	NY	11385	929-2950844
EASY RX PHARMACY	Maritza Barriga	6609 MYRTLE AVE	GLENDALE	NY	11385	845-7694578
MYRTLE DRUGMART	Piyush (Peter) Patel	65-62 MYRTLE AVE	GLENDALE	NY	11385	347-2278188
ISLAND PRESCRIPTION HM	Michael Manuszewski	1728 GRAND ISLAND BLVD	GRAND ISLAND	NY	14072	716-7735599
NORTH SHORE CHEMISTS	Kathy Elashvili	800 NORTHERN BLVD STE 4	GREAT NECK	NY	11021	516-4608343
PRECISION PHCY GREAT NECK	Richard Longo	665 MIDDLE NECK RD	GREAT NECK	NY	11023	516-4820005
PHAMCO DBA COLONIAL DRUG	KHALID CHAUDHARY	100 FRONT STREET	GREENPORT	NY	11944	631-4771111
WANAKAH PHARMACY HM	Joseph Rutowski	S 4923 LAKESHORE RD	HAMBURG	NY	14075	716-6273232
TROTТА'S WEST ST PHCY	Anthony Ciarletta	15 HALSTEAD AVE	HARRISON	NY	10528	914-8351125
BONAPARTE PHARMACY	Justin Besaw	8210 MAIN STREET	HARRISVILLE	NY	13648	315-5375032
D'S PHARMACY	DEMETRIUS PAVLOU	389-391 PENINSULA BLVD #E	HEMPSTEAD	NY	11550	516-2804100
SHIPMAN'S PHARMACY	HENRY CUNNINGHAM	210 SOUTH FRANKLIN ST	HEMPSTEAD	NY	11550	516-4831767
ER BLACK-HOLLAND PATENT	Robert Black	9553 MAIN ST	HOLLAND PATENT	NY	13354	315-8658141
HOLLEY PHARMACY	Sankar Sewnauth	3 GEDDES ST	HOLLEY	NY	14470	585-6385499
THORPES PHARMACY	Tejal Patel	24 CHURCH ST	HOOSICK FALLS	NY	12090	518-6865711
GEROULD'S PHCY 3	FRANK STEED	2887 WESTINGHOUSE RD	HORSEHEADS	NY	14845	607-7962193
MAIN SOURCE PHARMACY	Agneta Alayou	347 MAIN ST	HUNTINGTON	NY	11743	631-7601114
GULSHAN PHARMACY	Sharmin Haq	7321 BROADWAY	JACKSON HEIGHTS	NY	11372	718-6725500

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
CORNER DRUG WDL D HM	Sara Shelley	602 MAIN STREET	WOODLAND	CA	95695	530-6622813
WELLNESS SPECIALTY PHCY	Bahareh Golestanipou	19944 VENTURA BLVD	WOODLAND HILLS	CA	91364	818-8546600
OAKS COMMUNITY PHARMACY	Chris Sarafian	21910 VENTURA BLVD	WOODLAND HILLS	CA	91364	747-2543331
WEST VALLEY PHARMACY	MIHWA BANG	22554 VENTURA BLVD #100	WOODLAND HILLS	CA	91364	818-2229877
TOPANGA PHARMACY	Rima Asadourian	22124 VENTURA BLVD	WOODLAND HILLS	CA	91364	818-8053437
BLISS PHARMACY	Smbat Kln djuyan	22998 VENTURA BLVD	WOODLAND HILLS	CA	91364	818-9126104
RIVERSIDE PHARMACY	Khaled Sedki	866 PLUMAS STREET STE C	YUBA CITY	CA	95991	530-7511889
FRANKLIN PHARMACY	Khaled Sedki	1619 FRANKLIN RD BLDG A	YUBA CITY	CA	95993	530-6743277
NEW PHARMACY	MAHER MICHAEL	57725 29 PALMS HWY SUITE 209	YUCCA VALLEY	CA	92284	760-2281600
CARL'S PHARMACY LTD	STACY ADLER	306 E MAIN ST	ASPEN	CO	81611	970-9253273
APEX PHARMACY	Mary Desta	12597 E MISSISSIPPI #300	AURORA	CO	80012	303-7493864
BASALT CLINIC PHARMACY	Tad Anderson	110 MIDLAND AVE	BASALT	CO	81621	970-9273833
THE APOTHECARY WARDENBURG	Chelsea Johnson	WARDENBURG HEALTH CENTER	BOULDER	CO	80309	303-4928553
CEDAREDGE PHARMACY HM	John Breitnauer	215 W MAIN ST	CEDAREDGE	CO	81413	970-8563161
VALLEY PHARMACY HM	VICKILEE EINHELLIG	4493 BENT BROTHERS BLVD	COLORADO CITY	CO	81019	719-6763333
TKS PHARMACY.	ALICE SOREMEKUN	4809 ARGONNE ST STE 225	DENVER	CO	80249	720-5832110
WELLSHIRE PHARMACY HM	Carl Clark	4141 E DICKENSON PLACE	DENVER	CO	80222	303-5046699
MHCD PHARMACY HM	Carl Clark	4455 E 12TH AVE	DENVER	CO	80220	303-5047799
MEDSTUFF PHARMACY	Eduard Plotkin	7150 LEETSDALE DR 312	DENVER	CO	80224	303-3332035
RAPHA RX LLC	Fru Ngunjoh	1260 S PARKER RD STE B	DENVER	CO	80231	303-2198801
ALTO DENVER RETAIL	Layne Martin	929 N BROADWAY	DENVER	CO	80203	800-8745881
PENCOL SPECIALTY PHCY	Peter Case	1325 S COLORADO BLVD #B24	DENVER	CO	80222	303-3883613
TODD'S HARVARD PARK PHCY	Todd Hilst	950 E HARVARD AVE STE 170	DENVER	CO	80210	303-7333784
HUAN PHARMACY	TRANG THAN	633 S FEDERAL BLVD #203	DENVER	CO	80219	303-9363230
EAGLE PHARMACY HM	John Batson	301 BROADWAY	EAGLE	CO	81631	970-3286875
GOOD DAY PHCY #7 RXP HM	Vicki Einhellig	180 S ELM	EATON	CO	80615	970-4542110

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
QUEENS EXPRESS PHCY CORP	Silvia Segarra	3454 JUNCTION BLVD	JACKSON HEIGHTS	NY	11372	718-5651009
NAIMA PHARMACY	Silvia Segarra	82-10 37 AVE	JACKSON HEIGHTS	NY	11372	718-2055001
NEW YORK BLVD PHCY	SANDEEP DHAMIJA	107-45 GUY R BREWER BLVD	JAMAICA	NY	11433	718-2976500
TACONIC PHARMACY INC HM	Anthony Ciarletta	3659 LEE ROAD	JEFFERSON VALLEY	NY	10535	914-2453334
KENMORE RX CENTER	John Rutowski	2818 DELAWARE AVE	KENMORE	NY	14217	716-8746360
LARCHMONT PHARMACY	ANTHONY CIARLETTA	2141 PALMER AVE	LARCHMONT	NY	10538	914-3411900
DEGIULIO'S PHARMACY	Rick DeGiulio	220 PORTAGE RD	LEWISTON	NY	14092	716-4057821
PRECISION PHCY LONG BEACH	FRANK STELLA	629 E PARK AVE	LONG BEACH	NY	11561	516-8898899
AGUSTIN PHARMACY	Phillip Hong	39-20 29TH ST	LONG ISLAND	NY	11101	718-9378160
MAIN STREET PHARMACY HM	James Cataldi	11 EAST MAIN ST	MARCELLUS	NY	13108	315-6732410
PHARMACY ON GRAND	MIKHAIL HEIFITZ	7333 GRAND AVE	MASPETH	NY	11378	718-7342400
AJ'S VILLAGE CHEMIST	JOSPEH Lasala	74-05 METROPOLITAN AVE	MIDDLE VILLAGE	NY	11379	718-8949000
DRUG MART MILLWOOD	Rich Glotzer	230 SAW MILL RIVER RD	MILLWOOD	NY	10546	914-9239200
KIRYAS JOEL PHARMACY	Mr Wienburger	51 FOREST ROAD SUITE 211	MONROE	NY	10950	845-7833399
HEALTHMART PHCY OF MONROE	Mr. Wiesman	48 BAKERTOWN RD SUITE 101	MONROE	NY	10950	845-7741464
MAPLE PHARMACY	Moses Werzberger	59 ROUTE 59 STE 143	MONSEY	NY	10952	845-3716464
GREENBAUM'S	MOTTY GREENBAUM	42 MAIN STREET	MONSEY	NY	10952	845-3569300
MEDSPPLUS PHY & SURG SPLY	CHINTAN PATEL	531 GRAMATAN AVENUE	MOUNT VERNON	NY	10552	914-6646600
CHELSEA DRUGS INC HM	Robert Black	44 GENESEE ST	NEW HARTFORD	NY	13413	315-7321615
CUREMED RX	LuyBov Abramova	2020 LAKEVILLE RD	NEW HYDE PARK	NY	11040	516-7557999
EMPIRE- NEW ROCHELLE PHCY	THOMAS ABRAHAM	110 LOCKWOOD AVENUE	NEW ROCHELLE	NY	10801	914-6541222
RITE HOPE PHARMACY INC	AHMED Sabra	1793A MADISON AVE	NEW YORK	NY	10035	212-3483341
GOLDEN STAR PHARMACY	Alex Shen	1-3 ELDRIDGE ST STORE A	NEW YORK	NY	10002	646-4131050
CHARLIE PHARMACY	AMJID "CHARLIE" MUGHAL	2034 SECOND AVE	NEW YORK	NY	10029	646-5967028
GRISTEDES PHARMACY #0545	ANGELA PENGOS	227 9TH AVENUE	NEW YORK	NY	10011	212-8070950
NEWGEN PHARMACY	BOBBY KWOK	18 MOTT STREET	NEW YORK	NY	10013	212-3491857

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
VAIL VALLEY PHARMACY	Bruce Delnay	105 EDWARDS VILLAGE BLVD STE G-107	EDWARDS	CO	81632	970-5694150
EDWARDS MED CTR PHCY HM	Sheila Sherman	322 BEARD CREEK RD	EDWARDS	CO	81632	970-5697676
FRONT RANGE PHARMACY	Michael Scruggs	3401 S BROADWAY UNIT 180	ENGLEWOOD	CO	80113	720-4055125
FOX DRUG INC	Rashelle Trujillo	1100 E MAIN	FLORENCE	CO	81226	719-7843523
GOODDAY PHARMACY #10 HM	Vicki Einhellig	2601 S LEMAY AVE	FORT COLLINS	CO	80525	970-2251234
GOOD DAY PHCY#2ACHRXPHM	Vicki Einhellig	2001 SO. SHIELDS BLDG D	FORT COLLINS	CO	80526	970-2241212
GOODDAY@GREELEYCLN PHCY	David Lamb	1900 16TH ST STE 102	GREELEY	CO	80631	970-5763178
GOOD DAY PHARMACY CENTRAL	Vicki Einhellig	4775 LARIMER PKWY STE 101	JOHNSTOWN	CO	80534	970-4611975
GOODDAY #12 HM	Vickilee Einhellig	201 JOHNSTOWN CENTER DR	JOHNSTOWN	CO	80534	970-5871128
ABTS DRUG	Grant Kinn	121 CEDAR ST	JULESBURG	CO	80737	970-4743672
LAJARA PHARM CTR HM RXP	Joe Valdez	412 MAIN STREET	LA JARA	CO	81140	719-2745109
OPERA HOUSE PHARMACY RXP	Ed Vasquez	223 COLORADO AVE	LA JUNTA	CO	81050	719-3842521
UNION SQUARE PHARMACY	John Urratia	8015 W ALAMEDA AVE STE100	LAKEWOOD	CO	80226	303-2747877
ALLHEALTH NETWRK PHARMACY	JOAN DIMARIA	5500 S SYCAMORE ST SUITE 100	LITTLETON	CO	80120	303-7972500
ELITE PHARMACY	MICK DYER	8100 S LINCOLN ST	LITTLETON	CO	80122	303-2487234
FLATIRONS FAMILY PHARMACY	JENNIFER PALAZZOLO	603 KEN PRATT BLVD	LONGMONT	CO	80501	303-8273480
GOOD DAY PHCY #8 RXP HM	Vicki Einhellig	1749 MAIN ST. UNIT D	LONGMONT	CO	80501	303-7760709
GOOD DAY PHCY#1ACH RXPHM	Vicki Einhellig	2033 BOISE AVE	LOVELAND	CO	80538	970-6697500
RIVER VALLEY PHARMACY	Tom Harker	1010 S RIO GRANDE AVE	MONTROSE	CO	81401	970-7872044
UMC PHARMACY	Tom Harker	1350 ASPEN ST STE B	NORWOOD	CO	81423	970-3274233
PRESCRIPTION SHOP ACH RXP	James Sajbel	1728 S PRAIRIE	PUEBLO	CO	81005	719-5640220
MESA PHCY	Nick Rougas	25140 E HWY 50	PUEBLO	CO	81006	719-5441371
LYON'S CORNER DRUG	Matt Johnson	840 LINCOLN AVE	STEAMBOAT SPRINGS	CO	80487	970-8791114
WALKERS STERLING PHCY	BRIAN WILSON	410 W MAIN ST	STERLING	CO	80751	970-5221302
CJ PHARMACY II	Dorothy Wisdom	422 MAIN ST	STERLING	CO	80751	970-5269417
SUNSHINE PHARMACY	STEVE HEMPHILL	333 W. COLORADO AVE STE 3	TELLURIDE	CO	81435	970-7281365
VAIL PHARMACY	Sheila Shermn	181 W MEADOW DR	VAIL	CO	81657	970-4797253

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
SAN JUDAS TADEO	Chintan Joshi	520 W 207TH ST	NEW YORK	NY	10034	212-5671350
TWINS PHARMACY	CHRIS OLIVO	1538 ST. NICHOLAS AVE	NEW YORK	NY	10033	212-9275570
CAROL PHARMACY	Damaris Gutierrez	4230 BROADWAY	NEW YORK	NY	10033	215-8925125
92 DRUGS INC.	Fatima Chaudhry	1938 SECOND AVE	NEW YORK	NY	10029	212-4266484
THE PHARMACY @ LLC	JANELLE HARRIS	2541 7TH AVENUE	NEW YORK	NY	10039	212-4917900
S&J PHCY DBA COLUMBIA EDI	Jignesh Patel	3921 BROADWAY	NEW YORK	NY	10032	212-9286342
ANDY PHARMACY 2	KEYUR SHAH	1341 ST NICHOLAS AVE	NEW YORK	NY	10033	212-7953033
SAN PEDRO PHARMACY	KRUNAL VASANI	1381 ST NICHOLAS AVE	NEW YORK	NY	10033	212-9287263
79TH STREET PHARMACY	MARCI HAAS	215 WEST 79TH STREET	NEW YORK	NY	10024	646-3705978
ALTO NEW YORK RETAIL	Mattieu Gamache-Asselin	100 PARK AVE FRNT E	NEW YORK	NY	10017	180-0555555
FOUR K CHEMI/KARNABY DRGS	MAZEN KARNABY	3851 BROADWAY	NEW YORK	NY	10032	212-9287700
CEDRA PHARMACY BROADWAY	Mazen Karnaby	2268 BROADWAY	NEW YORK	NY	10024	212-8775000
ZITOMER PHARMACY	Mike Pearlman	969 MADISON AVE	NEW YORK	NY	10021	212-7375560
MY PHARMACY INC	Mushtaq Mughal	523 MALCOLM X BLVD	NEW YORK	NY	10037	212-2817408
PALACE PHARMACY	Oumar Tangara	543 LENNOX AVE	NEW YORK	NY	10037	212-2832136
PEOPLE CHOICE PHARMACY	PHOEBE TSE	527 GRAND STREET	NEW YORK	NY	10002	212-3880888
KINGS THIRD AVE PHCY HM	Ron Del Gaudio	1619 THIRD AVE	NEW YORK	NY	10128	212-5346000
SMS DBA JORGE PHCY HM	Sanjay Shan	101 SHERMAN AVE	NEW YORK	NY	10034	212-5672753
NAGLE PHARMACY	SUKHDEV SUHAGIYA	220 NAGLE AVE	NEW YORK	NY	10034	212-9420202
CT HEALTH CASTLE CORP	Sze Ching Ho	86 BOWERY	NEW YORK	NY	10013	212-9666039
HEALTHY PHARMACY	TRISTAN LIU	108 BOWERY	NEW YORK	NY	10013	212-9668682
FAMILY CARE PHARMACY	Trushna Patel	2518 ADAM CLAYTON POWELL JR BLVD	NEW YORK	NY	10039	212-9399594
ABACUS PHARMACY HM	Upendra Solanki	168 2ND AVENUE	NEW YORK	NY	10003	212-4776400
UMA PHARMACY DBA ANSONIA	Upendra Solonki	446 6TH AVE	NEW YORK	NY	10011	212-4770762
MELLAU PHARMACY	WILLIAM RYDER	593 FORT WASHINGTON AVE	NEW YORK	NY	10033	212-5685510
SMARTRX PHARMACY	Yaakov Mavashev	1706 LEXINGTON AVE	NEW YORK	NY	10029	212-7779777
137 MOTT PHARMACY INC	Yuen Chan	137 MOTT ST	NEW YORK	NY	10013	646-6698220

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
GOODDAY PHARMACY #3 HM	Vicki Einhellig	7702 FIFTH STREET #101	WELLINGTON	CO	80549	970-5687282
GOOD DAY PHARMACY 15	Vicki Einhellig	315 E 8TH AVE/PO BOX 287	YUMA	CO	80759	970-8485427
ENGLISH APOTHECARY	SRI POPURI	140 GREENWOOD AVE	BETHEL	CT	06801	203-7923363
TOWNE APOTHECARY HM	Kenneth Meady	95 MAIN ST SOUTH	BETHLEHEM	CT	06751	203-2667801
UNITY PHARMACY	Jack Yeung	679 FAIRFIELD AVE	BRIDGEPORT	CT	06604	646-5736168
BRIDGEPORT COMM PHCY	Zahan Akbar	192 FAIRFIELD AVE	BRIDGEPORT	CT	06604	203-3309191
MAIN STREET PHARMACY	Jack Yeung	345 MAIN STREET #7	DANBURY	CT	06810	203-2976130
DURHAM PHARMACY	Walter Douglass	321 MAIN STREET	DURHAM	CT	06422	860-3493478
FIRST CHOICE HLTH CTR PHY	Jeffrey Steele	110 CONNECTICUT BLVD	EAST HARTFORD	CT	06108	860-6106150
ABLE CARE PHY & MED SUPPLY	Ashraf Moustafa	15 PALOMBA DR	ENFIELD	CT	06082	860-7450183
BLACK ROCK PHARMACY	Ken Lee	1838 BLACK ROCK TPKE	FAIRFIELD	CT	06825	917-5321285
REDDING PHARMACY	DANIEL LIU	73 REDDING ROAD	GEORGETOWN	CT	06829	203-5448306
NORTH STREET PHARMACY	ALBANO COSTA	1043 NORTH STREET	GREENWICH	CT	06831	203-8692130
GRANNICKS PHARMACY	Jeff Grannick	277 GREENWICH AVENUE	GREENWICH	CT	06830	203-8693492
FINCH PHARMACY	SAL SCALISI	263 GLENVILLE RD	GREENWICH	CT	06831	203-5318495
JEWETT CITY PHARMACY	Tony Komari	78 MAIN STREET	JEWETT CITY	CT	06351	860-3764468
KENT STATION PHARMACY HM	Peter D'Aprile	38 NORTH MAIN ST	KENT	CT	06757	860-9273725
KILLINGWORTH FAM PHCY	Keith Lyke	183 ROUTE 81 UNIT 3	KILLINGWORTH	CT	06419	860-4524275
WESTOWN PHARMACY #2 HM	Kamal Swami	455 HARTFORD ROAD	MANCHESTER	CT	06040	860-6499946
GRAEBERS PHARMACY HM	Roger DeZinno	172 W MAIN ST	MERIDEN	CT	06451	203-2356305
MILFORD PHCY AND HOMECARE	Noura Jeblawi	78 BROAD ST	MILFORD	CT	06460	203-7138101
FREDERICK RAY PHARMACY	Dan Tavares	26 FALLS RD	MOODUS	CT	06469	860-3851072
TRUE-CARE PHARMACY	Chichun Fokus	1300 WHALLEY AVE	NEW HAVEN	CT	06515	203-8917031
UNITY PHARMACY	Justin Buturla	1351 WHALLEY AVE	NEW HAVEN	CT	06515	800-5555555
FAIR HAVEN PHARMACY	MANTHENA VARMA	72 GRAND AVE	NEW HAVEN	CT	06513	203-4983479
BELLA VISTA PHCY HM	Steve Vigilante	321 EASTERN STREET	NEW HAVEN	CT	06513	203-4671683
GREENVILLE DRUG	JAY KIZKIEL	213 CENTRAL AVENUE	NORWICH	CT	06360	860-8899857

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
SAFE HEART PHARMACY	Zunilda Lamorena	1400 ST. NICHOLAS AVE	NEW YORK	NY	10033	800-5555555
CROWN PHARMACY	David Aziz	66 DEER SHORE SQUARE	NORTH BABYLON	NY	11703	631-9405555
WORTHY PHARMACY	Lisa Worth	202 MAIN ST	OLEAN	NY	14760	716-8047979
ANTHONY BROWN PH-PSSNY	Randy Brown	4328 S. BUFFALO ST	ORCHARD PARK	NY	14127	716-6623800
HEALTHSMART PHCY	TULLIO BRUNO	203 MAIN STREET	OSSINING	NY	10562	914-9233000
WAYNE DRUG - OSWEGO HM	Jamie Branshaw	24 WEST BRIDGE ST	OSWEGO	NY	13126	315-3435722
BARTLES PHCY PS HM	Brian Bartle	10 LAFAYETTE PARK	OXFORD	NY	13830	607-8432841
MARVEL PHARMACY	Fariha Mirza	9612 LIBERTY AVE	OZONE PARK	NY	11417	201-4106995
KALISH PHARMACY	JOE BRUNO	93-20 LIBERTY AVE	OZONE PARK	NY	11417	718-6415648
RIGHT CHOICE PHCY	SYED ALI	84-01 101ST AVE	OZONE PARK	NY	11416	718-8450042
PLAINVIEW FAMILY PHARMACY	FRED SAMOUIHI	142A MANETTO HILL ROAD	PLAINVIEW	NY	11803	516-9327077
SALEM DRUGS	PAUL SCHIMEL	475 PORT WASHINGTON BLVD #8	PORT WASHINGTON	NY	11050	516-9448668
POUND RIDGE PHARMACY	Sonali Costa	55 WESTCHESTER AVE	POUND RIDGE	NY	10576	914-7643330
HEALTH AND HARMONY RX	Kaliroi Tsamboukos	3010 WESTCHESTER AVE 106A	PURCHASE	NY	10577	914-4379391
AJ'S WOODHAVEN PHCY	Olga Zargarova	62-04 B WOODHAVEN BLVD	REGO PARK	NY	11374	718-8992001
RYTE DRUGS	Angeliki Avgoustidis	12318 JAMAICA AVE	RICHMOND HILL	NY	11418	718-4414660
LEGACY SPECIALTY PHARMACY	Ilios Guma	6851 FRESH POND RD # 3STO	RIDGEWOOD	NY	11385	718-4567300
I&Y PHARMACY CORP	Inessa Iskhakova	6669 FRESH POND RD	RIDGEWOOD	NY	11385	718-3686060
FOREST PHARMACY	Jhony Siu	6644 FOREST AVE	RIDGEWOOD	NY	11385	718-4174700
AJ'S RIDGEWOOD CHEMIST	JOE LASALA	68-19 FRESH POND ROAD	RIDGEWOOD	NY	11385	718-4564400
ESSENTIAL PHARMACY	Waiming Siu	6825 FOREST AVE	RIDGEWOOD	NY	11385	347-5897077
LIFE SCRIPT PHARMACY INC	Yuri Ilyaich	54-56A MYRTLE AVENUE	RIDGEWOOD	NY	11385	718-3666900
VALENTI PHARMACY	Anthony Valenti	70 N VILLAGE AVE	ROCKVILLE CENTRE	NY	11570	516-7058282
NAMDOR, INC.	ANGELA PENGOS	686 NORTH MAIN STREET	ROOSEVELT ISLAND	NY	10044	212-6444125
SAG HARBOR PHARMACY	Tarique Chaudhary	120 MAIN ST P.O. BOX 1050	SAG HARBOR	NY	11963	631-7250074
BAKER'S DRUGS	KHALED ALI	20543 LINDEN BLVD	SAINT ALBANS	NY	11412	718-7495988
RELY RX PHARMACY	CHRISTINA LOEFFLER	731 B MIDDLE COUNTRY RD	SAINT JAMES	NY	11780	631-6568900

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number	Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
UTLEY AND JONES PHCY	SANTO JOHN GRILLO	112 LAFAYETTE ST	NORWICH	CT	06360	860-8872538	SHELTER ISL-SCOTT OFRIAS	PAULETTE OFRIAS	19 GRAND AVE PO BOX 1163	SHELTER ISLAND	NY	11965	631-7490445
OXFORD PHCY HM	Frank Diaferio	100 OXFORD ROAD	OXFORD	CT	06478	203-8884567	HAAS PHARMACY	LARRY HAAS	62 ORANGE TURNPIKE	SLOATSBURG	NY	10974	845-7539675
PLAINVILLE COMMUNITY PHAR	Suruchi Patel	170 EAST STREET	PLAINVILLE	CT	06062	860-2229422	TM PHARMACY INC HM	Timothy Sullivan	336 RT 202 BLDG B, 1ST FL	SOMERS	NY	10589	914-2762121
BISSELL PHARMACY HM	Edmund Kavorsky	23 GOVERNOR STREET	RIDGEFIELD	CT	06877	203-4386600	SOUTH DAYTON PHCY	DAWN EKLUM	303 PINE STREET	SOUTH DAYTON	NY	14138	716-9883410
ROCKY HILL COMM PHCY	RAKESH PATEL	366 CROMWELL AVE	ROCKY HILL	CT	06067	860-3724618	GURU SPECIALTY PHARMACY	PRABHJOT KAUR	118-04 ROCKAWAY BLVD	SOUTH OZONE PARK	NY	11420	718-3222228
SALEM PHARMACY	WENDY MIKOLINSKI	20 HARTFORD RD STE 16	SALEM	CT	06420	860-9498624	PAUL'S PHARMACY HM	Paul Roldan	222 OAKRIDGE COMMONS	SOUTH SALEM	NY	10590	914-5335679
SEYBRIDGE PHARMACY	PETER PRZYBLSKI	37 NEW HAVEN ROAD	SEYMOUR	CT	06483	203-8880073	SOUTHOLD PHARMACY	PAULETTE OFRIAS	53895 MAIN STREET	SOUTHOLD	NY	11971	631-7653434
SHARON PHARMACY	JOE HEACOX	8 GAY STREET	SHARON	CT	06069	860-3645105	RX CONSULTANT PHARMACY	Abe Biston	728 C NORTH MAIN STREET	SPRING VALLEY	NY	10977	845-3549320
RELIANT PHCY NEW	JACK YEUNG	200 MAIN STREET SO	SOUTHBURY	CT	06488	203-2628000	ECKERSON DRUGS	ASHISH AMIN	287 N. MAIN STREET	SPRING VALLEY	NY	10977	845-3521800
APPLE VALLEY PHCY & GIFTS	SRIDHAR ALLA	1 N MAIN ST STE 1	SOUTHINGTON	CT	06489	800-5555555	MEDWIZ PHARMACY	ERIC NEWHOUSE	240 N MAIN STREET	SPRING VALLEY	NY	10977	845-6245200
STAMFORD COMMUNITY PHCY	Lakshmi Poornima Grandhi	802 EAST MAIN ST	STAMFORD	CT	06902	904-3142276	DONGAN HILLS PHARMACY	Edward Morreale	1560 RICHMOND RD	STATEN ISLAND	NY	10304	718-6677733
ROTARY DRUG	SRI POPURI	1030 BARNUM AVE	STRATFORD	CT	06614	203-3789394	CASTLETON CHEMIST PHCY	Fady Hussein	831 CASTLETON AVE	STATEN ISLAND	NY	10310	929-3082727
THOMASTON PHARMACY PLLC	Steven Krasnowski	130 S MAIN ST STE 1B	THOMASTON	CT	06787	860-4844245	MIDLAND PHARMACY	GENNARO RAGIONE	606 MIDLAND AVE	STATEN ISLAND	NY	10306	718-3511689
MEDICAL ARTS PHARAMCY	NAGA MULPURI	15 CORPORATE DR STE 1-1	TRUMBULL	CT	06611	203-5903737	LUCIA PHARMACY	Michael Elkhoury	2090 HYLAN BLVD	STATEN ISLAND	NY	10306	917-8300600
MADISON PHARMACY	sherif elrefaei	4180 MADISON AVE	TRUMBULL	CT	06611	203-5028231	RANDALL MANOR	NICHOLAS AMAXAS	395 FOREST AVENUE	STATEN ISLAND	NY	10301	718-7202324
BUNKER HILL PHCY HM	Billy Suma	256 BUNKER HILL AVE	WATERBURY	CT	06708	203-5747825	DELCO DRUGS	ROBERT ANNICHARICO	3833 RICHMOND AVE	STATEN ISLAND	NY	10312	718-9846600
STOLL'S PHARMACY HM	Edward Schreiner	185 GROVE STREET	WATERBURY	CT	06710	203-5750199	PRIME PHARMACY INC	Azat Mets Hagopian	45 15 GREENPOINT AVE	SUNNYSIDE	NY	11104	917-7710768
PICKETT DRUG	Edward Stukshis	675 N MAIN ST	WATERBURY	CT	06704	203-7535158	AMAZON PHARMACY	SIMON DOLMAIAN	42-10 43RD AVENUE	SUNNYSIDE	NY	11104	718-7860707
DELLA PIETRA PHARMACY #2	Frank Diaferio	792 HIGHLAND AVE	WATERBURY	CT	06708	203-7540181	JERICO PHARMACY	PHILIP CHERIAN	340 JERICO TURNPIKE	SYOSSET	NY	11791	516-8640020
PARK PHARMACY	JALPA PATEL	1527 E MAIN ST	WATERBURY	CT	06705	203-7218022	SYOSSET PHARMACY	Shahbaz Chaudhary	175 JERICO TPKE LBBY STE	SYOSSET	NY	11791	516-8651151
ROYAL PHARMACY	Julia Oparaocha	1420 MERIDEN RD	WATERBURY	CT	06705	203-5275160	WESTSIDE FAMILY PHARMACY	Praveen Challa	216 SEYMOUR ST	SYRACUSE	NY	13204	315--928-63
SIMPLY PHARMACY	DAVID WU	92 BOSTON POST RD	WATERFORD	CT	06385	860-8651303	LINDSAY DRUG CO INC DA	Kathleen Bonnier	416 FIFTH AVE	TROY	NY	12182	518-2352522
PHARMACY AT BLUE BACK	Ariel Zurov	55 ISHAM RD	WEST HARTFORD	CT	06107	860-6566229	PARKWAY FRENCH RD HM	Rocco Femia	485 FRENCH RD	UTICA	NY	13502	315-7924669
WESTON PHARMACY	Ken Lee	190 WESTON RD	WESTON	CT	06883	917-5321285	PARKWAY ALBANY ST HM	Tony Chiffy	1256 ALBANY ST	UTICA	NY	13501	315-7353525
KALORAMA CARE PHARMACY	Bill Fadel	1841 COLUMBIA RD NW	WASHINGTON	DC	20009	202-7959711	PARKWAY LELAND AVE HM	Tony Chiffy	350 LELAND AVENUE	UTICA	NY	13502	315-6249988
HEALING TOUCH PHARMACY 3	Deepak Kapur	3415 23RD ST SE	WASHINGTON	DC	20020	202-5061886	VALLEY STREAM	AZZAM ELCHEIKH	42 ROCKAWAY AVE	VALLEY STREAM	NY	11580	516-4420200
FORT LINCOLN PHARMACY	ENOCK ADEWUYI	3180 BLADENSBURG RD N.E.	WASHINGTON	DC	20018	202-2690000	SINCLAIR PHCY - PSSN HM	Joseph Rutowski	75 NORTH MAIN ST	WARSAW	NY	14569	585-7862330

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
NATIONS CARE PHARMACY	Festus Opara	3818 12TH ST NE	WASHINGTON	DC	20017	202-6216325
GRUBBS PHCY OF D C INC	Michael Kim	326 E CAPITOL ST NE	WASHINGTON	DC	20003	202-5032644
GRUBBS CARE PHCY NW INC	Michael Kim	1517 17TH ST NW	WASHINGTON	DC	20036	202-5032644
PHARM-PRO, INC	Michael Kim	3001 P ST NW	WASHINGTON	DC	20007	202-3374100
WELLINGTON APOTH OP R	Rick Rosser	1160 VARNUM ST NE STE 2	WASHINGTON	DC	20017	202-8322200
RODMAN'S DISCOUNT DRUGS	Roy Rodman	5100 WISCONSIN AVENUE NW	WASHINGTON	DC	20016	301-9429210
GRUBB'S PHARMACY SE, INC.	William Fadel	1800 MLK JR AVE SE	WASHINGTON	DC	20020	202-5033610
ATLANTIC APOTH CAMDEN	Brandy Street	2 S MAIN ST	CAMDEN	DE	19934	302-6979355
CAMDEN PHARMACY	Leena Amin	4598 S DUPONT HWY	CAMDEN	DE	19934	302-5358604
SHAYONA PHARMACY #2	DIPAL PATEL	38660 SUSSEX HWY UNIT 10	DELMAR	DE	19940	302-9070074
EXPRESS PHARMACY	Tejas Sheth	30214 SUSSEX HWY UNIT 7	LAUREL	DE	19956	302-8755400
CAPE RX LLC	PAT CARROLL-GRANT	17252 N VILLAGE MAIN BLVD	LEWES	DE	19958	302-6450090
KENT PHARMACY	Percy Dhamodiwala	641 N DUPONT BLVD	MILFORD	DE	19963	302-4916886
SUSSEX PHARMACY	PAUL DANIELRAJ	32362 LONG NECK RD UNIT 5	MILLSBORO	DE	19966	302-9470333
NANTICOKE PHARMACY HM	Moushumi Datta	1609 MIDDLEFORD ROAD	SEAFORD	DE	19973	302-5367666
CAREPLUS PHARMACY	Percy Dhamodiwala	22948 SUSSEX HWY STE 102	SEAFORD	DE	19973	302-5367675
ATLANTIC APOTHECARY HM	Kenneth Musto	103 S DUPONT BLVD #2	SMYRNA	DE	19977	302-6539355
PIC INC/BUY RITE #8	PAULA NORMAN	117 HWY 98	APALACHICOLA	FL	32320	850-6538825
AUBURNDALE FAMILY PHCY IN	Kulmeet Bindra	382 HAVENDALE BLVD	AUBURNDALE	FL	33823	863-6038104
BAY HARBOR DRUGS	Adam Hasid	1015 KANE CONCOURSE	BAY HARBOR	FL	33154	305-3978319
K & M DRUGS	Haitham Kaki	364 S MAIN STREET	BELLE GLADE	FL	33430	561-9960228
BELLE GLADE PHARMACY	Urmil Shah	136 S MAIN ST, SUITE B	BELLE GLADE	FL	33430	800-5555555
MAA BHAWANI INC	Raj Patel	3791 N LECANTO HWY	BEVERLY HILLS	FL	34465	352-5273111
GOLDEN PHCY INC. HM	Clifford Goodman	17324 MAIN STREET NORTH	BLOUNTSTOWN	FL	32424	850-6744557
TRUSTEDMED RX	ANUP INAMDAR	1200 S ROGERS CIRCLE STE 4A	BOCA RATON	FL	33487	561-6136209
SPECIALTY CARE PHARMACY	AVI COHEN	4802 NW 2ND AVE	BOCA RATON	FL	33431	561-2417711

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
VALLEY PHCY HM	Rafiq Ahmad	12 WEST MAIN ST	WATERLOO	NY	13165	315-5399323
FISHER PHARMACY-PSSNY HM	Brian Loucks	138 NORTH MAIN ST	WELLSVILLE	NY	14895	585-5932611
MEDEXRX PHARMACY, INC	Soraya Ahmad	300 HEMPSTEAD TPKE UNIT 5	WEST HEMPSTEAD	NY	11552	718-7916520
WEST NYACK PHARMACY	Amgad Amir	719 W NYACK RD	WEST NYACK	NY	10994	845-4802957
PHARMACY IN THE SQUARE	Chris Todoro	940 UNION RD	WEST SENECA	NY	14224	716-6715281
NU-CASSEL PHARMACY	Adeyinka Ajayi	821 PROSPECT AV	WESTBURY	NY	11590	516-2809674
MIRRA PHY/MED CNTRE PHY	Jerry Mirra	170 MAPLE AVE	WHITE PLAINS	NY	10601	800-3611260
SUNSHINE PHARMACY	Mitesh Patel	276 MAIN ST	WHITE PLAINS	NY	10601	914-6073939
FAMILY MEDICAL PHARMACY	Joe Rutowski	120 PLAZA DR	WILLIAMSVILLE	NY	14221	716-5680800
WOODHAVEN CHEMIST CORP	Igor Matatov	86-22 JAMAICA AVE	WOODHAVEN	NY	11421	718-4417111
MERCY PHARMACY	Kavita Maharaj	30-100 51ST ST	WOODSIDE	NY	11377	718-2040026
SAWMILL PHARMACY	Angela Letts	321 SAW MILL RIVER RD	YONKERS	NY	10701	914-6139374
LE-MAC PHARMACY, INC HM	Anthony Ciarletta	623 MCLEAN AVE	YONKERS	NY	10705	914-9656100
MERK CHEMISTS	ANTHONY MANGIARACINA	973 MCLEAN AVENUE	YONKERS	NY	10704	914-2378821
GRASSY SPRAIN PHCY, INC	Dan Molino	640 TUCKAHOE RD	YONKERS	NY	10710	914-7795133
ROBERT JACOBSON	Joseph Paul	231 ASHBURTON AVENUE	YONKERS	NY	10701	914-9653050
AKRON PHARMACY	SHERIF MANKARYOUS	879 E. EXCHANGE ST.	AKRON	OH	44306	330-3755040
MAC PHARMACY	Sherif Mankaryous	1 PARK WEST BLVD SUITE 140	AKRON	OH	44320	330-5564515
THE PILL BOX HM	Robert Westbrook	1400 STATE ROUTE 125	AMELIA	OH	45102	513-7534700
ASHVILLE APOTH S C HM	Robert Mabe	3400 STATEROUTE 752	ASHVILLE	OH	43103	740-9832501
SHRIVERS PHY AND WELLNESS	John Coler	310 WEST UNION ST STE 101	ATHENS	OH	45701	740-4479201
BATAVIA COMM PHCY	Bhavesh Patel	2234 BAUER RD STE A	BATAVIA	OH	45103	513-7320356
COMUNITY MARKET 710 PHCY	Jeremy Best	878 E SANDUSKY AVE	BELLEFONTAINE	OH	43311	937-5933600
B & W PHARMACY SC	Jarrod Kasun	501 DIETZ LANE POB 697	BEVERLY	OH	45715	740-9842305
BUKMIR'S PHARMACY	MARK BUKMIR	908 THIRD ST	BRILLIANT	OH	43913	740-5984755
DAVIS DRUG SC	Gary Davis	109 WEST STREET	CALDWELL	OH	43724	740-7324503

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
URGENTMED RX	David Steingberg	6971 N FEDERAL HWY SUITE 203	BOCA RATON	FL	33487	800-5555555
LUXE HEALTH PHARMACY	Kyle Huckaby	7400 N FEDERAL HWY STE A10	BOCA RATON	FL	33487	561-3622244
BOCA PHARMA AND HHC#2 HM	Norbert Graber	22191 POWERLINE RD 22C	BOCA RATON	FL	33433	561-3916336
KPB PHARMACY	SULHBA PAI	19585 STATE RD 7 UNIT N	BOCA RATON	FL	33498	561-4094495
WESTWOOD/YAMATO PHY	Urmil Shah	9101 LAKE RIDGE BLVD #10	BOCA RATON	FL	33496	561-4879260
A PLUS PHARMACY HM	David Wilkerson	123 N J HARVEY ETHERIDGE	BONIFAY	FL	32425	850-5475596
EZ RX BONITA SPRINGS LLC	Austin Sharp	3501 HEALTH CTR BLVD#1200	BONITA SPRINGS	FL	34135	239-3015058
OCEANSIDE PHARMACY	Carlos Randulfe	25987 S TAMIAMI TRL STE 102	BONITA SPRINGS	FL	34134	239-3170771
MEADOWS PHARMACY	Aunker Barot	4761 N CONGRESS AVE	BOYNTON BEACH	FL	33426	561-6194387
MEDICATION STATION	DAVID GOODMANSON	141 E WOOLBRIGHT RD	BOYNTON BEACH	FL	33435	561-7361010
RIGHTCHOICE PHARMACY	JAIMINKUMAR PATEL	709 S FEDERAL HWY #1	BOYNTON BEACH	FL	33435	561-5090707
MED CONSLTANTS OF FL HCCE	Mazin Shikara	1485 GATEWAY BLVD STE 102	BOYNTON BEACH	FL	33426	561-5723227
KINGS PHCY BOYNTON HM	Mike Corbin	7410 WBOYNTON BCH BLVD A4	BOYNTON BEACH	FL	33437	561-7389494
SEACREST PHARMACY	Mina Attalla	1403 W BOYNTON BEACH BLVD STE 1	BOYNTON BEACH	FL	33426	561-7312929
PD & KD INC	Pritti Desai	3469 W BOYNTON BCH BVD #6	BOYNTON BEACH	FL	33436	561-3749200
AMERICA'S PHARMACY II	Elder Soria-Ferras	5612 - 14TH ST W	BRADENTON	FL	34207	941-7390000
BAYSHORE PHARMACY	SONI PATEL	6229 14TH ST WEST	BRADENTON	FL	34207	941-7536075
BILLS PRESCRIPTION HM	John Noriega	202 E BRANDON BLVD	BRANDON	FL	33511	813-6893521
MY PHARMACY OF BIG BEND	Matt Gonzales	1028 E BRANDON BLVD	BRANDON	FL	33511	813-6993496
PIC INC/BUY RITE #9	PAULA NORMAN	11049 STATE RD 20 NW	BRISTOL	FL	32321	850-6435454
OAK HILL PHARMACY	JOBY THOMAS	10101 CORTEZ BLVD	BROOKSVILLE	FL	34613	352-6781882
SUNSHINE DRUGS HM	Ken Norfleet	90 PONCE DE LEON BLVD	BROOKSVILLE	FL	34601	352-7967200
PALMYRA PHARMACY	MOHAB HARAKA	13060 CORTEZ BLVD	BROOKSVILLE	FL	34613	813-8992222
BUSHNELL PHARMACY	Indravadan Patel	417 N. WEST STREET	BUSHNELL	FL	33513	352-5695800
T-RX PHARMACY	TERRY CORDISCO	211 HANCOCK BRIDGE PKY #7	CAPE CORAL	FL	33990	239-6774945
CAMBRIDGE OAKS PHARMACY	ZAFIR ABDELRAHMAN	3950 SOUTH US HWY 17-92 SUITE 1048	CASSELBERRY	FL	32707	407-9604712
TURNER DRUGS CELEBRATION	Jack Turner	1530 CELEBRATION BLVD 105	CELEBRATION	FL	34747	407-5669060

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
NORTHSIDE CAMBRIDGE PHARM	Edward Stoepfel	1330 CLARK ST SUITE 1100	CAMBRIDGE	OH	43725	740-2555844
CEDAR CARE VILLAGE PHCY	John Ballentine	63 N MAIN ST PO BOX 662	CEDARVILLE	OH	45314	937-7662273
FOSTERS #2 HM	Mike Hoar	4584 COLUMBUS ROAD	CENTERBURG	OH	43011	740-6257626
ALLEN'S MEDICAL PHY, INC.	STEPHEN ALLEN	215 EASTERN AVENUE	CHILLICOTHE	OH	45601	740-7725180
ROHE PHARMACY	DIANA BRUNST	4047 HARRISON AVE	CINCINNATI	OH	45211	513-6610480
BERNEN'S PHARMACY	HOLLY ENGELHARDT	5053 Glenway Ave	CINCINNATI	OH	45238	513-4717575
TRI-STATE COMPOUNDING PHY	JOHN DINKELAKER	7715 BEECHMONT AVE	CINCINNATI	OH	45255	513-6247333
GEHRING PHARMACY	JOHN PIEPMEIER	210 E Sharon Rd	CINCINNATI	OH	45246	513-7717350
TISCHBEIN PHARMACY	JOSPEH LUTMER	3500 ERIE AVE	CINCINNATI	OH	45208	513-3219282
SCHAEPER'S PHARMACY	Richard Schaeper	4187 HAMILTON AVE	CINCINNATI	OH	45223	513-5410354
HART PHARMACY	Sarah Priestle	4861 GLENWAY AVE	CINCINNATI	OH	45238	513-4711605
CIRCLEVILLE APOTHECARY HM	Robert Mabe	1200 N COURT ST	CIRCLEVILLE	OH	43113	740-4203784
ASIA PLAZA PHCY	HUI MIN WANG	2999 PAYNE AVE, #130	CLEVELAND	OH	44114	216-8629688
MAC 3	Sherif Mankaryous	10414 SAINT CLAIR AVE	CLEVELAND	OH	44108	216-5383353
FAMILY DRUG	Brian Kale	120 VINE ST COLUMBIANA PLA	COLUMBIANA	OH	44408	330-4823816
GOODMED PHARMACY	Ali Fakh	3433 AGLER RD STE 1150	COLUMBUS	OH	43219	614-4766336
BRAVO PHARMACY	Amr Abualnadi	4125 W BROAD ST	COLUMBUS	OH	43228	614-4260813
BUCKEYE PHARMACY	Divyesh Patel	27 NORTON RD	COLUMBUS	OH	43228	513-5450114
DOCTORS PHARMACY	Emanuel Quainoo	4878 WEST BROAD STREET	COLUMBUS	OH	43228	614-7056222
DOCTORS PHCY DOWNTOWN	EMMANUEL QUAINOO	270 S GRANT AVE	COLUMBUS	OH	43215	800-5555555
DOCTORS PHARMACY HILLTOP	EMMANUEL QUAINOO	2575 W BROAD ST	COLUMBUS	OH	43204	614-6419687
ROYAL PHARMACY	Eric Obeng	2575 S HAMILTON RD	COLUMBUS	OH	43232	614-5470707
SHIFFA PHARMACY	Farhan Abdi	2330 MORSE RD UNIT D	COLUMBUS	OH	43229	614-4264222
DRUG STORE PHARMACY	Harry Taubman	2940 GROVEPORT RD	COLUMBUS	OH	43207	614-4913446
GIFTHEALTH	John Romano	1057 BETHEL RD	COLUMBUS	OH	43220	800-5555555
WHITE'S PHARMACY	JOHN WHITE	4057 E LIVINGSTON AVE	COLUMBUS	OH	43227	614-2377677
NORTH LINDEN PHARMACY	Omar Farah	1000 GEORGESVILLE RD #B	COLUMBUS	OH	43228	614-5913611

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
XXA CENTURY PHARMACY, LLC	JULIE BOOTH-MORAN	7531 MAYO ST	CENTURY	FL	32535	850-2563472
ALL CARE PHARMACY	Brandy Bui	14100 US HWY 19 N #129	CLEARWATER	FL	33764	727-3306991
BAY LIFE PHARMACY	JULIAN MATHEW	1235 S MISSOURI AVE	CLEARWATER	FL	33756	727-5815400
CURLEW PHARMACY	MIRAL PATEL	30226 US HIGHWAY 19 N	CLEARWATER	FL	33761	727-7731600
LINCOURT PHARMACY	Miral Patel	501 S LINCOLN AVE	CLEARWATER	FL	33756	727-4474248
UNITY EXPRESS PHARMACY	VICTORIA ZEIGLER	2340 STATE RD 580 STE G	CLEARWATER	FL	33763	727-6008880
CLERMONT FAMILY PHCY	Hardik Shah	2761 CITRUS TOWER BLVD #102	CLERMONT	FL	34711	352-2725944
K & M DRUGS CLEWISTON	Haitham Kaki	340 E SUGARLAND HWY STE A	CLEWISTON	FL	33440	863-9837251
COCONUT GROVE PHARMACY	Adriana Vergara	3001 SW 27TH AVE	COCONUT GROVE	FL	33133	305-4420211
H & N PHARMACY	Harni Patel	217 VALENCIA AVE	CORAL GABLES	FL	33134	305-4486116
KINGS PHARMACY HM	David Wolman	2814 N UNIVERSITY DRIVE	CORAL SPRINGS	FL	33065	954-5757085
DIABETIC SOLUTIONS	Deep Patel	10301 WEST SAMPLE RD	CORAL SPRINGS	FL	33065	800-5555555
CRESTVIEW PHARMACY	Jim Cox	1116 N FERDON BLVD	CRESTVIEW	FL	32536	850-6831111
RX CARE PHCY & KWIKMART	Hareesh Patel	14306 7TH STREET	DADE CITY	FL	33523	800-5555555
DANIA DISCOUNT DRUGS	Robert Kusher	16 S FEDERAL HWY	DANIA BEACH	FL	33004	954-9214661
MEDOZ PHCY OF POLK	Uday Desai	40230 US 27 STE 100-110	DAVENPORT	FL	33837	855-6336948
WEBB'S SQUARE PHARMACY	Yahaya Abuh	2200 SOUTH BLVD W	DAVENPORT	FL	33837	863-4219200
PATIENTS CHOICE PHCY	JUSTIN BROWNSTEIN	4801 S UNIVERSITYDRSTE105	DAVIE	FL	33328	954-6222222
NEIGHBORHOOD DRUGS	Richard Weiner	8844 W STATE RD 84	DAVIE	FL	33324	954-4243784
PILL BOX DAVIE	Tom Bohan	7701 NOVA DR	DAVIE	FL	33324	954-4757455
PALM BEACH PHARMACY	Samantha Lindo	120 N FEDERAL HWY	DEERFIELD BEACH	FL	33441	954-3792444
PETERS PHARMACY	Michael Kamel	121 VICTORIA CMNS STE 102	DELAND	FL	32724	386-7348477
SHIOVAM LLC ANGELS PHY IV	Virat Patel	319 S WOODLAND BLVD	DELAND	FL	32720	386-7343383
B J S PHARMACY INC	ALLEN RUTMAN	321 E ATLANTIC AVE	DELRAY BEACH	FL	33483	561-2766034
APEX PHARMACY	HEMAL PARIKH	6110 W ATLANTIC AVE BAY C	DELRAY BEACH	FL	33484	561-4997500
TOTAL CARE PHARMACY	Prokopios Panagakos	4900 LINTON BLVD STE 24	DELRAY BEACH	FL	33445	561-9212025

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
LT MEDICAL PHARMACY	Tan Thai	4300 CLIME RD STE 111	COLUMBUS	OH	43228	614-7320849
WESTLAND PHARMACY, LLC	THAI PHAM	100 N Murray Hill Rd	COLUMBUS	OH	43228	614-8539000
MILESTONE PHARMACY	Zahra Ahmed	3350 CLEVELAND AVE # 1946	COLUMBUS	OH	43224	614-6005524
SHRIVERS PHARMACY 6	JOHN COLER	120 SOUTH BUCKEYE STREET	CROOKSVILLE	OH	43731	740-9823081
KLEIN'S PHARMACY HM	Barry Klein	2015 STATE ROAD	CUYAHOGA FALLS	OH	44223	330-9299183
CONWAYS DANVILLE PHARMACY	Denise Conway	14 EAST MAIN STREET	DANVILLE	OH	43014	740-5013831
THE PHARMACY AT EASTWAY	Tom Mowbray	600 WAYNE AVE	DAYTON	OH	45410	937-3962538
COMMUNITY MARKET 310 PHCY	Jeremy Best	702 MAIN ST	DELTA	OH	43515	419-8220306
PATIENT CARE PHARMACY	THOMAS ARMENTROUT	5502 DIXIE HWY	FAIRFIELD	OH	45014	513-8745868
GREAT SCOT 80 PHARMACY	Jeremy Best	2017 BROAD AVE	FINDLAY	OH	45840	567-2513900
PRESCRIPTION SOLUTIONS	STANLEY SCARBROUGH	1809 S MAIN ST	FINDLAY	OH	45840	419-4231513
KAUP PHARMACY HM	Jillian Andrews	102 N WAYNE ST POB 605	FORT RECOVERY	OH	45846	419-3752323
FRANKLIN FURNACE PHARMACY	Marty Russell	561 NORWICH AVE	FRANKLIN FURNACE	OH	45629	740-3549983
QUAY DRUG HM	Rex Cramer	2 PUBLIC SQUARE	GALION	OH	44833	419-4683044
OLD VILLAGE PHARMACY	Tan Thai	978 GALLOWAY RD	GALLOWAY	OH	43119	614-8533498
GERMANTOWN PHARMACY	Katie Perry	28 N MAIN ST	GERMANTOWN	OH	45327	937-3363637
MIDVIEW DRUGS	JON KAUP	35053 E. ROYALTON ROAD	GRAFTON	OH	44044	440-7482137
CORNER PHARMACY LLC HM	Eric Zint	259 JEFFERSON ST	GREENFIELD	OH	45123	937-9812454
ULTIMATE CARE PHARMACY	JOSEPH OSEI OWUSU	3481 TYLERSVILLE RD	HAMILTON	OH	45011	800-5555555
VILLAGE PHARMACY HM	Jeffrey Biddle	114 HARRISON AVE	HARRISON	OH	45030	513-3674836
HOLLAND DISCOUNT PHCY	BILAL SALIM	909 S. MCCORD RD STE#1	HOLLAND	OH	43528	419-8657777
INDEPENDENT RX PHCY	TIM CLARK	7415 OLD TROY PIKE	HUBER HEIGHTS	OH	45424	937-7232880
COAL GROVE PHARMACY	JASON PLUMMER	600 MARION PIKE	IRONTON	OH	45638	740-5332479
JACKSON PHCY & WELL CTR	BRANDON HAAS	101 B EAST PIKE ST	JACKSON CENTER	OH	45334	937-5968100
WELLNESS 1 PHARMACY	AYMAN YAHYA	2420 S SMITHVILLE RD	KETTERING	OH	45420	937-2564000
MAIN DISCOUNT DRUG	EDWARD TING	8507 MAIN ST	KINSMAN	OH	44428	330-8761228

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
IRAS DISCOUNT PHARMACY	PROKOPIOS PANAGAKOS	4900 LINTON BLVD STE 21	DELRAY BEACH	FL	33445	561-4550090
LINTON SQUARE PHARMACY	WILLIAM BARNHART	1601 SOUTH CONGRESS	DELRAY BEACH	FL	33445	561-2720015
IPHARMACY	Jigar Patel	776 DELTONA BLVD	DELTONA	FL	32725	386-2594074
UNI-SCRIPT PHARMACY	Sal Castaner	8250 NW 27TH ST STE 301	DORAL	FL	33122	786-5170444
FLEMING ISLAND PHCY LLC	MIKHIL JOSEPH	2349 VILLAGE SQUARE PKWY 106	FLEMING ISLAND	FL	32003	904-6448233
OCEAN CHEMIST	Anthony Garofali	3535 GALT OCEAN DR STE 1N	FORT LAUDERDALE	FL	33308	954-3292690
A PLUS PHCY & MED SUPPLY	Antoine Mourani	1303 SE 17TH ST SUITE D1	FORT LAUDERDALE	FL	33316	954-6870774
PRESCRIPT RX PHARMACY	Lisa Quiñonez	1523 E COMMERCIAL BLVD	FORT LAUDERDALE	FL	33334	754-2005913
RELYON SPECIALTY PHARMACY	Sanon Lezeau	2727 E OAKLAND PARK BLVD STE 100	FORT LAUDERDALE	FL	33306	954-9904317
K&M DRUGS FORT MYERS	HAITHAM KAKI	14651 PALM BEACH BLVD SUITE 102	FORT MYERS	FL	33905	239-6895788
GATEWAY RX PLLC	Michael Gerbasio	12401 COMMERCE LAKES DR. UNIT C	FORT MYERS	FL	33913	239-7681222
PROMELL PHARMACY	Owusu Sakiy Agkum	8291 DANI DR STE 103	FORT MYERS	FL	33966	239-7668300
JABERS PHARMACY	Rajesh Patel	2210 ORANGE AVE	FORT PIERCE	FL	34950	772-7428269
FORT PIERCE DISCOUNT PHY	SAM KUMAR	1727 OKEECHOBEE RD	FORT PIERCE	FL	34950	772-5776469
GARDEN DRUGS	ANEESH LAKHANI	4400 N ANDREWS AVE	FT LAUDERDALE	FL	33309	954-7761521
LAS OLAS CHEMIST HM	Marc Leach	1211 EAST LAS OLAS BLVD	FT LAUDERDALE	FL	33301	954-4624166
MEDICAL HOTSPOTS/BAILEYS	Trisha Bailey	4500 N. FEDERAL HWY STE 6	FT LAUDERDALE	FL	33308	954-7664090
HEALTHCITE PHARMACY	Shyam Busireddy	4500 W MIDWAY RD STE 105	FT PIERCE	FL	34981	772-7422886
AVP PHARMA LLC	Miral Patel	7261 NW 4TH BLVD.	GAINESVILLE	FL	32607	352-4294633
WALDRUG, LLC MEDFLORIDA P	Ana Ochoa	3387 S JOG RD	GREENACRES	FL	33467	561-4448399
UNITY CARE RX	Brad Williams	6085 LAKE WORTH RD	GREENACRES	FL	33463	561-4448798
FAMILY CARE RX LLC	Christopher Leon	4752 JOG RD	GREENACRES	FL	33467	561-3703114
FAMILY CARE RX LLC	Christopher Leon	6428 MELALEUCA LANE	GREENACRES	FL	33463	561-8123058
CLARKE'S PHARMACY LLC	HUGH CLARKE	3989 JOG ROAD	GREENACRES	FL	33467	954-2885592
HC PHARMACY	SAMER SHEHAITA	32940 US HWY 27	HAINES CITY	FL	33844	863-5476921
PHARMCO LLC	Birute Norkute	400 ANSIN BLVD, STE A	HALLANDALE	FL	33009	786-2882991
BUDGET DRUGS #4 HM	Scott Henkin	2500 E HALLANDALE BCH BLV	HALLANDALE	FL	33009	954-4578011

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
DOCTORS PHARMACY LIMA	EMMANUEL QUAINOO	920 W MARKET ST STE 101	LIMA	OH	45805	614-6419687
SHRIVERS PHARMACY #8	John Coler	21 HOCKING MALL	LOGAN	OH	43138	740-2164496
SHRIVERS PHARMACY 11	Josh Stanton	202 W MAIN ST	LOUDONVILL E	OH	44842	419-9943221
HOLBROOK'S HOMETOWN PHCY	BRANDON HOLBROOK	37 C LUCASVILLE MINFORD RD	LUCASVILLE	OH	45648	740-2590041
WELLNESS 1 PHARMACY	AYMAN YAHYA	6681 WESTERN ROW RD	MASON	OH	45040	513-5480022
THORN CHERRY PHARMACY	Adam Williams	1607 AMHERST RD NE	MASSILLON	OH	44646	330-4131509
MAUMEE DISCOUNT PHCY	BILAL SALIM	316 W DUSSEL DR	MAUMEE	OH	43537	419-8870101
SHRIVERS PHARMACY #1 HM	John Coler	105 N KENNEBEC AVENUE	MCCONNELLS VILLE	OH	43756	740-9622552
SOUTHWEST COMM PHCY	Patricia Phillips	18697 E. BAGLEY RD.	MIDDLEBURG HEIGHTS	OH	44130	440-8168410
CONWAYS EASTSIDE HM	Denise Conway	1451 YAUGER ROAD SUITE 1H	MOUNT VERNON	OH	43050	740-3971420
FOSTERS PHARMACY HM	JP Hatfield	207 W HIGH ST	MOUNT VERNON	OH	43050	740-3920911
STERLING PHARMACY S C	Griff Vincent	283 YANKEETOWN RD	MT STERLING	OH	43143	740-8693784
SHRIVERS #4 HM	John Coler	40 WATKINS STREET	NELSONVILLE	OH	45764	740-7532484
BLACKBURN PHARMACY	ROGER FLAUTT	3520 RHODES AVE	NEW BOSTON	OH	45662	740-4564500
NORTHSIDE NEW CONCORD	Edward Stoepfel	10 EAST MAIN STREET	NEW CONCORD	OH	43762	740-8264000
VILLAGE NM PHCY HM	Rick Carano	10395 MAIN ST. PO BOX 289	NEW MIDDLETOW N	OH	44442	330-5422802
BERRY PHARMACY	Susan Upchurch	1041B OLD US 52 STE B	NEW RICHMOND	OH	45157	513-5534131
MEDI-WISE PHCY RX	JEFF NEIDIG	245 W. STATE STREET	NEWCOMERS TOWN	OH	43832	740-4986337
TROUTMAN DRUG HM	Joe Gioiello	501 ROBBINS AVE.	NILES	OH	44446	330-6521435
GREAT SCOT 90 PHARMACY	Jeremy Best	13710 DESHLER RD	NORTH BALTIMORE	OH	45872	419-2572221
COMUNITY MARKET 240 PHCY	Jeremy Best	279 W WATER ST	OAK HARBOR	OH	43449	419-8980954
MEDX PHARMACY	Imad Mourad	3021 NAVARRE AVE	OREGON	OH	43616	419-2149065
TUCKERS OTTAWA PHCY	ROY KLASS	1831 E MAIN ST	OTTAWA	OH	45875	419-5236122
ROYAL PHARMACY	Eric Obeng	730 CORYLUS DR	PATASKALA	OH	43062	614-2096253
ANSON PHARMACY	Lap Pan Chu	209 BIERLEY AVE	PEMBERVILLE	OH	43450	419-2877088
VITACARE PHARMACY	John Banahene	10501 BLACKLICK E. RD#800	PICKERINGTO N	OH	43147	614-7796846
BOSTICK'S PRESC PHY	DAN BOSTICK	549 S W St	PIKETON	OH	45661	740-2892269

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
PIC INC/BUY RITE #6	PAULA NORMAN	704 S US HWY 27	HAVANA	FL	32333	850-5398080
G & R PHARMACY	RAJESH PATEL	1298 E NORV BRYANT HWY,D	HERNANDO	FL	34442	352-4198949
41 PHARMACY DISCOUNT HM	Angelito Navarro	820 E 41ST ST	HIALEAH	FL	33013	305-8362200
ANGELITO PHCY DISCNT HM	Claudio Navarro	3890 E 4TH AVENUE	HIALEAH	FL	33013	305-8204010
ELSA PHARMACY INC HM	Giselle Casalduc	1802 EAST 4 AVE	HIALEAH	FL	33010	305-6911968
COTO'S PHARMACY HM	Mohammad Tabibi	4970 WEST 12 AVENUE	HIALEAH	FL	33012	305-8211430
IDEAL PHARMACY SOLUTIONS	Victor Hernandez	344 W 65TH STREET STE#101	HIALEAH	FL	33012	305-5583551
SHAMBHU INC	VARSHA CHAUDHARI	19214 NW HWY 441 #10	HIGH SPRINGS	FL	32643	386-4541586
RAYS PHARMACY HM	Biju Varghese	1936 US HWY 19 N	HOLIDAY	FL	34691	727-9458200
WATER LILLY PHARMACY	Gorjana Apostolovic	3700 WASHINGTON ST #206	HOLLYWOOD	FL	33021	954-4175698
POST HASTE PHARMACY HM	Greg Fishman	4401 SHERIDAN ST	HOLLYWOOD	FL	33021	954-9896524
EMERALD HILLS PHARMACY	Ivette Bowers	3000 STIRLING RD STE 120	HOLLYWOOD	FL	33021	954-9833336
MEDICAL ARTS PHCY	Alberto Fraga	944 KROME AVE	HOMESTEAD	FL	33030	305-2474488
MAA BHAWANI INC II	RAJESH PATEL	5691 S SUNCOAST BLVD	HOMOSASSA	FL	34446	352-6280096
DRUG STORE HM	Falgun Patel	7535 MEDICAL DRIVE STE #1	HUDSON	FL	34667	727-8693784
FAMILY DRUGS	Brian Rucks	15690 SW WARFIELD BLVD	INDIANTOWN	FL	34956	772-5972250
MEDTOWN PHARMACY	CHEN OEUR	11643 BEACH BLVD, UNIT A	JACKSONVILL E	FL	32246	904-2945310
PRESTON REXALL PHARMACY	Denise Stiles-Young	6022 ATLANTIC BLVD.	JACKSONVILL E	FL	32211	904-7251616
PUBLIC SQUARE PHARMACY	Diego Gomez	11757 BEACH BLVD #7	JACKSONVILL E	FL	32246	904-5314556
JACKSON PHARMACY	DIPA SHAH	4347-3 UNIVERSTIY BLVD S	JACKSONVILL E	FL	32216	904-3292251
LANE AVENUE PHARMACY INC	Felix Obasuyi	1233 LANE AVE S #9	JACKSONVILL E	FL	32205	904-6936633
PAXON PRESCRIPT CENTER HM	Greg Toole	757 NORTH EDGEWOOD AVE	JACKSONVILL E	FL	32254	904-3880514
ALL PEOPLES PHARMACY	JACOB WILLIAMS	4750 SOUTEL DR	JACKSONVILL E	FL	32208	904-7663145
HALLIDAY/KOIVISTO PPSC	JAMES KOIVISTO	4133-1 BLDG UNIV SOUTH	JACKSONVILL E	FL	32216	904-7372216
MONUMENT PHARMACY HM	Mitesh Patel	1301-22 MONUMENT RD	JACKSONVILL E	FL	32225	904-7273434
RICKER PHARMACY	MITESH PATEL	7628 103RD STREET UNIT #5	JACKSONVILL E	FL	32210	904-9003500

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
BREWSTER'S HOMETOWN PHCY	Hope Brewster	104 THORNTON DR	PIKETON	OH	45661	740-6483020
HOCKS PIQUA	Jeff Bartone	649 W HIGH ST	PIQUA	OH	45356	937-6897687
COMUNITY MARKET 320 PHCY	Jeremy Best	262 SANDUSKY ST	PLYMOUTH	OH	44865	419-6879491
BASSETT'S MARKET PHARMACY	DAWN FITT	3994 E HARBOR RD	PORT CLINTON	OH	43452	419-7326300
TCC HEALTH	Andy Pierron	840 GALLIA ST	PORTSMOUTH	OH	45662	740-3540700
COMPASS PHARMACY	Andy Pierron	1634 11TH ST	PORTSMOUTH	OH	45662	740-3557102
POWELL PHARMACY	Emlah Tubuo	4004 PRESIDENTIAL PKWY	POWELL	OH	43065	614-4937570
LCRG BROS LLC/WELLCARE PH	Raj Dobariya	7584 E MAIN STREET	REYNOLDSBURG	OH	43068	614-6046632
ROSEVILLE PHARMACY	Edward Stoepfel	157 SOUTH MAIN STREET	ROSEVILLE	OH	43777	740-6970348
FRED'S FAMILY PHARMACY	FREDERICK WOLKEN	1136 E STATE ST	SALEM	OH	44460	330-3329919
BUNNY'S PHARMACY	GREGORY BONNORONT	112 N MAIN AVE	SIDNEY	OH	45365	937-4927458
NORTHSIDE SOMERSET PHCY	Edward Stoepfel	110 WEST MAIN STREET	SOMERSET	OH	43783	740-7432185
HOCKS PHCY S CHARLESTON	Jeff Bartone	127 S CHILLICOTHE STREET	SOUTH CHARLESTON	OH	45368	937-4628331
MCMEANS PHARMACY S POINT	John Mcmeans	708 4TH ST E POBOX #416	SOUTH POINT	OH	45680	740-3772677
CANAL PHARMACY HM	Kathy Burkholder	102 S BROADWAY	SPENCERVILLE	OH	45887	419-6474584
HARDING ROAD PHCY	Dwight Dobbins	400 W HARDING RD	SPRINGFIELD	OH	45504	937-3998531
WHITACRE PHCY LAGONDA	Frank Fuschino	1574 LAGONDA AVE	SPRINGFIELD	OH	45503	937-3256444
WHITACRE PHCY LIMESTONE	Frank Fuschino	1816 S LIMESTONE ST	SPRINGFIELD	OH	45505	937-3221925
CARSON'S NORTHRIDGE PHCY	Joti Carson	4923 SECURITY DR	SPRINGFIELD	OH	45503	937-5047700
PROGRESSIVE WELLNESS PHY	Fatimah Farhat	7640 W SYLVANIA AVE # C-1	SYLVANIA	OH	43560	419-7493193
HOCK'S TIPP CITY PHARMACY	JEFFREY BARTONE	5175 S COUNTY RD 25A	TIPP CITY	OH	45371	937-6675803
LIFECARE PHARMACY	Ajay Patel	4730 N SUMMIT ST	TOLEDO	OH	43611	419-7200055
WOODVILLE PHARMACY	Ajay Patel	820 WOODVILLE RD.	TOLEDO	OH	43605	419-2141311
LIFECARE PHARMACY	BRIJESH BHAGAT	2011 STARR AVENUE	TOLEDO	OH	43605	419-7201116
WESTGATE FAMILY	HUSSEI EL KHATIB	3147 WEST CENTRAL AVE	TOLEDO	OH	43606	419-5310000
TOLEDO FAMILY PHCY	HUSSEIN EL KHATIB	1601 WEST SYLVANIA	TOLEDO	OH	43612	419-4700700

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
PRIME PHARMACY	Raj Warde	7685 103RD ST, STE 4	JACKSONVILLE	FL	32210	904-8137634
SAMARA-MEDSMART PHARMACY	SATISH BADAM	7855 ARGYLE FOREST STE801	JACKSONVILLE	FL	32244	904-8001888
NORTH BEACHES DBA DIP	Lynn Wood	730 BEACH BLVD #104	JACKSONVILLE BEACH	FL	32250	904-2415171
MARGATE PHARMACY	Piyasi Dadia	6725 W INDIANTOWN RD STE 40	JUPITER	FL	33458	954-5864546
ABACOA PHARMACY	Salim Soufan	500 UNIVERSITY BLVD #108	JUPITER	FL	33458	561-5622610
JUPITER DRUGS LLC	SANETTE JANSEN VAN VUUREN	1025 N MILITARY TRAIL	JUPITER	FL	33458	561-7467499
BENZER FL3 LLC/ELITE PHCY	Tejas Patel	901 WEST INDIANTOWN ROAD BAY 23	JUPITER	FL	33458	800-5555555
ETHOS WELLNESS PHARMACY	Javier Diaz	260 CRANDON BLVD. C 33	KEY BISCAYNE	FL	33149	305-9828727
PHARMACY AT THE REEF	Jennifer Marino	31 OCEAN REEF DR #A100	KEY LARGO	FL	33037	305-7807136
ROGERS PHARMACY - RETAIL	Ali Shakil	3063 MICHIGAN AVE	KISSIMMEE	FL	34744	407-2166533
AMERICA'S PHARMACY III	Elder Soria	4352 W VINE ST STE 106	KISSIMMEE	FL	34746	407-4790033
CITY RX PHARMACY	mirely aleman	715 E VINE ST STE 8	KISSIMMEE	FL	34744	727-8314392
XXA WEST LAKE PHARMACY HM	Napolean Onyechi	2544 SIMPSON RD	KISSIMMEE	FL	34744	407-3444555
THE HUNTER'S CREEK, LLC	RIAZ KHATTAK	1196 CYRESS GLEN CIR	KISSIMMEE	FL	34741	407-4838901
MEDINA-MEDS PHARMACY	ROSEMARY MEDINA	4675 OLD PLEASANT HILL RD	KISSIMMEE	FL	34759	407-3941111
JUAN & JOHN DRUGS	Haitham Kaki	149 W HICKPOCHEE AVE	LABELLE	FL	33935	863-6750004
BAYA PHCY - EAST HM	Carl Allison	780 SE BAYA DRIVE	LAKE CITY	FL	32025	386-7556677
BAYA PHCY WEST HM	Carl Allison	1465 US HWY 90 WEST #110	LAKE CITY	FL	32055	386-7552233
LAKE TOWN PHARMACY	RAJ MANI	2020 N CR 470 #B	LAKE PANASOFFKE	FL	33538	352-5668236
ROBALO PHARMACY	NIRAV PATEL	228 US HWY 1	LAKE PARK	FL	33403	561-8441191
OPS PHARMACY LLC	SMRUTHI JANNU	1110 DRUID CIR STE E	LAKE WALES	FL	33853	646-6730044
PERFECTION RX	Peter Bigley	3248 LANTANA RD	LAKE WORTH	FL	33462	561-8981450
P&M PHARMACY	Tejas Patel	7753 LAKE WORTH RD	LAKE WORTH	FL	33467	561-6608650
JAYVI CAPITAL LLC	JAYMISH PATEL	2455 US HIGHWAY 98 N	LAKELAND	FL	33805	863-6038104
ARIANA PHARMACY	Nilesh Patel	1354 ARIANA ST	LAKELAND	FL	33803	863-6033430

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
TOLEDO FAMILY PHARMACY	Hussein El Khatib	324 MAIN ST	TOLEDO	OH	43605	419-9305830
FRANKLIN PARK PHARMACY	Hussein Haidar	4020 SECOR RD UNIT A	TOLEDO	OH	43623	567-3158780
LAGRANGE SAV-MOR DRUGS	IMAD MOURAD	3103 LAGRANGE	TOLEDO	OH	43608	419-2418065
JAMES PHARMACY INC	JOHN PANGRAC	623 LAGRANGE ST	TOLEDO	OH	43604	419-2439161
KMG PHARMACY	MAHMOUD SHALTAF	846 E MAIN ST	TROTWOOD	OH	45426	937-5294433
TWINSBURG PHARMACY	MICHAEL MOAWAD	10735 RAVENNA RD.	TWINSBURG	OH	44087	330-4050501
MAKO'S PHARMACY	Laura Aubihl	240 E 3RD ST	UHRICHSVILLE	OH	44683	740-9225400
CURLEYS PHARMACY	Carl Willhite	244 N MAIN STREET	UTICA	OH	43080	740-8923784
HOCK'S VANDALIA PHARMACY	JEFFREY BARTONE	535 S DIXIE DR	VANDALIA	OH	45377	937-8985803
KAUP PHARMACY	JACKIE BRISCOE	42 WEST MAIN STREET	VERSAILLES	OH	45380	937-5263337
FRANKLIN PHCY HM	Frank Manios	1732 YOUNGSTOWN RD	WARREN	OH	44484	330-3698434
FAYETTE PHARMACY	Rod Banks	1500 COLUMBUS AVE	WASHINGTON COURT HOUSE	OH	43160	740-3359900
WELLNESS1PHARMACY W CRLTN	Ayman Yahya	2092 S ALEX RD STE A	WEST CARROLLTON	OH	45449	937-3847777
CENTRAL PHARMACY	Mohamed Abdel	9117 CINCINNATI COLUMBUS RD	WEST CHESTER	OH	45069	513-2297585
KLINGER PHARMACY	AARON DUNLAP	102 W JACKSON ST	WEST UNITY	OH	43570	419-9242444
TWC PHY & WELLNESS CENTER	LAURA ATKINSON	273 A WEST SCHROCK ROAD	WESTERVILLE	OH	43081	614-9426240
LINWORTHS PHARMACY	Ripal Patel	2245 W DUBLIN GRANVILLE #103	WORTHINGTON	OH	43085	614-3920960
NORTHSIDE MAYSVILLE PHCY	Edward Stoepfel	15 MAYSVILLE AVE	ZANESVILLE	OH	43701	740-4533700
NORTHSIDE MVHC PHARMACY	Edward Stoepfel	716 ADAIR AVENUE	ZANESVILLE	OH	43701	740-8688171
NORTHSIDE PHCY FOREST AVE	Edward Stoepfel	751 FOREST AVE # 204	ZANESVILLE	OH	43701	740-4546970
NORTHSIDE BELL STREET	EJ Stoepfel	2899 BELL STREET	ZANESVILLE	OH	43701	740-4530508
SHRIVERS PHARMACY #3 HM	John Coler	406 BRIGHTON BLVD	ZANESVILLE	OH	43701	740-4523691
ADA APOTHECARY	BEV SMITH	1201 E ARLINGTON ST	ADA	OK	74820	580-3322000
SOVEREIGNPHCYSOL&F NEGIFT	NANCY PHELPS	1007 N COUNTRY CLUB	ADA	OK	74820	580-4218775
TRADITION DRUG	Paul Grimes	1131 ARLINGTON ST	ADA	OK	74820	800-5555555

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
BAY BREEZE RX	JOHN WATKINS	3350 E BAY DR	LARGO	FL	33771	727-6149933
MICHAEL'S PHARMACY	Wagih Girgis	11936 SEMINOLE BLVD	LARGO	FL	33778	727-5852000
MEDIX PHARMACY	NADER HENRY	4850 W OAKLAND PARK BLVD	LAUDERDALE LAKES	FL	33313	954-5304793
BETTER HEALTH PHARMACY	Frank Osagie	1478 N STATE RD 7	LAUDERHILL	FL	33313	954-5309318
ADVANCED RX PHARMACY 027	Parvinder Kainth	755 W SR 434 STE B	LONGWOOD	FL	32750	727-2580628
MAXXYCOM RX	Parvinder Kainth	1825 COLLIER PARKWAY	LUTZ	FL	33549	813-4064929
RX EXPRESS PHARMACY	RAHUL PATEL	24718 STATE ROAD 54	LUTZ	FL	33559	813-9484321
MACCLENNY PHARMACY	INNOCENT OPARA	1254 S 6TH STREET	MACCLENNY	FL	32063	904-2591116
BAKER PHARMACY	Pavan Banoth	698 W MACCLENNY AVE #682	MACCLENNY	FL	32063	904-3970565
EXPRESS PHARMACY	Niren Dadia	2458 N. STATE RD 7	MARGATE	FL	33063	800-5555555
MANNING PHARMACY	Xue Mei	3179 N STATE ROAD 7	MARGATE	FL	33063	954-9332191
CARE RITE PHARMACY	Mohammed Albibi	4721 HWY 90	MARIANNA	FL	32446	850-5263030
KELSON DRUG	Virgil Oswald Jr	3008 JEFFERSON ST STE B	MARIANNA	FL	32446	850-5262839
WICKHAM DISCOUNT PHCY	ANKIT SHAH	1060 NORTH WICKHAM RD	MELBOURNE	FL	32935	321-2416433
BABCOCK PHCY AND SURGICAL	DEVANG MODI	1515 PALM BAY #108	MELBOURNE	FL	32901	321-4993999
EMPIRE SPECIALTY PHCY	Mallikarjuna Penumudi	749 S APOLLO BLVD	MELBOURNE	FL	32901	321-5496926
LORDONI DISCOUNT PHCY	OLU ONI	6300 N WICKHAM RD #126	MELBOURNE	FL	32940	321-6103114
SALUS PHARMACY LLC	ANABEL GALANO	4677 W FLAGLER ST	MIAMI	FL	33134	786-3602360
OCEANVIEW PHCY	Binita Patel	12753 SW 42ND ST.	MIAMI	FL	33175	305-2792465
SUNSET PHARMACY DISCOUNT	DAINERYS ROJAS	7400 NW 19TH ST, STE FGH	MIAMI	FL	33126	786-8038483
TU FAMILIA FARMACIA	Daniel Perez	10788 SW 24TH ST	MIAMI	FL	33165	786-8990403
RUBIO PHARMACY AND DISCOU	LERYCKA FONTE	18600 NW 87 AVE UNIT #109	MIAMI	FL	33015	305-4053333
MEDFLORIDA MED CENTERS	Mazin Shikara	21110 BISCAYNE BLVD #203	MIAMI	FL	33180	305-9489595
PHARMAG INC	RAYDEL LORENZO	6622 SW 24TH STREET	MIAMI	FL	33155	305-3823000
ORIENTE PHARMACY HM	Veronica Carballosa	285 NW 27TH AVE	MIAMI	FL	33125	305-6490064
SIR CHARLES PHARMACY	CHARLES AYEBAH	17560 NW 27TH STE119	MIAMI GARDENS	FL	33056	305-7053415
MYCARE PHARMACY	MIGUEL MORENO	15518 NW 77TH COURT	MIAMI LAKES	FL	33016	305-8233461
DENNING'S PHARMACY	Dan Denning	2620 BLANDING BLVD, STE 2	MIDDLEBURG	FL	32068	904-6524546

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
CLINIC PHARMACY HM	Brad Pickett	205 S PARK LANE #110	ALTUS	OK	73521	580-4826464
BROADWAY PHARMACY	CINDY RAY	601 EAST BROADWAY	ALTUS	OK	73521	580-4770800
REXCO DRUG	Kyle Keenum	2101 NORTH MAIN	ALTUS	OK	73521	580-4770381
CLINIC PHARMACY	PHILIP MELTON	1104 E CENTRAL STE 1	ANADARKO	OK	73005	405-2473081
PRUETT'S PHARMACY	DON RITTER	906 EAST MAIN	ANTLERS	OK	74523	580-2985064
APACHE DRUG	PHILIP MELTON	118 E EVANS	APACHE	OK	73006	580-5883639
HENRY ROBERTS EXPRESS PHC	Bill Moore	1316 12TH NW	ARDMORE	OK	73401	580-2262684
LONE GROVE PHARMACY	Elmer Humphreys III	45 ALMOND DR	ARDMORE	OK	73401	580-6574040
T & M PHARMACY 25	GREG TRENT	423 12TH NW	ARDMORE	OK	73401	580-2230671
STEELE DRUG	Jim Carter	907 GRAND AVE	ARDMORE	OK	73402	580-2233000
RITTER EXPRESS PHCY	DON RITTER	744 S MISSISSIPPI AVE #A	ATOKA	OK	74525	580-8890230
LIMESTONE PHARMACY	Jacqueline Gallery	3803 NOWATA RD STE C	BARTLESVILLE	OK	74006	918-3310000
MEDICATION STATION	AMY HOUSER	8054 HW 16 STE100 POB217	BEGGS	OK	74421	918-2674890
DON'S PHCY HM	Bill Wittrock	6801 NW 39TH EXPRESSWAY	BETHANY	OK	73008	405-7892453
DON COODY PHARMACY	Doug Sheffield	7530 NW 23RD ST B	BETHANY	OK	73008	405-7898921
RED CROSS DRUG	AJ Asgari	301 NE 10TH STREET	BLANCHARD	OK	73010	405-4859311
BOISE CITY FAM PHCY OTC	Theresa Weaver	318 W MAIN	BOISE CITY	OK	73933	580-5443441
SUPER H PHARMACY	AJ Asgari	201 E. 7TH AVE	BRISTOW	OK	74010	918-3673328
KEMP DRUG	SUSAN WELLS	215 NORTH MAIN	BRISTOW	OK	74010	918-3673391
NEXTGENRX	DJ Lees	811 W NEW ORLEANS STE 101	BROKEN ARROW	OK	74011	918-5780031
CAREFIRST PHARMACY	T.J. Marti	2530 N. ELM PL.	BROKEN ARROW	OK	74012	918-9941400
SHERILL'S PHCY & GIFT	Amy Hammonds	101 N MAIN	BROKEN BOW	OK	74728	580-5843353
MEDIC PHCY AND GIFTS	GREG HUENAGARDT	506 NORTH HOY POB 679	BUFFALO	OK	73834	580-7352161
HEROD'S DRUG STORE	MARK KOURT	212 W MAIN	CANTON	OK	73724	580-8863444
LIBERTY DRUG	BRIAN HARRISON	15 W MAIN ST POB 362	CARNEGIE	OK	73015	580-6541111
CATOOSA FAMILY PHARMACY	David Johnson	1818 N HWY 66 STE A	CATOOSA	OK	74015	918-2319034
CHECOTAH PHARMACY	Teresa Huggins	1002 W GENTRY AVE STE B	CHECOTAH	OK	74426	918-4733838
CHELSEA FAMILY PHARMACY	Joe Forcum	600 WALNUT ST	CHELSEA	OK	74016	918-7892241

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
ZENCARE PHARMACY	Emma Duong	12140 MIRAMAR PKWY	MIRAMAR	FL	33025	800-5555555
SCOTT'S PHARMACY HM	Ron Scott	6505 HWY 29 N	MOLINO	FL	32577	850-5872511
MULBERRY FOOD AND PHCY LL	Gisha Abraham	806 N CHURCH AVE	MULBERRY	FL	33860	813-7701394
NOBLE CARE PHARMACY	YOGI NOBLE	7066 N CHURCH AVE	MULBERRY	FL	33860	863-5834535
GULF SHORE APOTHECARY	ALEX HERWIG	1400 GULF SHORE BLVD N	NAPLES	FL	34102	239-2622222
GULF SHORE APOTH II	ALEX HERWIG	11669 COLLIER BLVD	NAPLES	FL	34116	239-3049084
MOTHER'S PHARMACY	BERNARD RENNER	6350 DAVIS BLVD	NAPLES	FL	34104	239-7327993
FAMILY HEALTHMART PHCY	Ram Samuel	5482 RATTLESNAKEHAMMO CKRD	NAPLES	FL	34113	239-2314852
USRX PHARMACY	Shant Khanlian	11121 HEALTH PARK #700	NAPLES	FL	34110	+18-0055555
Z ORANGE PHARMACY	JOHN FALTAOOS	7268 STATE ROAD 54	NEW PORT RICHEY	FL	34653	727-3123155
ANP GROUP LLC	LALICHAN GEORGE	5335 MAIN ST	NEW PORT RICHEY	FL	34652	727-8458000
MARINE PHARMACY	Manju George	5016 US HIGHWAY 19	NEW PORT RICHEY	FL	34652	727-4186900
FLORIDA PHARMACY	MIRAL PATEL	5445 JAMES STREET	NEW PORT RICHEY	FL	34652	727-8488300
AAP GROUP INC	RADHIKA PATEL	5812 STATE RD 54	NEW PORT RICHEY	FL	34652	727-8461300
BE WELL PHARMACY	Shady Basta	5429 LITTLE RD	NEW PORT RICHEY	FL	34655	727-3725600
MAXCARE PHARMACY	Suba Nathan	6624 US HWY 19	NEW PORT RICHEY	FL	34652	727-8077050
LITTLE DRUG CO INC HM	David Sikes	412 CANAL ST	NEW SMYRNA BEACH	FL	32168	386-4289041
RELIABLE SUPER DRUGS HM	Pyarali Charania	2168 NE 123RD STREET	NORTH MIAMI	FL	33181	305-8935252
PRESCRIPTION DRUG FUND	Urmil Shah	1777 NE 163RD STREET	NORTH MIAMI BEACH	FL	33162	800-5555555
TOWN PHARMACY	Alex Shulman	14826 TAMIAAMI TRL	NORTH PORT	FL	34287	941-4297766
FRIENDS PHARMACY/TLCRX1	Bhavik Patel	1714 SW 17TH ST	OCALA	FL	34471	813-6323200
3D WELLNESS SPLTY PHCY	PARVINDER KAINTH	3143 SW 32ND AVE STE 200	OCALA	FL	34474	813-4286000
HEALTHWELL PHARMACY	Ravi Patel	1426 S PINE AVE	OCALA	FL	34471	352-3046663
BNR PHARMACY	Brad Howard	1063 S CLARKE RD	OCOEEE	FL	34761	407-3766771
SMARTCARERX	SHASANKA THUMU	1572 CITRUS MEDICAL CT	OCOEEE	FL	34761	407-7297050
ACCORD SPECIALTY PHMY	Dharaben Patel	2752 ENTERPRISE RD STE B	ORANGE CITY	FL	32763	800-5555555

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
SMITH DRUG 14	DAMON HAWKINS	121 SOUTH GRAND	CHEROKEE	OK	73728	580-5962764
CHICKASHA CLINIC PHCY LLC	JACK JUSTICE	2224 W IOWA	CHICKASHA	OK	73018	405-2244851
MATT'S COUNTRY BOY PHCY	MATT EVANS	14890 SE 29TH ST STE 108	CHOCTAW	OK	73020	405-3903205
CHOUTEAU FAMILY PHCY LLC	Drew Turner	214 N CHOUTEAU AVE	CHOUTEAU	OK	74337	918-4766455
J&J PHARMACY & GIFTS	Joe Forcum	998 W WILL ROGERS BLVD	CLAREMORE	OK	74017	918-3411184
CLAYTON PHARMACY	Richard Cudd	536 N LAWSON BLVD	CLAYTON	OK	74536	918-5694884
PALACE DRUG STORE HM	Gary Moore	301 NORTH BROADWAY	CLEVELAND	OK	74020	918-3582524
SALISBURY PHARMACY	GREG ADAMS	815 FRISCO AVENUE	CLINTON	OK	73601	580-3231244
S & D HM DRUG HM	Scott Campbell	915 FRISCO	CLINTON	OK	73601	580-3232020
COLLINSVILLE FAMILY PHCY	COLTON TURNBULL	1205 W MAIN ST STE A	COLLINSVILLE	OK	74021	918-3712547
THOMPSON'S PHARMACY	RYAN WOODY	513 HILLERY ROAD STE B	COMANCHE	OK	73529	580-4398869
BAKER PHARMACY	DOUG BAKER	1022 E CHERRY ST	CUSHING	OK	74023	918-2252200
SOONER PHCY OF DAVIS INC	Mike Lee	705 EAST MAIN	DAVIS	OK	73030	580-3693776
LASSITER DISCOUNT DRUG	John Lassiter	3252 SE 29TH	DEL CITY	OK	73115	405-6770549
MURPHY'S DRUG	LARRY MURPHY	145 E. BROADWAY	DRUMRIGHT	OK	74030	918-3522468
BAKER EXPRESS PHCY	CHAD SCOTT	3344 N HWY 81	DUNCAN	OK	73533	580-2553784
MEDICAL CENTER PHARMACY	GREGORY SEAY	1026 RADIO RD	DURANT	OK	74701	580-9247425
THE MEDICINE STORE	Nelson Edgeman	311 N WASHINGTON AVENUE	DURANT	OK	74701	580-9243784
CANADIAN VALLEY RX INC	BARRY SMITH	1605 W ELM ST	EL RENO	OK	73036	405-2624154
ELGIN PHARMACY	Brendan Jones	7523 US HWY 277	ELGIN	OK	73538	580-4925007
GRANDVIEW PHARMACY	COLBY BREWSTER	1220 W 3RD ST POB 370	ELK CITY	OK	73644	580-2255550
EVANS PHARMACY	KYLE WHITEHEAD	1106 W WILLOW RD	ENID	OK	73703	580-2344343
EVANS EXPRESS PHARMACY	KYLE WHITEHEAD	110 N OAKWOOD RD	ENID	OK	73703	580-2331202
EUFAULA PHARMACY	Teresa Huggins	401 S MAIN ST	EUFAULA	OK	74432	918-6897701
FAIRFAX PHARMACY	Kim Tilley	400 N MAIN ST	FAIRFAX	OK	74637	800-5555555
FAIRVIEW RX, INC.	SCOTT HOLDER	210 E STATE RD	FAIRVIEW	OK	73737	580-2272045

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
H & R PHARMACY	Hany Badawy	870 SAXON BLVD #45	ORANGE CITY	FL	32763	386-2180926
ACCARDI CLINICAL PHARMACY	Roger Accardi	2583 S VOLUSIA AVE #100	ORANGE CITY	FL	32763	800-5555555
CARENOW PHARMACY	Tarak Patel	1039 HRLY STRCKLND BV,600	ORANGE CITY	FL	32763	386-4560055
DIRECT RETAIL PHARMACY	AN DANG	5050 CONWAY RD STE 1	ORLANDO	FL	32812	407-2030005
XXAORLANDO PROCARE PHCY	Anas Alashari	2021 SOUTH ORANGE AVE	ORLANDO	FL	32806	407-7303557
FIRST CHOICE PHARMACY	Behrooz Sojeri	754 SOUTH GOLDENROD ROAD	ORLANDO	FL	32822	407-2432513
VH HEALTH SOLUTIONS	CHIRANJIVI JANNU	5282 W COLONIAL DR	ORLANDO	FL	32808	407-2862996
A&M PHARMACY	Christopher Perseo	6564 OLD WINTER GARDEN RD	ORLANDO	FL	32835	407-3050443
ANGELS PHARMACY	Harry Patel	259 E MICHIGAN ST	ORLANDO	FL	32806	407-4267000
RADIANCE HEALTH RX	Marcus Martinez	723 VIRGINIA DR	ORLANDO	FL	32803	407-2345873
PRIORITY HEALTH RX	Mark Brown	1215 E LIVINGSTON ST #A	ORLANDO	FL	32803	855-6522163
RXWAY PHARMACY	Michelle Nguyen	448 S ALAFAYA TRAIL #2	ORLANDO	FL	32828	407-2033805
FREEDOM PHARMACY GPO	Naomi Adams	3901 E COLONIAL DR STE C	ORLANDO	FL	32803	407-8984427
PINE HILLS DRUGS	OSCAR MBIONWU	5000 W COLONIAL DR #100	ORLANDO	FL	32808	407-2911236
TRISTAR DISCOUNT PHARMACY	Sam Charr	1502 N SEMORAN BLVD #154	ORLANDO	FL	32807	407-4403436
BAILEYS PHARMACY II	TRISHA BAILEY	4401 S ORANGE AVE STE 121	ORLANDO	FL	32806	407-9303102
ANGELS PHARMACY II	Rajendra Patel	610 ZEAGLER DR	PALATKA	FL	32177	407-4267000
FIRST CHOICE PHARMACY	Satish Baddam	3208 CRILL AVE #2	PALATKA	FL	32177	386-2191988
SBF INVESTMENTS INC HM	ALLEN RUTMAN	151 N COUNTY RD	PALM BEACH	FL	33480	561-8324443
SUDDHA PHARMACY HM	Amar Patel	255 SUNRISE AVE	PALM BEACH	FL	33480	561-8333348
LEWIS PHCY PALM BEACH HM	Mike Patel	235 SOUTH COUNTY ROAD	PALM BEACH	FL	33480	561-6557867
GARDENS DRUGS	CHRIS CUTOLO	4270 DESIGN CENTER DR #C	PALM BEACH GARDENS	FL	33410	561-6222141
NORTHLAKE PHARMACY	Salim Soufan	9091 NORTH MILITARY TRAIL # 17	PALM BEACH GARDENS	FL	33418	561-6199900
PHARMACO MED SHOP	Chris Delmadoros	1003 VIRGINIA AVE	PALM HARBOR	FL	34683	727-7549497
ST. MARKS PHARMACY LLC	HANAN MANKARIOUS	4954 RIDGEMOOR BLVD.	PALM HARBOR	FL	34685	727-7727070
PROMISE PHARMACY	Mike Patel	31818 US HIGHWAY 19 N	PALM HARBOR	FL	34684	727-7720500

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
SCOTT'S VALU-MED PHARMACY	Lonny Wilson	1201 S LEE STREET	FORT GIBSON	OK	74434	918-4783002
FREDERICK PHARMACY INC	SHANE KELLY	1600 NORTH MAIN/POB 981	FREDERICK	OK	73542	580-3355501
GROVE DRIVE-IN PHCY HM	David Walker	1027 S MAIN ST	GROVE	OK	74345	918-7862268
PARKVIEW PHARMACY	Terry Moore	115 MEDICAL DR	GUYMON	OK	73942	580-3387565
HARRAH PHARMACY	Donald Brandt Casey	2060 N CHURCH AVE 247	HARRAH	OK	73045	405-4542476
BESTYET PHARMACY HM	Lonny Wilson	19671 NE 23RD STREET	HARRAH	OK	73045	405-4546261
HENRYETTA DRUG	RYAN RITTER	623 W. MAIN ST	HENRYETTA	OK	74437	918-6523361
HINTON PHARMACY	GREG GEORGE	407 N BROADWAY/POB 578	HINTON	OK	73047	405-5426222
CLINIC PHARMACY	Derek Woods	509 E CHESTNUT ST	HOLLIS	OK	73550	580-6882257
HUGO FAMILY PHARMACY	AMY HAMMONDS	420 E JACKSON ST	HUGO	OK	74743	580-3268337
HUGO EXPRESS PHARMACY	RYAN RITTER	1200 E JACKSON AVENUE	HUGO	OK	74743	580-3261600
IDABEL EXPRESS PHCY	Susan Ritter	810 SE WASHINGTON ST	IDABEL	OK	74745	580-8890230
INOLA DRUG INC	DREW TURNER	19 W COMMERCIAL/POB 700	INOLA	OK	74036	918-5438777
V & V DRUG HM	Kevin Culver	453 S MAIN	JAY	OK	74346	918-2534519
KANSAS PHARMACY, LLC	DREW TURNER	1119 E TULSA AVE	KANSAS	OK	74347	918-8686162
NEW SPRING PHARMACY	Kyle Rackley	3462 W 151ST ST S	KIEFER	OK	74041	918-9380440
DENNIS EXPRESS PHARMACY	CHRISTY SCHELLENBERG	1308 S MAIN	KINGFISHER	OK	73750	405-3755400
MEDIC PHCY & GIFTS	GREG HUENERGARDT	119 W ADMIRE	KINGFISHER	OK	73750	405-3756739
HERITAGE PHARMACY	Ryan Ritter	1309 S. MAIN STREET	KINGFISHER	OK	73750	405-3756300
KINGSTON PHARMACY	AJ Asgari	7 NORTH MAIN ST. PO BOX 548	KINGSTON	OK	73439	580-5642337
MEDIC DRUG AND GIFTS	Greg Huenergardt	102 W JANE JAYROE	LAVERNE	OK	73848	580-9213373
EASTSIDE CLINIC PHCY HM	Brent Brennon	3612 SE LEE BLVD	LAWTON	OK	73501	580-3556400
SHERIDAN EXPRESS PHCY	Darrell Woodson	205 S SHERIDAN ROAD	LAWTON	OK	73505	580-2480300
KEN'S RX HM	Ken Hawkins	802 WEST GORE	LAWTON	OK	73501	580-3534113
LAWTON HERITAGE COMP PHCY	LeeAnn Curet	12 NW SHERIDAN RD	LAWTON	OK	73505	580-3549860
ANDERSON PHCY AND ACCENTS	SHAWN ANDERSON	5366 NW CACHE RD STE 1	LAWTON	OK	73505	580-5959500

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
AMERICAN AFFORDABLE DRUGS	MOHAMED AHMED	32866 US HIGHWAY 19 N	PALM HARBOR	FL	34684	727-2022217
PALMS PHARMACY	ANAND TRIPATHI	3491 SOUTH CONGRESS AVE	PALM SPRINGS	FL	33461	561-5139161
PANAMA CITY DRUGS	MAGED SHALABY	3127 E HWY 98	PANAMA CITY	FL	32401	850-6155000
CALLAWAY GULF COAST PHCY	Maged Shalaby	420 N TYNDALL PKWY	PANAMA CITY	FL	32404	850-6153000
GULF COAST PHCY HM	Maged Shalaby	340 W 23RD ST #D2	PANAMA CITY	FL	32405	850-6151000
COOPER'S DRUGS, INC,	PAULA NORMAN	700 EAST BUSINESS HWY 98	PANAMA CITY	FL	32401	850-7850251
JAY CARE PHARMACY	Susheel Janga	1212 W 23RD STREET	PANAMA CITY	FL	32405	850-6404810
PILL BOX PINES WEST	BARBARA SAMMARCO	17503A PINES BLVD	PEMBROKE PINES	FL	33029	954-4437455
SIMFAROSE PHARMACY	Charles Bonanno	10016 PINES BLVD	PEMBROKE PINES	FL	33024	954-4357200
PINES HEALTHMART PHARMACY	MOHAMMED ARSHAD	2301 N UNIVERSITY DR STE 112	PEMBROKE PINES	FL	33024	954-4046610
A & A FAMILY PHARMACY	Navneet Johar	7936-38 PINES BLVD	PEMBROKE PINES	FL	33024	954-9875230
U TRUST PHARMACY	Osita Ezenwa	6974 PEMBROKE RD	PEMBROKE PINES	FL	33023	954-5890585
TRUST PHARMACY	RANIA SUNNA	9833 PINES BLVD	PEMBROKE PINES	FL	33024	954-4362359
PILL BOX PHARMACY HM	Tayler Zocco	1700 NW 122 TERRACE	PEMBROKE PINES	FL	33026	954-4327455
CORE HEALTH PHARMACY	Uche Ezenwa	11260 PINES BLVD	PEMBROKE PINES	FL	33026	954-4508873
ANDERSON'S THRIF-T DRUGS	DARRELL MILLER	4350 BAYOU BLVD STE 5	PENSACOLA	FL	32503	850-4844338
FIRST CITY DRUGS	Derek Stephens	6005 COLLEGE PKWY STE 1	PENSACOLA	FL	32504	850-7239403
JACKSON-PACE PHCY	STEVEN JACKSON	2256 W NINE MILE ROAD	PENSACOLA	FL	32534	850-4784450
ALEXANDER PHCY	MONGTRINH HUYNH	6540 PARK BLVD	PINELLAS PARK	FL	33781	727-6230962
VISTACARE II	Nazir Hassan	7599 PARK BLVD #100	PINELLAS PARK	FL	33781	727-9992067
NP PHARMACY	Thinh Nguyen	7644 PARK BLVD N	PINELLAS PARK	FL	33781	727-6850268
OSBORNE PHARM II INC	Chris Osborne	201 NW 82ND AVE STE 101	PLANTATION	FL	33324	954-4743887
OSBORNE PHARM INC HM	Chris Osborne	333 NW 70TH AVE STE 102	PLANTATION	FL	33317	954-7912000
XXA INTRAMED	LAWRENCE PIZIK	6950 CYPRESS RD #105	PLANTATION	FL	33317	954-9667578
K&M DRUGS SOLIVITA	Haitham Kaki	395 VILLAGE DRIVE SUITE C	POINCIANA	FL	34759	863-4967930
DRUGS 4 LESS, INC HM	Amir Serri	1247 S POWERLINE ROAD	POMPANO BEACH	FL	33069	954-9721822

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
CORNER DRUG	MARGARET PERKINS	100 E MAIN	MADILL	OK	73446	580-7953376
MANNFORD PHARMACY	Kimberly Tilley	231 W TROWER BLVD	MANNFORD	OK	74044	918-8657400
MARIETTA PHARMACY	RYAN RITTER	300 S HWY 77	MARIETTA	OK	73448	580-2765555
MARLOW MEDICINE	CHRIS SHELBY	129 N BROADWAY	MARLOW	OK	73055	580-6586060
NEWBERRY EXPRESS PHARMACY	RYAN RITTER	801 S. BROADWAY	MARLOW	OK	73055	580-6583784
JACKS RX HM	Jack Justice	500 WILLIAMS ST	MAYSVILLE	OK	73057	405-8674427
HUGHES PHARMACY	STEVEN HUGHES	107 EAST CHEROKEE	MEDFORD	OK	73759	580-3953116
CREST RX PHARMACY	JACK JUSTICE	249 N DOUGLAS BLVD	MIDWEST CITY	OK	73130	405-7414411
VALU-MED PHARMACY	LONNY WILSON	1212 A S DOUGLAS BLVD	MIDWEST CITY	OK	73130	405-7411200
WILSON PHARMACY	MARSHALL MATLOCK	911 S AIR DEPOT BLVD	MIDWEST CITY	OK	73110	405-7373464
MOORE RX	JEFF MCDOWN	2018 S I-35 SERVICE RD	MOORE	OK	73160	405-7355101
MEDS AND MOORE PHCY	Matthew Finn	1280 N EASTERN AVE STE F	MOORE	OK	73160	405-7355160
GADDY DRUG HM	Dave Carter	1126 W BROADWAY	MUSKOGEE	OK	74401	918-6825584
NICHOLS HILLS DRUG	AJ Asgari	7600 N WESTERN AVE	NICHOLS HILLS	OK	73116	405-8439501
DAVE'S HEALTHMART PHCY	DIVYESH (DAVE) PATEL	329 N PORTER AVENUE	NORMAN	OK	73071	405-3608882
SOVEREIGN PHCY SOLUTIONS	NANCY PHELPS	2080 HWY 9 WEST	NORMAN	OK	73072	405-3226868
DOCTORS PARK PHARMACY	Wende Posey	500 E ROBINSON ST STE 200	NORMAN	OK	73071	405-3645020
CITY DRUG	Wyatt Lively	128 E CHEROKEE	NOWATA	OK	74048	918-2733825
KRITTENBRINK PHARMACY	Brian Scheiber	315 KANSAS AVE	OKARCHE	OK	73762	405-2634433
LUCKIE DRUG	JIM LUCKIE	116 N MAIN STREET/PB 549	OKEENE	OK	73763	580-8223789
OKEMAH PHARMACY	RYAN RITTER	106 S. WOODY GUTHRIE ST.	OKEMAH	OK	74859	918-6232510
CHRIS EXPRESS DRUG	CHRISTOPHER PHILLIPS	12032 S WESTERN AVE	OKLAHOMA CITY	OK	73170	405-7353950
MEDIC PHARMACY-HEFNER PTE	Clay Moore	11101 HEFNER POINT DR 101	OKLAHOMA CITY	OK	73120	405-7553921
PREFERRED RX	Craig Patel	1111 LEE AVE STE 105	OKLAHOMA CITY	OK	73103	804-4335770
CLYDE PHARMACY	Greg Clyde	7158 NW 112TH	OKLAHOMA CITY	OK	73162	405-5176104
CREST PHARMACY HM	Jack Justice	10601 SOUTH MAY AVE STE11	OKLAHOMA CITY	OK	73170	405-3787171

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
DAVID'S PHCY & SURGICAL	DAVID ANDREWS	1637 NE 36TH ST	POMPANO BEACH	FL	33064	954-9420920
A1A PHARMACY	Jay Griffin	200 C SOLANA RD	PONTE VEDRA BEACH	FL	32082	904-3730835
PORT ORANGE PHARMACY	Emad Kamel	5820 S WILLIAMSON BLVD #2	PORT ORANGE	FL	32128	386-6894189
COMMUNITY PHY PORT ORANGE	Kalpesh Patel	3755 S NOVA RD UNIT A	PORT ORANGE	FL	32129	386-2563177
STAYWELL PHARMACY	BENNY GEORGE	10112 US HIGHWAY 19	PORT RICHEY	FL	34668	727-3784548
SUNTRUST PHARMACY	BINU CHERIYAN	6237 RIDGE ROAD	PORT RICHEY	FL	34668	727-9145900
PA GROUP INC	RADHIKA Patel	11618 US HIGHWAY 19	PORT RICHEY	FL	34668	727-8198200
VALU HLTH BUTTRFLD DRG HM	David Wright	1770 SE HILLMOOR DR	PORT SAINT LUCIE	FL	34952	772-4461100
ASTER DISCOUNT PHARMACY	SONIA SHARMA	718 SW PT ST LUCIE BLVD UNIT 2	PORT SAINT LUCIE	FL	34953	772-7772141
BUY RITE DRUGS #4	PAULA NORMAN	302 CECIL G COSTIN SR BLVD	PORT ST JOE	FL	32456	800-5555555
EASTPORT PHARMACY	HASS BAZZI	8972 SOUTH US HWY 1	PORT ST LUCIE	FL	34952	772-8007267
CROSTOWN PHARMACY	Lydell Morrison	8701 S US HIGHWAY 1	PORT ST LUCIE	FL	34952	772-3011095
NEW LIFE PHARMACY	Ricardo Reid	11200 SW VILLAGE PKWY STE 100	PORT ST LUCIE	FL	34987	772-8771125
FLORESTA PHARMACY	Urmil Shah	1550 SE FLORESTA DRIVE	PORT ST LUCIE	FL	34983	772-3404142
RX OASIS	Todd Tortoretti	9304 BALM RIVERVIEW RD	RIVERVIEW	FL	33569	813-6776000
MAIN STREET PHARMACY	CYNTHIA COMBER	531 MAIN STREET STE K	SAFETY HARBOR	FL	34695	727-3307530
PRESCRIPTIONS UNLIMITED	Eric Larson	2521 13TH ST STE A	SAINT CLOUD	FL	34769	407-8927166
SOUTHCARE PHARMACY HM	Carly Hingson	6499 38TH AVE N STE A1	SAINT PETERSBURG	FL	33710	727-3443902
ISLAND PHARMACY HM	Reggie Mathai	2330 PALM RIDGE ROAD #12	SANIBEL	FL	33957	239-4726188
HEDGES PRESCRIPTION SH HM	Chris Mottram	24 NORTH LIME AVE	SARASOTA	FL	34237	941-3662424
AMERICA'S PHARMACY	ELDER SORIA	3470 17TH ST	SARASOTA	FL	34235	941-9557700
HEALTHY LIVING PHARMACY	Hieu Khuc	7648 LOCKWOOD RIDGE ROAD	SARASOTA	FL	34243	941-2183088
CAREPLUS PHARMACY	Gerges Shanad	13260 US HIGHWAY 1	SEBASTIAN	FL	32958	772-5716496
GILBERT DRUG HM	Jack Kasmer	2190 LAKEVIEW DRIVE	SEBRING	FL	33870	863-3850741
SNEADS PHARMACY	BRIAN LEWIS	7995 HWY 90	SNEADS	FL	32460	850-5935288
DAYTONA DISCOUNT PHARMACY	MIKE PATEL	815 BEVILLE RD STE D	SOUTH DAYTONA	FL	32119	386-3225969
MEDWELL PHARMACY	Sunny Aggarwal	801 BEVILLE RD STE 103	SOUTH DAYTONA	FL	32119	386-8684050

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
JIM'S TOWER PHCY	JIM BRAKEBILL	1044 SW 44TH #103	OKLAHOMA CITY	OK	73109	405-6319625
OXFORD PHARMACY	Kiet Nguyen	6001 S SOONER RD #B	OKLAHOMA CITY	OK	73135	405-3512264
ASBURY PHARMACY	LAURA CUDD	3401 NORTH MAY AVENUE	OKLAHOMA CITY	OK	73112	405-8436691
EPIC PHARMACY	Victor Panara	2249 NW 39 ST	OKLAHOMA CITY	OK	73112	405-7247852
NEIGHBORHOOD PHARMACY	Zoreh Eskandari	3122 NORTH MAY AVE	OKLAHOMA CITY	OK	73112	405-6048010
OKMULGEE DISCOUNT PHCY	DON RITTER	1160 SOUTH BELMONT	OKMULGEE	OK	74447	918-7561223
REAVIS SUPER DRUG HM	Jack Justice	110 BURR AVENUE	PAULS VALLEY	OK	73075	405-2387391
LEGACY DRUG	Julie Justice	111 WEST GRANT AVE	PAULS VALLEY	OK	73075	405-2383305
PIEDMONT PHCY & GIFTS	JOHN SMITH	97 GOODER SIMPSON BLVD	PIEDMONT	OK	73078	405-3733090
THE PHARMACY OF POCOLA	CLAY HAISTEN	102 E FOLSOM BLVD	POCOLA	OK	74902	918-4362900
TONI'S WESTSIDE HEALTHMRT	TONI GIBSON	301 W GRAND	PONCA CITY	OK	74601	580-7654456
D&D PHARMACY	DOUG HORNE	1940 N BROADWAY	POTEAU	OK	74953	918-6473137
HOMETOWN DRUG CO LLC	JASON CARTER	307 N BROADWAY	POTEAU	OK	74953	918-6472349
ELLIOTT PLAZA PHARMACY	DREW TURNER	510 SOUTH ELLIOTT	PRYOR	OK	74361	918-8252225
THE CROSS PHARMACY	Randy Quattlebaum	1101 NE 1ST ST	PRYOR	OK	74361	918-8241300
UNITED DISC DG OF PURCELL	Jack Justice	1602 N GREEN AVENUE	PURCELL	OK	73080	405-5275900
TURNER DRUG	JULIE JUSTICE	1300 N GREEN AVE	PURCELL	OK	73080	405-5272107
MOORE DRUG	TOMMY HILDERBRANT	101 WEST MAIN STREET	RINGLING	OK	73456	580-6622366
JOHNNYS HOMETOWN PHCY	Chris Isbell	303 E RAY FINE BLVD #1	ROLAND	OK	74954	918-4270400
CLIF'S PHARMACY	MIKE MEECE	505 E REDWOOD	SALLISAW	OK	74955	918-7760100
PILL BOX PHARMACY	Melinda Mast	1329 S MAIN ST STE C	SAPULPA	OK	74066	+18-0055555
SEMINOLE DRUG	KERRY KINCAID	1717 N MILT PHILLIPS AVE	SEMINOLE	OK	74868	405-8083226
MEDIC PHARMACY HM	Greg Huenergardt	522 S MAIN	SHATTUCK	OK	73858	580-9382854
HOOVER DRUG, INC. HM	Teresa Huggins	1505 E MAIN ST STE C	STIGLER	OK	74462	918-9678321
CENTRAL DRUG	Chad Bayer	1220 W 12TH AVE	STILLWATER	OK	74074	405-3726120
STILWELL PHARMACY HM	Mike Pinkerton	202 S SECOND STREET	STILWELL	OK	74960	918-6962500
BAYLESS DRUG CO HM	Jack Justice	120 W. MAIN POB 150	STRATFORD	OK	74872	580-7592312

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
PRIME CARE PHARMACY LLC	Ashish Dua	2176 MARINER BLVD	SPRING HILL	FL	34609	352-6008083
ULTIMATE PHARMACY	Mohabi HARAKA	1250 MARINER BLVD	SPRING HILL	FL	34609	352-2133815
SPRING HILL PHARMACY	PARVINDER KAINTH	10475 COUNTY LINE RD	SPRING HILL	FL	34609	352-6006699
SUPER SAVER PHARMACY	Austin Sharp	924 CENTRAL AVE	ST PETERSBURG	FL	33705	727-5652299
PRIME RX PHARMACY	KAMLESH RAJANI	4860 48TH AVE N	ST PETERSBURG	FL	33714	727-5223222
DANANG PHARMACY	Nga Ho	5944 34TH ST N STE 1	ST PETERSBURG	FL	33714	727-6239854
BAILEYS PHY MED HOTSPOTS	Trisha Bailey	3065 34TH ST N STE B	ST PETERSBURG	FL	33713	727-2561416
MADISON STREET PHARMACY	Kiran Kali	395 WEST MADISON STREET	STARKE	FL	32091	904-9647774
APOTHECARY PHARMACY LLC	Emad Baydoun	4749 34TH ST	STPETERSBURG	FL	33711	727-3298868
HANSA PHARMACY LLC	Chiranjivi Jannu	1111 SE FEDERAL HWY # 122	STUART	FL	34994	904-5511552
SEWALL'S POINT PHARMACY	Cristal Totterman	3754 SE OCEAN BLVD STE B	STUART	FL	34996	772-6008077
PARK DRUG HM	Edward Justice	700 E OCEAN BLVD	STUART	FL	34994	772-2873201
VILLAGES PHARMACY	Irene Nada	17860 109TH AVE 616A	SUMMERFIELD	FL	34491	772-3219963
SUNRISE PHARMACY	Hiral Patel	139 S PEBBLE BCH BLVD 103	SUN CITY CENTER	FL	33573	813-6338222
SUNEXPRESS PHARMACY INC	Mohammed Visoughi	4051 UPPER CREEK DR STE102	SUN CITY CENTER	FL	33573	813-2961333
SUPERIOR CARE PHARMACY	Son Nguyen	765 CORTARO DR	SUN CITY CENTER	FL	33573	813-5512999
FAST MED HM	Deysi Cavanaugh	8237 SUNSET STRIP	SUNRISE	FL	33322	954-7416644
EASTWOOD PHARMACY INC	Anna Pawelczyk	1605 EAST PLAZA DR	TALLAHASSEE	FL	32308	850-8777108
WELLPACK PHARMACY	Kalpendra Patel	1624 CAPITAL CIRCLE NE	TALLAHASSEE	FL	32308	850-7654026
ARTHUR'S 'ORIGINAL' PHCY	Arthur Goldglantz	5816 N UNIVERSITY DR	TAMARAC	FL	33321	954-7261911
TAMARAC PHARMACY	HARNI PATEL	7120 N NOB HILL RD	TAMARAC	FL	33321	954-5864546
RX MARINE	Lenny Sigler	7800 N. UNIVERSITY # 103	TAMARAC	FL	33321	786-3107099
MORRISON'S RX INC	Marilyn Morrison	7535 W OAKLAND PARK BLVD	TAMARAC	FL	33319	954-5785858
DOLLEX PHARMACY	ADOLPHUS AKANIRU	7758 PALM RIVER RD	TAMPA	FL	33619	813-9715551
VISTARA PHARMACY	Arth Joshi	2706 W SAINT ISABEL ST	TAMPA	FL	33607	813-7716075
PALMA CEIA HM PHCY HM	Brad Esposito	2506 S MACDILL AVE STE A	TAMPA	FL	33629	813-8398700

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
HOBBS PHARMACY	Russell Hobbs	420 W BROADWAY AVE	SULPHUR	OK	73086	580-6222475
CHEROKEE HILLS PHARMACY	JASON CARTER	1607 S MUSKOGEE AVE STE D	TAHLEQUAH	OK	74464	918-4562531
TMC PHARMACY	Shanon Gower	1500 E DOWNING STE 106	TAHLEQUAH	OK	74464	918-4560694
TAHLEQUAH DRUG COMPANY	Shanon Gower	2028 MAHANEY AVE	TAHLEQUAH	OK	74464	918-4310555
THOMAS DRUG & VARIETY CTR	MARK KOURT	145 W BROADWAY	THOMAS	OK	73669	580-6613545
TISHOMINGO EXPRESS PHARMA	Susan Ritter	140 EAST MAIN	TISHOMINGO	OK	73460	580-3712355
FREELAND BROWN PHARMACY	Andrew Kohler	4112 S PEORIA	TULSA	OK	74105	918-7434491
FREELAND BROWN PHCY 3	Andrew KOHLER	4227 SOUTHWEST BLVD	TULSA	OK	74107	918-9868644
ROWLAND PHARMACY	Lindy Rowland	1725 E 19TH ST STE 103	TULSA	OK	74104	918-2364668
COUCH PHARMACY	Scott Evans	444 S SHERIDAN	TULSA	OK	74112	918-8359577
CAREFIRST PHARMACY TULSA	T.J. Marti	6214 S SHERIDAN RD	TULSA	OK	74133	918-9406767
CAREFIRST-GETMAN PHARMACY	T.J. Marti	2516 E 15TH ST	TULSA	OK	74104	918-7286420
APOTHECARY SHOPPE TULSA	TJ Marti	6136 E 51ST ST	TULSA	OK	74135	918-6652003
VIAN PHARMACY	JASON CARTER	401 S THORNTON ST	VIAN	OK	74962	918-7738111
V&V DRUG	AJ Asgari	201 N. SCRAPER ST	VINITA	OK	74301	918-2562541
COTTON COUNTY DRUG	Elizabeth Crew	619 E. MISSOURI	WALTERS	OK	73572	580-8756161
CITY PHARMACY	MARK KOURT	101 N CLARENCE NASH BLVD	WATONGA	OK	73772	580-6234545
SWANNS PHARMACY	MARK KOURT	407 W MAIN	WATONGA	OK	73772	580-6234505
ECK DRUG 25	Bill Eck	101 S MAIN	WAURIKA	OK	73573	580-2282383
EAGLE PHARMACY LLC	CLARK ARGANBRIGHT	3741 LEGACY	WEATHERFORD	OK	73096	580-7723300
HEALTH EXPRESS PHARMACY	JERRY LEE	1001 N WASHINGTON POB948	WEATHERFORD	OK	73096	580-7741200
WEATHERFORD PHCY	MIKE SCHMITZ	101 W MAIN ST/POB 1967	WEATHERFORD	OK	73096	580-7722781
WELEETKA DRUG	GALLEN SHENEMAN	309 W. 9TH ST	WELEETKA	OK	74880	405-7862247
WESTVILLE DRUG COMPANY	Jason Carter	301 S WILLIAMS ST	WESTVILLE	OK	74965	918-7235466
MICK'S FAMILY PHARMACY	Mick Charmason	2116 OKLAHOMA AVE	WOODWARD	OK	73801	580-2543504
WEST POINTE PHARMACY	CHAD HESTON	520 S MUSTANG RD	YUKON	OK	73099	405-2566653

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
QUICK N SAVE PHARMACY 2	Carla RODRIGUEZ	8207 N FLORIDA AVE	TAMPA	FL	33604	813-5495599
MEDWAY PHARMACY	Divyeshkumar Patel	3010 E 138TH AVE STE 102	TAMPA	FL	33613	551-6897139
ADVANCE PHARMACY SERVICE	Doaa Kotb	4910 N. ARMENIA AVE	TAMPA	FL	33603	813-3509999
NORA PHARMACY	Doaa Kotb	7926 W HILLSBOROUGH AV #E	TAMPA	FL	33615	813-4372100
WELLNESS PHARMACY	Gashaw Adane	120 W. BOUGAINVILLE AVE	TAMPA	FL	33612	813-7748856
SOUTHEAST COMPOUNDING PHY	Haresh Patel	3906 CRAGMONT DRIVE, SUITE B	TAMPA	FL	33619	813-6447700
LAND O LAKES PHARMACY	JOBY THOMAS	1931 DR MLK JR BLVD, #D	TAMPA	FL	33607	813-8037303
TAMPA PALMS PHARMACY LLC	JOBY THOMAS	15309 AMBERLY DR	TAMPA	FL	33647	813-2526846
TAMPABAY RX LLC	Joby Thomas	1010 E BUSCH BLVD # 109	TAMPA	FL	33612	352-6781882
HEALTHWISE PHARMACY	Ketan Patel	2708 W WATERS AVE	TAMPA	FL	33614	813-9326337
ROMAT VENTURES INC	Magdi Salhab	1329 E FLETCHER AVE	TAMPA	FL	33612	813-2524443
SENIORCARE COMMUNITY PHCY	Miral Patel	6712 HANLEY RD	TAMPA	FL	33634	813-6844090
VISTACARE PHARMACY	Nazir Hassan	1441 E FLETCHER AVE #113	TAMPA	FL	33612	813-4444410
VISTARA PHARMACY TAMPA	Rajdeep Patel	3134 E HILLSBOROUGH AVE	TAMPA	FL	33610	813-4444666
THE PALMS PHARMACY	SHAHIDA CHOUDHRY	17008 PALM POINTE DRIVE	TAMPA	FL	33647	813-2529063
GOYA PHARMACY	Syed Hassanyar	5802 N ARMENIA AVE # 1	TAMPA	FL	33603	813-7554331
RITE RX CARE	VINAY TANEJA	7520 W WATERS AVE #6	TAMPA	FL	33615	813-4667976
ANCLOTE PHARMACY HM	Chetan Shan	1933 NORTH PINELLAS AVE	TARPON SPRINGS	FL	34689	727-9445800
TARPON DISCOUNT DRUG HM	Steve Haskopoulos	742 SOUTH PINELLAS AVENUE	TARPON SPRINGS	FL	34689	727-9343400
SALHAB PHARMACY	ABDEL SALHAB	12643 56TH ST NORTH	TEMPLE TERRACE	FL	33617	813-5157918
TEMPLE TERRACE PHCY	YVONNE OKEKE	9780 N 56TH ST., STE D	TEMPLE TERRACE	FL	33617	813-3684873
TEQUESTA DRUGS HM	Elizabeth Brumer	1 MAIN ST STE 107	TEQUESTA	FL	33469	561-7418222
PREMIER PHARMACY	Dinesh Khanna	1580 SANTA BARBARA BLVD	THE VILLAGES	FL	32159	352-5613234
LAKE SUMTER LANDING PHCY	Virat Patel	910 OLD CAMP RD STE 170	THE VILLAGES	FL	32162	352-2683454
EAST COAST PHARMACY	Deepak Aggarwal	504 GARDEN ST	TITUSVILLE	FL	32796	321-7470206
ANGELS PHARMACY III	Raj Patel	7455 US-1 STE A	TITUSVILLE	FL	32780	551-3584242

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
CONRAD MARR #6 HM	Craig McAlister	948 SOUTH YUKON PARKWAY	YUKON	OK	73099	405-3542582
UNITED PHARMACY	STEVE WEAVER	901 S CORNWELL	YUKON	OK	73099	405-3545233
MILLER DRUG	WILLIAM "CHRIS" MILLER	11101 SURREY HILLS BLVD	YUKON	OK	73099	405-3731717
BROWNSVILLE PHCY HM	Joe Ervin	411 N. MAIN / P.O. 248	BROWNSVILLE	OR	97327	541-4665112
CRESWELL PHARMACY	Brian Marr	175 OREGON AVE	CRESWELL	OR	97426	541-8952413
RIVER ROAD PHARMACY HM	Brian Marr	884 RIVER ROAD	EUGENE	OR	97404	541-6363522
CORNER DRUG	trushar patel	29670 ELLENSBURG AVE	GOLD BEACH	OR	97444	541-2474544
TRINITY VALLEY PHARMACY	Clarissa Free	2001 FOOTHILL BLVD F3	GRANTS PASS	OR	97526	541-4749437
HERMISTON DRUG	ROBERT MULLAY	114 MAIN STREET	HERMISTON	OR	97838	541-5673072
HOWARDS DRUG HM	Jeff Howard	101 NORTH F STREET	LAKEVIEW	OR	97630	541-9472141
CENTRAL DRUG/BLACK OAK HM	Tim Lichlyter	2924 SISKIYOU, SUITE 102	MEDFORD	OR	97504	541-7735356
POSTAL PHARMACY	Laura Abrahamson	47809 HIGHWAY 58	OAKRIDGE	OR	97463	541-7822617
PHILOMATH FAMILY PHCY HM	SETH PHAN	1640 MAIN STREET	PHILOMATH	OR	97370	541-9292880
FAIRLEYS PHARMACY	An Nguyen	7206 NE SANDY BLVD	PORTLAND	OR	97213	503-2841159
GDC PHARMACY	Nghia Tran	8035 SE HOLGATE BLVD	PORTLAND	OR	97206	503-7886483
DIVISION STREET PHARMACY	Nzeribe Nwokoma	12112 NE GLISAN ST	PORTLAND	OR	97220	800-5555555
BROOKLYN PHARMACY	Pat Hubbell	3131 SE MILWAUKIE AVE	PORTLAND	OR	97202	503-2343488
LOWER UMPQUA HOSP PH HM	Kamy Mahdiyoum	600 RANCH ROAD	REEDSPORT	OR	97467	541-2716370
OAK TREE PHARMACY HM	John Sherman	2940 COMMERCIAL ST SE	SALEM	OR	97302	503-5852877
PHYSICIAN BLDG PHCY HM	TRUSHAR PATEL	1234 COMMERCIAL ST., SE	SALEM	OR	97302	503-3624874
SHADY COVE PHARMACY HM	Tim Lichlyter	21195 HWY 62	SHADY COVE	OR	97539	541-8783151
TILLAMOOK PHARMACY	Trushar Patel	915 MAIN AVENUE	TILLAMOOK	OR	97141	503-8424181
CASCADE PHARMACY HM	Corey Donovan	7591 CRATER LAKE HWY	WHITE CITY	OR	97503	541-8264414
HAMPTON PHCY AND WELLNESS	Jeni Obenrader	4678 WILLIAM FLYNN HWY	ALLISON PARK	PA	15101	412-4267866
TOWNE DRUG HM	Jon Akanowicz	227 COMMERCIAL AVE.	ASPINWALL	PA	15215	412-7822244
BEAVER PHCY HM	ADRIENNE CERVONE	533 3RD ST	BEAVER	PA	15009	724-7740919

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
BEST DRUG OF TRENTON	CARLY BRAND	405 SE 1ST AVE	TRENTON	FL	32693	352-4632240
VERNON DISCOUNT DRUG HM	Jack Paul	3248 MAIN STREET	VERNON	FL	32462	850-5352803
MILLER'S HEALTHMART PHCY	Doug Miller	777 37TH ST STE C-100	VERO BEACH	FL	32960	772-7788585
OSCEOLA PHARMACY	Kazi Imam	1635 14TH AVE	VERO BEACH	FL	32960	772-5623660
COREY'S PHARMACY	MARK FRANKENBERGER	2912 OCEAN DR	VERO BEACH	FL	32963	772-2316931
BAILEY'S PHARMACY	TRISHA BAILEY	780 US 1 SUITE 101	VERO BEACH	FL	32962	772-4928559
MY COMMUNITY PHCY, LLC	Johnny Meier	2615 STATE RD #7 B520-530	WELLINGTON	FL	33414	561-7536768
PROGRESS PHARMACY	Franck Kacou	8170 OKEECHOBEE BLVD #5	WEST PALM BEACH	FL	33411	561-7202676
SCHAEFER DRUG INC	Jay Henley	12797 W FOREST HILL	WEST PALM BEACH	FL	33414	561-7930151
ROBALO SPECIALTY PHARMACY	Nirav Patel	2580 METROCENTRE BLVD STE 5	WEST PALM BEACH	FL	33407	561-8808480
OMRX/BREAK FREE PHCY	Rochelle Houde	4603 OKEECHOBEE BLVD SUITE 118	WEST PALM BEACH	FL	33417	847-4710335
WEST PALM PHARMACY LLC	SALIM SOUFAN	5760 OKEECHOBEE BLVD	WEST PALM BEACH	FL	33417	561-2492130
GARDENS DRUG	TAPAN SHAH	2100 45TH ST SUITE B1	WEST PALM BEACH	FL	33407	561-8411801
CENTER CITY PHARMACY HM	TOM REBHANDL	416 CLEMATIS ST	WEST PALM BEACH	FL	33401	561-8057135
PILL BOX III HM	Wayne Linder	1932 WESTON RD	WESTON	FL	33326	954-3897455
BUY RITE DRUGS #11	PAULA NORMAN	218 SOUTH HWY 71	WEWAHITCH KA	FL	32465	850-6395065
QUICK SCRIPT PHCY HM	Hussein Fawaz	2408 WILTON DRIVE	WILTON MANORS	FL	33305	954-5147685
FORMULA PHARMACY	APURV SHAH	1201 WINTER GD VINELAND 7	WINTER GARDEN	FL	34787	407-6141737
KAY PHARMACY 003	Colin Conner	637 1ST ST S	WINTER HAVEN	FL	33880	863-2688218
NOVA PHARMACY CORP	MAHE MARRERO	950 1ST ST S STE 103	WINTER HAVEN	FL	33880	305-2626682
COLONIAL DRUGS	Krista Adams	6912 ALOMA AVE	WINTER PARK	FL	32792	407-3445588
365 HEALTH LLC	Shant Khanlian	6804 ALOMA AVE	WINTER PARK	FL	32792	407-7447792
TAYLORS PHCY SOUTH PARK	Shelby Owens	306 SOUTH PARK AVE	WINTER PARK	FL	32789	321-2749014
WINTER PARK PHARMACY	SHRUTI PATEL	3090 ALOMA AVE STE 140	WINTER PARK	FL	32792	407-6364670
WINTER SPRINGS PHARMACY	Deepak Aggarwal	5942 RED BUG LAKE RD RD.	WINTER SPRINGS	FL	32708	321-3164615
SIMPLYWELL SPCLTY PHCY	Kevin Bailey	463128 STATE ROAD 200	YULEE	FL	32097	904-8598886

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
BEAVER FALLS PHCY	LINDA DAVIS	1314 7TH AVENUE	BEAVER FALLS	PA	15010	724-3840766
BENSALEM PHARMACY	Kaushal Patel	2112 STREET RD	BENSALEM	PA	19020	215-2444244
BERWICK COMMUNITY PHCY	Harshil Patel	500 FOWLER AVE STE 202	BERWICK	PA	18603	570-5204170
VILLAGE PHCY HM	Richard Carano	1624 EAST POLAND ROAD	BESSEMER	PA	16112	724-6677124
BETHLEHEM PHARMACY	Pradeep Rayapudi	817 E 4TH STREET FL 1	BETHLEHEM	PA	18015	610-4196522
BOSWELL PRESCRIPTION CTR	Jacqueline Martella	210 OHIO STREET	BOSWELL	PA	15531	814-6296624
BRISTOL DISCOUNT PHARMACY	Umesh Patel	247 MILL ST	BRISTOL	PA	19007	267-8125867
POCONO COMMUNITY PHCY 1	Umesh Patel	1656 RT 209 UNIT 6	BRODHEADSVILLE	PA	18322	570-8017886
CAMBRIDGE SPRINGS PHCY HM	Christopher Shearer	227 S MAIN STREET	CAMBRIDGE SPRINGS	PA	16403	814-3984600
MEDICAL ARTS PHARMACY	Haresh Malaviya	220 WILSON ST STE 100	CARLISLE	PA	17013	717-9061246
PENN LAUREL PHCY HM	Jacqueline Martella	112 SUNSHINE AVE.	CENTRAL CITY	PA	15926	814-7545717
CSP PHARMACY INC	Chiranjivi Jannu	2224 W 9TH ST	CHESTER	PA	19013	610-4971015
COATESVILLE COMM PHCY INC	Kenny Patel	260 E LINCOLN HWY	COATESVILLE	PA	19320	610-3833800
COLLEGEVILLE PHARMACY	Harshil Patel	305 SECOND AVE STE 204	COLLEGEVILLE	PA	19426	484-9789009
HATFIELD COMMUNITY PHCY	Harshil Patel	120 BETHLEHEM PIKE #103	COLMAR	PA	18915	267-9568400
NICKMAN'S DRUG 119	JAMES NICKMAN	107 MEMORIAL BLVD	CONNELLSVILLE	PA	15425	724-6288125
BUCHANAN BRO-1-PSSNY HM	Michael Taylor	101 MAIN STREET	COUDERSPORT	PA	16915	814-2748660
POCONO COMMUNITY PHCY 2	Umesh Patel	175 E BROWN ST	EAST STROUDSBURG	PA	18301	570-6648226
BUCHANAN BRO-5 HM	Michael Taylor	170 MAIN ST, PO BOX 265	ELDRED	PA	16731	814-2254723
YORKTOWN PHARMACY	Ankur Shah	8110 OLD YORK RD STE B	ELKINS PARK	PA	19027	267-2820070
BUCHANAN BRO-2-PSSNY HM	Mick Taylor	206 WEST MAIN ST	ELKLAND	PA	16920	814-2587332
NICKMAN'S DRUG #129	JAMES NICKMAN JR	90 W. CHURCH ST.	FAIRCHANCE	PA	15436	724-5647817
FREELAND PHARMACY	Umesh Patel	611 CENTRE ST	FREELAND	PA	18224	570-5262400
GIRARD PHARMACY HM	Pat Harvey Harvey	83 MAIN STREET, WEST	GIRARD	PA	16417	814-7743070
GLADWYNE PHARMACY HM	Burton Zaslow	352 RIGHTER'S MILL RD.	GLADWYNE	PA	19035	610-6491100
RX XPRESS HLTH MART PHCY	Pam Grisnik	111 MILL STREET	GROVE CITY	PA	16127	724-4588420

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
ZEPHYRHILLS PHARMACY	Bhagavan Gottipati	36600 STATE RD 54	ZEPHYRHILLS	FL	33541	813-8157000
SOUTH LAKE PHARMACY	HECTOR MEDRANO	38101 5TH AVE	ZEPHYRHILLS	FL	33542	813-3955667
FORD'S PHARMACY HM	Michelle Ford	7441 ADAIRSVILLE HWY	ADAIRSVILLE	GA	30103	770-7731800
CHANCY DRUGS ADEL HM	Hugh Chancy	307 N HUTCHINSON AVE	ADEL	GA	31620	229-8964564
U SAVE IT - ADEL	PAULA NORMAN	714 W 4TH STREET	ADEL	GA	31620	229-8961602
U SAVE IT #1 - DOWNTOWN	PAULA NORMAN	400 N JEFFERSON STREET	ALBANY	GA	31701	229-4358351
U SAVE IT #2 - PALMYRA	PAULA NORMAN	2112 PALMYRA ROAD	ALBANY	GA	31701	229-4394939
U SAVE IT #3 - DAWSON RD	PAULA NORMAN	1315 DAWSON ROAD PO 72148	ALBANY	GA	31708	229-4361518
U SAVE IT - NORTHWEST	PAULA NORMAN	2624 MEREDYTH DRIVE	ALBANY	GA	31707	229-4352328
U SAVE IT - SOUTH ALBANY	PAULA NORMAN	1310 NEWTON ROAD	ALBANY	GA	31701	229-4355199
CARVER DRUG COMPANY	Phil Carver	135 GA HWY 32 BYPASS	ALMA	GA	31510	912-6327455
CLINIC DRUG STORE HM	Lee Pinnell	1001 E FORSYTH STREET	AMERICUS	GA	31709	229-9244538
RAINES PHARMACY	Christopher Brown	346 E WASHINGTON AVENUE	ASHBURN	GA	31714	229-5672515
VILLAGE DRUG SHOP ATHENS	Chris Thurmond	740 PRINCE AVE	ATHENS	GA	30606	706-5484444
VILLAGE DRUG AT ADVANTAGE	Christopher Thurmond	240 MITCHELL BRIDGE RD	ATHENS	GA	30606	706-8504955
HORTON-REID DRUG CO	JIM STOWE	101 EAST CLAYTON STREET	ATHENS	GA	30601	706-5433454
HODGSON'S PHARMACY HM	Rabun Neves	1260 S MILLEDGE AVE # F-1	ATHENS	GA	30605	706-5437386
THE PHCY PIGGLY WIGGLY AT	Robert Stinson	484 NORTH AVENUE	ATHENS	GA	30601	706-5104040
EXCELSIOR SPECIALTY PHCY	Amit Raval	3652 CHAMBLEE DUNWOODY ROAD STE 3	ATLANTA	GA	30341	470-2228320
PRIME PHARMACEUTICALS	Craig Burks	5505 P'TREE DUNWOODY G95	ATLANTA	GA	30342	404-2509656
CONCORD DRUGS EMORY	Jonathan Marquess	550 PEACHTREE ST NE #1450	ATLANTA	GA	30308	404-5234908
CONCORD CARLTONS PHARMACY	LAURENCE BROOME JR	5484 CHAMBLEE DUNWOODY RD	ATLANTA	GA	30338	770-3943233
WENDER & ROBERTS 2WPF HM	Loren Pierce	1262 WEST PACES FERRY RD	ATLANTA	GA	30327	404-2377551
DRUG-SVC CARE INC/TUXEDO	NAAVA LIEBER	164 W WIEUCA RD, SUITE 7	ATLANTA	GA	30342	404-2553022
BRIARCLIFF PHARMACY	PAM MARQUESS	2724 CLAIRMONT ROAD	ATLANTA	GA	30329	404-7280092

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
HALLSTEAD FAMILY PHARMACY	Neal Juraska	36 ROSE ST	HALLSTEAD	PA	18822	570-8799553
UPTOWN DISCOUNT DRUG	Prasad Mattupali	2336 N 3RD ST	HARRISBURG	PA	17110	717-2369999
LEHIGH CARE PHCY	Harshil Patel	59 W JUNIPER ST	HAZLETON	PA	18201	570-4974970
YOCUMS PHARMACY	Harshil Patel	1749 E BROAD ST	HAZLETON	PA	18201	570-4541135
WHITMAN PHARMACY HM	Jerry Whitman	4950 OLD YORK RD-BOX 299	HOLICONG	PA	18928	215-7948850
NICKMANS DRUG, #149	JAMES NICKMAN JR	1238 NATIONAL PIKE RD.	HOPWOOD	PA	15445	724-4372353
POTOMAC VALLEY PHCY 2	SHESHU METTU	138 WASHINGTON STREET	HYNDMAN	PA	15545	814-8423201
MARTELLA'S PHCY HM	Jaqueline Martella	1079 FRANKLIN ST	JOHNSTOWN	PA	15905	814-5351833
MARTELLA'S PHCY #2	JOE MARTELLA	1932 WILLIAM PENN AVENUE	JOHNSTOWN	PA	15909	814-3221011
KOP COMMUNITY PHARMACY	Harshil Patel	580 SHOEMAKER RD STE 140	KING OF PRUSSIA	PA	19406	267-9526200
KINGSTON COMMUNITY PHCY	BHAVNA PATEL	511 PIERCE ST UNIT 1	KINGSTON	PA	18704	570-7143641
COOKS PHARMACY	James Gaudino	777 WYOMING AVE	KINGSTON	PA	18704	570-2883633
ADVOCATE PHARMACY	RUTA PATEL	535 SOUTH BROAD STREET	LANSDALE	PA	19446	215-3622479
LEECHBURG PHCY HM	Alex Micklow	165 MARKET STREET	LEECHBURG	PA	15656	724-8421771
LEHIGHTON PHARMACY	Umesh Patel	428 S 7TH ST STE 3	LEHIGHTON	PA	18235	484-2745428
NICKMAN'S DRUG #109	JAMES NICKMAN	3 NICKMAN'S PLAZA	LEMONT FURNACE	PA	15456	724-4371179
NU WAY PHARMACY	Jignesh Patel	1639 HAINES RD	LEVITTOWN	PA	19055	215-5470250
VIP PHARMACY	Kaushal Patel	7737 NEW FALLS RD	LEVITTOWN	PA	19055	215-4867300
FAMILY 1 PHARMACY	Kaushal Patel	4005 VETERANS HIGHWAY	LEVITTOWN	PA	19056	215-9432221
PENNSBURY PHARMACY	KENNETH LEE	8545 NEW FALLS RD	LEVITTOWN	PA	19054	215-5472378
BURRELL PHARMACY HM	Alex Micklow	2889 LEECHBURG ROAD	LOWER BURRELL	PA	15068	724-3341067
LUZERNE DISCOUNT PHCY	Rinkal Patel	101 MAIN ST STE D	LUZERNE	PA	18709	570-7637813
MARIENVILLE PHCY HM	Ann Brooks	120 CHERRY ST PO BOX 434	MARIENVILLE	PA	16239	814-9278700
NICKMAN'S DRUG #139	JAMES NICKMAN	1878 MCCLELLANDTOWN RD	MASONTOWN	PA	15461	724-9521040
BRIGHTON PHARMACY HM	Harry Davis	525 5TH AVENUE	NEW BRIGHTON	PA	15066	724-8477979

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
LEES FAMILY PHARMACY	STEDMAN LEE	2600 MLK JR DR SW STE 103	ATLANTA	GA	30311	404-6968330
SURREY CENTER PHCY	Courtnee Russ	483 HIGHLAND AVE	AUGUSTA	GA	30909	800-5555555
PEACH ORCHARD DRUGS	TERRI FORDHAM	2529 PEACH ORCHARD RD	AUGUSTA	GA	30906	706-7983253
LIVING WELL PHARMACY	VICTOR JOHNSON	3736 MIKE PADGETT HWY	AUGUSTA	GA	30906	706-2624455
WEST COBB SPECIALTY PHCY	Jitendra Chaudhari	1700 HOSPITAL S DR STE 100	AUSTELL	GA	30106	470-2228320
PHYSICIANS PHARMACY	Jonathan Marquess	3875 AUSTELL RD STE 302	AUSTELL	GA	30106	770-9449101
THOMAS DRUG	RYAN CHAVERS	2704 JEFFERSON STREET	AUSTELL	GA	30168	770-9443100
RELIABLE PHARMACY	SAMUEL TAKOR	3999 AUSTELL ROAD	AUSTELL	GA	30106	770-8190032
BALDWIN PHARMACY	Ryan Gurley	1667 WILLINGHAM AVE	BALDWIN	GA	30511	706-7787174
BALL GROUND PHARMACY HM	Jeff Richardson	470 VALLEY ST STE #100	BALL GROUND	GA	30107	770-7356161
STAN'S PHARMACY	STAN SMITH	438 W PARKER ST	BAXLEY	GA	31513	912-3671155
BLUE RIDGE PHARMACY HM	Steve Purvis	6020 APPALACHIAN HWY	BLUE RIDGE	GA	30513	706-6322244
RIVERSTONE PHARMACY	steven purvis	101 RIVERSTONE VISTA	BLUE RIDGE	GA	30513	706-2582294
JOHNSON PHARMACY	MARTY JOHNSON	205 EAST COLLEGE ST	BOWDON	GA	30108	678-2575400
JOHNSONS RIVER PLACE PHCY	Joseph Johnson	2625 OLD WINDER HWY STE H	BRASELTON	GA	30517	770-9671000
LOVVORN DRUG COMPANY	Brandall Lovvorn	404 ALABAMA AVE	BREMEN	GA	30110	770-5378889
GARRETT DRUG CO HM	Joey Entrekin	116 BUCHANAN STREET	BREMEN	GA	30110	770-5372364
CLAYTON PHARMACY	Leroy Strickland	503 ALABAMA AVE	BREMEN	GA	30110	770-5372321
BECKY'S DRUGSTORE	BECKY POWELL	128 N BROAD STREET	BUENA VISTA	GA	31803	229-6493784
U SAVE IT #8 - BYRON	PAULA NORMAN	101 W WHITE ROAD PO 2090	BYRON	GA	31008	478-9563630
U SAVE IT #9 - CAIRO	PAULA NORMAN	445 9TH AVENUE, SE	CAIRO	GA	39828	229-3774304
CALHOUN DRUG COMPANY	Paul Bryant	450 RED BUD RD NE	CALHOUN	GA	30701	706-6292426
COLLINS FAMILY PHARMACY	Christine C. Collins	92 E BROAD ST	CAMILLA	GA	31730	229-5220180
PHAR MOORE PHARMACY	JONATHAN MARQUESS	3422 SIXES RD STE 106	CANTON	GA	30114	770-2133341
CANTON NORTHSIDE PHCY HM	Robert Bagwell	170 MARIETTA HWY POB 4460	CANTON	GA	30114	770-4792171
SULLIVAN DRUGS	JOHN MAYES	9563 LAVONIA ROAD	CARNESVILLE	GA	30521	706-3842022

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
TOWN & COUNTRY PHY	ANTHONY ROPERTI	2209 FREEPORT RD.	NEW KENSINGTON	PA	15068	724-3352330
DARLINGS OIL CITY PHCY	Chris Darling	811 GRANDVIEW RD STE 200	OIL CITY	PA	16301	814-6880113
RITECHOICE PHARMACY	ADRIAN ACCAY	6328 WOODLAND AVE	PHILADELPHI A	PA	19142	215-7277700
FUTURE PHARMACY INC	ARTHUR KILIMNIK	9831 BUSTLETON AVE #6	PHILADELPHI A	PA	19115	215-6710980
BROAD & LEHIGH PHCY	Brian Snyder	1300 WEST LEHIGH AVE #102	PHILADELPHI A	PA	19132	215-2289007
CARE PLUS PHARMACY	Chin Patel	110 W SUSQUEHANNA AVE	PHILADELPHI A	PA	19122	215-2797295
CAMBRIA PHARMACY	Dhruv Padodara	2860 N 5TH STREET	PHILADELPHI A	PA	19133	215-2252886
APEX PHARMACY	DIVYESH PATEL	7200 FRANKFORD AVE	PHILADELPHI A	PA	19135	215-3385100
LINSKY PHCY J&J MARTIN	Jerry Martin	1701 S 2ND ST	PHILADELPHI A	PA	19148	215-3894148
CENTENNIAL PHARMACY SVC	Joe Dymowski	1020 N DELAWARE AVE	PHILADELPHI A	PA	19125	267-3245347
CENTENNIAL PHY BRIDESBURG	Joseph Dymowski	2660 LEFEVRE ST	PHILADELPHI A	PA	19137	215-5354111
PENNCARE PHARMACY	Joseph Jibi	416 OAK LN RD	PHILADELPHI A	PA	19126	+18-0055555
BROAD AND SNYDER PHCY	Kevin Lam	2108 SOUTH BROAD ST FL 1	PHILADELPHI A	PA	19145	267-3243039
ATLAS PHARMACY	Mike Patel	4925 N 5TH ST	PHILADELPHI A	PA	19120	215-6905400
APOLLO PHARMACY	Mike Patel	460 W LEHIGH AVE	PHILADELPHI A	PA	19133	215-4265100
M R PHARMACY	Ngan Do	2510 N FRONT ST	PHILADELPHI A	PA	19133	215-6343939
COTTMAN 1 PHARMACY	Nikita Patel	1701 COTTMAN AVE	PHILADELPHI A	PA	19111	800-5555555
ANGEL CARE PHARMACY	Olivia Tchanque	7223A RISING SUN AVE	PHILADELPHI A	PA	19111	610-7083858
SS PHARMACY	Rita Patel	8275 BUSTLETON AVE	PHILADELPHI A	PA	19152	215-7225300
LANSDOWNE COMMUNITY PHCY	Umesh Patel	5936 LANSDOWNE AVE	PHILADELPHI A	PA	19151	215-8772051
FAMILY FARMACIA	Umesh Patel	2916 N 5TH ST	PHILADELPHI A	PA	19133	267-4573222
SILVERMAN PHCY INC HM	William Caracciolo	2501 S 7TH STREET	PHILADELPHI A	PA	19148	215-4653081
WILSON'S PHCY HM	Jeff Wilson	4101 PENN AVE.	PITTSBURGH	PA	15224	412-6216471
BLOOMFIELD DRUG	Kathryn Confer	4727 LIBERTY AVE	PITTSBURGH	PA	15224	412-6824909
NORTH SHORE HEALTH MART	Patrick Davis	127 ANDERSON ST STE 101	PITTSBURGH	PA	15212	724-4947615
CARRICK PHARMACY	RAJ DOBARIYA	2717 BROWNSVILLE RD	PITTSBURGH	PA	15227	412-2060996

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
U SAVE IT #11 - CNTRVILLE	PAULA NORMAN	202 GUNN ROAD	CENTERVILLE	GA	31028	478-9538118
TRACY'S MED CTR #1 APCI	BRETT TRACY	3650 CHAMBLEE TUCKER RD	CHAMBLEE	GA	30341	770-9347703
CARLTON'S PHARMACY HM	Cindy Peoples	101 MURRAY PLAZA	CHATSWORTH	GA	30705	706-6954576
CORNER DRUGS	Jim Richards	430 N 3RD AVE	CHATSWORTH	GA	30705	706-6950444
LIVING WELL PHCY CENTRAL	Paul Bryant	2976 HWY 76 UNIT A	CHATSWORTH	GA	30705	706-6950909
LIVING WELL PHCY EXPRESS	Paul Bryant	824 G I MADDOX PKWY	CHATSWORTH	GA	30705	706-5171901
ZAK PHARMACY	ASHENAFI MARIYE	4600 EAST PONCE DE LEON AVE #E	CLARKSTON	GA	30021	404-5001451
THE DRUG STORE/HIS CARE	Chad Hethcox	305 EAST LONG STREET	CLAXTON	GA	30417	912-7399393
U SAVE IT #12 - CLAYTON	PAULA NORMAN	321 HWY 441 NORTH PO 1469	CLAYTON	GA	30525	706-7823813
CLEVELAND DRUG CO	RAY BLACK	184 WEST KYTLE ST STE A	CLEVELAND	GA	30528	706-2192626
U SAVE IT PHCY-COMMERCE	PAULA NORMAN	1751 N ELM ST	COMMERCE	GA	30529	706-3353111
REAGAN HOME CARE PHCY	Jonathan Marquess	1600 MILSTEAD RD	CONYERS	GA	30012	770-4834727
VALUECARE PHARMACY	Nirmita Patel	2020 EASTSIDE DR STE 206	CONYERS	GA	30013	800-5555555
U SAVE IT #7 - CORDELE	PAULA NORMAN	405 4TH AVENUE EAST	CORDELE	GA	31015	229-2736422
TIM'S PHARMACY	KIM KAMINSKI	130 MAGNOLIA LANE	CORNELIA	GA	30531	706-7763784
CARMICHAELS OF COVINGTON	GREG HICKMAN	9148-D HWY 278	COVINGTON	GA	30014	678-7124570
GOODSON PHCY HM	Jimmy Goodson	116 MAPLE STREET	CUMMING	GA	30040	770-8875040
BETHELVIEW PHARMACY	Jonathan Marquess	2336 ATLANTA HWY	CUMMING	GA	30040	470-2534893
DACULA PHARMACY HM	Billy Stone	2555 2ND AVENUE NORTH	DACULA	GA	30019	770-3391593
DALLAS PRESCRIPTION SHOP	Thomas Sherrer	537 HARDEE ST	DALLAS	GA	30132	770-5050255
WHITE'S PHCY OF DALTON	Richard Crumpton	2955 B CLEVELAND ROAD	DALTON	GA	30721	706-2599707
FAMILY PHARMACY HM	Tracey Dailey	1100 EAST WALNUT AVENUE	DALTON	GA	30721	706-2266000
JET'S PHARMACY	Trey Stephens	1229 NORTH WAY	DARIEN	GA	31305	912-4373784
DAWSON PHARMACY HM	Charles Scott	101 E. LEE ST./PO BOX 430	DAWSON	GA	39842	229-9952131
MOSELEY DRUG COMPANY	Tara Jackson	412 JOHNSON ST SE	DAWSON	GA	39842	229-9952126
ANCHOR PHARMACY	Varun Patel	2139 LAWRENCEVILLE HWY	DECATUR	GA	30033	404-6008172
THE APOTHECARY HM	Julie Gay	227 W BROAD AVE	DOERUN	GA	31744	229-7825500

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
LEBANON SHOPS PHCY HM	Tom Riley	300 MT LEBANON BLVD	PITTSBURGH	PA	15234	412-3446700
READING COMMUNITY PHCY	Kenny Patel	526 PENN ST	READING	PA	19602	610-7506761
PRESCRIPTION CTR RIDGWAY	michael Depanfilis	223 MAIN STREET	RIDGWAY	PA	15853	814-7733131
ROCHESTER HEALTHMART PHCY	TIMOTHY DAVIS	176 VIRGINIA AVENUE	ROCHESTER	PA	15074	724-9876085
PALMER DRUG STORE	Kaitlyn Sullivan	738 LIL DEER CRK VLY RD	RUSSELLTON	PA	15076	724-2651632
SAXONBURG PHCY	MAURA TRAINOR	115 PITTSBURGH ST.	SAXONBURG	PA	16056	724-3523000
VALLEY CARE PHARMACY	Nimesh Patel	940 JEFFERSON AVE	SCRANTON	PA	18510	570-8002273
SCRANTON PHARMACY	Umesh Patel	311 MULBERRY ST	SCRANTON	PA	18503	570-3447828
COOKS PHARMACY	Frank Lombardo	1909 MEMORIAL HWY	SHAVERTOWN	PA	18708	570-6751191
SHEFFIELD PHCY HM	John Slagle	27 S MAIN ST	SHEFFIELD	PA	16347	814-9683636
SHENANDOAH PHARMACY	Kumal Patel	33 N MAIN ST	SHENANDOAH	PA	17976	703-4245494
SPROUT'S DRUG STORE	Chris Darling	122 E ACADEMY ST	SHINGLEHOUSE	PA	16748	814-6976331
SLIPPERY ROCK PHARMACY	CLINT KASSI	116 NEW CASTLE ST	SLIPPERY ROCK	PA	16057	724-4060800
BUCHANAN BRO-3-PSSNY HM	Michael Taylor	313 MAIN STREET	SMETHPORT	PA	16749	814-8875375
SPARTANSBURG PHCY	CHARLEEN HAJEC	317 MAIN STREET	SPARTANSBURG	PA	16434	814-6542333
DARLING'S SUGAR GROVE	Chris Darling	17 FOREST STREET	SUGAR GROVE	PA	16350	814-4897777
TIONESTA PHARMACY HM	John Slagle	105 FAULKNER DR	TIONESTA	PA	16353	814-7553557
UNION CITY PHCY HM	Tom Reichert	16395 RT 8	UNION CITY	PA	16438	814-4387570
VANDERGRIFT PHCY HM	Alex Micklow	224 LONGFELLOW ST,STE100	VANDERGRIFT	PA	15690	724-5676615
WATERFORD PHARMACY HM	John Slagle	216 HIGH ST/PO BOX 547	WATERFORD	PA	16441	814-7966655
MCCRACKEN PHARMACY	SCOTT ADAMSON	595 E HIGH STREET	WAYNESBURG	PA	15370	724-6275454
BUCHANAN BRO-4 HM	Michael Taylor	122 W MAIN ST	WESTFIELD	PA	16950	814-3672327
WE CARE PHARMACY	Piyush Patel	3671 CRESCENT CT E	WHITEHALL	PA	18052	484-3503999
WIND GAP PHARMACY	Umesh Patel	31 W 1ST ST UNIT B	WIND GAP	PA	18091	610-8814260
MARTELLA'S PHCY WINDBER	JOSEPH MARTELLA	901 GRAHAM AVENUE	WINDBER	PA	15963	814-4679700
ATWOOD PHARMACY	Zahan Akbar	1302 ATWOOD AVE	JOHNSTON	RI	02919	400-3004443
AJ PHARMACY	Charles Agwunobi	1017 SMITH ST	PROVIDENCE	RI	02908	401-4775427

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
ALLCARE PHARMACY LLC	Greg Drake	1004 SOUTH TENNILLE AVE	DONALSONVILLE	GA	39845	229-3834149
MCRAE'S PHCY OF DOUGLAS	Andrew Holt	1002 WEST WARD STREET	DOUGLAS	GA	31533	912-3845255
HOSPITAL DISCOUNT PHCY HM	Derrell Carter	308 WESTSIDE DRIVE	DOUGLAS	GA	31533	912-3840693
SWAINS PHARMACY	Jared Swain	855 BOWENS MILL RD SW STE E	DOUGLAS	GA	31533	912-3811119
MALCOLMS DISCOUNT PHCY	SUSAN PRESTON	250 S. PETERSON AVE	DOUGLAS	GA	31533	912-3841898
MAX BROWN PHARMACY HM	Max Brown	809 N JEFFERSON STREET	DUBLIN	GA	31021	478-2728086
YOO PHARMACY DULUTH	Byung Yoo	3610 PEACHTREE IND #400	DULUTH	GA	30096	770-2991971
EXPRESS PHARMACY	JO KIM	3182 STEVE REYNOLDS BLVD #106	DULUTH	GA	30096	770-5570306
HANA PLUS PHARMACY	Julie Kim Kong	3585 PEACHTREE IND'L BLVD #158	DULUTH	GA	30096	770-8287576
RIELLES PHARMACY	Stephen oseikakoto	3545 PEACHTREE IND BLVD #13	DULUTH	GA	30096	678-6871730
ANCHOR PLUS PHARMACY	Varun Patel	3800 PLEASANT HILL RD STE 2	DULUTH	GA	30096	770-2255077
SHOPPERS PHARMACY	MIKE FAULK	303 SOUTH JEFFERSON ST	EATONTON	GA	31024	706-4856262
HUFF'S DRUG STORE HM	Steve Purvis	136 INDUSTRIAL BLVD	ELLIJAY	GA	30540	706-6357931
LIVING WELL PHCY ETON	Paul Bryant	79 HWY 286 UNIT A	ETON	GA	30724	706-4229355
WILLS DRUG CO FITZGERALD	Alex Willis	134 OCILLA HWY	FITZGERALD	GA	31750	229-4230299
CASTLEBERRY DRUG COMPANY	Jonathan Marquess	67 N LEE STREET	FORSYTH	GA	31029	478-9942051
U SAVE IT #21 - FORSYTH	PAULA NORMAN	438 CABINESS RD STE C	FORSYTH	GA	31029	478-9942015
BATTLEFIELD PHARMACY	PANKAJ PATEL	1543 BATTLEFIELD PKWY	FORT OGLETHORPE	GA	30742	706-9568605
U SAVE IT #14 - FT. VALEY	PAULA NORMAN	609 BLUE BIRD BOULEVARD	FORT VALLEY	GA	31030	478-8258226
LAWRENCE PHARMACY	Christopher Sullens	631 BROAD STREET, SE	GAINESVILLE	GA	30501	770-5320186
MCELVEEN'S PHARMACY	David Stanley	1294 THOMPSON BRIDGE RD #A	GAINESVILLE	GA	30501	770-5347675
MEDICAL PARK PHARMACY	Jackson Woodall	2551 LIMESTONE PKWY	GAINESVILLE	GA	30501	770-5358860
LANIER PHARMACY	Russell Crow	3560 THOMPSON BRIDGE RD	GAINESVILLE	GA	30506	770-5368861
QUICK RX DRUG # 3 EDI	KAREN STEPHENS BROWN	516 US HWY 80 W	GARDEN CITY	GA	31408	912-9665665
STRICKLAND'S PHARMACY	Dennis Strickland	111 E BARNARD ST	GLENNVILLE	GA	30427	912-6542185
GORDON DRUG CO HM	Carl Stanley	240 MILLEDGEVILLE ROAD	GORDON	GA	31031	478-6282425

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
GREEN LINE APOTH OF PROV	Ken Procaccianti	905 N MAIN ST	PROVIDENCE	RI	02904	401-6338100
ANTHONY'S PHARMACY	Peter Solomon	219 MANTON AVE	PROVIDENCE	RI	02909	401-3519495
GREEN LINE APOTHECARY	CHRISTINA PROCACIANTI	245 MAIN STREET	WAKEFIELD	RI	02879	401-3603300
JB PHARMACY II HM	William Rosa	1165 MAIN AVE	WARWICK	RI	02886	401-8611194
SEASIDE PHCY OF WESTERLY	BILL QUIRK	224 POST ROAD	WESTERLY	RI	02891	401-6374577
SAVITZ DRUG STORE HMC	Steve Trumbell	815 WEST GREENWOOD ST #4	ABBEVILLE	SC	29620	864-3662165
HAWTHORNE AIKEN PHARMACY	KRISTIE CASSIDY	210 UNIVERSITY PKWY	AIKEN	SC	29801	803-6482985
OAKS PHARMACY	Hiren Nayak	2116 N HIGHWAY 81	ANDERSON	SC	29621	864-8449370
GOLDEN TOWN PHARMACY	Johnny Capps	2837 HWY 501 E	AYNOR	SC	29511	843-3587777
HIERS DRUG	EDDIE SANDERS	12253 HERITAGE HWY	BAMBERG	SC	29003	803-2454334
MORGAN'S PHCY BATESBURG	Becky Morgan	501 W RAILROAD AVE	BATESBURG	SC	29006	800-5555555
BEAUFORT PHY & COMPOUNDIN	JEREMY SIMMONS	968 RIBAUT RD STE 1	BEAUFORT	SC	29902	843-3793278
CSC COMM PHY BNTSVILLE	Ashley Singleton	999 CHERAW ST	BENNETTSVILLE	SC	29512	843-4567777
FOWLER PHARMACY	DAVID FOWLER	301 E MARKET STREET	BENNETTSVILLE	SC	29512	843-4793831
CSC COMM PHY BSHPVILLE	Ashley Singleton	545 SUMTER HWY	BISHOPVILLE	SC	29010	803-5887960
MCLEOD PHARMACY INC	David Roberson	127 N MAIN ST BOX 111	BISHOPVILLE	SC	29010	803-4846115
BISHOPVILLE DRUG COINC HM	JAMES ALEXANDER	302 SOUTH MAIN STREET	BISHOPVILLE	SC	29010	803-4843784
BRANCHVILLE PHARMACY	STEPHEN UNION	7615 FREEDOM ROAD	BRANCHVILLE	SC	29432	803-2748585
HAWTHORNE CAMDEN PHCY	KRISTIE CASSIDY	2534 BROAD STREET	CAMDEN	SC	29020	803-4258378
PLANTATION PHCY WAPPOO	DEBORAH DAPORE	531 WAPPOO ROAD	CHARLESTON	SC	29407	843-5561994
PLANTATION PHCY ELLIS	DEBORAH DAPORE	776 DANIEL ELLIS DR 2C	CHARLESTON	SC	29412	843-7959554
CSC COMM PHY CHERAW	Ashley Singleton	715 S DOCTORS DR STE A	CHERAW	SC	29520	843-8654080
BLACK'S DRUG STORE	Mark Richards	121 CHURCH ST	CHESTER	SC	29706	803-5812102
HUBBARD YOUNG PHARMACY	Tom Teasley	402 COLLEGE AVENUE	CLEMSON	SC	29631	864-6541771
CLINTON DISCOUNT PHARMACY	PANKAJ RAVANI	202 N BROAD ST	CLINTON	SC	29325	864-3877151
SADLER-HUGHES APOTHECARY	WALTER HUGHES	102 JACOBS HWY	CLINTON	SC	29325	864-8334000

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
U SAVE IT #23 - GRNVILLE	PAULA NORMAN	121 S COURT SQUARE	GREENVILLE	GA	30222	706-6724221
U SAVE IT PHCY GRIFFIN	PAULA NORMAN	222 WEST POPLAR ST	GRIFFIN	GA	30224	770-2277772
CHANCY DRUGS HAHIRA HM	Bert Chancy	205 EAST MAIN ST	HAHIRA	GA	31632	229-7943525
MOYE'S PHARM/HAMPTON HM	LOREN PIERCE	34 E MAIN ST S	HAMPTON	GA	30228	770-9465172
HARTWELL DRUGS	Lance Boles	118 ATHENS ST	HARTWELL	GA	30643	706-3765801
HARDIES DRUG STORE	Brian Bridges	38 S TALLAHASSEE ST	HAZLEHURST	GA	31539	912-3752545
MITCHS PHARMACY	Mitch Herrington	5 E COFFEE ST	HAZLEHURST	GA	31539	912-6993784
HIAWASSEE HOMETOWN PHCY	Jaime Pierson	230 CHATUGE WAY	HIAWASSEE	GA	30546	706-8961924
HOMER DRUGS, LLC	Ryan Gurley	1228 HISTORIC HOMER HWY	HOMER	GA	30547	706-6773223
JACKSON PHARMACY	STEVEN PURVIS	170 JOHN RANDOLPH DR	HOSCHTON	GA	30548	706-6580064
MOYES PHARMACY - JACKSON	Lee Echols	227 S MULBERRY ST	JACKSON	GA	30233	770-9575561
JASPER DRUG STORE HM	Jack Dunn	1 NORTH MAIN STREET	JASPER	GA	30143	706-6926427
CRAWFORD W LONG PHCY	Fred Gurley	86 N PUBLIC SQ	JEFFERSON	GA	30549	706--367-52
JEFFERSON DRUGS / K&C	Keith Chapman	23 LEE STREET	JEFFERSON	GA	30549	706-3675221
OH PHARMACY	Min Oh	10820 ABBOTTS BRIDGE RD STE 240	JOHNS CREEK	GA	30097	470-2234775
DRUGBUDDIES PHY	Fabian Agbonjiazoe	6457 TARA BLVD STE 7	JONESBORO	GA	30236	678-5192030
ARROWHEAD DRUGS / REFF	Ola Reffell	188 C UPPER RIVERDALE RD	JONESBORO	GA	30236	770-6035555
KENNESAW RX	Ritesh Patel	2851 COBB PARKWAY STE 107	KENNESAW	GA	30152	800-5555555
CHANCY DRUGS-LAKE PK HM	Hugh Chancy	453 LAKES BLVD	LAKE PARK	GA	31636	229-5599394
RX PLUS PHARMACY	Jonathan Marquess	738 OLD NORCROSS ROAD STE A	LAWRENCEVILLE	GA	30046	678-8782087
U SAVE IT #4 - LEESBURG	PAULA NORMAN	100 TABITHA STREET	LEESBURG	GA	31763	229-4366992
LITHIA SPRINGS PHARMACY	JASON JONES	6935 S SWEETWATER RD	LITHIA SPRINGS	GA	30122	770-9485208
EAGLES LANDING PHCY	David Rink	3796 HWY 42	LOCUST GROVE	GA	30248	770-9575556
MOYES PHCY & HOME HLTH HM	LOREN PIERCE	3798 HWY 42 SOUTH	LOCUST GROVE	GA	30248	770-9576004
LUMBER CITY DRUGS	Jordan Kolby Brown	3316 E. GOLDEN ISLES HWY	LUMBER CITY	GA	31549	912-3634979
MABLETON PHCY & UNIFOR HM	JONATHAN MARQUESS	5390 FLOYD ROAD	MABLETON	GA	30126	770-9483133

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
WELVISTA PHARMACY	Debbie Kinder	121 GREYSTONE BOULEVARD	COLUMBIA	SC	29210	803-4540868
HAWTHORNE PHCY ON TAYLOR	KRISTIE CASSIDY	1520 A TAYLOR STREET	COLUMBIA	SC	29201	803-2563440
HAWTHORNE PHCY OF LAUREL	KRISTIE CASSIDY	2761 LAUREL STREET	COLUMBIA	SC	29204	803-2542761
VISTARA PHARMACY	Rajdeep Patel	6323B N MAIN ST	COLUMBIA	SC	29203	803-7666075
SODA CITY PHCY & CMPDING	Tremain Cooper	380 SAINT ANDREWS RD	COLUMBIA	SC	29210	803-7662015
DARLINGTON FAMILY PHCY	Terry Lewis	203 S. MAIN STREET	DARLINGTON	SC	29532	843-3956020
ESTILL COMMUNITY PHARMACY	HEATHER EPTON	136 MARTIN L KING JR BLVD N	ESTILL	SC	29918	803-6259001
PALMETTO PRESCRIPTION CTR	DANNY POSTON	3198 W PALMETTO ST	FLORENCE	SC	29501	843-2929781
THE PHARMACY	Jarrold Tippins	2500 HOFFMEYER ROAD	FLORENCE	SC	29501	800-5555555
PIGGLY WIGGLY PHARMACY	Jeremy Simmons	1945 W PALMETTO ST UNIT 32	FLORENCE	SC	29501	843-6739107
WELL CENTER PHARMACY	Marlon Orias	605 S IRBY ST	FLORENCE	SC	29501	843-4094181
VISTARA PHARMACY NC	Rajdeep Patel	817 S CASHUA DR STE C	FLORENCE	SC	29501	800-5555555
FORT MILL PHARMACY HM	Mark Richards	601 SPRINGCREST DRIVE	FORT MILL	SC	29715	803-5482851
MEDICINE MART GAFFNEY	Thomas Beam	305 NORTH LIMESTONE	GAFFNEY	SC	29340	864-4895198
RIDGE LTC PHARMACY	Denise Derrick	4079 AUGUSTA HWY SUITE A	GILBERT	SC	29054	803-7564175
MORGAN'S PHCY OF GILBERT,	REBECCA MORGAN	309 BROAD ST	GILBERT	SC	29054	803-8925572
GREAT FALLS PHARMACY	Gary Milhorn	503 CHESTER AVE STE A	GREAT FALLS	SC	29055	803-4822249
GREELEYVILLE PHARMACY	Walter Rogan	215 VARNER AVE PO BOX 277	GREELEYVILLE	SC	29056	843-4262170
KASH & KARRY PHARMACY	KEVAN PAGE	101 PETE HOLLIS BLVD	GREENVILLE	SC	29601	864-2326711
GREENVILLE DISCOUNT PHCY	Rajadeep Patel	1701 AUGUSTA ST	GREENVILLE	SC	29605	864-3018441
CHERRYDALE PHARMACY	Vaishali Patel	2603 N PLEASANTBURG DR #B	GREENVILLE	SC	29609	973-4624429
WINGARD'S PHARMACY HM	Don Beam	202 SEABOARD AVENUE	GREENWOOD	SC	29646	864-2236120
PROFESSIONAL PHCY GREER	DON WALL	320 MEMORIAL DRIVE	GREER	SC	29650	864-8773386
PROFESSIONAL PHCY MT VIEW	JAGINA KING	428 MEMORIAL DRIVE EXT	GREER	SC	29651	864-8774281
MCLESKEY TODD FAMILY PHCY	RACHEL GODFREY	109 NORTH MAIN ST	GREER	SC	29650	864-8770753
CAROLINA PHCY LOWCOUNTRY	JEREMY SIMMONS	810 ELM ST EAST	HAMPTON	SC	29924	803-9140318

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
U SAVE IT PHCY MACON 2	Beverly Moody	1425 GEORGIA AVE STE 102	MACON	GA	31201	229-4354571
ORTHOGEORGIA PHARMACY	Lynn Johnson	3708 NORTHSIDE DRIVE	MACON	GA	31210	478-7502802
U SAVE IT #13 - MACON	PAULA NORMAN	3576 PIO NONO AVENUE	MACON	GA	31206	478-7811565
JASPER DRUG FOOHILLS	Jack Dunn	80 FOOHILLS PARKWAY	MARBLE HILL	GA	30148	770-8933784
DUE WEST HEALTHMART PHCY	JONATHAN MARQUESS	3880 DUE WEST RD NW #120	MARIETTA	GA	30064	770-4565895
EAST MARIETTA DRUG	Jonathan Marquess	1480 ROSWELL ROAD	MARIETTA	GA	30062	770-9737600
MEDEX RX LLC	Sweta Patel	833 CAMPBELL HILL ST 110	MARIETTA	GA	30060	470-3946100
POOLE'S PHARMACY	Thomas Sherrer	660 WHITLOCK AVE SUITE G	MARIETTA	GA	30064	770-5141414
RYALS DRUG	HUGH YAWN	12 SOUTH 2ND AVE	MC RAE	GA	31055	229-8686735
MOYES PHARMACY-MCDONOUGH	LOREN PIERCE	62 KEYS FERRY STREET	MCDONOUGH	GA	30253	770-9571851
CROSSROADS FAMILY RX	Beverly Moody	7838 HIGHWAY 48	MENLO	GA	30731	706-8622064
CANDLER PHARMACY	Rob Bowen	745 S. LEWIS STREET	METTER	GA	30439	912-6852008
EAGLE PHARMACY	KENNETH DELAY	936 E WINTHROPE AVE	MILLEN	GA	30442	478-9827979
CARMICHAEL DRUG CO	GREG HICKMAN	150 MLK JR BLVD	MONROE	GA	30655	770-2672559
CHANCY DRUGS MOULTRIE	HUGH CHANCY	101 N MAIN ST	MOULTRIE	GA	31768	229-9856725
NIDAY DRUG COMPANY	Mark Niday	2707 S. MAIN ST	MOULTRIE	GA	31768	229-5029900
DOGWOOD PHARMACY	GENA TYSON	501 NORTH DAVIS STREET	NASHVILLE	GA	31639	229-6862620
THOMPSON'S PHARMACY	Trey Thompson	134 MILLARD FARMER IND	NEWNAN	GA	30263	770-2514808
NICHOLLS PHARMACY	JAN SCOTT	1003 VAN STREAT HWY	NICHOLLS	GA	31554	912-3451021
NORCROSS PHCY	BILL HANKLA	2625 BEAVER RUIN ROAD	NORCROSS	GA	30071	770-4482288
WILLS DRUG CO OCILLA	Alex Willis	615 N IRWIN AVE	OCILLA	GA	31774	229-4689868
OMEGA PHARMACY	JT Thomas	246 OAK ST	OMEGA	GA	31775	229-5284276
PEACHTREE PHARMACY	April Hang	5270 PEACHTREE PKWY 114A	PEACHTREE CORNERS	GA	30092	804-3575355
PELHAM PHARMACY	Hunter Strickland	210 CHURCH ST	PELHAM	GA	31779	229-2132003
BEDINGFIELD PHARMACY	Teresa Smith	27 N MAIN ST PO BOX 326	PEMBROKE	GA	31321	912-6534596
U SAVE IT - PINE MOUNTAIN	PAULA NORMAN	145 NORTH MAIN AVENUE, A	PINE MOUNTAIN	GA	31822	706-6632255

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
CSC COMM PHY	Ashley Singleton	1280 S 4TH ST	HARTSVILLE	SC	29550	843-3395530
HARTSVILLE DRUG	JEB PERKINS	134 WEST CAROLINA AVE	HARTSVILLE	SC	29550	843-3326581
HOLLY HILL PHARMACY	RACHEL OSTEEN	904 HOLLY HILL STREET	HOLLY HILL	SC	29059	803-4960009
IVA DRUG STORE	Lance Boles	720 EAST FRONT STREET	IVA	SC	29655	864-3486138
GILDER AND WEEKS INC	EDDIE ABRAMS	200 NORTH MAIN ST	JOANNA	SC	29351	864-6976580
JOHNS ISLAND PHARMACY	DEBORAH DAPORE	3133 MAYBANK HWY	JOHNS ISLAND	SC	29455	843-7894777
MAXWELL & HALFORD DRUG	KENNETH DAVIS	432 CALHOUN STREET	JOHNSTON	SC	29832	803-2752021
KERSHAW FAMILY PHARMACY	Hugh Mobley	605 S HAMPTON ST	KERSHAW	SC	29067	803-4756979
MED CABINET OF LAKE CITY	TERRY BLACKMON	319 MERCY STREET	LAKE CITY	SC	29560	843-3742825
MOBLEY DRUGS INC	HUGH MOBLEY	1073 W MEETING ST	LANCASTER	SC	29720	803-2852021
CAROLINA PHARMACY AIRPORT	Vic Patel	1755 AIRPORT RD STE 100	LANCASTER	SC	29720	803-2890000
CAROLINA PHARMACY MEETING	Vic Patel	1228 COLONIAL COMMONS	LANCASTER	SC	29720	803-2868444
CAROLINA PHARMACY BYPASS	Vipul Patel	751 HWY 9 BYPASS W	LANCASTER	SC	29720	803-2866262
LANDRUM DRUG COMPANY HM	Dennis Burdette	104 WEST RUTHERFORD	LANDRUM	SC	29356	864-4572401
CSC COMM PHY LATTA	Ashley Singleton	122 LATIMER ST	LATTA	SC	29565	843-6276261
MY PHARMACY	Christopher Munnerlyn	808 HIGHWAY 378 STE B	LEXINGTON	SC	29072	803-7563460
MEDICINE MART PHARMACY	MICHAEL GLEATON	348B COLUMBIA AVENUE	LEXINGTON	SC	29072	803-9575969
HAWTHORNE LUGOFF PHCY	KRISTIE CASSIDY	710 HWY 1 SOUTH	LUGOFF	SC	29078	803-4089589
LYMAN DRUG HM	Richard High	204 SPARTANBURG HWY	LYMAN	SC	29365	864-4396127
ANDERSON PHARMACY HM	Rock Ouzts	419 SOUTH MILL STREET	MANNING	SC	29102	803-4332212
MAULDIN DISCOUNT PHARMACY	Rajdeep Patel	300 W BUTLER RD STE A	MAULDIN	SC	29662	864-4127775
CSC COMMUNITY PHMCMCCOL	Ashley Singleton	3080 HIGHWAY 15 401 E	MC COLL	SC	29570	843-5236212
STROM'S DRUG STORE HM	Tonya Calloway	124 SO MAIN STREET	MC CORMICK	SC	29835	864-4652011
MULLINS DISC PHCY INC HM	Todd Johnson	310 S. MAIN ST	MULLINS	SC	29574	843-4641757
HIBBITTS DRUG	AMY HIBBITTS	735 NORTH MAIN STREET	NEW ELLENTON	SC	29809	803-430077
LOREX DRUG	ANGELA JACKSON	1310 WILSON ROAD	NEWBERRY	SC	29108	803-2760990

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
PLAINS PHARMACY	LEE PINNELL	103 MAIN STREET	PLAINS	GA	31780	229-8245255
QUICK RX DRUG # 7 EDI	KAREN STEPHENS BROWN	110 MEDICAL PARK DRIVE	POOLER	GA	31322	912-7483194
U SAVE IT #5 - RICHLAND	PAULA NORMAN	676 ALSTON STREET	RICHLAND	GA	31825	229-8873747
QUICK RX DRUG # 4 EDI	KAREN STEPHENS BROWN	100 GOSHEN ROAD	RINCON	GA	31326	912-8266612
MAGNOLIA PHARMACY	Paul Bryant	4626 BATTLEFIELD PKWY	RINGGOLD	GA	30736	423-7188521
HEART DISCOUNT PHARMACY	Marvin Griffin	706 SPRINGDALE DR	RIVERDALE	GA	30274	770-9976500
ROCHELLE DRUG COMPANY	Carson Brooks	600 2ND AVE	ROCHELLE	GA	31079	229-3657447
SMITH LOCKWOOD PHCY	David Vest	114 S MARBLE ST	ROCKMART	GA	30153	770-6846573
SMITH LOCKWOOD PHCY #2	David Vest	701-B HOGUE AVE	ROCKMART	GA	30153	770-6847889
WEAVER'S ROCKY FACE PHY	Paul Bryant	2600 OLD CHATTANOOGA ROAD	ROCKY FACE	GA	30740	706-2590668
WINSLETTE PHARMACY	BRETT WINSLETTE	2444 SHORTER AVE	ROME	GA	30165	706-2900300
GMC DISCOUNT DRUGS HM	Rey Ozment	3402 ALABAMA HWY 20	ROME	GA	30165	706-2347616
AVERY DRUGS HM	Todd Avery	710 NORTH FIFTH AVE	ROME	GA	30165	706-2910999
RED APPLE INTERACTIVE PHY	Emmanuel Iyamu	1570 HOLCOMB BRIDGE RD	ROSWELL	GA	30076	770-5188870
MEDICAP PHARMACY	Mary Rene Starrett	100 FRANKLIN SPRINGS ST	ROYSTON	GA	30662	706-2459959
LO COST PHARMACY	Jason Conley	612 E 69TH ST	SAVANNAH	GA	31405	912-3520375
VILLAGE WALK PHARMACY	Jason Conley	1 SKIDAWAY VILLAGE WALK	SAVANNAH	GA	31411	912-5988669
QUICK RX DRUG # 5 EDI	KAREN STEPHENS BROWN	911 EAST 65TH STREET	SAVANNAH	GA	31405	912-3550122
QUICK RX DRUG #8 EDI	KAREN STEPHENS BROWN	1001 MEMORIAL LANE	SAVANNAH	GA	31410	912-8987535
PCI PHARMACY	Mba Kalu	3500 N. DECATUR RD, STE 108	SCOTTTDALE	GA	30079	404-5498447
SHELLMAN PHARMACY	Jessica Jones	75 W. RAILROAD STREET	SHELLMAN	GA	39886	229-6795070
SILVER CREEK PHARMACY	STEVEN PURVIS	4450 NEW ROCKMART HWY	SILVER CREEK	GA	30173	706-2920106
SHEGER PHARMACY	Dawit Antonios	3334 STONE MOUNTAIN HWY STE H	SNELLVILLE	GA	30078	770-6744800
EASTSIDE FAMILY PHCY	MICHELE DALTON	1795 PRESIDENTIAL CIRCLE	SNELLVILLE	GA	30078	770-8070137
WEBSTERS PHARMACY	Fred Webster	12707 BROAD STREET	SPARTA	GA	31087	706-4445296

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
ATLANTIC APOTHECARY	Teresa Shelley	3816 HWY 17 SOUTH STE 2	NORTH MYRTLE BEACH	SC	29582	843-2727900
ORANGE CUT RATE DRUGS	STEPHEN UNION	1144 RUSSELL ST	ORANGEBURG	SC	29115	803-5345931
GROVE PARK PHARMACY	STEPHEN UNION	1324 GROVE PARK NE	ORANGEBURG	SC	29115	803-5360007
PAGELAND FAMILY PHARMACY	Karla Milhorn	214 S VAN LINGLE MUNGO BL	PAGELAND	SC	29728	843-6752014
HAWTHORNE PELION PHCY	Kristie Cassidy	8073 EDMUND HIGHWAY	PELION	SC	29123	803-8944010
PREFERRED PHARMACY	Jeremy Simmons	10911 NORTH JACOB SMART BLVD	RIDGELAND	SC	29936	843-7295583
CAROLINA PHARMACY RH HM	Vipul Patel	725 CHERRY RD STE 103	ROCK HILL	SC	29732	803-3271640
SENECA PHARMACY	DON CALVERT	15891 WELLS HWY	SENECA	SC	29678	864-9851359
CSC COMM PHY SOC HILL	Ashley Singleton	743 SOUTH MAIN ST	SOCIETY HILL	SC	29593	843-3784148
U SAVE IT #19 - SPRNBRG	PAULA NORMAN	2310 CHESNEE HWY N SUITE 1	SPARTANBURG	SC	29303	864-5770087
BUY LOW PHARMACY	Payal Thadani	8007 WARREN H ABERNATHY	SPARTANBURG	SC	29301	864-5725727
ST. MATTHEW'S PHARMACY HM	MIKELL QUICK	708 F.R.HUFF DRIVE, NORTH	ST MATTHEWS	SC	29135	803-6557800
SUMMERTON DRUG COMPOUND	Trey Phillips	115-B MAIN STREET	SUMMERTON	SC	29148	803-4858586
COLONIAL RX	BRANDEE STUKES	325 BROAD ST SUITE 100	SUMTER	SC	29150	803-7735227
SUMTER CUT RATE DRUGS HM	CHAD GIBBONS	32 S MAIN STREET	SUMTER	SC	29150	803-7738432
MEDICAL COURT PHARMACY	Jake Holiday	776 W LIBERTY ST	SUMTER	SC	29150	803-7735605
ALDERMAN DRUG CO INC	Nichole Cross	40 NORTH MAIN ST	SUMTER	SC	29150	803-7738666
CHRISTMAS PHARMACY	Steve Christmas	1229 ALICE DR # B	SUMTER	SC	29150	803-9836297
DISC DRUG OF SWANSEA HM	ANTHONY RAY	400 NORTH CHURCH STREET	SWANSEA	SC	29160	803-5683251
TIMMONSVILLE PHARMACY HM	Mitchell Page	309 EAST SMITH STREET	TIMMONSVILLE	SC	29161	843-3467182
UNION FAMILY PHARMACY	ANGELA JACKSON	528 A RICE AVENUE	UNION	SC	29379	864-4273700
WAGENER DRUG	THERESA DYCHES	129 N MAIN ST	WAGENER	SC	29164	803-5645381
KENS THRIFTEE PHARMACY HM	Earl Carter	112 EAST MAIN STREET	WALHALLA	SC	29691	864-6389553
WALTERBORO PHARMACY	Jeremy Simmons	1315 N JEFFERIES BLVD	WALTERBORO	SC	29488	843-7295583
HAWTHORNE PHCY ON SUNSET	KRISTIE CASSIDY	2854 SUNSET BLVD	WEST COLUMBIA	SC	29169	803-7947990

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
QUICK RX DRUG # 6 EDI	KAREN STEPHENS BROWN	504 LAUREL STREET	SPRINGFIELD	GA	31329	912-7546444
CAMDEN PHARMACY	Anthony Kicklighter	214 B PROFESSIONAL CIR	ST MARYS	GA	31558	912-6738220
FREDERICA PHARMACY	Matt Luce-GA	3603 FREDERICA RD	ST SIMONS ISLAND	GA	31522	912-3572357
MCCOOKS PHARMACY INC	LEN MCCOOK	23630 US HWY 80 E	STATESBORO	GA	30461	912-7642223
BRIGHT PHARMACY	Bright Akpaka	899 HWY138 W	STOCKBRIDGE	GA	30281	770-7038661
EAGLES LANDING PROF PHCY	David Rink	1090 EAGLES LANDING PKWY	STOCKBRIDGE	GA	30281	770-4745005
MOYES PHARM-STOCKBRD HM	LOREN PIERCE	4467 NORTH HENRY BLVD	STOCKBRIDGE	GA	30281	770-4740704
DISCOUNT PHARMACY	GAUTAM JOSHI	827 NORTH HAIRSTON RD STE D	STONE MOUNTAIN	GA	30083	770-7555904
YOO PHARMACY	Byung Yoo	1299 OLD PEACHTREE NW 108	SUWANEE	GA	30024	770-8144515
SUWANEE PHARMACY	Karl Simon	2027 LAWRENCEVILLE SUWANEE #700	SUWANEE	GA	30024	678-8782082
SHINN'S PHARMACY	Sara Yim	2790 L'VILLE SUWANEE RD	SUWANEE	GA	30024	770-9323023
BELL'S FAMILY PHARMACY	Katherine Bell	4875A HWY 53 EAST	TATE	GA	30177	678-4542300
THOMASTON PRESCRIP SHOP	CARSON GLEATON	500 WEST GORDON ST	THOMASTON	GA	30286	706-6478965
DOGWOOD PHARMACY	Laura Tyson	1909 HWY 82 STE 11	TIFTON	GA	31793	229-2562411
TIFTON DRUG	Troy Allen	602 LOVE AVE	TIFTON	GA	31794	229-3965552
TRION DRUGS	Beverly Moody	49 HARRELL STREET	TRION	GA	30753	706-7342481
GRACE PHCY AND WELLNESS	Gabriel Aligwekwe	4404 HUGH HOWELL RD 17	TUCKER	GA	30084	470-5080555
TRACYS MED CTR #2 APCI	SHANNAN TRACY	3171 NORCROSS TUCKER RD	TUCKER	GA	30084	770-9399952
UNION PHARMACY	Chris Thurmond	624 SIBLEY AVE	UNION POINT	GA	30669	706-4862131
CHANCY DRUGS VALDOSTA	HUGH CHANCY	2333 N ASHLEY ST	VALDOSTA	GA	31602	229-2459922
U SAVE IT PHCY VALDOSTA	Jay Sharpe	2111 BEMISS RD	VALDOSTA	GA	31602	229-4354571
NORTHSIDE PHCY WALES HM	Robert R Bagwell Jr	6824 REINHARDT COLLEGE PK	WALESKA	GA	30183	770-4792172
U SAVE IT #16 - WOODBURY	PAULA NORMAN	18126 MAIN STREET	WOODBURY	GA	30293	706-5533351
CONCORD PHY LAWRENCEVILLE	Jonathan Marquess	575 PROFESSIONAL DR #170	WOODSTOCK	GA	30046	770-3380971
WOODSTOCK PHARMACY	Jonathan Marquess	8612 MAIN STREET	WOODSTOCK	GA	30188	770-9266478
COMMUNITY PHARMACY III	MARILYN FLORENDO	612 N MARINE DR STE 8	DEDEDO	GU	96929	671-6466415

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
ROCHE PHCY INC SERVAL HM	John Roche	68 MAIN STREET	WHITMIRE	SC	29178	803-6942445
VISTARA PHARMACY	Rajdeep Patel	10 N HAMILTON ST	WILLIAMSTON	SC	29697	864-7866075
MORGAN DRUGS	BECKY MORGAN	12935 MAIN STREET	WILLISTON	SC	29853	803-2663356
HAWTHORNE WINNSBORO PHCY	Kristie cassidy	110 S CONGRESS ST	WINNSBORO	SC	29180	803-6353565
WOODRUFF HEALTH MART PHCY	Charles Baumgardner	10195 HWY 221 SUITE 5	WOODRUFF	SC	29388	864-6708150
DT PHARMACY	DAVID TAFFE	815 1ST AVE SE STE 202	ABERDEEN	SD	57401	605-7254001
PLAZA PHARMACY	DAVID TAFFE	2201 6TH AVENUE SE	ABERDEEN	SD	57401	605-2256344
JONES DRUG	JERRAD AMAN	816 6TH AVE SE STE 1	ABERDEEN	SD	57401	605-2253010
TURNER DRUG	Dillon Kjerstad	3033 MAIN ST	BOWDLE	SD	57428	605-2856121
BURKE COMMUNITY PHARMACY	RENEE SUTTON	809 JACKSON STREET POB 358	BURKE	SD	57523	605-7752294
CARSON DRUG	Dillon Kjerstad	521 MOUNT RUSHMORE ROAD	CUSTER	SD	57730	605-6732225
DUNES FAMILY PHARMAC HM	Bill Orlando	101 TOWER RD STE 130	DAKOTA DUNES	SD	57049	605-2425050
VILAS HEALTH N VARIETY EB	JAMES STEPHENS	123 MAIN STREET	EAGLE BUTTE	SD	57625	605-9648955
DOSCH FAMILY PH	Michael Dosch	207 J AVE STE 3	EUREKA	SD	57437	605-2842752
VILAS HEALTH N VARIETY	JAMES STEPHENS	100 MAIN STREET	FAITH	SD	57626	605-9672123
VILAS GETTYSBURG	Dillon Kjerstad	103 E COMMERCIAL AVE	GETTYSBURG	SD	57442	605-7659458
LORIS PHARMACY	LORI GIEDT	1205 NORTH 1ST STREET	GROTON	SD	57445	605-3972363
VILAS HIGHMORE	Dillon Kjerstad	120 COMMERCIAL AVE	HIGHMORE	SD	57345	605-8522890
VILA'S PHARMACY-IPSWICH	JAMES STEPHENS	511 N 5TH ST	IPSWICH	SD	57451	605-4266551
VILAS PHARMACY	James Stephens	145 GLENDALE DR	LEAD	SD	57754	605-2244538
SMITH DRUG HM	Eric Sonsalla	301 MAIN AVE	LEMMON	SD	57638	605-3743897
MARTIN DRUG & MERCANTILE	KIRK WILSON	304 MAIN ST	MARTIN	SD	57551	605-6856200
MILLER REXALL DRUG	TRENT MERKWAN	209 N. BROADWAY	MILLER	SD	57362	605-8533647
MISSION COMMUNITY PHCY	RENEE SUTTON	161 S MAIN STREET	MISSION	SD	57555	605-8562120
PARKSTON DRUG RX	Richard Boetcher	112 WEST MAIN PO BOX 430	PARKSTON	SD	57366	605-9283125
DAKOTA COUNTRY PHARMACY	DILLON KJERSTAD	130 S CENTER	PHILIP	SD	57567	605-8592833

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number	Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
COMMUNITY PHARMACY II	JAKE ENTERPRISES	1244 N MARINE CORPS DR	UPPER TUMON	GU	96913	671-6466515	AVERA ST MARY'S WAC A34	Todd Forkel	100 MAC LANE STE 101	PIERRE	SD	57501	605-2247334
WESTSIDE SPECIALTY PHYLTC	Brian Carter	1-3845B KAUMUALII HIGHWAY	HANAPEPE	HI	96716	808-6450491	PRESHO COMMUNITY PHARMACY	RENEE SUTTON	116 NORTH MAIN ST, STE #2	PRESHO	SD	57568	605-8956337
SHIIGI DRUG CO INC HM	Louis Matsukado	333 KILAUEA AVE STE 102	HILO	HI	96720	808-9350001	BOYD'S DRUG RX EXPRESS HM	Scott Vincent	2650 MT RUSHMORE ROAD	RAPID CITY	SD	57701	605-7184040
FOODLAND PHY 26PUAIN MAIN	PUALEI SANTORRE	2100 KANOELEHUA AVE	HILO	HI	96720	808-9597300	BOYDS DRUG MART WEST HM	Scott Vincent	655 MOUNTAIN VIEW ROAD	RAPID CITY	SD	57702	605-3434445
WELLNESS PHARMACY	HENRY QUAN	100 N BERETANIA ST STE148	HONOLULU	HI	96817	808-5502833	BOYD DRUG MART EAST HM	Scott Vincent	909 E ST PATRICK ST	RAPID CITY	SD	57701	605-3480741
FAMILY PHARMACY	Jin Hee Kim	1451 S KING ST #203A	HONOLULU	HI	96814	808-3792347	BON HOMME PHARMACY	CAROL DEURMIER	410 W. 16TH AVE	TYNDALL	SD	57066	605-5894418
WELLNESS PHCY #2	JOANNA WONG	1120 MAUNAKEA ST STE 102	HONOLULU	HI	96817	808-5502888	CORNWELL DRUG	ROBERT KWASNIEWSKI	701 MAIN	WEBSTER	SD	57274	605-3453351
HAPPY PHARMACY	LIMON LIM	1441 KAPIOLANI BLVD # 304	HONOLULU	HI	96814	808-9559500	WHITE RIVER COMM PHCY	Rene Sutton	309 EAST 4TH ST	WHITE RIVER	SD	57579	605-2593102
DISCOVERY BAY PHCY	Wha Kimball	1778 ALA MOANA BLVD #208	HONOLULU	HI	96815	808-3123469	EAST MAIN PHARMACY	Chase Garrison	712 E MAIN STREET	ADAMSVILLE	TN	38310	731-6323278
FOODLAND MEDCAB37KAI MAIN	Ashok Kota	108 HEKILI ST	KAILUA	HI	96734	808-2617329	PETTIGREW REXALL DRUG	JIMMY PETTIGREW	139 WEST MAIN ST	ADAMSVILLE	TN	38310	731-6323118
FOODLAND MEDCAB38KAM MAIN	Ashok Kota	67-1185 MAMALAHOA HWY#109	KAMUELA	HI	96743	808-8852075	TODDS DISCOUNT DRUGS	Todd Gean	347 E MAIN ST	ADAMSVILLE	TN	38310	731-6320995
FOODLAND PHY 43KAPOL MAIN	TRENTON TERUYA	4850 KAPOLEI PKWY	KAPOLEI	HI	96707	808-6741156	WILEY'S PHARMACY HM	Larry Wiley	1595 MAIN STREET	ALTAMONT	TN	37301	931-6923888
MOLOKAI DRUGS - RX AIR	Kimberly Svetin	28 KAMOI ST, STE 100	KAUNAKAKAI	HI	96748	808-5535790	ANDERSON CROSSING PHCY	DEWAYNE HUNT	3318 ANDERSONVILLE HWY	ANDERSONVILLE	TN	37705	865-4948444
WAILEA PEOPLE PAWS RX	Michael Anton	34 WAILEA GATEWAY PL # A103	KIHEI	HI	96753	808-8790123	MADISON AVE PHY	JEFF WOLFENDEN	1001 MADISON AVE	ATHENS	TN	37303	423-7462626
FOODLAND PHY 32LAIE MAIN	Ashok Kota	55-510 KAMEHAMEHA HWY	LAIE	HI	96762	808-2939919	BOATWRIGHT PHCY OF ATOKA	STEVEN BOATWRIGHT	139 WESLEY REED DR STE F	ATOKA	TN	38004	901-8378801
MAKAWAO TOWN PHARMACY	Les Krenk	1120 MAKAWAO AVE	MAKAWAO	HI	96768	808-5731056	SOUTHERN EXPRESS PHARMACY	Elizabeth Ashley Willis	1355 W MARKET STREET	BOLIVAR	TN	38008	731-4721011
PAHOA PHARMACY	Ismail Abdolahi	15-2660 PAHOA VLGE RD#205	PAHOA	HI	96778	808-9650601	MULHERIN FAMILY PHCY	Sarah Mulherin	200 E MAIN ST	BROWNSVILLE	TN	38012	731-5850500
FOODLAND PHY 30PRINC 2ND	Ashok Kota	5-4280 KUHIO HWY	PRINCEVILLE	HI	96722	808-8264228	BULLS GAP DRUGS	JAMA BOS	412 HWY 11 E	BULLS GAP	TN	37711	423-2354600
FOODLAND MEDCAB24PUK MAIN	Ashok Kota	55 PUKALANI ST	PUKALANI	HI	96768	808-5728266	DAVIDSON'S DISCOUNT DRUGS	KENDLE DAVIDSON	110 HILLCREST DR	BYRDSTOWN	TN	38549	931-8643166
WAIMANALO PHARMACY INC	RICHARD CHANG	41-1610 KALANIANA'OLE HWY	WAIMANALO	HI	96795	808-2598488	CHARLOTTE'S HOMETOWN PHCY	STEPHANIE BATEY	3369 HWY 48 N	CHARLOTTE	TN	37036	615-7899393
ADEL HEALTH MART	Jane Clausen	113 N. 9TH ST	ADEL	IA	50003	515-9933644	SANGO PHARMACY	CATHERINE MEEKS	2622 MADISON ST #A	CLARKSVILLE	TN	37043	931-9192491
SUMPTER PHARMACY	Leslie Herron	628 NILE KINNICK DR STE 1	ADEL	IA	50003	515-9931119	HARRIS FAMILY PHARMACY	Hursh Patel	1157 FORT CAMPBELL BLVD.	CLARKSVILLE	TN	37042	931-2786171
AMANA PHARMACY	Neal Head	507 39TH AVE	AMANA	IA	52203	319-6223341	MEDSOURCE SCRIPTS	John Prichard	1849 MADISON ST STE D	CLARKSVILLE	TN	37043	931-8962126
NIGHTINGALE DRUG	Linda Nightingale	303 WEST MAIN	ANAMOSA	IA	52205	319-4623306	DIXIE PHARMACY 3	Navas Yoonus	311 LANDRUM PL. #600-A	CLARKSVILLE	TN	37043	931-2415688
MILLS PHARMACY PC	RANDY BOYER	120 E MAIN ST.	ANTHON	IA	51004	712-3735256	ST. BETHLEHEM DRUGS	Sara Harper	800 WEATHERLY DR #101A	CLARKSVILLE	TN	37043	931-6476561
REX PHCY	JOSHUA BORER	1607 E 7 STREET	ATLANTIC	IA	50022	712-2432110	COOKE'S PHARMACY #2	GINA MOSER	2010 BROOMFIELD RD	CLEVELAND	TN	37323	423-5997108

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
RENUX RX #9	Raj Chhadua	106 W RAMSEY ST	BANCROFT	IA	50517	214-4222598
CORNERSTONE APOTHECARY BP	BETHANY HOOPES	731 - 12TH ST	BELLE PLAINE	IA	52208	319-4442290
AMICARE PHCY BETTENDORF	NEAL HEAD	3740 UTICA RIDGE ROAD	BETTENDORF	IA	52722	563-3447450
LINCOLN HIGHWAY PHARMACY	Jerry Fleshner	859 E US HIGHWAY 30	CARROLL	IA	51401	712-7922402
CLINIC PHCY OF CARROLL	Jerry Fleshner	405 S CLARK ST STE 102	CARROLL	IA	51401	712-7925393
REUTZEL PHARMACY	Neal Head	617 8TH AVE SE	CEDAR RAPIDS	IA	52401	319-3644181
YOUR NEIGHBORHOOD PHCY	Denise Hook	510 E JEFFERSON ST STE A	CORYDON	IA	50060	641-8722030
SUPER SAVER PHCY #12	Mark Griffin	1141 N BROADWAY	COUNCIL BLUFFS	IA	51503	712-3229019
OARD-ROSS DRUG	Tony Beraldi	701 16TH AVE	COUNCIL BLUFFS	IA	51501	712-3222501
CASSADY PHARMACY HM	Don Cassady	3300 SW 9TH STREET #10	DES MOINES	IA	50315	515-2852474
FIFIELD PHARMACY HM	Don Cassady	501 UNIVERSITY	DES MOINES	IA	50314	515-2443221
CASH SAVER PHARMACY #33	Mark Griffin	1320 E EUCLID AVE	DES MOINES	IA	50316	515-2655946
CASH SAVER PHARMACY #34	Mark Griffin	4121 FLEUR DR	DES MOINES	IA	50321	515-2855927
INFOCUS PHARMACY SERVICES	ANGELA MILLER	1690 ELM ST STE 200	DUBUQUE	IA	52001	563-2399151
NIGHTINGALE D-DUBUQUE	Linda Nightingale	2541 CENTRAL AVE	DUBUQUE	IA	52001	563-5561493
NIGHTINGALE D-DYERSVILLE	Linda Nightingale	1020 12TH AVE SE	DYERSVILLE	IA	52040	563-8757455
HUGHES PHARMACY HM	Greg Hoyman	2216 MAIN STREET	EMMETSBURG	IA	50536	712-8523433
ESTHERVILLE PHARMACY	Josh Borer	1804 E CENTRAL AVE	ESTHERVILLE	IA	51334	712-3620330
SCOTT PHCY HM	Jeffrey Scott	238 S MAIN	FAYETTE	IA	52142	563-4254530
MANLY DRUG STORE HM	Dave Stufli	621 G AVENUE	GRUNDY CENTER	IA	50638	319-8245446
DOWD DRUG HEALTH MART	Julie Priestley	307 STATE ST BOX 99	GUTHRIE CENTER	IA	50115	641-7478317
NIGHTINGALE D-GUTTENBERG	Linda Nightingale	807 S HIGHWAY 52	GUTTENBERG	IA	52052	563-2521172
STONER DRUG #1	Chris Roup	1105 MAIN STREET	HAMBURG	IA	51640	712-3822551
HARLAN PHARMACY	Jean Feldman	1024 5TH ST	HARLAN	IA	51537	712-2357979
KWIK RX PHARMACY	Tom Fox	2308 12TH STREET	HARLAN	IA	51537	712-7553823
BLAIRS FERRY FAMILY PHCY	Doug Niedermann	1790 BLAIRS FERRY RD	HIAWATHA	IA	52233	319-3934944
TOWNCREST PHARMACY HM	Mike Deninger	2306 MUSCATINE AVENUE	IOWA CITY	IA	52240	319-3373526

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
COOKE'S PHARMACY	GINA MOSER	3400 KEITH STREET	CLEVELAND	TN	37312	423-4726478
BLACK BEAR PHARMACY	Gina Patterson	110 KEITH ST SW STE 1-2	CLEVELAND	TN	37311	423-6146650
CRAWFORD'S PHARMACY	JEFF WOLFENDEN	2260 CHAMBLISS AVE	CLEVELAND	TN	37320	423-4798601
PHARMACY HOME CARE	Jeff Wolfenden	120 23RD ST	CLEVELAND	TN	37311	423-7907336
WILLOUGHBY DRUGS	Todd Gean	104 MAIN ST	CLIFTON	TN	38425	931-6763318
COLLINWOOD DRUGS	CARLA STAGGS	313 HIGHWAY 13 SOUTH	COLLINWOOD	TN	38450	931-7249197
DOC'S HOMETOWN PHARMACY	Brent Smith	951 HIGHWAY 51 N	COVINGTON	TN	38019	901-5812032
MILLER'S PHARMACY	FRANK MILLER	110 STAR SHOPPING CTR	COVINGTON	TN	38019	901-4750535
YOUNG PHARMACY	Bob Young	23 WOODMERE MALL	CROSSVILLE	TN	38555	931-4568165
MITCHELL DRUG	James Petty	97 NORTH MAIN STREET	CROSSVILLE	TN	38555	931-4845117
CUMBERLAND VITAL CARE PHC	Landon Headrick	3106 MILLER AVE #101	CROSSVILLE	TN	38555	931-4560680
DOVER FAMILY PHARMACY	Marlin L. Blane	1307 DONELSON PKWY	DOVER	TN	37058	931-2320123
BOB'S DISCOUNT PHCY HM	Bob Daniel	8720 HERT PLZA A HWY 22	DRESDEN	TN	38225	731-3642207
KIMSEY PHARMACY	Linda Campbell	125 FIVE POINTS DR	DUCKTOWN	TN	37326	423-4965831
LONG AND GIBSON PHCY	Johnny Gibson	303 TICKLE STREET	DYERSBURG	TN	38024	731-2851711
JAMES & WILKS	MART JAMES	620 MALL BLVD STE A	DYERSBURG	TN	38024	731-2862025
LINGERFELT PHARMACY	Eric Carter	609 E ELK AVE	ELIZABETHTON	TN	37643	423-5422138
REED PHARMACY	Phillip Reed	851 WEST ELK AVE.	ELIZABETHTON	TN	37643	423-5181088
ROLLER PHARMACY	Terry Roller	109 N MAIN AVE	ERWIN	TN	37650	423-7437105
ANDERSON DRUGS	JEFF ANDERSON	721 N TENNESSEE AVE	ETOWAH	TN	37331	423-2637824
ALLENHILL PHARM & MEDICAL	Randy Allen	4096 CAROTHERS PKWY	FRANKLIN	TN	37067	615-7903885
GAINESBORO DRUGS	Hemal Patel	100 E HULL AVE.	GAINESBORO	TN	38562	931-2689919
TRICARE PHARMACY	JEOPU PETER	710 NASHVILLE PIKE STE 101	GALLATIN	TN	37066	615-4617078
AIRVILLE PHARMACY	UGOCHUKWU BEN-NWAUZOR	1785 AIRPORT ROAD STE A	GALLATIN	TN	37066	615-5878203
GERMANTOWN PHARMACY	Tammy Folk	2013 EXETER RD	GERMANTOWN	TN	38138	901-7296429
ROMAN PHARMACY	DOUG EVANS	250 LONG HOLLOW PIKE	GOODLETTSVILLE	TN	37072	615-8598999
GREENBRIER PHARMACY HM	Misty Williamson	2239 HWY 41 SOUTH STE A	GREENBRIER	TN	37073	615-6436979

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
RIEBER CLINIC PHARMACY	COLETTE VENTEICHER	920 SOUTH OAK ST STE 2	IOWA FALLS	IA	50126	641-6483733
KINGSLEY DRUG	Katie Howe	7 W 2ND ST	KINGSLEY	IA	51028	712-3833784
WOODLAWN PHCY	Julie Kraft	101 N WOODLAWN AVE	LAKE CITY	IA	51449	712-4648811
WIDNER DRUG	Jonathan Kallenbach	111 S FRANKLIN BOX 99	MANCHESTER	IA	52057	563-9274463
MANNING PHARMACY	Joshua M Borer	317 MAIN ST	MANNING	IA	51455	712-6552665
MAIER FAMILY PHARMACY	Kari Hanneman	411 MAIN STREET	MAPLETON	IA	51034	712-8811033
CORNERSTONE APOTH-MARENGO	Beth Hoopes	1035 COURT AVE	MARENGO	IA	52301	319-7416300
CARRUTHERS PHARMACY	Shannon Mohr	526 MAIN STREET	MEDIAPOLIS	IA	52637	319-3943420
MONROE COMMUNITY PHARMACY	Doug Niedermann	112 E WASHINGTON ST	MONROE	IA	50170	319-3934944
NIGHTINGALE D-MONTICELLO	Linda Nightingale	304 E 1ST ST	MONTICELLO	IA	52310	319-4654404
MT. VERNON PHARMACY	Neal Head	101 1ST ST NE	MOUNT VERNON	IA	52314	319-8956248
BENNETT PHARMACY	Mark Vogt	1 WEST MAIN ST	NEW HAMPTON	IA	50659	641-3944156
NORTH LIBERTY PHARMACY	Neal Head	555 W CHERRY ST	NORTH LIBERTY	IA	52317	319-6266188
OAKLAND PHARMACY	WILLIAM ROBINSON	601 PIONEER AVE PO BOX637	OAKLAND	IA	51560	712-4823015
SWANSON DRUG HM	Patty Swanson	305 WEST WALNUT STREET	OGDEN	IA	50212	515-2752362
STANGEL PHARMACY HM	James Stangel	821 IOWA AVE	ONAWA	IA	51040	712-4231131
HOMETOWN PHCY/DUTCH MILL	Blake Plender	512 8TH ST SE	ORANGE CITY	IA	51041	712-7374919
DUTCH MILL PHARMACY HM	Brent Plender	104 ALBANY AVE NE	ORANGE CITY	IA	51041	712-7374844
SIECH'S PARKERSBURG PHCY	Tom Reinert	226 3RD STREET	PARKERSBURG	IA	50665	319-3461970
PELLA REG HLTH CTR PHCY	Kent Breems	802 WASHINGTON STREET	PELLA	IA	50219	641-6281612
NIGHTINGALE D-POSTVILLE	Linda Nightingale	139 N LAWLER ST PO BOX773	POSTVILLE	IA	52162	563-8633666
PELLA REG PRAIRIE CITY PH	Kent Breems	404 E 2ND ST	PRAIRIE CITY	IA	50228	515-9942618
RED OAK PHARMACY	David Post	1400 SENATE AVE #104	RED OAK	IA	51566	712-6237245
REMSEN PHARMACY	Blake Plender	111 S WASHINGTON	REMSEN	IA	51050	712-7862093
PENN DRUG	MARK VOGT	714 ILLINOIS ST/POB 360	SIDNEY	IA	51652	712-3742513
JACK'S CORNER DRUG	Matthew Jacob Ives	118 S MAIN ST STE B	SIGOURNEY	IA	52591	641-6223184
THOMPSON DEAN DRUG HM	Gary Maly	911 W 7TH STREET	SIOUX CITY	IA	51103	712-2522761

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
GREENE COUNTY DRUG STORE	Benjie Cox	906 TUSCULUM BLVD STE 2	GREENEVILLE	TN	37745	423-6387101
CENTRAL DRUG STORE	Cindy Fisher	239 W SUMMER ST.	GREENEVILLE	TN	37743	423-6384711
ARNOLD'S DRUG CO APCI	WADE STANLEY	112 EAST MAIN	HALLS	TN	38040	731-8367211
TROUSDALE WELLNESS PHCY	Andrew Byrd	215 BROADWAY	HARTSVILLE	TN	37074	615-6337645
CITY DRUG HENDERSON	DERYL STEWART	118 EAST MAIN	HENDERSON	TN	38340	731-9892166
DEES DISCOUNT DRUGS	Todd Gean	689 KIMBERLY DR	HENDERSON	TN	38340	731-9897180
HENDERSONVILLE HM PHCY	Curt Willett	247 W MAIN STREET	HENDERSONVILLE	TN	37075	615-8242179
HERMITAGE PHARMACY	Dhaval Shah	3786 CENTRAL PIKE STE 120	HERMITAGE	TN	37076	615-4543300
MEDICINE COUNTER	Himanshu Patel	5506 HWY 153 STE 102	HIXSON	TN	37343	419-9448077
JONES HOMETOWN PHARMACY	Jonathan Jones	121 WEST MAIN STREET	HOHENWALD	TN	38462	931-7965901
DUREN APOTHECARY	Tiffany Hurst	110 KITTRELL ST	HOHENWALD	TN	38462	931-2953406
CITY DRUG COMPANY	Daniel Jones	630 RB WILSON DR	HUNTINGDON	TN	38344	731-9862228
HEALTH CARE PHARMACY	Matt Baker	505 ROLAND AVE	JACKSON	TN	38301	731-4232273
VANTREESE DISC PHCY HM	Todd Gean	1463 SO HIGHLAND STE A	JACKSON	TN	38301	731-4230316
MOONEYS PHARMACY	Chad Huntsman	1107 N ROAN ST	JOHNSON CITY	TN	37601	423-9267333
KENTON DRUG CO HM	Richard Skiles	116 E COLLEGE	KENTON	TN	38233	731-7495951
P AND S PHARMACY	Chad Huntsman	613 WATAUGA ST	KINGSPORT	TN	37660	423-2468351
CAVES DRUG STORE	WILLIAM CAVE	1328A SOUTH JB DENNIS HWY	KINGSPORT	TN	37660	423-2451341
ROCKY HILL PHARMACY	Anne Warren	7660 S NORTHSHORE DR	KNOXVILLE	TN	37919	865-3375887
FARRAGUT PHARMACY	BETSY SEGRAVES	11424 KINGSTON PIKE	KNOXVILLE	TN	37934	865-9669728
FOUR WAY PRESCRIPTIONSHOP	Brad C Lott	8707 A ASHEVILLE HWY	KNOXVILLE	TN	37924	865-6808834
LONGS DRUG STORE	Hank Peck	4604 KINGSTON PIKE	KNOXVILLE	TN	37919	865-5880581
GORDON'S DRUG	MIKE GORDON	7255 OAK RIDGE HWY	KNOXVILLE	TN	37931	865-6918822
UT STUDENT HEALTH CENTER	PEYTON ROBERTS	1800 VOLUNTEER BLVD #134	KNOXVILLE	TN	37996	865-9745932
LEBANON FAMILY PHARMACY	Hetal Patel	1311 W MAIN ST STE A	LEBANON	TN	37087	865-8059785
GIBBS PHARMACY	Jim Gibbs	1427 W BADDOUR PKWY STE B	LEBANON	TN	37087	615-4917924
FRESH PHARMACY	Joe Nowell	721 HWY 321 N	LENOIR CITY	TN	37771	800-5555555

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
LEEDS PHCY HM	ROB REHAL	2729 OUTER DR N	SIOUX CITY	IA	51104	712-2392051
GREENVILLE PHCY HM	Robert Rehal	2701 CORRECTIONVILLE RD	SIOUX CITY	IA	51105	712-2580113
SOLON TOWNCREST PHARMACY	MICHAEL DENINGER	101 WINDFLOWER LN STE 100	SOLON	IA	52333	319-6242239
BVRMC PHCY	Krista Ketcham	620 NW DRIVE (POD 2)	STORM LAKE	IA	50588	712-2138065
STONER DRUG #3	Angela Alley	712 MAIN STREET	TABOR	IA	51653	712-6292945
TIPTON PHARMACY	Neal Head	124 EAST FIFTH ST	TIPTON	IA	52772	563-8862158
LAGRANGE PHARMACY URBANA	Dan LaGrange	1002 W MAIN ST	URBANA	IA	52345	319-4724274
CORNERSTONE APOTH HM VH	Beth Hoopes	122 MAIN STREET	VAN HORNE	IA	52346	319-2288100
HONEYMAN DRUG	Chris Roup	408 S 3RD AVE	VILLISCA	IA	50864	712-8265262
LA GRANGE PHCY INC HM	Mike LaGrange	111 WEST 4TH STREET	VINTON	IA	52349	319-4724274
BEAN'S PHARMACY	JON THOMPSON	222 S. IOWA AVENUE	WASHINGTON	IA	52353	319-6534646
NIGHTINGALE DRUG	Eric Nightingale	606 ROSSVILLE RD	WAUKON	IA	52172	563-5680033
PHARMACY ON 8TH	Tess De Jesus-Roetlin	221 8TH AVE	WELLMAN	IA	52356	319-6463388
VILLAGER TELEPHARMACY	Steve Hoyman	105 SOUTH BROADWAY AVE	WEST BEND	IA	50597	712-8523433
HERITAGE FAMILY PHCY HM	Brian Anderson	1201 W AGENCY RD STE 2	WEST BURLINGTON	IA	52655	319-7533681
HERITAGE PARK PHCY HM	Brian Anderson	1223 S GEAR AVE SUITE 105	WEST BURLINGTON	IA	52655	319-7683950
WOODBINE DRUG/FOOD LAND	JOHN CORBETT	423 WALKER STREET	WOODBINE	IA	51579	712-6472840
NIGHTINGALE D-WYOMING	Linda Nightingale	126 W MAIN ST	WYOMING	IA	52362	563-4883993
MEDSYNC PHARMACY	DANIEL FUCHS	801 S VISTA AVENUE	BOISE	ID	83705	208-3647777
BUHL DRUG HM	Daniel Fuchs	419 BROADWAY AVE. SOUTH	BUHL	ID	83316	208-5435353
KWIK-MEDS HM	Daniel Fuchs	256 OVERLAND AVE	BURLEY	ID	83318	208-8786337
MEDICAL CLINIC PHARMACY	Tyler Higgins	315 E. ELM ST. STE 150	CALDWELL	ID	83605	208-4591503
WATKINS PHARMACY	BEN WATKINS	104 N. MAIN STREET	CASCADE	ID	83611	208-3824204
HOLLIS FAMILY PHARMACY	Anthony Hollis	845 S SUB STATION RD	EMMETT	ID	83617	208-2413786
IRWIN DRUG HM	Chad Jungert	146 WEST MAIN	GRANGEVILLE	ID	83530	208-9831090
COMMUNITY FAMILY CLINIC	Elisha Suldan	2100 ALAN ST	IDAHO FALLS	ID	83404	208-4707979

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
VISTARA PHARMACY	Rajdeep Patel	460 MEDICAL PARK DR STE 101	LENOIR CITY	TN	37772	865-3282482
DUREN'S HEALTHMART	Jerry Duren	119 SOUTH MILL STREET	LINDEN	TN	37096	931-5892146
LORETTO DRUGS HM	Tim Holt	106 CHURCH ST	LORETTO	TN	38469	931-8535910
WIL SAV DRUGS	Bryce Joslin	4249 HIGHWAY 411 STE 5	MADISONVILLE	TN	37354	423-4429727
BAKER BROTHERS DRUGS	Dawn Hafer	120 E MAIN ST.	MANCHESTER	TN	37355	931-7283226
VILLAGE PHARMACY	Lisa Lawson	2541 EAST BROADWAY AVE	MARYVILLE	TN	37804	865-9839591
SUPER DRUG	PAUL MOTHERAL	2340 CEDAR STREET	MCKENZIE	TN	38201	731-3523242
GRAVES FAMILY PHARMACY	Chad Graves	357 W MAIN ST	MCMINNVILLE	TN	37110	404-5509984
MCMINNVILLE PHARMACY	Hina Patel	2652 OLD NASHVILLE HWY	MCMINNVILLE	TN	37110	931-2135310
STACY'S WELLNESS PHARMACY	Stacy Hazelwood	485 N CHANCERY ST STE 1	MCMINNVILLE	TN	37110	931-4740600
THE RX SHOPPE	RODNEY TUBBS	3315 HACKS CROSS RD #111	MEMPHIS	TN	38125	901-7379797
MIDDLETON PHARMACY	Danny Austin	141 N MAIN ST	MIDDLETON	TN	38052	731-3761070
BOATWRIGHT DRUG HM	Steven Boatwright	7899 LEROY BOATWRIGHT ST	MILLINGTON	TN	38053	901-8722214
JJ BEANS AT HOWARDS LLC	Chad B Huntsman	3336 W ANDREW JOHNSON HWY	MORRISTOWN	TN	37814	423-5818436
COLLEGE PARK PHARMACY	Chad Huntsman	2106 EAST ANDREW JOHNSON HWY	MORRISTOWN	TN	37814	423-5860721
PHARMACY EXPRESS	Susan Taylor	1706 BUFFALO TRAIL	MORRISTOWN	TN	37814	423-8392401
ADAMS PHARMACY	Sam Adams	851 S. SHADY STREET	MOUNTAIN CITY	TN	37683	423-7271210
MILLS FAMILY PHARMACY	Craig Buckner	2994 SOUTH CHURCH ST	MURFREESBORO	TN	37127	615-8951641
BECKMAN'S PRESCRIPTION	Sylvia Beckman	120 E COLLEGE ST	MURFREESBORO	TN	37130	615-8936661
GREEN HILLS PHCY	Andrew Byrd	2140 BANDYWOOD DR	NASHVILLE	TN	37215	615-2923359
NEW HORIZON PHARMACY	Nehal Patel	3443 DICKERSON PIKE 110	NASHVILLE	TN	37207	615-8507969
BRADLEY DRUG CO HM	Phil Bradley	5208 CHARLOTTE AVE	NASHVILLE	TN	37209	615-3832741
FOUNTAINRX	Ryan Hollingsworth	6900 LENOX VILLAGE DR STE 14	NASHVILLE	TN	37211	615--864-89
STANIFER DRUGS	Russell Essary	420 N BROAD ST	NEW TAZEWELL	TN	37825	423-6267337
NEWBERN DRUG HEALTHMART	Mark Davis	625 W MAIN ST STE A	NEWBERN	TN	38059	731-6279573
OAK RIDGE PHARMACY	Saad Aqqad	854 MAIN STREET WEST	OAK RIDGE	TN	37830	865-4820345

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
JEROME DRUG HM	Dan Fuchs	111PIONEER CT STE 2	JEROME	ID	83338	208-3242440
OWL DRUG SOUTHWAY	Brian Auer	720 16TH AVE STE 1	LEWISTON	ID	83501	208-7435528
BEAR LAKE DRUG	DEAN WALLENTINE	836 WASHINGTON	MONTPELIER	ID	83254	208-8471421
BEAR LAKE CHC MONTPELIER	Melissa Duce	152 S 4TH ST	MONTPELIER	ID	83254	208-9043600
SAV MOR DRUG	JEFF JAUSORO	490 NORTH 2ND EAST	MOUNTAIN HOME	ID	83647	208-5873346
IDAHO DRUG	TY SWENSEN	139 EAST MAIN	RIGBY	ID	83442	208-7456831
MEDICAL OFFICE PHARMACY	DAN FUCHS	476 CHENEY DR. W. STE 140	TWIN FALLS	ID	83301	208-7343007
DICKS PHCY TWIN FALLS HM	Daniel Fuchs	526 K SHOUP AVE W	TWIN FALLS	ID	83301	208-7347373
ORCHARD DRUG HM	Daniel Fuchs	995 WASHINGTON ST SOUTH	TWIN FALLS	ID	83301	208-7367060
WINONA PHARMACY	Daniel S Fuchs, RPh	615 FILER AVE	TWIN FALLS	ID	83301	208-7347373
HUB CITY DRUG	Dan Fuchs	447 N IDAHO ST	WENDELL	ID	83355	800-5555555
ABINGDON TELEPHARMACY	Adonis Ducre	503 S COMMERICAL DR	ABINGDON	IL	61410	309-7031094
ADDISON PHARMACY	TUSHAR MEHTA	414 W. LAKE STREET	ADDISON	IL	60101	630-5430988
SHIELDS FAMILY PHARMACY	Seth Anato	1 PROFESSIONAL DRIVE	ALTON	IL	62002	618-4630000
NEUPATH VITAL RX	Nisha Jani	425 LAKE ST STE A	ANTIOCH	IL	60002	224-7888557
KEEFERS PHARMACY	Beau Diab	2012 E NORTHWEST HWY	ARLINGTON HEIGHTS	IL	60004	847-2553220
POTTER DRUG 2	Timothy Gleason	214 ABE LINCOLN DR UNIT 2	ATHENS	IL	62613	217-9527030
HARRYS PHARMACY INC HM	Scott Borntrreger	620 E JACKSON ST	AUBURN	IL	62615	217-4386141
YOUR PHARMACY	Sheren Alshwaiyat	4050 HEALTHWAY DR STE 100	AURORA	IL	60504	630-3183616
BARTLETT PHARMACY	NAHREN KHOSHABA	300 W BARTLETT AVE	BARTLETT	IL	60103	630-8555178
HIDEG PHARMACY HM	Don Johnston	8601 WEST MAIN	BELLEVILLE	IL	62223	618-3984400
WESTCHESTER PHARMACY	TUSHAR MEHTA	4009 WARREN AVE STE 100	BELLWOOD	IL	60104	708-8972424
GRAND PHARMACY	Behrouz Hoghoughi	229 W GRAND AVE STE F	BENSENVILLE	IL	60106	630-4223162
KIMMEL CHAPLAIN PHARMACY	JULIE GIACONE	315 NORTH MAIN STREET	BENTON	IL	62812	618-4382822
THE RIGHT PHARMACY	Faisal Khan	224 N BOLINGBROOK DR	BOLINGBROOK	IL	60440	800-5555555
BYRON SNYDERS PHARM	Kevin Fenwick	100 W BLACKHAWK DR	BYRON	IL	61010	815-2345466
FAMILY DRUG	Ben Calcaterra	2300 W MAIN ST	CARBONDALE	IL	62901	618-5295351

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
BETTERX LLC	Robert Self	200 CHICKASAW RIDGE DRIVE; SUITE 25	OAKLAND	TN	38060	901-2900428
COOKE'S PHARMACY	GINA MOSER	116 WHITEWATER DRIVE	OCOE	TN	37361	423-2160050
FIRST CARE PHARMACY	SAMUEL RANDOLPH	186 CREEKSIDE DRIVE	OCOE	TN	37361	423-2999029
VILLAGE RX	Thomas Heilman	1100 DONELSON AVE	OLD HICKORY	TN	37138	615-5743766
LEACH PHARMACY	Blake Leach	960 E TRI COUNTY BLVD	OLIVER SPRINGS	TN	37840	865-4326337
EASTWOOD PHARMACY HM	Casey Vernon	1325 EASTWOOD ST	PARIS	TN	38242	731-6420451
PARIS PHARMACY	MICHAEL SWAIM	1025 B MINERAL WELL	PARIS	TN	38242	731-4077220
PERKINS DRUGS PARIS HM	Randall Perkins	110 EAST WASHINGTON ST.	PARIS	TN	38242	731-6423531
MEDICAL CENTER PHCY HM	Rob Nichols	234 TYSON AVENUE	PARIS	TN	38242	731-6422451
CITYDRUGSTOREOFPAR SONSINC	Kimothy Phillips	18 W MAIN ST	PARSONS	TN	38363	731-8476337
STEPHENS PHARMACY	Kara Upchurch	3135 MAIN ST	PIKEVILLE	TN	37367	423-4472434
VAUGHN PHARMACY	DWIGHT DISNEY	2141 EMORY ROAD	POWELL	TN	37849	865-9471581
SUTTON FAMILY PHARMACY	Jennie Sutton	992 MILL STREET	PULASKI	TN	38478	931-2421080
ROAN MOUNTAIN PHARMACY	Jordan Baker	8251 HWY 19 E	ROAN MOUNTAIN	TN	37687	423-7723591
CORNER DRUG	David Dew	414 MAIN ST	ROCKY TOP	TN	37769	865-4262851
RURAL HLTH SERVICES PHCY	Linda Buck	4307 HIGHWAY 66 S	ROGERSVILLE	TN	37857	423-9211621
EAST END PHARMACY	Casey Waddell	5630 E ANDREW JOHNSON HWY	RUSSELLVILLE	TN	37860	423-2891755
HESTER DRUG	Todd Gean	114 E MAIN ST	RUTHERFORD	TN	38369	731-6656176
SALE CREEK/FIRST CARE	JARRETT SWAFFORD	14821 DAYTON PIKE STE 115	SALE CREEK	TN	37373	423-4869404
MAIN STREET PHARMACY HM	Catherine Brown	110 MAIN STREET	SAVANNAH	TN	38372	731-9256246
CARROLL PHARMACY	DAVID CARROLL	835 PICKWICK ST	SAVANNAH	TN	38372	731-9255551
THE PRESCRIPTION SHOP SAV	Julie C Cornise	765-B FLORENCE ROAD	SAVANNAH	TN	38372	731-9253956
BOB'S DISCOUNT PHCY HM	Todd Gean	555 PICKWICK ST	SAVANNAH	TN	38372	731-9251152
MID-TOWN PHARMACY	Ann Manley	270 E COURT AVE STE C	SELMER	TN	38375	731-6487008
JOYNER RX	Jack Tyler Joyner	185 W COURT AVE	SELMER	TN	38375	731-4340180
DEBERRY DRUGS HM	Todd Gean	834 MULBERRY AVE	SELMER	TN	38375	731-6456100
SEYMOUR ADVALUE PHCY HM	Joe Graham	10721 CHAPMAN HWY STE 6	SEYMOUR	TN	37865	865-5770471

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
C S FAMILY PHCY INC. HM	Phil Thomas	942 ARMY TRAIL ROAD	CAROL STREAM	IL	60188	630-2130800
FAMILY DRUG HM	Ben Calcaterra	1205 S. DIVISION	CARTERVILLE	IL	62918	618-9852441
BYRD WATSON DRUG HM	Wes Breeze	1071 W. BROADWAY POB 1747	CENTRALIA	IL	62801	618-5322200
COUNTY MARKET #518	ARTHUR AWERKAMP	2901 W. KIRBY AVE	CHAMPAIGN	IL	61821	217-3513108
COUNTY MARKET PHCY #224	CHRISTOPHER NIEMANN	1099 JASON PLACE	CHATHAM	IL	62629	217-4832496
VICTORS MEDICENTER PHCY	Eric Schreiber	2323 OLD PLANK RD	CHESTER	IL	62233	618-8262511
LOCAL HEALTH PHARMACY	Adonis Ducre	2545 W. DIVERSEY AVE. #104	CHICAGO	IL	60647	773-6735493
CUSTOM MED PLUS	ANTHONY PANICI	4312 N PULASKI RD	CHICAGO	IL	60641	773-2499100
TOUHY FAMILY PHARMACY	Chet Patel	6201 W TOUHY AVE STE 101	CHICAGO	IL	60646	708-8315910
CAREFIRST PHARMACY	Danneila Olmos	2253 N CICERO AVE	CHICAGO	IL	60639	773-4137540
CORNERSTONE PHARMACY	Danniela Olmos	10555 S EWING AVE STE 1	CHICAGO	IL	60617	773-9022356
UPTOWN PHARMACY	EDUARDO ALPIZAR	4535 N SHERIDAN RD	CHICAGO	IL	60640	773-9440525
NEW CITY HALSTED PHCY	Elliott Rock	1460 N HALSTED ST STE 101	CHICAGO	IL	60642	312-6249397
CHICAGO HEALTHMART PHCY	Ephrem Gebremedhin	1260 WEST DEVON AVE	CHICAGO	IL	60660	773-9631737
WECARE PHARMACY	Fadi Alahmed	104 W 111TH ST	CHICAGO	IL	60628	773-6608606
RISHI PHARMACY	HARESH KHAKHKHAR	4909 W DIVISION	CHICAGO	IL	60651	773-2871200
PHARMACY ONE PLUS	Jawad Rabi	4753-55 NORTH KEDZIE AVE.	CHICAGO	IL	60625	773-2679275
HEALTHY ZONE PHARMACY	Moutaz Hermaidat	7107 W BELMONT AVE STE 6	CHICAGO	IL	60634	708-7221061
OAK STREET PHARMACY	Omar Pharmacy	850 W 63RD PKWY STE E	CHICAGO	IL	60621	872-2157111
ELSDON MEDICAL PHARMACY	Suha Abdallah	4254 W 55TH ST	CHICAGO	IL	60632	773-5822660
FULLERTON PHARMACY	TAE HWANG	5305 W FULLERTON AVE	CHICAGO	IL	60639	773-8874052
KIRKS PHARMACY	JAMES KIRKPATRICK	114 WEST MARKET	CHRISTOPHER	IL	62822	618-7242741
HOMERUN FOOD AND PHARMACY	RIBHI QATTOUM	806 S JASPER ST	DECATUR	IL	62521	217-8481449
FELKERS SNYDER PHCY DIXON	Kevin Fenwick	301 N GALENA AVENUE	DIXON	IL	61021	815-2848000
ANDES HEALTH MART	Chip Andes	805 WEST FAYETTE AVENUE	EFFINGHAM	IL	62401	217-3429393
KIRBY FOODS	Courtney Carr	101 S MERCHANT	EFFINGHAM	IL	62401	217-3424301
PRIMISHA PHARMACY	PRITESH PATEL	750 FLETCHER DR STE 103	ELGIN	IL	60123	847-7426700

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
CALDWELL'S DRUG STORE	LYNN CALDWELL	511 W MAIN ST	SMITHVILLE	TN	37166	615-5971988
SMITH-TURNER DRUG STORE	Kendrick Smith	140 CHURCH ST	SNEEDVILLE	TN	37869	423-7332322
LANDRY'S EAST PHARMACY	Cindi Landry	17392 HWY 64	SOMERVILLE	TN	38068	800-5555555
LANDRY'S PHARMACY HM	Cindi Landry	25 WOODBRIDGE, STE B	SOMERVILLE	TN	38068	901-4931553
SPRING CITY PHARMACY	Jonathan Zimmerman	171 CLINTON AVE	SPRING CITY	TN	37381	423-3656351
SOUTH SIDE DRUG CO INC	Drew Sloan	1000 SOUTH MAIN ST	SPRINGFIELD	TN	37172	615-3843546
LITTLE DRUGS	Brent Hickey	510 S MAIN ST	SWEETWATER	TN	37874	423-3377933
TELLICO FAMILY WELLNESS	JASON MILLER	707 VETERAN'S MEMORIAL DRIVE	TELLICO PLAINS	TN	37385	423-2536003
EDDIE'S PHARMACY HM	Eddie Sturgeon	114 DAVY CROCKETT SHOP CN	TRENTON	TN	38382	731-8551000
VONORE DRUG FAMILY	KRISTI MILLER	1121 HIGHWAY 411	VONORE	TN	37885	423-8846274
GRIFFITH FAMILY PHARMACY	James Griffith	1236 KNOXVILLE HWY	WARTBURG	TN	37887	423-3466337
DUREN PHARMACY HM	Jerry Duren	215 WOODS MEMORIAL BLVD	WAYNESBORO	TN	38485	931-7225466
DURENS CLINIC PHCY	JERRY DUREN	107 J V MANGUBAT	WAYNESBORO	TN	38485	931-7224183
WHITE HOUSE PHARMACY	Andrew Bryd	491 SAGE RD N STE 1200	WHITE HOUSE	TN	37188	615-3341212
CLA RX BIG CTRY DERM PHCY	Cody Clark	17 WINDMILL CIR STE B	ABILENE	TX	79606	325-7045222
JAMES MCCOYS MIDTOWN DRUG	James McCoy	1417 S WILLIS ST	ABILENE	TX	79605	325-2328866
JAMES MCCOYS DRUG SOUTH	James McCoy	1725 ANTILLEY RD	ABILENE	TX	79606	325-6768900
JAMES MCCOYS DRUGSTORE	James McCoy	839 N JUDGE ELY BLVD	ABILENE	TX	79601	325-6772300
BARNES & WILLIAMS DRUG #1	Jordan Talley	701 HICKORY ST POBOX 2855	ABILENE	TX	79601	325-6779191
BARNES & WILLIAMS DRUG #2	Jordan Talley	4601 S 14TH ST	ABILENE	TX	79605	325-6953784
SANDERS DRUG STORE	Jera Fairley	104 S MAIN ST	ALBANY	TX	76430	325-7623979
RUSHING - GONZALEZ DHM	Roddy Gonzalez	301 E MAIN	ALICE	TX	78332	361-6644368
ALLEN FAMILY DRUG	Andrew Komuves	317 CENTRAL EXPY N	ALLEN	TX	75013	972-3909888
INTEGRICARE PHCY	Bich Pham	1505 W MCDERMOTT DR #125	ALLEN	TX	75013	972-2129368
ALLEN PHARMACY & WELLNESS	Deepa Pattani	945 W STACY RD STE 110	ALLEN	TX	75013	703-8617467
LIFETIME PHARMACY	Jay Gorle	960 RIDGEVIEW DR STE 120	ALLEN	TX	75013	214-4915599
CITY DRUG STORE HM	Mario Juarez	202 EAST AVE E	ALPINE	TX	79830	432-8372252

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
ELIZABETH PHARMACY	Karrie Sabinson	218 N MAIN ST	ELIZABETH	IL	61028	815-8583555
DBA ELMWOOD PHCY	Adonis Ducre	108 E. MAIN P.O BOX 167	ELMWOOD	IL	61529	309-7422611
ERIE TELEPHARMACY	Adonis Ducre	707 MAIN ST SUITE A	ERIE	IL	61250	309-5884064
SIMPLY PURE RX	Sami Musleh	1607 BENSON AVE	EVANSTON	IL	60201	847-2278020
WELLCARE PHARMACY LLC	Hani Abdullah	9760 S KEDZIE AVE STE12	EVERGREEN PARK	IL	60805	708-9305927
COUNTY MARKET PHARMACY	Art Awerkamp	1050 E FORT ST POB 290	FARMINGTON	IL	61531	309-2452335
GLEN ELLYN M/S 755	Robert ListECKi	486 ROOSEVELT ROAD	GLEN ELLYN	IL	60137	630-4695200
GOLCONDA PHARMACY	Amanda Etienne	226 S ADAMS ST	GOLCONDA	IL	62938	618-6838253
BOND COUNTY PHARMACY LLC	Scott Bornreger	224A E HARRIS AVE	GREENVILLE	IL	62246	618-6905000
J AND M PHARMACY	Adonis Ducre	31 W 155TH ST STE 1000	HARVEY	IL	60426	773-2856290
LOGAN PRIMARY PHARMACY	Ben Calcaterra	401 RUSHING DRIVE	HERRIN	IL	62948	618-9979997
WHOLESOME PHARMACY	Pooja Patel	2069 BARRINGTON RD.	HOFFMAN ESTATES	IL	60169	224-6539878
AMAR PHARMACY	Viral Parikh	2500 W HIGGINS RD STE 450	HOFFMAN ESTATES	IL	60169	847-9448261
BANDY DRUG HM	GARY BANDY	905 GRAND AVENUE	JOHNSTON CITY	IL	62951	618-9838272
JD BROWN & CO HM	Jim Pritz	837 PLAINFIELD ROAD	JOLIET	IL	60435	815-7230611
LANARK PHARMACY	Karrie Sabinson	102 N BROAD ST	LANARK	IL	61046	815-4932080
LENA DRUG STORE	Kip Sabinson	154 WEST MAIN BOX 666	LENA	IL	61048	815-7453700
COUNTY MRKT PHCY #458	CHRISTOPHER NIEMANN	518 S. MAIN STREET	LEWISTOWN	IL	61542	309-5473731
TELECARE PHARMACY	Ann Marie	324 PETERSON RD	LIBERTYVILLE	IL	60048	224-8421200
PETRANEKS PHARMACY	Beau Diab	426 N MILWAUKEE AVE	LIBERTYVILLE	IL	60048	847-3622005
CAREPARTNERS PHARMACY	Kam Ghazvini	326 PETERSON RD	LIBERTYVILLE	IL	60048	224-2941199
PROHEALTH DRUGS LV	Pankit Bhalodia	3021 FALLING WATERS BLVD STE A	LINDENHURST	IL	60046	224-9933737
SCHOTT'S PHARMACY	Adonis Ducre	800 W BLUFF ST	MARSEILLES	IL	61341	815-7952700
MARYVILLE PHARMACY	Harry Zollars	2700 NORTH CENTER ST	MARYVILLE	IL	62062	618-2887474
PARAS PHARMACY, INC	JITESH PATEL	1516 W MADISON	MAYWOOD	IL	60153	708-3454658
YORK PHARMACY	Keith Doehring	107 E MAIN STREET	MCLEANSBORO	IL	62859	618-6433524

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
ALVARADO PHARMACY	David Paschal	601 N PARKWAY DR STE A	ALVARADO	TX	76009	972-7751180
GRAND HEALTH MART PHCY	Mario Hernandez	3500 NE 24TH	AMARILLO	TX	79107	806-3507455
AMARILLO PHARMACY	RK SAMALA	6010 S WESTERN ST BLDG C STE 100	AMARILLO	TX	79110	806-8039401
SOUTH PARK PHARMACY	Sim Kongdara	5901 SOUTH BELL SUITE C32	AMARILLO	TX	79109	806-3542428
ANNA FAMILY PHCY	NAGA CHANDRIKA GOKARAJU	813 W WHITE ST STE 200	ANNA	TX	75409	972-8952450
ANSON PLAZA PHARMACY	Kelly Stovall	1150 W COURT PLAZA	ANSON	TX	79501	325-8233203
RANDOL MILL PHCY	GARY DALEY	1014 N FIELDER RD	ARLINGTON	TX	76012	817-2741883
FATE PHARMACY	Hari CHINTAPALLI	707 N FIELDER RD STE B	ARLINGTON	TX	76012	817-7732833
BOWEN PHARMACY	Hussein Younis	2417 W PLEASANT RIDGE RD	ARLINGTON	TX	76015	817-9184900
KVN PHARMACY	KEVIN NGUYEN	4860 MATLOCK RD STE 120	ARLINGTON	TX	76018	817-9620417
COOPER SPECIALTY PHARMACY	Rakesh Patel	6109 S COOPER ST STE 111	ARLINGTON	TX	76001	817-4192822
M & A PHARMACY	YALING LEE	8200 MATLOCK RD #150	ARLINGTON	TX	76002	682-2227830
AUBREY PHARMACY	Steve Coomes	701 S HIGHWAY 377	AUBREY	TX	76227	940-4400400
BRODIE LANE PHARMACY	Aaron Williams	8916 BRODIE LANE STE 300	AUSTIN	TX	78748	512-3628083
ALTO PHARMACY AUSTIN	Ajay Khatri	4175 FREIDRICH LN #202	AUSTIN	TX	78744	954-4464063
MEDSAVERS PHARMACY	CHRIS JOHNSON	1800 W 35TH STREET	AUSTIN	TX	78703	512-4659292
RITE CARE PHARMACY II AUS	Christina Garcia	3706 GUADALUPE ST STE C	AUSTIN	TX	78705	512-7179988
METRIX PHARMACY	Emmanuel Amadi	2121 PARMER LN #103C	AUSTIN	TX	78727	512-8140720
TARRYTOWN PHARMACY INC	Mark Newberry	2727 EXPOSITION BLVD	AUSTIN	TX	78703	512-6177312
LIBERTY PHARMACY	Rohit B. Chaudhary	8650 SPICEWOOD SPGS 106	AUSTIN	TX	78759	512-2497500
RITE-AWAY PHCY 4	ROHIT CHAUDHARY	4203 JAMES CASEY ST STE A	AUSTIN	TX	78745	512-8272250
RITE AWAY #3	ROHIT CHAUDHARY	730 W. STASSNEY LN #160	AUSTIN	TX	78745	512-8272600
LAURA'S PHARMACY	LAURA TEMPLE	232 WEST MAIN STREET	AZLE	TX	76020	817-4064546
BANDERA DRUG	WAYNE ANTENEN	1100 MULBERRY STREET	BANDERA	TX	78003	830-7963111
KINGS PHCY BEAUMONT	Greg Hamby	3610 N MAJOR DRIVE	BEAUMONT	TX	77713	409-8600040
LOVOI AND SONS PHARMACIES	Jasper Lovoi	3480 FANNIN ST	BEAUMONT	TX	77701	409-8337538

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
SAAHIL PHARMACY	KALPESH PATEL	1905 RICE STREET	MELROSE PARK	IL	60160	708-4500064
QUIRE PHARMACY	Lindsay Cunningham	1835 N 19TH STREET #101	MELROSE PARK	IL	60160	+18-0055555
BROADWAY AVE. PHARMACY	TUSHAR MEHTA	151 BROADWAY AVE	MELROSE PARK	IL	60160	708-4500400
METROPOLIS DRUG HM	Ashley Thompson	1001 E 5TH STREET	METROPOLIS	IL	62960	618-5248316
METROPOLIS DRUGS NO. HM	Tim Lawson	1201 WEST 10TH	METROPOLIS	IL	62960	618-5248400
BODE DRUG INC MOUND CITY	Carl Bode	211 MAIN ST. PO BOX 110	MOUND CITY	IL	62963	618-7489253
MT PROSPECT HM	SUNG CHOE	1012 S ELMHURST RD	MOUNT PROSPECT	IL	60056	224-7352218
BYRD-WATSON TIMES SQUARE	ADAM BREEZE	3401 BROADWAY	MOUNT VERNON	IL	62864	618-2445400
MOWEAQUA PHARMACY HM	Terry Traster	620 N PUTNAM STREET	MOWEAQUA	IL	62550	217-7683832
INTERDEPENDENT PHARMACY	Byron Strakusek	404 N SEYMOUR AVE	MUNDELEIN	IL	60060	224-4750020
OSWALD'S PHARMACY HM	Alex Anderson	88 W GARTNER RD STE 112	NAPERVILLE	IL	60540	630-3552500
NAPERVILLE PHARMACY	HAROON KHAN	1020 E OGDEN AVE, STE 114	NAPERVILLE	IL	60563	630-9221100
GARDEN FRESH PHCY INC	Majd Ibrahim	955 W 75TH ST	NAPERVILLE	IL	60565	708-9459058
DOEHRING PHARMACY	Keith Doehring	143 S WASHINGTON ST	NASHVILLE	IL	62263	618-3273214
YES VITAL RX INC	Nisha Jani	1817 SHERIDAN ROAD	NORTH CHICAGO	IL	60064	224-6565797
AVICENNA PHARMACY	AHMED MAHAFAZH	10837 S CICERO STE 110C	OAK LAWN	IL	60453	708-5297222
OAK LAWN HEALTHMART PHCY	MOUTAZ HEMAIDAT	4700 W 95TH ST STE 101	OAK LAWN	IL	60453	708-4434310
IMMEDIATE CARE PHARMACY	Julia Passarella	15210 SUMMIT AVE STE #1	OAKBROOK TERRACE	IL	60181	630-2826003
SCRIPTSRX PHARMACY	Matthew Cunningham	1815 S MEYERS RD STE 100	OAKBROOK TERRACE,	IL	60181	800-5927174
OREGON SNYDERS PHARM	Kevin Fenwick	201 N 4TH STREET	OREGON	IL	61061	815-7327340
PROHEALTH DRUGS	PANKIT BHALODIA	777 N QUENTIN RD	PALATINE	IL	60067	224-9933737
PECATONICA PHARMACY HM	Laura Wiegert	413 MAIN STREET	PECATONICA	IL	61063	815-2391200
POTTER DRUG	Timothy Gleason	200 S 6TH ST	PETERSBURG	IL	62675	217-6322288
COUNTY MARKET BEST BUY	Art Averkamp	825 WEST WASHINGTON ST	PITTSFIELD	IL	62363	217-2855515
POLO PHARMACY	Kip Sabinson	111 E MASON ST	POLO	IL	61064	815-7453700
SNYDER PHCY POP GROVE	Kevin Fenwick	13521 ILLINOIS ROUTE 76	POPLAR GROVE	IL	61065	815-7651300
ROGANS COUNTRY PHARMACY	Dean Rogan	201 E COMMERCIAL ST PO241	PULASKI	IL	62976	618-3426737

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
LUPARELLOS CORNER PHCY	Nick Patel	3570 FANNETT RD	BEAUMONT	TX	77705	409-8423222
DELIVERIT PHCY BEDFORD	Ehab Abughazaleh	2901 BROWN TRAIL	BEDFORD	TX	76021	713-5626775
BEDFORD PHARMACY	George Mathunny	2816 CENTRAL DRIVE	BEDFORD	TX	76021	817-7868011
WELL LAKE SPEC PHCY LLC	DEANDREA HOGG	6565 W LOOP S STE110B	BELLAIRE	TX	77401	281-9734731
SOUTHSIDE PHARMACY	HARISH KATHARANI	6330 W LOOP S STE 700D	BELLAIRE	TX	77401	713-6608890
ALTO PHARMACY HOUSTON	Mattieu Gamache-Asselin	4950 TERMINAL ST STE 200	BELLAIRE	TX	77401	800-8745881
BELLS FAMILY DRUG	Bruce Mcanally	103 W BELLS BLVD	BELLS	TX	75414	903-9657383
NORTHSTAR PHARMACY	Rima Patel	6014 SOUTHWEST BLVD	BENBROOK	TX	76109	804-4335720
CARVER DRUG	Colton Kidd	1110 E 11TH PLACE	BIG SPRING	TX	79720	432-6064961
RIVER ROAD PHARMACY	Adam Majors	910 RIVER ROAD STE 103	BOERNE	TX	78006	405-5907103
ROCK PHARMACY LLC	PETER ORAEKWE	1201 S MAIN ST STE 121	BOERNE	TX	78006	830-3575052
BONHAM FAMILY DRUG	Bruce McAnally	100 E SAM RAYBURN DR	BONHAM	TX	75418	903-5837325
CITY DRUG OF BRADY HM	Al Pearson	704 WEST 17TH STREET	BRADY	TX	76825	325-5972325
W5 PHARMACY	Cody Wimberley	1110 E WALKER ST	BRECKENRIDGE	TX	76424	254-5596979
LAS PALMAS PHARMACY	JOEL BENITEZ	864 CENTRAL BLVD SUITE 1200	BROWNSVILLE	TX	78520	956-5427400
LA FARMACIA	Joel Benitez	5460 PEREDESLINE RD STE199	BROWNSVILLE	TX	78526	956-6210228
COMPLETE RX PHARMACY	PABLO ESCOBAR	1885 E PRICE RD STE B	BROWNSVILLE	TX	78521	956-5543532
THE FRIENDLY PHCY	PAULA FRASER	3302 BOCA CHICA BLVE STE 107	BROWNSVILLE	TX	78521	956-5441200
UNITED CARE PHCY BRWNSVL	PAULA FRASER	1755 WEST PRICE ROAD STE C	BROWNSVILLE	TX	78520	956-5460444
LIVE OAK PHARMACY	DENNIS HELBERT	3707 AUSTIN AVE	BROWNWOOD	TX	76801	325-6432648
JACOBS FAMILY PHARMACY	Tim Jacobs	2701 AUSTIN AVE	BROWNWOOD	TX	76801	800-5555555
VILLAGE FOODS & PHARMACY	James Lewis	3030 E 29TH ST STE 100	BRYAN	TX	77802	800-5555555
BCS PHARMACY	Maikel Gadelseyed	2601 OSLER BLVD	BRYAN	TX	77802	979-4859123
JOHNSON PHARMACY	Kirat Shahiwal	113 NE JOHNSON AVE # 300	BURLESON	TX	76028	817-7894099
BEST VALUE WEST	Steven Maddox	124 W RENFRO ST	BURLESON	TX	76028	817-9955196
MEDIC PHARMACY @ CANADIAN	Greg Huenergardt	200 CHEYENNE AVE	CANADIAN	TX	79014	806-3236171
MEDI DRIVE PHARMACY	ANGELA BAZALDUA	507 23RD ST	CANYON	TX	79015	806-6551024

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
POTTER DRUG 3	Timothy Gleason	441 S STATE STREET	ROCHESTER	IL	62563	217-6322288
HARDIN COUNTY PHCY	Amanda Etienne	#7 FERRELL RD, PO BOX 37	ROSICLARE	IL	62982	618-2856618
COUNTY MARKET PHCY #212	Art Awerkamp	520 W CLINTON	RUSHVILLE	IL	62681	217-3223383
SHEFFIELD TELEPHARMACY	Adonis Ducre	134 S MAIN ST	SHEFFIELD	IL	61361	815-4548054
LV HEALTH & WELLNESS	Vincent Williams	1219 THOUVENOT #111	SHILOH	IL	62269	618-5899889
SUPER CARE PHARMACY	Jaward Rabi	8305 SKOKIE BLVD	SKOKIE	IL	60077	847-9838856
MOODY PHARMACY EDI HM	Seamus Kloos	109 E BROADWAY	SPARTA	IL	62286	618-4432715
JOHNSON'S PHCY	DAVID JOHNSON	203 E ST PAUL ST	SPRING VALLEY	IL	61362	815-6645050
COUNTY MARKET PHCY #225	ART AWERKAMP	210 EAST CARPENTER ST	SPRINGFIELD	IL	62702	217-5283182
COUNTY MARKET PHY 226	Art Awerkamp	1501 S DIRKSEN PARKWAY	SPRINGFIELD	IL	62703	217-5278408
COUNTY MARKET PHCY #228	Art Awerkamp	1903 W MONROE ST	SPRINGFIELD	IL	62704	217-7870340
COUNTY MARKET PHCY 227	Art Awerkamp	2777 S SIXTH AVE	SPRINGFIELD	IL	62703	217-7442296
ST. JOSEPH DRUGS INC	KATHLEEN MUNDAY	204 N MAIN	ST JOSEPH	IL	61873	217-4692232
TONY'S MEDICENTER PHCY	Eric Schreiber	324 WEST BROADWAY	STEELEVILLE	IL	62288	618-9653511
CAIN'S DRUG STORE INC	Scott Borntreger	1401 NORTH 8TH STREET	VANDALIA	IL	62471	618-2830196
BODE DRUG VIENNA	CARL BODE	803 1/2 N 1ST ST	VIENNA	IL	62995	618-6583784
WARREN DRUG STORE HM	Karrie Sabinson	137 E MAIN STREET	WARREN	IL	61087	815-7453700
J AND S PROFESSIONAL PHCY	JOYCE FOGELMAN	309 W ST LOUIS STREET	WEST FRANKFORT	IL	62896	618-9372416
WESTMONT PHARMACY	Sazan Sylejmani	2 N CASS AVE	WESTMONT	IL	60559	630-9692043
WINNEBAGO SNYDERS PHARM	Kevin Fenwick	101 LANDMARK DRIVE	WINNEBAGO	IL	61088	815-3353535
CONNEY'S PHARMACY	SADAF FECTO	736 ELM STREET	WINNETKA	IL	60093	847-4460032
MEDWIZ SPECIALTY PHARMACY	Ari Ungar	940 S FRONTAGE RD STE 500	WOODRIDGE	IL	60517	630-5801700
MEDWIZ OF ILLINOIS	Eric Newhouse	940 S FRONTAGE RD STE 400	WOODRIDGE	IL	60517	845-6371354
CROWDERS UPTOWN DRUG STOR	Steve Anderson	631 16TH ST	BEDFORD	IN	47421	+18-0055555
LINCOLN PLAZA PHARMACY	Steve Anderson	629 LINCOLN AVE	BEDFORD	IN	47421	812-2771702
KAUP PHARMACY	LORRI KAUP	104 W MAIN ST	BERNE	IN	46711	260-5893330
FAMILY PHARMACY HM	Stanley Deweese	508 W 11TH STREET	BICKNELL	IN	47512	812-7354444

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
PHARM HOUSE DRUG CARRIZO	LOREN PIERCE	314 N 5TH ST	CARRIZO SPRINGS	TX	78834	830-8762516
HEBRON PHARMACY	Dat Nguyen	4100 FAIRWAY DR. STE 500	CARROLLTON	TX	75010	972-3947015
TRINITY PHARMACY	JONATHAN LIPE	1925 E ROSEMEADE PKWY	CARROLLTON	TX	75007	972-4924411
PRESCRIPTION DISP LAB INC	Ray Solano	101 COMMERCIAL PKWY	CEDAR PARK	TX	78613	512-4269165
CAROLS PHARMACY	Landon Schwartz	316 SOUTH COMMERCE	CENTERVILLE	TX	75833	903-5367326
CLEBURNE DRUG INC	Monte Barron	310 N RIDGEWAY DR	CLEBURNE	TX	76033	817-6452415
BEST VALUE ROYCES PHCY	Steven Maddox	502 NORTH MAIN	CLEBURNE	TX	76033	817-9955196
TRINITY SPECIALTY PHCY 2	Kiran Kali	200 E BOOTHE ST # 103	CLEVELAND	TX	77327	281-8067680
CLEVELAND PHARMACY HM	Nick Patel	111 S.WILLIAM BARNETT AVE	CLEVELAND	TX	77327	281-5933800
ALBRECHTS PHARMACY @@@ HM	Gene Albrecht	506 W 5TH STREET	CLIFTON	TX	76634	254-6758398
VILLAGE LANE APOTHECARY	Gary Kirk	60 VILLAGE LN	COLLEYVILLE	TX	76034	817-7172000
THE MED PLACE CO CITY	Paul Johnson	2250 CHESTNUT ST	COLORADO CITY	TX	79512	325-7283489
COLUMBUS PHARMACY	Nick Patel	109 SHULT DR STE F	COLUMBUS	TX	78934	979-5004191
WOODLAKES PHARMACY	Andrew Green	525 WOODLANDS SQUARE#170	CONROE	TX	77384	832-5835002
WOODFOREST PHARMACY	Jeremy Coffey	404 RIVER POINTE DR STE 101	CONROE	TX	77304	832-2970017
COMMUNITY PHARMACY	Steven Walker	3001 FM 2181 STE 450	CORINTH	TX	76210	940-4877455
KELLYS PHARMACY	Kelechi Akpunku	520 EVERHART	CORPUS CHRISTI	TX	78411	361-3344500
SHORELINE PHARMACY	Ramana Mandadi	1335 SANTA FE ST #1	CORPUS CHRISTI	TX	78404	361-4149745
APOLLO PHARMACY	KRUNAL PAREKH	1397 W 7TH AVE	CORSICANA	TX	75110	903-6025102
GADDIS PHARMACY	Kiran Kali	302 N MAIN ST	COTULLA	TX	78014	830-8792323
REGIONAL PHARMACY	TARUN PATEL	622 WEST MAIN	CROSBYTON	TX	79322	806-6752001
SHAWS PHARMACY CROWELL	Mike Shaw	102 E COMMERCE	CROWELL	TX	79227	940-6841581
GATEWAY PHARMACY	MAGGIE MANKARIOUS	921 E. FM 1187 SUITE A	CROWLEY	TX	76036	817-2972000
PHARM HOUSE DRUG CRYSTAL	LOREN PIERCE	224 E ZAVALA ST	CRYSTAL CITY	TX	78839	830-3743436
REUSS PHARMACY	VIJAYA KALIDINDI	515 N ESPLANADE STREET	CUERO	TX	77954	361-2753411
HARVEST PHARMACY	Matthew Vo	9740 BARKER CYPRESS RD STE 107	CYPRESS	TX	77433	800-5555555
MORRISCARE PHARMACY	Nithya Subramanian	213 W SCURRY ST STE C	DAINGERFELD	TX	75638	203-5006127

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
FAMILY DRUG INC HM	Scott Butt	810 WEST COMMERCE STREET	BROWNSTOWN	IN	47220	812-3584502
MEDICENTER ALT CARE PHCY	STEPHEN SOMMER	100 W MAIN STREET, STE A	CAMBRIDGE CITY	IN	47327	765-3348331
WILLOWBROOK PHARMACY	Julie Cindric	720 ADAMS ST STE 100	CARMEL	IN	46032	463-3337100
BUTT DRUGS INC	Katie Butt Beckort	115 E CHESTNUT STREET	CORYDON	IN	47112	812-7383272
VALLEY PHARMACY	Mike Swart	325A N HALLECK ST	DEMOTTE	IN	46310	219-9873330
NATIONS MEDICINES	Mark Haywood	4849 POLLACK AVE	EVANSVILLE	IN	47715	812-9624664
NEPHEW PHCY - GOSHEN	Gary Nephew	2824 ELKHART RD	GOSHEN	IN	46526	574-2862259
HIGHCARE PHARMACY	Naren Patel	9030 CLINE AVE STE-B	HIGHLAND	IN	46322	219-5139513
NEEDLERS FRESH MKRT 929	Joanna Bergum	320 N NEW JERSEY ST	INDIANAPOLIS	IN	46204	463-2035177
EAGLE HIGHLAND PHARMACY	Ryan Barton	9010 CRAWFORDSVILLE RD	INDIANAPOLIS	IN	46234	317-2993771
SHAKAMAK	TRAVER WOLF	346 E MAIN STREET	JASONVILLE	IN	47438	812-6659760
PHIL'S DISCOUNT DRUG HM	Mark Robbins	702 EAST LINCOLNWAY	LAPORTE	IN	46350	219-3627133
LIBERTY MEDICENTER PHCY	STEPHEN SOMMER	10 S MAIN ST STE A	LIBERTY	IN	47353	765-2232121
PHIL'S HM PHARMACY	JASON STIMLEY	3535 FRANKLIN ST	MICHIGAN CITY	IN	46360	219-8747445
RIGHT MED PHARMACY	Ali Fakh	303 S MAIN ST STE 100	MISHAWAKA	IN	46544	734-8830785
STAT PHARMACY	Ali Fakh	212 W EDISON RD STE A	MISHAWAKA	IN	46545	574-2524495
HEALTHLINC PHARMACY	Lynn Thoma	420 W 4TH ST	MISHAWAKA	IN	46544	574-3077685
WE CARE	Sam Arzumanian	1810 45TH AVE	MUNSTER	IN	46321	219-6141032
NEPHEW PHCY - NAPPANEE	GARY NEPHEW	1953 WATERFALL DRIVE	NAPPANEE	IN	46550	574-7732404
MCGRADY FAMILY PHARMACY	James Mcgrady	1902 S MEMORIAL DR	NEW CASTLE	IN	47362	765-5299600
CHRIS' PHARMACY	CHRISTOPHER KISSEL	511 MAIN ST/POB 135	NEW HARMONY	IN	47631	812-6823044
OPTIMUM WELLNESS PHARMACY	Mark Hayward	8900 RUFFIAN LN	NEWBURGH	IN	47630	812-5183428
ODON PHARMACY	KENNETH HOLLAND	200 W MAIN ST	ODON	IN	47562	812-6364609
MIDTOWN PRESCRIPTION CTR	Steve Somer	11 SOUTH 9TH STREET	RICHMOND	IN	47374	765-9620025
FAMILY DRUG OF SEYMOUR	Scott Butt	202 EAST TIPTON STREET	SEYMOUR	IN	47274	812-5259190
HEALTHY U RX	Jada Bush	201 S WILLIAM ST	SOUTH BEND	IN	46601	574-4727881

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
MD KIDS PED PHCY	DAVID DUC NGUYEN	3201 W SANER AVE STE 100	DALLAS	TX	75233	214-3774310
BUCKNER VILLAGE PHARMACY	Elias Okonkwo	2947 S BUCKNER BLVD, STE 500	DALLAS	TX	75227	214-2758066
FATE PHARMACY	Hari Chintapalli	2409 ALCO AVENUE STE C	DALLAS	TX	75211	214-9192399
PRESTON ROAD PHARMACY	Jonathan Lipe	6901 PRESTON ROAD	DALLAS	TX	75205	214-5219991
PRESTON ROAD APOTHECARY	Jonathan Lipe	9301 NORTH CNTRL EXPW 110	DALLAS	TX	75231	214-3616172
CASH SAVER PHARMACY 46	Kiran Kali	1201 W CAMP WISDOM RD	DALLAS	TX	75232	214-3762709
CASH SAVER PHARMACY 19	Kiran Kali	2130 E LEDBETTER	DALLAS	TX	75216	214-3743559
POWERHOUSE PHARMACY	Kirat Shahiwal	4740 W MOCKINGBIRD LN	DALLAS	TX	75209	214-3502900
CEDRA PHARMACY	MAZEN KARNABY	9669 N CENTRAL EXPWY #190	DALLAS	TX	75231	214-9831000
MEDFRONT PHARMACY	OLAMIDE FASONU	4041 W WHEATLAND RD #204	DALLAS	TX	75237	972-7092190
RENUE RX #3	Raj Chhadua	600 N PEARL ST #H201	DALLAS	TX	75201	214-8550606
RENUE RX #2	Raj Chhadua	2701 S HAMPTON RD, #100	DALLAS	TX	75224	972-7078248
ASPCARES LANCASTER	Saad Hussain	4309 LEMMON AVE	DALLAS	TX	75219	214-3314500
BUCKNER NEIGHBORHOOD PHCY	Samson Berhe	3535 N BUCKNER BLVD ST106	DALLAS	TX	75228	214-3213000
NORTH TEXAS INF SPLTY PHY	Sandy Aaron	3409 WORTH ST.#725	DALLAS	TX	75246	214-2765617
WHITE ROCK PHARMACY	Xuan Nguyen	9037 GARLAND RD.	DALLAS	TX	75218	214-6602603
DEKALB PHARMACY	JANET TIDWELL	120 W FRONT ST	DE KALB	TX	75559	903-6670880
BEST VALUE RENSHAW DRUG	Steven Maddox	800 A MEDICAL CENTER DR	DECATUR	TX	76234	817-9955196
MED CHOICE PHCY HM	Susan Miller	2300 W MORTON ST STE 121	DENISON	TX	75020	903-4636979
COMMUNITY PHARMACY	Brandon Allen	1612 SCRIPTURE ST	DENTON	TX	76201	940-4840100
COMMUNITY PHARMACY	Kelly Shelby	4400 TEASLEY LN STE 100	DENTON	TX	76210	940-3821618
RENUE RX 1	Lauren Saavedra	306 N LOOP 288 #210	DENTON	TX	76209	210-9234404
PREMIUM FAMILY PHARMACY	Patience Tantoh	1776 TEASLEY LN STE 111	DENTON	TX	76205	214-7141842
DENVER CITY PHARMACY	DAVID FUNG	105 E BROADWAY ST	DENVER CITY	TX	79323	806-5923333
LIBERTY DRUG	Sequoia Gerken	403 N MUSTANG	DENVER CITY	TX	79323	806-5922765
DEVINE'S CRAWFORD RX	Narender Bangla	200 S TEEL DR	DEVINE	TX	78016	830-9880100

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
UNIVERSITY COMMONS PHCY	RAY KADI	6301 UNVRSTY COMMONS #500	SOUTH BEND	IN	46635	574-2732000
NEEDLERS FRESH MKRT 927	Joanna Bergum	899 E JEFFERSON ST	TIPTON	IN	46072	765-5514479
KAUP PHCY UNION CITY HM	Gerald Kaup	366 W DEERFIELD RD	UNION CITY	IN	47390	765-9643098
GIL DRUG CO INC HM	Gil Terlicher	52 LINCOLN WAY	VALPARAISO	IN	46383	219-4624146
HEALTHLINC PHARMACY	Lynn Thoma	1001 N STURDY RD	VALPARAISO	IN	46383	219-4627173
WOODSIDE PHARMACY	Mohamed Saleh	1551 STURDY RD	VALPARAISO	IN	46383	219-2863091
RUSCHS RX SOUTHSIDE PHCY	TRAVIS RUSCH	1107 SOUTH 15TH ST	VINCENNES	IN	47591	812-3160079
RITE CARE PHARMACY	JAYSHREE PATEL	2075 INDIANAPOLIS BLVD	WHITING	IN	46394	219-6555028
PATTERSON HLTH CARE PHCY	SCOTT PATTERSON	105 NW 3RD STREET	ABILENE	KS	67410	785-2632229
K AN D PHARMACY LLC HM	Daren Reese	224 SOUTH SUMMIT	ARKANSAS CITY	KS	67005	620-3076264
D & B PHARMACY INC	Debbie ISENBART	721 MAIN ST PO BOX 308	ASHLAND	KS	67831	620-6352322
MONARCH PHARMACY LLC	KELLY McAllister	1601 MILITARY AVE	BAXTER SPRINGS	KS	66713	620-8563030
OSHKINS PHARMACY	Tosha Bowen	1318 23RD ST	BELLEVILLE	KS	66935	785-5279010
S & S DRUG EDI	MAX HEIDRICK	110 S MILL ST	BELOIT	KS	67420	785-7382285
CHENEY PHARMACY EDI HM	Erika Fitzgerald	114 N MAIN ST	CHENEY	KS	67025	316-5420464
PATTERSON HEALTHMART RX	Scott Patterson	422 LINCOLN AVE EFT-01W	CLAY CENTER	KS	67432	785-6323115
CLEARWATER PHARMACY	Nancy Milledge	130 E ROSS, SUITE 111	CLEARWATER	KS	67026	620-5843784
MAIN STREET PHARMACY	LISA GALES	113 E MAIN	COLDWATER	KS	67029	620-5822134
EVANS DRUG INC EDI HM	Jason Hulvey	116 W PINE ST	COLUMBUS	KS	66725	620-4293322
ALDRICH APOTH CHARTERED	CONSTANCE ALDRICH	123 WEST MAIN	COUNCIL GROVE	KS	66846	620-7676731
CEDAR CREEK PHARMACY	LORI MURDOCK	34040 COMMERCE DR	DE SOTO	KS	66018	913-5831117
DIGHTON PHARMACY	JONATHAN BRUNSWIG	105 E PEARL STREET	DIGHTON	KS	67839	620-3975778
C & R CLINIC PHARMACY EDI	Jerry Scott	411 SUNSET PO BOX 962	ELKHART	KS	67950	620-6972131
THE RED HAUS PHARMACY	Ryan Stratmann	19 N. HUMBOLT AVE	ELLINWOOD	KS	67526	620-2423511
F & M DRUG LLC HM	BABARA KENNEDY	209 N DOUGLAS	ELLSWORTH	KS	67439	785-4723131
GRAVES DRUG STORE #8	BILL BAYS	609 COMMERCIAL	EMPORIA	KS	66801	620-3432323

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
OK PHARMACY	SYLVANUS ANIDU	122 S. MAIN	DONNA	TX	78537	956-4642000
OK PHARMACY NORTH	Sylvanus Anidu	311 N SALINAS BLVD	DONNA	TX	78537	956-4612020
SOLUTIONS PHARMACY	James Montgomery	13830 SAWYER RANCH RD#104	DRIPPING SPRINGS	TX	78620	512-3829381
PATRICK STREET PHARMACY	Sharon Maxwell	303 N PATRICK ST	DUBLIN	TX	76446	254-4454709
ROGER'S PHARMACY	Jason Saucedo	1021 E 1ST ST	DUMAS	TX	79029	806-9357494
BEN FRANKLIN APOTHECARY	DAN JESPERSEN	302 N MAIN ST	DUNCANVILLE	TX	75116	972-2984936
CCH PHARMACY	Lacye Crumpton	614 EAKER ST STE 100	EDEN	TX	76837	625-8698760
BULLDOG PHARMACY	Holly Randolph	115 N HOUSTON ST	EDGEWOOD	TX	75117	903-3851122
RGVMEDS PHARMACY	Benjamin Fombon	2606 E RICHARDSON RD	EDINBURG	TX	78542	214-6503918
JUNIOR'S PHARMACY	DAMASO NAVARRO, JR.	1313 S CLOSNER AVE #B	EDINBURG	TX	78539	956-5834441
MID COAST PHARMACY 1	David Mak	1201 NORTH MECHANIC ST	EL CAMPO	TX	77437	979-9423584
RIO GRANDE PHARMACY	Jose Salcido	5500 DONIPHAN DR 201-202	EL PASO	TX	79932	915-2608555
MED TIME PHARMACY HM	Lisa Espinoza	641 N. RESLER, STE 306 7	EL PASO	TX	79912	915-5846337
SURECARE SPECIALTY PHCY	Paul Galbiati	4005 N. MESA	EL PASO	TX	79902	915-5322400
HEALTHY CITY PHARMACY	RISH Patel	3028 TRAWOOD DR STE D	EL PASO	TX	79936	915-4007993
GOLDSMITH DRUG	REBECCA MCCAIN	111 W CLEVELAND ST	ELECTRA	TX	76360	940-4952335
TORRES FAMILY PHARMACY	Frank Torres	103 S. BROADWAY	ELSA	TX	78543	956-5672005
HOMETOWN DRUG	Diana Coile	718 W. LAMPASSAS ST.	ENNIS	TX	75119	972-8756798
FABENS PHARMACY	David Paschal	1420 FABENS RD B	FABENS	TX	79838	972-7751180
LA POPULAR PHARMACY	Narender Bangla	1118 S US HIGHWAY 281	FALFURRIAS	TX	78355	361-3233784
FATE PHARMACY	rajeswari attaluri	109 E FATE MAIN PL	FATE	TX	75087	972-4995044
US DRUG MART 4	David Paschal	103 SOUTH MAIN	FERRIS	TX	75125	972-5443660
COMMUNITY PHARMACY	DENNIS SONG	1001 CROSS TIMBERS RD STE 1170	FLOWER MOUND	TX	75028	972-3554614
BRISTOL PHARMACY	Jackson Dang	4001 LONG PRAIRIE RD #100	FLOWER MOUND	TX	75028	469-7714117
FORNEY SPECIALTY PHARMACY	Kiran Kali	426 FM 548 SUITE 122	FORNEY	TX	75126	972-4218283
BAGGETT PHCY HM	Mario Juarez	509 N MAIN ST	FORT STOCKTON	TX	79735	432-3362297

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number	Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
RICHEY'S DRUG STORE	Morgan Buntin	511 NORTH MAIN ST	ERIE	KS	66733	620-2443661	ALLIANCE PHARMACY	Jakson Dang	9601 N BEACH ST STE 105	FORT WORTH	TX	76244	817-9521999
PLAZA PHARMACY	Jenifer Bemecheck	911 N MAIN ST	GARDEN CITY	KS	67846	620--276-82	A&P PHARMACY	Kiran Kali	2329 N RIVERSIDE DR	FORT WORTH	TX	76111	817-8382319
KIOWA COUNTY PHARMACY	Julie Keeton	721 WEST KANSAS STE 101	GREENSBURG	KS	67054	620-7233112	HALLS PHARMACY #2	KIRAN KALI	8808 CAMP BOWIE W BLVD120	FORT WORTH	TX	76116	817-2413300
HARPER PHARMACY HM	Erika Fitzgerald	1404 MAPLE STREET	HARPER	KS	67058	620-8967700	GATEWAY PHARMACY	Maggie Mankarious	5505 S HULEN ST.	FORT WORTH	TX	76132	800-5555555
U-SAVE HM	Doug Stecklein	2505 CANTERBURY DRIVE	HAYS	KS	67601	785-6252529	MACPRINCE PHARMACY	Prince Ogbonna	3401 ALTAMESA BLVD #122	FORT WORTH	TX	76133	806-6261079
HAYSVILLE HEALTHMART PHCY	AMR ABUALNADI	145 N MAIN	HAYSVILLE	KS	67060	316-5244234	RENUE RX #4	Raj Chhadua	201 COMMERCE STREET #201	FORT WORTH	TX	76102	682-2851100
HESSTON PHARMACY	SANDIE KUEKER	101 S. MAIN	HESSTON	KS	67062	620-3272211	BEST VALUE RIDGLEA	Steven Maddox	5932 LOVELL AVE	FORT WORTH	TX	76107	817-9955196
CARDINAL PHARMACY LLC	Marla Mooney	821 N MAIN	HOISINGTON	KS	67544	620-6532200	BEST VALUE COUNTRY DAY	Steven Maddox	6020 A HARRIS PKWY	FORT WORTH	TX	76132	817-7380722
HUGOTON DRUG	BRETT HORYNA	531 S MAIN ST	HUGOTON	KS	67951	620-5444065	HALLS PHARMACY	VENKATA KIRAN KALI	708 PENNSYLVANIA AVE	FORT WORTH	TX	76104	817-8773677
HUTCHINSON CLINIC PHCY HM	Celeste Ontjes	2101 N WALDRON	HUTCHINSON	KS	67502	620-6639542	PRESCRIPTION LABORATORY	RICHARD TERRY	205 W WINDCREST STE 160	FREDERICKSBURG	TX	78624	830-9972163
WALDRONS PHARMACY EDI	KENT WALDRON	111 S MAIN PO BOX 579	JOHNSON	KS	67855	620-4923263	JRX PHARMACY	Bhavna Rao	5899 PRESTON RD BLDG 6 #602	FRISCO	TX	75034	214-6185050
KINGMAN DRUG STORE EDI	Merlin McFarland	211 N MAIN ST	KINGMAN	KS	67068	620-5325113	LIFETIME PHARMACY	Hany Youssef	255 WEST LEBANON RD #200A	FRISCO	TX	75036	469-4797777
RUSH COUNTY PHARMACY	LISA FLAX	708 MAIN ST POB 100	LA CROSSE	KS	67548	785-2229091	INDEPENDENCE PHARMACY	Hari Chintapalli	5350 INDEPENDENCE PKWY STE 110A	FRISCO	TX	75035	469-8859100
J&J PHARMACY	JENNIFER NEMECHEK	500 THORPE	LAKIN	KS	67860	620-3557712	CATALYST HEALTH RX	JOHN GREGG	9990 DALLAS PKWY STE 115	FRISCO	TX	75033	214-2915087
JAYHAWK PHCY WEST	ERICK AXCELL	6265 ROCK CHALK DR #1401	LAWRENCE	KS	66049	785-4231998	SPS RX SOLUTIONS	Linh Nguyen	3550 PARKWOOD BLVD #111	FRISCO	TX	75034	214-6180052
JAYHAWK PHARMACY	ERICK AXCELL	3510 CLINTON PKWY STE 220	LAWRENCE	KS	66047	785-4231998	SANDS RX FRISCO	Nabil Hallak	5150 WARREN PARKWAY STE 700	FRISCO	TX	75034	469-6060449
ORCHARDS DRUG	Will Anderson	1410 KASOLD DRIVE A16	LAWRENCE	KS	66049	785-8438555	RENUE RX #12 LEGACY	Raj Chhadua	2840 LEGACY DR STE 400A	FRISCO	TX	75034	800-5555555
KARE HEALTHMART LANSING	KARISHMA KHANDLWAL	2500 S 4TH ST	LEAVENWORTH	KS	66048	913-7275273	RENUE RX #1	Raj Chhadua	3010 LEGACY DR. STE 110	FRISCO	TX	75034	469-2942001
WICHITA COUNTY PHCY HM	JON BRUNSWIG	111 W BROADWAY	LEOTI	KS	67861	620-3752323	FRITCH DRUG & GIFT HM	Keith Reed	105 BROADWAY BOX 1167	FRITCH	TX	79036	806-8573176
EL-KAN DRUG INC HM	Brett Horyna	1033 N KANSAS	LIBERAL	KS	67901	620-6244065	CATALYST HEALTH RX	collin kelley	855 MONTGOMERY ST #150	FT WORTH	TX	76107	180-0555555
PATTERSON HM PHCY LINCOLN	SCOTT PATTERSON	204 W LINCOLN AVE	LINCOLN	KS	67455	785-5244649	PLAZA PHARMACY	Neal Head	411 NORTH GRAND	GAINESVILLE	TX	76240	940-6658401
CANDLEWOOD HEALTHMART PHY	Amy Hellerich	3254 KIMBALL AVE	MANHATTAN	KS	66503	785-7764100	GALVESTON BROADWAY DRUG	Nandan Kumar	2027 BROADWAY ST J	GALVESTON	TX	77550	409-7657701
LANNING PHARMACY	Traci Lanning	217 E. MAIN	MARION	KS	66861	620-3822135	ST PAUL PHARMACY	Hoa Pham	3307 BELTLINE RD	GARLAND	TX	75044	469-2681879
AR-EX DRUG STORE	CHARIS DUNLAP	801 BROADWAY	MARYSVILLE	KS	66508	785-5623196	CARECHOICE PHARMACY	Hung Lai	813 N JUPITER RD	GARLAND	TX	75042	469-9096430
MONTEZUMA DRUG	Jami Helm	300 N AZTEC	MONTEZUMA	KS	67867	620-8462202	MERCY PHARMACY	Mahmoud Ahmad	2231 PEGGY LN # B	GARLAND	TX	75042	972-2725274
THE MULVANE PHARMACY	Chad Ball	1008 SE LOUIS DR	MULVANE	KS	67110	316-7771601	GUS'S DRUG STORE HM	GARTH HINZE	702 E UNIVERSITY	GEORGETOWN	TX	78626	512-8632506
G & L PHARMACY HM	GREG FLAX	207 S PENNSYLVANIA	NESS CITY	KS	67560	785-7982897	THE MED SHOP PHARMACY	Patrick Powers	825 US HIGHWAY 271 N	GILMER	TX	75644	903-6802600

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
HARVEY DRUG LLC	Sandy Kueker	115 W 5TH ST.	NEWTON	KS	67114	316-3330120
OAKLEY HEALTHMART PHARMAC	Kezia Schwieterman	103 CENTER AVENUE	OAKLEY	KS	67748	785-6724727
MAINSTREET DRUG HM	Kaylene Mick	103 WEST MAIN	OSBORNE	KS	67473	785-3462136
CAPSTONE PHARMACY	Amr Abualnadi	11844 QUIVIRA RD	OVERLAND PARK	KS	66210	816-9454593
OVERLAND PARK PHARMACY	Samir Desai	7940 W. 151ST ST.	OVERLAND PARK	KS	66223	913-3361625
MIDWEST FAMILY HEALTH	ROB WENZL	300 STATE STREET	PHILLIPSBURG	KS	67661	785-5435131
MIDWEST FAMILY HLTH PLNLV	ROB WENZL	210 W MILL	PLAINVILLE	KS	67663	785-4344615
MIDWEST FAMILY HLTH RUSL	Rob Ricker	208 S FOSSIL STREET	RUSSELL	KS	67665	785-4832119
PHARM ASSOC II HM	JULIE HAMMES	934 MAIN	SABETHA	KS	66534	785-2843414
KEY REXALL HM	Scott Patterson	901 E CRAWFORD	SALINA	KS	67401	785-8270408
SCOTT CITY HM PHARMACY	JON BRUNSWIG	102 ALBERT AVENUE	SCOTT CITY	KS	67871	620-8722146
MEDICAL ARTS PHARMACY HM	JULIE HAMMES	701 MAIN	SENECA	KS	66538	785-3366146
MIDWEST FAMILY HEALTH	ROB WENZL	317 E HWY 36	SMITH CENTER	KS	66967	785-2823333
ASHCRAFT PHARMACY	TAMI FRIDAY	503 N MAIN	SOUTH HUTCHINSON	KS	67505	620-6632258
CONTINENTAL PHARMACY	Meghan Lem	821 SW 6TH AVE	TOPEKA	KS	66603	785-2326975
D.C. DRUG	Doug Hynek	101 N MAIN ST.	TROY	KS	66087	785-9822500
GIBSON DR INC H/M E-FM	Bernita Augustine	125 MAIN ST	WAKEENEY	KS	67672	785-7435753
CONSUMERS PHARMACY	Charles Buzard	1035 N EMPORIA	WICHITA	KS	67214	316-2636233
PROFESSIONAL PHCY EDI	Erika Fitzgerald	744 N WACO	WICHITA	KS	67203	316-2635218
BARNEYS PHCY HM	George Sagbene	3108 W CENTRAL	WICHITA	KS	67203	316-9453388
DANDURAND WELLNESS INC	Jason Schmitz	550 N HILLSIDE STE 3-100	WICHITA	KS	67214	800-5555555
HART PHARMACY HM	NEAL HEAD	6217 E 13TH STREET	WICHITA	KS	67208	316-6835621
DANDURAND COMP INC	Neal Head	2233 N RIDGE RD	WICHITA	KS	67205	316-7296000
DANDURAND DRUG STORE HM	Neal Head	7732 E CENTRAL AVENUE	WICHITA	KS	67206	316-6852354
DANDURAND DRUGSTORE	NEAL HEAD	4183 E HARRY ST	WICHITA	KS	67218	316-6896100
DANDURAND INC HM	Neal Head	800 CARRIAGE PARKWAY	WICHITA	KS	67208	316-8585890
WINFIELD PHARMACY INC HM	Gary Vratil	1708 E NINTH	WINFIELD	KS	67156	620-2210450

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
WALKER PHARMACY	DWAYNE BARNHILL	402-B W UPSHUR	GLADEWATER	TX	75647	903-8452573
GLEN ROSE DISCOUNT DRUG	Jonathon Lipe	906 N.E. BIG BEND TRAIL	GLEN ROSE	TX	76043	254-8972711
BEST VALUE MEDICAL CENTER	Steven Maddox	1100 BLUEBONNET ST	GLEN ROSE	TX	76043	817-9955196
GOLIAD PHARMACY	Sri Vatti	208 S COMMERCIAL ST#1227	GOLIAD	TX	77963	361-6453261
MOHRMANN'S DRUG STORE LLC	John Mohrmann	2405 WINDING WAY	GONZALES	TX	78629	830-6722317
PECAN DISCOUNT DRUG HM	Milton Schultz	9203 PLANTATION DRIVE STE 1	GRANBURY	TX	76049	817-5739344
BEST VALUE RONS PHCY	Steven Maddox	420 WEST PEARL	GRANBURY	TX	76048	817-9955196
ACUSCRIPT PHARMACY	Nguyen Dinh	3950 S CARRIER PKWY 100	GRAND PRAIRIE	TX	75052	469-9094093
LIVE WELL PHARMACY	Hari Chintapalli	4200 STUART ST	GREENVILLE	TX	75401	903-2596797
GREENVILLE PHARMACY	Venkata "Venny" Majeti	4209 WESLEY ST	GREENVILLE	TX	75401	800-5555555
JORDAN PHARMACY INC.	Jan Pattillo	107 N RICE PO BOX 112	HAMILTON	TX	76531	254-3863111
DOYLE HIGH THE DRUG STORE	Nathan Buerkle	100 S AVENUE E	HASKELL	TX	79521	940-8642673
RED DOOR PHARMACY	Randy Shipp	2488 AVONDALE HASLET #168	HASLET	TX	76052	817-2592636
WALLER COMMUNITY PHCY	Stephen Okwor	745 AUSTIN ST STE B	HEMPSTEAD	TX	77445	857-3120725
BEST VALUE HICO PHARMACY	Steven Maddox	320 WEST 1ST STREET	HICO	TX	76457	817-9955196
HITCHCOCK HOMETOWN PHCY	Nandan Kumar	8719 HIGHWAY 6	HITCHCOCK	TX	77563	409-2090847
EAGLE PHARMACY	Dustin Hays	700 S COLLEGE AVE	HOLLIDAY	TX	76366	940-6311534
PRIME EXPRESS RX	AKOSUA ADU ADDAI	1701 FM 1960 RD W STE L	HOUSTON	TX	77090	832-4463224
TEJAS PHARMACY #2	Amy Imber	5228 ALDINE MAIL RT.	HOUSTON	TX	77039	800-5555555
WE CARE RX	Brandy Williams	12390 KINGSRIDE LN	HOUSTON	TX	77024	832-5826933
HEALTHCO PHARMACY 2	BRENDA RICHARDSON	8604 MARTIN LUTHER KING JR BLVD	HOUSTON	TX	77033	713-6405575
HEALTHCO PHARMACY	BRENDA RICHARDSON	5730 CHIMNEY ROCK RD	HOUSTON	TX	77081	713-2186337
PRONTO PHARMACY	Carol DiCesare	8635 LONG POINT RD. SUITE C	HOUSTON	TX	77055	800-5555555
PHARMACY 1 PLUS INC	Chimezie Iloanya	6776 SOUTHWEST FWY STE 102	HOUSTON	TX	77074	800-5555555
PROMED PHARMACY	Chris Quintann	2421 ALDINE MAIL ROUTE RD	HOUSTON	TX	77039	936-4445027
BARKER CYPRESS HOME CARE	Cynthia Ngwaba	810 S HIGHWAY 6 STE 115	HOUSTON	TX	77079	832-8600492
IRIDIUM PHARMACY	Del Ingram	2240 NAVIGATION STE 200A	HOUSTON	TX	77003	713-3247241

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
ALEXANDRIA DRUGS	AMY GLASER	7857 US HWY 27	ALEXANDRIA	KY	41001	859-6352171
HOWARD FAMILY PHARMACY #2	Wesley Howard	6363 KY ROUTE 1428	ALLEN	KY	41601	606-4220688
GILLUM DRUG	Amanda Gillum	1237 CARTER AVE	ASHLAND	KY	41101	540-5980441
HEALTHY PHY CEDAR KNOLL	BRETT DICKERSON	1410 Eagle Dr	ASHLAND	KY	41102	606-9281001
MCMEANS PHARMACY ASHLAND	John McMean	2920 CARTER AVE	ASHLAND	KY	41101	606-3258400
GALLAHER'S PHARMACY	SONYA MUNCY	2914 BLACKBURN AVE	ASHLAND	KY	41101	606-3292122
MEDICA PHARMACY	ALYSON ROBY	202 W STEPHEN FOSTER AVE	BARDSTOWN	KY	40004	502-3486623
C & G PHARMACY LLC	Ashley Commes	111 WEST FLAGET STREET	BARDSTOWN	KY	40004	502-3483938
HURST DISCOUNT DRUG	KIM WHEATLEY	102 N THIRD ST	BARDSTOWN	KY	40004	502-3489261
BARDWELL PHARMACY	SHAWN BOAZ	178 US HWY 51 N	BARDWELL	KY	42023	270-6285445
STUFFLEBEAN PHCY	ROSEMARY SMITH	1031 GRAND AVENUE	BEATTYVILLE	KY	41311	606-4643396
VILLAGE APOTHECARY	ROSEMARY SMITH	1075 HIGHWAY 11 NORTH	BEATTYVILLE	KY	41311	606-4643656
J&R PHARMACY	Andy Brown	817 MAIN ST	BENTON	KY	42025	270-5279374
MEDICA PHY - BLOOMFIELD	ALYSON ROBY	204 CHAPLIN RD.	BLOOMFIELD	KY	40008	502-2528242
OWSLEY PRESCRIPTION CNT	ROSEMARY SMITH	820 KY 11 NORTH	BOONEVILLE	KY	41314	606-5936306
HINES PHARMACY AT WKOA	Beth Murley	165 NATCHEZ TRACE STE 101	BOWLING GREEN	KY	42103	270-7961818
CLINIC PHARMACY	DONALD RILEY	201 PARK ST	BOWLING GREEN	KY	42101	270-7813095
HINES PHARMACY HM	GREG HINES	1340 KY HWY 185	BOWLING GREEN	KY	42101	270-8424341
SPRING HILL PHARAMCY HMCY	Jeff Halter	2305 RUSSELLVILLE RD	BOWLING GREEN	KY	42101	270-7963909
NORTHGATE PHARMACY	Myra Ray	3158 LOUISVILLE RD	BOWLING GREEN	KY	42101	270-8426161
LAKESHORE PHARMACY	PATTY GUINN	51 W LAKESHORE DR/POB 508	BURNSIDE	KY	42519	606-5617104
FAMILY DRUG OF WHEELWRIGHT	Heather Daniels	107 KY-ROUTE 306	BYPRO	KY	41612	606-4524134
MAIN STREET PHARMACY	Jenny Shown	289 MAIN STREET	CADIZ	KY	42211	270-8822222
CADIZ PHARMACY	MARY KATHERINE SMITH	435 LAKOTA DRIVE	CADIZ	KY	42211	270-5223441
WOLFE PRESCRIPTION CTR	ROSEMARY SMITH	217 MOUNTAIN PARKWAY SPUR	CAMPTON	KY	41301	606-6683900
CAMPTON DISCOUNT DRUGS	STEVE WHITAKER	33 MAIN ST STE 2 POB 1359	CAMPTON	KY	41301	606-6683153

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
RICHMOND PHARMACY	HELEN VO	9536 RICHMOND AVE SUITE I	HOUSTON	TX	77063	832-9918997
PRIVIA GULF COAST PHCY	Jim Edwards	9539 HUFFMEISTER RD #C	HOUSTON	TX	77095	800-5555555
HEALTH RX SCRIPTS PHCY	Joseph Lee	900 S WAYSIDE DR, STE 400A	HOUSTON	TX	77023	832-7404353
TEXAS CARE PHARMACY	Joseph Nidhin	7814 ALMEDA RD	HOUSTON	TX	77054	832-7690088
MEMORIAL PHARMACY	LAN VU	10101 SW FREEWAY STE 315	HOUSTON	TX	77074	832-3588500
FRIENDSWOOD HM PHCY	LONG NGUYEN	4606 FM 1960 W STE 250	HOUSTON	TX	77069	281-3151300
CEDRA PHARMACY	MAZEN KARNABY	1607 SOUTH POST OAK LANE	HOUSTON	TX	77056	713-6210621
SENA RX PHARMACY	MITCH VOSOUGHI	5050 FM 1960 RD W STE125	HOUSTON	TX	77069	281-4400018
MEDPLUS RX	Moji Cardozo	7636 HARWIN DR STE C 319	HOUSTON	TX	77036	713-7795400
TX RX SOLUTIONS & COMP	Ngozi Anaduaka	7501 FANNIN ST STE 701	HOUSTON	TX	77054	713-7901222
TX RX SOLUTIONS & COMP 2	Ngozi Anaduaka	7505 FANNIN ST SUITE 140	HOUSTON	TX	77054	713-7901222
MAXCARE FAMILY PHARMACY	SAJU ASTHAPPAN	2620 E CROSSTIMBERS ST145	HOUSTON	TX	77093	281-5012228
BIOCARE PHARMACY	Sandra Scott	10603 BELLAIRE BLVD B114	HOUSTON	TX	77072	(83-2) 454-
ST JOSEPH PHARMACY	William Sherman	1315 ST JOSEPH PKWY STE 100	HOUSTON	TX	77002	713-5895878
HUBBARD CITY DRUG	Landon Schwartz	200 N MAGNOLIA AVE	HUBBARD	TX	76648	254-5762241
MCNEASE PHARMACY HM	Danny McNease	103 B MEDICAL PARK LANE	HUNTSVILLE	TX	77340	936-2938333
MIDCITIES PHARMACY	AEMAD ASLAM	2000 PRECINCT LINE RD#102	HURST	TX	76054	817-6053500
HIPPO PHARMACY	Sajid Shaikh	107A EAST ST	HUTTO	TX	78634	512-8466004
IOWA PARK PHARMACY	REBECCA MCCAIN	405 SE ACCESS RD STE #A	IOWA PARK	TX	76367	940-5922731
AMN PHARMACY/REMEDY SHOP	Aemad Aslam	8722 N ROYAL LN	IRVING	TX	75063	214-6053875
BROWN'S PHARMACY	Christopher Tapper	2021 N MACARTHUR BLVD 120	IRVING	TX	75061	972-2548156
FATE PHARMACY	Hari Chintapalli	3600 CONFLANS RD, STE 210	IRVING	TX	75061	469-3404030
LAS COLINAS PHARMACY HM	Jim Jim HrnCir	6420 N MACARTHUR BLVD#100	IRVING	TX	75039	972-9939700
IRVING PHARMACY	Mohammad Sandeesh	2000 ESTERS RD STE 202	IRVING	TX	75061	972-3130585
AMERICA FIRST PHARMACIES	Nadeem Akhtar	7801 MESQUITE BEND DR#108	IRVING	TX	75063	972-9472400
LEMON PHARMACY	Viroopaksha Velishala	3501 MACARTHUR BLVD #340	IRVING	TX	75062	603-7034001

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
CORNERSTONE CARE ASSOC	JACOB DOTSON	8010 LAKE BONITA RD	CATLETTSBURG	KY	41129	800-5555555
POOLE'S PHY CENTRAL CITY	RON POOLE	102 WEST BROAD STREET	CENTRAL CITY	KY	42330	270-7541545
CLARKSON DRUG STORE S U	Jim Marshall	201 MILLERSTOWN/PO BOX 146	CLARKSON	KY	42726	270-2423811
CLAY DRUG, INC	WHITNEY WRIGHT	9055 STATE RTE 132 W	CLAY	KY	42404	270-6642270
POWELL PRESCRIPTION CENTE	ROSEMARY SMITH	4644 MAIN ST HWY 15 WEST	CLAY CITY	KY	40312	606-6633481
BYASSEE DRUG COMPANY	JOHNNY BYASSEE	107 E CLAY ST	CLINTON	KY	42031	270-6532151
CLINTON PHARMACY	Shawn Boaz	119 EAST CLAY ST	CLINTON	KY	42031	270-6535361
NORTH CENTURY PHCY	HARRY PYLES	3058 CAMPBELLSVILLE RD	COLUMBIA	KY	42728	270-3801230
CENTURY MEDICINES	SHEILA BRYANT	706 JAMESTOWN ST POB 97	COLUMBIA	KY	42728	270-3845874
RUWE FAMILY PHY COVINGTON	JEANNE ZEIS	434 SCOTT ST	COVINGTON	KY	41011	859-4313304
RUWE FAMILY PHY LATONIA	JEANNE ZEIS	3712 Winston Ave	COVINGTON	KY	41015	859-2610605
SCRIPTS PHARMACY	ALISON SHIRLEY	101 BLAKENROD BLVD	COXS CREEK	KY	40013	502-3488338
CUMBERLAND DRUG COMP	ERNIE WATTS	1803 E MAIN ST	CUMBERLAND	KY	40823	606-5890003
EASTSIDE PHCY SX	Nancy Walker	430 E PLEASANT ST STE 2	CYNTHIANA	KY	41031	859-2346800
BLUEGRASS DRUG STORE	DAVID ADAMS	150 WAR ADMIRAL STE 1	DANVILLE	KY	40422	859-2363535
WOODBURN PHARMACY, LLC	MICHAEL KELLER	400 E ARCADIA AVE	DAWSON SPRINGS	KY	42408	270-7972761
DIXON DRUG STORE	Whitney Wright	1335 US HIGHWAY 41A S	DIXON	KY	42409	270-2132028
J&R PHARMACY DRAFFENVILLE	Andy Brown	34 US HWY 68 E UNIT A	DRAFFENVILLE	KY	42025	270-5273135
HOWARD FAMILY PHCY	WESLEY HOWARD	327 KY RT 550	EASTERN	KY	41622	606-3584800
LYON DRUG STORE HM	Edwin Nickell	201 MAIN STREET	EDDYVILLE	KY	42038	270-3882236
INSPIRE RX PHARMACY	Nathaniel Adams	950 N MULBERRY ST #100A	ELIZABETHTON	KY	42701	270-6006337
ETOWN PHARMACY, LLC	NAVAS YOONUS	914 N DIXIE AVE # 103	ELIZABETHTON	KY	42701	270-9001583
DIXIE PHARMACY 2	Navas Yoonus	1311 RING RD STE 107	ELIZABETHTON	KY	42701	270-8720588
CLOVER FORK CLINIC PHY	BRITT LEWIS	101 CHAD ST	EVARTS	KY	40828	606-8372108
RUWE FAMILY PHY FLORENCE	JEANNE ZEIS	7220 Burlington Pike	FLORENCE	KY	41042	859-7462800
FT MITCHELL DRUG SHOPPE	Richard Baudendistel	2515 DIXIE HWY	FORT MITCHELL	KY	41017	859-3412000

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
MERCURY DRIVE PHCY HM	James Macdrow	918 MERCURY DRIVE	JACINTO CITY	TX	77029	713-6746122
JOHNSON CITY HM PHCY-NEW	PHIL LIETZ	405 HIGHWAY 281 SOUTH	JOHNSON CITY	TX	78636	830-8687185
JOSHUA PHARMACY	JONATHAN LIPE	504 N BROADWAY/POB 939	JOSHUA	TX	76058	817-2958531
BEST VALUE MT VALLEY PHCY	Steven Maddox	3521 SW WILSHIRE BLVD #B	JOSHUA	TX	76058	817-9955196
JOURDANTON PHARMACY	Narender Bangla	1810 EAST STATE HWY 97	JOURDANTON	TX	78026	830-7700770
CITY PHARMACY	Floyd Butler	1610 MAIN ST	JUNCTION	TX	76849	325-4462511
HEALTH CENTER PHARMACY	Rolando Ramon	1003 COLLEGE ST STE 100	JUNCTION	TX	76849	325-4463999
KAUFMAN PHARMACY	Naga Chandrika Gokaraju	105 N SHANNON ST	KAUFMAN	TX	75142	972-9240404
MEDCURE PHARMACY	Jonathan Nguyen	4525 HERITAGE TRACE # 101	KELLER	TX	76244	817-4313334
THE PRESCRIPTION SHOP	Nick Millington	143 CRAIG STREET	KENEDY	TX	78119	830-5839652
THE MEDICINE STOP	Austin McAnally	1000 MAIN ST.	KERRVILLE	TX	78028	830-8967440
KERRVILLE DRUG INC HM	Sean Schmidt	1050 JUNCTION HWY	KERRVILLE	TX	78028	(83-0) 895-
KINGSLAND RX PHCY HM	Todd Humphries	306 RANCH ROAD 2900	KINGSLAND	TX	78639	325-3884593
MENDOZA'S PHARMACY	Alice Mendoza	102 S. UNIVERSITY BLVD.	KINGSVILLE	TX	78363	361-3554040
GREENPATH PHARMACY	Yusuf Hassanali	24000 HWY 59 N	KINGWOOD	TX	77339	832-4450500
KNOX COUNTY PHARMACY	Lance Sloan	712 SOUTH EAST 5TH STREET	KNOX CITY	TX	79529	940-6574036
PHARM HOUSE DRUG KOUNZE	Loren Pierce	800 S PINE STREET	KOUNTZE	TX	77625	409-2463492
PLUM CREEK PHARMACY	Michael Boccieri	4217 BENNER STE 430	KYLE	TX	78640	512-2890257
PHARM HOUSE DRUG LAGRANGE	LOREN PIERCE	110 E TRAVIS ST	LA GRANGE	TX	78945	979-9685835
SAENZ MED PHY OF PENITAS	ELVIA SAENZ	1000 E. EXPRESSWAY 83 STE 1	LA JOYA	TX	78560	956-5852704
PHARM HOUSE DRUG VERNIA	Johnathan Mechlowe	13857 HWY 87 #100	LA VERNIA	TX	78121	830-7792219
JONES MCCALL PHCY RD HM	Chad Norris	1605 N BRYAN AVE	LAMESA	TX	79331	806-8725455
LANRX PHARMACY	DAVIES DAVIES	2110 LOMAS DEL SUR #105	LAREDO	TX	78046	956-7256000
LAREDO DOWNTOWN PHCY L HM	Tomas Izaguirre	1219 MATAMOROS	LAREDO	TX	78040	956-7264512
ALTO PHARMACY DALLAS	Ajay Khatri	475 ST HWY 121 BYPASS 150	LEWISVILLE	TX	75067	800-8745881
FIRST STOP PHARMACY	EMMANUEL OFORI	101 E CORPORATE DR 130	LEWISVILLE	TX	75067	972-2998990

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
HOMETOWN PHY FRANKFORT	Bijalkumar Patel	1140 US HIGHWAY 127 S	FRANKFORT	KY	40601	502-6992440
HOMETOWN PHY FRANKFORT EA	Bj Pate	190 VERSAILLES ROAD	FRANKFORT	KY	40601	859-9402950
CLINIC PHCY OF FRANKLIN	Donnie Riley	1112 S MAIN ST	FRANKLIN	KY	42134	270-4820130
FRENCHBURG PHARMACY	DEBBIE BREWER	732 Highway 36	FRENCHBURG	KY	40322	606-7686617
MENIFEE COUNTY PHARMACY	JOE WELLS	70 MAIN ST/POB 109	FRENCHBURG	KY	40322	606-7682161
EVANS DRUG COMPANY	David Prater	214 LAKE STREET	FULTON	KY	42041	270-4722421
NOBLE'S PHARMACY	KEVIN NOBLE	162 GARRISON LANE	GARRISON	KY	41141	606-7573535
HOMETOWN PHARMACY GEORGTOWN	BIJALKUMAR PATEL	1502 OXFORD DR STE 150	GEORGETOWN	KY	40324	502-8633784
J & L PHARMACY	Bj Patel	705 SOUTH BROADWAY	GEORGETOWN	KY	40324	502-8639823
HORTON BROS & BROWN HM	Michael Akers	201 EAST MAIN ST	GRAYSON	KY	41143	606-4745655
POOLE'S PHCY CARE GREEN	RON POOLE	159 S MAIN ST	GREENVILLE	KY	42345	270-3386060
HARLAN MEDICAL CENTER PHY	ERNIE WATTS	132 VILLAGE CTR RD	HARLAN	KY	40831	606-5732004
HAROLD PRIM CARE CLC PHY	STEVE DAWSON	159 KY 680 EAST	HAROLD	KY	41635	606-4781600
EAST MAIN STREET PHARMACY	DACHEA WOOTON	279 E Main St	HAZARD	KY	41701	606-4870107
SMITH DRUG COMPANY	STEVE DOOM	104 N LINCOLN ROAD	HODGENVILLE	KY	42748	270-3583306
RAPIDRX PHARMACY	Maulik Patel	2713 FORT CAMPBELL BLVD	HOPKINSVILLE	KY	42240	270-9627530
TOWN & COUNTRY DISC DRUGS	Travis Shown	3217 LAFAYETTE RD	HOPKINSVILLE	KY	42240	270-8891845
CHEROKEE DRUG SHOPPE	Don Gubser	6439 TAYLOR MILL RD	INDEPENDENCE	KY	41051	859-3563121
NIE'S INDEPENDENCE PHY	JACK NIE	11745 MADISON PIKE	INDEPENDENCE	KY	41051	859-3563941
ISOM COMMUNITY PHARMACY	ERNIE WATTS	93 Isom Plaza	ISOM	KY	41824	606-6339238
JACKSON APOTHECARY	ROSEMARY SMITH	842 HIGHWAY 15 NORTH	JACKSON	KY	41339	606-6667060
MCCONNELLS DRUG STORE	EDWIN NICKELL	86 CEDAR ST, PO BOX 159	KUTTAWA	KY	42055	270-3887371
LACKEY FAMILY PHY, LLC	DANNY BILITER	RT 550-77 MILARD ALLEN DR	LACKEY	KY	41643	606-3582661
SUTTON PHARMACY HM	Scott Graham	330 W MAPLE AVE	LANCASTER	KY	40444	859-7924611
HOMETOWN PHY LAWRENCEBURG	BIJALKUMAR PATEL	1185 GLENSBORO RD STE 5	LAWRENCEBURG	KY	40342	502-5170888
SOUTHALL PHARMACY HM	Frank Southall, Jr.	325 W WALNUT ST STE 500	LEBANON	KY	40033	270-6923111

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
COMMUNITY PHARMACY	Mark Gilbert	1301 FM 407 JUSTIN RD 212	LEWISVILLE	TX	75077	800-5555555
EAGLE PHARMACY	John Droblyn	14077 FM 849	LINDALE	TX	75771	903-8815752
EAGLE PHARMACY	JOHN DROBLYN	1404 S MAIN ST	LINDALE	TX	75771	903-8815752
LIVINGSTON PHARMACY	NICK PATEL	714 CHURCH ST	LIVINGSTON	TX	77351	936-3275510
CORNER DRUG HM	David Humphries	600 BESSEMER AVE	LLANO	TX	78643	325-2474155
LOUIS MORGAN DRUGS 1	Cheryl Gilliam	1900 S. HIGH ST.	LONGVIEW	TX	75602	903-7588286
SPRING HILL PHARMACY	Dwayne Barnhill	3600 GILMER RD	LONGVIEW	TX	75604	903-2127900
LOUIS MORGAN DRUGS 4	Shawn Sams	110 JOHNSTON ST	LONGVIEW	TX	75601	903-7586164
PARKWAY PHARMACY	JAGESH PATEL	1824 PARKWAY PL STE 100	LUBBOCK	TX	79403	806-7679999
TWIN OAKS PHARMACY	Jigna Patel	3436 34TH ST	LUBBOCK	TX	79410	806-7993636
SPECIAL CARE PHARMACY	Tarun Patel	3406 INTERSTATE 27	LUBBOCK	TX	79404	806-7411777
HIGHLAND PHARMACY	Terry Patel	2604 50TH STREET	LUBBOCK	TX	79413	806-7015111
RAFF AND HALL FAMILY PHCY	Terry Patel	3404 INTERSTATE 27	LUBBOCK	TX	79404	806-7448477
ABELDTS GASLIGHT PHCY	Buford Abeldt	200 GASLIGHT BLVD	LUFKIN	TX	75904	800-5555555
LUFKIN PHARMACY & CO	Garth Hinze	903 W FRANK AVE	LUFKIN	TX	75904	936-6343006
KINGS PHCY LUMBERTON	Greg Hamby	139 NORTH LHS DR	LUMBERTON	TX	77657	409-6733978
MABANK FAMILY PHCY HM	Dewayne Chapman	207 N 3RD/PO BOX 561	MABANK	TX	75147	903-8873711
MFM PHARMACY	Charbel Boujaoude	6912 FM 1488 STE B	MAGNOLIA	TX	77354	281-2144040
ATKINS PHCY SERVICES HM	Kevin Atkins	701 THIRD STREET	MARBLE FALLS	TX	78654	830-6932972
HAMARSYL PHARMACY	Annunciatta Kume	2528 BUDDY OWENS AVE	MCALLEN	TX	78504	956-6274358
SAENZ MED PHY OF MCALLEN	ELVIA SAENZ	212 LINDBERG	MCALLEN	TX	78501	956-6306465
SAENZ MED PHY NOLANA	ELVIA SAENZ	801 E NOLANA STE 22	MCALLEN	TX	78504	956-6872500
SAENZ MED PHCY RIDGE	ELVIA SAENZ	1200 E RIDGE ROAD STE 13	MCALLEN	TX	78503	956-6302500
SAENZ MED PHY AT NORTH	JESUS SAENZ	6900 NORTH 10TH STE 6	MCALLEN	TX	78504	956-9280911
PECAN PHARMACY	Ruben Fonseca	1623 PECAN BLVD	MCALLEN	TX	78501	956-7938568
MEDROCS PHARMACY	Ann Andraws	8901 VIRGINIA PKWY #200	MCKINNEY	TX	75071	972-7772070

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
ADAMS PHARMACY	JUDY ADAMS	125 W MAIN ST	LEBANON	KY	40033	270-6929115
POOLES PHCY CARE LEW	Lisa Poole	8180 US HWY 60 W	LEWISPORT	KY	42351	270-2953131
HOMETOWN PHY OF LEXINGTON	Bijalkumar Patel	2860 RICHMOND RDSTE190	LEXINGTON	KY	40509	859-4074135
WHEELER PHARMACY	Claire Lewis	336 ROMANY RD	LEXINGTON	KY	40502	859-2661131
THE PHARMACY SHOP	CLARENCE SULLIVAN	450A SOUTHLAND DRIVE	LEXINGTON	KY	40503	859-2787282
PASADENA PHARMACY	Daren White	280 PASADENA DR	LEXINGTON	KY	40503	859-2602469
PROFESSIONAL PHARMACY	GENE THOMPSON	3050 HARRODSBURG RD	LEXINGTON	KY	40503	859-2786449
GRASSROOTS PHARMACY	Shelley Roberts	2304 SIR BARTON WAY STE 195	LEXINGTON	KY	40509	859-2631382
POOLE'S PHCY CARE LIVE	RON POOLE	311 HENTON STREET	LIVERMORE	KY	42352	270-2785537
RX ALTERNATIVES	Ann Logsdon	9813 MERIONETH DRIVE	LOUISVILLE	KY	40299	502-3388481
LIFEWELL RX PHARMACY	Felix Gyamfi	2200 BUECHEL AVE STE 104	LOUISVILLE	KY	40218	502-7425958
EAST BROADWAY PHARMACY	JAMAL ABOULHOSN	2304 HURSTBOURNE VILLAGE #700	LOUISVILLE	KY	40299	502-5891828
TRIPLE CROWN PHARMACY	Krishma Patel	13332 SHELBYVILLE RD.	LOUISVILLE	KY	40223	502-2814900
DIXIE PHARMACY LLC	NAVAS YOONUS	8442 DIXIE HIGHWAY, # 100	LOUISVILLE	KY	40258	502-8121920
MY PHARMACY	NIMISH PATEL	170 DR. ARLA WAY ST105	LOUISVILLE	KY	40229	502-2771425
BLUEGRASS PHARMACY	GARY RUSSELL	1128 N MAIN ST	MADISONVILLE	KY	42431	270-8252775
KB PHARMACY	BRAD BOONE	320 S MAIN ST	MARION	KY	42064	270-9679007
STONE DRUGS HM	David Whaley	414 S 9TH STREET	MAYFIELD	KY	42066	270-2473232
DUNCAN SPECIALTY PHCY	Mykel Tidwell	1522 CUBA ROAD	MAYFIELD	KY	42066	270-2473725
DUNCAN PRESCRIPTION CTR	Mykel Tidwell	1520 CUBA ROAD	MAYFIELD	KY	42066	270-2473345
DUNCAN CLINIC PHARMACY	Mykel Tidwell	1111 MEDICAL CENTER CIR	MAYFIELD	KY	42066	270-2477000
MCDOWELL PROF. PHARMACY	STEVE DAWSON	9549 KY RTE 122 STE 2	MC DOWELL	KY	41647	606-3771088
PARKVIEW PHARMACY HM	Valerie Akers	8274 KY RTE 122 POB 70	MINNIE	KY	41651	606-3772117
SOUTH CREEK DRUGS	Tim Robinson	130 WALMART PLAZA DRIVE	MONTICELLO	KY	42633	606-3481800
CAVE RUN PHARMACY	BILL SHELLEY	255 OLD FLEMINGSBURG RD	MOREHEAD	KY	40351	606-7831511
MOUNT VERNON DRUG	Timothy Carnes	410 RICHMOND ST	MOUNT VERNON	KY	40456	606-2563447

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
NORTH CENTRAL PHCY LLC	Chinedu Okocha	5080 VIRGINIA PKWY #550	MCKINNEY	TX	75071	972-5409900
SANDSRX MCKINNEY	Mahdi Hallak	1717 W UNIVERSITY DR #412	MCKINNEY	TX	75069	502-8020215
MCKINNEYPHYSICIAN AND COMPOUND	Rahul Gandhi	4601 MEDICAL CENTER DR STE B	MCKINNEY	TX	75069	972-3252273
APOLLO PHARMACY	Santhi Challa	4987 W UNIVERSITY DR#120	MCKINNEY	TX	75071	972-5426337
MERKEL DRUG @@@ HM	Danny Woodall	121 EDWARDS STREET	MERKEL	TX	79536	325-9285012
TOPLINE PHARMACY	Georgina Nnanna	4400 W LOOP 250 #102	MIDLAND	TX	79707	432-2875620
MIDKIFF PHARMACY	Vin Bommisetty	1111 N MIDKIFF RD STE A	MIDLAND	TX	79701	432-2992996
US DRUG MART 3	David Paschal	540 GEORGE HOPPER RD	MIDLOTHIAN	TX	76065	972-7751180
KELLY DRUG	Kelly Williams	125 EAST BROAD	MINEOLA	TX	75773	903-5693882
BEST VALUE WADDY PHCY	Steven Maddox	106 SW 6TH AVENUE	MINERAL WELLS	TX	76067	940-3250734
SAENZ MED PHCY LONESTAR	ELVIA SAENZ	2121 E GRIFFIN PARKWAY STE 18	MISSION	TX	78572	956-5196500
ECO PHCY SIENNA PLANATION	JASMEET SINGH	8721 HIGHWAY 6 SOUTH #200	MISSOURI CITY	TX	77459	832-4400085
MEDLIN PHARMACY	Nkiru Chinedo	2755 TEXAS PARKWAY #101	MISSOURI CITY	TX	77489	281-4371818
HAECKERVILLE PHARMACY	Waylon Haecker	9402 HIGHWAY 6 STE 400	MISSOURI CITY	TX	77459	281-9150793
MEDICAL CTR FAMILY PHARM	LARRY KRPEC	2001 N JEFFERSON STE 132	MOUNT PLEASANT	TX	75455	903-5726418
LEEDS PHARMACY	Yan Frankel	318 W FM 544 STE B3	MURPHY	TX	75094	469-2090766
STRIPLINGS PHARMACY	Garth Hinze	1205 NORTH MOUND ST	NACOGDOCHES	TX	75961	936-5644646
M&S PHARMACY	Garth Hinze	917 E AUSTIN ST	NACOGDOCHES	TX	75965	281-2173425
ASA PHARMACY	Ahmad Alala	419 N LASALLE ST	NAVASOTA	TX	77868	561-9006336
MID COUNTY PHARMACY	Bala Sreenivas	1505 S HWY 69	NEDERLAND	TX	77627	409-8534100
PHARM HOUSE DRUG NEEDVILL	Loren Pierce	13500 HWY 36	NEEDVILLE	TX	77461	979-7935534
NB PHARMACY	Trey Coleman	409 N EAST FRONT ST	NEW BOSTON	TX	75570	903-5049020
GRUENE ROAD PHARMACY	Andrew Noonan	910 GRUENE RD #3	NEW BRAUNFELS	TX	78130	830-3874378
TEN MINUTE PHARMACY	Malik Moti	18 GRUENE PARK DR	NEW BRAUNFELS	TX	78130	830-3874914
GRUENE RD PH HUNTERS VLG	Michael Weissling	1929 STATE HWY 46 W # 101	NEW BRAUNFELS	TX	78132	830-2219030
SIGMA PHARMACY	Vira Viradia	1312 E COMMON ST #402	NEW BRAUNFELS	TX	78130	972-3470250

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
CAMARGO PHARMACY	Daren White	3404 CAMARGO RD,	MT STERLING	KY	40353	859-4970009
WHITAKER PHARMACY	STEVE WHITAKER	570 INDIAN MOUND DR	MT STERLING	KY	40353	859-4983141
ROCKCASTLE PROF PHY	TIM YOUNG	110 NEWCOMB AVE/POB 1860	MT VERNON	KY	40456	606-2564613
JANE'S PHARMACY	Navas Yoonus	950 MAIN ST, STE 100	MUNFORDVILLE	KY	42765	270-5241210
ALEXS FAMILY PHARMACY	Alexandria Mehr	801 PARAMOUNT DR	MURRAY	KY	42071	270-9171424
WALTERS PHARMACY	Daniel Jones	604 S 12TH ST	MURRAY	KY	42071	270-7537688
NANCY PHARMACY	Kendall KILBOURNE	9919 W HIGHWAY 80 #100	NANCY	KY	42544	606-2880018
TAILOR MADE COMPOUNDING	Blake Mcleod	200 MOORE DR	NICHOLASVILLE	KY	40356	859-8870013
NORTONVILLE PHARMACY	ADAM COFFMAN	229 S HOPKINSVILLE ST	NORTONVILLE	KY	42442	270-6768268
DANHAUER DRUG	JEFF DANHAUER	330 FREDERICA ST	OWENSBORO	KY	42301	270-6842341
WILSON FAMILY PHCY INC	JIGNA PATEL	2845 W PARRISH AVE	OWENSBORO	KY	42301	270-6880100
POOLE'S PHY SPRINGS CTR	RON POOLE	2200 E PARRISH AVE # 102	OWENSBORO	KY	42303	270-9266260
FAMILY DISCOUNT DRUGS	Lindsay Ferrell	60 SLATE AVENUE POB #1119	OWINGSVILLE	KY	40360	606-6746979
BATH HOMETOWN PHCY	STEVE WHITAKER	19 MILLER DR	OWINGSVILLE	KY	40360	606-6742423
WEST TOWNE PHARMACY	Brandy Key	2755 W PARK DR	PADUCAH	KY	42001	270-4430909
STRAWBERRY HILLS PHARMACY	Daniel Jones	2670D NEW HOLT ROAD	PADUCAH	KY	42001	270-4447070
STRAWBERRY HILLS PHCY SS	Daniel Jones	3837 CLARKS RIVER RD	PADUCAH	KY	42003	270-4083784
RICK'S PHARMACY	RICK TIMMONS	3001 SCHNEIDMAN RD	PADUCAH	KY	42003	270-4437200
MOUNTAIN PHARMACY	Tom Parker	8857 META HIGHWAY	PIKEVILLE	KY	41501	606-6379011
PROSPECT PHARMACY	Priyanka Marfatia	9549 B US HWY 42	PROSPECT	KY	40059	502-7853000
RAM PHARMACY	Curtis Bradley	719 GREENUP AVE	RACELAND	KY	41169	606-8367267
RADCLIFF PHARMACY LLC	NAVAS YOONUS	800 W LINCOLN TRAIL BLVD #100	RADCLIFF	KY	40160	270-3517400
BLUEGRASS FAMILY PHARMACY	DANNY BILITER	2187 LEXINGTON RD # 1	RICHMOND	KY	40475	859-6249797
RILEY-WHITE INC.	DONALD RILEY	153 PARK SQ NW	RUSSELLVILLE	KY	42276	270-7267626
CLINIC PHARMACY	MICHAEL KELLER	141 HOSPITAL DR	SALEM	KY	42078	270-9883230
HERITAGE PHARMACY	Mike Burchett	870 PARKWAY DRIVE	SALYERSVILLE	KY	41465	502-5922394

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
SUNFLOWER RX	Brian Meyer	700 N GRANT SUITE 150	ODESSA	TX	79761	432-6062394
UNIVERSITY PHARMACY HM	Grayson Hankins	4850 E UNIVERSITY BLVD A	ODESSA	TX	79762	432-3668821
WESTEX PHARMACY	Vin Bommisetty	601 E 7TH ST	ODESSA	TX	79761	432-2992995
PARIS APOTHECARY	Leslie Lange	707 LAMAR AVE SUITE B	PARIS	TX	75460	903-7854208
MEDPLUS PHARMACY 3	Sam Al-Atah	5150 CRENSHAW RD	PASADENA	TX	77505	202-6412221
PYRAMIDS SPECIALTY PHCY	Dalia Abdelhalim	10970SHADOW CRK PKWY#110.1	PEARLAND	TX	77584	832-2844933
FRIO DRUG STORE	Kiran Kali	223 S OAK ST	PEARSALL	TX	78061	830-9651666
PROFESSIONAL PHCY HM	Leo Hung	1010 S EDDY STE A	PECOS	TX	79772	432-4472266
AXTELLS PHARMACY	JONATHAN LIPE	1246 HWY 377 SO, STE 100	PILOT POINT	TX	76258	940-6862218
LIVE OAK PHARMACY	BILAL ATIEH	2105 W SPRING CRK PKWY325	PLANO	TX	75023	972-5321008
CARINGRX PHARMACY	Connie Gelineau	6020 W PARKER RD STE 270	PLANO	TX	75093	972-3784107
RENUE RX #2 TELP PLANO	Raj Chhadua	5501 INDEPENDENCE PKWY STE. 110-B	PLANO	TX	75023	800-5555555
MEDSCRIPT PHARMACY	Varun Patel	1101 OHIO DR. STE 115	PLANO	TX	75093	469-2980592
BLUESTONE PHARMACY	Vira Viradia	915 W PARKER RD STE 321A	PLANO	TX	75023	469-5911680
REXCO PHARMACY HM	James Magel	120 N. SMITH ST	PLEASANTON	TX	78064	830-5694060
PRINCETON PHARMACY	PRAVEEN "KUMAR" DAIDA	100 W PRINCETON DR STE A	PRINCETON	TX	75407	972-7363777
PROSPER PHARMACY	ADI GELLI	1000 N PRESTON RD STE10	PROSPER	TX	75078	214-3384010
STARCARE PHARMACY	CRAIG PATEL	210 S PRESTON RD STE B	PROSPER	TX	75078	972-3476331
SAVE MART PHARMACY	Daniel Craig Waters	733 E QUINLAN PKWY	QUINLAN	TX	75474	903-3562449
SCOTTS QUITMAN PHARMACY	Scott Parton	310 E GOODE ST	QUITMAN	TX	75783	903-7639600
TORRES FAM RAYMONDVILLE	Francisco Torres	182 E KIMBALL AVE	RAYMONDVILLE	TX	78580	956-6904280
BEST VALUE RHOME	Steven Maddox	400 S MAIN ST	RHOME	TX	76078	817-9955196
RITE CARE PHARMACY IV RCH	Christina Garcia	3005 E RENNER RD STE 120	RICHARDSON	TX	75082	214-3245100
DANA DISCOUNT PHARMACY	MAHMOUD AHMAD	420 N COIT RD #2019	RICHARDSON	TX	75080	972-2318885
FAMILY DISCOUNT PHARMACY	Z. MArgulis	970 N COIT ROAD #2403	RICHARDSON	TX	75080	972-2350444
BEST RX PHARMACY	Purvi Agrawal	7200 GLENVIEW DR STE 1	RICHLAND HILLS	TX	76180	817-3698988

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
HEALTHY WAY PHARMACY	BRETT DICKERSON	RT 7 MAIN STREET	SANDY HOOK	KY	41171	606-7384041
DISCOUNT DRUG MART	DEBORAH BREWER	121 S KY 7	SANDY HOOK	KY	41171	606-7385111
SCIENCE HILL DRUG	Timothy Carnes	5775 N HWY 27 STE 10	SCIENCE HILL	KY	42553	606-4239959
DIXIE PHARMACY-4	Navas Yoonus	124 N MAIN ST	SMITHS GROVE	KY	42171	270-4515353
BOGLE STREET PHARMACY	Amy Scott	311 BOGLE ST	SOMERSET	KY	42503	606-4511200
SOMERSET PHARMACY	Laurence Weiss	101 S MAIN STREET	SOMERSET	KY	42501	606-6791571
WRIGHT PHARMACY	JOE WRIGHT	82 BIGGS LANE	SOUTH SHORE	KY	41175	606-9322202
MEDICA PHARMACY	Leon Claywell	100 DEPOT ST	SPRINGFIELD	KY	40069	859-4817100
COLEMAN'S DRUG STORE	ALFRED PENCE	105 W MAIN ST	STANFORD	KY	40484	606-3652164
STANFORD DRUG	KENDALL KILBOURNE	107 METKER TRAIL STE D	STANFORD	KY	40484	606-3652100
STANTON DRUGS	STEVE WHITAKER	638 E COLLEGE AVE	STANTON	KY	40380	606-6638990
HARRISON PHARMACY	JEFFREY HARRISON	606 N MAIN ST/POB 416	TOMPKINSVILLE	KY	42167	270-4876408
OSMAN PHARMACY	CHRISTOPHER MCLONE	89 SECOND ST	VANCEBURG	KY	41179	606-7962932
WARFIELD PRESC CENTER	CARA HALE	9251 BEAUTY ROAD	WARFIELD	KY	41267	606-3956477
CLINIC PHARMACY	DAVID O'QUINN	412 LIBERTY ROAD/POB 277	WEST LIBERTY	KY	41472	606-7434957
PEYTON'S PHARMACY, INC.	STEVE ROY	414 Main St	WEST LIBERTY	KY	41472	606-7433163
PARKWAY PHARMACY	ERNIE WATTS	2354 HIGHWAY 15	WHITESBURG	KY	41858	606-6334435
WHITESBURG MED CTR PHY	ERNIE WATTS	226 MEDICAL PLAZA LANE	WHITESBURG	KY	41858	606-6334871
KYVA PHARMACY	WILLIAM COLLINS	109 E MAIN ST	WHITESBURG	KY	41858	606-6334488
HOMETOWN PHCY WINCHESTER	Bijalkumar Patel	200 CODELLA DR STE C	WINCHESTER	KY	40391	859-7592102
SENTRY DRUG	Kent Allen	1002 3RD STREET	ALEXANDRIA	LA	71301	318-4424475
THRIFTTOWN HM	Ray Glasgow	512 N 2ND ST POB 918	AMITE	LA	70422	985-7488191
ARCADIA FAMILY PHCY	Peter Saad	1311 HAZEL ST	ARCADIA	LA	71001	318-2633948
FRANCISE PHARMACY	Norman Francise	14620 PLANK RD	BAKER	LA	70714	225-7742795
WELLNESS PHARMACY	Duy Nguyen	12726 PERKINS RD	BATON ROUGE	LA	70810	255-2563083
RED STICK PHARMACY	Rebeca Ramirez	18181 JEFFERSON HWY #101	BATON ROUGE	LA	70817	225-4081777

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
LINO'S PHARMACY #2 HM	JESSE RIOS	201 N FM 3167 SUITE A/B	RIO GRANDE CITY	TX	78582	956-4881811
FRED'S PHARMACY	MARLO CANALES	2790 PHARMACY ROAD STE A	RIO GRANDE CITY	TX	78582	800-5555555
RISING STAR PHARMACY	Misty Hill	1870B ST HWY 36	RISING STAR	TX	76471	254-6433231
ROANOKE PHARMACY	Scott Palmer	207 E BRYON NELSON BLVD	ROANOKE	TX	76262	817-4919111
ROCKWALL DG & GEN STORE	CARRIE HUNT	106 S GOLIAD ST	ROCKWALL	TX	75087	972-7223784
LINO'S PHARMACY HM	JESSE RIOS	708 GRANT ST POB 2945	ROMA	TX	78584	956-8491811
BRAZOS HYBRID PHARMACY	Chuks Nwankwo	545 FM 2977 ROAD, #110	ROSENBERG	TX	77469	281-2505411
VITASOURCE PHARMACY	Shailendra Gupta	3806 AVENUE I STE 28	ROSENBERG	TX	77471	844-7440101
CLINIC PHARMACY ROTAN	MIKE MCWILLIAMS	774 NORTH HWY 70 STE A	ROTAN	TX	79546	325-7352500
QUICK PHARMACY LLC	Garth Hinze	701 E PALM VALLEY BLVD	ROUND ROCK	TX	78664	512-2552144
SAGINAW CARE PHARMACY	Sravanthi Venna	200 WJ BOAZ RD STE 100	SAGINAW	TX	76179	682--200-10
COMMUNITY PHARMACY HM	Marty Daniel	3520 KNICKERBOCKER STE A	SAN ANGELO	TX	76904	325-9494577
GOODSENSE PHARMACY	Amrishkumar Patel	8042 WURZBACH ROAD # 150	SAN ANTONIO	TX	78229	210-8022640
LIFECARE PHCY OF AUSTIN	Anusha Annapureddy	3110 NOGALITOS #107	SAN ANTONIO	TX	78225	512-9530949
LIFECARE EMPIRE PHARMACY	Chakra Lattupally	2207 S ZARZAMORA	SAN ANTONIO	TX	78207	210-2233863
NEXTDOOR PHARMACY	Cyriac Scaria	5920 FM 78	SAN ANTONIO	TX	78244	210-5304442
ALAMO RANCH PHARMACY & WE	Eugenia Osei-Wusu	5514 LONE STAR PKWY STE 103	SAN ANTONIO	TX	78253	210-3535343
MEDPLUS PHARMACY	Kiran Kali	7220 LOUIS PASTEUR DR STE152	SAN ANTONIO	TX	78229	210-8686440
MEDPLUS PHARMACY LTC	Kiran Kali	7220 LOUIS PASTEUR DR STE152B	SAN ANTONIO	TX	78229	210-6146200
ALAMO SPECIALTY PHARMACY	Kiran Kali	8832 HUEBNER RD	SAN ANTONIO	TX	78240	409-2252098
DGD PHARMACY	Kiran Kali	5107 MEDICAL DR	SAN ANTONIO	TX	78229	210-6148612
VAMPS RX	Nate Lekwa	2004 E HOUSTON ST	SAN ANTONIO	TX	78202	210-2247676
MEDICAL CENTER PHARMACY	Pravallika Kali	1342 FAIR AVE	SAN ANTONIO	TX	78223	210-5345457
TRINITY SPECIALTY PHCY	Pravallika Kali	7323 MARBACH RD STE 105	SAN ANTONIO	TX	78227	409-2252098
SOUTH SAN MED BLDG PHCY	Richardo Leal	919 SW MILITARY #105	SAN ANTONIO	TX	78221	210-3925200
GOODSENSE PHARMACY	Rish Patel	3320 OAKWELL CT STE 103	SAN ANTONIO	TX	78218	972-2070045

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
BOLTON HM	STEVE YELLOTT	2958 PERKINS RD	BATON ROUGE	LA	70808	225-3434869
C & F PHARMACY HM	Crystal Holcomb	424 AUSTIN STREET	BOGALUSA	LA	70427	985-7322501
LIL BOOS PHARMACY	Robert Maddox	415 SAINT CLAIR RD STE C	BOYCE	LA	71409	318-7932028
DON'S PHARMACY	Don Serpas	2201 PARIS ROAD STE E&F	CHALMETTE	LA	70043	504-5162706
DIXIE PHARMACY	Daniel Reitzell	615 8TH ST POB 268	COLFAX	LA	71417	318-6275428
JAMES DRUG STORE HM	Patrick Brian	257 FLORIDA BLVD SE #A	DENHAM SPRINGS	LA	70726	225-6655186
IDEAL HEALTHMART PHARMACY	Kesa Lane	610 N PINE	DERIDDER	LA	70634	337-4637210
NOLA DISC PHCY DESTREHAN	Zach Duncan	3001 ORMOND BLVD	DESTREHAN	LA	70047	504-4733714
VIALLO DRUG CO	Brandy Viallon	309 MARCHAND DR	DONALDSON VILLE	LA	70346	225-9319237
BELLARD'S HM	Aurdie Bellard	621 WEST MAPLE	EUNICE	LA	70535	337-5466386
VAUGHANS CITY DRUG	Christopher Vaughan	109 N WALLACE BLVD	FERRIDAY	LA	71334	318-7574811
CASHWAY PHCY OF FRANKLIN	OSCAR (JAY) BERGERON IV	1419 HOSPITAL AVE	FRANKLIN	LA	70538	337-8280950
CREEL'S FAMILY PHARMACY	James Creel	26496 HWY 62	FRANKLINTON	LA	70438	985-8485555
HEALTHMART OF GUEYDAN	Tisha Dupree	200 MAIN STREET	GUEYDAN	LA	70542	337-5369600
ASPEN PHARMACY	JASON HAMIDE	5745 PLAUCHE COURT	HARAHAN	LA	70123	504-7340333
CIOLINO DRUGS	JEFFREY CIOLINO	7335 JEFFERSON HWY 300A	HARAHAN	LA	70123	504-6029744
CLAIBORNE PHARMACY	John Bannister	833 W MAIN ST	HOMER	LA	71040	318-9273523
BROADMOOR HM	Dean Pellegrin	6096 WEST PARK AVE	HOUMA	LA	70364	985-8762584
PEOPLE'S DRUG STORE	SUSAN BRUNET	7869 MAIN ST	HOUMA	LA	70360	985-8738526
LA PHARMACY	Stacey Paul LaBorde	839 S CLEARVIEW PARKWAY	JEFFERSON	LA	70121	504-4916985
MITCHELL'S PHARMACY HM	Dwayne Mitchell	202 E MAIN STREET	JONESBORO	LA	71251	318-2597466
FAMILY PHARMACY JONESBORO	Peter Saad	500 ALEXANDER ST	JONESBORO	LA	71251	416-8254430
ALL SAINTS PHARMACY	Paul Matar	2124 38TH ST	KENNER	LA	70065	504-4431294
SINCERE RX	Peter Saad	715 FIRST AVE	KINDER	LA	70648	337-7382614
LACOMBE FAMILY PHARMACY	ANTHONY BONDI	28079 US HWY 190	LACOMBE	LA	70445	985-8825999
TECHE DRUGS	RYAN DARTEZ	509 JEFFERSON ST	LAFAYETTE	LA	70501	337-2354578
HM OF LAFAYETTE HM	Wes David	600 JOHNSTON ST.	LAFAYETTE	LA	70501	337-2353523

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
RITE AWAY PHARMACY 6	ROHIT CHARDHARY	426 CASTROVILLE RD - 5	SAN ANTONIO	TX	78207	210-4339991
RITE-AWAY PHARMACY #1	Rohit Chaudhary	2235 THOUSAND OAKS #102	SAN ANTONIO	TX	78232	210-4902733
RITE-AWAY PHCY #2 HM	Rohit Chaudhary	2716 SW MILITARY DR.	SAN ANTONIO	TX	78224	210-9273742
ALAMO SPECIALTY PHARMACY	SRINIVASU VATTI	104 GALLERY CIR #104	SAN ANTONIO	TX	78258	210-8686140
SAN DIEGO PHARMACY	Nandana Kavuri	500 SOUTH DR EE DUNLAP	SAN DIEGO	TX	78384	800-5555555
B AND J PHARMACY	JOHN ANDERSON	2111 HUNTER RD	SAN MARCOS	TX	78666	512-3923301
APOTHECARY OF MED ASSOC	Nick Patel	38 EAST AVE	SCHULENBURG	TX	78956	979-7433265
SEALY PHARMACY	NICK PATEL	707 MEYER	SEALY	TX	77474	979-2563045
TEN MINUTE PHARMACY 2	Malik Moti	254 S N HWY 123 BYPASS	SEGUIN	TX	78155	830-491-50
SEGUIN PHARMACY	Merlin Yimga	211 E COURT	SEGUIN	TX	78155	857-4458030
SHEPHERD PHARMACY	Nick Patel	11011 HWY 150	SHEPHERD	TX	77371	936-6282099
CARERX PHARMACY	DINESH SRIPERAMBUDUR	1733 TEXOMA PKWY STE 200	SHERMAN	TX	75090	903-8931700
TEXOMA PHARMACY	Manny Moturi	140 W LAMBERTH RD #A	SHERMAN	TX	75092	903-7714995
SHERMAN PHARMACY	Maria Mariol	1916 N GRAND AVE	SHERMAN	TX	75090	903-3286655
RENUE RX	Raj Chhadua	1906 W US HWY 82	SHERMAN	TX	75092	903-8938222
LAKELAND PHARMACY	Rama Paladugu	204 MEDICAL DR STE 120	SHERMAN	TX	75092	903-3750083
QUALITY PHARMACY INC HM	William Patek	408 N AVENUE B POB 697	SHINER	TX	77984	361-5942262
SLATON PHARMACY	DAVID FUNG	165 S 9TH ST STE A	SLATON	TX	79364	806-8284444
MCWILLIAMS PHCY	MIKE MCWILLIAMS	3706 COLLEGE AVE	SNYDER	TX	79549	325-5737582
PHARM HOUSE DRUG SONORA	Loren Pierce	417 HIGHWAY 277 N	SONORA	TX	76950	325-3872541
SPLENDORA HEALTHCARE	NICK PATEL	13841 HWY 59, STE C	SPLENDORA	TX	77372	281-6897700
RITE CARE PHARMACY SPRING	Christina Garcia	3403 LOUETTA RD STE D	SPRING	TX	77388	713-9555700
BEEHEALTHY PHARMACY	Phibi Gabir	25115 GOSLING RD	SPRING	TX	77389	832-6636444
STANTON DRUG	COLTON KIDD	201 NORTH ST. PETER ST	STANTON	TX	79782	432-7563731
TANGLEWOOD PHARMACY	Edmund Horton	2445 NORTHWEST LOOP STE A	STEPHENVILLE	TX	76401	254-9687657
RITE CARE PHARMACY III SL	Christina Garcia	15271 SOUTHWEST FWY	SUGAR LAND	TX	77478	713-9555700
DELIVERIT PCYINC SUGARLAN	EHAB ABUGHAZALEH	13303 W AIRPORT BLVD	SUGAR LAND	TX	77478	346-9013168

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
THRIFTY WAY PHARMACY HM	Debra Mccann	1019 W FERTITTA BLVD	LEESVILLE	LA	71446	337-2393474
THRIFT TOWN DRUGS HM	Anthony Wilkinson	29680 SOUTH FROST ROAD	LIVINGSTON	LA	70754	225-6867241
SAVOY DRUG	Peter Saad	813 POINCIANA AVENUE	MAMOU	LA	70554	337-4683666
BAHAM PHARMACY	MEGAN BAHAM	3916 HYW 22	MANDEVILLE	LA	70471	985-2735099
CURTIS FAMILY PHARMACY	Leslie Curits	536 HIGHWAY 171 BYP	MANY	LA	71449	318-2732650
ELLIOTT PHARMACY HM	Eric Elliott	77395 LANDRY ST.	MARINGOUIN	LA	70757	225-6252353
MATTE'S HM	BRUCE MATTE	314 MAIN ST/PO BOX 17	MARION	LA	71260	318-2924570
MONTECINO DRUGS	Douglas Montecino	5917 LAPALCO BLVD	MARRERO	LA	70072	504-3470085
DBS PHARMACY	ELLA VASQUEZ	3735 AIRLINE DR	METAIRIE	LA	70001	504-2647206
NOLA DISCOUNT PHARMACY	ROSS MOREL	4305 -B CLEARVIEW PKWY	METAIRIE	LA	70006	504-8889411
NOLA DISCOUNT PHCY #2	ZACKARY DUNCAN	1107 VETERANS MEMORL BLVD	METAIRIE	LA	70005	504-8356060
L AND M PHARMACY	Rahul Patel	1033 ANDRE ST	NEW IBERIA	LA	70563	337-3651411
BEST LIFE PHCY	CHRIS SYLVAIN	2655 TULANE AVE	NEW ORLEANS	LA	70119	504-6216048
MED-PRO PHARMACY #3	Cyrena Jackson	3035 1/2 PARIS AVE	NEW ORLEANS	LA	70119	504-2662646
MED-PRO PHARMACY	CYRENA JACKSON	3601 SAINT CLAUDE AVE	NEW ORLEANS	LA	70117	504-3222200
MED-PRO PHARMACY#2	CYRENA JACKSON	2600 S.CLAIBORNE AVE	NEW ORLEANS	LA	70125	504-2341056
POINTE COUPEE PHCY HM	Eric Elliott	222 HOSPITAL RD.	NEW ROADS	LA	70760	225-6386321
OAKDALE DRUG COMPANY	Johnny Doxey	149 HOSPITAL DR	OAKDALE	LA	71463	318-3351360
BULLARD DRUG AND WELLNESS	Ashley Bullard-la	3515 MAIN ST HWY 165	OLLA	LA	71465	800-5555555
HOLLOWAY PHARMACY	BRANDON WILLIS	12805 HIGHWAY 28E STE A	PINEVILLE	LA	71360	318-4663113
WALKER BROS DRUG	Casey Surmick	200 E PALMETTO AVE	PLAIN DEALING	LA	71064	318-3264759
GOUDEAU'S PHARMACY HM	Shane Johnson	57930 LABAUVE AVENUE	PLAQUEMINE	LA	70764	225-6874349
BOURGS DRUG STORE	Kyle Romero	484 LOUISIANA AVE	PORT ALLEN	LA	70767	225-3441077
ISLAND PHARMACY	John Bannister	311 CHISUM ST	SICILY ISLAND	LA	71368	318-3895807
SPRINGHILL FAMILY PHCY	Peter Saad	1190 S ARKANSAS ST	SPRINGHILL	LA	71075	318-5393258
BEENES DRUG STORE	Peter Saad	402 E DARROW ST	TALLULAH	LA	71282	318-5741351

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
MEDHOPE PHARMACY	Sejal Shan	12946 DAIRY ASHFORD #450	SUGAR LAND	TX	77478	346-2279804
ROSH PHARMACY	Tesh Shan	101 SOUTHWESTERN BLV 100	SUGARLAND	TX	77478	800-5555555
APEX PHARMACY	Varun Patel	9722 US HWY 90 A STE 108	SUGARLAND	TX	77478	469-4043686
CODY DRUG LLC	Will Douglas	1505 S BROADWAY ST	SULPHUR SPRINGS	TX	75482	903-8852639
THE MED PLACE SWEETWATER	Ted Basye	1410 LAMAR ST	SWEETWATER	TX	79556	325-2366800
TAHOKA DRUG	NA'LYN SWARTZ	1610 N MAIN ST	TAHOKA	TX	79373	806-5614041
ACP PHARMACY AT ST LUKES	Binh Le	17350 ST LUKES WAY #150	THE WOODLANDS	TX	77384	281-6023493
PINECROFT PHARMACY HM	Edna Ngu	9305 PINECROFT DR STE 102	THE WOODLANDS	TX	77380	281-4663650
TOMBALL HM PHARMACY	David Yousenasna	506 GRAHAM DRIVE #140	TOMBALL	TX	77375	832-5596413
PHARM HOUSE DRUG TRINITY	Loren Pierce	485 S. ROBB ST	TRINITY	TX	75862	936-5943593
GOOD VALUE PHARMACY	Amrish Patel	13027 STATE HIGHWAY 155 S STE 200	TYLER	TX	75703	903-7078011
FAMILY FIRST PHARMACY	Elizabeth Mason	16623-A FM 2493 STE A	TYLER	TX	75703	903-5612822
FAMILY PHARMACY HM-VERNON	Terry Spears	1720 HILLCREST	VERNON	TX	76384	940-5522999
SPRINGWOOD PHARMACY	Melissa Tieu	6404 NURSERY DR SUITE 101	VICTORIA	TX	77904	800-5555555
KILLIONS PHARMACY	Walter Killion	396 W TEXAS AVE	WASKOM	TX	75692	903-6872525
BEST VALUE HOMETOWN	Steven Maddox	1702 SANTA FE DR	WEATHERFO RD	TX	76086	817-9955196
DELIVERIT PHCY CLEAR LAKE	Ehab ABUGHAZALEH	600 N KOBAYASHI RD	WEBSTER	TX	77598	281-7244828
THE PHARMACY SHOP	Judy Henneke	406 YOUENS DR	WEIMAR	TX	78962	979-7256713
PRO-SCRIPT PHCY SVCS HM	Joe Fischer	911 S .AIRPORT DRIVE	WESLACO	TX	78596	956-9693784
WESLACO PHARMACY	RUBEN P FONSECA	1102 S AIRPORT DR	WESLACO	TX	78596	956-9690636
THE OTHER GUYS PHARMACY	Sem Garza	1116 E. 8TH ST. STE 1	WESLACO	TX	78596	956-4601834
WEST DRUG	Ankit Patel	206 N MAIN ST	WEST	TX	76691	254-8265292
AXTELL RITE VAL PHCY INC	Tom Axtell	304 1/2 CHARLIE DR	WHITESBORO	TX	76273	903-5643216
PRESCRIPTION PHARMACY	WILL DOUGLAS	203 E JEFFERSON AVE	WHITNEY	TX	76692	254-6942249
PARK PLAZA	David Paschal	1900 9TH STREET	WICHITA FALLS	TX	76301	972-7751180
TROTTS CALL FIELD DRUG	David Paschal	4122 CALL FIELD RD	WICHITA FALLS	TX	76308	972-7751180

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
MEDICINE CHEST PHCY HM	MICHAEL SOILEAU	409 EAST LINCOLN RD	VILLE PLATTE	LA	70586	337-3638065
CARAWAY PHARMACY	Evette Ange	820 MCKINLEY ST	WESTLAKE	LA	70669	337-4334692
VIALLO DRUG CO	Brandy VIALLO	32555 BOWIE ST	WHITE CASTLE	LA	70788	225-5452277
DRYS PHARMACY	Rahul Patel	4344 CHURCH STREET	ZACHARY	LA	70791	225-6541175
COUNTY SQUARE PHARMACY	Abe Agayby	289 COUNTY ST	ATTLEBORO	MA	02703	508-2227620
AUBURN PHCY HOME HLTH CAR	Venu Chaluvadi	689 SOUTHBRIDGE ST	AUBURN	MA	01501	774-9223904
LAMAS DBA BARRE PHCY	ALFREDO LAMAS	547 SUMMER STREET	BARRE	MA	01005	978-3552359
V CARE PHCY CHESTNUT HILL	Vipul Patel	1244 BOYLSTON ST	CHESTNUT HILL	MA	02467	617-4409622
CHICOPEE PHCY RETAIL	MICHAEL GERMANI	505 FRONT STREET	CHICOPEE	MA	01013	413-4202122
HAMILTON PHARMACY	Marjan Mottaghi	246 BOWDOIN ST	DORCHESTER	MA	02122	617-4759600
HEALTH CARE FAMILY PHARMA	Sam Hantzis	14 LOON HILL RD	DRACUT	MA	01826	978-4550570
SAVCARE PHARMACY	Shivang Patel	15 PAYSON ROAD SUITE 101	FOXBOROUGH	MA	02035	774-7651616
METROWEST PHARMACY	Shivang Patel	214 UNION AVENUE	FRAMINGHAM	MA	01702	508-4050609
SPRINGFIELD PHARMACY	Harsh Patel	284 HIGH STREET	HOLYOKE	MA	01040	413-2616664
HOLYOKE HLTH CTR RETAIL	MICHAEL GERMANI	230 MAPLE STREET	HOLYOKE	MA	01040	413-5337323
WHOLE HEALTH PHARMACY	KARRYN LEWIS	596 WEST MAIN ST	HYANNIS	MA	02601	508-7785928
MAPLEWOOD WELLNESS PHCY	Thao Huynh	904 SALEM ST	MALDEN	MA	02148	781-6051775
ALLENS PHARMACY HM	Jay Sibulkin	40 BEACH ST UNIT G	MANCHESTER	MA	01944	978-5261321
MILFORD CENTRAL PHCY	Ali Ardakani	105 E MAIN ST	MILFORD	MA	01757	508-3812740
NANTUCKET PHCY HM	Allen Bell	45 MAIN STREET	NANTUCKET	MA	02554	508-2280180
ISLAND PHARMACY HM	Allen Bell	122 PLEASANT STREET	NANTUCKET	MA	02554	508-2286400
ACC APOTHECARY	ARTHUR MARGOLIS	153 CALIFORNIA STREET	NEWTON	MA	02458	617-5271563
UNION PHARMACY	Xiaoyan Qin	103 UNION ST	NEWTON	MA	02459	800-5555555
GOLDENSEAL APOTHECARY	Hashim Azam	70 MAIN ST STE 101	NORTH ANDOVER	MA	01845	978-5523390
ST MARY PHARMACY	Margaret Bassanty	1060 NORTH OSGOOD	NORTH ANDOVER	MA	01845	508-3167100
PHARMAHEALTH	Srinivas Athuluri	535 FAUNCE CORNER RD	NORTH DARTMOUTH	MA	02747	508-9987888

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
DOWNTOWN PHARMACY	RICKY WARDELL	1100 SCOTT ST	WICHITA FALLS	TX	76301	940-7674345
GUFFEYS DRUG STORE	VENKATAKIRAN KALI	1610A NINTH ST	WICHITA FALLS	TX	76301	940-3228626
BRUCE HUMAN DRUG	GARY DALEY	145 NORTH FOURTH STREET	WILLS POINT	TX	75169	903-8732538
WIMBERLEY PHARMACY	JOHN ANDERSON	120 JOE WIMBERLEY BLVD	WIMBERLEY	TX	78676	512-8472288
SCOTTS PHARMACY	Scott Parton	211 E COKE RD	WINNSBORO	TX	75494	903-3423669
MURPHY HEALTH MART PHCY	John Arango	709 BUSINESS WAY STE 120	WYLIE	TX	75098	972-5229358
SANDSRX	Stephen McGee	4 REGENCY DR	WYLIE	TX	75098	214-3349212
CITY DRUG STORE HM	John Mohrmann	602 US HIGHWAY 77A S	YOAKUM	TX	77995	361-2932181
BOUNTIFUL DRUG	Mary Rogers	47 E 500 S	BOUNTIFUL	UT	84010	801-2953463
BOYD'S FAMILY PHARMACY HM	Boyd Nielson	590 E MAIN ST	CASTLE DALE	UT	84513	435-3815464
WESTSIDE HEALTH MART	HAL ROE	1407 N 2000 W STE E	CLINTON	UT	84015	801-7845495
VALLEY HEALTH	Carter Musgrave	2555 N WOLF CREEK DR	EDEN	UT	84310	801-7451800
STAPLEY PHCY ENTERPRISE	BRAD STAPLEY	167 E. MAIN STREET	ENTERPRISE	UT	84725	435-8782300
BEAR LAKE COMM HLTH CTR	LAVAL JENSEN	325 WEST LOGAN HIGHWAY	GARDEN CITY	UT	84028	435-9462770
GUNNISON FAMILY	CLIFF HOLT	77 S. MAIN ST.	GUNNISON	UT	84634	435-5283455
MEIER'S PHARMACY HM	Devin Meier	4698 HOLLADAY BLVD	HOLLADAY	UT	84117	801-6793278
HURRICANE FAMILY PHARMACY	Cliff Holt	25 N 2000 W	HURRICANE	UT	84737	435-6358200
SPENCES NO HM	JOAN GRAF	550 E 1400 NO	LOGAN	UT	84341	435-7538500
OQUIRRH MOUNTAIN PHCY	Jeff Gatzemeier	3665 S. 8400 W.	MAGNA	UT	84044	801-2521000
MAPLE MOUNTAIN PHARMACY	MICHAEL JOHNSON	724 SOUTH 1600 WEST	MAPLETON	UT	84664	801-5156048
MORGAN DRUG HM	Justin Smith	109 N COMMERCIAL ST	MORGAN	UT	84050	801-8293262
CACHE VALLEY CMMTY HLC	LAVAL JENSEN	1515 N. 400 E. STE 104	NORTH LOGAN	UT	84341	435-7558424
WASATCH PHARMACY CARE HM	Christine Jacobson-Ware	1028 CHAMBERS ST	OGDEN	UT	84403	801-4790331
CANYON VIEW PHARMACY HM	Hal Roe	698 12TH STREET	OGDEN	UT	84404	801-4753795
OGDEN CLINIC	Hal Roe	4650 HARRISON BLVD.	OGDEN	UT	84403	801-4794030
MOUNTAIN VIEW PHARMACY HM	Hal Roe	1100 W 2700 N	PLEASANT VIEW	UT	84404	801-4753695

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number	Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
SERIOS PHARMACY 8 C	Paul Serio	63 STATE ST	NORTHAMPTON	MA	01060	413-5848980	PRICE FAMILY PHARMACY	Mike Johnson	4 E MAIN ST	PRICE	UT	84501	435-6373737
BALBONIS DRUG STORE HM	Richard Tassinari	289 COURT ST	PLYMOUTH	MA	02360	508-7461251	CACHE VALLEY CHC SOUTH	LaVal Jensen	517 W 100 N SUITE 110	PROVIDENCE	UT	84332	435-2134225
GALAXY PHARMACY QUINCY	Chris Le	343 NEWPORT AVE	QUINCY	MA	02170	617-3023599	COOK BROTHERS PHARMACY	Robert Cook	435 N GATEWAY DR	PROVIDENCE	UT	84332	435-7522665
RANDOLPH PHARMACY	Triet Ngo	1187 N MAIN ST	RANDOLPH	MA	02368	781-8851181	ROCK CANYON PHCY LLC HM	Brian Campbell	3179 N. CANYON ROAD	PROVO	UT	84604	801-3772002
PHARMALUXE PHARMACY	Michael McNamara	50 JOHN ELIOT SQUARE	ROXBURY	MA	02119	978-9443903	STAPLEY PHARMACY HM	Jana Stapley	102 E CITY CENTER ST	SAINT GEORGE	UT	84770	435-6733575
RUTLAND PHCY	Alfredo Lamas	18 MAPLE AVE	RUTLAND	MA	01543	508-8866261	VRX @ CITY CREEK	Brittany Cottle	50 EAST S. TEMPLE STE145	SALT LAKE CITY	UT	84111	801-2368879
BAKER PHARMACY	Harsh Patel	52 BRIDGE ST	SHELBURNE FALLS	MA	01370	413-6256324	SOUTHEAST PHCY HM	Robert Hunter	2670 SOUTH 2000 EAST	SALT LAKE CITY	UT	84109	801-4662181
PINE HILL PHARMACY	Ali Ardakani	19 N MAIN ST	SHERBORN	MA	01770	617-7976500	LARRY'S SMITHFIELD PHC HM	Larry Durrant	502 SOUTH MAIN, STE B	SMITHFIELD	UT	84335	435-5636262
GALAXY PHARMACY	Chris Le	534 DORCHESTER AVE #C-1	SOUTH BOSTON	MA	02127	617-2680800	SOJO PHARMACY	Spencer Snyder	3583 W 9800 S	SOUTH JORDAN	UT	84095	385-2740098
SPRINGFIELD PHARMACY	Alexander Wu	2547 MAIN ST	SPRINGFIELD	MA	01107	413-2663462	STONE DRUG HM	Mike Stone	159 NORTH MAIN STREET	SPANISH FORK	UT	84660	801-7988611
MCNABB #1 TOWNSEND HM	Karen McNabb-Noon	233 MAIN STREET	TOWNSEND	MA	01469	978-5972392	S. O. S. DRUG	GARRETT CRANE	214 SO MAIN	SPRINGVILLE	UT	84663	801-4896041
VINEYARD SCRIPTS HM	David Perzanowski	117 BEACH ROAD	VINEYARD HAVEN	MA	02568	508-6937979	ART CITY PHARMACY HM	Michael Johnson	405 SO MAIN	SPRINGVILLE	UT	84663	801-4895618
LESLIE DRUG HM	Donna Holmberg	65-12 MAIN ST/PO BOX 417	VINEYARD HAVEN	MA	02568	508-6931010	STAPLEY PHCY DINOCROSSING	EVAN STAPLEY	446 S. MALL DR. STE B8	ST GEORGE	UT	84790	435-6272910
CONROY APOTHECARY WT HM	Tamera Hersh	459 STATE ROAD	WEST TISBURY	MA	02575	508-6937070	SIENA'S PHARMACY	STEVE KIRKLAND	1664 S DIXIE DR STE L-106	ST GEORGE	UT	84770	435-6736777
ARROW PRESC CTR 031	Michael Sajewicz	427 NORTH ELM STREET	WESTFIELD	MA	01085	413-5688911	TUYET'S PHARMACY	Tuyet Nguyen	4128 S CARRIAGE SQ	TAYLORSVILLE	UT	84129	801-9873265
DAILY CARE PHARMACY	Adaoma Chinweuba	167 JENNIFER RD STE D	ANNAPOLIS	MD	21401	443-7755810	TREMONTON COMUNITY PHC HM	Larry Durrant	44 EAST MAIN	TREMONTON	UT	84337	435-2575249
PATIENT CARE PHARMACY	VAIBHAV PATEL	2047 WEST ST STE A	ANNAPOLIS	MD	21401	443-9499005	ROE FAMILY HEALTH MART	Hal Roe	5257 S ADAMS AVENUE PKWY	WASHINGTON TERRACE	UT	84405	801-6893420
EXTRACARE PHARMACY HM	Abdulmoheed Lawal	883 N HOWARD STREET	BALTIMORE	MD	21201	410-3324666	LAKE VIEW PHARMACY	Hal Roe	3000 W 145 S	WEST POINT	UT	84015	385-3277200
JAMES DRUG	AMAR KALIDINDI	1119 LIGHT STREET	BALTIMORE	MD	21230	410-7525810	OLIVE PHARMACY	KAMRAN KHAN	2290 SOUTH REDWOOD RD	WEST VALLEY CITY	UT	84119	801-9725155
CHARLESMEAD PHARMACY	MITCHELL KROMSKY	6242 BELLONA AVE	BALTIMORE	MD	21212	410-4350210	FALCON PHARMACY	KEVIN WOOD	795 CUMMINGS STREET	ABINGDON	VA	24211	276-2585251
THE PHCY AT BELVEDERE SQ	Peter Nguyen	524 E BELVEDERE AVE # A	BALTIMORE	MD	21212	443-4387168	DUKE PHARMACY	Mohamed Hadi	5130 DUKE ST STE 7B	ALEXANDRIA	VA	22304	703-6479939
SOUTH BALTIMORE PHARMACY	Phillip Marsiglia	631 CHERRY HILL ROAD	BALTIMORE	MD	21225	410-3558500	MEDPLUS PHARMACY	YOUSSEF SAKR	5130 DUKE ST STE 2	ALEXANDRIA	VA	22304	703-7511111
FREEDOM DRUGS	RAJ BRAHMANAPALLI	7568 NORTH POINT ROAD	BALTIMORE	MD	21219	410-4775131	PROCARE PHY HEALTH CNTR	Robyn Doam	7202 POPLAR ST	ANNANDALE	VA	22003	571-8306583
LIFELINE BALTIMORE PHCY	Raj Pingili	6821 REISTERSTOWN RD STE 207	BALTIMORE	MD	21215	410-7646500	REED'S #6	Fernando Andrzejewski	15A CROW ST	BERRYVILLE	VA	22611	540-9552020
MT VERNON PHARMACY HM	Stephen Wiener	900 CATHEDRAL STREET	BALTIMORE	MD	21201	410-5398030	RAYFIELD'S PHARMACY #2	SEVERN RAYFIELD	2 FIG STREET	CAPE CHARLES	VA	23310	757-3311212
KEYSTONE PHARMACY INC	SYAM POTLURI	1358 W NORTH AVE	BALTIMORE	MD	21217	800-5555555	PIEDMONT PHARMACY	Vance Kiser	305 MOUNT CROSS RD	DANVILLE	VA	24540	434-7913784

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
VD & SR PARK AVE PHARMACY	SYAM POTLURI	1535 PARK AVENUE	BALTIMORE	MD	21217	410-2250800
FULLER PHARMACY	Syam Potluri	6918 RIDGE ROAD	BALTIMORE	MD	21237	410-5741440
COASTAL DRUG	ARTI PATEL	11307 MANKLIN CREEK RD #1	BERLIN	MD	21811	410-6290089
TH HOMESCRIPTS BERLIN	Bill Cooper	11101 CATHAGE RD	BERLIN	MD	21811	410-5434769
ATLANTIC DISCOUNT PHCY	Tejas Sheth	500 FRANKLIN AVE	BERLIN	MD	21811	410-7758195
FOER MED ARTS PHC-WIS	Mike Foer	8218 WISCONSIN AVENUE	BETHESDA	MD	20814	301-6573500
PADEK HLTHCARE PHCY LLC	Prince Adekoya	5403-A ANNAPOLIS ROAD	BLADENSBURG	MD	20710	301-2777107
CRAIGS DRUG STORE INC HM	Charles Kelly	409 RACE STREET	CAMBRIDGE	MD	21613	410-2283322
MECMO PHARMACY	Otis Cleveland	5831 ALLENTOWN RD	CAMP SPRINGS	MD	20746	786-3850917
NATURECARE PHARMACY	SYAM POTLURI	6483 BALTIMORE NTL PIKE	CATONSVILLE	MD	21228	800-5555555
CHESTER RIVER PHARMACY	Anil Cherukuri	601 WASHINGTON AVE	CHESTERTOWN	MD	21620	410-8103600
PROCARE PHARMACY	Mercy Asong	23213 STRINGTOWN RD	CLARKSBURG	MD	20871	240-9124318
MARION PHARMACY	Karen Kitching	26427 BURTON AVE	CRISFIELD	MD	21817	410-9682300
WALSH-MCCAGH KELLOUGH HM	David McCagh	101 N CENTRE STREET	CUMBERLAND	MD	21502	301-7243646
POTOMAC VALLEY PHCY 1	SHESHU METTU	501 N CENTRE STREET	CUMBERLAND	MD	21502	301-7222342
LIFEWAY PHARMACY	Edmond Ngazal	700 MERIT BLVD SUITE 1A	DUNDALK	MD	21222	443-5303731
HILL'S DRUG CYNWOOD HM	Jennifer Harrison	503 CYNWOOD DR	EASTON	MD	21601	410-8223700
NORTHSIDE PHARMACY	DAVID AYRES	707 N BRIDGE ST SUITE B	ELKTON	MD	21921	410-3983784
CROSSROADS PHARMACY	Prasad Mattualli	4801 DORSEY HALL DR SUITE 120	ELLICOTT CITY	MD	21042	410-7727912
CANTNER'S DRUG STORE	SHALENDRA CHERUKURI	323 BLOOMINGDALE AVE	FEDERALSBURG	MD	21632	410-7545200
URBANA PHARMACY	Adetola Daramola	3420 WORTHINGTON BLVD # B	FREDERICK	MD	21704	240-8315155
MASTER SPECIALTY PHCY	Emeka Munonye	1100 WEST PATRICK ST. SUITE A	FREDERICK	MD	21703	240-6515966
ARUNDEL PHARMACY	PRASAD MATTUPALLI	7571 RITCHIE HWY	GLEN BURNIE	MD	21061	410-7613443
SOLEIL PHARMACY	Thuy Cao	801 LANDMARK DR STE B	GLEN BURNIE	MD	21061	443-2819157
AVALON PROFESSIONAL PHCY	JASON MADUKA	12100 ANNAPOLIS RD	GLENN DALE	MD	20769	301-3830142
HANOVER PARK PHARMACY	PATIENCE FOFUNG	7229 HANOVER PKWY SUITE A	GREENBELT	MD	20770	301-3451124

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
MARTINS PHARMACY DUBLIN	William Hale	180 BROAD ST	DUBLIN	VA	24084	540-2356139
FOREST PHARMACY	Bala Karnam-Virginia	1415 CROSSINGS CENTRE DR	FOREST	VA	24551	434-5343350
FAMILY PHARMACY SERVI HM	Greg Evans	240 REMOUNT RD	FRONT ROYAL	VA	22630	540-6362222
JONESVILLE DRUG CO INC.	Kimberly Coffey	154 CHAPPELL DRIVE	JONESVILLE	VA	24263	276-3462180
KC PHARMACY	GIHAN SERAKA	8988 LORTON STA BLVD #102	LORTON	VA	22079	703-3399599
SUDLEY PHARMACY	Sam Atat	8609 SUDLEY RD STE 103	MANASSAS	VA	20110	703-3663666
MACARTHUR PHARMACY	DAVID BASS	261 GRANBY STREET	NORFOLK	VA	23510	757-5336566
BAYVIEW SRC PHARMACY	Dileep Potnuri	710 E LITTLE CREEK RD	NORFOLK	VA	23518	940-7818992
DRUG CENTER PHCY #3	ROBERT WOODS	912 AIRLINE BLVD	PORTSMOUTH	VA	23707	757-3996361
DRUG CTR DISC PHCY #2	RON WOODS	600 HIGH STREET	PORTSMOUTH	VA	23704	757-3934039
MARTINS PHARMACY	Will Hale	400 N WASHINGTON AVE	PULASKI	VA	24301	540-2694434
SCOTTIE PHARMACY	Jenny Koslow	1951 SECOND STREET BOX337	RICHLANDS	VA	24641	276-9630284
BUFORD ROAD PHARMACY INC	Craig Patel	2608 BUFORD ROAD	RICHMOND	VA	23235	804-2721423
RVA PHARMACY	Mehulkumar Patel	7801 W BROAD ST STE 19	RICHMOND	VA	23294	804-5285589
WEST PHARMACY	MITCH WEST	2012 ELECTRIC RD SW	ROANOKE	VA	24018	540-7745500
MARTINS RURAL RETREAT	William Hale	100 WEST BUCK AVE	RURAL RETREAT	VA	24368	276-2502160
BROOKS BYRD PHMCY HM	C. Cameron Brooks	2 EAST MAIN ST	SALEM	VA	24153	540-3898111
A & D PHARMACY LLC	AZITA TAVAKOLIAN	6134 BRANDON AVENUE	SPRINGFIELD	VA	22150	703-6440060
HARBOUR VIEW PHARMACY	SONAL MCPHEE	5839 HARBOUR VIEW BLVD STE 102	SUFFOLK	VA	23435	757-3941870
VIENNA DRUG CENTER	Bob Borgatti, Jr.	150 W MAPLE AVE	VIENNA	VA	22180	703-9387111
CUNDIFF DRUG STORE HM	Sam Cundiff	119 E CLEVELAND AVE	VINTON	VA	24179	540-3428928
THE PRESCRIPTION SHOPPE	Henry Ranger	5223 MONTICELLO AVE #C	WILLIAMSBURG	VA	23188	757-2061630
CAVALIER PHARMACY HM	Rick Mullins	301 CHURCH ST	WISE	VA	24293	276-3289141
LIFETIME PHARM AND CMPDNG	Ali Alshaikhli	2068 DANIEL STUART SQ #34	WOODBRIIDGE	VA	22191	571-3803881
NORTHFIELD PHCY MWFB HM	Jill Donahue	14 DEPOT SQUARE	NORTHFIELD	VT	05663	802-4854771
SWANTON REXALL PHARMACY	Courtney Bates	13 YORK ST	SWANTON	VT	05488	802-8683338

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
HEALTHFIRST PHARMACY	SHIVAKUMAR PINNOJU	186 EASTERN BLVD N	HAGERSTOWN	MD	21740	240-5136059
FAMILY PHARMACY, INC HM	Eric Yospa	907 S MAIN STREET STE A	HAMPSTEAD	MD	21074	410-2393100
RPHC LLC REEDS #3	Fernando Andrzejewski	343 N PENNSYLVANIA AVE	HANCOCK	MD	21750	301-6782930
THE PHARMACY AT PJ BEAN	Vipul Shah	24035 THREE NOTCH RD	HOLLYWOOD	MD	20636	240-3094062
THE DRUG STORE	Amar Kalidindi	103 POPLAR ST	HURLOCK	MD	21643	410-9434959
LANGLEY PARK PHARMACY	Abbey Arewa	8004 NEW HAMPSHIRE AVE	HYATTSVILLE	MD	20783	301-8445280
PADEK HEALTHCARE PHY II	Prince Adekoya Jr	5814 BALTIMORE AVE	HYATTSVILLE	MD	20781	240-7313766
LAWSON PROF PHCY HM	Richard Sabatelli	3415 HAMILTON STREET	HYATTSVILLE	MD	20782	301-8644043
KENSINGTON PHARMACY HM	Hatice Tunc	3737 UNIVERSITY BLVD WEST	KENSINGTON	MD	20895	301-9336165
CROWNS PHCY AND CLINIC	Ed Okotcha	9705 FORT MEADE	LAUREL	MD	20707	+18-0055555
LAUREL PHARMACY HM	Ej Unegb	7350 VAN DUSEN ROAD, #120	LAUREL	MD	20707	301-6040566
LAVALE PHCY HM	John Stanley	1221 C NATIONAL HWY	LAVALE	MD	21502	301-7293535
CYREENE PHARMACY	Dominic Aidoo	25805 POINT LOOKOUT RD #C	LEONARDTOWN	MD	20650	240-3094101
LUTHERVILLE PHCY	Mike Nye	1776 YORK RD	LUTHERVILLE	MD	21093	410-2525247
MANCHESTER PHARMACY	JOHN GLEESPEN	3321 MAIN STREET	MANCHESTER	MD	21102	410-2392300
CARROLL DRUGS-MANCHESTER	TOM BOLTON	3128 WESTMINSTER STREET	MANCHESTER	MD	21102	410-3741414
CHOICE PHARMACY HM	Venkat Chalasani	9151 REISTERSTOWN ROAD	OWINGS MILLS	MD	21117	410-3638222
ALLCARE PHARMACY	VRUSHALI TICKLET	6196 OXON HILL RD STE 130	OXON HILL	MD	20745	301-4850000
HEREFORD PHARMACY	Keith Pfaff	216 MT CARMEL ROAD	PARKTON	MD	21120	410-3296209
MIKE'S PHARMACY II	Anil Cherukuri	3820 MOUNTAIN RD STE G	PASADENA	MD	21122	410-2550099
POCOMOKE CITY PHARMACY	Prudvi Pedaveeti	1300 MARKET ST	POCOMOKE CITY	MD	21851	410-9577941
LEX PHARMACY	Pascal Kemelong	36 SOLOMONS ISLAND RD S	PRINCE FREDERICK	MD	20678	240-6433132
NATURECARE PHARMACY	Syam POTLURI	40 MAIN ST	REISTERSTOWN	MD	21136	800-5555555
ROLLINS CARE PHARMACY	Ellie Darj	184 ROLLINS AVE	ROCKVILLE	MD	20852	301-8162801
WELLBEING CARE PHARMACY	IN OK JUNG	9715 MEDICAL CTR DR	ROCKVILLE	MD	20850	301-4241411
PROFESSIONAL PHARMACY	Christine Lee	9106 PHILADELPHIA RD #100	ROSEDALE	MD	21237	410-6878113

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
CORNER DRG WHT RVR HM	William Aimi	213 MAPLE ST	WHITE RIVER JUNCTION	VT	05001	802-2952501
ABERDEEN HEALTH MART PHCY	Bruce Quinby	1812 SUMNER AVE SUITE H	ABERDEEN	WA	98520	360-5331525
PHARMACY PLUS, INC HM	Boris Povzner	1299 156TH AVE NE, #140	BELLEVUE	WA	98007	425-6448887
ALTO BELLEVUE RETAIL	Brian Meewes	13010 NE 20TH ST #200	BELLEVUE	WA	98005	765-5924609
CHENEY OWL PHARMACY	AMANDA GOYKE	120 F ST	CHENEY	WA	99004	509-2358441
VALLEY DRUG HEALTHMART	Kevin Herda	102 E MAIN	CHEWELAH	WA	99109	509-6750038
OWL TRI-STATE PHARMACY	Brian Auer Brian Auer	1275 HIGHLAND AVE	CLARKSTON	WA	99403	509-7585533
TICK KLOCK DRUG HM	Mark Johnson	109 S MAIN STREET	COLFAX	WA	99111	509-3972111
ELK DRUG HM	SEAN THURSTON	176 EAST MAIN STREET	DAYTON	WA	99328	509-3822536
DUVALL FAMILY DRUG HM	Kari VanderHouwen	15602 MAIN ST NE	DUVALL	WA	98019	425-7882644
WASHINGTON VALLEY PHCY	Apurva Patel	636 VALLEY MALL PKWY #7	EAST WENATCHEE	WA	98802	509-8887797
PAKTIA PHARMACY	RASHID JAMALI	315 5TH AVE S SUITE C	EDMONDS	WA	98020	425-9675375
ELMA PHARMACY HM	Tom Huttula	221 WEST MAIN ST	ELMA	WA	98541	360-4822442
EAST COUNTY PHARMACY	Tom Huttula	610 E MAIN ST STE 200	ELMA	WA	98541	360-8618670
FAIRFIELD OWL PHARMACY	AMANDA GOYKE	E 208 MAIN	FAIRFIELD	WA	99012	509-2834299
ANGEL PHARMACY	Hyun Yoon	31217 PACIFIC HWY SOUTH	FEDERAL WAY	WA	98003	253-6427850
ONURI PHARMACY	Jin Koo	1014 S 320TH ST STE G	FEDERAL WAY	WA	98003	253-7198554
HIGHLAND PHARMACY HM	YONGJOO SHIM	31840 PACIFIC HWY S #A2	FEDERAL WAY	WA	98003	253-8391399
COULEE OWL PHARMACY	Amanda Goyke	411 FORTUYN RD	GRAND COULEE	WA	99133	509-6336425
PHARM A SAVE GF	Kari Vanderhouwen	207 E STANLEY ST #A	GRANITE FALLS	WA	98252	360-6917778
KETTLE FALLS PHARMACY HM	John Herda	280 WEST 3RD AVE	KETTLE FALLS	WA	99141	509-6750038
HAWKS PRAIRIE PHCY HM	SUNIL THIMMEGOWDA	2539 MARVIN RD NE STE E	LACEY	WA	98516	360-4383072
INTL PHCY	JAKEYOUNG RHEE	11228 BRIDGEPORT WAY SW	LAKEWOOD	WA	98499	253-3024553
MCCLEARY HEALTHMART PHCY	TOM HUTTULA	115 W SIMPSON AVE	MCCLEARY	WA	98557	360-4950700
MEDICAL LAKE OWL PHARMACY	AMANDA GOYKE	E 123 LAKE	MEDICAL LAKE	WA	99022	509-2995113
SOUTHGATE PHARMACY HM	Lateef Olaniyan	2709 W BROADWAY AVE	MOSES LAKE	WA	98837	509-7659332

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
SHAYONA PHARMACY	DIPAL PATEL	803 WEST RD	SALISBURY	MD	21801	443-7364662
SHAYONA PHARMACY II	Dipal Patel	811 PRISCILLA STREET	SALISBURY	MD	21804	443-9787777
APPLE DISCOUNT DRUG HM	Jeff Sherr	404A N FRUITLAND BLVD	SALISBURY	MD	21801	410-7498401
APPLE DISCOUNT DRUG #2	Jeff Sherr	1210 NANTICOKE RD STE 11	SALISBURY	MD	21801	410-5438401
MILFORD ST PHARMACY	Sanjay Rayathatha	106 MILFORD ST	SALISBURY	MD	21804	410-8600700
SHARPSBURG PHARMACY	Brian Hose	17316 SHEPHERDSTOWN PIKE	SHARPSBURG	MD	21782	301-4327223
SMITHSBURG PHARMACY	Mir Ali	22026 JEFFERSON BLVD	SMITHSBURG	MD	21783	301-8241111
SNOW HILL PHARMACY HM	Jeff Sherr	5610 MARKET ST UNIT #2	SNOW HILL	MD	21863	410-6323500
GIG PHCY HOME HLTHCARE	Sam Kuti	3611 BRANCH AVE, #103	TEMPLE HILLS	MD	20748	301-4238070
TOWSON PHARMACY HM	Mitchell Kromsky	32 WEST ROAD, SUITE 100	TOWSON	MD	21204	410-8231818
DULANEY VALLEY PHCY	THEO NDJE	716 DULANEY VALLEY RD	TOWSON	MD	21204	410-2964900
THE PHCY AT ST PATRICK'S	Prakruti Shah	10 SAINT PATRICKS DR	WALDORF	MD	20603	301-6321000
ANCHOR PHARMACIES #111	James Miller	205 WASH HGTS MEDICAL CTR	WESTMINSTER	MD	21157	410-8488900
AMED COMMUNITY PHARMACY	Saleem Ahmed	218 WASHTON HEIGHTS CTR 1A	WESTMINSTER	MD	21157	410-3696590
XXXCOLONIAL-KENXXXX HM	Gary Tito	40 DOCK SQUARE PO BOX 646	KENNEBUNKPORT	ME	04046	207-9674442
ALLEGAN MEDICAL CNTR PHCY	Fadi Nuseibeh	551 LINN STREET STE 120	ALLEGAN	MI	49010	269-6734700
ALLEN PARK DISCOUNT PHCY	Haroun Odeh	6811 ALLEN RD	ALLEN PARK	MI	48101	800-5555555
PHARMOR ALLEN PK	NABEEL ALBADANY	8221 ALLEN ROAD	ALLEN PARK	MI	48101	313-3889560
THE DRUG STORE	Wes Nunneley	2236 US 23 SOUTH	ALPENA	MI	49707	989-3542171
ARMADA PHCY HM	Hussein Smidi	23032 EAST MAIN STREET	ARMADA	MI	48005	586-7849222
LARMOUR'S VILLAGE DRUG	Bhavesh Patel	106 S CAPITAL AVE	ATHENS	MI	49011	269-7295161
AUBURN HILLS PHARMACY	ARUP SHOME	3089 E WALTON BLVD	AUBURN HILLS	MI	48326	734-7716317
LUXCARE PHARMACY	Hamad Ali	2503 CAPITAL AVE SW	BATTLE CREEK	MI	49015	269-8839900
CAPITAL AVE PHARMACY	Jignesh Patel	629 CAPITAL AVE SW	BATTLE CREEK	MI	49015	269-3390121
QC PHARMACY LLC	Ali Fakih	204 E COLUMBIA AVE	BELLEVILLE	MI	48111	313-3188900
ORCHARD PHCY CENTER HM	Ali Nasser	19731 SUMPTER RD	BELLEVILLE	MI	48111	734-3918284

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
HILLTOP PHARMACY	Kevin Bingham	1223 E. DIVISION ST.	MOUNT VERNON	WA	98274	360-4281710
SEEBERS DRUG HM	Greg Seeber	336 S WASHINGTON	NEWPORT	WA	99156	509-4472484
ODESSA DRUGS HM	Ted Bruga	19 WEST FIRST AVE	ODESSA	WA	99159	509-9822541
SAMYS DRUG STORE	SUNIL DULLA	3525 ENSIGN RD NE STE #H	OLYMPIA	WA	98506	360-8788174
OROVILLE PHARMACY	RICHARD LARSON	1416 MAIN ST	OROVILLE	WA	98844	509-4763411
BENTON SOUTHGATE PHARMACY	Lateef Olaniyan	471 WINE COUNTRY RD	PROSSER	WA	99350	509-7508319
WASHINGTON PHARMACY	Apurva Patel	918 13TH AVE SW STE F	QUINCY	WA	98848	509-7977676
HIMERX PHARMACY	Himer Rivera	3901 NE 4TH ST STE 102A	RENTON	WA	98056	425-7381262
REPUBLIC DRUG	Brant Truman	6 N CLARK AVE	REPUBLIC	WA	99166	509-7753351
ST. JOHN PHARMACY HM	Michelle Welch	10 E FRONT ST	SAINT JOHN	WA	99171	509-6483430
OTHELLO STATION PHARMACY	Ahmed Abdille	4219 S. OTHELLO ST 105 F	SEATTLE	WA	98118	206-6202400
NGUYEN PHARMACY - RAINIER	John Nguyen	2120 RAINIER AVE S, STE A	SEATTLE	WA	98144	206-3239525
NGUYEN PHCY - MAIN STREET	John Nguyen	1221 S. MAIN ST STE 103	SEATTLE	WA	98144	206-3236003
LUKES PHARMACY HM	Sam Chan	611 MAYNARD SO	SEATTLE	WA	98104	206-6218883
KP PHCY & MED SUPPLIES	TRANG TRAN	7101 MLK JR WAY S #101B	SEATTLE	WA	98118	206-7215009
SHELTON PHARMACY	SRINI TUMMALA	110 WEST K ST	SHELTON	WA	98584	360-5454333
LIDGERWOOD OWL PHARMACY	Amanda Goyke	220 E ROWAN AVE #170	SPOKANE	WA	99207	509-4833592
VALLEY MISSION PHARMACY	David Redmond	12509 E MISSION AVE # 103	SPOKANE	WA	99216	509-9286400
ULRICH'S VALLEY PHCY HM	Sara Ulrich	423 E METHOW VALLEY HWY	TWISP	WA	98856	509-9972191
UP PHARMACY	Carlo Cadiz	7311 40TH ST W	UNIVERSITY PLACE	WA	98466	253-4482460
SQUARE CARE MEDICAL PHCY	Ike Ekeya	8600 E MILL PLAIN BLVD A	VANCOUVER	WA	98664	360-5834633
PREFERRED RX PHARMACY	Scott Montgomery	10303 NE 4TH PLAIN #109	VANCOUVER	WA	98662	360-5587633
WENATCHEE CLINIC PHCY HM	Dale Murray	9TH & CHELAN ST	WENATCHEE	WA	98807	509-6625801
WOODINVILLE MED CTRPHCYHM	Betsy Faulkner	17000 140TH AVE NE #E101	WOODINVILLE	WA	98072	425-4852900
TIETON VILLAGE DRUGS HM	Phil Luther	3708 TIETON DRIVE	YAKIMA	WA	98902	509-9666850
ABBOTSFORD PHARMACY	Josh Prohaska	206 N 4TH ST	ABBOTSFORD	WI	54405	715-7216068

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
LIVE WELL RX LLC	Kassem Kleit	3270 GREENFIELD RD #101	BERKLEY	MI	48072	248-2846969
WEST MICHIGAN PHARMACY	GIRISH JUNEJA	20095 GILBERT RD	BIG RAPIDS	MI	49307	231-3054095
WOODWARD SQUARE PHARMACY	Mandy Morris	43121 WOODWARD AVENUE	BLOOMFIELD HILLS	MI	48302	248-4997840
DISCOUNT DRUGS LLC	RENU PATHAK	19145 ALLEN RD STE 105	BROWNSTOWN	MI	48183	734-2246400
ABC DISCOUNT PHARMACY	KALA MODI	5446 LAPEER RD - UNIT A	BURTON	MI	48509	810-3090886
BISHOP PHARMACY	Rajeshkumar Khunt	2358 N CENTER RD	BURTON	MI	48509	810-5533266
ARFSTROM PHCY CEDARVILLE	Jeanine LaCross	4 E M 134	CEDARVILLE	MI	49719	906-4843355
CENTERLINE CITY PHCY	CHANDRA S CHITTIPROLU	8033 E 10 MILE RD STE 103	CENTER LINE	MI	48015	586-4275344
CENTRAL PHCY CHARLOTTE	Fadi Nuseibeh	354 S COCHRAN #3	CHARLOTTE	MI	48813	517-5439990
MODERN PHARMACY HM	Mike Kane	127 N MAIN	CHEBOYGAN	MI	49721	231-6279949
CENTRAL PHCY - CHESANING	FADI NUSEIBACH	126 W BROAD ST	CHESANING	MI	48616	989-8453609
CLAWSON CARE PHARMACY	SAED SOUED	117 W 14 MILE RD	CLAWSON	MI	48017	248-4392400
APEXX PHARMACY	Maher Beydoun	43900 GARFIELD RD STE 102	CLINTON TOWNSHIP	MI	48038	586-6462323
CAREWELL PHARMACY	Rajani Thomas	41940 HAYES ROAD	CLINTON TOWNSHIP	MI	48038	586-2212829
CAREMOR PHARMACY	Yousef Alasri	407 EAST CHICAGO ST	COLDWATER	MI	49036	517-9241999
CURTIS FAMILY PHARMACY	KRISTIN ZERBY	W17344 MAIN STREET	CURTIS	MI	49820	906-5863333
JANA PHARMACY	Abbas Baydoun	14650 W WARREN STE 200	DEARBORN	MI	48126	313-6339185
CHASE MEDICAL PHARMACY	ABDO SHOUBAH	5901 CHASE RD STE 100	DEARBORN	MI	48126	313-7917390
TRUSTED CARE PHARMACY	Abdul Fadel	24710 MICHIGAN AVE	DEARBORN	MI	48124	313-4293444
KINGS PHARMACY HM	Akram Obeid	4700 SCHAEFER RD.#162	DEARBORN	MI	48126	313-5847800
EASTBORN RX PHCY	ALI CHEAITO	7526 WYOMING-STE#1	DEARBORN	MI	48126	313-4911010
CHERRY HILL PHCY #2	ALICE PUTRUS	23100 CHERRY HILL	DEARBORN	MI	48124	313-2745990
LIFETIME RX	Hasan Sabbagh	1022 N TELEGRAPH RD	DEARBORN	MI	48128	313-9702458
DIX DRUGS	Hassane Fadlallah	10066 DIX AVENUE	DEARBORN	MI	48120	313-8432400
NOUR PHARMACY	HUSSEIN ALZAGHIR	6500 SCHAEFER RD	DEARBORN	MI	48126	313-5816500
WOODHAVEN MEDICAL HM	Kassem Baydoun	4700 GREENFIELD ROAD	DEARBORN	MI	48126	313-5818200
WEST VILLAGE PHCY	MAHA ELNAZIR	2040 MONROE ST STE 201	DEARBORN	MI	48124	313-5619700

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
CHET JOHNSON DRUG INC HM	Matt Johnson	204 N KELLER AVE	AMERY	WI	54001	715-2683471
LAKE SIDE PHARMACY HM	James Schofield	536 5TH AVENUE	ANTIGO	WI	54409	715-6232631
HUHN PHCY HM	McKenzie Krause	522 WEST MAIN ST	ASHLAND	WI	54806	715-6823123
WESTERN WISCONSIN HLTH RX	James Korson	1100 BERGSLIEN ST	BALDWIN	WI	54002	715-6841401
BALSAM LAKE PHCY HM	Thomas Swanson	315 MAIN STREET	BALSAM LAKE	WI	54810	715-4853374
BLACK RIVER FALLSCLPHC HM	Barb Hagenbrock	610 W ADAMS ST	BLACK RIVER FALLS	WI	54615	715-2844089
BLAIR PHARMACY HM	John Hogden	125 WEST BROADWAY	BLAIR	WI	54616	608-9892919
IPACK PHARMACY	Sunny Patel	17000 W NORTH AVE #108W	BROOKFIELD	WI	53005	414-2410273
MILLER PHARMACY HM	Thomas Swanson	318 N MAIN STREET	CADOTT	WI	54727	715-2893243
HAYAT PHARMACY 8	FATIMA HAYEK	110 W MAIN ST	CAMPBELLSPORT	WI	53010	920-5334012
YE OLDE PHCY & WELLNESS CT	John Jankowski	N 54W 6135 MILL ST STE300	CEDARBURG	WI	53012	262-3750010
CHIPPEWA CLINIC PHCY HM	Thomas Swanson	2509 COUNTY HWY I	CHIPPEWA FALLS	WI	54729	715-7232824
VILLAGE PHARMACY	Casey Blom	633 BUSINESS 141 N	COLEMAN	WI	54112	920-8975333
CORNELL PHARMACY, INC	Tom Swanson	300 MAIN ST	CORNELL	WI	54732	715-2396453
HAYAT PHARMACY 12	Fatima Hayek	5911 SOUTH PACKARD AVE	CUDAHY	WI	53110	414-7125200
TRIG'S PHCY HM ER	Lee Guenther	925 EAST WALL STREET	EAGLE RIVER	WI	54521	715-4796413
HAYAT PHARMACY 14	Fatima Hayek	2501 W SILVER SPRING DR#5	GLENDALE	WI	53209	414-7125200
STREU'S PHCY INC - RETAIL	JEFF KIRCHNER	635 MAIN STREET	GREEN BAY	WI	54301	920-4374750
HAYAT PHARMACY 6	HASHIM ZAIBAK	4931 S 27TH STREET #400	GREENFIELD	WI	53221	414-8176666
HAYAT PHARMACY 15 RDS	Tamir Kaloti	5233 SOUTH 27TH ST #1	GREENFIELD	WI	53221	262-8932100
COUNTY MARKET PHCY-HUDSON	DANA GLADE	2310 CRESTVIEW DR	HUDSON	WI	54016	715-3815923
MICKLESEN DRUG	MARK ANDERSON	530 2ND ST	HUDSON	WI	54016	715-3863344
WHITE CROSS PHARMACY HM	Thomas Swanson	314 SILVER ST	HURLEY	WI	54534	715-5615666
SWEET MEDICINE PRESCRIPTION PLUS	SUSAN SHAMBEAU	155 N MAIN STREET	IOLA	WI	54945	715-4453117
MUELLER DRUGS HM	JOSH LOTZ	132 SOUTH MAIN	JEFFERSON	WI	53549	920-6745733
GOOD VALUE LARSEN MAYER	ALEX BERCE	3825 39TH AVE STE 100	KENOSHA	WI	53144	262-6588124
GOOD VALUE PHARMACY HM	Alex Berce	3207 80TH STREET STE 100	KENOSHA	WI	53142	262-6975744

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
SAM PHARMACY	Majed Alkawri	9550 DIX ROAD	DEARBORN	MI	48120	313-3779791
SAVEMAX PHARMACY	Mohamed Alasri	10035 W VERNOR HWY	DEARBORN	MI	48120	313-5519949
WESTBORN PHARMACY 8	Mohammad Hamdan	1800 GRINDLEY PK. STE1	DEARBORN	MI	48124	313-4386476
HAMZEH PHARMACY	NANCY HAMZEH	10437 WEST WARREN AVE	DEARBORN	MI	48126	313-5821670
MEDINA PHARMACY	NASSER MANSOUR	8744 W. WARREN AVE.	DEARBORN	MI	48126	313-3976919
INSTACARE PHARMACY LLC	Rafi Rayes	14300 MICHIGAN AVE	DEARBORN	MI	48126	313-7971111
MY CARE PHARMACY	Sam Ozeir	6200 CHASE RD	DEARBORN	MI	48126	313-4518730
JULIA'S PHARMACY	SHADI SAAD	5220 OAKMAN BLVD	DEARBORN	MI	48126	313-4063363
DEARBORN CAREMOR PHY	SUMAYA MUSLEH	10633 W. WARREN AVE	DEARBORN	MI	48126	313-2542996
PREMIER HOME PHCY OF MI	SYED RAZA	23874 KEAN ST STE 120	DEARBORN	MI	48124	313-8879111
AMERICO PHARMACY	Talal Maisari	24355 FORD ROAD	DEARBORN	MI	48128	313-5637777
SAVERX DISCOUNT PHCY	Eyad Khadr	3915 PELHAM STREET	DEARBORN HEIGHT	MI	48125	866-8444142
PHARMOR PHCY GREENFIELD	Abdo Ali Abdulla	14661 GREENFIELD RD STE B	DETROIT	MI	48227	313-6352788
CADIEUX DISCOUNT PHARMACY	Ahmad Kaid	17163 HARPER AVE	DETROIT	MI	48224	313-4991110
SAVON MEDICAL PHARMACY	Ahmed Abouhaswa	18000 LIVERNOIS AVENUE	DETROIT	MI	48221	313-8628800
GRISWOLD PHARMACY	AHMED ANKOUNI	1411 WASHINGTON BLVD	DETROIT	MI	48226	313-2379000
ROSA PARK MEDICAL PHCY	Ahmed Said	8665 ROSA PARK BLVD	DETROIT	MI	48206	313-3618800
BARTON PHARMACY	Ali Fakih	3950 MOUNT ELLIOTT ST	DETROIT	MI	48207	734-8830785
DUNDEE FAMILY PHARMACY	Bilal Chaaban	2925 RUSSELL ST STE 100	DETROIT	MI	48207	313-4624828
PHARMOR PHARMACY SIX MILE	Charm Washington	10420 W MCNICHOLS RD	DETROIT	MI	48221	313-6232662
PHARMOR PHCY GRATIOT	Charm Washington	12740 GRATIOT AVE STE 100	DETROIT	MI	48205	248-6633380
CARE-MOR PHARMACY	Emeka Chukwuji	17256 W.7 MILE RD	DETROIT	MI	48235	313-8382500
CANFIELD PHARMACY	Faris Gammoh	4673 CONNER ST	DETROIT	MI	48215	313-4587529
SMARTRX	Ghazi Alsafari	23601 W 7 MILE RD	DETROIT	MI	48219	313-5911010
MEDSTOP PHARMACY	GHAZI ALSAFARI	10041 FENKELL ST	DETROIT	MI	48238	313-9330630
SAFARI DRUGS	Ghazi Alsafari	17100 W 7 MILE RD	DETROIT	MI	48235	313-8556385
EXPRESS MEDS PHARMACY	HUSSEIN Safawi	17731 E WARREN AVE	DETROIT	MI	48224	313-3084500

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
GVP MEDCARE WEST HM	Alex Berce	9916 75TH ST #103	KENOSHA	WI	53142	262-9250201
RUSK COUNTY PHARMACY, INC	JOSH PROHASKA	400 W 9TH ST N	LADYSMITH	WI	54848	715-5323339
COMMUNITY PHARMACY	Aimee Speers	130 S FAIR OAKS AVE	MADISON	WI	53704	608-2513242
HOEY APOTHECARY	KEVIN HOEY	4002 MONONA DRIVE	MADISON	WI	53716	608-2214639
NEUHAUSER PHCY HM	Peg Beckman	1875 MONROE ST	MADISON	WI	53711	608-2568712
VALUCARE CENTER HM	Stephen Wilke	1378 MAIN ST	MARINETTE	WI	54143	715-7320717
PHILLIPS PHARMACY HM	James O'Keefe	123 E STATE STREET	MAUSTON	WI	53948	608-8475949
MEDFORD PHARMACY, INC	Thomas Swanson	210 S MAIN STREET	MEDFORD	WI	54451	715-7484477
MEQUON FAMILY PHARMACY	Milena Melkonyan	1424 W MEQUON RD #B	MEQUON	WI	53092	262-5810411
XPERIENCE PHARMACY	Debbie Isiekwene	5715 W APPLETON AVE	MILWAUKEE	WI	53210	414-9882188
HAYAT 21 RDS	Fatima Hayek	2500 W LAYTON AVE STE 150	MILWAUKEE	WI	53221	414-7125200
HAYAT PHARMACY 2	HASHIM ZAIBAK	5928 W VLIET ST	MILWAUKEE	WI	53208	414-4540000
HAYAT PHARMACY 7	HASHIM ZAIBAK	5312 W. VILLARD AVE	MILWAUKEE	WI	53218	414-8581111
HAYAT PHARMACY 5	Hashim Zaibak	1919 W. NORTH AVE	MILWAUKEE	WI	53205	262-3445024
HAYAT PHARMACY 10	Hashim Zaibak	5308 W BURLEIGH ST	MILWAUKEE	WI	53210	414-8375555
HAYAT PHARMACY 16	Hashim Zaibak	603 N 36TH ST SUITE 400	MILWAUKEE	WI	53208	414-5439999
HAYAT PHARMACY 9	HASHIM ZAIBAK	8434 W SILVER SPRING DR	MILWAUKEE	WI	53225	262-3445024
HAYAT PHARMACY 1	Hashim Zaibak	3727 W. WISCONSIN AVE	MILWAUKEE	WI	53208	414-9310000
HAYAT PHARMACY 3	HASHIM ZAIBAK	8500 W CAPITOL DRIVE	MILWAUKEE	WI	53222	414-4631111
HAYAT PHARMACY 4	HASHIM ZAIBAK	5434 W. CAPITOL DR	MILWAUKEE	WI	53216	414-8171111
MILWAUKEE PHARMACY	Jamal Elzeibagh	2400 W BURLEIGH ST	MILWAUKEE	WI	53206	414-4428760
LONG LIFE PHARMACY 2	Moath Sarsour	1225 W HISTO MTCHLL ST	MILWAUKEE	WI	53204	414-3777717
LONG LIFE PHARMACY 1	Moath Sarsour	1672 S 9TH ST UNIT D	MILWAUKEE	WI	53204	800-5555555
LIFE CHANGE PHARMACY	Mohame Elsheikh	1844 S. 15TH STREET	MILWAUKEE	WI	53204	414-3354617
HAYAT PHARMACY 19	Tamir Kaloti	805 W LAYTON AVE STE A	MILWAUKEE	WI	53221	414-4830000
TRIG'S PHCY HM MI	Randy Athens	9750 STATE HWY 70	MINOCQUA	WI	54548	715-3569449
BENTLEY PHARMACY	Nancie Gallagher	25 W MONTELLO ST BOX 159	MONTELLO	WI	53949	608-2972474

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
CITY PHARMACY	HUSSEIN SAFAWI	15617 W MCNICHOLS RD	DETROIT	MI	48235	313-5447144
COMPREHENSIVE MEDS LLC	HUSSEIN SAFAWI	14825 W MCNICHOLS RD	DETROIT	MI	48235	313-3077367
NEXT DOOR PHARMACY	HUSSEIN YASSINE	18250 W. WARREN AVE	DETROIT	MI	48228	313-8181810
PARKVIEW PHARMACY	Imad Aoun	670 CHENE ST	DETROIT	MI	48207	313-2590246
INDIAN VILLAGE PHARMACY	IMAD AOUN	8415 EAST JEFFERSON AVE	DETROIT	MI	48214	313-3312000
JEFFERSON PHARMACY	ISMAIL ABUHANIEH	8656 WYOMING	DETROIT	MI	48204	313-3311200
RUSSELL'S PHCY 60	John Gallizzi	3011 W. GRAND BLVD. #107	DETROIT	MI	48202	313-8755384
MEDPLUS CARE PHCY	MADAN AHEER	14071 E 7 MILE RD	DETROIT	MI	48205	313-3719000
QUICK SERVE PHARMACY HM	Mahmoud Jaward	13433 WEST EIGHT MILE RD	DETROIT	MI	48235	313-3418948
MIDTOWN RX PHARMACY	Mahmoud Srou	4100 WOODWARD AVE	DETROIT	MI	48201	313-8325900
RIVERVIEW PHARMACY	MAHMOUD SROUR	7633 E JEFFERSON AVE #130	DETROIT	MI	48214	313-4455656
PARK MEDICAL RX	MAITHAM ALSHARIFT	20720 PLYMOUTH RD	DETROIT	MI	48228	313-6515887
HEALTHVEST PHARMACY	Mike Qumsieh	3611 CARPENTER ST STE C	DETROIT	MI	48212	313-3661221
PHARMOR PHCY DOCTORS	Mohamed Sohoubah	3169 WOODWARD AVENUE	DETROIT	MI	48201	313-8324810
PHARMOR EVERGREEN	Mohamed Sohoubah	20250 WEST 7 MILE ROAD	DETROIT	MI	48219	313-5359755
PHYSICIANS PHCY & MED SUP	Mohamed Sohoubah	40 E. ALEXANDRINE AVE	DETROIT	MI	48201	313-8322050
PHARMOR GRAND LAHSER	Mohamed Sohoubah	21673 GRAND RIVER	DETROIT	MI	48219	313-5330500
DETROIT MEDICAL PHARM,INC	Mohamed Sohoubah	500 E WARREN	DETROIT	MI	48201	313-8312400
PHARMOR LAFAYETTE	Mohamed Sohoubah	1565 EAST LAFAYETTE	DETROIT	MI	48207	313-3965555
FARMACITY PHARMACY	Nassem Saleh	3456 W VERNOR HWY	DETROIT	MI	48216	313-7898934
METRO MEDICAL PHARMACY	NASSER MANSOUR	6461 W WARREN AVE STE 200	DETROIT	MI	48210	313-8942888
SEVEN VAN DRUGS	NASSER MOZEP	7701 E 7 MILE STE A	DETROIT	MI	48234	313-7338587
REMEDY RX WEST	NASSER MOZEP	13403 W 7 MILE RD	DETROIT	MI	48235	313-3401300
REMEDY RX	Nasser Mozep	16841 SCHAEFER HWY	DETROIT	MI	48235	(31-3)443-3
REMEDY RX	Nasser Mozep	22341 MOROSS RD STE R-113	DETROIT	MI	48236	313-6421800
LIVERNOS EXPRESS	OLIVER DURU	15530 PURITAN	DETROIT	MI	48227	313-6591622
PRAMUKH ASHISH LLC	RAJDEEP PATEL	14039 W MCNICHOLS RD	DETROIT	MI	48235	313-8619300

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
RAABES PHARMACY	James O'Keefe	112-118 S ADAMS ST	NEW LISBON	WI	53950	608-5623302
PARK PHARMACY HM	Thomas Swanson	138 NORTH SECOND AVENUE	PARK FALLS	WI	54552	715-7623283
BENTLEY PHARMACY	Nancie Gallagher	528 W WATER ST # 5	PRINCETON	WI	54968	920-2956271
GOOD VALUE PHCY RACINE	Alex Berce	5220 WASHINGTON AVE #101	RACINE	WI	53406	262-6326500
TRIG'S PHCY HM RH	Randy Athens	232 S COURTNEY STREET	RHINELANDER	WI	54501	715-3694849
FREEMAN DRUG	LEAH GAVIN	104 S MAIN ST	RIVER FALLS	WI	54022	715-4252255
DREIER PHARMACY HM	Tim Dreier	117 S MAIN ST	SHAWANO	WI	54166	715-5262011
HAYAT PHARMACY 17	Tamir Kaloti	577 SOUTH TAYLOR DR.	SHEBOYGAN	WI	53081	414-7125200
SHELL LAKE PHARMACY HM	Thomas Swanson	113 4TH AVE	SHELL LAKE	WI	54871	715-4687800
NS HEALTH CARE LLC	Kyle Beyer	1421 EAST CAPITOL DRIVE	SHOREWOOD	WI	53211	414-9629665
SPARTA PHARMACY HM	Tom Brieske	201 SOUTH WATER STREET	SPARTA	WI	54656	608-2692949
RED CROSS PHARMACY HM	William Busch	146 WALNUT ST	SPOONER	WI	54801	715-6352117
SPRING GREEN PHCY HM	Alisha Hahn	208 E JEFFERSON ST POB 69	SPRING GREEN	WI	53588	608-5882541
WELLTOPIA PHARMACY	Tarek Elawa	136 N MAIN ST	THIENSVILLE	WI	53092	262-4299429
THREE LAKES PHARMACY HM	SETH MOE	1790 SUPERIOR ST POB 437	THREE LAKES	WI	54562	715-5463266
TRIG'S PHARMACY TH	Randy Athens	662 N 4TH ST	TOMAHAWK	WI	54487	715-4532741
JAMES PHCY-TURTLE LA HM	Thomas Swanson	215 MAPLE STREET S	TURTLE LAKE	WI	54889	715-9862225
MORELAND PLAZA PHCY	Scott Hoff	827 W MORELAND BLVD	WAUKESHA	WI	53188	262-5424488
STRATTON DRUG INC	RICHARD KEMPFERT	107 N MAIN STREET	WAUPACA	WI	54981	715-2587057
COUNTY MARKET PHCY-WAUSAU	DANA GLADE	220 S. 18TH AVE	WAUSAU	WI	54401	715-8423541
SWAN SERV-U PHARMACY	Randy Dawes	9130 W NORTH AVE	WAUWATOSA	WI	53226	800-5555555
HAYAT PHARMACY 18	Tamir Kaloti	140 E WATER ST STE 3	WEST BEND	WI	53095	414-4549798
WEST SALEM PHARMACY HM	Tom Brieske	880 MILL ST	WEST SALEM	WI	54669	608-7860210
COMMUNITY HEALTH PHCY LLC	Tom Brieske	880 N MILL ST, SUITE 101	WEST SALEM	WI	54669	608-7862520
BENTLEY PHARMACY	Nancie Gallagher	206 S MAIN ST # 186	WESTFIELD	WI	53964	608-2962877
WHITEFISH PHARMACY	Hashim Zaibak	424 E SILVER SPRING DR	WHITEFISH BAY	WI	53217	414-9091111
OWEN-WITHEE PHCY	JOSH PROHASKA	514 DIVISION ST; POB 123	WITHEE	WI	54498	715-2292074

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
SAMS PHARMACY	SAM HARATI	14470 LIVERNOIS AVE	DETROIT	MI	48238	313-3407777
NEW MO-TOWN PHCY	Sammy Salem	3040 E 7 MILE RD	DETROIT	MI	48234	313-8912253
TONY'S PHARMACY	TONY RUSTOM	18360 FENKELL	DETROIT	MI	48223	313-2723744
SAVE-MART PHARMACY	Waddah Almattery	18330 W. CHICAGO	DETROIT	MI	48228	313-6355103
PHARMOR-SCHOOLCRAFT	Wally Abdulla	14424 SCHAEFER HWY-#100	DETROIT	MI	48227	313-2703333
CENTRAL PHCY EAST LANS	FADI NUSEIBACH	248 E SAGINAW ST STE 5	EAST LANSING	MI	48823	517-5804216
PAYLESS RX	ADAM BAZZI	22480 KELLY RD STE 101A	EASTPOINTE	MI	48021	586-2222224
KELLYS PHARMACY	Ahmed Elwaseem	20715 KELLY ROAD	EASTPOINTE	MI	48021	313-2314432
MEDPOINTE PHARMACY	GHAZI ALSAFARI	22640 KELLY RD	EASTPOINTE	MI	48021	586-5332835
RITE MED PHARMACY	Joe Naim	19070 E 10 MILE RD #PHCY	EASTPOINTE	MI	48021	586-2175454
ROTNBUCHR PHY/CNTRL EATON	Fadi Nuseibeh	124 S MAIN ST	EATON RAPIDS	MI	48827	517-6636811
EVART PHARMACY PLLC	MICHELLE LADD	107 N MAIN ST	EVART	MI	49631	231-7345581
SPECIALTY MEDS	Hamzieh Nagi	29930 W 12 MILE RD STE 2	FARMINGTO N HILLS	MI	48334	248-2813636
QUALITY CARE PHARMACY	Insia Hussain	28300 ORCHARD LAKE #101	FARMINGTO N HILLS	MI	48334	248-9878866
FARMINGTON HILLS PHARMACY	Tarek Haddo	27970 ORCHARD LAKE ROAD	FARMINGTO N HILLS	MI	48334	248-5380010
FERNDAL E FAMILY PHARMACY	Amin Khraizat	733 W 9 MILE RD	FERNDAL E	MI	48220	313-4157754
FLATROCK CITY PHCY	MADAN AHEER	25620 GIBALTAR ROAD	FLAT ROCK	MI	48134	734-7898950
PHARMACARE DRUGS 2 INC	Ali Nasser	2469 W HILL RD	FLINT	MI	48507	810-3912020
CENTRAL PHARMACY-EAST	FADI NUSEIBACH	3097 N GENESEE RD	FLINT	MI	48506	810-7449101
VILLA LINDE PHARMACY	HALA KHOULANI	1260 S LINDEN RD	FLINT	MI	48532	810-8209855
BEECHER RD FAMILY PHCY	Isam Tahboub	G3169 BEECHER RD STE 102	FLINT	MI	48532	810-3371121
RAPID RX	Mustafa Ahmad	4800 S SAGINAW ST 3 1600	FLINT	MI	48507	810-5355220
CLIO ROAD PHARMACY	ROB ROSSOW	4902 CLIO ROAD	FLINT	MI	48504	810-7897084
FOWLERVILLE PHARMACY	Fadi Nuseibeh	119 EAST GRAND RIVER AVE	FOWLERVILLE	MI	48836	517-2239832
CORNER DRUG OF FRANKFORT	Ben MacRae	401 MAIN ST	FRANKFORT	MI	49635	231-3524471
MI PHARMACY	Ankush Sharma	30040 FORD ROAD	GARDEN CITY	MI	48135	734-4692310
EAST PARIS PHARMACY	Akerm Mutahr	2060 E PARIS AVE STE #102	GRAND RAPIDS	MI	49546	616-8054601

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
E. A. HAWSE PHARMACY HM	Charlie Rohrbaugh	17978 STATE RT 55	BAKER	WV	26801	304-8978220
MACE'S PHARMACY #2	RICH MACE	204 SOUTH CRIM AVENUE	BELINGTON	WV	26250	304-8231001
REEDS PHARMACY #1	Fernando Andrzejewski	261 BERKMORE PL STE 1C	BERKELEY SPRINGS	WV	25411	304-2583800
BLUEWELLS FAMILY PHARMACY	HAROLD WELLS	3675 COAL HERITAGE RD	BLUEFIELD	WV	24701	304-5897788
SOUTHVIEW PHARMACY	Harold Wells	140 MAJESTIC PLACE	BLUEFIELD	WV	24701	800-5555555
WMH RX CTR COWEN	J. Shane Beam	6815 WEBSTER RD	COWEN	WV	26206	304-2263600
CRAIGSVILLE HOMETOWN PHCY	James Burr	18077 WEBSTER RD	CRAIGSVILLE	WV	26205	304-7426040
CARDINAL PHARMACY	Ronald Mckinney	483 COURT STREET, PO BOX 74	ELIZABETH	WV	26143	304-2754687
PILLBOX PHARMACY HM	Jamie Hudson	203 N MAIN ST PO BOX 189	FRANKLIN	WV	26807	304-3582887
COUNTRY ROADS PHARMA HM	Teresa Thompson	109 BOLT RD POB 460	GLEN DANIEL	WV	25844	304-9345327
PILL BOX HARMAN	LAUREN JONES	15 MOTT STREET	HARMAN	WV	26270	304-2273661
REED'S #2	Fernando Andrzejewski	71 COWARDLY LION DR STE A	HEDGESVILLE	WV	25427	304-7545800
VALLEY HEALTH PHARMACY	Ashley Houvouras	1301 HAL GREER BLVD	HUNTINGTON	WV	25701	304-3993355
VALLEY HEALTH PHARMACY	Ashley Mouvouras	3377 US RT 60 EAST	HUNTINGTON	WV	25705	304-5254112
MEDICAL ARTS PHARMACY	MICHAEL WILSON	949 Sixth Ave	HUNTINGTON	WV	25701	304-5297141
GRIFFITH FEIL DRUG S J	Heidi Romero	1405 CHESTNUT	KENOVA	WV	25530	304-4532381
MEDICINE CABINET PHARMACY	Larry Bartoe	50 LINCOLN STREET	KERMIT	WV	25674	304-3933386
REEDS DRUG STORE LLC HM	Mark Reed	41 PIN OAK LANE	KEYSER	WV	26726	304-7881643
REEDS PHARMACY #4	Fernando Andrzejewski	5078 WILLIAMSPORT PIKE STE A	MARTINSBURG	WV	25404	304-2676655
VALLEY HEALTH MILTON PHAR	Ashley Houvouras	1347 HILLVIEW DR	MILTON	WV	25541	304-7815011
DOUG'S DRUGS,LLC	GERARD POWERS	1125 COOK PKWY/POB 669	OCEANA	WV	24870	304-6826900
GROVE STREET PHARMACY	Charlie Rohrbaugh	111 SOUTH GROVE STREET	PETERSBURG	WV	26847	800-5555555
JUDYS DRUG STORE HM	Emily Judy	24 N MAIN ST	PETERSBURG	WV	26847	304-2571044
MACE'S PHARMACY HM	Ralph Richard	440 SOUTH MAIN ST	PHILIPPI	WV	26416	304-4574233
PHARMACY CARE	GERARD POWERS	35 MAIN AVE POB 1167	PINEVILLE	WV	24874	304-7329011
PHILLIPS PHARMACY	Troy Winland	329 2ND ST	SAINT MARYS	WV	26170	304-6843784
PROCARE PHARMACY	YVONNE WEST	720 PIKE STREET	SHINNSTON	WV	26431	304-5922682

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
THE CHEMIST SHOPPE HM	David McDiarmid	1900 WEALTHY SE STE105	GRAND RAPIDS	MI	49506	616-7747799
HEART OF THE CITY PHCY CS	FREDRICK SCHMIDT	100 CHERRY STREET	GRAND RAPIDS	MI	49503	616-9658278
NOTRE DAME PHCY 90	WILLIAM LEMANSKE	16926 KERCHEVAL	GROSSE POINTE PARK	MI	48230	313-8852154
CAMPAU PHARMACY	ALI DARWICH	12169 JOS CAMPAU-STE#101	HAMTRAMCK	MI	48212	313-3652400
INFINITY DRUGS	ALI THABET	11521 JOSEPH CAMPAU	HAMTRAMCK	MI	48212	313-7336098
HOLBROOK PHARMACY	Ghazi Alsafari	3301 HOLBROOK ST	HAMTRAMCK	MI	48212	313-8711010
THERA SCRIPT HAMTRAMCK	MOHAMMED UDDIN	9740 CONANT- STE#3	HAMTRAMCK	MI	48212	313-8757979
KELBEL, PHARMACY HM	Jim Kelbel	205 E. MAIN STREET	HARBOR SPRINGS	MI	49740	231-5265971
HASLETT PHARMACY HM	FADI NUSEIBEH	1620 HASLETT RD UNIT B	HASLETT	MI	48840	517-3390300
ADVANCE CARE PHCY	ABDULGHANI HASSAN	24822 JOHN R.	HAZEL PARK	MI	48030	248-5455515
PHARMOR PHY OAK ST CLINIC	Fouad Omar	14529 WOODWARD AVE	HIGHLAND PARK	MI	48203	313-4852971
PHARMOR-WOODWARD PLACE	Mohamed Sohoubah	15131 WOODWARD AVE	HIGHLAND PARK	MI	48203	313-9570099
PRO CARE PHCY #3	Mohamed Sohoubah	13111 WOODWARD AVE	HIGHLAND PARK	MI	48203	313-8659900
COUNTY PHARMACY 2	Fadi Nuseibeh	233 W CARLETON RD	HILLSDALE	MI	49242	517-6105665
PHARMACARE DRUGS 3 INC	Ali Nasser	3439 E GRAND RIVER AVE	HOWELL	MI	48843	800-5555555
MODERN RX	Kane Geri	3944 S STRAITS HIGHWAY	INDIAN RIVER	MI	49749	231-2382499
RED CAP PHARMACY	Ali Maki	214 N WEST AVE	JACKSON	MI	49201	517-9174877
CENTER FOR FAMILY HEALTH	Molly Kaser	505 N JACKSON ST	JACKSON	MI	49201	517-7485400
ARCADIA PHCY	MICHAEL DABAJA	615 E. CROSSTOWN PKWY #100	KALAMAZOO	MI	49001	269-5536000
GULL POINTE PHARMACY	MICHAEL DABAJA	5585 GULL ROAD SUITE 120	KALAMAZOO	MI	49048	269-5535000
K-MED PHARMACY	Waqas Akhtar	316 N. DRAKE RD	KALAMAZOO	MI	49009	269-8884488
SABOURIN'S PHARMACY HM	Kevin McParlan	1461 S HURON ROAD	KAWKAWLIN	MI	48631	989-6674877
CENTRAL PHCY-LAINGSBURG	FADI NUSEIBEH	209 E GRAND RIVER RD	LAINGSBURG	MI	48848	517-6511777
L'ANSE PHARMACY #6319	Al Hendricks	18341 US HWY 41	LANSE	MI	49946	906-5246202
ATLAS MEDS PHARMACY	Ahmed Said	4801 S MARTIN LUTHER KING JR BLVD	LANSING	MI	48910	517-5800991
HOLT PHARMACY MLK	Amna Khan	1100 WEST SAGINAW ST	LANSING	MI	48915	517-4557740

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
PHILLIPS DRUG	BRIAN CAMERLIN	615 WELLS STREET	SISTERSVILLE	WV	26175	304-6523080
BOND DRUG HM	Dan Bond	800 GRAND CENTRAL MALL	VIENNA	WV	26105	304-2957356
DUTTON PHARMACY	ROBERT DUTTON	3201 Grand Central Ave	VIENNA	WV	26105	304-2959594
WARDENSVILLE PHARMACY	Charlie Rohrbaugh	333 E. MAIN STREET	WARDENSVILLE	WV	26851	304-8743687
BONDS DRUG STORE S C	Tim Bond	1649 HARRIS HIGHWAY	WASHINGTON	WV	26181	304-8633051
VALLEY HEALTH WAYNE PHCY	Ashley Houvouras	42 MCGINNIS DR	WAYNE	WV	25570	304-3993341
WMH RX CTR WEBSTER SPGS	J Shane Brown	324 MILLER MOUNTAIN DR	WEBSTER SPRINGS	WV	26288	304-2263600
FLAT IRON DRUG	Aaron Trager	69 MCDOWELL ST	WELCH	WV	24801	304-4363380
BUFFALO PRES SHOP ACH	TOM MAERTENS	431 FORT STREET	BUFFALO	WY	82834	307-6847003
HEALTHWORKS PHARMACY	David Squires	2508 E FOX FARM RD #1B	CHEYENNE	WY	82007	307-6353618
EVANSTON COMM PHCY	LAVAL JENSEN	75 YELLOW CREEK RD STE102	EVANSTON	WY	82930	307-7898291
K-PACK PHARMACY	Alma Killpack	170 COMMERCE DR STE B	GREEN RIVER	WY	82935	307-8719764
REGISTER CLIFF PHARMACY	Vicki Einhellig	437 W. WHALEN ST	GUERNSEY	WY	82214	307-8369270
STONE DRUG	LAURA LEE NELSON	830 W. BROADWAY	JACKSON	WY	83001	307-7336222
KEMMERER PHARMACY	Ken Archer	613 MOOSE ST	KEMMERER	WY	83101	307-8008880
POLE MOUNTAIN PHARMACY	Brett Kvenild	319 E HARNEY ST	LARAMIE	WY	82072	307-4604080
LOVELL DRUG M/TH	Brent Reasch	164 E MAIN ST	LOVELL	WY	82431	307-5487231
RAWHIDE DRUG	Grant Kinn	232 S MAIN ST	LUSK	WY	82225	307-3343132
UINTA DRUG PHARMACY	Bryce Habel	2822 HIGHWAY 414	LYMAN	WY	82937	307-7862222
VILAS TELEPHCY MOORCROFT	James stephens	208 N BIG HORN	MOORCROFT	WY	82721	307-7563966
CAMBRIA DISCOUNT DRUG	Ruth Minzel	701 WASHINGTON BLVD	NEWCASTLE	WY	82701	307-7469191
PIONEER PHARMACY	Sommer Pedersen	832 W MAIN ST	RIVERTON	WY	82501	307-4638400
ROCK SPRINGS COMHLTHCTRPH	Laval Jensen	2620 COMMERCIAL WAY STE 140	ROCK SPRINGS	WY	82901	307-2125105
VILAS PHARMACY	JAMES STEPHENS	224 E MAIN ST	SUNDANCE	WY	82729	307-2833883
VANDEL DRUG	Grant Kinn	2041 MAIN ST	TORRINGTON	WY	82240	307-5322214
COWBOY DRUG LLC	Lyndsi Davis	977 GILCHRIST	WHEATLAND	WY	82201	307-3319394
WORLAND PHARMACY	David Albright	1095 CIRCLE RD	WORLAND	WY	82401	307-3474500

EXHIBIT L-2

LIST OF NOT YET OPERATIONAL FRANCHISEES AS OF MARCH 31, 2022

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number	Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
TPS	Joe Shirley	3524 DECATUR HWY STE 302	FULTONDALE	AL	35068	205-246-2491	VOSHELL'S PHARMACY	Thuy Cao	3455 WILKENS AVE STE 103	BALTIMORE	MD	21229	443-421-5126
The Pharmacy of Shannon Hills	Callie Bench	13907 HIGH RD	MABELVALE	AR	72103	501-658-2515	Saint Peters Community Pharmacy	Raj Jhala	4885 MEXICO ROAD	SAINT PETERS	MO	63376	636-244-5385
ATOZ PHARMACY	Divya Pachika	8989 E VIA LINDA STE 110	SCOTTSDALE	AZ	85258	480-500-1235	Curemed	Ghada Abukuwaik	715 BROADWAY	PATERSON	NJ	7514	862-249-1150
Dimas Pharmacy	Ratilal Rajyaguru	3805 SAN DIMAS ST STE A	BAKERSFIELD	CA	93301	661-489-4000	CITY DRUG	Quirina Garcia	7 MAIN ST	CLAYTON	NM	88415	575-374-9121
care pharmacy	Hardik Dave	246 W COLLEGE ST 101	COVINA	CA	91723	248-854-1027	86st RX INC	Yongqi Chin	2041 86TH ST UNIT A2	BROOKLYN	NY	11214	718-360-5680
Seaside Pharmacy	Afifa Soliman	599 W 7TH ST STE A	SAN PEDRO	CA	90731	310-833-3551	Uttara Pharmacy	Salauddin Rahman	75-24 37TH AVE	JACKSON HEIGHTS	NY	11372	718-440-9606
Safety First Pharmacy	Don Bui	1605 W 1ST ST STE A	SANTA ANA	CA	92703	714-486-3708	Sb pharmacy	Yasir Mahmood Chaudhary	27-29 EAST 124TH ST	NEW YORK	NY	10035	631-404-2850
MedFlorida Pharmacy	Ana Ochoa	1950 W HLLSBORO BLVD #102	DEERFIELD BEACH	FL	33442	561-658-1362	Memorial Pharmacy	Edward Lartevi	7017 S STAPLES STE 103B	CORPUS CHRISTI	TX	78413	504-782-1733
Circle S Pharmacy	Arnaldo Garcia	323 BACOM POINT RD #100	PAHOKEE	FL	33476	561-924-5238	VALLEY PHARMACY, LLC	Marlo Canales	129 N FM 3167 STE B	RIO GRANDE CITY	TX	78582	956-352-1100
MEDICINE MAXX PHARMACY	Abdul Ibssa	646 S DILLARD ST	WINTER GARDEN	FL	34787	321-695-4443	Roanoke Pharmacy	Kiran Kali	207 E BYRON NELSON BLVD	ROANOKE	TX	76262	817-491-9111
Concord Pharmacy Medical Quarters	Jonathan Marquess	5555 PEACHTREE DUNWOODY RD	ATLANTA	GA	30342	678-923-4263	ZIKAM NEIGHBORHOOD PHARMACY	Alex Oguamanam	21920 BULVERDE RD #102/103	SAN ANTONIO	TX	78259	708-250-5180
Concord Pharmacy Roswell	Jonathan Marquess	2500 HOSPITAL BLVD #300	ROSWELL	GA	30076	678-923-4263	Starcrest rx	Maria Mariol	12151 JONES MALTSBRGR 113	SAN ANTONIO	TX	78247	210-310-3113
Eastland Pharmacy	Ameer Allouch	1301 WINCHESTER RD STE 69	LEXINGTON	KY	40505	859-806-8722	ZIKAM DRIVE THRU PHARMACY	Alex Oguamanam	17323 IH 35 N STE 100	SCHERTZ	TX	78154	708-250-5180
CAVE RUN PHARMACY	Cheyenne Baber	255 OLD FLEMINGSBURG RD	MOREHEAD	KY	40351	606-336-0394							

EXHIBIT L-3

**LIST OF FRANCHISEES WHO HAVE CEASED TO DO BUSINESS UNDER THEIR
AGREEMENT OR WHO LEFT THE SYSTEM AS OF MARCH 31, 2022**

EXHIBIT M
FINANCIAL STATEMENTS

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
WIREGRASS COMMUNITY P HM	Marion Cook	430 BROADWAY STREET	ASHFORD	AL	36312	334-8993100
EASTWOOD PHARMACY		4500 MONTEVALLO RD	BIRMINGHAM	AL	35210	205-9007200
PHARMSOUTH		34 MANNING PL	BIRMINGHAM	AL	35242	205-9915265
BEASLEY PHARMACY		111 E CHURCH ST	COLUMBIA	AL	36319	334-6964611
SCOTT-COOK PHARMACY HM	Marvin Cook Jr.	1233 WESTGATE PKWY	DOTHAN	AL	36303	334-7122000
WESTSIDE PHARMACY INC	Dawn West	4440 W MAIN ST #1	DOTHAN	AL	36305	334-6996337
DOTHAN PHARMACY		301 W. INEZ RD. #8	DOTHAN	AL	36301	334-4798448
DEBBIE S DRUGS		1716 TEMPLE AVE N	FAYETTE	AL	35555	205-9327455
TIMS DISCOUNT DRUGS HM	Tim McAlpin	2401 HELTON DR	FLORENCE	AL	35630	256-7667170
MIDTOWN PHARMACY		278 NORTH THIRD ST	GADSDEN	AL	35901	256-5437777
PHARMACY FIRST HM	William Ray Carter Jr.	2302 WHITESBURG DRIVE	HUNTSVILLE	AL	35801	256-5339314
FIVE POINTS PHCY HM	Teresa Sherer	41 CURRY HWY	JASPER	AL	35503	205-2951750
EAST POINT PHCY HM	Teresa Sherer	1442 JONES DAIRY RD	JASPER	AL	35501	205-2215595
CURRY DISCOUNT PHCY		5558 CURRY HWY STE 9	JASPER	AL	35503	205-2216330
Sons Discount Pharmacy		400 9TH AVE N	JASPER	AL	35501	205-2950025
KING DRUG		7 NORTH BROAD ST	SAMSON	AL	36477	334-8982115
FOODLAND PHCY SCOTTSBORO		1402 COUNTY PARK #1	SCOTTSBORO	AL	35769	256-2591011
SECTION PHARMACY INC HM	Derrell Massey	5295 TAMMY LITTLE DRIVE	SECTION	AL	35771	256-2287179
INTERLINK APOTHECARY		618 MEDICAL CENTER PARKWAY #B	SELMA	AL	36701	334-8757686
SMITHS STATION PHCY LLC		2828 LEE ROAD 430	SMITHS	AL	36877	334-4086106
VALLEY HEAD DRUGS, LLC	Cynthia Wootten	114 COMMERCE AVE	VALLEY HEAD	AL	35989	256-6356812
#13 ALLCARE CORRECTIONAL		624 CLAY STREET	ARKADELPHIA	AR	71923	870-2465233

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
DRUG MAX	Leila Fawaz	5472 SCHAEFER ROAD	DEARBORN	MI	48126	313-5844600
Pelham Pharmacy		3815 PELHAM RD STE 3	DEARBORN	MI	48124	313-5652745
TOTAL COMMUNITY PHCY		8623 N TELEGRAPH STE 2	DEARBORN HEIGHTS	MI	48127	313-2774546
DAVIS CUT RATE DRUGS		14033-39 WEST MCNICHOLS	DETROIT	MI	48235	313-8619300
MCNICHOLS DRUGSTORE		10123 W.MCNICHOLS RD	DETROIT	MI	48221	313-3404242
SAIF PHARMACY		18254 LIVERNOIS AVE STE 1	DETROIT	MI	48221	313-6355244
MINAL PHCY		13031 CONANT STREET	DETROIT	MI	48212	313-8933339
ROSEDALE COMM PHCY HM	Zainab Jaafar	19220 GRAND RIVER	DETROIT	MI	48223	313-5310100
WYOMING DISCOUNT PHCY		18200 WYOMING ST	DETROIT	MI	48221	313-3418888
HEYDEN PHARMACY HM	Saad Shafie	20201 WEST SEVEN MILE	DETROIT	MI	48219	313-5338200
Giant Pharmacy		14040 GREENFIELD RD	DETROIT	MI	48227	313-2727777
Grand Mercy Pharmacy		18428 GRAND RIVER AVE	DETROIT	MI	48223	
HEALTH CHOICE PHARMACY 2		600 W 9 MILE RD	FERNDALE	MI	48220	248-9653962
DISCOUNT RX PHARMACY		4129 S SAGINAW STREET	FLINT	MI	48507	810-2392667
FREELAND PHARMACY	Jim Horton	7620 MIDLAND ROAD	FREELAND	MI	48623	989-6956500
FIRST CARE PHARMACY		217 MIDDLEBELT ROAD	GARDEN CITY	MI	48135	313-3270040
HUNTINGTON PHARMACY		26711 WOODWARD AVE STE LL6	HUNTINGTON WOODS	MI	48070	248-9512754
CREAMS N CAPS MICHIGAN		31035 SCHOOLCRAFT RD	LIVONIA	MI	48150	248-5305640
FARMINGTON DRUGS & MEDICAL SUPPLIES		20434 FARMINGTON RD	LIVONIA	MI	48152	248-4783922
MEDICAL CITY PHARMACY		30551 STEPHENSON HWY STE1	MADISON HEIGHTS	MI	48071	248-7074500
GREAT HEALTH PHARMACY		28147 JOHN R RD	MADISON HTS	MI	48071	586-9455802
DOWNTOWN DRUG	Jim Horton	121 E BROADWAY	MT PLEASANT	MI	48858	989-7735544

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
WILSON WIL-SAV PHARMACY	Royce Wilson	5 ALLEN CHAPEL RD	BATESVILLE	AR	72501	870-2512432
MEDIC PHARMACY BRYANT INC	Pat Kauffman	306 N REYNOLDS RD	BRYANT	AR	72022	501-8473596
Gurdon Pharmacy		104 S 6TH ST	GURDON	AR	71743	
HOLIDAY ISLAND PHARMACY		2 FOREST PARK DR STE A	HOLIDAY ISLAND	AR	72631	479-2392121
SOUTHERN PHY AR LAKE CITY		803 HIGHWAY 18 STE B	LAKE CITY	AR	72437	870-2378010
YOUNG'S MEDICARE HM	Doug Young	1304 S MAIN ST	MALVERN	AR	72104	
OAK GROVE EXPRESS RX		4763 HWY 135 N	PARAGOULD	AR	72450	870-5869200
STONEVIEW PHARMACY		459 N GILBERT RD STE A148	GILBERT	AZ	85234	480-8094289
KEY HEALTH PHARMACY		560 N ESTRELLA PKY #B9-B10	GOODYEAR	AZ	85338	623-2718577
Sun Pharmacy		4838 E BASELINE RD STE 127	MESA	AZ	85206	520-5100144
Thriftee Pharmacy		755 CENTRAL AVENUE	SAFFORD	AZ	85546	928-4281156
ALL-CARE PHARMACY		9015 E PIMA CTR PRKWY #3	SCOTTSDALE	AZ	85258	480-2706700
Starcare pharmacy		10953 FRANK L WRIGHT 101	SCOTTSDALE	AZ	85259	614-7079737
BELLES PHARMACY		15170 W. BELL RD, STE 2-100	SURPRISE	AZ	85374	623-3983650
LA Pharmacy		1048 S GARFIELD AVE #101	ALHAMBRA	CA	91801	626-2817870
MAT'S PHARMACY		2264 LINCOLN AVE	ALTADENA	CA	91001	626-7947197
PHARMACY PLUS		1012 N EUCLID ST	ANAHEIM	CA	92801	714-9563830
ANZA VALLEY PHARMACY		56555 HIGHWAY 371	ANZA	CA	92539	951-7637670
CAL CARE PHARMACY		1009 E GRANDE AVE	ARROYO GRANDE	CA	93420	805-9255511
LEE'S CLINICAL PHARMACY		1201 24TH STREET #120	BAKERSFIELD	CA	93301	661-3237006
ST JOHNS FAMILY PHARMACY		14514 RAMONA BLVD STE 4	BALDWIN PARK	CA	91706	626-9626471
The Medicine Cabinet #5		6399 ATLANTIC AVE	BELL	CA	90201	323-7731261
PRIME HEALTH PHARMACY		2915 TELEGRAPH AVE 100	BERKELEY	CA	94705	510-5702103
Valor Compounding Pharmacy		2461 SHATTUCK AVE	BERKELEY	CA	94704	510-5488777

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
New Hudson Family Pharmacy		56270 GRAND RIVER AVE	NEW HUDSON	MI	48165	248-4860720
WILTSE COMMUNITY PHARMACY		330 SOUTH MAIN STREET	PLYMOUTH	MI	48170	734-4534848
KINGS MEDICAL PHARMACY		681 UNIVERSITY DR	PONTIAC	MI	48342	
AROGYA PHARMACY		5470 GRATIOT RD	SAGINAW	MI	48638	989-6073379
Saint Clair Shores Pharmacy		23600 HARPER AVE #101	SAINT CLAIR SHORES	MI	48080	586-3500370
Liberty Drugs		14799 DIX TOLEDO RD	SOUTHGATE	MI	48195	734-7858026
QUALITY CARE PHARMACY		33740 SCHOENHERR RD	STERLING HEIGHTS	MI	48312	586-6935755
TAYLOR CITY PHARMACY		23268 ECORSE RD	TAYLOR	MI	48180	313-3952120
PHARMAX DRUGS HM	Ahmad Dabliz	10501 TELEGRAPH	TAYLOR	MI	48180	313-3572700
Taylor Discount Drugs		9320 S TELEGRAPH RD	TAYLOR	MI	48180	313-2998810
MED EX DIRECT		13201 STEPHENS RD.-STE.B	WARREN	MI	48089	877-8996337
WARREN CITY PHARMACY		27379 VAN DYKE AVE	WARREN	MI	48093	586-5104662
Romeo Plank Pharmacy		64580 VAN DYKE AVE.#D	WASHINGTON	MI	48095	586-3152290
MED SYNC PHARMACY		8275 N WAYNE RD STE.B	WESTLAND	MI	48185	734-3292454
MEDS & MORE PHARMACY		2300 BIDDLE STE 101	WYANDOTTE	MI	48192	734-2462800
Sheba Pharmacy 3		2201 FORD AVENUE	WYANDOTTE	MI	48192	313-2586660
AT HOME PHARMACY		10 N HEWITT SUITE 3	YPSILANTI	MI	48197	313-6052160
TWIN CITIES PHARMACY		133 W LAKE STREET	MINNEAPOLIS	MN	55408	612-8059454
ROCHESTER COMMUNITY PHCY		120 ELTON HILLS LN NW	ROCHESTER	MN	55901	507-3226124
MARSHFIELD CLINIC RX EDI		483 POMME DE TERRE DR	MARSHFIELD	MO	65706	417-4684442
HOMETOWN PHARMACY #4		606 E MT VERNON BLVD	MOUNT VERNON	MO	65712	417-4662000
POWERS FAMILY PHARMACY		7776 WINGHAVEN BLVD	OFALLON	MO	63368	636-2652924
ST CLAIR REXALL DRUG HM	Susan Lindeman	855 N COMMERCIAL AVE	SAINT CLAIR	MO	63077	636-6290710
TUPELO DRUGS		715 GARFIELD ST	TUPELO	MS	38801	662-3503272

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number	Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
MICKEY FINE PHARMACY HM		433 N ROXBURY DRIVE	BEVERLY HILLS	CA	90210	310-2716123	VALLEY DRUGS, INC		327B S MAIN ST	WATER VALLEY	MS	38965	662-8874135
MICKEY FINE- CAMDEN		414 N. CAMDEN DR.	BEVERLY HILLS	CA	90210	310-2733363	TOWN & COUNTRY FOODS	Daniel Gustafson	205 WEST MADISON	BELGRADE	MT	59714	
UMC PHARMACY #2		4318 W VICTORY BLVD	BURBANK	CA	91505	818-5592223	CASTLE MTN DRUG HM		4271 US HWY 12 E	WHITE SULPHUR SPRING	MT	59645	406-5472316
BURBANK MEDICAL PHARMACY		2701 W ALAMEDA BLVD	BURBANK	CA	91505	818-5597401	DRUGCO DISCOUNT PHCY #2		312 SOUTH ACADEMY ST	AHOSKIE	NC	27910	252-3324101
GLENOAKS RX PHARMACY		303 S GLENOAKS BLVD STE 16	BURBANK	CA	91502	818-8469011	RANDOLPH MEDICAL PHCY	Kuntal Lala	3541 RANDOLPH ROAD	CHARLOTTE	NC	28211	
KD Pharmacy Inc		10970 SHERMAN WAY #110	BURBANK	CA	91505	818-8478600	CPC Pharmacy		109 W. RIVER ST	COLERAIN	NC	27924	252-3562404
CHINO PLAZA PHARMACY		5562 PHILADELPHIA ST #110	CHINO	CA	91710	909-4640300	DAVIE DISCOUNT DRUGS		141 MARGINAL ST	COOLEEMEE	NC	27014	336-2842537
CHINO MEDICAL PHARMACY		5365 WALNUT AVE STE D	CHINO	CA	91710	909-5916038	ALLIEDRx PHARMACY		505 SAMARITANS RDG CT 101	ELKIN	NC	28621	180-055555
CLOVERDALE PHARMACY HM	Fred Besio	790 SOUTH CLOVERDALE BLVD	CLOVERDALE	CA	95425	707-8944414	MYSCRIPTS PHARMACY		502 MCKNIGHT DR STE 100	KNIGHTDALE	NC	27545	919-2298115
OLIVE CITY PHARMACY		954 HIGHWAY 99 W	CORNING	CA	96021	530-8240954	DRUGCO DISCOUNT PHCY #3		139 ELAMS RD	LITTLETON	NC	27850	252-5863836
Creative Compounding Pharmacy		3303 HARBOR BLVD STE C4	COSTA MESA	CA	92626	714-6275600	DRUGCO DISCOUNT PHCY #4		163 NASHVILLE COMMONS DR	NASHVILLE	NC	27856	252-6775565
BONNIE COVE		20540 EAST ARROW HWY #D	COVINA	CA	91724	626-7272083	Drugco Discount Pharmacy		107 SMITH CHURCH RD	ROANOKE RAPIDS	NC	27870	252-5377010
NOFEL PHARMACY		1001 N GRAND AVE STE A	COVINA	CA	91724	626-3439435	WINDSOR COMM HEALTH PHCY		104 RHODES AVE	WINDSOR	NC	27983	
PALM CARE PHARMACY		505 N MOLLISON AVE #102	EL CAJON	CA	92021	619-4570545	PRAIRIE PHARMACY FA1		4731 13TH AVE SW	FARGO	ND	58103	701-3730325
SANTA MARIA PHARMACY		11004 VALLEY MALL	EL MONTE	CA	91731	626-4433089	WEST ACRES PHARMACY		3902 S 13 AVE STE 3706	FARGO	ND	58103	701-2820285
QUALITY SCRIPTS PHARMACY		17609 VENTURA BLVD LL06	ENCINO	CA	91316	818-8216830	DAKOTA CLINIC PHARMACY		1702 SOUTH UNIVERSITY DR	FARGO	ND	58103	800-5555555
DSK PHARMACY		9580 GARDEN GROVE BLVD108	GARDEN GROVE	CA	92844	714-5376619	DAKOTA CLINIC PHY-32 AVE		3000 32ND AVE S	FARGO	ND	58103	701-3647800
MEDICA INC		14133 S VERMONT AVE	GARDENA	CA	90247	310-5376060	HANKINSON DRUG		323 SO MAIN AVE PO BOX 160	HANKINSON	ND	58041	701-2427414
GLENDALE WEST PHARMACY		1109 S GLENDALE AVE #A&B	GLENDALE	CA	91205	818-5485157	HEALTH CENTER PHARMACY		1401 13TH AVE E STE B	WEST FARGO	ND	58078	701-3645800
ABM PHARMACY		1385 E COLORADO ST	GLENDALE	CA	91205	818-2424216	ARAPAHOE PHARMACY		507 NEBRASKA AVENUE	ARAPAHOE	NE	68922	308-9627895
RAMA DRUGS INC		1022 E CHEVY CHASE STE D	GLENDALE	CA	91205		KEX RX PHCY & HOMECARE		120 E 18TH ST	FALLS CITY	NE	68355	402-2452029
MEMORIAL MEDICAL PHARMACY		1510 S CENTRAL AVE #110	GLENDALE	CA	91204	818-2470526	GOOD LIFE DISCOUNT PHC HM	Jim Anderson	727 O STREET	LOUP CITY	NE	68853	

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
AVS Pharmacy		511 1/2 E BROADWAY BLVD	GLENDALE	CA	91205	818-4848680
Prime Med Pharmacy		839 W GLENOAKS BLVD	GLENDALE	CA	91202	818-6000777
BALBOA PHARMACY		10700 BALBOA BLVD # 101	GRANADA HILLS	CA	91344	818-8312090
Postmeds		3121 DIABLO AVENUE	HAYWARD	CA	94545	650-3535495
Cabot Pharmacy		3100 DIABLO AVE	HAYWARD	CA	94545	
SLAUSON COMMUNITY PHARMAC		2701 E SLAUSON AVE	HUNTINGTO N PARK	CA	90255	323-5886000
MEDICAL CENTER PHCY		501 E HARDY ST STE 130	INGLEWOOD	CA	90301	310-6717636
ALLIANCE PHARMACY		323 N PRAIRIE AVE STE 100	INGLEWOOD	CA	90301	310-4194479
ANVIRX PHARMACY		13925 YALE AVE #145	IRVINE	CA	92620	949-3087511
MEDLIFE PHCY & COMPNDING		6644 IRVINE CENTER DRIVE	IRVINE	CA	92618	949-5027272
PARS PHARMACY		4050 BARRANCA PKWY STE. 150	IRVINE	CA	92604	949-7162300
CORTEXRX		7301 GIRARD AVE #100	LA JOLLA	CA	92037	858-2466918
VALLEY DRUGS		17313 E VALLEY BLVD	LA PUENTE	CA	91744	626-9642301
BEEMANS LAKE ARROWHEAD		29099 HOSPITAL RD STE 101	LAKE ARROWHEAD	CA	92352	909-3370747
PACIFIC PLAZA PHARMACY		2777 PACIFIC AVE STE A	LONG BEACH	CA	90806	562-4266588
New Phnom Pich Pharmacy		2100 E ANAHEIM ST STE A	LONG BEACH	CA	90804	669-4001005
GRAND PHARMACY		505 S VIRGIL AVE #107	LOS ANGELES	CA	90020	213-3805100
HEALTH GUARD PHARMACY		1833B E CESAR E CHAVEZ AV	LOS ANGELES	CA	90033	323-2228882
FARMACIA SUPERIOR		1175 S ROBERTSON BLVD	LOS ANGELES	CA	90035	310-7093581
UMC PHARMACY		1201 1/2 N VERMONT	LOS ANGELES	CA	90029	323-6612223
MICKY FINE PHARMACY		2000 AVENUE OF THE STARS QSR 45	LOS ANGELES	CA	90067	310-2776123

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
SCHUYLER PHARMACY		122 W 16TH STREET	SCHUYLER	NE	68661	402-3523020
VALLEY PHARMACY		123 E GARDINER	VALLEY	NE	68064	402-3592284
CLIFTON PHARMACY RX		730 CLIFTON AVE	CLIFTON	NJ	7013	862-2259726
CAFE RX		2 PIERMONT RD UNIT 2	CRESSKILL	NJ	7626	201-6278800
Avon Pharmacy		222 JACKSON ST	HOBOKEN	NJ	7030	201-4208300
Bayshore Homecare Pharmacy		733 N BEERS ST SUITE L1	HOLMDEL	NJ	7733	732-8880303
Ramtown Pharmacy		145 NEWTONS CORNER RD	HOWELL	NJ	7731	732-8403100
COMMUNITY PHARMACY		79 MONTICELLO AVENUE	JERSEY CITY	NJ	7304	201-3334700
JERSEY CITY PHARMACY		1815 JOHN F KENNEDY BLVD STE D	JERSEY CITY	NJ	7305	201-4338900
POMARICO PHARMACY		239 OLD BERGEN RD	JERSEY CITY	NJ	7305	201-4348062
JFK PHARMACY		2818A JOHN F KENNEDY	JERSEY CITY	NJ	7306	551-7950480
NOBLE PHARMACY		47 TONNELE AVE	JERSEY CITY	NJ	7306	201-6045813
DrugSmart Pharmacy		300 MAIN STREET	KEANSBURG	NJ	7734	732-7695550
LITTLE FALLS PHARMACY		75 NEWARK POMPTON TPKE	LITTLE FALLS	NJ	7424	973-6381561
Marlboro Medical Arts Pharmacy		479 COUNTY RD 520 #A102	MARLBORO	NJ	7746	732-9461600
Texas road pharmacy		355 APPLGARTH RD	MONROE	NJ	8831	609-2359368
SOL PHARMACY		450B BROAD AVE	PALISADES PARK	NJ	7650	201-9478877
Pharmacy express inc		991 MAIN ST UNIT 1B	PATERSON	NJ	7503	973-7541000
FABIOS PHARMACY 2		3413 BERGENLINE AVE	UNION CITY	NJ	7087	862-2573313
PRESCRIPTION CENTER PHARMACY INC		1914 BERGENLINE AVE	UNION CITY	NJ	7087	201-8642004
HINES PHARMACY		2301 BERGENLINE ROAD	UNION CITY	NJ	7087	201-3482667

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
LA DRUGS		3030 W OLYMPIC BLVD #118	LOS ANGELES	CA	90006	213-3873030
BEYOND THE PHARMACY		3730 SUNSET BLVD	LOS ANGELES	CA	90026	323-6603667
CENTURY BEVERLY HILLS PHARMACY		412 SOUTH SAN VICENTE BLVD	LOS ANGELES	CA	90048	310-3601015
BIOMED PHARMACY SOLUTIONS		8640 W 3RD ST STE 100	LOS ANGELES	CA	90048	310-2990808
SHYN'S PHARMACY INC		520 S VIRGIL AVE #102	LOS ANGELES	CA	90020	213-4877535
PLATINUM PHARMACY		1377 WESTWOOD BLVD	LOS ANGELES	CA	90024	310-4447979
HYUNDAI DRUGS		461 S WESTERN AVE	LOS ANGELES	CA	90020	213-4803322
Care Pharmacy, Inc		1600 S HILL ST STE B	LOS ANGELES	CA	90015	213-7463777
Avalon Pharmacy		447A E EL SEGUNDO BLVD	LOS ANGELES	CA	90061	800-5555555
Smith Pharmacy Inc.		1107 N WESTERN AVE	LOS ANGELES	CA	90029	323-4618331
SMITH PHARMACY		1732 S WESTERN AVE	LOS ANGELES	CA	90006	323-7339390
Noubar's El adobe Pharmacy Inc		5207 HOLLYWOOD BLVD	LOS ANGELES	CA	90027	323-4619451
Barrington Wilshire Pharmacy		11701 WILSHIRE BLVD #3	LOS ANGELES	CA	90025	310-4733323
S and S Pharmacy		2922 DIVISION ST	LOS ANGELES	CA	90065	
LOS BANOS DRUG		601 J ST	LOS BANOS	CA	93635	209-8265834
Cleveland pharmacy		2311 W CLEVELAND AVE #105	MADERA	CA	93637	559-3954127
CALAVERAS PHARMACY		114 S PARK VICTORIA DR	MILPITAS	CA	95035	408-2622056
Garfield Medical Square Pharmacy		500 N GARFIELD AVE # 103	MONTEREY PARK	CA	91754	626-2886120
Sun Sun Pharmacy		600 N GARFIELD AVE	MONTEREY PARK	CA	91754	626-2886560
DATE PHARMACY		39765 DATE ST #101	MURRIETA	CA	92563	951-6965400
PALM CARE PHARMACY		101 N. HIGHLAND AVE SUITE E, F, G	NATIONAL CITY	CA	91950	619-4348338
My Rx Pharmacy		12506 VANOWEN ST	NORTH HOLLYWOOD	CA	91605	818-7472010

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
MAY MAPLE MORIARTYPHARMHM	Connie Tsui	600 CENTRAL ROUTE 66	MORIARTY	NM	87035	
TRINITY PHARMACY		2797 S. MARYLAND PKWY #28	LAS VEGAS	NV	89109	702-7768210
ASPCares		501 S. RANCHO DR. G46	LAS VEGAS	NV	89106	702-9124844
ASPCares		4040 N MARTIN L KING BLVD	NORTH LAS VEGAS	NV	89032	702-6256624
Guy Park Pharmacy LLC		151 GUY PARK AVE	AMSTERDAM	NY	12010	518-7554929
Medwiz Solutions INC		167 RT 304- SUITE 101	BARDONIA	NY	10954	845-6248080
Beacon Wellness Pharmacy		333 MAIN ST	BEACON	NY	12508	845-7658878
LIFESTYLE PHARMACY		584A E 187TH STREET	BRONX	NY	10458	347-8998499
SAINATHPHCYDBAKING SBRIDGE		200 WEST 231ST STREET	BRONX	NY	10463	718-4322240
MOSCOSO PHARMACY	Henry Molano	151 E 170 ST	BRONX	NY	10452	718-2935832
LEROY HEALTH MART PHARMACY		314 EAST 204TH STREET	BRONX	NY	10467	718-8825614
LEMED HEALTH MART PHARMACY		2417 THIRD AVE, SUITE 406	BRONX	NY	10451	347-9134656
Karnaby drugs 2 llc		662 E 233RD ST	BRONX	NY	10466	347-3465134
MARCO DRUGS		814 E TREMONT AVE	BRONX	NY	10460	917-2597376
Legend Drugs 1 llc		159 E GUNHILL RD	BRONX	NY	10467	718-7087427
MILL PARK PHARMACY		6602 AVENUE U	BROOKLYN	NY	11234	718-4447200
CROWN HEIGHTS PHARMACY		376 KINGSTON AVENUE	BROOKLYN	NY	11213	718-4676700
NEVINS DRUGS INC		739 FULTON ST	BROOKLYN	NY	11217	718-4220100
Greenfield Pharmacy		1526 CORTELYOU RD	BROOKLYN	NY	11226	718-2827661
Oceana Pharmacy		3211 CONEY ISLAND AVE	BROOKLYN	NY	11235	646-4632226
Trinity Pharmacy		1224 AVENUE U	BROOKLYN	NY	11229	718-9752800
Truepill NY LLC		850 3RD AVE STE 404	BROOKLYN	NY	11232	180-055555

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
SUPREME CARE PHARMACY		6007 LANKERSHIM BLVD #7	NORTH HOLLYWOOD	CA	91606	818-7637007
OLIVEHURST DRUG		4897 OLIVEHURST AVE	OLIVEHURST	CA	95961	530-7435451
Crystal Medical Center Pharmacy		2809 OLIVE HIGHWAY SUITE 160	OROVILLE	CA	95966	530-5331545
Heritage Pharmacy		275 N EL CIELO RD #D405	PALM SPRINGS	CA	92262	760-4167999
Santa Maria Pharmacy 4		16444 PARAMOUNT BLVD #105	PARAMOUNT	CA	90723	562-7908618
Santa Maria Pharmacy		16279 PARAMOUNT BLVD #G	PARAMOUNT	CA	90723	562-6301620
GRACE PHARMACY		1724 E WASHINGTON BLVD	PASADENA	CA	91104	818-9575555
CAL OAKS PHARMACY	Hong Park	55 E CALIFORNIA BLVD #103	PASADENA	CA	91105	
Santa Maria Pharmacy		2288 S GAREY AVE	POMONA	CA	91766	909-9930242
PORTOLA VILLAGE PHCY		157 COMMERCIAL ST	PORTOLA	CA	96122	530-8324218
UNITED PHARMACY		10841 WHITE OAK AVE #101	RANCHO CUCAMONGA	CA	91730	909-9416942
ABC Pharmacy		1600 E CITRUS AVE STE K	REDLANDS	CA	92374	909-7263080
ARLINGTON MEDICA PHARMACY		8207 ARLINGTON AVE	RIVERSIDE	CA	92503	951-2405555
ROSECARE PHARMACY		1415 W ROSAMOND BLVD	ROSAMOND	CA	93560	661-2561118
BUI'S DEL MAR PHARMACY		9008 GARVEY AVE NO A	ROSEMEAD	CA	91770	626-9279773
ADVANCE MEDICAL RX		9122 VALLEY BLVD	ROSEMEAD	CA	91770	626-9880818
Sacr corporation		6540 STOCKTON BLVD #3B	SACRAMENTO	CA	95823	916-7307116
Well Care- Pharmacy		3645 NORTHGATE BLVD SUITE F	SACRAMENTO	CA	95834	916-6491615
VASCONI'S HM	Mario Vasconi	1381 MAIN ST	SAINT HELENA	CA	94574	707-9631444
BEEMANS PRESCRIPTION PHCY		355 EAST 21ST	SAN BERNARDINO	CA	92404	909-8823719

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
IRVING PHARMACY		118 WYCKOFF AVE	BROOKLYN	NY	11237	718-4848510
MARRA'S PHARMACY INC HM	John McDonald	217 REMSEN ST	COHOES	NY	12047	
CONGERS PHARMACY		15 SOUTH ROUTE 303	CONGERS	NY	10920	845-2675945
Browns Pharmacy		115 FRONT ST	DEPOSIT	NY	13754	607-4672294
Turnpike Meds RX Inc		179-14 UNION TPKE	FLUSHING	NY	11366	
CURE PHARMACY II		6 N CHURCH ST	GOSHEN	NY	10924	845-2375557
HAMBURG PHARMACY	Robin Fruehauf	206 LAKE STREET	HAMBURG	NY	14075	
DELIVER MY MEDS		380 OSER AVE	HAUPPAUGE	NY	11788	646-4632226
L&M PHARMACY INC		53 NORTH BROADWAY	HICKSVILLE	NY	11801	516-9311099
MEA PHARMACY INC		8144 LEFFERTS BLVD	KEW GARDENS	NY	11415	718-4801301
MONROE PHARMACY		581 NYS ROUTE 17M	MONROE	NY	10950	845-3950909
New City Pharmacy		174 SOUTH MAIN ST	NEW CITY	NY	10956	845-2502570
103 PHARMACY INC		2002 2ND AVE	NEW YORK	NY	10029	212-4104410
CIBAO PHARMACY		1303 SAINT NICHOLAS AVENUE	NEW YORK	NY	10033	212-5431900
MMAZ CHEMISTS INC		1207 SECOND AVE	NEW YORK	NY	10065	212-7589614
Blockchain Pharmacy		2139 3RD AVE	NEW YORK	NY	10035	212-3485019
PLEASANTVILLE PHARMACY		62 WHEELER AVE	PLEASANTVILLE	NY	10570	914-7690002
Sherman Pharmacy 2		5810 MYRTLE AVE	RIDGEWOOD	NY	11385	718-6288190
ROOSEVELT PHARMACY		348 NASSAU RD	ROOSEVELT	NY	11575	516-4424995
THE COMPOUNDING FACILITY		100 GREAVES LANE	STATEN ISLAND	NY	10308	718-2270667

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
BEEMANS HIGHLAND PHCY		399 E HIGHLAND SUITE 103	SAN BERNARDINO	CA	92404	909-8866851
ELDAHMY WELLNESS PHARMACY		1985 NATIONAL AVE #1103	SAN DIEGO	CA	92113	619-8695895
CENTRAL DRUG STORE		4494 MISSION STREET	SAN FRANCISCO	CA	94112	415-5850111
UNITED FAMILY PHARMACY		1221 SOUTH SAN JACINTO ST.	SAN JACINTO	CA	92583	951-6540995
VIETNAM PHARMACY		2451 S KING RD STE A1	SAN JOSE	CA	95122	408-6084105
MEDEX DRUG HM	Tri Nguyen	405 E SANTA CLARA ST	SAN JOSE	CA	95113	
SUN PHARMACY		2559 S KING RD STE B10	SAN JOSE	CA	95122	408-4402077
MARBELLA PHARMACY		31103 RANCHO VIEJO RD #D1	SAN JUAN CAPISTRANO	CA	92675	949-3882365
CAL OAKS III HM PHARMACY		2010 HUNTINGTON DRIVE #A	SAN MARINO	CA	91108	626-3822580
ROSE PHARMACY		1220 W HEMLOCK WAY #110	SANTA ANA	CA	92707	714-6620548
FEDERAL DRUG COMPANY		3327 STATE ST	SANTA BARBARA	CA	93105	
PRESCRIPTION PHARMCY		215 PESETAS LANE	SANTA BARBARA	CA	93110	805-9644831
PRESCRIPTION PHARMACY		317 W PUEBLO STREET	SANTA BARBARA	CA	93105	805-6826507
WESTSIDE PHARMACY SC HM	Chris Quesenberry	1401 MISSION STREET	SANTA CRUZ	CA	95060	831-4237175
DRUGTOWN PHARMACY		802 SEVENTH STREET	SANTA MONICA	CA	90403	310-3939821
OLYMPUS PHARMACY INC		14437 VENTURA BLVD	SHERMAN OAKS	CA	91423	888-6709080
ALAMO PHARMACY		3695 ALAMO ST STE 100	SIMI VALLEY	CA	93063	805-3061636
SFV Pharmacy		9375 SAN FERNANDO RD # A	SUN VALLEY	CA	91352	
Best Choice Pharmacy & Medical Supplies		7148 FOOTHILL BLVD	TUJUNGA	CA	91042	818-3535384
Tujunga Pharmacy		7341 FOOTHILL BLVD #101	TUJUNGA	CA	91042	818-3529200
KOVAC'S CARE RX		14423 GILMORE ST	VAN NUYS	CA	91401	818-7862669
GREEN VALLEY PHARMACY		33733 YUCAIPA BLVD STE 1	YUCAIPA	CA	92399	909-7901688

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
PRESCRIPTION CTR OF STATEN		3948 RICHMOND AVE	STATEN ISLAND	NY	10312	718-3561789
DRUG MART TALLMAN INC.		214 ROUTE 59	SUFFERN	NY	10901	845-3575200
SYRACUSE COMM HLTH PHCY		819 S SALINA ST	SYRACUSE	NY	13202	863-6020499
WINDHAM PHARMA INC		61 STATE RTE 296	WINDHAM	NY	12496	518-7343033
HERBERT'S PHARMACY		270 E MAIN ST/POB 1087	ANDOVER	OH	44003	440-2936358
SYCAMORE HILLS PHARMACY		9683 KENWOOD RD	BLUE ASH	OH	45242	480-8094289
CANFIELD PHARMACY CARE		11 E MAIN ST	CANFIELD	OH	44406	330-2860226
COMMUNITY FIRST DAYTON		300 FOREST AVE	DAYTON	OH	45405	937-8134367
MedCare Pharmacy		3029 SMITH RD STE 100	FAIRLAWN	OH	44333	330-9601014
COMMUNITY FIRST HAMILTON		210 S SECOND STEET	HAMILTON	OH	45011	513-6455447
COMMUNITY FIRST-MDLETWN		1036 SOUTH VERITY PKWY	MIDDLETOWN	OH	45044	513-2178900
LIFECARE PHARMACY		3156 DUSTIN RD STE 101	OREGON	OH	43616	
Gromoll Drug Store		227 N 15TH ST	SEBRING	OH	44672	330-9386670
MADISON AVENUE PHARMACY		640 N FOUNTAIN AVE	SPRINGFIELD	OH	45504	937-3231841
Simpson Pharmacy		802 N. PARK DRIVE	BROKEN BOW	OK	74728	580-5842850
POPKESS PHARMACY		524 E DON TYLER AVE	DEWEY	OK	74029	918-5342262
1ST CHOICE PHARMACY		1147A W 15TH ST	EDMOND	OK	73013	405-5092469
RiteScripts Pharmacy		16309 N SANTA FE AVE ST C	EDMOND	OK	73013	800-5555555
WEST END DRUG		7210 NW CACHE ROAD	LAWTON	OK	73505	580-5361133
THE MEDICINE CABINET		211 N ROBINSON STE 150-S	OKLAHOMA CITY	OK	73102	405-2320707
23rd Street Pharmacy		2316 NW 23RD ST	OKLAHOMA CITY	OK	73107	405-6026442
ASPCares		3405 NW EXPRESSWAY	OKLAHOMA CITY	OK	73112	405-6073995

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
HP COMPOUNDING PHCY		1555 S HAVANA ST UNIT HJ	AURORA	CO	80012	303-7503600
Palace Drug		601 MAIN ST	CANON CITY	CO	81212	719-2753375
COMPASS PHARMACY LLC		3960 MAIZELAND ROAD	COLORADO SPRINGS	CO	80909	719-4444774
CHINOOK HEALTHCARE PHCY		275 WANEKA PKWY STE 10	LAFAYETTE	CO	80026	720-4584887
Paragon Pharmacy		7720 S. BROADWAY SUITE 100	LITTLETON	CO	80122	720-6276123
MEEKER DRUG		315 6TH STREET	MEEKER	CO	81641	970-8789988
HAYS DRUG STORE RXP		224 GRAND AVE	PAONIA	CO	81428	970-5274109
DANIELSON PHARMACY		77 WESTCOTT RD	DANIELSON	CT	6239	860-7740050
NostrumRx Pharmacy		2286 BERLIN TURNPIKE	NEWINGTON	CT	6111	860-3435220
SERAFINO PHARMACY INC HM	Ron Serafino	36 NO MAIN ST	SOUTHINGTON	CT	6489	
A&S PHARMACY		910 SUMMER STREET	STAMFORD	CT	6905	800-5555555
COLONIAL DRUGGISTS INC		611 POST ROAD EAST	WESTPORT	CT	6880	203-2279539
RAMDASS PHARMACY		475 INGRAHAM ST NE	WASHINGTON	DC	20011	800-5555555
RODNEY VILLAGE PHARMACY		1664 S. GOVERNORS AVE	DOVER	DE	19904	302-7477533
JOINT SCRIPTS		612 DRUID RD E STE C	CLEARWATER	FL	33756	727-4436400
RADIANT CARE PHARMACY AND COMPOUNDING		5779 S UNIVERSITY DR	DAVIE	FL	33328	954-5304808
ATLANTIC PHARMACY		7495 W ATLANTIC AVE # 206	DELRAY BEACH	FL	33446	561-4960338
West Atlantic Pharmacy		15071 S STATE RD 7 STE 150	DELRAY BEACH	FL	33446	561-7742920
MOUNT DORA PHARMACY		17435 US HWY 441 STE 102	EUSTIS	FL	32726	352-3571406
Eventus RX Inc		11300 LINDBERGH BLVD #107	FORT MYERS	FL	33913	
JULIO'S PHARMACY		2875 W 2ND AVE	HIALEAH	FL	33010	305-8840703
FLORIDA SOLUTIONS PHARMACY		1057 WEST 29TH STREET	HIALEAH	FL	33012	305-8835791
AZALIA'S PHARMACY & DISCOUNT	Azalia Rodriguez	428 EAST 49 STREET	HIALEAH	FL	33013	305-6859556

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
Oklahoma Specialty Pharmacy		13921 N MERIDIAN #102	OKLAHOMA CITY	OK	73134	787-9806778
Thackerville Pharmacy		11530 RIDGE RD STE 1 E	THACKERVILLE	OK	73459	580-2765161
WESTVILLE PRESC CENTER		301S WILLIAMS ST PO 405	WESTVILLE	OK	74965	918-7235466
Corvallis pharmacy		3680 NW SAMARITAN DR	CORVALLIS	OR	97330	800-5555555
DCCT		207 E 5TH AVE STE 223	EUGENE	OR	97401	800-5555555
ABINGTON PHCY		1460 YORK ROAD	ABINGTON	PA	19001	215-8842767
St Luke's Homestar Pharmacy		1736 HAMILTON ST FL 1	ALLENTOWN	PA	18104	610-6287577
ALTOONA PHARMACY		620 HOWARD AVE BDGG ST403	ALTOONA	PA	16601	814-2830602
BATH DRUG		310 SOUTH WALNUT STREET	BATH	PA	18014	610-8379992
St Luke's Homestar Pharmacy		801 OSTRUM ST 101A	BETHLEHEM	PA	18015	484-5267500
EVERGREEN PHARMACY II		702 DEKALB PIKE	BLUE BELL	PA	19422	610-6160608
CLARION PHARMACY		30 PINNACLE DRIVE	CLARION	PA	16214	814-2264015
St Luke's Homestar Pharmacy		1700 ST LUKE'S BLVD	EASTON	PA	18045	484-5037500
OXFORD VALLEY PHARMACY HM	Jason Barrett	403 S OXFORD VALLEY RD	FAIRLESS HILLS	PA	19030	
WESLEY APOTHECARY		108 -110 SOUTH EASTON RD	GLENSIDE	PA	19038	215-8874577
CAREFILL PHARMACY		43 WILLIAMSON ROAD STE 1	GREENVILLE	PA	16125	724-3738533
JAMESTOWN PHARMACY		121 LIBERTY STREET	JAMESTOWN	PA	16134	724-9325355
HILAND PHARMACY HM	Richard Pratkanis	231 BUTLER ROAD	KITTANNING	PA	16201	724-5432504
LINESVILLE PHARMACY		123 ERIE STREET	LINESVILLE	PA	16424	814-8180010
MERCER PHARMACY		737 GREENVILLE RD	MERCER	PA	16137	724-6621414
MOUNT MORRIS PHCY		120 LOCUST AVE EXT STE 2	MT MORRIS	PA	15349	724-3245555
NEW CASTLE PHARMACY		1112 SOUTH MILL STREET	NEW CASTLE	PA	16101	724-6565000
Small Town Pharmacy 2		80 W GERMANTOWN PIKE	NORRISTOWN	PA	19401	856-9057610

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number	Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
Elite Rx		6602 STIRLING RD	HOLLYWOOD	FL	33024	954-3716122	Evergreen Pharmacy		1222 WELSH RD STE C1	NORTH WALES	PA	19454	180-055555
HUDSON PHARMACY		8117 STATE ROAD 52	HUDSON	FL	34667	727-3785882	PETROLIA HEALTH MART PHARMACY		296 CHURCH STREET	PETROLIA	PA	16050	724-7564050
UNIV PHY OF JACKSONVILLE		3901 UNIVERSITY BLVD S STE 237	JACKSONVILLE	FL	32216	904-5358792	SMALL TOWN PHARMACY		1 N WEST END BLVD	QUAKERTOWN	PA	18951	215-5388800
SHEPPARD APOTHECARY		3793 HWY 4	JAY	FL	32565	850-6756990	SHARON HEALTH MART PHARMACY		63 PITT ST STE 102	SHARON	PA	16146	724-3477000
AARAV PHARMACY		6650 W INDIANTOWN RD #100	JUPITER	FL	33458	561-4270947	FINDLEY'S PHARMACY		136 W MAIN ST	SOMERSET	PA	15501	814-4457939
SIMFAROSE PHARMACY		6338 LANTANA RD STE 52/53	LAKE WORTH	FL	33463	954-4357200	REYNOLDS PHARMACY		3676 N. HERMITAGE RD.	TRANSFER	PA	16154	724-6461131
BTV PHARMACY		1495 NW 54TH ST	MIAMI	FL	33142	305-7517882	ROSS PHCY		114 GRANT AVENUE	VANDERGRIFT	PA	15690	724-5681221
HOLLEY NAVARRE PHY&GIFTS		8440 NEVEDA ST	NAVARRE	FL	32566	850-3596619	TEPPER PHARMACY		333 E. LANCASTER AVE	WYNNEWOOD	PA	19096	610-6490390
GRACIOUS HEALTHMART LLC		6518 MASSACHUSETTS AVE	NEW PORT RICHEY	FL	34653	727-3393030	PROFESSIONAL PHARMACY		1409 N MAIN ST	ANDERSON	SC	29621	864-2243581
FAMILY PHYSICIANS RX		901 N MIAMI BEACH BLVD #1	NORTH MIAMI BEACH	FL	33162	954-3218029	CHESTER FAMILY PHARMACY		1645 J A COCHRAN BYPASS SUITE G	CHESTER	SC	29706	803--581-10
FAMILY PHYSICIANS RX		1160 S SEMORAN BLVD D,E,F	ORLANDO	FL	32807	407-3813085	EASLEY HEALTHMART PHCY		401 HILLCREST DR	EASLEY	SC	29640	864-6424879
Pace Pharmacy		4880 WOODBINE RD	PACE	FL	32571	850-4634232	HONEA PATH PHARMACY		309 E GREER ST	HONEA PATH	SC	29654	864-3695337
PharmCo Rx 1002		3208 2ND AVE N BAY 4	PALM SPRINGS	FL	33461	305-9197399	PIEDMONT FAMILY PHARMACY		903 ANDERSON STREET	PIEDMONT	SC	29673	215-2370352
RX EXPRESS PHARMACY		3104 W 23RD ST	PANAMA CITY	FL	32405	850-2157455	POWDERSVILLE FAMILY PHCY		11061 ANDERSON ROAD	PIEDMONT	SC	29673	864-3739229
Community Health Northwest Florida-Pharmacy		14 W JORDAN ST	PENSACOLA	FL	32501	850-4332165	RICHBURG DISCOUNT PHY		3191 LANCASTER HWY STE H	RICHBURG	SC	29729	215-2370352
Community Health Northwest Florida		2315 W JACKSON ST	PENSACOLA	FL	32505	850-4953955	CONNECTED HEALTH PHCY		3907 D GRANDVIEW DR	SIMPSONVILLE	SC	29680	864-9627101
HALIFAX PHARMACY		3830 S NOVA RD STE C4	PORT ORANGE	FL	32127	386-2389734	Ladson Pharmacy		4550 LADSON RD STE #6	SUMMERVILLE	SC	29485	843-2855282
MedPlus Pharmacy		5751 BENEVA RD	SARASOTA	FL	34233	941-9602549	UNITED CLINIC PHARMACY		3015 3RD AVENUE SE	ABERDEEN	SD	57401	605-2254001
BAY LIFE PHARMACY II		5665 PARK ST N	ST PETERSBURG	FL	33709	727-2166374	Kessler's Pharmacy		621 6TH AVE SE	ABERDEEN	SD	57401	605-2256673
V&T PHARMACY		4040 W WATERS AVE STE 105	TAMPA	FL	33614	813-4434732	ABERDEEN MEDICAL CENTER PHARMACY INC		105 SO STATE ST, STE 111	ABERDEEN	SD	57401	605-2251945
EXPRESS SPECIALTY PHCY		4111 HENDERSON BLVD #A	TAMPA	FL	33629	813-2880777	CHURCH HILL DRUG STORE		104 E MAIN BLVD	CHURCH HILL	TN	37642	423-3577441

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
GNAMS LLC		6102 S MACDILL AVE STE B	TAMPA	FL	33611	813-5707194
TAMPA DRUGS AND DIABETIC CENTER		3209 N 22ND ST	TAMPA	FL	33605	813-2317788
MY PHARMACY OF TAMPA		7108 CAUSEWAY BLVD	TAMPA	FL	33619	813-6284441
JRX PHARMACY		3940 W HILLSBOROUGH AVE	TAMPA	FL	33614	813-8742900
BUSCH PHARMACY LLC		6751 N ARMENIA AVE STE 4	TAMPA	FL	33604	813-9908300
West Coast Pharmacy		8439 N. FLORIDA AVE	TAMPA	FL	33604	813-9328380
Memorial Family Pharmacy		7009 N. ARMENIA AVE	TAMPA	FL	33604	813-8740795
ISLAND RX		90130 OLD HWY STE 1A	TAVERNIER	FL	33070	305-7477061
RX Care Pharmacy and Kwikmart		38008 NORTH AVE	ZEPHYRHILLS	FL	33542	813-7807126
CONCORD MEDICAL QUARTERS PHARMACY		5555 PEACHTREE DUNWOODY	ATLANTA	GA	30342	404-2523607
CONCORD PHARMACY	Mac McCord	550 PEACHTREE ST NE #1450	ATLANTA	GA	30308	404-5234908
ALTAMA DISCOUNT PHARMACY		5711 ALTAMA AVE STE G	BRUNSWICK	GA	31525	912-2642622
CLARKESVILLE DRUG INC		596 W LOUISE ST STE D	CLARKESVILLE	GA	30523	706-7543763
GREENSBORO PHARMACY		111 N MAIN ST	GREENSBORO	GA	30642	706-2224544
MEDICINE CABINET VERNON		205 VERNON STREET	LAGRANGE	GA	30240	706-2984928
THE MEDICINE CABINET		1704 ROANOKE RD	LAGRANGE	GA	30240	706-2986460
THE MEDICINE CABINET		300 MOOTY BRIDGE RD	LAGRANGE	GA	30240	706-2984930
CONCORD PHARMACY		575 PROFESSNAL DR. STE170	LAWRENCEVILLE	GA	30046	770-3380971
NAMASTE PHARMACY LLC		4051 STONE MTN HWY D101A	LILBURN	GA	30047	770-8372625
SCOTT'S HEALTHMART PHCY 1	Wade Scott	635 PIO NONO POB 2267	MACON	GA	31204	478-7423098
THE MEDICINE CABINET		1194 WARM SPRINGS HWY	MANCHESTER	GA	31816	706-8462002
CONCORD PHARMACY		4800 OLDE TOWNE PKWY #120	MARIETTA	GA	30068	678-5405409

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
ZOREN PHCY AND GIFTS		588 FIRE STATION RD STE F	CLARKSVILLE	TN	37043	615-5878203
GRAY PHARMACY/TRITENN LLC		208 SUNCREST ST	GRAY	TN	37615	423-4773847
MEDI-THRIFT PHARMACY		346 W CENTRAL AVE	JAMESTOWN	TN	38556	931-8798133
BLOOMINGDALE DRUG		2900 BLOOMINGDALE RD	KINGSPORT	TN	37660	423-2884812
MARCUM'S PHARMACY		121 E RAVINE ST	KINGSPORT	TN	37660	423-2466166
BAGGETT PHARMACY INC HM	Ronnie Baggett	133 EAST RACE STREET	KINGSTON	TN	37763	
THE PHOENIX PHARMACY		418 SOUTH GAY ST	KNOXVILLE	TN	37902	865-6921603
PARSONS PHARMACY		117 W COMMERCE POB 1616	LEWISBURG	TN	37091	931-3594067
DEL MAR MEDICAL		198 E DIVISION ST POB 787	MOUNT JULIET	TN	37122	615-7544667
PARDUE'S PHARMACY		1900 PATTERSON ST STE 200	NASHVILLE	TN	37230	615-3271350
BRADLEYPHARMACYME TROCENTE		131 FRENCH LANDING	NASHVILLE	TN	37228	615-6874938
BROADWAY AND MAIN PHARMAC		136 E BROADWAY	NEWPORT	TN	37821	
RIVER CITY PHARMACY		5564 LITTLE DEBBIE PKWY102	OOLTEWAH	TN	37363	423-5037279
SURGOINSVILLE PHARMACY		114 BELLAMY AVENUE	SURGOINSVILLE	TN	37873	423-3450333
SURE-RX-PHARMACY		816 FRANKLIN STREET STE A	ANTHONY	TX	79821	915-8867222
RENUE RX 10		2217 PARK BEND DR STE 310	AUSTIN	TX	78758	512-2566979
ASPCares		13831 US HWY 183	AUSTIN	TX	78750	956-6223273
River City Pharmacy LLC		4150 FREIDRICH LN STE 1	AUSTIN	TX	78744	800-5555555
SOUTHSIDE PHARMACY 10		2802 GARTH RD STE 101	BAYTOWN	TX	77521	832-8318031
1960 PHARMACY		5202 BISSONNET ST STE B	BELLAIRE	TX	77401	281-8936000
THE PHARMACY AT BERGHEIM		1 FM 3351 STE 115	BOERNE	TX	78006	866-2374434
BORGER PHARMACY		524 W 10TH	BORGER	TX	79007	806-2749635

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
CONCORD PHARMACY		2500 HOSPITAL BLVD #300	ROSWELL	GA	30076	770-6645428
MEDICAL CNTR PHCY ELINKHM	Lem Nevil	57 GRANADE STREET	STATESBORO	GA	30458	912-7645643
CONCORD PHARMACY		3890 JOHNS CREEK PKWY 160	SUWANEE	GA	30024	678-4170122
NORTHSIDE DRUGS/MEDI CAB		1109 HWY 19 N	THOMASTON	GA	30286	706-6482181
AMERIMED PHCY		3782 OLD US HIGHWAY 41 N	VALDOSTA	GA	31602	229-2530067
KALAHEO PHARMACY		2436 KAUMUALII HIGHWAY	KALAHEO	HI	96741	808-3326000
PAVILION PHARMACY		202 10TH ST SE STE 115	CEDAR RAPIDS	IA	52403	319-3642406
WAGNER PHCY 1 CO HM	Edwin Wright	1726 N 2ND ST	CLINTON	IA	52732	563-2420626
MCGREGOR PHARMACY		230 MAIN STREET	MC GREGOR	IA	52157	563-8733781
PARKVIEW PHARMACY HM	Pete Bilden	1727 SOUTH B AVE	NEVADA	IA	50201	515-3822134
ROCKLAND PHARMACY		524 TYHEE AVENUE	AMERICAN FALLS	ID	83211	208-2262411
Timberline Pharmacy		4574 N TEN MILE RD #110	MERIDIAN	ID	83646	208-6161722
RIGG FAMILYCARE PHCY		37 WEST MAIN STREET	ALBION	IL	62806	618-4452581
GLOBAL PHARMACY		7124 W 83RD ST UNIT D	BRIDGEVIEW	IL	60455	708-9073960
HWANG PHARMACY		3535 W LAWRENCE	CHICAGO	IL	60625	773-2673344
WATERMAN TELEPHARMACY		2215 W 95TH ST	CHICAGO	IL	60643	815-2831054
Drug Center Pharmacy		845 W WILSON AVE	CHICAGO	IL	60640	773-6810080
Millennium Pharmacy		10604 SOUTHWEST HWY #102	CHICAGO RIDGE	IL	60415	708-5297222
Prime Plus Pharmacy		2955 W 95TH ST SUITE 100	EVERGREEN PARK	IL	60805	708-7417501
Evergreen Park Pharmacy		2850 W 95TH ST STE 100	EVERGREEN PARK	IL	60805	708-4234700
GEORGETOWN TELEPHARMACY		712 N MAIN ST	GEORGETOWN	IL	61846	217-6012131
HERRIN DRUG		116 NORTH PARK AVE	HERRIN	IL	62948	618-9425315

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
JOE PHARMACY		1609 LIVE OAK ST	COMMERCE	TX	75428	903-8208200
VILLAGE PHARMACY HM	R.W. McMillan	1336 LEAGUE LINE RD #100	CONROE	TX	77304	936-7567456
Abana Health pharmacy		3301 W DAVIS ST STE F	CONROE	TX	77304	
CRYSTAL CITY PHARMACY		1313 VETERANS AVE #1	CRYSTAL CITY	TX	78839	830-2552201
Abounding Prosperity Community Pharmacy		1619 MARTIN LUTHERN KING	DALLAS	TX	75215	800-5555555
OneSource Specialty Medicine		8989 FOREST LN SUITE 138	DALLAS	TX	75243	469-5471441
PHARMACIA HENRIQUE INC		2406 EMMETT ST STE100	DALLAS	TX	75211	817-7011930
DENTON'S PRES SHOP HM	Rick Appling	2501 W OAK STREET STE 100	DENTON	TX	76201	940-3826758
CLR X DENTON		2401 W OAK ST. STE 101	DENTON	TX	76201	817-4378521
ALAMEDA THRIFTY PHCY HM	Mike Estrada	4900 ALAMEDA AVE	EL PASO	TX	79905	
ASPCares		1015 N ZARAGOZA ROAD	EL PASO	TX	79907	915-8607225
HILL COUNTRY PHARMACY		501 E HIGHWAY ST STE 100	FREDERICKSBURG	TX	78624	830-3079390
ADVANCED PRESC SVC INC		3671 BROADWAY BLVD STE 300	GARLAND	TX	75043	214-7039100
ANNES PHARMACY		133 W MAIN STREET	GUN BARREL CITY	TX	75156	469-9959958
Rio Health Pharmacy		201 E JACKSON ST #B	HARLINGEN	TX	78550	
CYPRESS COMPOUNDING PHCY		9511 HUFFMEISTER RD #104	HOUSTON	TX	77095	832-6170290
RC3 PHARMACY		1200 BINZ ST STE 260A	HOUSTON	TX	77004	713-5416567
LOCAL HLTH SPLTY HOUSTON		7515 MAIN ST STE 160	HOUSTON	TX	77030	386-2140639
Pyramids Pharmacy TMC		7400 FANNIN ST STE 120	HOUSTON	TX	77054	866-2939097
CARIE BOYDS PRESC SHOP		8400 ESTERS BLVD STE 190	IRVING	TX	75063	817-2829376
BOARDWALK PHARMACY		6161 STATE HWY 161 #100	IRVING	TX	75038	972-8127559
KERMIT PHARMACY		810 MYER LANE	KERMIT	TX	79745	432-5862556

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
JOHN'S MEDICAL PHARMACY		300 SOUTH MAIN STREET	HILLSBORO	IL	62049	217-5325060
DOCTORS RX		3021 FALLING WATERS STE B	LINDENHURST	IL	60046	847-8930505
LOMBARD PHCY HM	Craig Kuelto	211 S MAIN ST	LOMBARD	IL	60148	630-4952333
MAIN STREET PHARMACY		24 W 1ST STREET	MANTENO	IL	60950	630-9690036
GOOD HEALTH PHARMACY		3027 ENGLISH ROWS AVE STE 101	NAPERVILLE	IL	60564	630-2108995
MEDSCRIPT PHARMACY LLC		14400 JOHN HUMPHREY DR	ORLAND PARK	IL	60462	855-9006001
ILLINI HEALTH SERVICE,LLC		321 N MONROE ST	PITTSFIELD	IL	62363	217-2854214
MEDICENTER PHARMACY		6294 STATE HIGHWAY 154 #A	SESSER	IL	62884	618-6258400
BRISTOL PHARMACY		300 E ELKHART ST	BRISTOL	IN	46507	574-8480660
MEDICENTER PHCY-CNRSVILLE		1475 EAST STATE RD 44	CONNERSVILLE	IN	47331	765-8271934
GOOD NEIGHBOR PHARMACY		1030 E MAIN ST	GAS CITY	IN	46933	765-6746976
HANGER DRUGS		207 SPARKS AVE STE 1	JEFFERSONVILLE	IN	47130	812-2833591
ENGLEKING RX		125 W OLD SHORT ST	MARENGO	IN	47140	812-3650001
ENGLEKING RX		1494 W MAIN ST	MITCHELL	IN	47446	812-8653266
KEX-RX ATCHISON		807 MAIN STREET	ATCHISON	KS	66002	913-3675252
YUNGBERG DRUG		17 PUBLIC SQ	BLUE RAPIDS	KS	66411	785-3637444
CANEY DRUG		208 W 4TH AVE	CANEY	KS	67333	620-8795822
KEX RX PHCY & HOMECARE		101 S SIXTH	HIAWATHA	KS	66434	785-7422125
TICE E-FM HM	Leland Hansen	618 OREGON STREET	HIAWATHA	KS	66434	
KEX RX - HORTON		1903 EUCLID	HORTON	KS	66439	785-4863651
HUTCHINSON DRUG STORE	Aaron Hirst	703 E 30TH AVE	HUTCHINSON	KS	67502	620-6696698
INDEPENDENCE PHARMACY		205 N PENN	INDEPENDENCE	KS	67301	620-3313784
CENTRAL CARE PHARMACY		8919 PARALLEL PKWY # 250	KANSAS CITY	KS	66112	180-0555555

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
BELL RX DISCOUNT PHARMACY		2710 S.CLEAR CREEK RD STE #113	KILLEEN	TX	76549	254-7812405
CLARX HUB CITY PHRMACY		3716 22ND STREET	LUBBOCK	TX	79410	806-7496133
SOUTHSIDE PHCY 4		300 2ND STREET STE B	MCALLEN	TX	78501	832-8774636
ASPCares		1401 E RIDGE ROAD UNIT B	MCALLEN	TX	78503	956-2846687
Texas Scripts		720 EAST DOVE AVE	MCALLEN	TX	78504	956-7875259
Coach's Pharmacy		100 N TEXAS STE A	MERCEDES	TX	78570	956-5142420
Galloway pharmacy		910 GALLOWAY AVE STE 100	MESQUITE	TX	75149	972-2167000
Super Mercado Pharmacy		2208 N BIG SPRING ST	MIDLAND	TX	79705	432-6829501
LETDIN PHARMACY		1512 E GRIFFIN PKWY STE 1	MISSION	TX	78572	956-5819566
PHARMAVIDA RX		1337 E PALMA VISTA DR STEB	PALMVIEW	TX	78572	956-4246640
KEYES PHARMACY		928 N HOBART	PAMPA	TX	79065	806-6691202
Pyramids Mail Order Pharmacy		3569 BUSINESS CTR DR #175	PEARLAND	TX	77584	888-4890038
PHARRMACY		1002 W SAM HOUSTON BLVD 1	PHARR	TX	78577	956-2830911
COURAGE PHARMACY		3200 14TH ST STE 404	PLANO	TX	75074	972-9430628
ROYSE CITY PHARMACY		205 MAIN STREET POB 760	ROYSE CITY	TX	75189	972-6352451
OAKDELL PHCY IN STONE OAK	John Carson	104 GALLERY CIR. STE104	SAN ANTONIO	TX	78258	210-4967070
WHITE CROSS PHARMACY		1303 MCCULLOUGH STE 128	SAN ANTONIO	TX	78212	210-2277207
OAK HILLS PHARMACY		7711 LOUIS PASTEUR DR.	SAN ANTONIO	TX	78229	210-6144101
RENUE RX #6		6428 BANDERA RD	SAN ANTONIO	TX	78238	210-2568629
RENUE RX #5		810 SE MILITARY DR	SAN ANTONIO	TX	78214	210-9234404
Lifecare Garza Pharmacy		311 CAMDEN ST STE 103	SAN ANTONIO	TX	78215	210-2254561
HILL'S DRUG STORE, INC.		705 W KIRK PLACE	SAN ANTONIO	TX	78226	210-2257284
GIBSON DISCOUNT PHARMACY		112 HALL RD	SEAGOVILLE	TX	75159	972-2877070

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number	Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
KRILEY'S FAMILY DRUG HM	Kevin Kriley	125 S MAIN	SMITH CENTER	KS	66967		COUNTRY DRUG STORE HM		1517 COLUMBIA RT3 BOX 33A	STAMFORD	TX	79553	325-7733511
WASHINGTON HEALTH MART	Dustin Rogge	227 C STREET	WASHINGTON	KS	66968	785-3253130	SCRIPT RX		101 SOUTHWESTERN BLVD#120	SUGARLAND	TX	77478	832-9152448
BROADWAY PHARMACY		1610 S BROADWAY ST	WICHITA	KS	67211	316-2608880	PHARM HOUSE DRUG SWEENEY		200 N MAIN ST	SWEENEY	TX	77480	979-4592220
HART PHARMACY	Mick Tranbarger	7111 EAST 21ST STREET N	WICHITA	KS	67206	316-6847899	TAYLOR AREA PHARMACY		1001 N MAIN ST	TAYLOR	TX	76574	
CENTURY MEDICINES		1608 OLD LEBANON RD	CAMPBELLSVILLE	KY	42718	270-7894734	Comprehensive Pharmacy		6807 EMMETT F LWRY E #104	TEXAS CITY	TX	77591	409-9453381
AVENUE PHARMACY		201 6TH AVENUE STE A	DAYTON	KY	41074	859-4911700	ELEVATE RX		2700 TECH FOREST #200	THE WOODLANDS	TX	77381	800-5555555
PHARMACY CARE CENTER		101 TOWN & COUNTRY LN STE 101	HAZARD	KY	41701	606-4350460	SOUTHSIDE 9		1111 MEDICAL PL DR STE 160	THE WOODLANDS	TX	77380	832-6163528
EAST KENTUCKY PHY, INC.		588 HWY 899	HINDMAN	KY	41822	606-7853784	ASPCares		1109 E 5TH STREET	TYLER	TX	75701	903-6307263
MEDWIZ		116 VENTURE CT STE 4	LEXINGTON	KY	40511	859-4793990	PYRAMIDS PHARMACY WEBSTER		500 KOBAYASHI ROAD STE E	WEBSTER	TX	77598	281-7240531
NEWPORT DRUG CENTER		39 W 10TH STREET	NEWPORT	KY	41071	859-2912578	MEARS PHARMACY		1050 W. SHEPARD LANE SUITE #1	FARMINGTON	UT	84025	801-4479484
OWENSBORO FAMILY PHY		720 W BYERS AVE	OWENSBORO	KY	42303	270-6832400	DAVIS FOOD AND DRUG #4		495 NORTH STATE STREET	LA VERKIN	UT	84745	435-6356944
PRINCETON DRUG		103 W MAIN ST	PRINCETON	KY	42445	601-9461826	TIBBITTS FAMILY PHARMACY		2940 N. CHURCH ST, STE201	LAYTON	UT	84040	801-7710363
		103 W MAIN ST	PRINCETON	KY	42445		BETTERCARE FAMILY PHY		545 COLUMBIA LN	PROVO	UT	84604	385-4774942
VICCO PHARMACY		10616 S KY HIGHWAY 15	SCUDDY	KY	41760	606-4762183	DAVIS JUBILEE PHARMACY	Jim Davis	750 EAST 200 NORTH	ROOSEVELT	UT	84066	435-7222255
Daniel Pharmacy		409 E MAIN ST.	BRUSLY	LA	70719	225-7492020	DAVIS FOOD & DRUG	Jim Davis	575 W MAIN STREET	VERNAL	UT	84078	435-7897010
COMMUNITY PHARMACY		731 S MAIN ST SUITE B	CHURCH POINT	LA	70525	337-6841911	BATTLETOWN PHARMACY		33 W. MAIN STREET SUITE A	BERRYVILLE	VA	22611	540-9550500
NEIGHBORS PHARMACY		6770 JOHNSTON ST. STEA	LAFAYETTE	LA	70503	337-7067706	BROADWAY DRUG CENTER HM	Nelson Showalter	169 E SPRINGBROOK ROAD	BROADWAY	VA	22815	540-8963251
CLINIC PHCY OF MANGHAM		252 HIGHWAY 132	MANGHAM	LA	71259	318-2483338	NEWMAN FAMILY PHARMACY		800 S. BATTLEFIELD BLVD #105-107	CHESAPEAKE	VA	23322	757-4820960
PELICAN DELIVERY PHARMACY		909 AVENUE C	MARRERO	LA	70072	504-3410800	FALLS CHURCH PHARMACY	Thu Bui	6795 WILSON BLVD, #1-A	FALLS CHURCH	VA	22044	703-2372182
ARON'S PHARMACY HM	Carl Aron	1209 NORTH 18TH AVE	MONROE	LA	71201	318-3232242	HAMPTON HEALTHMART PHCY		3321 W MERCURY BLVD STE D	HAMPTON	VA	23666	757-8640380
RAYVILLE FAMILY PHARMACY		1821 LOUISA ST	RAYVILLE	LA	71269	318-7282430	BAYVIEW COMMUNITY PHCY		1846 E LITTLE CREEK RD	NORFOLK	VA	23518	757-3836636
Medic Specialty Pharmacy		745 OLIVE ST STE 201	SHREVEPORT	LA	71104	318-8650234	PUDDLEDOK PHARMACY		4720 PUDDLEDOK RD	PRINCE GEORGE	VA	23875	804-793800

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
LACOUR'S PHRAMACY		16237 HWY 1	SIMMESPORT	LA	71369	318-9412423
ELLIOTT PHARMACY #4 HM		5455 LIVE OAK CENTRE DR	ST FRANCISVILLE	LA	70775	225-6353878
VanMol Family Pharmacy		9374 HIGHWAY 165 S	WOODWORTH	LA	71485	318-4437073
CONNOLLYS PHARMACY		44 BAY RD	HAMILTON	MA	1982	978-4683711
ONE WORLD PHARMACY		138 HIGHLAND AVE #5	LOWELL	MA	1851	978-3284636
VOSHELL'S PHARMACY	Jan Dorsch	3455 WILKENS AVE	BALTIMORE	MD	21229	410-6448400
FOER'S MEDICAL ARTS PHCY	Michael Foer	6420 ROCKLEDGE DRIVE	BETHESDA	MD	20817	
Edwards Pharmacy		102 S COMMERCE ST	CENTREVILLE	MD	21617	410-7581715
AUSTIN PHARMACY		10757 YORK ROAD	COCKEYSVILLE	MD	21030	410-7730300
PADONIA VILLAGE PHCY		17 E PADONIA RD	LUTHERVILLE TIMONIUM	MD	21093	443-3305987
MILLINGTON PHARMACY	Dennis Hager	SASSAFRAS&CYPRESS BOX 390	MILLINGTON	MD	21651	
CHOICE PHARMACY 2		10309 GRAND CENTRAL AVE #110	OWINGS MILLS	MD	21117	410-3638222
Ambulatory Care Pharmacy		9601 BLACKWELL RD STE 230	ROCKVILLE	MD	20850	301-5450193
SJMC PHARMACY ST.JOSEPH MEDICAL CENTER PHARMACY		7505 OSLER DR STE 102	TOWSON	MD	21204	800-5555555
STADIUM PHARMACY HM	Xavier Tato	1930 W STADIUM BLVD	ANN ARBOR	MI	48103	734-9134752
HEARTLAND DRUGS HM		43614 GARFIELD ROAD	CLINTON TOWNSHIP	MI	48038	586-2281551
LFC PHARMACY LLC		15400 MICHIGAN AVE STE 2	DEARBORN	MI	48126	
packard discount pharmacy		4726 GREENFIELD #101	DEARBORN	MI	48126	313-6339310
Sheba pharmacy 2		4132 SCHAEFER	DEARBORN	MI	48126	313-4964006

Store Name	Owner/Mgr Full Name	Address	City	State	Zip Code	Phone Number
WEBER CITY DRUG CTR		1482 US HIGHWAY 23 NORTH	WEBER CITY	VA	24290	276-3863482
WHITE STONE PHARMACY HM	Susan Sanders	416 CHESAPEAKE DR	WHITE STONE	VA	22578	804-4351051
GREEN HEALTH PHARMACY		2898 DALE BLVD UNIT 105	WOODBRIIDGE	VA	22193	703-6703640
LOGAR PHARMACY		516 9TH ST. STE B	BENTON CITY	WA	99320	509-5888600
SOUTH PARK REXALL		1743 VILLAGE LN SE	PORT ORCHARD	WA	98366	360-8711020
JEFFERSON FAMILY PHCY INC		2005 E SIMS WAY	PORT TOWNSEND	WA	98368	360-3853850
Overlake Pharmacy LLC		4124 148TH AVE NE STE JA	REDMOND	WA	98052	855-9108606
JOHNSON DRUG AT ARMC HM	Matt Johnson	265 EAST GRIFFIN STREET	AMERY	WI	54001	715-2680678
RASMUSSEN VIL PHARM HM	Dane Rasmussen	840 MAIN STREET	BALDWIN	WI	54002	715-6842674
ERICKSON HM PHARMACY HM		8 S. MAIN ST	CLINTONVILLE	WI	54929	715-8232222
VILLAGE PHCY GLENWOOD		224 W OAK STREET	GLENWOOD CITY	WI	54013	715-5653465
MTH / HAYAT PHCY 11		1001 CECELIA DR STE 200A	PEWAUKEE	WI	53072	414-3740000
TRIG'S PHCY HM SP		1600 ACADEMY AVENUE	STEVENS POINT	WI	54481	715-3416102
MEDICAL CENTER PHARMACY		1111 DELAFIELD ST STE 109	WAUKESHA	WI	53188	262-5445303
TRIG'S PHCY HM WA		110 SOUTH 17TH AVE	WAUSAU	WI	54401	
TRAVELMART PHARMACY HM	Gary Gussel	802 BROADWAY	WISCONSIN DELLS	WI	53965	
KINES FAMILY PHARMACY		6097 SISSONVILLE DR	CHARLESTON	WV	25312	304-9841001
JARRELLS PHARMACY	Douglas Jarrell	PO BOX 159 RT#19 RITTER	DANIELS	WV	25832	304-7632442
Moore's Pharmacy		1311 EDWIN MILLER BLVD	MARTINSBURG	WV	25404	304-2640300

EXHIBIT M
FINANCIAL STATEMENTS

HEALTH MART SYSTEMS, INC.
FINANCIAL STATEMENTS

Health Mart Systems, Inc.

(A Wholly Owned Subsidiary of
McKesson Corporation)

Financial Statements as of and for the Years
Ended March 31, 2022 and 2021, and
Independent Auditor's Report



Deloitte & Touche LLP
JPMorgan Chase Tower
2200 Ross Avenue, Suite 1600
Dallas, TX 75201-6778
USA
Tel: +1 214 840 7000
www.deloitte.com

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Health Mart Systems, Inc.

Opinion

We have audited the financial statements of Health Mart Systems, Inc. (the "Company"), which comprise the balance sheets as of March 31, 2022 and 2021, and the related statements of operations and retained earnings, and cash flows for the years then ended, and the related notes to the financial statements (collectively referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Company as of March 31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Company and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Emphasis of Matter

As discussed in Note 3 to the financial statements, the Company receives managerial and administrative services from McKesson, and the Company's cash receipts and payments are facilitated by McKesson through a cash management program. Certain of the Company's affiliates provide services to the Company's customers either through a separate agreement or as part of the performance obligation included in the franchise fee. In addition, the Company was allocated and recorded its estimated portion of the opioid litigation liability from McKesson and purchased an insurance policy from a captive insurance affiliate to cover the related losses, resulting in premium expense and an insurance recovery receivable. Accordingly, the financial statements may not be indicative of financial conditions that would have existed or the results of operations that would have been achieved if the Company had operated without such affiliation. Our opinion is not modified with respect to this matter.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair

presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for one year after the date that the financial statements are issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Deloitte & Touche LLP

June 17, 2022

HEALTH MART SYSTEMS, INC.
(A Wholly Owned Subsidiary of McKesson Corporation)

BALANCE SHEETS
AS OF MARCH 31, 2022 AND MARCH 31, 2021

	2022	2021
ASSETS		
CURRENT ASSETS:		
McKesson cash management program	\$ 59,220,522	\$ 48,241,608
Accounts receivable from customers — net	1,701,292	1,884,029
Prepaid expenses	552,750	-
Insurance recovery receivable	4,497,800	-
Total current assets	65,972,364	50,125,637
Deferred tax assets	-	2,198,317
Insurance recovery receivable	31,047,089	34,688,100
TOTAL	\$ 97,019,453	\$ 87,012,054
LIABILITIES AND STOCKHOLDER'S EQUITY		
CURRENT LIABILITIES:		
Accounts payable	\$ 1,167,372	\$ 1,246,726
Accrued salaries and wages, and other	1,611,783	1,391,494
Litigation liability	4,497,800	-
Total current liabilities	7,276,955	2,638,220
Deferred tax liabilities	529,055	-
Long-term litigation liability	31,047,089	34,688,100
Other non-current liabilities	125,862	-
STOCKHOLDER'S EQUITY:		
Common stock, \$1 par value — authorized, 1,000 shares; issued and outstanding, 100 shares	100	100
Capital in excess of par value	36,247,398	36,247,398
Retained earnings	21,792,994	13,438,236
Total stockholder's equity	58,040,492	49,685,734
TOTAL	\$ 97,019,453	\$ 87,012,054

See notes to financial statements.

HEALTH MART SYSTEMS, INC.**(A Wholly Owned Subsidiary of McKesson Corporation)****STATEMENTS OF OPERATIONS AND RETAINED EARNINGS
FOR THE YEARS ENDED MARCH 31, 2022 AND 2021**

	2022	2021
NET SALES AND OTHER REVENUES:		
Franchise fees, merchandise revenue and other	\$ 18,931,306	\$ 19,477,859
Channel management service fees	<u>13,326,137</u>	<u>12,900,019</u>
Total net sales and other revenues	32,257,443	32,377,878
OPERATING COSTS AND EXPENSES:		
Cost of merchandise sold	6,643,888	6,108,421
Selling, general, and administrative expenses	16,703,397	15,773,457
Insurance premium expense	<u>-</u>	<u>31,247,498</u>
Total operating costs and expenses	23,347,285	53,129,376
INCOME (LOSS) FROM OPERATIONS	8,910,158	(20,751,498)
INTEREST INCOME	<u>2,297,840</u>	<u>1,735,986</u>
INCOME (LOSS) BEFORE INCOME TAXES	11,207,998	(19,015,512)
INCOME TAX EXPENSE (BENEFIT)	<u>2,853,240</u>	<u>(1,961,001)</u>
NET INCOME (LOSS)	8,354,758	(17,054,511)
RETAINED EARNINGS — Beginning of year	<u>13,438,236</u>	<u>30,492,747</u>
RETAINED EARNINGS — End of year	<u>\$ 21,792,994</u>	<u>\$ 13,438,236</u>

See notes to financial statements.

HEALTH MART SYSTEMS, INC.
(A Wholly Owned Subsidiary of McKesson Corporation)

STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED MARCH 31, 2022 AND 2021

	2022	2021
OPERATING ACTIVITIES		
Net income (loss)	\$ 8,354,758	\$ (17,054,511)
Adjustments to reconcile net income (loss) to net cash used in operating activities:		
Deferred taxes	2,853,234	(1,961,001)
Changes in operating assets and liabilities:		
McKesson cash management program	(10,978,914)	(13,053,748)
Accounts receivable from customers — net	182,737	(45,001)
Prepaid expenses	(552,750)	475,947
Insurance recovery receivable	(856,789)	(34,688,100)
Current liabilities	140,935	390,816
Litigation liability	856,789	34,688,100
Net cash used in operating activities	-	(31,247,498)
FINANCING ACTIVITIES		
Capital contribution from McKesson	-	31,247,498
Net cash provided by financing activities	-	31,247,498
NET INCREASE IN CASH AND CASH EQUIVALENTS	-	-
CASH AND CASH EQUIVALENTS — Beginning of year	-	-
CASH AND CASH EQUIVALENTS — End of year	\$ -	\$ -

See notes to financial statements.

HEALTH MART SYSTEMS, INC.
(A Wholly Owned Subsidiary of McKesson Corporation)

NOTES TO FINANCIAL STATEMENTS
AS OF AND FOR THE YEARS ENDED MARCH 31, 2022 AND 2021

1. ORGANIZATION AND BUSINESS

Health Mart Systems, Inc. (the "Company") is a wholly owned subsidiary of McKesson Corporation ("McKesson," or the "Parent"). The Company offers franchises for sale that provide independent retailers with a name and logo to foster regional recognition and an exclusive trade area. The Company also sells signs, decorative accessories, and private label products and provides marketing support services to McKesson (see Note 3). The franchisees pay franchise fees and generally purchase certain goods, supplies, and services from the Company or its affiliates. The Company receives managerial and administrative services from McKesson and the Company utilizes the McKesson cash management program to facilitate working capital receipts and payments. In addition, the Company receives fees from McKesson for Channel Management Services. As such, the Company's financial position, results of operations, and cash flows may not be indicative of conditions that would have existed or results that would have occurred had the Company operated as a stand-alone entity.

2. SIGNIFICANT ACCOUNTING POLICIES

Basis of Accounting — The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The prior year balances have been reclassified to conform with current year presentation where applicable

Fiscal Period — The Company's fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references in this document to a particular year shall mean the Company's fiscal year.

Use of Estimates — The preparation of the financial statements, in conformity with accounting principles generally accepted in the United States of America, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during such reporting periods. Actual results could differ from these estimates.

On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 a pandemic, which continues to spread throughout the United States. To date, the Company has not experienced any significant negative economic impact due to COVID-19. Further, the Company does not foresee further material risk to operations but does continue to monitor its activities for any potential impact.

McKesson Cash Management Program — As discussed in Note 3, the Company participates in the McKesson cash management program. As part of this program, McKesson collects and distributes cash on behalf of the Company. As such, the Company has no direct cash flows. The net effect of the cash inflows and outflows under the program is presented

in the statements of cash flows as an operating activity. The Company's balance under such program is available on demand.

Prepaid Expenses — Prepayments include costs relating to future periods and are measured at cost.

Income Taxes — The Company is included in the McKesson Corporation U.S. consolidated income tax return. The Company has calculated income taxes on a separate return basis whereby current and deferred taxes are calculated pursuant to the asset and liability method as if the Company were a separate taxpayer.

This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the book carrying amounts and the tax basis of assets and liabilities. Income taxes are recognized based on the amounts that more likely than not will be sustained upon ultimate settlement with taxing authorities. The liability for income taxes is settled with McKesson through the cash management program. For balance sheet purposes, amounts have been recorded as "Deferred Tax Assets" or "Deferred Tax Liabilities."

Retained Earnings — The change in retained earnings for the year ended March 31, 2022 is related to net income of \$8,354,758. The change in retained earnings for the year ended March 31, 2021 is composed of a decrease for net loss of \$17,054,511 and an increase related to a capital contribution from the Parent of \$31,247,498.

Revenue Recognition —

The Company derives its revenues primarily from the following services:

	2022	2021
Franchise fees	\$ 14,942,725	\$ 14,049,646
Channel management service fees	13,326,137	12,900,019
Merchandise revenue and other	<u>3,988,581</u>	<u>5,428,213</u>
	<u><u>\$ 32,257,443</u></u>	<u><u>\$ 32,377,878</u></u>

Franchise fees: The Company provides multiple resources and stand-ready services to customers that join the Health Mart franchise for an agreed upon monthly fee. Revenue is recognized over time when services and access to resources have been provided to the customer.

Channel management service fees: The Company entered into a services agreement with McKesson to provide marketing, oversight, and communication services to pharmacies that join the Health Mart franchise. Revenue is recognized over time when services are provided.

Merchandise revenue and other: The Company sells Health Mart branded fixtures and décor to customers who join the Health Mart franchise. Revenue from merchandise sales is recognized at a point in time upon transfer of goods or services to customers. The Company also provides logistic services related to COVID-19 test kit distribution and provides services related to optimization of front-end sales for merchandisers and recognizes revenue when services are rendered.

Revenues are recorded gross when the Company is the principal in the transaction, has the ability to direct the use of the goods or services prior to transfer to a customer, is responsible for fulfilling the promise to its customer, has latitude in establishing prices, and controls the relationship with the customer. Revenues are recorded net when the Company is the agent in the transaction. The Company records its revenues net of sales taxes. Franchise fees and merchandise revenue and other are due within one month subsequent to when the revenue is recognized. Channel management service fees are due on demand.

No material contract assets, contract liabilities, or deferred contract costs were recorded on the balance sheet as of March 31, 2022 and 2021.

Recently Adopted Accounting Pronouncement -

Income taxes - In the first quarter of 2022, the Company prospectively adopted *Accounting Standards Update ("ASU") 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes*, which eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. The guidance also simplifies and clarifies certain other aspects of accounting for income taxes. The adoption of this amended guidance did not have a material impact on the Company's consolidated financial statements or disclosures.

3. RELATED-PARTY TRANSACTIONS

Substantially all of the Company's sales and consulting services were with customers that are also customers of McKesson.

The Company has entered into contracts with customers along with its Parent and other affiliates, which are under common control of the Parent. As part of the franchise services, certain of the Company's affiliates provide services to the Company's customers.

Pursuant to an agreement with McKesson, the Company participates daily in the McKesson cash management program, invests excess cash with McKesson, and has access to the cash invested. As the Company does not retain any cash balances, all operating costs of the Company are funded by McKesson. Receivables arising from sales and consulting services are collected by McKesson. The Company's cash management program balance earns interest at prime, plus 1% (4.37% at March 31, 2022 and 4.25% at March, 31 2021) and is available on demand.

The Company pays McKesson, through the cash management program, for certain administrative services performed by McKesson. Under this arrangement, the Company is required to reimburse McKesson for administrative and back office services at an amount equal to allocated costs. Such amounts were \$2,029,543 and \$1,849,766 for the years ended March 31, 2022 and 2021, respectively, and are included in selling, general, and administrative expenses.

The salary costs for direct employees are charged directly to the Company and includes stock-based compensation of \$266,909 and \$327,307 for fiscal year 2022 and 2021, respectively. All such employees are eligible to participate in the benefit plans offered by McKesson.

The Services Agreement provides for the Company to earn fees from McKesson for Channel Management Services. Such fees are based on the cost of such services provided, plus 5%.

Under the agreement, the Company recognized revenue of \$13,326,137 and \$12,900,019 for the years ended March 31, 2022 and 2021, respectively.

As discussed in Note 5, the Company recorded a \$35,544,889 liability as an estimate of the Company's portion of the expected settlements and/or judgments arising from the opioid-related claims of governmental entities.

To insure against losses arising from such opioid-related claims brought by governmental entities, the Company obtained insurance coverage from a captive insurance company wholly-owned by McKesson ("the Captive") in exchange for premiums of \$31,247,498. The cost of the insurance coverage was funded through a cash capital contribution which the Company received from McKesson in fiscal year 2021. As it is probable that the insurance coverage will provide a full recovery of the opioid loss allocated to the Company as of March 31, 2022 and 2021, we have also recognized an insurance receivable due from the Captive of \$35,544,889 and \$34,688,100, respectively. Loss recovery income due from the Captive for March 31, 2022 and 2021 was \$856,789 and \$34,688,100, respectively.

4. **INCOME TAXES**

For fiscal year 2022, the Company's total effective tax rate was 25.4%, which includes 4.5% for state income taxes. For 2021, the Company's total effective tax rate was 10.3%, which includes 1.4% for state income taxes. The primary difference between the effective tax rate and the statutory tax rate are the various impacts of the opioid-related claims including the increase in the unrecognized tax benefits noted below.

	Years Ended March 31,	
	2022	2021
Provision for income taxes:		
Current:		
Federal and State	\$ -	\$ -
Total current income taxes	-	-
Deferred:		
Deferred tax expense (net of uncertain tax benefit)	2,853,240	(1,961,006)
Total deferred income taxes	2,853,240	(1,961,006)
Provision for income taxes	<u>\$ 2,853,240</u>	<u>\$ (1,961,006)</u>

Deferred tax balances consist of the following:

	March 31,	
	2022	2021
Compensation and benefit-related accruals	\$ 302,565	\$ 453,776
Loss and credit carryforward	-	2,530,863
Subtotal	302,565	2,984,639
Valuation allowance		
Total deferred tax assets	<u>302,565</u>	<u>2,984,639</u>
Opioid-related litigation and claims	(831,620)	(786,316)
Other		-
Total deferred tax liabilities	<u>(831,620)</u>	<u>(786,316)</u>
Net deferred taxes	<u>(529,055)</u>	<u>2,198,322</u>
Long-term deferred tax assets	302,565	2,984,639
Long-term net deferred tax liability	(831,620)	(786,316)
Net deferred taxes	<u>\$ (529,055)</u>	<u>\$ 2,198,322</u>

The Company assesses the available positive and negative evidence to determine whether deferred tax assets are more likely than not to be realized.

A valuation allowance has not been recorded as it is more likely than not the Company will have the ability to generate sufficient taxable income within the loss carryforward period after considering all available positive and negative evidence as of March 31, 2021.

The Company reports interest and penalties on income taxes as income tax expense. No interest and penalties have been recognized in fiscal year 2022 and fiscal year 2021.

The Company presents the net operating loss deferred tax asset net of the unrecognized tax benefits for reporting purposes under the applicable income tax accounting guidance. For fiscal year 2021, the uncertain tax position was entirely offset by net operating loss deferred tax assets. In fiscal year 2022, the net operating loss deferred tax assets totaled \$1,899,158, and the offsetting unrecognized tax benefit amount is \$2,025,020, resulting in a net unrecognized tax benefit of \$125,862, which is reported on the balance sheet as "Other noncurrent liabilities."

Unrecognized tax benefit consists of the following:

	Years Ended March 31,	
	2022	2021
Unrecognized tax benefits at beginning of period	\$ 1,957,844	\$ -
Additions based on tax positions related to current year	67,176	1,957,844
Unrecognized tax benefits at end of period	<u>\$ 2,025,020</u>	<u>\$ 1,957,844</u>

Income taxes are recognized based on the amounts that more likely than not will be sustained upon ultimate settlement with taxing authorities. As of March 31, 2022, the Company had \$2,025,020 of unrecognized tax benefit related to the uncertainty in connection with the deductibility of associated opioid-related litigation and claims. The increase in unrecognized tax benefit in fiscal 2022 compared to 2021 is primarily attributable to additional opioid litigation accrual based on the latest developments reached with Alabama, New York, Rhode Island, Texas and Washington. McKesson updated the reserve calculation using the methodology from its March 31, 2021 year end. Because many uncertainties associated with any potential settlement arrangements or other resolutions of opioid-related claims including provisions related to deductibility have not been finalized, the actual amount of the tax benefit related to uncertain tax positions may differ from these estimates. See Note 5.

5. COMMITMENTS AND CONTINGENT LIABILITIES

In addition to commitments and obligations in the ordinary course of business, we are subject to various claims, including claims with customers and vendors, pending and potential legal actions for damages, investigations relating to governmental laws, and regulations and other matters arising out of the normal conduct of our business.

When a loss is considered probable and reasonably estimable, we record a liability in the amount of our best estimate for the ultimate loss. However, the likelihood of a loss with respect to a particular contingency is often difficult to predict and determining a meaningful estimate of the loss or a range of loss may not be practicable based on the information available and the potential effect of future events and decisions by third parties that will determine the ultimate resolution of the contingency. Moreover, it is not uncommon for such matters to be resolved over many years, during which time relevant developments and new information must be reevaluated at least quarterly to determine both the likelihood of potential loss and whether it is possible to reasonably estimate a range of possible loss. When a loss is probable, but a reasonable estimate cannot be made, disclosure of the proceeding is provided.

Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. We review all contingencies annually to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or range of loss can be made. As discussed above, development of a meaningful estimate of loss or a range of potential loss is complex when the outcome is directly dependent on negotiations with or decisions by third parties, such as regulatory agencies, the court system, and other interested parties. Such factors bear directly on whether it is possible to reasonably estimate a range of potential loss and boundaries of high and low estimates.

We are party to the legal proceedings described below. Unless otherwise stated, we are currently unable to estimate a range of reasonably possible losses for the unresolved proceedings described below. Should any one or a combination of more than one of these proceedings be ruled in favor of the plaintiffs, or should we determine to settle any or a combination of these matters, we may be required to pay substantial sums, become subject to the entry of an injunction, or be forced to change the manner in which we operate our business, which could have a material adverse impact on our financial position or results of operations.

Litigation claims: In re: National Prescription Opiate Litigation, Case No. 1:17-md-02804-DAP (December 8, 2017), U.S. District Court, Northern District of Ohio. McKesson, our parent

company, and its affiliates, including the Company, are defendants in many cases asserting claims related to distribution of controlled substances. They are named as defendants along with other pharmaceutical wholesale distributors, pharmaceutical manufacturers, and retail pharmacy chains in these cases. The Company is named as a defendant in 39 of those cases, all of which are part of the multidistrict litigation pending in the Northern District of Ohio. The plaintiffs in the opioid actions include state attorneys general, county and municipal governments, tribal nations, hospitals, health and welfare funds, third-party payors, and individuals. These cases were filed in state and federal courts throughout the United States, but the vast majority of them have been transferred for consolidated pre-trial proceedings to the multi-district litigation pending in the U.S. District Court for the Northern District of Ohio. These matters allege numerous causes of action, including negligence, public nuisance, unjust enrichment, civil conspiracy, violation of the Racketeer Influenced and Corrupt Organizations Act, violation of state and federal controlled substance laws, and other state statutes, including various state deceptive and unfair trade practices acts, and fraudulent or misleading advertising and other practices. Plaintiffs are seeking, among other things, (1) to enjoin all defendants from failing to report suspicious orders as required by federal and state law; (2) the disgorgement of profits by defendants, and (3) an order requiring defendants to pay an unspecified amount of damages and attorneys' fees and costs.

On July 21, 2021, McKesson and the two other national pharmaceutical distributors (collectively "Distributors") announced that they had negotiated a comprehensive proposed settlement agreement which, if all conditions were satisfied, would result in the settlement of a substantial majority of opioid lawsuits filed by state and local governmental entities. On February 25, 2022, the Distributors determined that there was sufficient State and subdivision participation to proceed with an agreement ("Settlement") to settle a substantial majority of opioids-related lawsuits filed against the Distributors by U.S. states, territories, and local governmental entities. 46 of 49 eligible states and their participating subdivisions, as well as the District of Columbia and all eligible territories (collectively, "Settling Governmental Entities"), have agreed to join the Settlement. To date, over 98% of eligible political subdivisions that have brought opioid-related suits against the Company, as calculated by population under the agreement, have agreed to participate in the settlement or have had their claims addressed by state legislation.

The Settlement became effective on April 2, 2022. If all conditions to the Settlement are satisfied, including the receipt of approval by relevant courts of consent decrees to dismiss the lawsuits, the Distributors would pay the Settling Governmental Entities up to approximately \$19.5 billion over 18 years, with up to approximately \$7.4 billion to be paid by the McKesson for its 38.1% portion. Under the Settlement, a minimum of 85% of the settlement payments must be used by state and local governmental entities to remediate the opioid epidemic. Most of the remaining percentage relates to plaintiffs' attorneys' fees and costs, and would be payable over a shorter time period. Under the Settlement, the Distributors will establish a clearinghouse to consolidate their controlled-substance distribution data, which will be available to the settling U.S. states to use as part of their anti-diversion efforts. The Settlement provides that the Distributors do not admit liability or wrongdoing and do not waive any defenses.

McKesson recorded a charge of \$8.1 billion during the year ended March 31, 2021 related to its estimated liability to U.S. governmental entities, including those expected to participate in the Settlement, the states and subdivisions that were not expected to participate or were not eligible, and the Native American tribes. In connection with the Settlement and other opioid-related settlement accruals, McKesson recorded additional charges of \$274 million during the year ended March 31, 2022. McKesson's total estimated liability for opioid-related

claims was \$8.3 billion as of March 31, 2022, of which \$36 million was recorded by the Company for the year ended March 31, 2022.

Although the vast majority of opioid claims have been brought by governmental entities in the U.S., the Company is also a defendant in cases brought in the U.S. by private plaintiffs, such as hospitals, health and welfare funds, third-party payors, and individuals, as well as four cases brought in Canada (three by governmental or tribal entities and one by an individual). These claims, and those of private entities generally, are not included in the Settlement or in the charges recorded by the Company, described above. The Company believes it has valid legal defenses in these matters and intends to mount a vigorous defense. Trial is scheduled for July 18, 2022 in one such case brought by a group of individual plaintiffs in Glynn County, Georgia Superior Court. These plaintiffs seek to recover for damages allegedly arising from their family members' abuse of prescription opioids. Poppell v. Cardinal Health, Inc. et al., CE19-00472. The Company has not concluded a loss is probable in any of these matters; nor is any possible loss or range of loss reasonably estimable.

Because of the many uncertainties associated with the remaining opioid-related litigation matters, the Company is not able to reasonably estimate the upper or lower ends of the range of ultimate possible loss for all opioid-related litigation matters. An adverse judgment or negotiated resolution in any of these matters could have a material adverse impact on the Company's financial position, cash flows or liquidity, or results of operations.

6. SUBSEQUENT EVENTS

The Company evaluated subsequent events through June 17, 2022, the date the financial statements were available to be issued. No additional disclosure is required.

* * * * *

Health Mart Systems, Inc.

(A Wholly Owned Subsidiary of
McKesson Corporation)

Financial Statements as of and for the Years
Ended March 31, 2021 and 2020, and
Independent Auditors' Report

**Deloitte & Touche LLP**

1100 Walnut Street
Suite 3300
Kansas City, MO 64106
USA

Tel: +1 816 474 6180
Fax: +1 816 881 0000
www.deloitte.com

INDEPENDENT AUDITORS' REPORT

To the Board of Directors of
Health Mart Systems, Inc.:

We have audited the accompanying financial statements of Health Mart Systems, Inc. (the "Company") (a wholly-owned subsidiary of McKesson Corporation ("McKesson")), which comprise the balance sheets as of March 31, 2021 and 2020, and the related statements of operations and retained earnings, and cash flows for the years then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.


We believe that the audit evidence that we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects the financial position of the Company as of March 31, 2021 and 2020, and the results of its operations and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Emphasis of Matter

As discussed in Note 3 to the financial statements, the Company receives managerial and administrative services from McKesson, and the Company's cash receipts and payments are facilitated by McKesson through a cash management program. The Company receives fees from McKesson for services under a Channel Management Service Agreement. Certain of the Company's affiliates provide services to the Company's customers either through a separate agreement or as part of the performance obligation included in the franchise fee. In addition, the Company was allocated and recorded its estimated portion of the opioid litigation liability from McKesson and purchased an insurance policy from a captive insurance affiliate to cover the related losses, resulting in premium expense and an insurance recovery receivable. As such, the Company's financial position, results of operations and cash flows may not be indicative of conditions that would have existed or results that would have occurred had the Company operated as a stand-alone entity. Our opinion is not modified with respect to this matter.

A handwritten signature in dark ink that reads "Deloitte & Touche LLP". The signature is written in a cursive, flowing style.

June 30, 2021

HEALTH MART SYSTEMS, INC.
(A Wholly Owned Subsidiary of McKesson Corporation)

BALANCE SHEETS
AS OF MARCH 31, 2021 AND MARCH 31, 2020

	2021	2020
ASSETS		
CURRENT ASSETS:		
McKesson cash management program	\$ 48,241,608	\$ 35,187,860
Accounts receivable from customers — net	1,884,029	1,839,028
Prepaid expenses	-	475,947
Total current assets	50,125,637	37,502,835
Deferred tax assets	2,198,317	237,316
Insurance recovery receivable	34,688,100	-
TOTAL	\$ 87,012,054	\$ 37,740,151
LIABILITIES AND STOCKHOLDER'S EQUITY		
CURRENT LIABILITIES:		
Accounts payable	\$ 1,246,726	\$ 818,786
Accrued salaries and wages, and other	1,391,494	1,428,618
Total current liabilities	2,638,220	2,247,404
Long-term litigation liability	34,688,100	-
STOCKHOLDER'S EQUITY:		
Common stock, \$1 par value — authorized, 1,000 shares; issued and outstanding, 100 shares	100	100
Capital in excess of par value	36,247,398	4,999,900
Retained earnings	13,438,236	30,492,747
Total stockholder's equity	49,685,734	35,492,747
TOTAL	\$ 87,012,054	\$ 37,740,151

See notes to financial statements.

HEALTH MART SYSTEMS, INC.**(A Wholly Owned Subsidiary of McKesson Corporation)****STATEMENTS OF OPERATIONS AND RETAINED EARNINGS
FOR THE YEARS ENDED MARCH 31, 2021 AND 2020**

	2021	2020
NET SALES AND OTHER REVENUES:		
Franchise fees, merchandise revenue, and other	\$ 19,477,859	\$ 16,152,425
Channel management service fees	<u>12,900,019</u>	<u>13,078,676</u>
Total net sales and other revenues	32,377,878	29,231,101
OPERATING COSTS AND EXPENSES:		
Cost of merchandise sold	6,108,421	6,881,380
Selling, general, and administrative expenses	15,773,457	15,118,508
Insurance premium expense	<u>31,247,498</u>	<u>-</u>
Total operating costs and expenses	53,129,376	21,999,888
INCOME (LOSS) FROM OPERATIONS	(20,751,498)	7,231,213
INTEREST INCOME	<u>1,735,986</u>	<u>1,316,443</u>
INCOME (LOSS) BEFORE INCOME TAXES	(19,015,512)	8,547,656
INCOME TAX EXPENSE (BENEFIT)	<u>(1,961,001)</u>	<u>2,141,889</u>
NET INCOME (LOSS)	(17,054,511)	6,405,767
RETAINED EARNINGS — Beginning of year	<u>30,492,747</u>	<u>24,086,980</u>
RETAINED EARNINGS — End of year	<u>\$ 13,438,236</u>	<u>\$ 30,492,747</u>

See notes to financial statements.

HEALTH MART SYSTEMS, INC.
(A Wholly Owned Subsidiary of McKesson Corporation)

STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED MARCH 31, 2021 AND 2020

	2021	2020
OPERATING ACTIVITIES		
Net (loss) income	\$ (17,054,511)	\$ 6,405,767
Adjustments to reconcile net income (loss) to net cash provided/used by operating activities:		
Deferred taxes	(1,961,001)	(11,355)
Changes in operating assets and liabilities:		
McKesson cash management program	(13,053,748)	(7,324,254)
Accounts receivable from customers — net	(45,001)	(116,066)
Prepaid expenses	475,947	(23,712)
Current liabilities	390,816	1,069,620
Net cash used by operating activities	<u>(31,247,498)</u>	<u>-</u>
FINANCING ACTIVITIES		
Capital contribution from McKesson	<u>31,247,498</u>	<u>-</u>
Net cash provided by financing activities	<u>31,247,498</u>	<u>-</u>
NET INCREASE IN CASH AND CASH EQUIVALENTS	-	-
CASH AND CASH EQUIVALENTS — Beginning of year	<u>-</u>	<u>-</u>
CASH AND CASH EQUIVALENTS — End of year	<u>\$ -</u>	<u>\$ -</u>

See notes to financial statements.

HEALTH MART SYSTEMS, INC.
(A Wholly Owned Subsidiary of McKesson Corporation)

NOTES TO FINANCIAL STATEMENTS
AS OF AND FOR THE YEARS ENDED MARCH 31, 2021 AND 2020

1. ORGANIZATION AND BUSINESS

Health Mart Systems, Inc. (the "Company") is a wholly owned subsidiary of McKesson Corporation ("McKesson"). The Company offers franchises for sale that provide independent retailers with a name and logo to foster regional recognition and an exclusive trade area. The Company also sells signs, decorative accessories, and private label products and provides marketing support services to McKesson (see Note 3). The franchisees pay franchise fees and generally purchase certain goods, supplies, and services from the Company or its affiliates. The Company receives managerial and administrative services from McKesson and the Company utilizes the McKesson cash management program to facilitate working capital receipts and payments. In addition, the Company receives fees from McKesson for Channel Management Services. As such, the Company's financial position, results of operations, and cash flows may not be indicative of conditions that would have existed or results that would have occurred had the Company operated as a stand-alone entity.

2. SIGNIFICANT ACCOUNTING POLICIES

Basis of Accounting — The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America.

Fiscal Period — The Company's fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references in this document to a particular year shall mean the Company's fiscal year.

Use of Estimates — The preparation of the financial statements, in conformity with accounting principles generally accepted in the United States of America, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during such reporting periods. Actual results could differ from these estimates.

On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 a pandemic, which continues to spread throughout the United States. To date, the Company has not experienced any significant economic impact due to COVID-19. Further, the Company does not foresee further material risk to operations but does continue to monitor its activities for any potential impact.

McKesson Cash Management Program — As discussed in Note 3, the Company participates in the McKesson cash management program. As part of this program, McKesson collects and distributes cash on behalf of the Company. As such, the Company has no direct cash flows. The net effect of the cash inflows and outflows under the program is presented in the statements of cash flows as an operating activity. The Company's balance under such program is available on demand.

Prepaid Expenses — Prepayments include costs relating to future periods and are measured at cost.

Income Taxes — The Company is included in the McKesson Corporation U.S. consolidated income tax return. The Company has calculated income taxes on a separate return basis whereby current and deferred taxes are calculated pursuant to the asset and liability method as if the Company were a separate taxpayer.

This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the book carrying amounts and the tax basis of assets and liabilities. Income taxes are recognized based on the amounts that more likely than not will be sustained upon ultimate settlement with taxing authorities. The liability for income taxes is settled with McKesson through the cash management program. For balance sheet purposes, amounts have been recorded as "Deferred Tax Assets".

Stockholder's Equity — The change in retained earnings for the year ended March 31, 2021 and 2020 is related to net loss of \$17,054,511 and net income of \$6,405,767, respectively. The change in capital in excess of par value is related to a capital contribution from McKesson of \$31,247,498 for the year ended March 31, 2021.

Revenue Recognition —

The Company adopted ASC 606, *Revenue from Contracts with Customers* ("ASC 606"), using the modified retrospective method. The reported results for the fiscal year ended March 31, 2021 reflect the application of the guidance of ASC 606 while the reported results for the fiscal year ended March 31, 2020 were prepared under the guidance of ASC 605, *Revenue Recognition* ("ASC 605"). There was not a material impact to any of the line items within the Company's Balance Sheet or Statements of Operations and Retained Earnings as a result of applying ASC 606 for the fiscal year ended March 31, 2021.

The Company derives its revenues primarily from the following services:

	2021	2020
Franchise fees	\$ 14,049,646	\$ 13,633,995
Channel management service fees	12,900,019	\$ 13,078,676
Merchandise revenue and other	<u>5,428,213</u>	<u>2,518,430</u>
	<u>\$ 32,377,878</u>	<u>\$ 29,231,101</u>

Franchise fees: The Company provides multiple resources and stand-ready services to customers that join the Health Mart franchise for an agreed upon monthly fee. Revenue is recognized over time when services and access to resources have been provided to the customer.

Channel management service fees: The Company entered into a services agreement with McKesson to provide marketing, oversight, and communication services to pharmacies that join the Health Mart franchise. Revenue is recognized over time when services are provided.

Merchandise revenue and other: The Company sells Health Mart branded fixtures and décor to customers who join the Health Mart franchise. Revenue from merchandise sales is recognized at a point in time upon transfer of goods or services to customers. The

Company also provides logistic services related to COVID-19 test kit distribution and provides services related to optimization of front-end sales for merchandisers and recognizes revenue when services are rendered.

Revenues are recorded gross when the Company is the principal in the transaction, has the ability to direct the use of the goods or services prior to transfer to a customer, is responsible for fulfilling the promise to its customer, has latitude in establishing prices, and controls the relationship with the customer. The Company records its revenues net of sales taxes.

No material contract assets, contract liabilities, or deferred contract costs were recorded on the balance sheet as of March 31, 2021.

Recently Adopted Accounting Pronouncement -

Beginning of the fiscal year 2021, the Company adopted amended guidance in ASC 606 for revenue recognition using the modified retrospective method and applied the amended guidance to those contracts which were not completed as of April 1, 2020. The adoption of this amended guidance did not have a material impact on the financial statements.

The Company elected the practical expedient to not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less, (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice for services performed and (iii) contracts for which the variable consideration is allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied promise to transfer a distinct good or service that forms part of a single performance obligation.

New Accounting Pronouncements Not Yet Adopted —

Income taxes - In December 2020, ASU 2019-12, Income Taxes (Topic 740): *Simplifying the Accounting for Income Taxes*, amended guidance was issued with the intent to simplify various aspects related to accounting for income taxes. The guidance eliminates certain exceptions related to the approach for intraperiod tax allocation and the recognition of deferred tax liabilities for outside basis differences. The guidance also simplifies and clarifies certain other aspects of accounting for income taxes. The guidance is effective for the Company in the first quarter of 2023 and early adoption is permitted. The Company is currently evaluating the impact of this amended guidance on its financial statements.

3. RELATED-PARTY TRANSACTIONS

Substantially all of the Company's sales and consulting services were with customers that are also customers of McKesson or McKesson affiliates. As part of the franchise services, certain of the Company's affiliates provide part of the services to the Company's customers.

Pursuant to an agreement with McKesson, the Company participates daily in the McKesson cash management program, invests excess cash with McKesson, and has access to the cash invested. As the Company does not retain any cash balances, all operating costs of the Company are paid by McKesson through the cash management program. Receivables arising from sales and consulting services are collected by McKesson through the cash management program. The Company's cash management program balance earns interest

at prime, plus 1% (4.25% at March 31, 2021 and 2020, respectively) and is available on demand.

The Company pays McKesson, through the cash management program, for certain administrative services performed by McKesson. Under this arrangement, the Company is required to reimburse McKesson for administrative and back office services at an amount equal to allocated costs. Such amounts were \$1,849,766 and \$1,269,760 for the years ended March 31, 2021 and 2020, respectively, and are included in selling, general, and administrative expenses.

The salary costs for direct employees are charged directly to the Company and includes stock-based compensation of \$327,307 for 2021 and \$428,358 for 2020. All such employees are eligible to participate in the health and benefit plans offered by McKesson.

The Services Agreement provides for the Company to earn fees from McKesson for Channel Management Services. Such fees are based on the cost of such services provided, plus 5%. Under the agreement, the Company recognized revenue of \$12,900,019 and \$13,078,676 for the years ended March 31, 2021 and 2020, respectively.

As discussed in Note 5, the Company recorded a \$34,688,100 liability as an estimate of the Company's portion of the expected settlements and/or judgments arising from the opioid-related claims of governmental entities.

To insure against losses arising from such opioid-related claims brought by governmental entities, the Company obtained insurance coverage from a captive insurance company wholly-owned by McKesson ("the Captive") in exchange for premiums of \$31,247,498. The cost of the insurance coverage was funded through a cash capital contribution which the Company received from McKesson. As it is probable that the insurance coverage will provide a full recovery of the opioid loss allocated to the Company as of March 31, 2021, we have also recognized an insurance receivable and loss recovery income due from the Captive of \$34,688,100.

4. INCOME TAXES

For fiscal year 2021, the Company's total effective tax rate was 10.3%, which includes 1.4% for state income taxes. Fluctuations in the Company's reported income tax rates are primarily due to the impact of opioid-related claims in 2021. For 2020, the Company's total effective tax rate in 2020 was 24.7%, which includes 3.7% for state income taxes.

	Years Ended March 31,	
	2021	2020
Provision for income taxes:		
Current:		
Federal and State	\$ -	\$ 2,153,244
Total current income taxes	-	2,153,244
Deferred:		
Deferred Tax Expense (net of uncertain tax benefit)	(1,961,001)	(11,355)
Total deferred income taxes	(1,961,001)	(11,355)
Provision for income taxes	\$ (1,961,001)	\$ 2,141,889

Deferred tax balances consist of the following:

	March 31,	
	2021	2020
Compensation and benefit-related accruals	\$ 453,776	\$ 237,316
Loss and credit carryforward	2,530,863	47,248
Subtotal	2,984,639	284,564
Valuation allowance		(47,248)
Total deferred tax assets	2,984,639	237,316
Opioid-related litigation and claims	(786,322)	-
Total deferred tax liabilities	(786,322)	-
Net deferred tax asset	2,198,317	237,316
Long-term deferred tax assets	2,984,639	237,316
Long-term net deferred tax liability	(786,322)	-
Net deferred tax asset	\$ 2,198,317	\$ 237,316

The Company assesses the available positive and negative evidence to determine whether deferred tax assets are more likely than not to be realized. A valuation allowance has not been recorded as it is more likely than not the Company will have the ability to generate sufficient taxable income within the loss carryforward period after considering all available positive and negative evidence.

The net operating loss carryforwards of \$2,530,863 as of March 31, 2021 have indefinite lives.

The Company reports interest and penalties on income taxes as income tax expense. No interest and penalties have been recognized in fiscal year 2021 and fiscal year 2020.

Unrecognized tax benefit consists of the following:

	Years Ended March 31,	
	2021	2020
Unrecognized tax benefits at beginning of period	\$ -	\$ -
Additions based on tax positions related to current year	1,957,844	-
Unrecognized tax benefits at end of period	\$ 1,957,844	\$ -

Income taxes are recognized based on the amounts that more likely than not will be sustained upon ultimate settlement with taxing authorities. As of March 31, 2021, the Company had \$1,957,844 million of unrecognized tax benefit. The increase in unrecognized tax benefit in fiscal 2021 compared to 2020 is primarily attributable to uncertainty in connection with the deductibility of associated Opioid-related litigation and

claims. Because many uncertainties associated with any potential settlement arrangements or other resolutions of opioid claims including provisions related to deductibility have not been finalized, the actual amount of the tax benefit related to uncertain tax positions may differ from these estimates. See Note 5.

5. COMMITMENTS AND CONTINGENT LIABILITIES

In addition to commitments and obligations in the ordinary course of business, we are subject to various claims, including claims with customers and vendors, pending and potential legal actions for damages, investigations relating to governmental laws, and regulations and other matters arising out of the normal conduct of our business.

When a loss is considered probable and reasonably estimable, we record a liability in the amount of our best estimate for the ultimate loss. However, the likelihood of a loss with respect to a particular contingency is often difficult to predict and determining a meaningful estimate of the loss or a range of loss may not be practicable based on the information available and the potential effect of future events and decisions by third parties that will determine the ultimate resolution of the contingency. Moreover, it is not uncommon for such matters to be resolved over many years, during which time relevant developments and new information must be reevaluated at least quarterly to determine both the likelihood of potential loss and whether it is possible to reasonably estimate a range of possible loss. When a loss is probable, but a reasonable estimate cannot be made, disclosure of the proceeding is provided.

Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. We review all contingencies annually to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or range of loss can be made. As discussed above, development of a meaningful estimate of loss or a range of potential loss is complex when the outcome is directly dependent on negotiations with or decisions by third parties, such as regulatory agencies, the court system, and other interested parties. Such factors bear directly on whether it is possible to reasonably estimate a range of potential loss and boundaries of high and low estimates.

We are party to the legal proceedings described below. Unless otherwise stated, we are currently unable to estimate a range of reasonably possible losses for the unresolved proceedings described below. Should any one or a combination of more than one of these proceedings be ruled in favor of the plaintiffs, or should we determine to settle any or a combination of these matters, we may be required to pay substantial sums, become subject to the entry of an injunction, or be forced to change the manner in which we operate our business, which could have a material adverse impact on our financial position or results of operations.

Litigation claims:

In re: National Prescription Opiate Litigation, Case No. 1:17-md-02804-DAP (December 8, 2017), U.S. District Court, Northern District of Ohio. McKesson, our parent company, and its affiliates, including the Company, are defendants in many cases asserting claims related to distribution of controlled substances. They are named as defendants along with other pharmaceutical wholesale distributors, pharmaceutical manufacturers, and retail pharmacy chains in over 3,000 prescription opiate cases. The Company is named as a defendant in 106 of those cases, including *Broward County, Florida v. Purdue Pharma L.P., et al*; U.S. District Court Southern District of Florida; Case No. 0:18-cv-60535-BB

and *Levy County, Florida v. Purdue Pharma L.P., et al*; Circuit Court in the Eighth Judicial Circuit, Levy County, Florida; Case No. 2018 CA 000283. The plaintiffs in the opioid actions include state attorneys general, county and municipal governments, tribal nations, hospitals, health and welfare funds, third-party payors, and individuals. These cases were filed in state and federal courts throughout the United States, but the vast majority of them have been transferred for consolidated pre-trial proceedings to the multi-district litigation pending in the U.S. District Court for the Northern District of Ohio. These matters allege numerous causes of action, including negligence, public nuisance, unjust enrichment, civil conspiracy, violation of the Racketeer Influenced and Corrupt Organizations Act, violation of state and federal controlled substance laws, and other state statutes, including various state deceptive and unfair trade practices acts, and fraudulent or misleading advertising and other practices. Plaintiffs are seeking, among other things, (1) to enjoin all defendants from failing to report suspicious orders as required by federal and state law; (2) the disgorgement of profits by defendants, and (3) an order requiring defendants to pay an unspecified amount of damages and attorneys' fees and costs. Trial began May 3, 2021 for the claims brought by the City of Huntington and Cabell County, West Virginia pending in the U.S. District Court for the Southern District of West Virginia. The multi-district cases in which we are one of multiple defendants are currently stayed.

McKesson is in ongoing, advanced discussions with state attorneys general and plaintiffs' representatives regarding a framework under which, in order to resolve the claims of governmental entities, the three largest U.S. pharmaceutical distributors would pay up to approximately \$21 billion over a period of 18 years to remediate the opioids crisis.

McKesson and its affiliates, including the Company, concluded the discussions under that framework have reached a stage at which a broad settlement of opioid claims by governmental entities was probable, and the loss related thereto can be reasonably estimated as of March 31, 2021. As a result of that conclusion, McKesson recorded a charge of \$8.1 billion related to its share of the settlement framework, of which \$34,688,100 was recorded by the Company for the year ended March 31, 2021.

Discussions with attorneys general and other parties continue. If the negotiating parties agree on terms under the framework for a broad resolution of claims of governmental entities, then those potential terms would need to be agreed to by numerous other state and local governments before an agreement could be accepted by the Company and finalized. In some cases, discovery has been paused during the parties' discussions. While McKesson continues to be involved in discussions regarding a potential broad settlement framework, McKesson also continues to prepare for trial in these pending matters. McKesson believes that it has valid defenses to the claims pending against it, and it intends to vigorously defend against all such claims if acceptable settlement terms are not achieved.

McKesson and its affiliates maintain insurance programs through wholly-owned captive insurance subsidiaries of McKesson (each a "Captive"), from which they obtain coverage for catastrophic exposures. On March 5, 2021, one of the Captives provided insurance coverage to certain McKesson affiliates, including the Company, for potential exposures for settlements and/or judgments arising from the opioid-related claims of governmental entities against McKesson and its affiliates. The Company recorded a charge of \$31,247,498 within "Insurance premiums expense" in the Statements of Operations and Retained Earnings related to insurance premiums paid during fiscal 2021 for this insurance coverage.

Although the vast majority of opioid claims have been brought by governmental entities in the U.S., McKesson is also a defendant in cases brought in the U.S. by private plaintiffs, such as hospitals, health and welfare funds, third-party payors, and individuals. These claims, and those of private entities generally, are not included in the settlement framework for governmental entities, or in the charges recorded by McKesson, described above. McKesson believes it has valid legal defenses in these matters and intends to mount a vigorous defense. McKesson and the Company have not concluded a loss is probable in any of these matters; nor is the amount of any loss reasonably estimable.

Because of the many uncertainties associated with any potential settlement arrangement or other resolution of all of these opioid-related litigation matters, including the uncertain scope of participation by governmental entities in any potential settlement under the framework described above, McKesson is not able to reasonably estimate the upper or lower ends of the range of ultimate possible loss for all opioid-related litigation matters. The Company is further unable to reasonably estimate a range associated with our relative share of any potential exposure. An adverse judgment or negotiated resolution in any of these matters could have a material adverse impact on the Company's financial position, cash flows or liquidity, or results of operations.

6. SUBSEQUENT EVENTS

The Company evaluated subsequent events through June 30, 2021, the date the financial statements were available to be issued. No additional disclosure is required.

* * * * *

McKESSON CORPORATION

Item 8. Financial Statements and Supplementary Data.

INDEX TO CONSOLIDATED FINANCIAL INFORMATION

	<u>Page</u>
<u>Management's Annual Report on Internal Control Over Financial Reporting</u>	<u>64</u>
<u>Report of Independent Registered Public Accounting Firm</u>	<u>65</u>
Consolidated Financial Statements:	
Consolidated Statements of Operations for the years ended March 31, 2022, 2021, and 2020	70
Consolidated Statements of Comprehensive Income (Loss) for the years ended March 31, 2022, 2021, and 2020	71
Consolidated Balance Sheets as of March 31, 2022 and 2021	72
Consolidated Statements of Stockholders' Equity (Deficit) for the years ended March 31, 2022, 2021, and 2020	73
Consolidated Statements of Cash Flows for the years ended March 31, 2022, 2021, and 2020	74
<u>Financial Notes</u>	<u>75</u>
<u>Note 1 - Significant Accounting Policies</u>	<u>75</u>
<u>Note 2 - Held for Sale</u>	<u>83</u>
<u>Note 3 - Restructuring, Impairment, and Related Charges, Net</u>	<u>86</u>
<u>Note 4 - Business Acquisitions and Divestitures</u>	<u>89</u>
<u>Note 5 - Share-Based Compensation</u>	<u>91</u>
<u>Note 6 - Other Income, Net</u>	<u>95</u>
<u>Note 7 - Income Taxes</u>	<u>95</u>
<u>Note 8 - Redeemable Noncontrolling Interests and Noncontrolling Interests</u>	<u>99</u>
<u>Note 9 - Earnings (Loss) per Common Share</u>	<u>100</u>
<u>Note 10 - Leases</u>	<u>101</u>
<u>Note 11 - Goodwill and Intangible Assets, Net</u>	<u>104</u>
<u>Note 12 - Debt and Financing Activities</u>	<u>107</u>
<u>Note 13 - Variable Interest Entities</u>	<u>109</u>
<u>Note 14 - Pension Benefits</u>	<u>109</u>
<u>Note 15 - Hedging Activities</u>	<u>116</u>
<u>Note 16 - Fair Value Measurements</u>	<u>119</u>
<u>Note 17 - Financial Guarantees and Warranties</u>	<u>121</u>
<u>Note 18 - Commitments and Contingent Liabilities</u>	<u>122</u>
<u>Note 19 - Stockholders' Equity (Deficit)</u>	<u>129</u>
<u>Note 20 - Related Party Balances and Transactions</u>	<u>132</u>
<u>Note 21 - Segments of Business</u>	<u>132</u>

McKESSON CORPORATION

MANAGEMENT'S ANNUAL REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING

The management of McKesson Corporation is responsible for establishing and maintaining an adequate system of internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). With the participation of the Chief Executive Officer and the Chief Financial Officer, our management conducted an assessment of the effectiveness of our internal control over financial reporting based on the framework and criteria established in *Internal Control—Integrated Framework (2013)*, issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, our management has concluded that our internal control over financial reporting was effective as of March 31, 2022.

Deloitte & Touche LLP, an independent registered public accounting firm, audited the financial statements included in this Annual Report on Form 10-K and has also audited the effectiveness of the Company's internal control over financial reporting as of March 31, 2022. This audit report appears on the following page of this Annual Report on Form 10-K.

May 9, 2022

/s/ Brian S. Tyler

Brian S. Tyler

Chief Executive Officer

(Principal Executive Officer)

/s/ Britt J. Vitalone

Britt J. Vitalone

Executive Vice President and Chief Financial Officer

(Principal Financial Officer)

McKESSON CORPORATION**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

To the Stockholders and the Board of Directors of McKesson Corporation

Opinions on the Financial Statements and Internal Control over Financial Reporting

We have audited the accompanying consolidated balance sheets of McKesson Corporation and subsidiaries (the “Company”) as of March 31, 2022 and 2021, the related consolidated statements of operations, comprehensive income (loss), stockholders’ equity, and cash flows, for each of the three years in the period ended March 31, 2022, and the related notes and the schedule listed in the Index at Item 15 (collectively referred to as the “financial statements”). We also have audited the Company’s internal control over financial reporting as of March 31, 2022, based on criteria established in *Internal Control — Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of March 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended March 31, 2022, in conformity with accounting principles generally accepted in the United States of America. Also, in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of March 31, 2022, based on criteria established in *Internal Control — Integrated Framework (2013)* issued by COSO.

Basis for Opinions

The Company’s management is responsible for these financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying *Management’s Annual Report on Internal Control Over Financial Reporting*. Our responsibility is to express an opinion on these financial statements and an opinion on the Company’s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Our audits of the financial statements included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures to respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

McKESSON CORPORATION**Definition and Limitations of Internal Control over Financial Reporting**

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

Contingent Liabilities - Opioid Claims brought by United States (U.S.) Governmental Entities - Refer to Note 1 and Note 18 to the financial statements***Critical Audit Matter Description***

The Company and its affiliates are defendants in many cases asserting claims related to distribution of controlled substances, including opioids. The Company is named as a defendant along with other pharmaceutical wholesale distributors, pharmaceutical manufacturers and retail pharmacy chains. The plaintiffs in these actions include state attorneys general, county and municipal governments, hospitals, tribal nations, health and welfare funds, third-party payors and individuals.

On February 25, 2022, the Company and two other United States pharmaceutical distribution companies (collectively, "Distributors") determined that there is sufficient State and subdivision participation to proceed with an agreement ("Settlement") to settle a substantial majority of opioid-related lawsuits filed against the Distributors by U.S. states, territories and local governmental entities (collectively, "Settling Governmental Entities"). The Settlement became effective on April 2, 2022. If all conditions to the Settlement are satisfied, the Distributors would pay the Settling Governmental Entities up to approximately \$19.5 billion over 18 years, with up to approximately \$7.4 billion to be paid by the Company for its 38.1% portion. Although the Settlement terminated the substantial majority of opioid-related suits pending against the Company, a small number of subdivisions in participating states have opted not to participate in the Settlement, and those suits remain pending. The Company continues to prepare for trial in these pending matters, and believes that it has valid defenses to the claims pending against it, and it intends to vigorously defend against all such claims if acceptable settlement terms are not achieved.

When a loss is considered probable and reasonably estimable, the Company records a liability in the amount of its estimate for the ultimate loss. The Company reviews all loss contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or range of loss can be made. The Company also performs an assessment of loss contingencies where a loss is reasonably possible. If it is reasonably possible that a loss may have been incurred and the effect on the financial statements could be material, the Company discloses the nature of the loss contingency and an estimate of the possible loss or range of loss or a statement that such an estimate cannot be made within the notes to the financial statements. For the year ended March 31, 2022, management believes that a loss from opioid claims is both probable and reasonably estimable, and accordingly, an \$8.3 billion liability has been recorded by management, inclusive of claims brought by U.S. governmental entities, which represents the Company's best estimate of future loss related to opioid litigation.

McKESSON CORPORATION

We identified the liabilities associated with opioid claims brought by both Settling Governmental Entities, as well as U.S. governmental entities who are not party to the Settlement, collectively “Governmental Entities,” as a critical audit matter because of the significant judgment in auditing management’s accounting for these matters. Such judgment led to an increased extent of effort, including the need to involve specialists. Specifically, auditing management’s assessment of the magnitude of the liability and the determination of whether there is a reasonably estimable range of loss in excess of the amount accrued, is subjective and requires significant judgment given the size and complexity of opioid claims brought by Governmental Entities.

How the Critical Audit Matter Was Addressed in the Audit

Our audit procedures related to liabilities arising from opioid claims brought by Governmental Entities included the following, among others:

- We tested the effectiveness of internal controls related to liabilities arising from opioid claims brought by Governmental Entities, and approval of the accounting treatment and related disclosures.
- We inquired of the Company’s internal and external legal counsel, as well as executives and other members of management, to understand the basis for the Company’s conclusion that a loss related to opioid claims brought by Governmental Entities is probable and reasonably estimable, and that it is not possible to estimate a range of loss in excess of the amount accrued as of March 31, 2022. In addition, we inspected responses to inquiry letters sent to both internal and external legal counsel as it relates to the terms of settlements with Governmental Entities. We also made inquiries of legal counsel regarding the status of discussions and legal proceedings with Governmental Entities who are not currently party to the Settlement.
- We evaluated management’s analysis of liabilities arising from opioid claims brought by Governmental Entities, including the methodology used by management to determine the probability of such loss and conclusion that it is not possible to estimate a range of loss in excess of the amount accrued as of March 31, 2022. We also evaluated the methodology used by management to estimate the most likely loss to be incurred by the Company as a result of these specific opioid claims.
- We examined Board of Directors meeting minutes, including relevant sub-committee meeting minutes, held inquiries with a director serving on the sub-committee, and compared to internal and external counsel’s written responses to our inquiry letters.
- With the assistance of our specialists in accounting for loss contingencies, we evaluated the facts, evidence and the Company’s related accounting treatment for liabilities arising from opioid claims brought by Governmental Entities.
- We evaluated any events subsequent to March 31, 2022 that might impact management’s accounting treatment.
- We obtained written representations from executives and internal counsel of the Company.
- We examined the terms related to settlements with Governmental Entities.
- We evaluated the adequacy of the Company’s related disclosures for consistency with our testing.

Uncertain Tax Position - Opioid Claims brought by Governmental Entities - Refer to Note 1 and Note 7 to the financial statements*Critical Audit Matter Description*

The Company has recorded charges and related tax benefit for opioid-related claims, inclusive of those brought by Governmental Entities. In order to account for the uncertainty associated with the ultimate realization of the tax benefit related to opioid claims, the Company recorded an uncertain tax position reserve. Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. The net amount recognized by management is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized. The Company uses significant judgment in evaluating the technical tax merits of income tax benefits that qualify for recognition, including the determination of the amount that is more likely than not of being realized for U.S. federal and state income tax purposes.

McKESSON CORPORATION

We identified the Company's uncertain tax position related to liabilities arising from opioid claims brought by Governmental Entities as a critical audit matter because of the challenges in auditing management's estimate of the amount of income tax benefit that qualifies for recognition. Specifically, there is significant judgment associated with the assessment of the technical tax merits of such a settlement, including the related interpretation of applicable, newly-enacted tax laws and regulations. Auditing the uncertain tax position related to liabilities arising from opioid claims brought by Governmental Entities required a high degree of auditor judgment and an increased extent of effort, including the need to involve our tax specialists.

How the Critical Audit Matter Was Addressed in the Audit

Our audit procedures related to the Company's uncertain tax position associated with liabilities arising from opioid claims brought by Governmental Entities included the following, among others:

- We tested the effectiveness of internal controls related to the Company's assessment of the technical merits of its tax position, including the Company's assessment as to the amount of benefit that is more likely than not to be realized upon settlement with a taxing authority that has full knowledge of all relevant information.
- With the assistance of our tax specialists, we evaluated the facts, evidence and the Company's related income tax analysis for liabilities arising from opioid claims brought by Governmental Entities, including assumptions used by management to measure the related recognized and unrecognized tax benefits.
- We inquired of the Company's internal and external legal counsel to understand the basis for the Company's conclusion that a portion of the liabilities arising from opioid claims brought by Governmental Entities would be deductible based on the settlement terms, and expected documentation to be received from Governmental Entities regarding how settlement funds are used.
- We held inquiries with the Company's internal and external income tax specialists related to the uncertain tax position for liabilities arising from opioid claims brought by Governmental Entities.
- We compared management's income tax assessment of this matter to the Company's treatment of other recorded opioid charges to evaluate the consistency of the Company's judgments related to the uncertain tax position.
- We evaluated any events subsequent to March 31, 2022 that might impact management's accounting treatment.
- We obtained written representations from executives and internal counsel of the Company.
- We examined terms related to settlements of opioid claims brought by Governmental Entities.
- We evaluated the Company's related disclosures for consistency with our testing and also searched for contradictory evidence by reading disclosures from peer companies, who are also party to the opioid litigation with Governmental Entities.

Goodwill - Refer to Note 1 and Note 11 to the financial statements*Critical Audit Matter Description*

The Company's evaluation of goodwill for impairment involves comparing the carrying amount of each reporting unit to its fair value on the first day of the third fiscal quarter or whenever the Company believes a potential indicator of impairment requiring a more frequent assessment has occurred. The Company uses a combination of the income and market approaches to estimate reporting unit fair value. Under the market approach, fair value is estimated by comparing the business to similar businesses, or guideline companies whose equity securities are actively traded in public markets. Under the income approach, the Company uses a discounted cash flow ("DCF") model where cash flows anticipated over future periods, plus a terminal value at the end of that time horizon, are discounted to their present value using an appropriate discount rate that is commensurate with the risk inherent within the reporting unit. The rate used to discount to present value includes an unsystematic risk premium, which is intended to address uncertainty related to the reporting unit's future cash flow projections. The goodwill balance was \$9.5 billion as of March 31, 2022, of which \$1.5 billion was allocated to the McKesson Canada reporting unit. The fair value of all reporting units exceeded their respective carrying amounts as of the measurement date and, therefore, no impairment was recognized.

McKESSON CORPORATION

We identified the estimation of the fair value of the McKesson Canada reporting unit used to evaluate the recoverability of goodwill as a critical audit matter because of the challenges auditing significant judgments used in the selection of a discount rate, including the unsystematic risk premium. In particular, the fair value estimate is sensitive to the unsystematic risk premium assumption, which is affected by potential additional risk of changes in the Canadian business and regulatory environments. Auditing management's selected discount rate required a high degree of auditor judgment and an increased extent of effort, including the need to involve our fair value specialists.

How the Critical Audit Matter Was Addressed in the Audit

Our audit procedures related to the Company's selection of a discount rate, including determination of the unsystematic risk premium, for the McKesson Canada reporting unit, included the following, among others:

- We tested the effectiveness of internal controls related to management's goodwill impairment evaluation, including those related to the selection of a discount rate and determination of an unsystematic risk premium.
- We evaluated management's ability to accurately forecast operating results for the McKesson Canada reporting unit by comparing actual results to management's historical forecasts, in order to consider the reasonableness and adequacy of management's selected unsystematic risk premium.
- As part of our assessment of the unsystematic risk premium, we evaluated the reasonableness of strategic plans expected to be implemented during the forecast period by comparing the forecasts to:
 - Actual results of historical strategic plans
 - Internal communications to management and the Board of Directors
- With the assistance of our fair value specialists, we evaluated the reasonableness of the discount rate, including the unsystematic risk premium, by developing a range of independent estimates, testing the mathematical accuracy of the calculation, and comparing to the discount rate selected by management.

/s/ Deloitte & Touche LLP

Dallas, Texas

May 9, 2022

We have served as the Company's auditor since 1968.

McKESSON CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS
(In millions, except per share amounts)

	Years Ended March 31,		
	2022	2021	2020
Revenues	\$ 263,966	\$ 238,228	\$ 231,051
Cost of sales	(250,836)	(226,080)	(219,028)
Gross profit	13,130	12,148	12,023
Selling, distribution, general, and administrative expenses	(10,537)	(8,849)	(9,182)
Claims and litigation charges, net	(274)	(7,936)	(82)
Goodwill impairment charges	—	(69)	(2)
Restructuring, impairment, and related charges, net	(281)	(334)	(268)
Total operating expenses	(11,092)	(17,188)	(9,534)
Operating income (loss)	2,038	(5,040)	2,489
Other income, net	259	223	12
Equity earnings and charges from investment in Change Healthcare Joint Venture	—	—	(1,108)
Loss on debt extinguishment	(191)	—	—
Interest expense	(178)	(217)	(249)
Income (loss) from continuing operations before income taxes	1,928	(5,034)	1,144
Income tax benefit (expense)	(636)	695	(18)
Income (loss) from continuing operations	1,292	(4,339)	1,126
Loss from discontinued operations, net of tax	(5)	(1)	(6)
Net income (loss)	1,287	(4,340)	1,120
Net income attributable to noncontrolling interests	(173)	(199)	(220)
Net income (loss) attributable to McKesson Corporation	\$ 1,114	\$ (4,539)	\$ 900
Earnings (loss) per common share attributable to McKesson Corporation			
Diluted			
Continuing operations	\$ 7.26	\$ (28.26)	\$ 4.99
Discontinued operations	(0.03)	—	(0.04)
Total	\$ 7.23	\$ (28.26)	\$ 4.95
Basic			
Continuing operations	\$ 7.35	\$ (28.26)	\$ 5.01
Discontinued operations	(0.03)	—	(0.03)
Total	\$ 7.32	\$ (28.26)	\$ 4.98
Weighted-average common shares outstanding			
Diluted	154.1	160.6	181.6
Basic	152.3	160.6	180.6

See Financial Notes

McKESSON CORPORATION

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(In millions)

	Years Ended March 31,		
	2022	2021	2020
Net income (loss)	\$ 1,287	\$ (4,340)	\$ 1,120
Other comprehensive income, net of tax			
Foreign currency translation adjustments	60	184	(66)
Unrealized gains (losses) on cash flow hedges	14	(36)	86
Changes in retirement-related benefit plans	41	22	129
Other comprehensive income, net of tax	115	170	149
Comprehensive income (loss)	1,402	(4,170)	1,269
Comprehensive income attributable to noncontrolling interests	(172)	(146)	(223)
Comprehensive income (loss) attributable to McKesson Corporation	\$ 1,230	\$ (4,316)	\$ 1,046

See Financial Notes

McKESSON CORPORATION

CONSOLIDATED BALANCE SHEETS
(In millions, except per share amounts)

	March 31,	
	2022	2021
ASSETS		
Current assets		
Cash and cash equivalents	\$ 3,532	\$ 6,278
Receivables, net	18,583	19,181
Inventories, net	18,702	19,246
Assets held for sale	4,516	12
Prepaid expenses and other	898	665
Total current assets	46,231	45,382
Property, plant, and equipment, net	2,092	2,581
Operating lease right-of-use assets	1,548	2,100
Goodwill	9,451	9,493
Intangible assets, net	2,059	2,878
Other non-current assets	1,917	2,581
Total assets	\$ 63,298	\$ 65,015
LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS, AND EQUITY (DEFICIT)		
Current liabilities		
Drafts and accounts payable	\$ 38,086	\$ 38,975
Current portion of long-term debt	799	742
Current portion of operating lease liabilities	297	390
Liabilities held for sale	4,741	9
Other accrued liabilities	4,543	3,987
Total current liabilities	48,466	44,103
Long-term debt	5,080	6,406
Long-term deferred tax liabilities	1,418	1,411
Long-term operating lease liabilities	1,366	1,867
Long-term litigation liabilities	7,220	8,067
Other non-current liabilities	1,540	1,715
Commitments and contingent liabilities (Note 18)		
Redeemable noncontrolling interests	—	1,271
McKesson Corporation stockholders' deficit		
Preferred stock, \$0.01 par value, 100 shares authorized, no shares issued or outstanding	—	—
Common stock, \$0.01 par value, 800 shares authorized, 275 and 273 shares issued at March 31, 2022 and 2021, respectively	2	2
Additional paid-in capital	7,275	6,925
Retained earnings	9,030	8,202
Accumulated other comprehensive loss	(1,534)	(1,480)
Treasury shares, at cost, 130 and 115 shares at March 31, 2022 and 2021, respectively	(17,045)	(13,670)
Total McKesson Corporation stockholders' deficit	(2,272)	(21)
Noncontrolling interests	480	196
Total equity (deficit)	(1,792)	175
Total liabilities, redeemable noncontrolling interests, and equity (deficit)	\$ 63,298	\$ 65,015

See Financial Notes

McKESSON CORPORATION

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)
(In millions, except per share amounts)

	McKesson Corporation Stockholders' Equity (Deficit)									
	Common Stock		Additional Paid-in Capital	Other Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury		Noncontrolling Interests	Total Equity (Deficit)
	Shares	Amount					Common Shares	Amount		
Balances, March 31, 2019	271	\$ 3	\$ 6,435	\$ (2)	\$ 12,409	\$ (1,849)	(81)	\$ (8,902)	\$ 193	\$ 8,287
Opening retained earnings adjustments: adoption of new accounting standards	—	—	—	—	11	—	—	—	—	11
Balances, April 1, 2019	271	3	6,435	(2)	12,420	(1,849)	(81)	(8,902)	193	8,298
Issuance of shares under employee plans, net of forfeitures	1	—	113	—	—	—	—	(20)	—	93
Share-based compensation	—	—	115	—	—	—	—	—	—	115
Payments to noncontrolling interests	—	—	—	—	—	—	—	—	(154)	(154)
Other comprehensive income	—	—	—	—	—	146	—	—	—	146
Net income	—	—	—	—	900	—	—	—	178	1,078
Repurchase of common stock	—	—	—	—	—	—	(14)	(1,934)	—	(1,934)
Change Healthcare share exchange	—	—	—	—	—	—	(15)	(2,036)	—	(2,036)
Cash dividends declared, \$1.62 per common share	—	—	—	—	(294)	—	—	—	—	(294)
Other	—	(1)	—	2	(4)	—	—	—	—	(3)
Balances, March 31, 2020	272	2	6,663	—	13,022	(1,703)	(110)	(12,892)	217	5,309
Opening retained earnings adjustments: adoption of new accounting standard	—	—	—	—	(13)	—	—	—	—	(13)
Balances, April 1, 2020	272	2	6,663	—	13,009	(1,703)	(110)	(12,892)	217	5,296
Issuance of shares under employee plans, net of forfeitures	1	—	92	—	—	—	—	(28)	—	64
Share-based compensation	—	—	151	—	—	—	—	—	—	151
Payments to noncontrolling interests	—	—	—	—	—	—	—	—	(177)	(177)
Other comprehensive income	—	—	—	—	—	223	—	—	—	223
Net income (loss)	—	—	—	—	(4,539)	—	—	—	156	(4,383)
Exercise of put right by noncontrolling shareholders of McKesson Europe AG	—	—	3	—	—	—	—	—	—	3
Repurchase of common stock	—	—	—	—	—	—	(5)	(750)	—	(750)
Cash dividends declared, \$1.67 per common share	—	—	—	—	(270)	—	—	—	—	(270)
Other	—	—	16	—	2	—	—	—	—	18
Balances, March 31, 2021	273	2	6,925	—	8,202	(1,480)	(115)	(13,670)	196	175
Issuance of shares under employee plans, net of forfeitures	2	—	220	—	—	—	—	(71)	—	149
Share-based compensation	—	—	154	—	—	—	—	—	—	154
Payments to noncontrolling interests	—	—	—	—	—	—	—	—	(155)	(155)
Other comprehensive income (loss)	—	—	—	—	—	116	—	—	(4)	112
Net income	—	—	—	—	1,114	—	—	—	165	1,279
Exercise of put right by noncontrolling shareholders of McKesson Europe AG	—	—	178	—	—	(170)	—	—	—	8
Repurchase of common stock	—	—	(204)	—	—	—	(15)	(3,304)	—	(3,508)
Reclassification of McKesson Europe AG redeemable noncontrolling interests	—	—	—	—	—	—	—	—	287	287
Reclassification of recurring compensation to other accrued liabilities	—	—	—	—	—	—	—	—	(7)	(7)
Cash dividends declared, \$1.83 per common share	—	—	—	—	(279)	—	—	—	—	(279)
Other	—	—	2	—	(7)	—	—	—	(2)	(7)
Balances, March 31, 2022	275	\$ 2	\$ 7,275	\$ —	\$ 9,030	\$ (1,534)	(130)	\$ (17,045)	\$ 480	\$ (1,792)

See Financial Notes

McKESSON CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions)

	Years Ended March 31,		
	2022	2021	2020
OPERATING ACTIVITIES			
Net income (loss)	\$ 1,287	\$ (4,340)	\$ 1,120
Adjustments to reconcile to net cash provided by operating activities:			
Depreciation	279	321	321
Amortization	481	566	601
Goodwill and long-lived asset impairment charges	175	242	139
Equity earnings and charges from investment in Change Healthcare Joint Venture	—	—	1,084
Deferred taxes	34	(908)	(342)
Credits associated with last-in, first-out inventory method	(23)	(38)	(252)
Non-cash operating lease expense	241	334	366
Loss (gain) from sales of businesses and investments	(132)	(9)	33
European businesses held for sale	1,509	—	—
Other non-cash items	501	188	615
Changes in assets and liabilities, net of acquisitions:			
Receivables	(1,843)	1,145	(2,494)
Inventories	(1,169)	(2,276)	(376)
Drafts and accounts payable	2,802	1,267	3,952
Operating lease liabilities	(356)	(362)	(377)
Taxes	243	(166)	(8)
Litigation liabilities	199	8,067	—
Other	206	511	(8)
Net cash provided by operating activities	4,434	4,542	4,374
INVESTING ACTIVITIES			
Payments for property, plant, and equipment	(388)	(451)	(362)
Capitalized software expenditures	(147)	(190)	(144)
Acquisitions, net of cash, cash equivalents, and restricted cash acquired	(6)	(35)	(133)
Proceeds from sales of businesses and investments, net	578	400	37
Other	(126)	(139)	23
Net cash used in investing activities	(89)	(415)	(579)
FINANCING ACTIVITIES			
Proceeds from short-term borrowings	11,192	6,323	21,437
Repayments of short-term borrowings	(11,192)	(6,323)	(21,437)
Proceeds from issuances of long-term debt	498	500	—
Repayments of long-term debt	(1,648)	(1,040)	(298)
Payments for debt extinguishments	(184)	—	—
Common stock transactions:			
Issuances	220	92	113
Share repurchases	(3,516)	(742)	(1,934)
Dividends paid	(277)	(276)	(294)
Exercise of put right by noncontrolling shareholders of McKesson Europe AG	(1,031)	(49)	(3)
Other	(383)	(178)	(318)
Net cash used in financing activities	(6,321)	(1,693)	(2,734)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	55	(61)	(19)
Cash, cash equivalents, and restricted cash classified within Assets held for sale	(540)	—	—
Net increase (decrease) in cash, cash equivalents, and restricted cash	(2,461)	2,373	1,042
Cash, cash equivalents, and restricted cash at beginning of year	6,396	4,023	2,981
Cash, cash equivalents, and restricted cash at end of year	3,935	6,396	4,023
Less: Restricted cash at end of year included in Prepaid expenses and other	(403)	(118)	(8)
Cash and cash equivalents at end of year	\$ 3,532	\$ 6,278	\$ 4,015
SUPPLEMENTAL CASH FLOW INFORMATION			
Cash paid for:			
Interest, net	\$ 186	\$ 220	\$ 235
Income taxes, net of refunds	359	379	368

See Financial Notes

McKESSON CORPORATION

FINANCIAL NOTES

1. Significant Accounting Policies

Nature of Operations: McKesson Corporation (“McKesson,” or the “Company,”) is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. McKesson’s teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable. The Company reports its financial results in four reportable segments: U.S. Pharmaceutical, Prescription Technology Solutions (“RxTS”), Medical-Surgical Solutions, and International. The Company’s equity method investment in Change Healthcare LLC (“Change Healthcare JV”), which was split-off from McKesson in the fourth quarter of 2020, has been included in Other for retrospective periods presented. Refer to Financial Note 21, “Segments of Business,” for additional information.

Basis of Presentation: The consolidated financial statements and accompanying notes are prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“GAAP”). The consolidated financial statements of McKesson include the financial statements of all wholly-owned subsidiaries and majority-owned or controlled companies. For those consolidated subsidiaries where the Company’s ownership is less than 100%, the portion of the net income or loss allocable to the noncontrolling interests is reported as “Net income attributable to noncontrolling interests” in the Consolidated Statements of Operations. All significant intercompany balances and transactions have been eliminated in consolidation, including the intercompany portion of transactions with equity method investees.

The Company considers itself to control an entity if it is the majority owner of or has voting control over such entity. The Company also assesses control through means other than voting rights and determines which business entity is the primary beneficiary of the variable interest entity (“VIE”). The Company consolidates VIEs when it is determined that it is the primary beneficiary of the VIE. Investments in business entities in which the Company does not have control but has the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method.

Fiscal Period: The Company’s fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year shall mean the Company’s fiscal year.

Reclassifications: Certain prior period amounts have been reclassified to conform to the current year presentation.

Use of Estimates: The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. Actual amounts could differ from those estimated amounts. The Company continues to evaluate the ongoing impacts, including the economic consequences, of the pandemic caused by the SARS-CoV-2 coronavirus (“COVID-19”). As COVID-19 further evolves, the Company’s accounting estimates and assumptions may change over time and may change materially in future periods.

Cash and Cash Equivalents: All highly liquid debt and money market instruments purchased with an original maturity of three months or less at the date of acquisition are included in cash and cash equivalents. Cash equivalents are carried at fair value. Cash equivalents are primarily invested in AAA-rated U.S. government money market funds and overnight deposits with financial institutions. Deposits with financial institutions are primarily denominated in U.S. dollars and the functional currencies of the Company’s foreign subsidiaries, including Euro, British pound sterling, and Canadian dollars. Deposits may exceed the amounts insured by the Federal Deposit Insurance Corporation in the U.S. and similar deposit insurance programs in other jurisdictions. The Company mitigates the risk of its short-term investment portfolio by depositing funds with reputable financial institutions and monitoring risk profiles and investment strategies of money market funds.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

Restricted Cash: Cash that is subject to legal restrictions or is unavailable for general operating purposes is classified as restricted cash and is included in “Prepaid expenses and other” and “Other non-current assets” in the Consolidated Balance Sheets. Restricted cash at March 31, 2022 primarily consists of \$395 million held in escrow related to obligations under settlement agreements for opioid-related claims of governmental entities, as discussed in more detail in Financial Note 18, “Commitments and Contingent Liabilities.” Additionally, restricted cash at March 31, 2022 and 2021 includes funds temporarily held on behalf of unaffiliated medical practice groups related to their COVID-19 business continuity borrowings. These amounts have been designated as restricted cash due to contractual provisions requiring their segregation from all other funds until utilized by the medical practices for a limited list of qualified activities. Corresponding deposit liabilities associated with these funds have been recorded by the Company within “Other accrued liabilities” in the Company’s Consolidated Balance Sheets at March 31, 2022 and 2021.

Equity Method Investments: Investments in business entities in which the Company does not have control, but has the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method. The Company evaluates its equity method investments for impairment whenever an event or change in circumstances occurs that may have a significant adverse impact on the carrying value of the investment. If a loss in value has occurred that is deemed to be other-than-temporary, an impairment loss is recorded.

Receivables, Net and Allowances for Credit Losses: The Company’s receivables are presented net of an allowance for credit losses and primarily consist of trade accounts receivable from customers that result from the sale of goods and services. Receivables, net also includes other receivables, which primarily represent amounts due from suppliers.

We are exposed to credit losses on accounts receivable balances. The Company estimates credit losses by considering historical credit losses, the current economic environment, customer credit ratings, legal disputes, or bankruptcies, as well as reasonable and supportable forecasts. Management reviews these factors quarterly to determine if any adjustments are needed to the allowance.

Trade accounts receivable represent the majority of the Company’s financial assets, for which an allowance for credit losses of \$89 million and \$198 million were included in “Receivables, net” on the Consolidated Balance Sheets as of March 31, 2022 and 2021, respectively. Changes in the allowance for the year ended March 31, 2022, were primarily within the U.S Pharmaceutical and International segments.

The following table presents the components of the Company’s receivables as of March 31, 2022 and 2021:

<i>(In millions)</i>	March 31,	
	2022	2021
Customer accounts	\$ 16,438	\$ 17,106
Other	2,289	2,325
Total receivables	18,727	19,431
Allowances	(144)	(250)
Receivables, net	\$ 18,583	\$ 19,181

McKESSON CORPORATION

FINANCIAL NOTES (Continued)

Concentrations of Credit Risk and Receivables: The Company's trade accounts receivable are subject to concentrations of credit risk with customers primarily in its U.S. Pharmaceutical segment. During 2022, sales to the Company's ten largest customers, including group purchasing organizations ("GPOs"), accounted for approximately 52% of its total consolidated revenues and approximately 43% of total trade accounts receivable at March 31, 2022. Sales to the Company's largest customer, CVS Health Corporation ("CVS"), accounted for approximately 21% of its total consolidated revenues in 2022 and comprised approximately 28% of total trade accounts receivable at March 31, 2022. As a result, the Company's sales and credit concentration is significant. The Company has agreements with GPOs, each of which functions as a purchasing agent on behalf of member hospitals, pharmacies, and other healthcare providers, as well as with government entities and agencies. The accounts receivables balances are with individual members of the GPOs, and therefore no significant concentration of credit risk exists. A material default in payment, a material reduction in purchases from GPOs or any other large customers, or the loss of a large customer or customer groups could have a material adverse impact on the Company's financial condition, results of operations, and liquidity. In addition, trade accounts receivables are subject to concentrations of credit risk with customers in the institutional, retail, and healthcare provider sectors, which can be affected by a downturn in the economy and changes in reimbursement policies. This credit risk is mitigated by the size and diversity of the Company's customer base as well as its geographic dispersion.

Inventories: Inventories consist of merchandise held for resale. The Company reports inventories at the lower of cost or net realizable value, except for inventories determined using the last-in, first-out ("LIFO") method which are valued at the lower of LIFO cost or market. The LIFO method presumes that the most recent inventory purchases are the first items sold and the inventory cost under LIFO approximates market. The majority of the cost of domestic inventories is determined using the LIFO method. The majority of the cost of inventories held in foreign and certain domestic locations is based on the first-in, first-out ("FIFO") method and weighted-average purchase prices. Rebates, cash discounts, and other incentives received from vendors are recognized in cost of sales upon the sale of the related inventory.

At March 31, 2022 and 2021, total inventories, net were \$18.7 billion and \$19.2 billion, respectively, in the Company's Consolidated Balance Sheets. The LIFO method was used to value approximately 63% and 58% of the Company's inventories at March 31, 2022 and 2021, respectively. If the Company had used the moving average method of inventory valuation, inventories would have been approximately \$383 million and \$406 million higher than the amounts reported at March 31, 2022 and 2021, respectively. These amounts are equivalent to the Company's LIFO reserves. The Company's LIFO valuation amount includes both pharmaceutical and non-pharmaceutical products. The Company recognized LIFO credits of \$23 million, \$38 million, and \$252 million in 2022, 2021, and 2020, respectively, in "Cost of sales" in its Consolidated Statements of Operations. The lower LIFO credits in 2022 compared to 2021 and 2020 is primarily due to higher brand inflation and delays of branded off-patent to generic drug launches. A LIFO charge is recognized when the net effect of price increases on pharmaceutical and non-pharmaceutical products held in inventory exceeds the impact of price declines, including the effect of branded pharmaceutical products that have lost market exclusivity. A LIFO credit is recognized when the net effect of price declines exceeds the impact of price increases on pharmaceutical and non-pharmaceutical products held in inventory.

The Company believes that the moving average inventory costing method provides a reasonable estimation of the current cost of replacing inventory (i.e., "market"). As such, its LIFO inventory is valued at the lower of LIFO cost or market. As of March 31, 2022 and 2021, inventories at LIFO did not exceed market.

Shipping and Handling Costs: The Company includes costs to pack and deliver inventory to its customers in "Selling, distribution, general, and administrative expenses" in its Consolidated Statements of Operations. Shipping and handling costs of \$1.1 billion was recognized in 2022, and \$1.0 billion was recognized in each of 2021 and 2020.

Held for Sale: Assets and liabilities to be disposed of by sale ("disposal groups") are classified as "held for sale" if their carrying amounts are principally expected to be recovered through a sale transaction rather than through continuing use. The classification occurs when the disposal group is available for immediate sale and the sale is probable. These criteria are generally met when management has committed to a plan to sell the assets within one year. Disposal groups are measured at the lower of carrying amount or fair value less costs to sell, and long-lived assets included within the disposal group are not depreciated or amortized. The fair value of a disposal group, less any costs to sell, is assessed each reporting period it remains classified as held for sale and any remeasurement to the lower of carrying value or fair value less costs to sell is reported as an adjustment to the carrying value of the disposal group. When the net realizable value of a disposal group increases during a period, a gain can be recognized to the extent that it does not increase the value of the disposal group beyond its original carrying value when the disposal group was reclassified as held for sale. Refer to Financial Note 2, "Held for Sale," for additional information.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

Property, Plant, and Equipment, Net: Property, plant, and equipment, net is stated at historical cost and depreciated under the straight-line method over the estimated useful life of each asset, which ranges from 15 to 30 years for building and improvements and 3 to 15 years for machinery, equipment, and other. Leasehold improvements and property, plant, and equipment, net under finance leases are amortized over their respective useful lives of the right-of-use (“ROU”) asset or over the term of the lease, whichever is shorter. Depreciation and amortization begins when an asset is placed in service and ready for its intended use. Repairs and maintenance costs are expensed as incurred. When certain events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable, an impairment assessment may be performed on the recoverability of the carrying amounts.

The following table presents the components of the Company’s property, plant, and equipment, net as of March 31, 2022 and 2021:

(In millions)	March 31,	
	2022	2021
Land	\$ 104	\$ 156
Building and improvements	1,331	1,745
Machinery, equipment, and other	2,338	2,512
Construction in progress	313	382
Total property, plant, and equipment	4,086	4,795
Accumulated depreciation and amortization	(1,994)	(2,214)
Property, plant, and equipment, net	\$ 2,092	\$ 2,581

Total depreciation expense for property, plant, and equipment, net and amortization of the ROU assets of finance leases was \$312 million, \$344 million, and \$335 million for the years ended March 31, 2022, 2021, and 2020, respectively.

Leases: The Company leases facilities and equipment primarily under operating leases. The Company recognizes lease expense on a straight-line basis over the term of the lease, taking into account, when applicable, lessor incentives for tenant improvements, periods where no rent payment is required, and escalations in rent payments over the term of the lease. As a practical expedient, the Company does not separate lease components from non-lease components, such as common area maintenance, utilities, and repairs and maintenance. Remaining terms for facility leases generally range from one to 15 years, while remaining terms for equipment leases generally range from one to five years. Most real property leases contain renewal options (typically for five-year increments). Generally, the renewal option periods are not included within the lease term as the Company is not reasonably certain to exercise that right at lease commencement. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.

Operating ROU assets and operating lease liabilities are recognized at the lease commencement date. ROU assets represent the Company’s right to use an underlying asset for the lease term and operating lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease liabilities are recognized based on the present value of the future lease payments over the lease term, discounted at the Company’s incremental borrowing rate as the implicit rate in the lease is not readily determinable for most of the Company’s leases. The Company estimates the discount rate as its incremental borrowing rate based on qualitative factors including Company specific credit rating, lease term, general economics, and the interest rate environment. For existing leases that commenced prior to the adoption of the amended leasing guidance, the Company determined the discount rate on April 1, 2019 using the full lease term. Operating lease liabilities are recorded in “Current portion of operating lease liabilities” and “Long-term operating lease liabilities,” and the corresponding lease assets are recorded in “Operating lease right-of-use assets” in the Company’s Consolidated Balance Sheets. Finance lease assets are included in “Property, plant, and equipment, net” and finance lease liabilities are included in “Current portion of long-term debt” and “Long-term debt” in the Company’s Consolidated Balance Sheets. As a practical expedient, short-term leases with an initial term of 12 months or less are excluded from the Consolidated Balance Sheets and charges from these leases are expensed as incurred.

As a lessor, the Company primarily leases certain owned equipment, classified as direct financing or sales-type leases, to physician practices.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

Refer to Financial Note 10, “Leases,” for additional information on the Company’s leases.

Goodwill: Goodwill is tested for impairment on an annual basis in the third quarter and more frequently if indicators of potential impairment exist. Impairment testing is conducted at the reporting unit level, which is generally defined as an operating segment or one level below an operating segment (also known as a component), for which discrete financial information is available and segment management regularly reviews the operating results.

The Company applies the goodwill impairment test by comparing the estimated fair value of a reporting unit to its carrying value and recording an impairment charge equal to the amount of excess carrying value above estimated fair value, if any, but not to exceed the amount of goodwill allocated to the reporting unit.

To estimate the fair value of its reporting units, the Company generally uses a combination of the market approach and the income approach. Under the market approach, it estimates fair value by comparing the business to similar businesses, or guideline companies whose securities are actively traded in public markets. Under the income approach, it uses a discounted cash flow (“DCF”) model in which cash flows anticipated over future periods, plus a terminal value at the end of that time horizon, are discounted to their present value using an appropriate rate that is commensurate with the risk inherent within the reporting unit. Other estimates inherent in both the market and income approaches include long-term growth rates, projected revenues, and earnings and cash flow forecasts for the reporting units. In addition, the Company compares the aggregate of the reporting units’ fair values to the Company’s market capitalization as a further corroboration of the fair values. Goodwill testing requires a complex series of assumptions and judgments by management in projecting future operating results, selecting guideline companies for comparisons and assessing risks. The use of alternative assumptions and estimates could affect the fair values and change the impairment determinations.

Intangible Assets: Currently all of the Company’s intangible assets are subject to amortization and are amortized based on the pattern of their economic consumption or on a straight-line basis over their estimated useful lives, ranging from one to 24 years. The Company reviews intangible assets for impairment at an asset group level whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Determination of recoverability is based on the lowest level of identifiable estimated future undiscounted cash flows resulting from use of the asset and its eventual disposition. Measurement of any impairment loss is based on the excess of the carrying value of the asset group over its estimated fair market value.

Capitalized Software Held for Internal Use: The Company capitalizes costs of software held for internal use during the application development stage of a project and amortizes those costs using the straight-line method over their estimated useful lives, not to exceed 10 years. As of March 31, 2022 and 2021, capitalized software held for internal use was \$320 million and \$513 million, respectively, net of accumulated amortization of \$1.4 billion, and is included in “Other non-current assets” in the Consolidated Balance Sheets. The decrease in capitalized software held for internal use is primarily due to the planned exit of the Company’s European businesses which resulted in an impairment of certain internal-use software that will not be utilized in the future and classification of certain software as held for sale, as discussed in Note 2, “Held for Sale.” Costs incurred during the preliminary project and post-implementation stages are expensed as incurred. Amortization expense for capitalized software held for internal use was \$116 million, \$117 million, and \$129 million for the years ended March 31, 2022, 2021, and 2020, respectively.

Insurance Programs: The Company maintains insurance programs through its wholly-owned captive insurance subsidiaries (“Captives”) from which it obtains coverage for various exposures, including certain exposures arising from the opioid-related claims of governmental entities against the Company as discussed in more detail in Financial Note 18, “Commitments and Contingent Liabilities,” as well as those risks required to be insured by law or contract. It is the Company’s policy to retain a significant portion of certain losses, including those related to workers’ compensation and comprehensive general, product, and vehicle liability. Provisions for losses expected under insurance programs are recorded based on the Company’s estimate of the aggregate liability for claims incurred as well as for claims incurred but not yet reported. Such estimates utilize certain actuarial assumptions followed in the insurance industry. The Captives receive direct premiums, which are eliminated on consolidation against the Company’s premium costs within “Selling, distribution, general, and administrative expenses” in the Consolidated Statements of Operations.

Revenue Recognition: Revenue is recognized when an entity satisfies a performance obligation by transferring control of a promised good or service to a customer in an amount that reflects the consideration to which the entity expects to be entitled for that good or service.

McKESSON CORPORATION**FINANCIAL NOTES (Continued)**

Revenues generated from the distribution of pharmaceutical and medical products represent the majority of the Company's revenues. The Company orders product from the manufacturer, receives and carries the product at its central distribution facilities, and delivers the product directly to its customers' warehouses, hospitals, or retail pharmacies. The distribution business primarily generates revenue from a contract related to a confirmed purchase order with a customer in a distribution arrangement. Revenue is recognized when control of goods is transferred to the customer which occurs upon the Company's delivery to the customer or upon customer pick-up. The Company also earns revenues from a variety of other sources including its retail, services, and technology businesses. Retail revenues are recognized at the point of sale. Service revenues, including technology service revenues, are recognized when services are rendered. Revenues derived from distribution and retail business at the point of sale, and revenues derived from services represent approximately 98% and 2% of total revenues for each of the years ended March 31, 2022, 2021, and 2020.

Revenues are recorded gross when the Company is the principal in the transaction, has the ability to direct the use of the goods or services prior to transfer to a customer, is responsible for fulfilling the promise to its customer, has latitude in establishing prices, and controls the relationship with the customer. The Company records its revenues net of sales taxes. Revenues are measured based on the amount of consideration that the Company expects to receive, reduced by estimates for return allowances, discounts, and rebates using historical data. Sales returns from customers were approximately \$3.2 billion in 2022 and \$3.1 billion in each of 2021 and 2020. Assets for the right to recover products from customers and the associated refund liabilities for return allowances were not material as of March 31, 2022 and 2021. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as fulfillment costs. The Company records deferred revenues when payments are received or due in advance of its performance. Deferred revenues are primarily from the Company's services arrangements and are recognized as revenues over the periods when services are performed.

The Company had no material contract assets, contract liabilities, or deferred contract costs recorded in its Consolidated Balance Sheets as of March 31, 2022 and 2021. The Company generally expenses costs to obtain a contract as incurred when the amortization period is less than one year.

Supplier Incentives: Fees for services and other incentives received from suppliers, relating to the purchase or distribution of inventory, are considered product discounts and are generally reported as a reduction to cost of sales.

Supplier Reserves: The Company establishes reserves against amounts due from suppliers relating to various fees for services and price and rebate incentives, including deductions taken against payments otherwise due to it. These reserve estimates are established based on judgment after considering the status of current outstanding claims, historical experience with the suppliers, the specific incentive programs, and any other pertinent information available. The Company evaluates the amounts due from suppliers on a continual basis and adjusts the reserve estimates when appropriate based on changes in facts and circumstances. Adjustments to supplier reserves are generally included in cost of sales unless consideration from the vendor is in exchange for distinct goods or services or for pass-through rebate purchases. The ultimate outcome of any outstanding claims may be different than the Company's estimate. The supplier reserves primarily pertain to the Company's U.S. Pharmaceutical segment.

Income Taxes: The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or the tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statements and the tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon effective settlement.

Interest Expense: Interest expense primarily includes interest for the Company's long-term debt obligations, commercial paper, net interest settlements of interest rate swaps, and the amortization of deferred issuance costs and original issue discounts on debt.

McKESSON CORPORATION**FINANCIAL NOTES (Continued)**

Foreign Currency Translation: The reporting currency of the Company and its subsidiaries is the U.S. dollar. Its foreign subsidiaries generally consider their local currency to be their functional currency. Foreign currency-denominated assets and liabilities of these foreign subsidiaries are translated into U.S. dollars at period-end exchange rates, while revenues and expenses are translated at average exchange rates during the corresponding period and stockholders' equity (deficit) accounts are primarily translated at historical exchange rates. Foreign currency translation adjustments are included in "Other comprehensive income, net of tax" in the Consolidated Statements of Comprehensive Income (Loss), and the cumulative effect is included in the stockholders' equity (deficit) section of the Consolidated Balance Sheets. Realized gains and losses from currency exchange transactions are recorded in "Selling, distribution, general, and administrative expenses" in the Consolidated Statements of Operations and were not material in 2022, 2021, or 2020. The Company releases cumulative translation adjustments from stockholders' equity into earnings as a gain or loss only upon a complete or substantially complete liquidation of a controlling interest in a subsidiary or a group of assets within a foreign entity. It also releases all or a pro-rata portion of the cumulative translation adjustments into earnings upon the sale of an equity method investment that is a foreign entity or has a foreign component.

Derivative Financial Instruments: Derivative financial instruments are used principally in the management of foreign currency exchange and interest rate exposures and are recorded in the Consolidated Balance Sheets at fair value. If a derivative is designated as a fair value hedge, the changes in the fair value of the derivative and of the hedged item attributable to the hedged risk are recognized in earnings. The Company uses foreign currency-denominated notes and cross-currency swaps to hedge a portion of its net investment in its foreign subsidiaries. It uses cash flow hedges primarily to reduce the effects of foreign currency exchange rate risk related to intercompany loans denominated in non-functional currencies. If the financial instrument is designated as a cash flow hedge or net investment hedge, the effective portions of changes in the fair value of the derivative are included in "Other comprehensive income, net of tax" in the Consolidated Statements of Comprehensive Income (Loss), and the cumulative effect is included in the stockholders' equity (deficit) section of the Consolidated Balance Sheets. The cumulative changes in fair value are reclassified to the same line as the hedged item in the Consolidated Statements of Operations when the hedged item affects earnings. The Company evaluates hedge effectiveness at inception and on an ongoing basis, and ineffective portions of changes in the fair value of cash flow hedges and net investment hedges are recognized in earnings following the date when ineffectiveness was identified. Derivative instruments not designated as hedges are marked-to-market at the end of each accounting period with the change included in earnings. Refer to Financial Note 15, "Hedging Activities," for additional information.

Comprehensive Income (Loss): Comprehensive income (loss) consists of two components: net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) refers to revenue, expenses, as well as gains and losses that are recorded as an element of stockholders' equity (deficit) but are excluded from earnings. The Company's other comprehensive income (loss) primarily consists of foreign currency translation adjustments from those subsidiaries where the local currency is the functional currency, including gains and losses on net investment hedges, as well as unrealized gains and losses on cash flow hedges and unrealized gains and losses on retirement-related benefit plans.

Noncontrolling Interests and Redeemable Noncontrolling Interests: Noncontrolling interests represent the portion of profit or loss, net assets, and comprehensive income or loss that is not allocable to McKesson Corporation. Net income attributable to noncontrolling interests includes recurring compensation that McKesson is obligated to pay to the noncontrolling shareholders of McKesson Europe AG ("McKesson Europe"), formerly known as Celesio AG, under the domination and profit and loss transfer agreement. Net income attributable to noncontrolling interests also includes third-party equity interests in the Company's consolidated entities including Vantage Oncology Holdings, LLC ("Vantage") and ClarusONE Sourcing Services LLP ("ClarusONE"), which was established between McKesson and Walmart, Inc in 2017. Noncontrolling interests with redemption features, such as put rights, that are not solely within the Company's control are considered redeemable noncontrolling interests. Redeemable noncontrolling interests are presented outside of stockholders' equity (deficit) in the Company's Consolidated Balance Sheets. Refer to Financial Note 8, "Redeemable Noncontrolling Interests and Noncontrolling Interests," for additional information.

Share-Based Compensation: The Company accounts for all share-based compensation transactions at fair value. The share-based compensation expense, for the portion of the awards that is ultimately expected to vest, is recognized on a straight-line basis over the requisite service period. The share-based compensation expense recognized is classified in the Consolidated Statements of Operations in the same manner as cash compensation paid to the Company's employees. Refer to Financial Note 5, "Share-Based Compensation," for additional information.

McKESSON CORPORATION**FINANCIAL NOTES (Continued)**

Loss Contingencies: The Company is subject to various claims, including, but not limited to, claims with customers and vendors, pending and potential legal actions for damages, investigations relating to governmental laws and regulations, and other matters arising out of the normal conduct of its business. When a loss is considered probable and reasonably estimable, the Company records a liability in the amount of its best estimate for the ultimate loss. However, the likelihood of a loss with respect to a particular contingency is often difficult to predict and determining a meaningful estimate of the loss or a range of loss may not be practicable based on the information available and the potential effect of future events and decisions by third parties that will determine the ultimate resolution of the contingency. Moreover, it is not uncommon for such matters to be resolved over many years, during which time relevant developments and new information must be reevaluated at least quarterly to determine both the likelihood of potential loss and whether it is possible to reasonably estimate the loss or a range of possible loss. When a material loss is reasonably possible or probable, but a reasonable estimate cannot be made, disclosure of the proceeding is provided. The Company recognizes legal fees as incurred when the legal services are provided.

The Company reviews all material contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or a range of the loss can be made. As discussed above, development of a meaningful estimate of loss or a range of potential loss is complex when the outcome is directly dependent on negotiations with or decisions by third parties, such as regulatory agencies, the court system, and other interested parties. Refer to Financial Note 18, “Commitments and Contingent Liabilities,” for additional information related to ongoing controlled substances claims to which the Company is a party.

Restructuring Charges: Employee severance costs are generally recognized when payments are probable and amounts are reasonably estimable. Costs related to contracts without future benefit or contract termination are recognized at fair value at the earlier of the contract termination or the cease-use dates. Other exit-related costs are expensed as incurred. Refer to Financial Note 3, “Restructuring, Impairment, and Related Charges, Net,” for additional information.

Business Combinations: The Company accounts for business combinations using the acquisition method of accounting whereby the identifiable assets and liabilities of the acquired business, as well as any noncontrolling interest in the acquired business, are recorded at their estimated fair values as of the date that the Company obtains control of the acquired business. Any purchase consideration in excess of the estimated fair values of the net assets acquired is recorded as goodwill. Acquisition-related expenses and related restructuring costs are expensed as incurred.

Several valuation methods may be used to determine the fair value of assets acquired and liabilities assumed. For intangible assets, the Company typically uses a method that is a form or variation of the income approach, whereby a forecast of future cash flows attributable to the asset are discounted to present value using a risk-adjusted discount rate. Some of the more significant estimates and assumptions inherent in the income approach include the amount and timing of projected future cash flows, the discount rate selected to measure the risks inherent in the future cash flows, and the assessment of the asset’s expected useful life.

Treasury Stock: We record purchases of treasury stock at cost, which is reflected as a reduction to stockholders’ equity in the Company’s Consolidated Balance Sheets. Incremental direct costs to purchase treasury stock are included in the cost of the shares acquired. Treasury stock also includes shares withheld to satisfy the tax obligations of recipients of share-based compensation.

Recently Adopted Accounting Pronouncements

In the first quarter of 2022, the Company prospectively adopted Accounting Standards Update (“ASU”) 2019-12, *Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes*, which eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. The guidance also simplifies and clarifies certain other aspects of accounting for income taxes. The adoption of this amended guidance did not have a material impact on the Company’s consolidated financial statements or disclosures.

Recently Issued Accounting Pronouncements Not Yet Adopted

There were no recently issued accounting standards that could have a material impact to the Company’s financial position, results of operations, cash flows, or notes to the financial statements upon their adoption.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

2. Held for Sale

In July 2021, the Company announced its intention to exit its businesses in Europe (“European Divestiture Activities”). These activities, further described below, constitute the majority of the assets and liabilities classified as held for sale as of March 31, 2022. Total assets and liabilities that have met the classification as held for sale were \$4.5 billion and \$4.7 billion, respectively, as of March 31, 2022 and \$12 million and \$9 million, respectively, as of March 31, 2021, primarily included within the Company’s International segment. The Company determined that the disposal groups classified as held for sale do not meet the criteria for classification as discontinued operations. During the year ended March 31, 2022, the Company recorded charges totaling \$1.6 billion, primarily to remeasure the assets and liabilities of the disposal groups to fair value less costs to sell. These charges were largely driven by declines in the British pound sterling and the Euro. During the years ended March 31, 2021 and 2020, the Company recorded losses of \$58 million and \$275 million, respectively, related to the contribution of a majority of its German pharmaceutical wholesale business to a joint venture with Walgreens Boots Alliance (“WBA”) which was completed on November 1, 2020. These charges in each year were recorded within “Selling, distribution, general, and administrative expenses” in the Consolidated Statements of Operations.

European Divestiture Activities

On July 5, 2021, the Company entered into an agreement to sell certain of its businesses in the European Union (“E.U.”) located in France, Italy, Ireland, Portugal, Belgium, and Slovenia, along with its German headquarters and wound-care business, part of a shared services center in Lithuania, and its ownership stake in a joint venture in the Netherlands (“E.U. disposal group”) to the PHOENIX Group for a purchase price of €1.2 billion (or, approximately \$1.4 billion) adjusted for certain items, including cash, net debt, and working capital adjustments, and reduced by the value of the noncontrolling interest held by minority shareholders of McKesson Europe AG (“McKesson Europe”) at the transaction closing date. The transaction is anticipated to close within the second half of fiscal year 2023, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approvals, as applicable.

During the year ended March 31, 2022, the Company recorded charges totaling \$438 million to remeasure the E.U. disposal group to fair value less costs to sell. These charges also included impairments of individual assets, such as certain internal-use software that will not be utilized in the future, prior to adjusting the E.U. disposal group as a whole. The remeasurement adjustment includes net losses of \$151 million related to the accumulated other comprehensive income balances associated with the E.U. disposal group, driven by declines in the Euro. The charges were recorded within “Selling, distribution, general, and administrative expenses” in the Consolidated Statement of Operations. The Company’s measurement of the fair value of the E.U. disposal group was based on the total consideration expected to be received by the Company as outlined in the transaction agreement. Certain components of the total consideration included fair value measurements that fall within Level 3 of the fair value hierarchy.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

The total assets and liabilities of the E.U. disposal group that have met the classification of held for sale in the Company's Consolidated Balance Sheet are as follows:

<i>(In millions)</i>	March 31, 2022
Assets	
Current assets	
Receivables, net	\$ 1,322
Inventories, net	809
Prepaid expenses and other	72
Property, plant, and equipment, net	304
Operating lease right-of-use assets	224
Intangible assets, net	267
Other non-current assets	328
Remeasurement of assets of businesses held for sale to fair value less costs to sell ⁽¹⁾	(302)
Total assets held for sale	<u>\$ 3,024</u>
Liabilities	
Current liabilities	
Drafts and accounts payable	\$ 1,826
Current portion of long-term debt	4
Current portion of operating lease liabilities	33
Other accrued liabilities	473
Long-term debt	11
Long-term deferred tax liabilities	55
Long-term operating lease liabilities	180
Other non-current liabilities	138
Total liabilities held for sale	<u>\$ 2,720</u>

(1) Excludes charges related to the impairment of individual assets, which are primarily comprised of a \$113 million impairment of internally developed software recorded directly against the gross value of the assets impacted.

On November 1, 2021, the Company announced an agreement to sell its retail and distribution businesses in the United Kingdom ("U.K. disposal group") to Aurelius Elephant Limited. In April 2022, the Company entered into an amendment to the agreement for a purchase price of £110 million (or, approximately \$144 million), including certain adjustments. During the year ended March 31, 2022, the Company recorded charges totaling \$1.2 billion, primarily consisting of adjustments to remeasure the U.K. disposal group to fair value less costs to sell. The remeasurement adjustments include a \$734 million loss related to the accumulated other comprehensive income balances associated with the U.K. disposal group, driven by declines in the British pound sterling. The charges were recorded within "Selling, distribution, general, and administrative expenses" in the Consolidated Statement of Operations. The Company's measurement of the fair value of the U.K. disposal group was based on the total consideration expected to be received by the Company as outlined in the transaction agreement. Certain components of the total consideration included fair value measurements that fall within Level 3 of the fair value hierarchy. The transaction closed on April 6, 2022 and, at closing the buyer assumed and repaid a note payable to the Company of approximately \$118 million.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

The total assets and liabilities of the U.K. disposal group that have met the classification of held for sale in the Company's Consolidated Balance Sheet are as follows:

<i>(In millions)</i>	March 31, 2022
Assets	
Current assets	
Cash and cash equivalents	\$ 531
Receivables, net	931
Inventories, net	563
Prepaid expenses and other	50
Property, plant, and equipment, net	91
Operating lease right-of-use assets	270
Intangible assets, net	117
Other non-current assets	88
Remeasurement of assets of businesses held for sale to fair value less costs to sell	(1,159)
Total assets held for sale	<u>\$ 1,482</u>
Liabilities	
Current liabilities	
Drafts and accounts payable	\$ 1,593
Current portion of operating lease liabilities	50
Other accrued liabilities	59
Long-term deferred tax liabilities	16
Long-term operating lease liabilities	262
Other non-current liabilities	38
Total liabilities held for sale	<u>\$ 2,018</u>

On January 31, 2022, the Company completed the sale of its Austrian business to Quadrifolia Management GmbH in a management-led buyout for a purchase price of €244 million (or, approximately \$276 million), including certain adjustments. The Company divested net assets of the Austrian business of \$272 million, primarily within the International segment, and the buyer assumed a note payable to the Company of approximately \$63 million which was paid to McKesson in the fourth quarter of 2022. During the year ended March 31, 2022, the Company recognized a loss of \$32 million which was recorded within "Selling, distribution, general, and administrative expenses" in the Consolidated Statement of Operations.

German Pharmaceutical Wholesale Joint Venture

On November 1, 2020, the Company completed a transaction with WBA whereby the majority of its German pharmaceutical wholesale business was contributed to a newly formed joint venture in which McKesson had a 30% noncontrolling interest.

Transaction consideration for the contribution included a receivable amount of \$41 million, primarily related to working capital and net debt adjustments from WBA, which was received in the first quarter of 2022, and the 30% interest in the newly formed joint venture. At the transaction date, the carrying value of the equity investment in the joint venture was recorded at its fair value, which was measured using inputs that fell within Level 3 of the fair value hierarchy. The carrying value of the investment in the joint venture was nil as of March 31, 2021. The Company accounted for its interest in the joint venture as an equity method investment within the International segment. The joint venture also assumed a note payable to the Company in the amount of approximately \$291 million as of the transaction date, which was paid to the Company in 2021.

McKESSON CORPORATION**FINANCIAL NOTES (Continued)**

In conjunction with the contribution, the Company recorded losses of \$58 million and \$275 million, respectively, in the years ended March 31, 2021 and 2020, which included adjustments to remeasure the assets and liabilities held for sale to fair value less costs to sell. These charges were included within “Selling, distribution, general, and administrative expenses” in the Consolidated Statements of Operations. The Company’s measurement of the fair value of the German pharmaceutical wholesale business disposal group was based on estimates of total consideration to be received by the Company as outlined in the contribution agreement between the Company and WBA.

3. Restructuring, Impairment, and Related Charges, Net

The Company recorded restructuring, impairment, and related charges, net, of \$281 million, \$334 million, and \$268 million in 2022, 2021, and 2020, respectively. These charges are included in “Restructuring, impairment, and related charges, net” in the Consolidated Statements of Operations. In addition, for the years ended March 31, 2021 and 2020, certain charges related to restructuring initiatives were included in “Cost of sales” in the Consolidated Statements of Operations and were not material.

Restructuring Initiatives

During the first quarter of 2022, the Company approved an initiative to increase operational efficiencies and flexibility by transitioning to a partial remote work model for certain employees. This initiative primarily included the rationalization of the Company’s office space in North America. Where the Company ceased using office space, it exited the portion of the facility no longer used. It also retained and repurposed certain other office locations. The Company recorded charges of \$124 million for the year ended March 31, 2022, primarily related to lease right-of-use and other long-lived asset impairments, lease exit costs, and accelerated depreciation and amortization. This initiative was substantially complete in 2022 after which immaterial charges will continue to be incurred through the termination date of certain leases.

During the first quarter of 2021, the Company committed to an initiative within the United Kingdom (“U.K.”), which is included in the Company’s International segment, to further drive operational changes in technologies and business processes, efficiencies, and cost savings. The initiative included reducing the number of retail pharmacy stores, decommissioning obsolete technologies and processes, reorganizing and consolidating certain business operations, and related headcount reductions. Charges incurred for this initiative were not material for the year ended March 31, 2022 and were \$57 million for the year ended March 31, 2021, primarily related to asset impairments and accelerated depreciation expense as well as employee severance and other employee-related costs. This initiative was substantially complete in 2022 and remaining costs the Company expects to record under this initiative are not material.

During the fourth quarter of 2019, the Company committed to certain programs to continue its operating model and cost optimization efforts. The Company continues to implement centralization of certain functions and outsourcing through an expanded arrangement with a third-party vendor to achieve operational efficiency. The programs also include reorganization and consolidation of business operations, related headcount reductions, the further closures of retail pharmacy stores in Europe, and closures of other facilities. The Company recorded charges of \$62 million and \$72 million in 2021 and 2020, respectively, consisting primarily of employee severance, accelerated depreciation expense, and project consulting fees. This initiative was substantially complete in 2021 and remaining costs the Company recorded under this initiative were not material.

As previously announced on November 30, 2018, the Company relocated its corporate headquarters, effective April 1, 2019, from San Francisco, California to Irving, Texas to improve efficiency, collaboration, and cost competitiveness. As a result, the Company recorded charges of \$28 million and \$44 million in 2021 and 2020, respectively, consisting primarily of employee retention expenses, severance, long-lived asset impairments, and accelerated depreciation. The relocation was substantially complete in January 2021 and remaining costs the Company recorded under this initiative, primarily relating to lease costs, were not material.

On April 25, 2018, the Company announced a strategic growth initiative intended to drive long-term incremental profit growth and to increase operational efficiency. The initiative consisted of multiple growth priorities and plans to optimize the Company’s operating models and cost structures primarily through centralization, cost management, and outsourcing of certain administrative functions. As part of the growth initiative, the Company committed to implement certain actions including a reduction in workforce, facility consolidation, and store closures. This set of initiatives was substantially complete by the end of 2020 and charges in 2021 were not material. The Company recorded charges of \$15 million in 2020.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

Fiscal 2022

Restructuring, impairment, and related charges, net for the year ended March 31, 2022 consisted of the following:

		Year Ended March 31, 2022					
<i>(In millions)</i>	U.S. Pharmaceutical	Prescription Technology Solutions	Medical-Surgical Solutions	International	Corporate	Total	
Severance and employee-related costs, net	\$ 8	\$ 1	\$ (1)	\$ 8	\$ (7)	\$ 9	
Exit and other-related costs ⁽¹⁾	9	4	5	33	46	97	
Asset impairments and accelerated depreciation ⁽²⁾	18	20	5	35	61	139	
Total	\$ 35	\$ 25	\$ 9	\$ 76	\$ 100	\$ 245	

- (1) Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. For the Company's International segment, costs primarily relate to optimization programs in Canada, exit-related actions for the Company's European Divestiture Activities, and programs for operating model and cost optimization efforts in the U.K. as described above. For Corporate, primarily represents costs related to the transition to the partial remote work model described above and various other initiatives.
- (2) Costs primarily relate to the transition to the partial remote work model described above.

Fiscal 2021

Restructuring, impairment, and related charges, net for the year ended March 31, 2021 consisted of the following:

		Year Ended March 31, 2021					
<i>(In millions)</i>	U.S. Pharmaceutical	Prescription Technology Solutions	Medical-Surgical Solutions	International ⁽¹⁾	Corporate ⁽²⁾	Total	
Severance and employee-related costs, net	\$ 10	\$ 4	\$ (1)	\$ 22	\$ 69	\$ 104	
Exit and other-related costs ⁽³⁾	11	—	4	17	27	59	
Asset impairments and accelerated depreciation	—	—	1	46	9	56	
Total	\$ 21	\$ 4	\$ 4	\$ 85	\$ 105	\$ 219	

- (1) Primarily represents costs associated with the operating model and cost optimization efforts described above.
- (2) Represents costs associated with the operating model cost optimization efforts and the relocation of the Company's headquarters described above in addition to various other initiatives.
- (3) Exit and other-related costs primarily include project consulting fees.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

Fiscal 2020

Restructuring, impairment, and related charges, net for the year ended March 31, 2020 consisted of the following:

<i>(In millions)</i>	Year Ended March 31, 2020					
	U.S. Pharmaceutical ⁽¹⁾	Prescription Technology Solutions	Medical-Surgical Solutions ⁽²⁾	International ⁽³⁾	Corporate ⁽⁴⁾	Total
Severance and employee-related costs, net	\$ 12	\$ (1)	\$ 4	\$ 2	\$ 30	\$ 47
Exit and other-related costs ⁽⁵⁾	1	—	19	13	46	79
Asset impairments and accelerated depreciation	10	—	1	6	13	30
Total	\$ 23	\$ (1)	\$ 24	\$ 21	\$ 89	\$ 156

(1) Represents costs associated with dispositions and costs related to the relocation of the Company's corporate headquarters described above.

(2) Primarily represents costs associated with the growth initiative described above.

(3) Primarily represents costs associated with the operating model and cost optimization efforts described above.

(4) Represents costs associated with the growth initiative, operating model cost optimization efforts, and with the relocation of the Company's corporate headquarters described above.

(5) Exit and other-related costs primarily include project consulting fees.

The following table summarizes the activity related to the restructuring liabilities associated with the Company's restructuring initiatives for the years ended March 31, 2022 and 2021:

<i>(In millions)</i>	U.S. Pharmaceutical	Prescription Technology Solutions	Medical-Surgical Solutions	International	Corporate	Total
Balance, March 31, 2020	\$ 29	\$ 1	\$ 22	\$ 66	\$ 39	\$ 157
Restructuring, impairment, and related charges, net	21	4	4	85	105	219
Non-cash charges	—	—	(1)	(46)	(9)	(56)
Cash payments	(31)	(1)	(21)	(31)	(75)	(159)
Other	—	—	(1)	(8)	(1)	(10)
Balance, March 31, 2021 ⁽¹⁾	19	4	3	66	59	151
Restructuring, impairment, and related charges, net	35	25	9	76	100	245
Non-cash charges	(18)	(20)	(5)	(35)	(61)	(139)
Cash payments	(18)	(6)	(6)	(28)	(29)	(87)
Other	(7)	—	—	(23)	(10)	(40)
Balance, March 31, 2022 ⁽²⁾	\$ 11	\$ 3	\$ 1	\$ 56	\$ 59	\$ 130

(1) As of March 31, 2021, the total reserve balance was \$151 million, of which \$99 million was recorded in "Other accrued liabilities" and \$52 million was recorded in "Other non-current liabilities" in the Company's Consolidated Balance Sheets.

(2) As of March 31, 2022, the total reserve balance was \$130 million, of which \$58 million was recorded in "Other accrued liabilities," \$36 million was recorded in "Liabilities held for sale," and \$36 million was recorded in "Other non-current liabilities" in the Company's Consolidated Balance Sheets.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

Long-Lived Asset Impairments*Fiscal 2022*

In 2022, the Company recognized charges totaling \$36 million to impair certain long-lived assets within the International segment related to the Company's operations in Denmark and its retail pharmacy businesses in Canada. The Company used an income approach (a DCF method) and a market approach to estimate the fair value of the long-lived assets.

Fiscal 2021

In 2021, the Company recognized charges of \$115 million to impair certain long-lived assets within the Company's International segment. These charges primarily related to long-lived assets associated with the Company's retail pharmacy businesses in Canada and Europe and were due to declines in estimated future cash flows partially driven by a revised outlook regarding the impacts of COVID-19. The Company used both an income approach and a market approach to estimate the fair value of the long-lived assets.

Fiscal 2020

In 2020, the Company recognized charges of \$82 million to impair certain long-lived and intangible assets for its retail pharmacy business in Europe within the Company's International segment. These charges related primarily to intangible assets associated with pharmacy licenses within the U.K. retail business due to a decline in estimated future cash flows driven by additional U.K. government reimbursement reductions communicated in the third quarter of 2020. The Company used a combination of an income approach and a market approach to estimate the fair value of the long-lived and intangible assets.

In 2020, the Company performed an interim impairment test of long-lived and intangible assets for its Rexall Health retail business, within the Company's International segment, due to the decline in the estimated future cash flows primarily driven by lower than expected growth in both prescription volume and sales of non-prescription goods. As a result, the Company recognized a charge of \$30 million to impair certain long-lived and intangible assets, primarily customer relationships. The Company used an income approach for estimating the fair value of the long-lived and intangible assets.

4. Business Acquisitions and Divestitures**Acquisitions**

During 2022, 2021, and 2020, the Company did not complete any material acquisitions. For the three years presented, the Company completed several de minimis acquisitions within its operating segments. Financial results for the Company's business acquisitions have been included in the Company's consolidated financial statements since their respective acquisition dates. Purchase prices for business acquisitions have been allocated based on estimated fair values at the respective acquisition dates. Goodwill recognized for business acquisitions is generally not expected to be deductible for tax purposes. However, if the assets of another company are acquired, the goodwill may be deductible for tax purposes.

Divestitures

In July 2021, the Company announced its intention to exit its businesses in Europe. In 2022, the Company entered into agreements to sell the E.U. disposal group and U.K. disposal group and completed the previously announced sale of its Austrian business, as described in Financial Note 2, "Held for Sale." In 2021, the Company contributed the majority of its German pharmaceutical wholesale business to a newly formed joint venture with WBA as discussed in Financial Note 2, "Held for Sale," and, in 2022, sold its interest in the joint venture to WBA, as described in Financial Note 6, "Other Income, Net." In 2020, the Company completed the separation of the Change Healthcare JV, as described below.

Investment in the Change Healthcare Joint Venture

In the fourth quarter of 2017, the Company contributed the majority of its McKesson Technology Solutions businesses to form a joint venture, the Change Healthcare JV, under a contribution agreement between McKesson and Change Healthcare Inc. ("Change") and others, including shareholders of Change. In exchange for the contribution, the Company initially owned approximately 70% of the joint venture, with the remaining equity ownership of approximately 30% held by Change. The Change Healthcare JV was jointly governed by McKesson and shareholders of Change.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

On June 27, 2019, common stock and certain other securities of Change began trading on the NASDAQ (“IPO”). Change was a holding company and did not own any material assets or have any operations other than its interest in the Change Healthcare JV. On July 1, 2019, upon the completion of its IPO, Change contributed net cash proceeds it received from its offering of common stock to the Change Healthcare JV in exchange for additional membership interests of the Change Healthcare JV (“LLC Units”). As a result, McKesson’s equity interest in the Change Healthcare JV was diluted from approximately 70% to approximately 58.5%. Accordingly, in the second quarter of 2020, the Company recognized a dilution loss of \$246 million, primarily representing the difference between its proportionate share of the IPO proceeds and the dilution effect on the investment’s carrying value. This amount was included in “Equity earnings and charges from investment in Change Healthcare Joint Venture” in the Company’s Consolidated Statement of Operations for the year ended March 31, 2020.

In the second quarter of 2020, the Company recorded an other-than-temporary impairment (“OTTI”) charge of \$1.2 billion to its investment in the Change Healthcare JV, representing the difference between the carrying value of the Company’s investment and the fair value derived from the corresponding closing price of Change’s common stock at September 30, 2019. This charge was included in “Equity earnings and charges from investment in Change Healthcare Joint Venture” in the Company’s Consolidated Statement of Operations for the year ended March 31, 2020.

Separation of the Change Healthcare Joint Venture

On March 10, 2020, the Company completed the separation of its interest in the Change Healthcare JV. The separation was affected through the split-off of PF2 SpinCo, Inc. (“SpinCo”), a wholly-owned subsidiary of the Company that held all of the Company’s interest in the Change Healthcare JV, to certain of the Company’s stockholders through an exchange offer (“Split-off”), followed by the merger of SpinCo with and into Change, with Change surviving the merger (“Merger”).

In connection with the Split-off, on March 9, 2020, the Company distributed all 176.0 million outstanding shares of common stock of SpinCo to participating holders of the Company’s common stock in exchange for 15.4 million shares of McKesson common stock which now are held as treasury stock on the Company’s Consolidated Balance Sheets. Refer to Financial Note 19, “Stockholders’ Equity (Deficit),” for more information. Following consummation of the exchange offer, on March 10, 2020, SpinCo was merged with and into Change Healthcare, and each share of SpinCo common stock converted into one share of Change common stock, par value \$0.001 per share, with cash being paid in lieu of fractional shares of Change common stock. The Split-off and the Merger are intended to be generally tax-free transactions for U.S. federal income tax purposes. Following the Split-off, the Company does not beneficially own any of Change’s outstanding securities. In the fourth quarter of 2020, the Company recognized a net gain of \$414 million related to the transaction which is included under the caption “Equity earnings and charges from investment in Change Healthcare Joint Venture” in the Company’s Consolidated Statement of Operations for the year ended March 31, 2020. The net gain was calculated as follows:

(In millions, except per share data)

Fair value of McKesson common stock accepted (15.4 million shares at \$131.97 per share on March 9, 2020)	\$	2,036
Investment in the Change Healthcare JV at exchange date		(2,096)
Reversal of deferred tax liability ⁽¹⁾		521
Release of accumulated other comprehensive loss attributable to the joint venture		(24)
Less: Transaction costs incurred		(23)
Net gain on split-off of the Change Healthcare JV	\$	414

- (1) Under the agreement with the Change Healthcare JV, McKesson, Change, and certain subsidiaries of the Change Healthcare JV, there may be changes in future periods to the amount reversed as the relevant periods are audited by tax authorities. Any such change is not expected to have a material impact on the Company’s consolidated financial statements.

Equity Method Investment in the Change Healthcare Joint Venture

Until the separation of the Company’s interest in the Change Healthcare JV, this investment was accounted for using the equity method of accounting. Effective April 1, 2019, the Change Healthcare JV adopted the amended revenue recognition guidance and, in the first quarter of 2020, the Company recorded its proportionate share of the joint venture’s adoption impact of the amended revenue recognition guidance of approximately \$80 million, net of tax, in the Company’s opening retained earnings.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

Excluding the OTTI and transaction-related items described above, the Company recorded its proportionate share of loss from its investment in the Change Healthcare JV of \$119 million in 2020, which includes transaction and integration expenses incurred by the Change Healthcare JV and basis differences between the joint venture and McKesson, including amortization of fair value adjustments primarily representing incremental intangible amortization and removal of profit associated with the recognition of deferred revenue. This amount was recorded under the caption “Equity earnings and charges from investment in Change Healthcare Joint Venture” in the Company’s Consolidated Statement of Operations for the year ended March 31, 2020.

Related Party Transactions

In connection with the formation of the Change Healthcare JV, McKesson, the Change Healthcare JV, and certain shareholders of Change entered into various ancillary agreements, including a transition services agreement (“TSA”), a transaction and advisory fee agreement (“Advisory Agreement”), a tax receivable agreement (“TRA”) and certain other agreements. The Advisory Agreement was terminated in 2020 and fees incurred or earned from the agreement were not material for 2020. Fees incurred or earned from the TSA were not material in 2022 nor 2021 and were \$22 million in 2020.

Under the TRA, McKesson had the ability to adjust the manner in which certain depreciation or amortization deductions are allocated among Change and McKesson. McKesson exercised its right under the agreement and allocated certain depreciation and amortization deductions to Change for the tax year ended March 31, 2020.

After McKesson’s separation of its interest in the Change Healthcare JV, the aforementioned TRA agreement requires the Change Healthcare JV to pay McKesson 85% of the net cash tax savings realized, or deemed to be realized, by Change resulting from the depreciation or amortization allocated to Change by McKesson. The receipt of any payments from the Change Healthcare JV under the TRA is dependent upon Change benefiting from this depreciation or amortization in future tax return filings. This creates uncertainty over the amount, timing, and probability of the gain recognized. As such, the Company accounts for the TRA as a gain contingency, with no receivable recognized as of March 31, 2022 or 2021.

5. Share-Based Compensation

The Company provides share-based compensation to its employees, officers, and non-employee directors, including restricted stock units (“RSUs”), performance-based stock units (“PSUs”), stock options, and an employee stock purchase plan (“ESPP”) (collectively, “share-based awards”). Most of the share-based awards are granted in the first quarter of each fiscal year.

Compensation expense for the share-based awards is recognized for the portion of awards ultimately expected to vest. The Company estimates the number of share-based awards that will ultimately vest primarily based on historical experience. The estimated forfeiture rate established upon grant is re-assessed throughout the requisite service period and is adjusted when actual forfeitures occur. The actual forfeitures in future reporting periods could be higher or lower than current estimates.

Compensation expense is classified in the Consolidated Statements of Operations in the same manner as cash compensation paid to the Company’s employees.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

Impact on Net Income

The components of share-based compensation expense and related tax benefits are as follows:

<i>(In millions)</i>	Years Ended March 31,		
	2022	2021	2020
Restricted stock unit awards ⁽¹⁾	\$ 148	\$ 137	\$ 104
Stock options	2	4	7
Employee stock purchase plan	11	10	8
Share-based compensation expense	161	151	119
Tax benefit for share-based compensation expense ⁽²⁾	(35)	(23)	(18)
Share-based compensation expense, net of tax	\$ 126	\$ 128	\$ 101

(1) Includes compensation expense recognized for RSUs and PSUs.

(2) Income tax benefit is computed using the tax rates of applicable tax jurisdictions. Additionally, a portion of compensation expense is not tax-deductible. Income tax expense for 2022, 2021, and 2020 included discrete income tax expense of \$10 million, \$2 million, and \$2 million, respectively.

Stock Plans

In July 2013, the Company's stockholders approved the 2013 Stock Plan to replace the 2005 Stock Plan. Under these stock plans, the Company may issue restricted stock, RSUs, PSUs, stock options, and other share-based awards to selected employees, officers, and non-employee directors. The 2013 Stock Plan reserves 30 million shares plus unused reserved shares under the 2005 Stock Plan. As of March 31, 2022, 19 million shares remain available for future grant under the 2013 Stock Plan.

Restricted Stock Unit Awards

RSUs entitle the holder to receive a specified number of shares of the Company's common stock which vest over a period of generally three to four years as determined by the Compensation Committee at the time of grant. The fair value of the award is determined based on the price of the Company's common stock on the grant date and the related compensation expense is recognized over the vesting period on a straight-line basis.

Non-employee directors receive an annual grant of RSUs, which vest immediately and are expensed upon grant. The director may elect to receive the underlying shares immediately or defer receipt of the shares if they meet director stock ownership guidelines. The shares will be automatically deferred for those directors who do not meet the director stock ownership guidelines. At March 31, 2022, approximately 57,000 RSUs for the Company's directors are vested.

PSUs are conditional upon the attainment of market and performance objectives over a specified period. The number of vested PSUs is assessed at the end of a three-year performance period upon attainment of meeting certain earnings per share targets, average return on invested capital, and for certain participants, total shareholder return relative to a peer group of companies and, for special PSUs granted in 2019, meeting certain cumulative operating profit metrics. The Company uses the Monte Carlo simulation model to measure the fair value of the total shareholder return portion of the PSUs. The earnings per share portion of the PSUs is measured at the grant date market price. PSUs have a requisite service period of generally three years. Expense is attributed to the requisite service period on a straight-line basis based on the fair value of the PSUs, adjusted for the performance modifier at the end of each reporting period. For PSUs that are designated as equity awards, the fair value is measured at the grant date.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

The weighted-average assumptions used in the Monte Carlo valuations are as follows:

	Years Ended March 31,		
	2022	2021	2020
Expected stock price volatility	35 %	36 %	30 %
Expected dividend yield	0.9 %	1.1 %	1.3 %
Risk-free interest rate	0.3 %	0.2 %	2.2 %
Expected life (in years)	3	3	3

The following table summarizes activity for restricted stock unit awards (RSUs and PSUs) during 2022:

(In millions, except per share data)	Shares	Weighted-Average Grant Date Fair Value Per Share
Nonvested, March 31, 2021	3	\$ 142.13
Granted	1	200.64
Cancelled	—	142.40
Vested	(1)	141.16
Nonvested, March 31, 2022	3	\$ 160.47

The following table provides data related to restricted stock unit award activity:

(In millions)	Years Ended March 31,		
	2022	2021	2020
Total fair value of shares vested	\$ 144	\$ 79	\$ 67
Total compensation cost, net of estimated forfeitures, related to nonvested restricted stock unit awards not yet recognized, pre-tax	\$ 165	\$ 147	\$ 155
Weighted-average period in years over which restricted stock unit award cost is expected to be recognized	2	2	3

Stock Options

Stock options are granted with an exercise price at no less than the fair market value and those options granted under the stock plans generally have a contractual term of seven years and follow a four-year vesting schedule. The Company did not grant any stock options during the years ended March 31, 2022, 2021, and 2020.

Compensation expense for stock options is recognized on a straight-line basis over the requisite service period and is based on the grant-date fair value for the portion of the awards that is ultimately expected to vest. The Company uses the Black-Scholes options-pricing model to estimate the fair value of its stock options. Once the fair value of an employee stock option is determined, current accounting practices do not permit it to be changed, even if the estimates used are different from actual.

The following is a summary of stock options outstanding at March 31, 2022:

Range of Exercise Prices	Options Outstanding			Options Exercisable	
	Number of Options Outstanding at Year End (In millions)	Weighted-Average Remaining Contractual Life (Years)	Weighted-Average Exercise Price	Number of Options Exercisable at Year End (In millions)	Weighted-Average Exercise Price
\$123.98 — \$159.00	1	3	\$ 150.35	1	\$ 152.20
159.00 — 237.86	—	1	201.56	—	201.56
	1			1	

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

The following table summarizes stock option activity during 2022:

<i>(In millions, except per share data)</i>	Shares	Weighted-Average Exercise Price	Weighted-Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value ⁽²⁾
Outstanding, March 31, 2021	2	\$ 183.29	2	\$ 36
Granted	—	—		
Cancelled	—	207.92		
Exercised	(1)	190.96		
Outstanding, March 31, 2022	1	\$ 175.23	2	\$ 114
Vested and expected to vest ⁽¹⁾	1	\$ 175.23	2	\$ 114
Vested and exercisable, March 31, 2022	1	178.48	2	101

(1) The number of options expected to vest takes into account an estimate of expected forfeitures.

(2) The intrinsic value is calculated as the difference between the period-end market price of the Company's common stock and the exercise price of "in-the-money" options.

The following table provides data related to stock option activity:

<i>(In millions, except per share data)</i>	Years Ended March 31,		
	2022	2021	2020
Weighted-average grant date fair value per stock option	\$ —	\$ —	\$ —
Aggregate intrinsic value on exercise	\$ 28	\$ 5	\$ 17
Cash received upon exercise	\$ 157	\$ 38	\$ 66
Tax benefits realized related to exercise	\$ 5	\$ 4	\$ 4
Total fair value of stock options vested	\$ 5	\$ 10	\$ 16
Total compensation cost, net of estimated forfeitures, related to unvested stock options not yet recognized, pre-tax	\$ —	\$ 2	\$ 6
Weighted-average period in years over which stock option compensation cost is expected to be recognized	0	2	2

Employee Stock Purchase Plan

The Company has an ESPP under which 21 million shares have been authorized for issuance. The ESPP allows eligible employees to purchase shares of the Company's common stock through payroll deductions. The deductions occur over three-month purchase periods and the shares are then purchased at 85% of the market price at the end of each purchase period. Employees are allowed to terminate their participation in the ESPP at any time during the purchase period prior to the purchase of the shares. The 15% discount provided to employees on these shares is included in compensation expense. The shares related to funds outstanding at the end of a quarter are included in the calculation of diluted weighted-average shares outstanding. These amounts have not been significant for all the years presented. The Company recognizes costs for employer matching contributions as ESPP expense over the relevant purchase period. Shares issued under the ESPP were not material in 2022, 2021, and 2020. At March 31, 2022, 2 million shares remain available for issuance.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

6. Other Income, Net

Other income, net consists of the following:

<i>(In millions)</i>	Years Ended March 31,		
	2022	2021	2020
Interest income	\$ 10	\$ 12	\$ 49
Equity in earnings, net ⁽¹⁾	43	48	36
Net gains on investments in equity securities ⁽²⁾	98	133	17
Actuarial gains (losses) from pension plans ⁽³⁾	5	—	(127)
Other, net ⁽⁴⁾	103	30	37
Total	\$ 259	\$ 223	\$ 12

(1) Primarily recorded within the Company's International segment.

(2) Represents net realized and unrealized gains on the Company's investments in equity securities of certain U.S. growth stage companies in the healthcare industry. These net gains primarily relate to mark-to-market adjustments for investments which are measured at fair value based on changes in the observable price of the securities and realized gains on disposal of certain of these investments. Refer to Financial Note 16, "Fair Value Measurements" and Financial Note 21, "Segments of Business" for more information.

(3) The year ended March 31, 2020 includes \$116 million from the termination of the U.S. defined benefit pension plan and \$11 million related to a settlement from the executive benefit retirement plan for a retired executive. Refer to Financial Note 14, "Pension Benefits" for more information.

(4) Includes a gain of \$42 million for the year ended March 31, 2022 as part of the completed sale of the Company's 30% interest in its German pharmaceutical wholesale joint venture to WBA. Other, net for all periods presented also includes income recognized from finance charges to customers primarily for late fees.

7. Income Taxes

<i>(In millions)</i>	Years Ended March 31,		
	2022	2021	2020
Income (loss) from continuing operations before income taxes			
U.S.	\$ 1,944	\$ (6,019)	\$ 216
Foreign	(16)	985	928
Income (loss) from continuing operations before income taxes	\$ 1,928	\$ (5,034)	\$ 1,144

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

Income tax expense (benefit) related to continuing operations consists of the following:

(In millions)	Years Ended March 31,		
	2022	2021	2020
Current			
Federal	\$ 233	\$ (15)	\$ 170
State	129	47	48
Foreign	240	181	142
Total current	602	213	360
Deferred			
Federal	88	(562)	(204)
State	(16)	(204)	(105)
Foreign	(38)	(142)	(33)
Total deferred	34	(908)	(342)
Income tax expense (benefit)	\$ 636	\$ (695)	\$ 18

The Company reported an income tax expense (benefit) rate of 33.0%, (13.8)%, and 1.6% in 2022, 2021, and 2020. Fluctuations in the Company's reported income tax rates are primarily due to non-cash charges related to remeasuring the value of certain of its European businesses to fair value less costs to sell in 2022, the impact of opioid-related claims, including charges of \$8.1 billion (\$6.8 billion after-tax) in 2021, the impact of the Change Healthcare joint venture divestiture in 2020, and changes in the mix of earnings between various taxing jurisdictions.

The reconciliation of income tax expense (benefit) and the amount computed by applying the statutory federal income tax rate of 21.0% to income before income taxes is as follows:

(In millions)	Years Ended March 31,		
	2022	2021	2020
Income tax expense (benefit) at federal statutory rate	\$ 405	\$ (1,057)	\$ 240
State income taxes, net of federal tax benefit	83	(206)	(41)
Tax effect of foreign operations	(186)	(77)	(81)
Unrecognized tax benefits and settlements	(26)	41	(7)
Opioid-related litigation and claims	38	715	—
Net tax benefit on intellectual property transfer	—	(105)	—
Tax-free gain on investment exit ⁽¹⁾	—	—	(87)
E.U. disposal transaction loss	345	—	—
Capital loss carryback	—	—	(19)
Other, net ⁽²⁾	(23)	(6)	13
Income tax expense (benefit)	\$ 636	\$ (695)	\$ 18

(1) Refer to Financial Note 4, "Business Acquisitions and Divestitures," for additional information regarding the separation of the Change Healthcare JV.

(2) The Company's effective tax rates were impacted by other favorable U.S. federal permanent differences including research and development credits of \$4 million, \$5 million, and \$7 million in 2022, 2021, and 2020.

During the year ended March 31, 2022, the Company recorded non-deductible, non-cash pre-tax charges of \$438 million primarily to remeasure the E.U. disposal group to fair value less costs to sell, and \$1.2 billion to remeasure the U.K. disposal group, as described in Financial Note 2, "Held for Sale."

McKESSON CORPORATION

FINANCIAL NOTES (Continued)

The Company's reported income tax rates for 2021 and 2020 were unfavorably impacted by non-deductible, non-cash charges of \$58 million and \$275 million, respectively, primarily to remeasure the carrying value of assets and liabilities held for sale related to the formation of a new German pharmaceutical wholesale joint venture within the Company's International segment. Refer to Financial Note 2, "Held for Sale," for more information.

The Company's reported income tax rates for 2022 and 2021 were impacted by the charge for pending and future opioid-related claims of \$274 million (\$237 million after-tax) and \$8.1 billion (\$6.8 billion after-tax), respectively, as described further in Financial Note 18, "Commitments and Contingent Liabilities."

During 2021, the Company sold intellectual property between wholly-owned legal entities within McKesson that are based in different tax jurisdictions. The transferor entity recognized a gain on the sale of assets which was not subject to income tax in its local jurisdiction; such gains were eliminated upon consolidation. The acquiring entities of the intellectual property were entitled to amortize the purchase price of the assets for tax purposes. In accordance with ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory," discrete tax benefits of \$105 million was recognized for 2021, with a corresponding increase to a deferred tax assets for the temporary difference arising from the buyer's excess tax basis.

On March 10, 2020, the Company completed the previously announced separation of its interest in the Change Healthcare JV as described in Financial Note 4, "Business Acquisitions and Divestitures." The Company's reported income tax expense rate for 2020 was favorably impacted by this transaction given that it was intended to generally be a tax-free split-off for U.S. federal income tax purposes. In the fourth quarter of 2020, the Company recognized a net gain for financial reporting purposes of \$414 million related to the separation transaction.

Deferred tax balances consisted of the following:

(In millions)	March 31,	
	2022	2021
Assets		
Receivable allowances	\$ 49	\$ 69
Opioid-related litigation and claims	755	724
Compensation and benefit related accruals	285	305
Net operating loss and credit carryforwards	739	974
Lease obligations	422	539
Other	83	115
Subtotal	2,333	2,726
Less: valuation allowance	(726)	(864)
Total assets	1,607	1,862
Liabilities		
Inventory valuation and other assets	(1,993)	(1,939)
Fixed assets and systems development costs	(184)	(196)
Intangibles	(233)	(411)
Lease right-of-use assets	(401)	(505)
Other	(17)	(37)
Total liabilities	(2,828)	(3,088)
Net deferred tax liability	\$ (1,221)	\$ (1,226)
Long-term deferred tax asset	\$ 197	\$ 185
Long-term deferred tax liability	(1,418)	(1,411)
Net deferred tax liability	\$ (1,221)	\$ (1,226)

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

Excluded from the amounts above were \$48 million of net deferred tax liabilities which were classified as held for sale for European divestitures at March 31, 2022, as discussed in Financial Note 2, “Held for Sale.”

The Company assesses the available positive and negative evidence to determine whether deferred tax assets are more likely than not to be realized. As a result of this assessment, valuation allowances have been recorded on certain deferred tax assets in various tax jurisdictions. The valuation allowances were approximately \$726 million and \$864 million in 2022 and 2021, respectively, and primarily relate to net operating and capital losses incurred in certain tax jurisdictions for which no tax benefit was recognized. The decrease in the valuation allowance of \$138 million in the current year relates primarily to classification of deferred tax balances as held for sale for European divestitures, as discussed in Financial Note 2, “Held for Sale,” partially offset by the net operating losses incurred and deferred tax movements in certain tax jurisdictions for which no tax benefit was recognized.

The Company has federal, state, and foreign net operating loss carryforwards of \$303 million, \$3.9 billion, and \$1.5 billion at March 31, 2022, respectively. Federal and state net operating losses will expire at various dates from 2023 through 2042. Substantially all its foreign net operating losses have indefinite lives. In addition, the Company has foreign capital loss carryforwards of \$785 million with indefinite lives.

The following table summarizes the activity related to the Company’s gross unrecognized tax benefits for the last three years:

<i>(In millions)</i>	Years Ended March 31,		
	2022	2021	2020
Unrecognized tax benefits at beginning of period	\$ 1,754	\$ 958	\$ 1,052
Additions based on tax positions related to prior years	14	53	20
Reductions based on tax positions related to prior years	(131)	(5)	(168)
Additions based on tax positions related to current year	14	755	82
Reductions based on settlements	(20)	(8)	(8)
Reductions based on the lapse of the applicable statutes of limitations	(102)	(12)	(13)
Exchange rate fluctuations	(6)	13	(7)
Unrecognized tax benefits at end of period	\$ 1,523	\$ 1,754	\$ 958

As of March 31, 2022, the Company had \$1.5 billion of unrecognized tax benefits, of which \$1.3 billion would reduce income tax expense and the effective tax rate, if recognized. The decrease in unrecognized tax benefits in 2022 compared to 2021 is primarily attributable to statute of limitation expirations in various taxing jurisdictions and the reclassification of \$23 million of unrecognized tax benefits as held for sale for European divestitures, as discussed in Financial Note 2, “Held for Sale.” The increase in unrecognized tax benefits in 2021 compared to 2020 is primarily attributable to uncertainty in connection with the deductibility of opioid-related litigation and claims. Because many uncertainties associated with any potential settlement arrangements or other resolutions of opioid claims including provisions related to deductibility have not been finalized, the actual amount of the tax benefit related to uncertain tax positions may differ from these estimates. Refer to Financial Note 18, “Commitments and Contingent Liabilities,” for more information.

During the next twelve months, it is reasonably possible that the Company’s unrecognized tax benefit may decrease by as much as \$170 million due to settlements of tax examinations and statute of limitations expirations in the U.S. federal and state jurisdictions and in foreign jurisdictions. However, this amount may change as the Company continues to have ongoing negotiations with various taxing authorities throughout the year.

The Company reports interest and penalties on income taxes as income tax expense. It recognized income tax expense of \$8 million, \$9 million, and \$23 million in 2022, 2021, and 2020, respectively, representing interest and penalties, in its Consolidated Statements of Operations. As of March 31, 2022 and 2021, it accrued \$108 million and \$101 million, cumulatively, in interest and penalties on unrecognized tax benefits.

McKESSON CORPORATION**FINANCIAL NOTES (Continued)**

The Company files income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. The Internal Revenue Service (“IRS”) is currently examining the Company’s U.S. corporation income tax returns for 2018 and 2019. The Company is generally subject to audit by taxing authorities in various U.S. states and in foreign jurisdictions for fiscal years 2014 through the current fiscal year.

Undistributed earnings of the Company’s foreign operations of approximately \$5.0 billion were considered indefinitely reinvested at March 31, 2022. Following enactment of the 2017 Tax Act, the repatriation of cash to the U.S. is generally no longer taxable for federal income tax purposes. However, the repatriation of cash held outside the U.S. could be subject to applicable foreign withholding taxes and state income taxes. The Company may remit foreign earnings to the U.S. to the extent it is tax efficient to do so. It does not expect the tax impact from remitting these earnings to be material.

8. Redeemable Noncontrolling Interests and Noncontrolling Interests*Redeemable Noncontrolling Interests*

The Company’s redeemable noncontrolling interests primarily related to its consolidated subsidiary, McKesson Europe. Under the December 2014 domination and profit and loss transfer agreement (the “Domination Agreement”), the noncontrolling shareholders of McKesson Europe are entitled to receive an annual recurring compensation amount of €0.83 per share. As a result, during 2022, 2021, and 2020, the Company recorded a total attribution of net income to the noncontrolling shareholders of McKesson Europe of \$8 million, \$43 million, and \$42 million, respectively. All amounts were recorded in “Net income attributable to noncontrolling interests” in the Company’s Consolidated Statements of Operations and the corresponding liability balance was recorded in “Other accrued liabilities” in the Company’s Consolidated Balance Sheets.

Under the Domination Agreement, the noncontrolling shareholders of McKesson Europe had a right to put (“Put Right”) their noncontrolling shares at €22.99 per share, increased annually for interest in the amount of five percentage points above a base rate published by the German Bundesbank semi-annually, less any compensation amount or guaranteed dividend already paid by McKesson with respect to the relevant time period (“Put Amount”).

Subsequent to the Domination Agreement’s registration, certain noncontrolling shareholders of McKesson Europe initiated appraisal proceedings (“Appraisal Proceedings”) with the Stuttgart Regional Court to challenge the adequacy of the Put Amount, annual recurring compensation amount, and/or the guaranteed dividend. During the pendency of the Appraisal Proceedings, such amount was paid as specified in the Domination Agreement. On September 19, 2018, that court ruled that the Put Amount shall be increased by €0.51 resulting in an adjusted Put Amount of €23.50. The annual recurring compensation amount and/or the guaranteed dividend remained unadjusted. Noncontrolling shareholders of McKesson Europe appealed this decision. McKesson Europe Holdings GmbH & Co. KGaA also appealed the decision. On April 12, 2021, the Company received notice that the Stuttgart Court of Appeals ruled that the Put Amount remained at €22.99, thereby rejecting the lower court’s increase, and the recurring compensation remained at €0.83 per share.

Exercises of the Put Right reduced the balance of redeemable noncontrolling interests. The redeemable noncontrolling interest was adjusted each period for the proportion of other comprehensive income or loss, primarily due to changes in foreign currency exchange rates, attributable to the noncontrolling shareholders.

During 2022 and 2021, the Company paid \$1.0 billion and \$49 million, respectively, to purchase 34.5 million and 1.8 million shares, respectively, of McKesson Europe through exercises of the Put Right by the noncontrolling shareholders. This decreased the carrying value of the noncontrolling interests by \$983 million and \$49 million, respectively, and the Company recorded the associated effect of the increase in the Company’s ownership interest of \$178 million and \$3 million, respectively, as an increase to McKesson stockholders’ additional paid-in capital. During 2020, there were no material exercises of the Put Right. The Put Right expired on June 15, 2021, at which point the remaining shares owned by the minority shareholders, with a carrying value of \$287 million, were transferred from “Redeemable noncontrolling interests” to “Noncontrolling interests” in the Consolidated Balance Sheet.

Prior to the expiration of the Put Right, the balance of the redeemable noncontrolling interests was reported at the greater of its carrying value or its maximum redemption value at each reporting date. At March 31, 2021, the carrying value of redeemable noncontrolling interests of \$1.3 billion exceeded the maximum redemption value of \$1.2 billion and the Company owned approximately 78% of McKesson Europe’s outstanding common shares.

McKESSEON CORPORATION
FINANCIAL NOTES (Continued)

Noncontrolling Interests

Noncontrolling interests represent third-party equity interests in the Company's consolidated entities primarily related to ClarusONE Sourcing Services LLP, and Vantage Oncology Holdings, LLC. As discussed above, after June 15, 2021, noncontrolling interests also include minority shareholder equity interests in McKesson Europe. Noncontrolling interests in the Company's Consolidated Balance Sheets were \$480 million and \$196 million at March 31, 2022 and 2021, respectively.

At March 31, 2022, the Company owned approximately 95% of McKesson Europe's outstanding common shares. The Company's noncontrolling interest in McKesson Europe will be included in the sale of the E.U. disposal group, as discussed in Financial Note 2, "Held for Sale." During 2022, 2021, and 2020, the Company allocated a total of \$165 million, \$156 million, and \$178 million of net income to noncontrolling interests, respectively.

Changes in redeemable noncontrolling interests and noncontrolling interests for the years ended March 31, 2022, 2021, and 2020 were as follows:

<i>(In millions)</i>	Noncontrolling Interests	Redeemable Noncontrolling Interests
Balance, March 31, 2019	\$ 193	\$ 1,393
Net income attributable to noncontrolling interests	178	42
Other comprehensive income	—	3
Reclassification of recurring compensation to other accrued liabilities	—	(42)
Payments to noncontrolling interests	(154)	—
Other	—	6
Balance, March 31, 2020	217	1,402
Net income attributable to noncontrolling interests	156	43
Other comprehensive loss	—	(79)
Reclassification of recurring compensation to other accrued liabilities	—	(43)
Payments to noncontrolling interests	(177)	—
Exercises of Put Right	—	(49)
Other	—	(3)
Balance, March 31, 2021	196	1,271
Net income attributable to noncontrolling interests	165	8
Other comprehensive income (loss)	(4)	3
Reclassification of recurring compensation to other accrued liabilities	(7)	(8)
Payments to noncontrolling interests	(155)	—
Exercises of Put Right	—	(983)
Reclassification of McKesson Europe redeemable noncontrolling interests	287	(287)
Other	(2)	(4)
Balance, March 31, 2022	\$ 480	\$ —

9. Earnings (Loss) Per Common Share

Basic earnings (loss) per common share are computed by dividing net income (loss) by the weighted-average number of common shares outstanding during the reporting period. The computation of diluted earnings (loss) per common share is similar to that of basic earnings (loss) per common share, except that the former reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. Potentially dilutive securities include outstanding stock options, restricted stock units, and performance-based and other restricted stock units.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

Diluted loss per common share for the year ended March 31, 2021 was calculated by excluding all dilutive securities from the denominator of the share computation due to their anti-dilutive effects. Approximately nil and 2 million of potentially dilutive securities for 2022 and 2020, respectively, were excluded from the computation of diluted net earnings per common share, as they were anti-dilutive.

The computations for basic and diluted earnings or loss per common share are as follows:

<i>(In millions, except per share amounts)</i>	Years Ended March 31,		
	2022	2021	2020
Income (loss) from continuing operations	\$ 1,292	\$ (4,339)	\$ 1,126
Net income attributable to noncontrolling interests	(173)	(199)	(220)
Income (loss) from continuing operations attributable to McKesson	1,119	(4,538)	906
Loss from discontinued operations, net of tax	(5)	(1)	(6)
Net income (loss) attributable to McKesson	<u>\$ 1,114</u>	<u>\$ (4,539)</u>	<u>\$ 900</u>
Weighted-average common shares outstanding:			
Basic	152.3	160.6	180.6
Effect of dilutive securities:			
Stock options	0.2	—	—
Restricted stock units ⁽¹⁾	1.6	—	1.0
Diluted	<u>154.1</u>	<u>160.6</u>	<u>181.6</u>
Earnings (loss) per common share attributable to McKesson: ⁽²⁾			
Diluted			
Continuing operations	\$ 7.26	\$ (28.26)	\$ 4.99
Discontinued operations	(0.03)	—	(0.04)
Total	<u>\$ 7.23</u>	<u>\$ (28.26)</u>	<u>\$ 4.95</u>
Basic			
Continuing operations	\$ 7.35	\$ (28.26)	\$ 5.01
Discontinued operations	(0.03)	—	(0.03)
Total	<u>\$ 7.32</u>	<u>\$ (28.26)</u>	<u>\$ 4.98</u>

(1) Includes dilutive effect from restricted stock units and performance-based stock units.

(2) Certain computations may reflect rounding adjustments.

10. Leases

In the first quarter of 2020, the Company adopted amended guidance for leases using the modified retrospective method. Upon adoption of this amended guidance, the Company recorded \$2.2 billion of operating lease liabilities, \$2.1 billion of operating lease ROU assets, and a cumulative-effect adjustment of \$69 million to opening retained earnings as of April 1, 2019. The adjustment to opening retained earnings included impairment charges of \$89 million, net of tax, to the ROU assets primarily related to previously impaired long-lived assets at the retail pharmacies in the Company's U.K. and Canadian businesses, partially offset by the derecognition of an existing deferred gain on the Company's sale-leaseback transaction related to its former corporate headquarters building. The Company also elected to adopt the transition package of practical expedients provided within the amended guidance which eliminated the requirements to reassess lease identification, lease classification, and initial direct costs for leases which commenced before April 1, 2019. The adoption of this guidance did not have a material impact on the Company's consolidated statements of operations and cash flows.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

Lessee

Supplemental balance sheet information related to leases was as follows:

<i>(In millions, except lease term and discount rate)</i>	March 31,	
	2022	2021
Operating leases ⁽¹⁾		
Operating lease right-of-use assets ⁽²⁾	\$ 1,548	\$ 2,100
Current portion of operating lease liabilities	\$ 297	\$ 390
Long-term operating lease liabilities	1,366	1,867
Total operating lease liabilities ⁽³⁾	<u>\$ 1,663</u>	<u>\$ 2,257</u>
Finance leases		
Property, plant and equipment, net	\$ 206	\$ 237
Current portion of long-term debt	\$ 25	\$ 22
Long-term debt	185	206
Total finance lease liabilities	<u>\$ 210</u>	<u>\$ 228</u>
Weighted-average remaining lease term (Years) ⁽⁴⁾		
Operating leases	6.9	7.8
Finance leases	8.8	10.1
Weighted-average discount rate ⁽⁴⁾		
Operating leases	2.47 %	2.53 %
Finance leases	2.50 %	2.71 %

- (1) As discussed in Financial Note 3, "Restructuring, Impairment, and Related Charges, Net," the Company rationalized its office space, including certain property leases, in North America during 2022. Where the Company ceased using office space, it exited the portion of the facility no longer used and repurposed other office locations which resulted in changes to certain lease agreements. This initiative did not have a material financial impact to the Company's operating lease ROU assets and liabilities.
- (2) Excludes operating lease right-of-use assets of approximately \$494 million as of March 31, 2022 related to the European divestiture activities discussed in more detail in Financial Note 2, "Held for Sale." These amounts were included under the caption "Assets held for sale" in the Consolidated Balance Sheet as of March 31, 2022. Amortization of these assets ceased upon classification as held for sale.
- (3) Excludes current and long-term operating lease liabilities of approximately \$83 million and \$442 million, respectively, as of March 31, 2022 related to the European divestiture activities discussed in more detail in Financial Note 2, "Held for Sale." These amounts were included under the caption "Liabilities held for sale" in the Consolidated Balance Sheet as of March 31, 2022.
- (4) Lease terms and discount rates as of March 31, 2022 exclude leases classified as held for sale in the Consolidated Balance Sheet related to the European divestiture activities discussed in more detail in Financial Note 2, "Held for Sale."

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

The components of lease cost were as follows:

<i>(In millions)</i>	Years Ended March 31,		
	2022	2021	2020
Short-term lease cost	\$ 43	\$ 32	\$ 29
Operating lease cost	431	465	459
Finance lease cost:			
Amortization of right-of-use assets	33	23	14
Interest on lease liabilities	5	6	5
Total finance lease cost	38	29	19
Variable lease cost ⁽¹⁾	127	125	125
Sublease income	(41)	(36)	(33)
Total lease cost ⁽²⁾	\$ 598	\$ 615	\$ 599

(1) These amounts include payments for maintenance, taxes, payments affected by the consumer price index, and other similar metrics and payments contingent on usage.

(2) These amounts were primarily recorded in “Selling, distribution, general, and administrative expenses” in the Consolidated Statements of Operations.

Supplemental cash flow information related to leases was as follows:

<i>(In millions)</i>	Years Ended March 31,		
	2022	2021	2020
Cash paid for amounts included in the measurement of lease liabilities:			
Operating cash flows from operating leases	\$ (356)	\$ (362)	\$ (377)
Operating cash flows from finance leases	—	(4)	(3)
Financing cash flows from finance leases	(31)	(31)	(18)
Right-of-use assets obtained in exchange for lease obligations:			
Operating leases ⁽¹⁾	\$ 286	\$ 321	\$ 2,378
Finance leases	32	75	166

(1) The amount for the year ended March 31, 2020 includes the transition adjustment of \$2.1 billion for operating lease right-of-use assets recorded as of April 1, 2019 upon adoption of the amended leasing guidance included in ASU 2016-02, Leases.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

Maturities of lease liabilities as of March 31, 2022 were as follows:

<i>(In millions)</i>	Operating Leases	Finance Leases	Total
2023	\$ 328	\$ 29	\$ 357
2024	310	29	339
2025	268	27	295
2026	223	25	248
2027	180	24	204
Thereafter	506	103	609
Total lease payments ⁽¹⁾	1,815	237	2,052
Less imputed interest	(152)	(27)	(179)
Present value of lease liabilities	\$ 1,663	\$ 210	\$ 1,873

(1) Total lease payments are not reduced by minimum sublease income of \$201 million which are due under future noncancellable subleases.

As of March 31, 2022, the Company entered into additional leases primarily for facilities that have not yet commenced with future lease payments of \$285 million that are not reflected in the table above. These operating leases will commence between 2023 and 2024 with noncancellable lease terms of five to 15 years.

Lessor

The Company leases certain owned equipment, classified as direct financing or sales-type leases, to physician practices. As of March 31, 2022 and 2021, the total lease receivable was \$298 million, respectively, with a weighted-average remaining lease term of approximately seven years. Interest income from these leases was not material for the years ended March 31, 2022, 2021, and 2020.

11. Goodwill and Intangible Assets, Net

Goodwill

Changes in the carrying amount of goodwill were as follows:

<i>(In millions)</i>	U.S. Pharmaceutical	Prescription Technology Solutions	Medical- Surgical Solutions	International	Total
Balance, March 31, 2020	\$ 3,924	\$ 1,540	\$ 2,453	\$ 1,443	\$ 9,360
Goodwill acquired	—	—	—	5	5
Acquisition accounting, transfers, and other adjustments	—	2	—	—	2
Other changes/disposals	(1)	—	—	—	(1)
Impairment charges	—	—	—	(69)	(69)
Foreign currency translation adjustments, net	40	—	—	156	196
Balance, March 31, 2021	3,963	1,542	2,453	1,535	9,493
Goodwill acquired	—	—	—	5	5
Foreign currency translation adjustments, net	(40)	—	—	(7)	(47)
Balance, March 31, 2022	\$ 3,923	\$ 1,542	\$ 2,453	\$ 1,533	\$ 9,451

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

Goodwill Impairment Charges

The Company evaluates goodwill for impairment as of October 1 on an annual basis each year and at an interim date if indicators of potential impairment exist. Goodwill impairment testing is conducted at the reporting unit level, which is generally defined as an operating segment or one level below an operating segment (also known as a component), for which discrete financial information is available and segment management regularly reviews the operating results of that reporting unit.

The fair value of the reporting units was determined using a combination of an income approach based on a DCF model and a market approach based on appropriate valuation multiples observed for the reporting unit's guideline public companies. Fair value estimates result from a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions that have been deemed reasonable by management as of the measurement date. Any material changes in key assumptions, including failure to improve operations of certain retail pharmacy stores, additional government reimbursement reductions, deterioration in the financial markets, an increase in interest rates or an increase in the cost of equity financing by market participants within the industry, or other unanticipated events and circumstances, may affect such estimates. The discount rates are the weighted-average cost of capital measuring the reporting unit's cost of debt and equity financing weighted by the percentage of debt and percentage of equity in a company's target capital. The unsystematic risk premium is an input factor used in calculating the discount rate that specifically addresses uncertainty related to the reporting unit's future cash flow projections. Fair value assessments of the reporting unit are considered a Level 3 measurement due to the significance of unobservable inputs developed using company-specific information.

The annual impairment testing performed for 2022, 2021, and 2020 did not indicate any impairment of goodwill.

In the second quarter of 2021, the Company implemented a new segment reporting structure which resulted in four reportable segments: U.S. Pharmaceutical, RxTS, Medical-Surgical Solutions, and International. These reportable segments encompass all operating segments of the Company. This segment change prompted changes in multiple reporting units across the Company. As a result, goodwill included in impacted reporting units was reallocated using a relative fair value approach and assessed for impairment both before and after the reallocation.

The Company recorded a goodwill impairment charge of \$69 million in 2021 as the estimated fair value of the Europe Retail Pharmacy reporting unit was lower than its reassigned carrying value based on changes in the composition of the Europe Retail Pharmacy reporting unit within the International segment. This charge was recorded in "Goodwill impairment charges" in the Consolidated Statements of Operations. At March 31, 2021, the balance of goodwill for the reporting units in Europe was approximately nil and the remaining balance of goodwill in the International segment primarily relates to one of its reporting units in Canada.

Refer to Financial Note 16, "Fair Value Measurements," for more information on these nonrecurring fair value measurements. As of March 31, 2022 and 2021, accumulated goodwill impairment losses in the Company's International segment were \$0.7 billion and \$3.6 billion, respectively. Most of the goodwill impairment for these reporting units was generally not deductible for income tax purposes.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

Intangible Assets

Information regarding intangible assets is as follows:

		March 31, 2022				March 31, 2021							
		Weighted-Average Remaining Amortization Period (Years)	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount					
<i>(Dollars in millions)</i>													
Customer relationships	12	\$	2,777	\$	(1,691)	\$	1,086	\$	3,739	\$	(2,269)	\$	1,470
Service agreements	9		1,085		(573)		512		1,081		(513)		568
Pharmacy licenses	—		—		—		—		497		(244)		253
Trademarks and trade names	12		819		(386)		433		925		(394)		531
Technology	1		128		(116)		12		150		(122)		28
Other	9		187		(171)		16		254		(226)		28
Total		\$	4,996	\$	(2,937)	\$	2,059 ⁽¹⁾	\$	6,646	\$	(3,768)	\$	2,878

- (1) Excludes net intangible assets of approximately \$384 million related to the European divestiture activities discussed in more detail in Financial Note 2, “Held for Sale.” This amount was included under the caption “Assets held for sale” in the Consolidated Balance Sheet as of March 31, 2022. Amortization of these assets ceased upon classification as held for sale in the second and third quarters of 2022.

All intangible assets were subject to amortization as of March 31, 2022 and 2021. Amortization expense of intangible assets was \$332 million, \$422 million, and \$462 million for 2022, 2021, and 2020, respectively. Estimated annual amortization expense of intangible assets is as follows: \$225 million, \$214 million, \$208 million, \$177 million, and \$171 million for 2023 through 2027, and \$1.1 billion thereafter.

Refer to Financial Note 3, “Restructuring, Impairment, and Related Charges, Net,” for more information on intangible asset impairment charges recorded in 2022, 2021, and 2020.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

12. Debt and Financing Activities

Long-term debt consisted of the following:

(In millions)	March 31,	
	2022	2021
U.S. Dollar notes ^{(1) (2)}		
2.70% Notes due December 15, 2022	\$ 400	\$ 400
2.85% Notes due March 15, 2023	360	400
3.80% Notes due March 15, 2024	918	1,100
0.90% Notes due December 3, 2025	500	500
1.30% Notes due August 15, 2026	498	—
7.65% Debentures due March 1, 2027	150	167
3.95% Notes due February 16, 2028	343	600
4.75% Notes due May 30, 2029	196	400
6.00% Notes due March 1, 2041	217	282
4.88% Notes due March 15, 2044	255	411
Foreign currency notes ^{(1) (3)}		
0.63% Euro Notes due August 17, 2021	—	704
1.50% Euro Notes due November 17, 2025	662	700
1.63% Euro Notes due October 30, 2026	554	587
3.13% Sterling Notes due February 17, 2029	582	627
Lease and other obligations ⁽⁴⁾	244	270
Total debt	5,879	7,148
Less: Current portion	799	742
Total long-term debt	\$ 5,080	\$ 6,406

(1) These notes are unsecured and unsubordinated obligations of the Company.

(2) Interest on these U.S. dollar notes is payable semi-annually.

(3) Interest on these foreign currency notes is payable annually.

(4) Excludes current and long-term debt of approximately \$4 million and \$11 million, respectively, as of March 31, 2022 related to the European divestiture activities discussed in more detail in Financial Note 2, “Held for Sale.” These amounts were included under the caption “Liabilities held for sale” in the Consolidated Balance Sheet as of March 31, 2022.

Long-Term Debt

The Company’s long-term debt includes both U.S. dollar and foreign currency-denominated borrowings. At March 31, 2022 and 2021, \$5.9 billion and \$7.1 billion, respectively, of total debt was outstanding, of which \$799 million and \$742 million, respectively, was included in “Current portion of long-term debt” in the Company’s Consolidated Balance Sheets.

On August 12, 2021, the Company completed a public offering of 1.30% Notes due August 15, 2026 (the “2026 Notes”) in a principal amount of \$500 million. Interest on the 2026 Notes is payable semi-annually on February 15th and August 15th of each year, commencing on February 15, 2022. Proceeds received from this note issuance, net of discounts and offering expenses, were \$495 million. The Company utilized the net proceeds from this note for general corporate purposes.

On December 3, 2020, the Company completed a public offering of 0.90% Notes due December 3, 2025 (the “2025 Notes”) in a principal amount of \$500 million. Interest on the 2025 Notes is payable semi-annually on June 3rd and December 3rd of each year, commencing on June 3, 2021. Proceeds received from this note issuance, net of discounts and offering expenses, were \$496 million. The Company utilized the net proceeds from this note for general corporate purposes.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

Each note, which constitutes a “Series,” is an unsecured and unsubordinated obligation of the Company and ranks equally with all of the Company’s existing and, from time-to-time, future unsecured and unsubordinated indebtedness outstanding. Each Series is governed by materially similar indentures and officers’ certificates. Upon required notice to holders of notes with fixed interest rates, the Company may redeem those notes at any time prior to maturity, in whole or in part, for cash at redemption prices. In the event of the occurrence of both (1) a change of control of the Company and (2) a downgrade of a Series below an investment grade rating by each of Fitch Inc., Moody’s Investors Service, Inc., and Standard & Poor’s Ratings Services within a specified period, an offer must be made to purchase that Series from the holders at a price equal to 101% of the then outstanding principal amount of that Series, plus accrued and unpaid interest to, but not including, the date of repurchase. The indenture and the related officers’ certificate for each Series, subject to the exceptions and in compliance with the conditions as applicable, specify that the Company may not consolidate, merge or sell all or substantially all of its assets, incur liens, or enter into sale-leaseback transactions exceeding specific terms, without the lenders’ consent. The indentures also contain customary events of default provisions.

On July 17, 2021, the Company redeemed its 0.63% €600 million (or, approximately \$709 million) total principal Euro-denominated notes, originally due on August 17, 2021, prior to maturity. The notes were redeemed at par value using cash on hand. On December 1, 2020, the Company redeemed its 4.75% \$323 million total principal of notes due on March 1, 2021 prior to maturity. On November 30, 2020, the Company retired its 3.65% \$700 million total principal of notes upon maturity. These notes were redeemed using cash on hand and the proceeds of the notes offering discussed above. In 2020, the Company repaid at maturity its €250 million Floating Rate Euro Notes due February 12, 2020.

Tender Offer

On July 23, 2021, the Company completed a cash tender offer for a portion of its existing outstanding (i) 2.85% Notes due 2023, (ii) 3.80% Notes due 2024, (iii) 7.65% Debentures due 2027, (iv) 3.95% Notes due 2028, (v) 4.75% Notes due 2029, (vi) 6.00% Notes due 2041, and (vii) 4.88% Notes due 2044 (collectively referred to herein as the “Tender Offer Notes”). In connection with the tender offer, the Company paid an aggregate consideration of \$1.1 billion to redeem \$922 million principal amount of the notes at a redemption price equal to 100% of the principal amount and premiums of \$182 million, plus accrued and unpaid interest of \$14 million. The redemption of the Tender Offer Notes was accounted for as a debt extinguishment. As a result of the redemption, the Company incurred a pre-tax loss on debt extinguishment of \$191 million in the year ended March 31, 2022, which included premiums of \$182 million as well as the write-off of unamortized debt issuance costs and transaction fees incurred totaling \$9 million.

Other Information

Scheduled principal payments of long-term debt are \$799 million in 2023, \$966 million in 2024, \$35 million in 2025, \$1.2 billion in 2026, \$1.2 billion in 2027, and \$1.7 billion thereafter.

Revolving Credit Facilities

In the second quarter of 2020, the Company entered into a Credit Agreement, dated as of September 25, 2019 (the “2020 Credit Facility”), that provides a syndicated \$4.0 billion five-year senior unsecured credit facility with a \$3.6 billion aggregate sublimit of availability in Canadian dollars, British pound sterling, and Euro. Borrowings under the 2020 Credit Facility bear interest based upon the London Interbank Offered Rate (“LIBOR”), Canadian Dealer Offered Rate for credit extensions denominated in Canadian dollars, a prime rate, or alternative overnight rates as applicable, plus agreed margins. The 2020 Credit Facility matures in September 2024 and had no borrowings during 2022 and 2021 and no amounts outstanding as of March 31, 2022 and 2021.

On March 31, 2021, the Company entered into Amendment No. 2 to the 2020 Credit Facility, which superseded Amendment No. 1, dated as of February 1, 2021. The 2020 Credit Facility, as amended, contains various customary investment grade covenants, including a financial covenant which obligates the Company to maintain a maximum Total Debt to Consolidated EBITDA ratio, as defined in the amended credit agreement. If the Company does not comply with these covenants, its ability to use the 2020 Credit Facility may be suspended and repayment of any outstanding balances under the 2020 Credit Facility may be required. At March 31, 2022, the Company was in compliance with all covenants. The remaining terms and conditions of the 2020 Credit Facility are substantially similar to those previously in place under the \$3.5 billion five-year senior unsecured revolving credit facility (the “Global Facility”), which was scheduled to mature in October 2020. The Global Facility was terminated in connection with the execution of the 2020 Credit Facility in September 2019 and had no borrowings during the six months ended September 30, 2019.

McKESSON CORPORATION**FINANCIAL NOTES (Continued)**

The Company also maintains bilateral credit facilities primarily denominated in Euros with a committed amount of \$7 million and an uncommitted amount of \$111 million as of March 31, 2022. Borrowings and repayments were not material in 2022 and 2021 and amounts outstanding under these credit lines were not material as of March 31, 2022 and 2021.

Commercial Paper

The Company maintains a commercial paper program to support its working capital requirements and for other general corporate purposes. Under the program, the Company can issue up to \$4.0 billion in outstanding commercial paper notes. During 2022, 2021, and 2020, the Company borrowed \$11.2 billion, \$6.3 billion, and \$21.4 billion, respectively, and repaid \$11.2 billion, \$6.3 billion, and \$21.4 billion, respectively, under the program. At March 31, 2022 and 2021, there were no commercial paper notes outstanding.

13. Variable Interest Entities

The Company evaluates its ownership, contractual, and other interests in entities to determine if they are VIEs if it has a variable interest in those entities, and the nature and extent of those interests. These evaluations are highly complex and involve management judgment and the use of estimates and assumptions based on available historical information, among other factors. Based on its evaluations, if the Company determines it is the primary beneficiary of such VIEs, it consolidates such entities into its financial statements.

Consolidated Variable Interest Entities

The Company consolidates a VIE when it has the power to direct the activities that most significantly impact the VIE's economic performance and the obligation to absorb losses or the right to receive benefits of the VIE and, as a result, is considered the primary beneficiary of the VIE. It consolidates certain single-lessee leasing entities where it, as the lessee, has the majority risk of the leased assets due to its minimum lease payment obligations to these leasing entities. As a result of absorbing this risk, the leases provide the Company with the power to direct the operations of the leased properties and the obligation to absorb losses or the right to receive benefits of the entity. Consolidated VIEs do not have a material impact on the Company's Consolidated Statements of Operations and Cash Flows. Total assets and liabilities included in its Consolidated Balance Sheets for these VIEs were \$660 million and \$65 million, respectively, at March 31, 2022, and \$662 million and \$74 million, respectively, at March 31, 2021.

Investments in Unconsolidated Variable Interest Entities

The Company is involved with VIEs which it does not consolidate because it does not have the power to direct the activities that most significantly impact their economic performance and thus is not considered the primary beneficiary of the entities. Its relationships include equity method investments and lending, leasing, contractual, or other relationships with the VIEs. The Company's most significant VIE relationships are with oncology and other specialty practices. Under these practice arrangements, the Company generally owns or leases all of the real estate and equipment used by the practices and manages the practices' administrative functions. Prior to the divestment of the Austrian businesses in 2022, the Company had relationships with certain pharmacies in Europe with whom it provided financing, had equity ownership, and/or had a supply agreement whereby it supplied the vast majority of the pharmacies' purchases. The Company's maximum exposure to loss (regardless of probability) as a result of all unconsolidated VIEs was \$1.4 billion and \$1.5 billion at March 31, 2022 and 2021, respectively, which primarily represents the value of intangible assets related to service agreements, equity investments, and lease and loan receivables. This amount excludes the customer loan guarantees discussed in Financial Note 17, "Financial Guarantees and Warranties." The Company believes there is no material loss exposure on these assets or from these relationships.

14. Pension Benefits

The Company maintains a number of qualified and nonqualified defined benefit pension plans and defined contribution plans for eligible employees.

Defined Benefit Pension Plans

The Company has an unfunded nonqualified supplemental defined benefit plan for certain U.S. executives, as well as benefit pension plans for eligible employees outside the U.S.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

On May 23, 2018, the Company's Board of Directors approved the termination of its frozen U.S. defined benefit pension plan ("Plan"). During the first quarter of 2020, the Company offered the option of receiving a lump sum payment to certain participants with vested qualified Plan benefits in lieu of receiving monthly annuity payments. Approximately 1,300 participants elected to receive the settlement, and lump sum payments of approximately \$49 million were made from Plan assets to these participants in June 2019. The benefit obligation settled approximated payments to Plan participants and a settlement charge of \$17 million was recorded during the first quarter of 2020. During the second quarter of 2020, the Company transferred the remainder of the Plan's pension obligation to a third-party insurance provider by purchasing annuity contracts for approximately \$280 million which was fully funded directly by Plan assets. The third-party insurance provider assumed the obligation to pay future pension benefits and provide administrative services on November 1, 2019 and a pre-tax settlement charge of \$105 million was recorded during the second quarter of 2020. Settlement charges were included within "Other income, net," in the Consolidated Statement of Operations for the year ended March 31, 2020. As of March 31, 2020, this defined benefit pension plan had an accumulated comprehensive loss of approximately nil.

The Company's non-U.S. defined benefit pension plans cover eligible employees located predominantly in Norway, the United Kingdom, Germany, and Canada. Benefits for these plans are based primarily on each employee's final salary, with annual adjustments for inflation. The obligations in Norway are largely related to the state-regulated pension plan which is managed by the Norwegian Public Service Pension Fund ("SPK"). According to the terms of the SPK, the plan assets of state regulated plans in Norway must correspond very closely to the pension obligation calculated using the principles codified in Norwegian law. In the U.K., the Company has subsidiaries that participate in a joint pension plan. The pension obligation in Germany is unfunded with the exception of the contractual trust arrangement used to fund pensions of McKesson Europe's Management Board.

During the fourth quarter of 2022, the Company derecognized \$43 million of pension liabilities included in liabilities held for sale and \$11 million of accumulated other comprehensive loss related to the sale of its Austrian business. During the third quarter of 2021, the Company derecognized \$187 million of pension liabilities included in liabilities held for sale and \$33 million of accumulated other comprehensive loss related to its German pharmaceutical wholesale business contributed to a joint venture, as discussed in more detail in Financial Note 2, "Held for Sale."

Defined benefit plan assets and obligations are measured as of the Company's fiscal year-end. The net periodic expense for the Company's pension plans is as follows:

	U.S. Plans			Non-U.S. Plans		
	Years Ended March 31,			Years Ended March 31,		
(In millions)	2022	2021	2020	2022	2021	2020
Service cost - benefits earned during the year	\$ —	\$ —	\$ —	\$ 11	\$ 15	\$ 16
Interest cost on projected benefit obligation	—	—	6	14	19	19
Expected return on assets	—	—	(4)	(19)	(20)	(22)
Amortization of unrecognized actuarial loss and prior service costs	—	—	2	3	5	6
Curtailment/settlement loss (gain)	—	—	127	(5)	—	—
Net periodic pension expense	\$ —	\$ —	\$ 131	\$ 4	\$ 19	\$ 19

The projected unit credit method is utilized in measuring net periodic pension expense over the employees' service life for the pension plans. Unrecognized actuarial losses exceeding 10% of the greater of the projected benefit obligation or the market value of assets are amortized straight-line over the average remaining future service period of active employees.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

Information regarding the changes in benefit obligations and plan assets for the Company's pension plans is as follows:

	U.S. Plans		Non-U.S. Plans	
	Years Ended March 31,		Years Ended March 31,	
(In millions)	2022	2021	2022	2021
Change in benefit obligations				
Benefit obligation at beginning of period ⁽¹⁾	\$ 9	\$ 10	\$ 875	\$ 896
Service cost	—	—	11	15
Interest cost	—	—	14	19
Actuarial loss (gain)	—	—	(55)	89
Benefits paid	(1)	(1)	(35)	(34)
Curtailment/settlement	—	—	(32)	—
Expenses paid	—	—	(1)	—
Divestiture ⁽²⁾	—	—	(43)	(187)
Foreign exchange impact and other	—	—	(33)	77
Benefit obligation at end of period ⁽¹⁾	\$ 8	\$ 9	\$ 701	\$ 875
Change in plan assets				
Fair value of plan assets at beginning of period	\$ —	\$ —	\$ 735	\$ 594
Actual return on plan assets	—	—	(4)	87
Employer and participant contributions	1	1	43	27
Benefits paid	(1)	(1)	(35)	(34)
Expenses paid	—	—	(1)	—
Settlements	—	—	(24)	—
Foreign exchange impact and other	—	—	(33)	61
Fair value of plan assets at end of period	\$ —	\$ —	\$ 681	\$ 735
Funded status at end of period	\$ (8)	\$ (9)	\$ (20)	\$ (140)
Amounts recognized on the balance sheet				
Current assets ⁽³⁾	\$ —	\$ —	\$ 49	\$ —
Long-term assets	—	—	40	54
Current liabilities ⁽³⁾	(1)	(1)	(90)	(9)
Long-term liabilities	(7)	(8)	(19)	(185)
Total	\$ (8)	\$ (9)	\$ (20)	\$ (140)

(1) The benefit obligation is the projected benefit obligation.

(2) The divestiture relates to the sale of the Company's Austrian business in 2022 and to the contribution of the Company's German pharmaceutical wholesale business to a joint venture in 2021 as discussed in more detail in Financial Note 2, "Held for Sale."

(3) Current assets at March 31, 2022 include \$49 million reclassified from long-term assets to assets held for sale as part of the Company's U.K. disposal group. Current liabilities at March 31, 2022 include \$85 million reclassified from long-term liabilities to liabilities held for sale as part of the Company's E.U. disposal group. Refer to Financial Note 2, "Held for Sale" for additional information.

The actuarial gain of \$55 million in 2022 was primarily attributable to:

- *Discount rates* (\$69 million gain): The weighted average discount rate for Non-U.S. plans increased to 2.67% as of March 31, 2022 from 1.89% as of March 31, 2021.

McKESSON CORPORATION

FINANCIAL NOTES (Continued)

- *Demographic and assumption changes* (\$14 million loss): This represents the difference between actual and estimated participant data and demographic factors, including items such as inflation assumption, compensation changes, mortality, and other changes including losses related to the divestitures in 2022.

The actuarial loss of \$89 million in 2021 was primarily attributable to:

- *Discount rates* (\$32 million loss): The weighted average discount rate for Non-U.S. plans decreased to 1.89% as of March 31, 2021 from 2.03% as of March 31, 2020.
- *Demographic and assumption changes* (\$57 million loss): This represents the difference between actual and estimated participant data and demographic factors, including items such as inflation assumption, compensation changes, mortality, and other changes including losses related to the divestiture in 2021.

The following table provides the projected benefit obligation, accumulated benefit obligation, and fair value of plan assets for all the Company's pension plans, including accumulated benefit obligation in excess of plan assets:

(In millions)	U.S. Plans March 31,		Non-U.S. Plans March 31,	
	2022	2021	2022	2021
Projected benefit obligation	\$ 8	\$ 9	\$ 701	\$ 875
Accumulated benefit obligation	8	9	689	847
Fair value of plan assets	—	—	681	735

Amounts recognized in accumulated other comprehensive loss consist of:

(In millions)	U.S. Plans March 31,		Non-U.S. Plans March 31,	
	2022	2021	2022	2021
Net actuarial loss	\$ 1	\$ 1	\$ 70	\$ 120
Prior service credit	—	—	(2)	(2)
Total	\$ 1	\$ 1	\$ 68	\$ 118

Other changes in accumulated other comprehensive income were as follows:

(In millions)	U.S. Plans Years Ended March 31,			Non-U.S. Plans Years Ended March 31,		
	2022	2021	2020	2022	2021	2020
Net actuarial loss (gain)	\$ —	\$ —	\$ (3)	\$ (32)	\$ (9)	\$ (24)
Amortization of:						
Net actuarial loss	—	—	(129)	(14)	(35)	(6)
Prior service credit (cost)	—	—	—	1	1	—
Foreign exchange impact and other	—	—	—	(5)	15	(6)
Total recognized in other comprehensive loss (income)	\$ —	\$ —	\$ (132)	\$ (50)	\$ (28)	\$ (36)

McKESSON CORPORATION

FINANCIAL NOTES (Continued)

In 2022, the Company recognized \$11 million in actuarial losses for pension plans to stockholders' equity as a result of the sale of its Austrian business. In 2021, the Company recognized \$33 million in actuarial losses for pension plans to stockholders' equity as a result of the contribution of its German pharmaceutical wholesale business to a joint venture. Refer to Financial Note 2, "Held for Sale," for more information. The Company recognized \$127 million in actuarial losses for the pension plans to stockholders' equity in 2020 as a result of the termination of the U.S. defined benefit pension plan and the settlement from the executive benefit retirement plan for a retired executive.

Projected benefit obligations related to the Company's unfunded U.S. plans were \$8 million and \$9 million at March 31, 2022 and 2021, respectively. Pension obligations for its unfunded plans are based on the recommendations of independent actuaries. Projected benefit obligations relating to the Company's unfunded non-U.S. plans were \$101 million and \$162 million at March 31, 2022 and 2021, respectively. Funding obligations for its non-U.S. plans vary based on the laws of each non-U.S. jurisdiction.

Expected benefit payments for the Company's pension plans are as follows: \$34 million, \$33 million, \$33 million, \$34 million, and \$35 million for 2023 to 2027, respectively, and \$186 million for 2028 through 2032. Expected benefit payments are based on the same assumptions used to measure the benefit obligations and include estimated future employee service. Expected contributions to be made for the Company's pension plans are \$13 million for 2023.

Weighted-average assumptions used to estimate the net periodic pension expense and the actuarial present value of benefit obligations were as follows:

	U.S. Plans Years Ended March 31,			Non-U.S. Plans Years Ended March 31,		
	2022	2021	2020	2022	2021	2020
Net periodic pension expense						
Discount rates	2.35%	3.08%	3.66%	1.89 %	1.89 %	2.03 %
Rate of increase in compensation	N/A ⁽¹⁾	N/A ⁽¹⁾	N/A ⁽¹⁾	3.20	3.20	2.93
Expected long-term rate of return on plan assets	N/A	N/A	4.00	2.56	2.56	3.01
Benefit obligation						
Discount rates	3.35%	2.35%	3.08%	2.67 %	1.89 %	2.03 %
Rate of increase in compensation	N/A ⁽¹⁾	N/A ⁽¹⁾	N/A ⁽¹⁾	3.67	3.20	2.93

(1) This assumption is no longer needed in actuarial valuations as U.S. plans are frozen or have fixed benefits for the remaining active participants.

The Company's defined benefit pension plan liabilities are valued using a discount rate based on a yield curve developed from a portfolio of high quality corporate bonds rated AA or better whose maturities are aligned with the expected benefit payments of its plans. For March 31, 2022, the Company's U.S. defined benefit liabilities are valued using a weighted-average discount rate of 3.35%, which represents an increase of 100 basis points from its 2021 weighted-average discount rate of 2.35%. The Company's non-U.S. defined benefit pension plan liabilities are valued using a weighted-average discount rate of 2.67%, which represents an increase of 78 basis points from its 2021 weighted-average discount rate of 1.89%.

Plan Assets

Investment Strategy: For non-U.S. plan assets, the investment strategies are subject to local regulations and the asset/liability profiles of the plans in each individual country. Plan assets of the non-U.S. plans are broadly invested in a manner appropriate to the nature and duration of the expected future retirement benefits payable under the plans. Plan assets are primarily invested in high-quality corporate and government bond funds and equity securities. Assets are properly diversified to avoid excessive reliance on any particular asset, issuer, or group of undertakings so as to avoid accumulations of risk in the portfolio as a whole.

The Company develops the expected long-term rate of return assumption based on the projected performance of the asset classes in which plan assets are invested. The target asset allocation was determined based on the liability and risk tolerance characteristics of the plans and at times may be adjusted to achieve overall investment objectives.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

Fair Value Measurements: The fair value hierarchy has three levels based on the reliability of the inputs used to determine fair value. Level 1 refers to fair values determined based on unadjusted quoted prices in active markets for identical assets. Level 2 refers to fair values estimated using significant other observable inputs and Level 3 includes fair values estimated using significant unobservable inputs. The following tables represent the Company's pension plan assets as of March 31, 2022 and 2021, using the fair value hierarchy by asset class:

(In millions)	Non-U.S. Plans							
	March 31, 2022				March 31, 2021			
	Level 1	Level 2	Level 3	Total	Level 1	Level 2	Level 3	Total
Cash and cash equivalents	\$ 15	\$ —	\$ —	\$ 15	\$ 5	\$ —	\$ —	\$ 5
Equity securities:								
Equity commingled funds	—	38	—	38	64	117	—	181
Fixed income securities:								
Government securities	—	6	—	6	5	144	—	149
Corporate bonds	—	11	—	11	6	30	—	36
Fixed income commingled funds	336	25	—	361	51	222	1	274
Other:								
Annuity contracts	—	—	173	173	—	—	—	—
Real estate funds and Other	31	4	2	37	31	4	3	38
Total	<u>\$ 382</u>	<u>\$ 84</u>	<u>\$ 175</u>	<u>\$ 641</u>	<u>\$ 162</u>	<u>\$ 517</u>	<u>\$ 4</u>	<u>\$ 683</u>
Assets held at NAV practical expedient (1):								
Other				40				52
Total plan assets				<u>\$ 681</u>				<u>\$ 735</u>

(1) Equity commingled funds, fixed income commingled funds, real estate funds, and other investments for which fair value is measured using the NAV per share as a practical expedient are not leveled within the fair value hierarchy and are included as a reconciling item to total investments.

Cash and cash equivalents - Cash and cash equivalents include short-term investment funds that maintain daily liquidity and aim to have constant unit values of \$1.00. The funds invest in short-term fixed income securities and other securities with debt-like characteristics emphasizing short-term maturities and high credit quality. Directly held cash and cash equivalents are classified as Level 1 investments. Cash and cash equivalents include money market funds and other commingled funds, which have daily net asset values derived from the underlying securities; these are classified as Level 1 investments.

Equity commingled funds - Some equity investments are held in commingled funds, which have daily net asset values derived from quoted prices for the underlying securities in active markets; these are classified as Level 1 or Level 2 investments.

Fixed income securities - Government securities consist of bonds and debentures issued by central governments or federal agencies; corporate bonds consist of bonds and debentures issued by corporations. Inputs to the valuation methodology include quoted prices for similar assets in active markets, and inputs that are observable for the asset, either directly or indirectly, for substantially the full term of the asset. Multiple prices and price types are obtained from pricing vendors whenever possible, enabling cross-provider price validations. Fixed income securities are generally classified as Level 1 or Level 2 investments.

Fixed income commingled funds - Some fixed income investments are held in exchange traded or commingled funds, which have daily net asset values derived from the underlying securities; these are classified as Level 1, 2, or 3 investments.

McKESSON CORPORATION

FINANCIAL NOTES (Continued)

Annuity contracts - The value of the annuity contracts is reported by the Trustee and is based on a valuation of the remaining contracted cash flow of the contract. Inputs in the valuation include discounted future cash flows; these are classified as Level 3 investments.

Real estate funds - The value of the real estate funds is reported by the fund manager and is based on a valuation of the underlying properties. Inputs used in the valuation include items such as cost, discounted future cash flows, independent appraisals, and market based comparable data. The real estate funds are classified as Level 1, 2, or 3 investments.

Other - At March 31, 2022 and 2021, this includes \$35 million and \$36 million, respectively, of plan asset value relating to the SPK. In principle, the SPK is organized as a pay-as-you-go system guaranteed by the Norwegian government as it holds no Company-owned assets to back the pension liabilities. The Company pays a pension premium used to fund the plan, which is paid directly to the Norwegian government who establishes an account for each participating employer to keep track of the financial status of the plan, including managing the contributions and the payments. Further, the investment return credited to this account is determined annually by the SPK based on the performance of long-term government bonds.

The following table presents the changes in the Level 3 plan assets measured on a recurring basis for the year ended March 31, 2022:

<i>(In millions)</i>		Level 3
Balance as of March 31, 2021	\$	4
Purchases		196
Return on assets		(25)
Balance as of March 31, 2022	\$	175

The activity attributable to Level 3 plan assets was not material for the year ended March 31, 2021.

Multiemployer Plans

The Company contributes to a number of multiemployer pension plans under the terms of collective-bargaining agreements that cover union-represented employees in the U.S. In 2017, it also contributed to the Pensjonsordningen for Apoteketaten ("POA"), a mandatory multiemployer pension scheme for its pharmacy employees in Norway, managed by the association of Norwegian Pharmacies.

The risks of participating in these multiemployer plans are different from single-employer pension plans in the following aspects: (i) assets contributed to the multiemployer plan by one employer may be used to provide benefits to employees of other participating employers; (ii) if a participating employer stops contributing to the plan, the unfunded obligations of the plan may be borne by the remaining participating employers; and (iii) if the Company chooses to stop participating in some of its multiemployer plans, the Company may be required to pay those plans an amount based on the underfunded status of the plan, referred to as a withdrawal liability. Actions taken by other participating employers may lead to adverse changes in the financial condition of a multiemployer benefit plan and the Company's withdrawal liability and contributions may increase.

Contributions and amounts accrued for U.S. plans were not material for the years ended March 31, 2022, 2021, and 2020. Contributions to the POA for non-U.S. plans exceeding 5% of total plan contributions were \$20 million, \$22 million, and \$17 million in 2022, 2021, and 2020, respectively. Based on actuarial calculations, the Company estimates the funded status for its non-U.S. Plans to be approximately 88% as of March 31, 2022. No amounts were accrued for liability associated with the POA as the Company has no intention to withdraw from the plan.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

Defined Contribution Plans

The Company has a contributory retirement savings plan (“RSP”) for U.S. eligible employees. Eligible employees may contribute to the RSP up to 75% of their eligible compensation on a pre-tax or post-tax basis not to exceed IRS limits. The Company makes matching contributions in an amount equal to 100% of the employee’s first 3% of pay contributed and 50% for the next 2% of pay contributed. The Company also may make an additional annual matching contribution for each plan year to enable participants to receive a full match based on their annual contribution. The Company also contributed to non-U.S. plans that are available in certain countries. Contribution expenses for the RSP and non-U.S. plans were \$116 million for the year ended March 31, 2022 and \$102 million for each of the years ended March 31, 2021 and 2020.

Postretirement Benefits

The Company maintains a number of postretirement benefit plans, primarily consisting of healthcare and life insurance (“welfare”) benefits, for certain eligible U.S. employees. Eligible employees consist of those who retired before March 31, 1999 and those who retired after March 31, 1999, but were an active employee as of that date, after meeting other age-related criteria. It also provides postretirement benefits for certain U.S. executives. Defined benefit plan obligations are measured as of the Company’s fiscal year-end. The net periodic (credit) expense for the Company’s postretirement welfare benefits was not material for the years ended March 31, 2022, 2021, and 2020. The benefit obligation at March 31, 2022 and 2021 was \$56 million and \$64 million, respectively.

15. Hedging Activities

In the normal course of business, the Company is exposed to interest rate and foreign currency exchange rate fluctuations. At times, the Company limits these risks through the use of derivatives such as cross-currency swaps, foreign currency forward contracts, and interest rate swaps. In accordance with the Company’s policy, derivatives are only used for hedging purposes. It does not use derivatives for trading or speculative purposes.

Foreign currency exchange risk

The Company conducts its business worldwide in U.S. dollars and the functional currencies of its foreign subsidiaries, including Euro, British pound sterling, and Canadian dollars. Changes in foreign currency exchange rates could have a material adverse impact on the Company’s financial results that are reported in U.S. dollars. The Company is also exposed to foreign currency exchange rate risk related to its foreign subsidiaries, including intercompany loans denominated in non-functional currencies. The Company has certain foreign currency exchange rate risk programs that use foreign currency forward contracts and cross-currency swaps. These forward contracts and cross-currency swaps are generally used to offset the potential income statement effects from intercompany loans and other obligations denominated in non-functional currencies. These programs reduce but do not entirely eliminate foreign currency exchange rate risk.

Non-Derivative Instruments Designated as Hedges

At March 31, 2022 and 2021, the Company had €1.1 billion and €1.7 billion, respectively, of Euro-denominated notes designated as non-derivative net investment hedges. These hedges are utilized to hedge portions of the Company’s net investments in non-U.S. subsidiaries against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar. For all notes that are designated as net investment hedges and meet effectiveness requirements, the changes in carrying value of the notes attributable to the change in spot rates are recorded in foreign currency translation adjustments in “Accumulated other comprehensive loss” in the Consolidated Statements of Stockholders’ Equity (Deficit) where they offset foreign currency translation gains and losses recorded on the Company’s net investments. To the extent foreign currency-denominated notes designated as net investment hedges are ineffective, changes in carrying value attributable to the change in spot rates are recorded in earnings.

On September 30, 2019, the Company de-designated its £450 million British pound sterling-denominated notes prospectively from net investment hedges as the hedging relationship ceased to be effective.

Foreign currency gains or losses from net investment hedges recorded within Other comprehensive income were gains of \$73 million in 2022, losses of \$118 million in 2021, and gains of \$39 million in 2020. Ineffectiveness on the Company’s non-derivative net investment hedges during 2020 resulted in gains of \$34 million which were recorded in earnings in “Other income, net” in the Consolidated Statement of Operations. There was no ineffectiveness in the Company’s net investment hedges for the years ended March 31, 2022 and 2021.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

Derivatives Designated as Hedges

At March 31, 2022 and 2021, the Company had cross-currency swaps designated as net investment hedges with a total gross notional amount of \$500 million Canadian dollars. Under the terms of the cross-currency swap contracts, the Company agrees with third parties to exchange fixed interest payments in one currency for fixed interest payments in another currency at specified intervals and to exchange principal in one currency for principal in another currency, calculated by reference to agreed-upon notional amounts. These swaps are utilized to hedge portions of the Company's net investments denominated in Canadian dollars against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar. The changes in the fair value of these derivatives attributable to the changes in spot currency exchange rates and differences between spot and forward interest rates are recorded in "Accumulated other comprehensive loss" in the Consolidated Statements of Stockholders' Equity (Deficit) where they offset foreign currency translation gains and losses recorded on the Company's net investments denominated in Canadian dollars. To the extent cross-currency swaps designated as hedges are ineffective, changes in carrying value attributable to the change in spot rates are recorded in earnings. There was no ineffectiveness in the Company's net investment hedges for the years ended March 31, 2022, 2021, and 2020. The cross-currency swaps will mature in November 2024.

In 2020, the Company terminated its cross-currency swaps designated as net investment hedges with a total gross notional amount of £932 million British pound sterling swaps. The termination was due to ineffectiveness in its British pound sterling hedging program that arose due to 2019 impairments of goodwill and certain long-lived assets in the U.K. businesses. Proceeds from the termination of these swaps totaled \$84 million and resulted in a settlement gain of \$34 million in 2020. This gain was recorded in earnings in "Other income, net" in the Consolidated Statements of Operations.

Gains or losses from the Company's cross-currency swaps designated as net investment hedges recorded in Other comprehensive income were losses of \$4 million and \$119 million in 2022 and 2021, respectively, and gains of \$76 million in 2020. There was no ineffectiveness in the Company's hedges for the years ended March 31, 2022, 2021 and 2020.

On September 30, 2019, the Company entered into a number of cross-currency swaps designated as fair value hedges with total notional amounts of £450 million British pound sterling. Under the terms of the cross-currency swap contracts, the Company agreed with third parties to exchange fixed interest payments in British pound sterling for floating interest payments in U.S. dollars based on three-month LIBOR plus a spread. These swaps are utilized to hedge the changes in the fair value of the underlying £450 million British pound sterling notes resulting from changes in benchmark interest rates and foreign exchange rates. The changes in the fair value of these derivatives, which are designated as fair value hedges, and the offsetting changes in the fair value of the hedged notes are recorded in earnings. Gains from these fair value hedges recorded in earnings were largely offset by the losses recorded in earnings related to these notes. The swaps will mature in February 2023.

From time to time, the Company also enters into cross-currency swaps to hedge intercompany loans denominated in non-functional currencies. For cross-currency swap transactions, the Company agrees with third parties to exchange fixed interest payments in one currency for fixed interest payments in another currency at specified intervals and to exchange principal in one currency for principal in another currency, calculated by reference to agreed-upon notional amounts. These cross-currency swaps are designed to reduce the income statement effects arising from fluctuations in foreign exchange rates and have been designated as cash flow hedges. At March 31, 2022 and 2021, the Company had cross-currency swaps with total gross notional amounts of approximately \$1.3 billion and \$2.6 billion, respectively, which are designated as cash flow hedges. These swaps will mature between July 2022 and January 2024.

For forward contracts and cross-currency swaps that are designated as cash flow hedges, the effective portion of changes in the fair value of the hedges is recorded in Accumulated other comprehensive loss and reclassified into earnings in the same period in which the hedged transaction affects earnings. Changes in fair values representing hedge ineffectiveness are recognized in current earnings.

McKESSON CORPORATION**FINANCIAL NOTES (Continued)**

On April 27, 2020, the Company entered into forward starting interest rate swaps designated as cash flow hedges, with combined notional amounts of \$500 million and €600 million, to hedge the variability of future benchmark interest rates on planned bond issuances. Under the terms of the forward interest rate swap contracts, the Company agreed with third parties to pay fixed interest payments for the \$500 million swaps for floating interest payments in U.S. dollars based on three-month LIBOR and to pay fixed interest payments for floating interest payments in Euros based on six-month Euro Interbank Offered Rate (“EURIBOR”) for the €600 million swaps. The \$500 million swaps were terminated upon the issuance of the 2025 Notes in November 2020. The settlement loss on the swaps was not material and will be amortized on a straight-line basis as interest expense over the five-year life of the 2025 Notes. The €600 million swaps were terminated in the second quarter of 2022 and the loss on termination of the swaps recorded in interest expense was not material for the year ended March 31, 2022. Refer to Financial Note 12, “Debt and Financing Activities,” for more information.

During 2022, the Company entered into forward starting interest rate swaps designated as cash flow hedges, with a combined notional amount of \$500 million, to hedge the variability of future benchmark interest rates on a planned bond issuance. Under the terms of the forward interest rate swap contracts, the Company agreed with third parties to pay fixed interest payments for the \$500 million swaps for floating interest payments in U.S. dollars based on three-month LIBOR.

Gains or losses from cash flow hedges recorded in Other comprehensive income were gains of \$21 million in 2022, losses of \$42 million in 2021, and gains of \$98 million in 2020. Gains or losses reclassified from Accumulated other comprehensive income and recorded in “Selling, distribution, general, and administrative expenses” in the Consolidated Statements of Operations were not material in 2022, 2021, and 2020. There was no ineffectiveness in the Company’s cash flow hedges for the years ended March 31, 2022, 2021, and 2020.

Derivatives Not Designated as Hedges

Derivative instruments not designated as hedges are marked-to-market at the end of each accounting period with the change in value included in earnings.

From time to time, the Company enters into forward contracts to hedge the Euro against cash flows denominated in British pound sterling and other European currencies. At March 31, 2022 and 2021, the total gross notional amounts of these contracts were nil and \$39 million, respectively. Changes in the fair values for contracts not designated as hedges are recorded directly into earnings in “Selling, distribution, general, and administrative expenses” in the Consolidated Statements of Operations. Changes in the fair values were not material in 2022, 2021, and 2020. Gains or losses from these contracts are largely offset by changes in the value of the underlying intercompany obligations.

In 2020, the Company also entered into a number of forward contracts and swaps to offset a portion of the earnings impacts from the ineffectiveness of the non-derivative net investment hedges discussed above. These contracts matured through January 2020 and none of these contracts were designated for hedge accounting. In December 2019, the Company entered into a series of forward contracts with a total notional amount of €250 million to offset the earnings impact from its Euro-denominated notes. These contracts and the notes against which they are offsetting matured in February 2020 and were not designated for hedge accounting. Changes in the fair value for contracts not designated as hedges are recorded directly in earnings. In 2020, losses of \$44 million were recorded in earnings in “Other income, net” in the Consolidated Statements of Operations, which offset the ineffectiveness on the Company’s non-derivative net investment hedges noted above.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

Information regarding the fair value of derivatives on a gross basis is as follows:

(In millions)	Balance Sheet Caption	March 31, 2022			March 31, 2021		
		Fair Value of Derivative		U.S. Dollar Notional	Fair Value of Derivative		U.S. Dollar Notional
		Asset	Liability		Asset	Liability	
Derivatives designated for hedge accounting							
	Prepaid expenses and other/Other accrued liabilities	\$ 30	\$ 39	\$ 1,537	\$ 4	\$ 47	\$ 826
Cross-currency swaps (current)							
Cross-currency swaps (non-current)	Other non-current assets/liabilities	—	36	679	72	92	2,663
Forward starting interest rate swaps (current)	Other accrued liabilities	31	—	500	—	7	704
Total		<u>\$ 61</u>	<u>\$ 75</u>		<u>\$ 76</u>	<u>\$ 146</u>	
Derivatives not designated for hedge accounting							
	Prepaid expenses and other	\$ —	\$ —	\$ —	\$ —	\$ —	\$ 29
Foreign exchange contracts (current)							
Foreign exchange contracts (current)	Other accrued liabilities	—	—	—	—	1	10
Total		<u>\$ —</u>	<u>\$ —</u>		<u>\$ —</u>	<u>\$ 1</u>	

Refer to Financial Note 16, “Fair Value Measurements,” for more information on these recurring fair value measurements.

16. Fair Value Measurements

The Company measures certain assets and liabilities at fair value in accordance with Accounting Standards Codification (“ASC”) Topic 820, *Fair Value Measurements and Disclosures*. The fair value hierarchy consists of three levels of inputs that may be used to measure fair value as follows:

Level 1 - quoted prices in active markets for identical assets or liabilities.

Level 2 - significant other observable market-based inputs.

Level 3 - significant unobservable inputs for which little or no market data exists and requires considerable assumptions that are significant to the fair value measurement.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

Cash and cash equivalents at March 31, 2022 and 2021 included investments in money market funds of \$981 million and \$1.6 billion, respectively, which are reported at fair value. The fair value of money market funds was determined using quoted prices for identical investments in active markets, which are considered to be Level 1 inputs under the fair value measurements and disclosure guidance. The carrying value of all other cash equivalents approximates their fair value due to their relatively short-term nature. Fair values for the Company’s marketable securities were not material at March 31, 2022 and 2021.

Fair values of the Company’s interest rate swaps and foreign currency forward contracts were determined using observable inputs from available market information, including quoted interest rates, foreign currency exchange rates, and other observable inputs from available market information. These inputs are considered Level 2 under the fair value measurements and disclosure guidance, and may not be representative of actual values that could have been realized or that will be realized in the future. Refer to Financial Note 15, “Hedging Activities,” for fair value and other information on the Company’s derivatives including interest rate swaps, forward foreign currency contracts, and cross-currency swaps.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

The Company holds investments in equity securities of U.S. growth stage companies that address both current and emerging business challenges in the healthcare industry and which had carrying values of \$346 million and \$269 million at March 31, 2022 and 2021, respectively. These investments primarily consist of equity securities without readily determinable fair values and are included in “Other non-current assets” in the Consolidated Balance Sheets. During 2022 and 2021, certain of the Company’s investments in equity securities without readily determinable fair values experienced transactions which resulted in changes in the observable price of those securities. Additionally, in 2021, certain of the Company’s investments in equity securities were converted into shares of public common stock through initial public offerings and an acquisition. The Company exited most of its investments in publicly traded shares in the fourth quarter of 2021. Net gains related to the Company’s investments in these equity securities were approximately \$98 million and \$133 million, respectively, for the years ended March 31, 2022 and 2021. These net gains were recorded in “Other income, net” in the Consolidated Statements of Operations. The carrying value of publicly traded investments was determined using quoted prices for identical investments in active markets and are considered to be Level 1 inputs.

Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis

In addition to assets and liabilities that are measured at fair value on a recurring basis, the Company’s assets and liabilities are also subject to nonrecurring fair value measurements. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges, including long-lived assets associated with the Company’s restructuring initiatives as discussed in more detail in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net.”

At March 31, 2022, the assets and liabilities associated with the E.U. disposal group and U.K. disposal group classified as held for sale were measured at the lower of carrying value or fair value less costs to sell, as discussed in more detail in Financial Note 2, “Held for Sale.” Additionally, at March 31, 2022, assets measured at fair value on a nonrecurring basis included certain long-lived assets within the International segment related to the Company’s operations in Denmark and its retail pharmacy businesses in Canada, as discussed in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net.”

At March 31, 2021, assets measured at fair value on a nonrecurring basis included long-lived assets of the Company’s International segment and its Europe Retail Pharmacy reporting unit within the International segment. Refer to Financial Note 3, “Restructuring, Impairment, and Related Charges, Net” and Financial Note 11, “Goodwill and Intangible Assets, Net,” for more information.

The aforementioned investments in equity securities of U.S. growth stage companies include the carrying value of investments without readily determinable fair values, which were determined using a measurement alternative and are recorded at cost less impairment, plus or minus any changes in observable price from orderly transactions of the same or similar security of the same issuer. These inputs are considered Level 2 under the fair value measurements and disclosure guidance and may not be representative of actual values that could have been realized or that will be realized in the future.

There were no other liabilities measured at fair value on a nonrecurring basis at March 31, 2022 and 2021.

Other Fair Value Disclosures

At March 31, 2022 and 2021, the carrying amounts of cash, certain cash equivalents, restricted cash, marketable securities, receivables, drafts and accounts payable, short-term borrowings, and other current liabilities approximated their estimated fair values because of the short maturity of these financial instruments.

The Company determines the fair value of commercial paper using quoted prices in active markets for identical instruments, which are considered Level 1 inputs under the fair value measurements and disclosure guidance.

The Company’s long-term debt is also recorded at amortized cost. The carrying value and fair value of the Company’s long-term debt was as follows:

<i>(In millions)</i>	March 31, 2022		March 31, 2021	
	Carrying Value	Fair Value	Carrying Value	Fair Value
Long-term debt, including current maturities	\$ 5,879	\$ 5,999	\$ 7,148	\$ 7,785

McKESSON CORPORATION

FINANCIAL NOTES (Continued)

The estimated fair value of the Company's long-term debt was determined using quoted market prices in a less active market and other observable inputs from available market information, which are considered to be Level 2 inputs, and may not be representative of actual values that could have been realized or that will be realized in the future.

Goodwill

Fair value assessments of the reporting unit and the reporting unit's net assets, which are performed for goodwill impairment tests, are considered a Level 3 measurement due to the significance of unobservable inputs developed using company-specific information. The Company considered a market approach as well as an income approach using a DCF model to determine the fair value of each reporting unit.

Refer to Financial Note 11, "Goodwill and Intangible Assets, Net," for more information regarding goodwill impairment charges recorded for certain reporting units during 2021.

Long-lived Assets

The Company utilizes multiple approaches including the DCF model and market approaches for estimating the fair value of intangible assets. The future cash flows used in the analysis are based on internal cash flow projections from its long-range plans and include significant assumptions by management. Accordingly, the fair value assessment of the long-lived assets is considered a Level 3 fair value measurement.

The Company measures certain long-lived and intangible assets at fair value on a nonrecurring basis when events occur that indicate an asset group may not be recoverable. If the carrying amount of an asset group is not recoverable, an impairment charge is recorded to reduce the carrying amount by the excess over its fair value. Refer to Financial Note 3, "Restructuring, Impairment, and Related Charges, Net" under the heading "*Long-Lived Asset Impairments*" for more information.

17. Financial Guarantees and Warranties*Financial Guarantees*

The Company has agreements with certain of its customers' financial institutions, primarily in its International segment, under which it has guaranteed the repurchase of its customers' inventory or its customers' debt in the event these customers are unable to meet their obligations to those financial institutions. For the Company's inventory repurchase agreements, among other requirements, inventories must be in a resalable condition and any repurchase would be at a discount. The inventory repurchase agreements mostly relate to certain Canadian customers and generally range from one to two years. Customers' debt guarantees generally range from one to 10 years and are primarily provided to facilitate financing for certain customers. The majority of the Company's customers' debt guarantees are secured by certain assets of the customer. At March 31, 2022, the maximum amounts of inventory repurchase guarantees and customers' debt guarantees were \$367 million and \$84 million, respectively, of which the Company has not accrued any material amounts. The expirations of these financial guarantees are as follows: \$309 million, \$45 million, \$6 million, \$15 million, and \$12 million from 2023 through 2027, respectively, and \$64 million thereafter.

At March 31, 2022, the Company's banks and insurance companies have issued \$214 million of standby letters of credit and surety bonds, which were issued on the Company's behalf primarily related to its customer contracts and in order to meet the security requirements for statutory licenses and permits, court and fiduciary obligations, pension obligations in Europe, and its workers' compensation and automotive liability programs.

The Company's software license agreements generally include certain provisions for indemnifying customers against liabilities if its software products infringe a third party's intellectual property rights. To date, the Company has not incurred any material costs as a result of such indemnification agreements and has not accrued any liabilities related to such obligations.

In conjunction with certain transactions, primarily divestitures, the Company may provide routine indemnification agreements (such as retention of previously existing environmental, tax, and employee liabilities) whose terms vary in duration and often are not explicitly defined. Where appropriate, obligations for such indemnifications are recorded as liabilities. Because the amounts of these indemnification obligations often are not explicitly stated, the overall maximum amount of these commitments cannot be reasonably estimated. Other than obligations recorded as liabilities at the time of divestiture, the Company has historically not made material payments as a result of these indemnification provisions.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

Warranties

In the normal course of business, the Company provides certain warranties and indemnification protection for its products and services. For example, the Company provides warranties that the pharmaceutical and medical-surgical products it distributes are in compliance with the U.S. Food, Drug, and Cosmetic Act and other applicable laws and regulations. It has received the same warranties from its suppliers, which customarily are the manufacturers of the products. In addition, the Company has indemnity obligations to its customers for these products, which have also been provided from its suppliers, either through express agreement or by operation of law. Accrued warranty costs were not material to the Consolidated Balance Sheets.

18. Commitments and Contingent Liabilities

In addition to commitments and obligations incurred in the ordinary course of business, the Company is subject to a variety of claims and legal proceedings, including claims from customers and vendors, pending and potential legal actions for damages, governmental investigations, and other matters. The Company and its affiliates are parties to the legal claims and proceedings described below. The Company is vigorously defending itself against those claims and in those proceedings. Significant developments in those matters are described below. If the Company is unsuccessful in defending, or if it determines to settle, any of these matters, it may be required to pay substantial sums, be subject to injunction and/or be forced to change how it operates its business, which could have a material adverse impact on its financial position or results of operations.

Unless otherwise stated, the Company is unable to reasonably estimate the loss or a range of possible loss for the matters described below. Often, the Company is unable to determine that a loss is probable, or to reasonably estimate the amount of loss or a range of loss, for a claim because of the limited information available and the potential effects of future events and decisions by third parties, such as courts and regulators, that will determine the ultimate resolution of the claim. Many of the matters described are at preliminary stages, raise novel theories of liability or seek an indeterminate amount of damages. It is not uncommon for claims to remain unresolved over many years. The Company reviews loss contingencies at least quarterly to determine whether the likelihood of loss has changed and whether it can make a reasonable estimate of the loss or range of loss. When the Company determines that a loss from a claim is probable and reasonably estimable, it records a liability for an estimated amount. The Company also provides disclosure when it is reasonably possible that a loss may be incurred or when it is reasonably possible that the amount of a loss will exceed its recorded liability. Amounts included within "Claims and litigation charges, net" in the Consolidated Statement of Operations consist of estimated loss contingencies related to opioid-related litigation matters.

I. Litigation and Claims Involving Distribution of Controlled Substances

The Company and its affiliates have been sued as defendants in many cases asserting claims related to distribution of controlled substances. They have been named as defendants along with other pharmaceutical wholesale distributors, pharmaceutical manufacturers, and retail pharmacy chains. The plaintiffs in these actions have included state attorneys general, county and municipal governments, school districts, tribal nations, hospitals, health and welfare funds, third-party payors, and individuals. These actions have been filed in state and federal courts throughout the U.S., and in Puerto Rico and Canada. They seek monetary damages and other forms of relief based on a variety of causes of action, including negligence, public nuisance, unjust enrichment, and civil conspiracy, as well as alleging violations of the Racketeer Influenced and Corrupt Organizations Act ("RICO"), state and federal controlled substances laws, and other statutes.

On July 21, 2021, the Company and the two other national pharmaceutical distributors (collectively "Distributors") announced that they had negotiated a comprehensive proposed settlement agreement which, if all conditions were satisfied, would result in the settlement of a substantial majority of opioid lawsuits filed by state and local governmental entities. On February 25, 2022, the Distributors determined that there was sufficient State and subdivision participation to proceed with an agreement ("Settlement") to settle a substantial majority of opioids-related lawsuits filed against the Distributors by U.S. states, territories, and local governmental entities. As previously disclosed, 46 of 49 eligible states and their participating subdivisions, as well as the District of Columbia and all eligible territories (collectively, "Settling Governmental Entities"), have agreed to join the Settlement. To date, over 98% of eligible political subdivisions that have brought opioid-related suits against the Company, as calculated by population under the agreement, have agreed to participate in the settlement or have had their claims addressed by state legislation.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

The Settlement became effective on April 2, 2022. If all conditions to the Settlement are satisfied, including the receipt of approval by relevant courts of consent decrees to dismiss the lawsuits, the Distributors would pay the Settling Governmental Entities up to approximately \$19.5 billion over 18 years, with up to approximately \$7.4 billion to be paid by the Company for its 38.1% portion. Under the Settlement, a minimum of 85% of the settlement payments must be used by state and local governmental entities to remediate the opioid epidemic. Most of the remaining percentage relates to plaintiffs' attorneys' fees and costs, and would be payable over a shorter time period. Under the Settlement, the Distributors will establish a clearinghouse to consolidate their controlled-substance distribution data, which will be available to the settling U.S. states to use as part of their anti-diversion efforts. The Settlement provides that the Distributors do not admit liability or wrongdoing and do not waive any defenses.

Before the effective date of the Settlement, the Company entered into separate settlement agreements with the states of New York, Ohio, Rhode Island, Texas, and Florida. These states intended to participate in the Settlement when it was finalized, and these agreements provided that each state and its participating subdivisions would receive a settlement consistent with their allocation under the comprehensive Settlement framework, as well as, in some cases, certain attorneys' fees and costs. Now that the Settlement has become effective, these separate settlement agreements have become part of that broader agreement.

Three eligible states, Alabama, Oklahoma, and Washington, did not join the Settlement.

With respect to the claims of the Alabama attorney general, the Company has negotiated an agreement in principle under which the Company will pay \$141 million in ten equal annual installments and an additional approximately \$33 million in attorney fees and costs to resolve the opioid-related claims of the state of Alabama and its subdivisions. On May 3, 2022, the Distributors announced an agreement with the attorney general of Washington to settle the claims of the state of Washington and its subdivisions. Under that agreement, Washington and its subdivisions would be paid up to \$518 million, of which the Company's portion would be 38.1% (or approximately \$197 million), consistent with Washington's allocation under the comprehensive framework, as well as certain additional attorneys' fees and costs. The claims of the Oklahoma attorney general are pending in the District Court of Bryan County, Oklahoma (Case No. CJ-2020-84, 85, and 86), and trial is scheduled to begin in January 2023. The Company's loss contingency accruals for these three states and their subdivisions reflect the amounts of these agreements in principle or, where there is no agreement in principle, amounts equivalent to what that state and its subdivisions would have been allocated under the framework of the Settlement.

The Company previously settled with the state of West Virginia, and West Virginia and its subdivisions were not eligible to participate in the comprehensive Settlement. Claims of various West Virginia subdivisions remain pending in both state and federal courts. Trial in the case of Cabell County and City of Huntington occurred in the U.S. District Court for the Southern District of West Virginia and concluded on July 28, 2021. The outcome of that trial is pending. The claims of certain other West Virginia subdivisions are pending in the federal Multi-district Litigation and before the state Mass Litigation Panel. On September 30, 2021, the Mass Litigation Panel issued an order scheduling a liability-only trial on the public nuisance claims of certain political subdivisions against the Distributors for July 5, 2022. The Company's loss contingency accruals for the West Virginia subdivisions are reflected in the estimated liability for the opioid-related claims as of March 31, 2022.

With respect to the claims of Native American tribes, on September 28, 2021, the Company announced that the Distributors reached an agreement with the Cherokee Nation to pay approximately \$75 million over 6.5 years to resolve opioid-related claims, of which the Company's portion would be 38.1% (or, approximately \$29 million). The Company has also negotiated a broad resolution of opioid-related claims brought by Native American tribes. Under the proposed agreement, which has been endorsed by the leadership committee of counsel representing the tribes, the Distributors would pay the Native American tribes other than the Cherokee Nation approximately \$440 million over 6 years, of which the Company's portion would be 38.1% (or, approximately \$167 million). This broad resolution is contingent on the participation of a substantial majority of the Native American tribes that have brought opioid-related claims against the Distributors. Under these agreements, a minimum of 85% of the settlement payments must be used by the Native American tribes to remediate the opioid epidemic. The Company's loss-contingency accruals for the Native American tribes reflect these amounts and are reflected in the estimated liability for the opioid-related claims as of March 31, 2022.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

Although the Settlement terminated the substantial majority of opioid-related suits pending against the Company, a small number of subdivisions in participating states have opted not to participate in the comprehensive settlement, and other suits brought by subdivisions in non-participating states remain pending. The Company continues to prepare for trial in these pending matters and believes that it has valid defenses to the claims pending against it, and it intends to vigorously defend against all such claims if acceptable settlement terms are not achieved. The Company's loss contingency accruals for these subdivisions are reflected in the estimated liability for the opioid-related claims consistent with what would be allocated under the framework of the settlement.

The Company has paid \$157 million in payments to date associated with the Settlement and separate settlement agreements of opioid-related claims of participating states, subdivisions, and Native American tribes.

The Company's estimated accrued liability for the opioid-related claims of governmental entities is as follows:

<i>(In millions)</i>	March 31, 2022	March 31, 2021
Current litigation liabilities ^{(1) (2)}	\$ 1,046	\$ —
Long-term litigation liabilities	7,220	8,067
Total litigation liabilities	\$ 8,266	\$ 8,067

- (1) This amount, recorded in "Other accrued liabilities" in the Consolidated Balance Sheet, is the amount estimated to be paid prior to March 31, 2023.
- (2) In light of the uncertainty of the timing of amounts that would be paid with respect to the charge, the charge was recorded in "Long-term litigation liabilities" in our Consolidated Balance Sheet as of March 31, 2021.

Consistent with the terms of the Settlement, the Company placed approximately \$354 million into escrow on September 30, 2021. During the second half of 2022, the Company placed an additional net \$41 million into escrow to reflect the participation of additional states, and as part of a separate agreement in principle with the Alabama attorney general. Those escrow amounts were presented as restricted cash within "Prepaid expenses and other" in our Consolidated Balance Sheet as of March 31, 2022. These amounts excluded the proportionate allocation under the Settlement for each non-participating state. The Settlement created a binding obligation to release the funds from escrow upon entry of consent judgments and establishment of a settlement administrator.

Although the vast majority of opioid claims have been brought by governmental entities in the U.S., the Company is also a defendant in cases brought in the U.S. by private plaintiffs, such as hospitals, health and welfare funds, third-party payors, and individuals, as well as four cases brought in Canada (three by governmental or tribal entities and one by an individual). These claims, and those of private entities generally, are not included in the Settlement or in the charges recorded by the Company, described above. The Company believes it has valid legal defenses in these matters and intends to mount a vigorous defense. Trial is scheduled for July 18, 2022 in one such case brought by a group of individual plaintiffs in Glynn County, Georgia Superior Court. These plaintiffs seek to recover for damages allegedly arising from their family members' abuse of prescription opioids. *Poppell v. Cardinal Health, Inc. et al.*, CE19-00472. The Company has not concluded a loss is probable in any of these matters; nor is any possible loss or range of loss reasonably estimable.

Because of the many uncertainties associated with the remaining opioid-related litigation matters, the Company is not able to reasonably estimate the upper or lower ends of the range of ultimate possible loss for all opioid-related litigation matters. An adverse judgment or negotiated resolution in any of these matters could have a material adverse impact on the Company's financial position, cash flows or liquidity, or results of operations.

On August 8, 2018, the Company was served with a *qui tam* complaint pending in the United States District Court for the District of Massachusetts alleging that the Company violated the federal False Claims Act and various state false claims acts due to the alleged failure of the Company and other defendants to report providers who were engaged in diversion of controlled substances. *United States ex rel. Manchester v. Purdue Pharma, L.P., et al.*, Case No. 1-16-cv-10947. On August 22, 2018, the United States filed a motion to dismiss. The relator died, and on February 25, 2019 the court entered an order staying the matter until a proper party can be substituted, and providing that if no party is substituted within 90 days of February 25, 2019, the case would be dismissed. In April 2019, the widow of the relator filed a motion to substitute their daughter as the relator; the United States and defendants opposed this substitution request. The motion remains pending and the case remains stayed.

McKESSON CORPORATION**FINANCIAL NOTES (Continued)**

In December 2019, the Company was served with two *qui tam* complaints filed by the same two relators alleging violations of the federal False Claims Act, the California False Claims Act, and the California Unfair Business Practices statute based on alleged predicate violations of the Controlled Substances Act and its implementing regulations, *United States ex rel. Kelley*, 19-cv-2233, and *State of California ex rel. Kelley*, CGC-19-576931. The complaints seek relief including treble damages, civil penalties, attorney fees, and costs in unspecified amounts. On February 16, 2021, the court in the federal action dismissed the second amended complaint with prejudice, and the relators appealed the dismissal to the U.S. Court of Appeals for the Ninth Circuit, which affirmed the dismissal on March 10, 2022. On June 28, 2021, the court in the state action dismissed the complaint with prejudice, and the relators appealed the dismissal to the Superior Court of California, County of San Francisco.

Insurance Coverage Litigation

Two cases pending in the Northern District of California were filed against McKesson by its liability umbrella insurers about policies they issued to the Company for the period 1999-2017, AIU Insurance Company and National Union Fire Insurance Company of Pittsburgh, Pa. (together "AIG") and ACE Property and Casualty Insurance Company ("ACE"). *AIU Insurance Company et al. v. McKesson Corporation*, No. 3:20-cv-07469 (N.D. Cal.) was initiated by AIG in the Northern District of California on October 23, 2020. *Ace Property and Casualty Insurance Company v. McKesson Corporation et al.*, No. 3:20-cv-09356 (N.D. Cal.) was brought by ACE in California state court on November 2, 2020, and was removed by McKesson to federal court, transferred to the Northern District of California, and designated as related to the AIU action. AIG and ACE are seeking declarations that they have no duty to defend or indemnify McKesson in the thousands of lawsuits pending in federal and state courts related to opioids. In both actions, McKesson has asserted claims under the AIG and ACE policies seeking declarations and damages for past and future defense and indemnity costs. On April 5, 2022, the court issued an order granting partial summary judgment to the insurers that the Company's defense costs in certain opioid-related litigation were not covered by two of the insurance policies.

II. Other Litigation and Claims

On May 17, 2013, the Company was served with a complaint filed in the United States District Court for the Northern District of California by True Health Chiropractic Inc., alleging that McKesson sent unsolicited marketing faxes in violation of the Telephone Consumer Protection Act of 1991 ("TCPA"), as amended by the Junk Fax Protection Act of 2005 or JFPA, *True Health Chiropractic Inc., et al. v. McKesson Corporation, et al.*, No. CV-13-02219 (HG). Plaintiffs seek statutory damages from \$500 to \$1,500 per violation plus injunctive relief. True Health Chiropractic later amended its complaint, adding McLaughlin Chiropractic Associates as an additional named plaintiff and McKesson Technologies Inc. as a defendant. Both plaintiffs alleged that defendants violated the TCPA by sending faxes that did not contain notices regarding how to opt out of receiving the faxes. On August 13, 2019, the court granted plaintiffs' renewed motion for class certification. After class notice and the opt-out period, 9,490 fax numbers remain in the class, representing 48,769 faxes received. On October 8, 2021, the court de-certified the class citing the plaintiffs lacked class-wide proof identifying the manner of receipt, thus leaving two named Plaintiffs remaining in the case. On April 27, 2022, the Court found that the named Plaintiffs had failed to meet their burden to show Defendants willfully or knowingly violated the TCPA and therefore were not entitled to treble damages. The Court found McKesson liable for statutory damages in the amount of \$6,500.

On April 16, 2013, the Company's subsidiary, U.S. Oncology, Inc. ("USON"), was served with a third amended *qui tam* complaint filed in the United States District Court for the Eastern District of New York by two relators, purportedly on behalf of the United States, 21 states and the District of Columbia, against USON and five other defendants, alleging that USON solicited and received illegal "kickbacks" from Amgen in violation of the Anti-Kickback Statute, the False Claims Act, and various state false claims statutes, and seeking damages, treble damages, civil penalties, attorneys' fees and costs of suit, all in unspecified amounts, *United States ex rel. Piacentile v. Amgen Inc., et al.*, CV 04-3983 (SJ). Previously, the United States declined to intervene in the case as to all allegations and defendants except for Amgen. On September 30, 2013, the court granted the United States' motion to dismiss the claims pled against Amgen. On September 17, 2018, the court granted USON's motion to dismiss the claims pled against it, with leave to amend. On November 16, 2018, the relators filed a fourth amended complaint; that complaint was dismissed with prejudice on December 1, 2021. Plaintiffs filed a notice of appeal with the Court of Appeals for the Second Circuit on January 4, 2022.

McKESSEN CORPORATION
FINANCIAL NOTES (Continued)

On June 17, 2014, U.S. Oncology Specialty, LP (“USOS”) was served with a fifth amended *qui tam* complaint filed in the United States District Court for the Eastern District of New York by a relator alleging that USOS, among others, solicited and received illegal “kickbacks” from Amgen in violation of the Anti-Kickback Statute, the federal False Claims Act, and various state false claims statutes, and seeking damages, treble damages, civil penalties, attorneys’ fees and costs of suit, all in unspecified amounts, *United States ex rel. Hanks v. Amgen, Inc., et al.*, CV-08-03096 (SJ). Previously, the U.S. declined to intervene in the case as to all allegations and defendants except for Amgen. On September 17, 2018, the court granted USOS’s motion to dismiss. Following the relator’s appeal, the United States Court of Appeals for the Second Circuit vacated the district court’s order and remanded the suit to the district court, directing it to consider the question of whether the suit should be dismissed for lack of jurisdiction. The district court granted the relator leave to amend the complaint for a seventh time. The relator filed the seventh amended complaint on November 30, 2020.

On April 3, 2018, a second amended *qui tam* complaint was filed in the United States District Court for the Eastern District of New York by a relator, purportedly on behalf of the United States, 30 states, the District of Columbia, and two cities against McKesson Corporation, McKesson Specialty Care Distribution Corporation, McKesson Specialty Distribution LLC, McKesson Specialty Care Distribution Joint Venture, L.P., Oncology Therapeutics Network Corporation, Oncology Therapeutics Network Joint Venture, L.P., US Oncology, Inc. and US Oncology Specialty, L.P., alleging that from 2001 through 2010 the defendants repackaged and sold single-dose syringes of oncology medications in a manner that violated the federal False Claims Act and various state and local false claims statutes, and seeking damages, treble damages, civil penalties, attorneys’ fees and costs of suit, all in unspecified amounts, *United States ex rel. Omni Healthcare Inc. v. McKesson Corporation, et al.*, 12-CV-06440 (NG). The United States and the named states have declined to intervene in the case. On October 15, 2018, the Company filed a motion to dismiss the complaint as to all named defendants. On February 4, 2019, the court granted the motion to dismiss in part and denied it in part, leaving the Company and Oncology Therapeutics Network Corporation as the only remaining defendants in the case. On December 9, 2019, the United States District Court for the Eastern District of New York ordered the unsealing of another complaint filed by the same relator, alleging the same misconduct and seeking the same relief with respect to US Oncology, Inc., purportedly on behalf of the same government entities, *United States ex rel. Omni Healthcare, Inc. v. US Oncology, Inc.*, 19-cv-05125. The United States and the named states declined to intervene in the case.

The Company is a defendant in an amended complaint filed on June 15, 2018 in a case pending in the United States District Court for the Southern District of Illinois alleging that the Company’s subsidiary, McKesson Medical-Surgical Inc., among others, violated the Sherman Act by restraining trade in the sale of safety and conventional syringes and safety IV catheters. *Marion Diagnostic Center, LLC v. Becton, Dickinson, et al.*, No. 18:1059. The action is filed on behalf of a purported class of purchasers, and seeks treble damages and further relief, all in unspecified amounts. On July 20, 2018, the defendants filed a motion to dismiss. On November 30, 2018, the district court granted the motion to dismiss, and dismissed the complaint with prejudice. On December 27, 2018, plaintiffs appealed the order to the United States Court of Appeals for the Seventh Circuit. On March 5, 2020, the United States Court of Appeals for the Seventh Circuit vacated the district court’s order, and ruled that dismissal was appropriate on alternative grounds. The case was remanded to the district court to allow the plaintiffs an opportunity to amend their complaint. Plaintiffs filed an amended complaint on August 21, 2020. Defendants filed a motion to dismiss the amended complaint, which the district court granted on March 15, 2021. Plaintiffs appealed the order to the United States Court of Appeals for the Seventh Circuit, which affirmed the district court’s dismissal on March 18, 2022.

On December 30, 2019, a group of independent pharmacies and a hospital filed a purported class action complaint alleging that the Company and other distributors violated the Sherman Act by colluding with manufacturers to restrain trade in the sale of generic drugs. *Reliable Pharmacy, et al. v. Actavis Holdco US, et al.*, No. 2:19-cv-6044; MDL No. 16-MD-2724. The complaint seeks relief including treble damages, disgorgement, attorney fees, and costs in unspecified amounts.

On December 12, 2018, the Company received a purported class action complaint in the United States District Court for the Northern District of California, alleging that McKesson and two of its former officers, CEO John Hammergren and CFO James Beer, violated the Securities Exchange Act of 1934 by reporting profits and revenues from 2013 until early 2017 that were false and misleading, due to an alleged undisclosed conspiracy to fix the prices of generic drugs. *Evanston Police Pension Fund v. McKesson Corporation*, No. 3:18-06525. The complaint seeks relief including damages, attorney fees, and costs in unspecified amounts. On February 8, 2019, the court appointed the Pension Trust Fund for Operating Engineers as the lead plaintiff. On April 10, 2019, the lead plaintiff filed an amended complaint that added insider trading allegations against defendant Hammergren. On April 8, 2021, the court granted plaintiff’s motion for class certification.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

In July 2015, The Great Atlantic & Pacific Tea Company (“A&P”), a former customer of the Company, filed for reorganization in bankruptcy under Chapter 11 of the United States Bankruptcy Code in the Bankruptcy Court for the Southern District of New York. *In re The Great Atlantic & Pacific Tea Company, Inc., et al.*, Case No. 15-23007. A suit filed in 2017 against the Company in this bankruptcy case seeks to recover alleged preferential transfers. *The Official Committee of Unsecured Creditors on behalf of the bankruptcy estate of The Great Atlantic & Pacific Tea Company, Inc., et al. v. McKesson Corporation d/b/a McKesson Drug Co.*, Adv. Proc. No. 17-08264.

In October 2019, the Company’s subsidiary NDCHealth Corporation dba RelayHealth (“RelayHealth”) was served with three purported class action complaints filed in the United States District Court for the Northern District of Illinois. The complaints allege that RelayHealth violated the Sherman Act by entering into an agreement with co-defendant Surescripts, LLC not to compete in the electronic prescription routing market, and by conspiring with Surescripts, LLC to monopolize that market, *Powell Prescription Center, et al. v. Surescripts, LLC, et al.*, No. 1:19-cv-06627; *Intergrated Pharmaceutical Solutions LLC v. Surescripts, LLC, et al.*, 1:19-cv-06778; *Falconer Pharmacy, Inc. v. Surescripts LLC, et al.*, No. 1:19-cv-07035. In November 2019, three similar complaints were filed in the United States District Court for the Northern District of Illinois. *Kennebunk Village Pharmacy, Inc. v. SureScripts, LLC, et al.*, 1:19-cv-7445; *Whitman v. SureScripts, LLC et al.*, No. 1:19-cv-7448; *BBK Global Corp. v. SureScripts, LLC et al.*, 1:19-cv-7640. In December 2019, the six actions were consolidated in the Northern District of Illinois. The complaints seek relief including treble damages, attorney fees, and costs. Plaintiffs and RelayHealth reached an agreement in June 2020 to resolve the class action lawsuits and RelayHealth paid into escrow an amount not material in the context of the Company’s overall financial results. The settlement does not include any admission of liability, and RelayHealth expressly denies wrongdoing. The Court granted Plaintiffs’ motion for final approval of the settlement on February 24, 2022.

In July 2020, the Company was served with a first amended *qui tam* complaint filed in the United States District Court for the Southern District of New York by a relator on behalf of the U.S., 27 states and the District of Columbia against McKesson Corporation, McKesson Specialty Distribution LLC, and McKesson Specialty Care Distribution Corporation, alleging that defendants violated the Anti-Kickback Statute, federal False Claims Act, and various state false claims statutes by providing certain business analytical tools to oncology practice customers, *United States ex rel. Hart v. McKesson Corporation, et al.*, 15-cv-00903-RA. The U.S. and the named states have declined to intervene in the case. The complaint seeks relief including damages, treble damages, civil penalties, attorney fees, and costs of suit, all in unspecified amounts. On May 5, 2022, the district court granted the Company’s motion to dismiss the complaint, but granted the plaintiff leave to amend the complaint.

III. Government Subpoenas and Investigations

From time to time, the Company receives subpoenas or requests for information from various government agencies. The Company generally responds to such subpoenas and requests in a cooperative, thorough, and timely manner. These responses sometimes require time and effort and can result in considerable costs being incurred by the Company. Such subpoenas and requests can lead to the assertion of claims or the commencement of civil or criminal legal proceedings against the Company and other members of the health care industry, as well as to settlements of claims against the Company. The Company responds to these requests in the ordinary course of business. The following are examples of the type of subpoenas or requests the Company receives from time to time.

In May 2017 and August 2018, respectively, the Company was served with two separate Civil Investigative Demands by the U.S. Attorney’s Office for the Eastern District of New York relating to the certification the Company obtained for two software products under the U.S. Department of Health and Human Services’ Electronic Health Record Incentive Program.

In April and June 2019, the United States Attorney’s Office for the Eastern District of New York served grand jury subpoenas seeking documents related to the Company’s anti-diversion policies and procedures and its distribution of Schedule II controlled substances. The Company believes the subpoenas are part of a broader investigation by that office into pharmaceutical manufacturers’ and distributors’ compliance with the Controlled Substances Act and related statutes.

In January 2020, the United States Attorney’s Office for the District of Massachusetts served a Civil Investigative Demand on the Company seeking documents related to certain discounts and rebates paid to physician practice customers.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

On November 21, 2016, the Belgian Competition Authority carried out inspections at the premises of several Belgian wholesalers, including Belmedis SA, which was subsequently acquired by the Company. Pharma Belgium NV was also part of the investigation. The Company resolved this matter in April 2022 by paying fines not material in the context of the Company's overall financial results that had been fully reserved for in the third quarter of 2022.

On May 19, 2021, the Norwegian Competition Authority carried out an inspection of Norsk Medisinaldepot AS regarding its and its competitors alleged sharing of competitively sensitive information.

In June 2021, the United States Department of Justice served a Civil Investigative Demand on the Company seeking documents related to distribution arrangements for ophthalmology products.

IV. State Opioid Statutes

Legislative, regulatory, or industry measures to address the misuse of prescription opioid medications could affect the Company's business in ways that it may not be able to predict. For example, in April 2018, the State of New York adopted the Opioid Stewardship Act (the "OSA") which required the creation of an aggregate \$100 million annual surcharge on all manufacturers and distributors licensed to sell or distribute opioids in New York. The initial surcharge payment would have been due on January 1, 2019 for opioids sold or distributed during calendar year 2017. On July 6, 2018, the Healthcare Distribution Alliance filed a lawsuit challenging the constitutionality of the law and seeking an injunction against its enforcement. On December 19, 2018, the U.S. District Court for the Southern District of New York found the law unconstitutional and issued an injunction preventing the State of New York from enforcing the law. The State appealed that decision. On September 14, 2020, a panel of the U.S. Court of Appeals for the Second Circuit reversed the district court's decision on procedural grounds. The Company has accrued a \$50 million pre-tax charge (\$37 million after-tax) as its estimated share of the OSA surcharge for calendar years 2017 and 2018. This OSA provision was recognized in "Selling, distribution, general, and administrative expenses" in the Consolidated Statement of Operations for the year ended March 31, 2021 and in "Other accrued liabilities" in the Consolidated Balance Sheet as of March 31, 2021. The State of New York adopted an excise tax on sales of opioids in the State, which became effective July 1, 2019. The law adopting the excise tax made clear that the OSA does not apply to sales or distributions occurring after December 31, 2018. The Healthcare Distribution Alliance filed a petition for panel rehearing, or, in the alternative, for rehearing en banc with the U.S. Court of Appeals for the Second Circuit; that petition was denied on December 18, 2020. On February 12, 2021, the Court of Appeals for the Second Circuit granted a motion by the Healthcare Distribution Alliance to stay its mandate pending the filing and disposition of a petition for writ of certiorari before the U.S. Supreme Court. That petition was denied on October 4, 2021. In December 2021, McKesson paid \$26 million for the assessment for calendar year 2017 while reserving all rights to challenge the constitutionality of the assessment.

V. Environmental Matters

Primarily as a result of the operation of the Company's former chemical businesses, which were fully divested by 1987, the Company is involved in various matters pursuant to environmental laws and regulations. The Company has received claims and demands from governmental agencies relating to investigative and remedial actions purportedly required to address environmental conditions alleged to exist at five sites where it, or entities acquired by it, formerly conducted operations and the Company, by administrative order or otherwise, has agreed to take certain actions at those sites, including soil and groundwater remediation.

Based on a determination by the Company's environmental staff, in consultation with outside environmental specialists and counsel, the current estimate of the Company's probable loss associated with the remediation costs for these five sites is \$15 million, net of amounts anticipated from third parties. The \$15 million is expected to be paid out between April 2022 and March 2052. The Company has accrued for the estimated probable loss for these environmental matters.

McKESSON CORPORATION**FINANCIAL NOTES (Continued)**

The Company has been designated as a Potentially Responsible Party (“PRP”) under the Superfund law for environmental assessment and cleanup costs as the result of its alleged disposal of hazardous substances at 14 sites. With respect to these sites, numerous other PRPs have similarly been designated and while the current state of the law potentially imposes joint and several liabilities upon PRPs, as a practical matter, costs of these sites are typically shared with other PRPs. At one of these sites, the United States Environmental Protection Agency has selected a preferred remedy with an estimated cost of approximately \$1.4 billion. It is not certain at this point in time what proportion of this estimated liability will be borne by the Company. Accordingly, the Company’s estimated probable loss at those 14 sites is approximately \$29 million, which has been accrued for in the Consolidated Balance Sheets. However, it is possible that the ultimate costs of these matters may exceed or be less than the reserves.

VI. Value Added Tax Assessments

The Company operates in various countries outside the U.S. which collect value added taxes (“VAT”). The determination of the manner in which a VAT applies to the Company’s foreign operations is subject to varying interpretations arising from the complex nature of the tax laws. The Company has received assessments for VAT which are in various stages of appeal. The Company disagrees with these assessments and believes that it has a strong legal argument to defend its tax positions. Certain VAT assessments relate to years covered by an indemnification agreement. Due to the complex nature of the tax laws, it is not possible to estimate the outcome of these matters. However, based on currently available information, the Company believes the ultimate outcome of these matters will not have a material adverse effect on its financial position, cash flows or results of operations.

VII. Antitrust Settlements

Numerous lawsuits have been filed against certain brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market. These lawsuits are typically brought as class actions. The Company has not been named a plaintiff in any of these class action lawsuits, but has been a member of the class of those who purchased directly from the pharmaceutical manufacturers. Some of these class action lawsuits have settled in the past with the Company receiving proceeds, including \$46 million, \$181 million, and \$22 million in 2022, 2021, and 2020, respectively, which were included in “Cost of sales” in the Consolidated Statements of Operations.

VIII. Other Matters

The Company is involved in various other litigation, governmental proceedings, and claims, not described above, that arise in the normal course of business. While it is not possible to determine the ultimate outcome or the duration of such litigation, governmental proceedings, or claims, the Company believes, based on current knowledge and the advice of counsel, that such litigation, proceedings, and claims will not have a material impact on the Company’s financial position or results of operations.

19. Stockholders’ Equity (Deficit)

Each share of the Company’s outstanding common stock is permitted one vote on proposals presented to stockholders and is entitled to share equally in any dividends declared by the Board.

In July 2021, the quarterly dividend was raised from \$0.42 to \$0.47 per common share for dividends declared on or after such date by the Board. Dividends were \$1.83 per share in 2022, \$1.67 per share in 2021, and \$1.62 in 2020. The Company anticipates that it will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remain within the discretion of the Board and will depend upon the Company’s future earnings, financial condition, capital requirements, and other factors.

Share Repurchase Plans

Stock repurchases may be made from time-to-time in open market transactions, privately negotiated transactions, through accelerated share repurchase (“ASR”) programs, or by combinations of such methods, any of which may use pre-arranged trading plans that are designed to meet the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934. The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including the Company’s stock price, corporate and regulatory requirements, restrictions under the Company’s debt obligations, and other market and economic conditions. During the last three years, the Company’s share repurchases were transacted through both open market transactions and ASR programs with third-party financial institutions.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

Information regarding share repurchase activity over the last three years is as follows:

Share Repurchases ⁽¹⁾			
<i>(In millions, except price per share data)</i>	Total Number of Shares Purchased ⁽²⁾	Average Price Paid Per Share	Approximate Dollar Value of Shares that May Yet Be Purchased Under the Programs
Balance, March 31, 2019			\$ 3,469
Shares repurchased - Open market	9.2	\$ 144.68	(1,334)
Shares repurchased - May 2019 ASR	4.7	\$ 127.68	(600)
Balance, March 31, 2020			1,535
Shares repurchase authorization increase in 2021			2,000
Shares repurchased - Open market ⁽³⁾	4.7	\$ 160.33	(750)
Balance, March 31, 2021			2,785
Shares repurchased - May 2021 ASR	5.2	\$ 193.22	(1,000)
Shares repurchased - Open market	4.6	\$ 217.73	(1,007)
Shares repurchase authorization increase in 2022			4,000
Shares repurchased - February 2022 ASR ⁽⁴⁾	4.8	\$ 265.56	(1,500)
Balance, March 31, 2022			\$ 3,278

- (1) This table does not include the value of equity awards surrendered to satisfy tax withholding obligations or forfeitures of equity awards. It also excludes shares related to the Company's Split-off of the Change Healthcare JV as described below.
- (2) The number of shares purchased reflects rounding adjustments.
- (3) Of the total dollar value, \$8 million was accrued within "Other accrued liabilities" in the Company's Consolidated Balance Sheet as of March 31, 2021 for share repurchases that were executed in late March and settled in early April.
- (4) In February 2022, the Company entered into an ASR program with a third-party financial institution to repurchase \$1.5 billion of the Company's common stock. The average price paid per share and total number of shares purchased under this program are estimates based on the initial share purchase price and initial delivery of shares under an ASR agreement and may differ from the average price paid per share and total number of shares purchased under the ASR program upon its final settlement in May 2022.

On March 9, 2020, the Company completed the Split-off of its interest in the Change Healthcare JV. In connection with the Split-off, the Company distributed all 176.0 million outstanding shares of SpinCo common stock, which held all of the Company's interests in the Change Healthcare JV, to participating holders of the Company's common stock in exchange for 15.4 million shares of McKesson stock, which are now held as treasury stock on the Company's Consolidated Balance Sheets. Following consummation of the exchange offer, on March 10, 2020, SpinCo merged with and into Change with each share of SpinCo common stock converted into one share of Change common stock, par value \$0.001 per share, with cash being paid in lieu of fractional shares of Change common stock. See Financial Note 4, "Business Acquisitions and Divestitures," for more information.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

Accumulated Other Comprehensive Income (Loss)

Information regarding changes in the Company's accumulated other comprehensive income (loss) by component are as follows:

	Foreign Currency Translation Adjustments		Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax	Unrealized Gains (Losses) and Other Components of Benefit Plans, Net of Tax	Total Accumulated Other Comprehensive Loss
	Foreign Currency Translation Adjustments, Net of Tax ⁽¹⁾	Unrealized Gains (Losses) on Net Investment Hedges, Net of Tax ⁽²⁾			
<i>(In millions)</i>					
Balance at March 31, 2019	\$ (1,628)	\$ 53	\$ (37)	\$ (237)	\$ (1,849)
Other comprehensive income (loss) before reclassifications	(151)	85	86	33	53
Amounts reclassified to earnings and other ⁽³⁾	—	—	—	96	96
Other comprehensive income (loss)	(151)	85	86	129	149
Less: amounts attributable to noncontrolling and redeemable noncontrolling interests	1	—	—	2	3
Other comprehensive income (loss) attributable to McKesson	(152)	85	86	127	146
Balance at March 31, 2020	(1,780)	138	49	(110)	(1,703)
Other comprehensive income (loss) before reclassifications	312	(175)	(36)	(2)	99
Amounts reclassified to earnings and other ⁽⁴⁾	47	—	—	24	71
Other comprehensive income (loss)	359	(175)	(36)	22	170
Less: amounts attributable to noncontrolling and redeemable noncontrolling interests	(60)	(1)	—	8	(53)
Other comprehensive income (loss) attributable to McKesson	419	(174)	(36)	14	223
Balance at March 31, 2021	(1,361)	(36)	13	(96)	(1,480)
Other comprehensive income (loss) before reclassifications	(51)	41	18	31	39
Amounts reclassified to earnings and other ⁽⁵⁾	71	(1)	(4)	10	76
Other comprehensive income	20	40	14	41	115
Less: amounts attributable to noncontrolling and redeemable noncontrolling interests	5	(6)	—	—	(1)
Other comprehensive income attributable to McKesson	15	46	14	41	116
Exercise of put right by noncontrolling shareholders of McKesson Europe AG	(158)	—	—	(12)	(170)
Balance at March 31, 2022	\$ (1,504)	\$ 10	\$ 27	\$ (67)	\$ (1,534)

- (1) Primarily results from the conversion of non-U.S. dollar financial statements of the Company's operations in Europe and Canada into the Company's reporting currency, U.S. dollars.
- (2) Amounts before reclassifications recorded in 2022, 2021, and 2020 include gains (losses) of \$73 million, \$(118) million, and \$39 million, respectively, related to net investment hedges from Euro-denominated notes and gains (losses) of \$(4) million, \$(119) million, and \$76 million, respectively, related to net investment hedges from cross-currency swaps. These amounts are net of income tax benefit (expense) of \$(23) million, \$62 million, and \$(30) million in 2022, 2021, and 2020, respectively.

McKESSON CORPORATION**FINANCIAL NOTES (Continued)**

- (3) Primarily reflects a reclassification of losses of \$127 million, net of \$33 million of income tax benefit, predominantly on the termination of the Company's U.S. defined benefit pension plan from "Accumulated other comprehensive loss" to "Other income, net" in the Company's Consolidated Statement of Operations.
- (4) Primarily includes adjustments for amounts related to the contribution of the Company's German pharmaceutical wholesale business to a joint venture, as discussed in more detail in Financial Note 2, "Held for Sale" and Financial Note 6, "Other Income, Net." These amounts were included in the 2021 and 2020 calculation of charges to remeasure the assets and liabilities held for sale to fair value less costs to sell recorded within Selling, distribution, general, and administrative expenses in the Consolidated Statements of Operations.
- (5) Primarily includes adjustments for amounts related to the sale of the Company's Austrian business, as discussed in more detail in Financial Note 2, "Held for Sale." These amounts were included in the 2022 calculation of charges to remeasure the assets and liabilities held for sale to fair value less costs to sell recorded within Selling, distribution, general, and administrative expenses in the Consolidated Statement of Operations.

20. Related Party Balances and Transactions

McKesson Europe has investments in pharmacies located across Europe that are accounted for under the equity method. McKesson Europe maintains distribution arrangements with these pharmacies for the sale of related goods and services under which revenues of \$137 million, \$178 million, and \$141 million are included in the Consolidated Statements of Operations for the years ended March 31, 2022, 2021, and 2020, respectively, and receivables related to these transactions included in the Consolidated Balance Sheets were not material as of March 31, 2022 and 2021. Predominately all of these pharmacies were divested from the Company in the fourth quarter of 2022 as part of the completed sale of the Company's Austrian business, while certain other remaining pharmacies are included in the E.U. disposal group and U.K. disposal group. Refer to Financial Note 2, "Held for Sale," for additional information.

In 2022, 2021, and 2020, the Company's pharmaceutical sales to one of its equity method investees in the U.S. Pharmaceutical segment totaled \$100 million, \$111 million, and \$60 million, respectively. Trade receivables related to these transactions from this investee were not material as of March 31, 2022 and 2021. During 2022, the Company's investment in this investee was no longer accounted for using the equity method and is not considered a related party as of March 31, 2022.

Refer to Financial Note 4, "Business Acquisitions and Divestitures," for information regarding related party balances and transactions with Change and the Change Healthcare JV.

21. Segments of Business

Commencing with the second quarter of 2021, the Company began reporting under four reportable segments: U.S. Pharmaceutical, RxTS, Medical-Surgical Solutions, and International. Other, for retrospective periods presented, consists of the Company's previous equity method investment in the Change Healthcare JV, which was split-off from McKesson in the fourth quarter of 2020. The organizational structure also includes Corporate, which consists of income and expenses associated with administrative functions and projects, and the results of certain investments. The factors for determining the reportable segments include the manner in which management evaluates the performance of the Company combined with the nature of the individual business activities. The Company evaluates the performance of its operating segments on a number of measures, including revenues and operating profit (loss) before interest expense and income taxes. Assets by operating segment are not reviewed by management for the purpose of assessing performance or allocating resources.

The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices. In addition, the segment sells financial, operational, and clinical solutions to pharmacies (retail, hospital, alternate site) and provides consulting, outsourcing, technological, and other services.

The RxTS segment serves McKesson's biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys. RxTS works across healthcare to connect pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions designed to benefit stakeholders and help people get the medicine they need to live healthier lives. RxTS also offers third-party logistics and wholesale distribution support across various therapeutic categories and temperature ranges to biopharma customers throughout the product lifecycle.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. This segment offers more than 285,000 national brand medical-surgical products as well as McKesson's own line of high-quality products through a network of distribution centers within the U.S.

The International segment includes the Company's operations in Europe and Canada, bringing together non-U.S.-based drug distribution services, specialty pharmacy, retail, and infusion care services. The Company's operations in Europe provide distribution and services to wholesale, institutional, and retail customers in 11 European countries where it owns, partners, or franchises with retail pharmacies and operates through two businesses: Pharmaceutical Distribution and Retail Pharmacy. The Company's Canada operations deliver vital medicines, supplies, and information technology solutions throughout Canada and includes Rexall Health retail pharmacies. In 2022, the Company entered into agreements to sell the E.U. disposal group and U.K. disposal group, and completed the sale of its Austrian business. Refer to Financial Note 2, "Held for Sale," for more information.

Other, for retrospective periods presented consists of the Company's previous investment in the Change Healthcare JV, which was split-off from the Company in the fourth quarter of 2020.

McKESSON CORPORATION
FINANCIAL NOTES (Continued)

Financial information relating to the Company's reportable operating segments and reconciliations to the consolidated totals is as follows:

<i>(In millions)</i>	Years Ended March 31,		
	2022	2021	2020
Segment revenues ⁽¹⁾			
U.S. Pharmaceutical	\$ 212,149	\$ 189,274	\$ 181,700
Prescription Technology Solutions	3,864	2,890	2,705
Medical-Surgical Solutions	11,608	10,099	8,305
International	36,345	35,965	38,341
Total revenues	<u>\$ 263,966</u>	<u>\$ 238,228</u>	<u>\$ 231,051</u>
Segment operating profit (loss) ⁽²⁾			
U.S. Pharmaceutical ⁽³⁾	\$ 2,879	\$ 2,763	\$ 2,745
Prescription Technology Solutions	500	395	396
Medical-Surgical Solutions ⁽⁴⁾	959	707	499
International ⁽⁵⁾	(968)	(37)	(161)
Other ⁽⁶⁾	—	—	(1,113)
Subtotal	3,370	3,828	2,366
Corporate expenses, net ⁽⁷⁾	(1,073)	(8,645)	(973)
Loss on debt extinguishment ⁽⁸⁾	(191)	—	—
Interest expense	(178)	(217)	(249)
Income (loss) from continuing operations before income taxes	<u>\$ 1,928</u>	<u>\$ (5,034)</u>	<u>\$ 1,144</u>
Segment depreciation and amortization ⁽⁹⁾			
U.S. Pharmaceutical	\$ 228	\$ 211	\$ 208
Prescription Technology Solutions	82	87	85
Medical-Surgical Solutions	129	130	136
International	204	334	357
Corporate	117	125	136
Total depreciation and amortization	<u>\$ 760</u>	<u>\$ 887</u>	<u>\$ 922</u>
Segment expenditures for long-lived assets ⁽¹⁰⁾			
U.S. Pharmaceutical	\$ 137	\$ 246	\$ 109
Prescription Technology Solutions	10	22	23
Medical-Surgical Solutions	74	57	36
International	177	212	218
Corporate	137	104	120
Total expenditures for long-lived assets	<u>\$ 535</u>	<u>\$ 641</u>	<u>\$ 506</u>

(1) Revenues from services on a disaggregated basis represent less than 1% of the U.S. Pharmaceutical segment's total revenues, less than 40% of the RxTS segment's total revenues, less than 3% of the Medical-Surgical Solutions segment's total revenues, and less than 8% of the International segment's total revenues. The International segment reflects foreign revenues. Revenues for the remaining three reportable segments are domestic.

(2) Segment operating profit (loss) includes gross profit, net of total operating expenses, as well as other income (expense), net, for the Company's reportable segments. For retrospective periods presented, operating loss for Other reflects equity earnings and charges from the Company's previous equity method investment in the Change Healthcare JV, which was split-off from McKesson in the fourth quarter of 2020.

McKESSON CORPORATION**FINANCIAL NOTES (Continued)**

- (3) The Company's U.S. Pharmaceutical segment's operating profit for 2022, 2021, and 2020 includes credits of \$23 million, \$38 million, and \$252 million, respectively, related to the LIFO method of accounting for inventories. Operating profit for 2022, 2021, and 2020 also includes \$46 million, \$181 million, and \$22 million, respectively, of cash receipts for the Company's share of antitrust legal settlements. In addition, operating profit for 2021 includes a charge of \$50 million recorded in connection with the Company's estimated liability under the State of New York's OSA, as further discussed in Financial Note 18, "Commitments and Contingent Liabilities."
- (4) The Company's Medical-Surgical Solutions segment's operating profit for 2022 and 2021 includes inventory charges of \$164 million and \$136 million, respectively, on certain PPE and other related products.
- (5) The Company's International segment's operating loss for 2022, 2021, and 2020 reflects the following:
- 2022 includes charges of \$1.1 billion to remeasure assets and liabilities of the U.K. disposal group to fair value less costs to sell, as discussed in more detail in Financial Note 2, "Held for Sale;"
 - 2022 includes charges of \$383 million to remeasure assets and liabilities of the E.U. disposal group to fair value less costs to sell and to impair certain assets, including internal-use software that will not be utilized in the future, as discussed in more detail in Financial Note 2, "Held for Sale;"
 - 2022 includes a gain of \$59 million related to the sale of the Company's Canadian health benefit claims management and plan administrative services business;
 - 2022 includes a gain of \$42 million related to the sale of the Company's 30% interest in its German pharmaceutical wholesale joint venture to WBA. 2021 and 2020 includes charges of \$58 million and \$275 million, respectively, related to the contribution of a majority of its German pharmaceutical wholesale business to the joint venture with WBA completed on November 1, 2020. See Financial Note 2, "Held for Sale," and Financial Note 6, "Other Income, Net," for further details;
 - 2021 includes a goodwill impairment charge of \$69 million related to one of the Company's reporting units in Europe, as discussed in more detail in Financial Note 11, "Goodwill and Intangible Assets, Net;" and
 - 2021 and 2020 includes long-lived asset impairment charges of \$115 million and \$112 million, respectively, primarily related to retail pharmacy businesses in Canada and Europe, as discussed in more detail in Financial Note 3, "Restructuring, Impairment, and Related Charges, Net."
- (6) Operating loss for Other for 2020 includes an impairment charge of \$1.2 billion and a dilution loss of \$246 million associated with the Company's previous investment in the Change Healthcare JV, partially offset by a net gain of \$414 million (pre-tax and after-tax) related to the separation of its interest in the Change Healthcare JV completed during the fourth quarter of 2020. Operating loss for 2020 also includes the Company's proportionate share of loss from the Change Healthcare JV of \$119 million.
- (7) Corporate expenses, net, for 2022, 2021, and 2020 reflects the following:
- 2022 includes charges of \$55 million primarily related to the effect of accumulated other comprehensive loss components from the E.U. disposal group, as discussed in more detail in Financial Note 2, "Held for Sale;"
 - 2022 includes charges of \$42 million primarily related to the effect of accumulated other comprehensive loss components from the U.K. disposal group, as discussed in more detail in Financial Note 2, "Held for Sale;"
 - 2022 and 2021 includes charges of \$274 million and \$8.1 billion, respectively, related to the estimated liability for opioid-related claims, as discussed in more detail in Financial Note 18, "Commitments and Contingent Liabilities;"
 - 2022 and 2021 includes net gains of \$98 million and \$133 million, respectively, associated with certain of the Company's equity investments, as discussed in more detail in Financial Note 16, "Fair Value Measurements;"
 - 2021 includes a net gain of \$131 million recorded in connection with insurance proceeds received from the settlement of the shareholder derivative action related to the Company's controlled substances monitoring program;
 - 2020 includes settlement charges of \$122 million for the termination of the Company's defined benefit pension plan; and
 - 2020 includes a settlement charge of \$82 million related to opioid claims.
- (8) Loss on debt extinguishment for 2022 consists of a charge of \$191 million related to the Company's July 2021 tender offer to redeem a portion of its existing debt, as discussed in more detail in Financial Note 12, "Debt and Financing Activities."
- (9) Amounts primarily consist of amortization of acquired intangible assets purchased in connection with business acquisitions and capitalized software for internal use as well as depreciation and amortization of property, plant, and equipment, net.
- (10) Long-lived assets consist of property, plant, and equipment, net and capitalized software.

McKESSON CORPORATION
FINANCIAL NOTES (Concluded)

Segment assets and long-lived assets by geographic areas were as follows:

<i>(In millions)</i>	March 31,	
	2022	2021
Segment assets		
U.S. Pharmaceutical	\$ 38,346	\$ 35,236
Prescription Technology Solutions	3,528	3,446
Medical-Surgical Solutions	5,830	5,986
International	13,717	14,987
Corporate	1,877	5,360
Total assets	<u>\$ 63,298</u>	<u>\$ 65,015</u>
Long-lived assets ⁽¹⁾		
United States	\$ 2,060	\$ 2,110
Foreign	352	984
Total long-lived assets	<u>\$ 2,412</u>	<u>\$ 3,094</u>

(1) Long-lived assets consist of property, plant, and equipment, net and capitalized software and excludes amounts classified as assets held for sale.

EXHIBIT N
GENERAL RELEASE

GENERAL RELEASE

This **GENERAL RELEASE** ("Release") is made this _____ day of _____, _____, by _____ ("Franchisee"), with reference to the following facts which they incorporate as part of the Release:

A. Health Mart Systems, Inc. ("Franchisor") and Franchisee have previously entered into a Franchise Agreement ("Franchise Agreement") dated _____ under which Franchisor has granted Franchisee the right to use the System and Proprietary Marks to operate a HEALTH MART® Drugstore. All capitalized terms that are not specifically defined in this Release shall have the same meaning assigned to them in the Franchise Agreement.

B. The parties execute this Release pursuant to the requirements of the Franchise Agreement. Specifically:

[COMPLETE BY CHECKING APPROPRIATE BOX]

☐ This Release is being executed in connection with Franchisee's request to renew its franchise rights, in which case the parties agree that this Release shall become effective when Franchisee satisfies all of the conditions of renewal including, without limitation, execution of a new Franchise Agreement for the renewal term and payment of the fees specified in the Franchise Agreement.

☐ This Release is being executed in connection with Franchisee's request to complete an Event of Transfer to an approved transferee, in which case the parties agree that this Release shall become effective when Franchisee satisfies all of the conditions of transfer set forth in the Franchise Agreement including, without limitation, payment of the fees specified in the Franchise Agreement in connection with a transfer, Franchisor's approval of the proposed transferee, and the proposed transferee's execution of a new Franchise Agreement.

☐ This Release is being executed in connection with the termination of the Franchise Agreement for reasons other than due to renewal or transfer.

NOW THEREFORE, for good and valuable consideration the receipt and sufficiency of which are hereby acknowledged, Franchisee agrees as follows:

1. General Release.

Franchisee, for itself, himself or herself, and, if applicable, additionally, for Franchisee's Affiliates, if any, and for each of their respective officers, directors, shareholders, members, managers, trustees, partners, employees, attorneys, heirs and successors (Franchisee and such other persons are collectively referred to as the "Releasing Parties"), hereby release and forever discharge Franchisor, Franchisor's Affiliates, and their respective officers, directors, shareholders, agents, employees, representatives, attorneys, successors and assigns (collectively the "Released Parties"), and each of them, from any and all claims, demands, obligations, liabilities, actions, causes of action, suits, proceedings, controversies, disputes, agreements, promises, allegations, costs and expenses, at law or in equity, of every nature, character or description whatsoever, whether known or unknown, suspected or unsuspected or anticipated or unanticipated, which any of the Releasing Parties ever had, now has, or may, shall or can hereafter have or acquire (collectively referred to as "Claims"). This Release includes, but is not limited to, all Claims arising out of, concerning, pertaining to or connected with any agreement, tort, statutory violation, representation, nondisclosure, act, omission to act, fact, matter or thing whatsoever, occurring as of or prior to the date of this Release, so that after the date of this Release, none of the Releasing Parties shall have any claim of any kind or nature whatsoever against the Released Parties, directly or indirectly, or by reason of any matter, cause, action, transaction or thing whatsoever done, said or omitted to have been done or said at any time prior to the date of this Release. The terms, "Franchisor's Affiliates" and "Franchisees Affiliates," respectively include every entity that controls, is controlled by, or is under common control with Franchisor or Franchisee.

2. Waiver of Civil Code Section 1542.

This Release is intended by Franchisee to be a full and unconditional general release, as that phrase is used and commonly interpreted, and to constitute a full, unconditional and final accord and satisfaction, extending to all claims of any nature, whether or not known, expected or anticipated to exist in favor of Franchisee or any of the other Releasing Parties against the Released Parties regardless of whether any unknown, unsuspected or unanticipated claim would materially affect settlement and compromise of any matter mentioned herein. Franchisee, for itself, himself or herself, for each of the other Releasing Parties hereby expressly, voluntarily and knowingly waives, relinquishes and abandons each and every right, protection and benefit to which Franchisee or any of the Releasing Parties would be entitled, now or at any time hereafter under Section 1542 of the Civil Code of the State of California, as well as under any other statutes or common law principles of similar effect to said Section 1542, whether now or hereinafter existing under the laws of California or any other applicable federal and state law with jurisdiction over the parties relationship. Franchisee, for itself, himself or herself, for each of the other Releasing Parties, acknowledges that Section 1542 of the Civil Code of the State of California provides as follows:

“A general release does not extend to claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him must have materially effected his settlement with the debtor.”

In making this voluntary express waiver, Franchisee acknowledges that claims or facts in addition to or different from those which are now known or believed to exist with respect to the matters mentioned herein may later be discovered and that it is Franchisee's intention to hereby fully and forever settle and release any and all matters, regardless of the possibility of later discovered claims or facts. This Release is and shall be and remain a full, complete and unconditional general release. Franchisee acknowledges and agrees that the foregoing waiver of Section 1542 is an essential, integral and material term of this Release.

3. Release Not Admission. Franchisor's acceptance of this Release shall not constitute or be construed as an admission of the validity of any claims made by or against Franchisor.

4. Authority of Parties. The person executing this Release on behalf of Franchisee represents that he or she is duly authorized to execute this Release on behalf of Franchisee.

5. No Prior Assignments. Franchisee represents and warrants that Franchisee has not previously assigned or transferred, or attempted to assign or transfer, to any third party any of the Claims which are the subject of this Release, all of such Claims being released.

This Release shall be construed in accordance with and governed by the law California, without regard to California's conflict of laws rules.

IN WITNESS WHEREOF, the parties have caused this Release to be signed by their duly authorized representatives.

Franchisee:

Signature

Print Name

If Franchisee is a Business Entity:

By: _____

Its: _____

Print Name

Store Name: _____

Account #: _____

Address: _____

City/State: _____

EXHIBIT O
STATE-SPECIFIC ADDENDA

HEALTH MART SYSTEMS, INC.
STATE SPECIFIC ADDENDA

CALIFORNIA

The California Department of Financial Protection and Innovation requires that certain provisions contained in franchise documents be amended to be consistent with California law, including the California Franchise Investment Law, CAL. CORP. CODE Section 31000 *et seq.*, and the California Franchise Relations Act, CAL. BUS. & PROF. CODE Section 20000 *et seq.* To the extent that the Disclosure Document/and or Franchise Agreement contain provisions that are inconsistent with the following, such provisions are hereby amended:

1. Item 3 of the Disclosure Document is supplemented by the following language:

Neither we nor any person or franchise broker in Item 2 of the Franchise Disclosure Document is subject to any currently effective order of any national securities association or national securities exchange, as defined in the Securities Exchange Act of 1934, 15 U.S.C.A.78a *et seq.*, suspending or expelling such persons from membership in such association or exchange.
2. Item 17 of the Franchise Disclosure Document is supplemented by the following language:
 - a. California Business and Professions Code Sections 20000 through 20043 provides rights to the franchisee concerning termination, transfer or non-renewal of a franchise. If the franchise agreement contains a provision that is inconsistent with the law, the law will control.
 - b. The franchise agreement provides for termination upon bankruptcy. This provision may not be enforceable under federal bankruptcy law (11 U.S.C.A. Sec. 101 *et seq.*).
 - c. The franchise agreement contains a covenant not to compete which extends beyond the termination of the franchise. This provision may not be enforceable under California law.
 - d. The franchise agreement requires application of the laws of the state of Texas.
2. OUR WEBSITE HAS NOT BEEN REVIEWED OR APPROVED BY THE CALIFORNIA DEPARTMENT OF FINANCIAL PROTECTION AND INNOVATION. ANY COMPLAINTS CONCERNING THE CONTENT OF THIS WEBSITE MAY BE DIRECTED TO THE CALIFORNIA DEPARTMENT OF FINANCIAL PROTECTION AND INNOVATION AT www.dfpi.ca.gov.
3. THE CALIFORNIA FRANCHISE INVESTMENT LAW REQUIRES THAT A COPY OF ALL PROPOSED AGREEMENTS RELATING TO THE SALE OF THE FRANCHISE BE DELIVERED TOGETHER WITH A COPY OF THE DISCLOSURE DOCUMENT.
4. Corporations Code 31512 provides that: "Any conditions, stipulation or provision purporting to bind any person acquiring a franchise to waive compliance with any provision of this law or any rule or order hereunder is void." The franchise agreement requires a shortened status of limitations period. Pursuant to Corporations Code Section 31512, this provision is void, to the extent that it is inconsistent with the provisions of Corporations Code Sections 31303 and 31304.
5. You must sign a general release if you renew or transfer your franchise. California Corporations Code Section 31512 voids a waiver of your rights under the Franchise Investment Law (California Corporations Code Sections 31000 through 31516). Business and Professions Code Section 20010 voids a waiver of your rights under the Franchise Relations Act (Business and Professions Code Sections 20000 through 20043).
6. SECTION 31125 OF THE CALIFORNIA CORPORATIONS CODE REQUIRES US TO GIVE YOU A DISCLOSURE DOCUMENT, IN A FORM CONTAINING THE INFORMATION THAT THE COMMISSIONER MAY BY RULE OR ORDER REQUIRE, BEFORE A SOLICITATION OF A PROPOSED MATERIAL MODIFICATION OF AN EXISTING FRANCHISE.

Each provision of this addendum is effective only to the extent that the jurisdictional requirements of the laws described above, with respect to each provision of the law, are met independent of this addendum. This addendum will have no force or effect if such jurisdictional requirements are not met.

HAWAII

1. THESE FRANCHISES WILL BE/HAVE BEEN FILED UNDER THE FRANCHISE INVESTMENT LAW OF THE STATE OF HAWAII. FILING DOES NOT CONSTITUTE APPROVAL, RECOMMENDATION, OR ENDORSEMENT BY THE DIRECTOR OF COMMERCE AND CONSUMER AFFAIRS OR A FINDING BY THE DIRECTOR OF COMMERCE AND CONSUMER AFFAIRS THAT THE INFORMATION PROVIDED HEREIN IS TRUE, COMPLETE, AND NOT MISLEADING.

THE FRANCHISE INVESTMENT LAW MAKES IT UNLAWFUL TO OFFER OR SELL ANY FRANCHISE IN THIS STATE WITHOUT FIRST PROVIDING TO THE PROSPECTIVE FRANCHISEE, OR SUBFRANCHISOR, AT LEAST SEVEN DAYS PRIOR TO THE EXECUTION BY THE PROSPECTIVE FRANCHISEE, OF ANY BINDING FRANCHISE OR OTHER AGREEMENT, OR AT LEAST SEVEN DAYS PRIOR TO THE PAYMENT OF ANY CONSIDERATION BY THE FRANCHISEE, OR SUBFRANCHISOR, WHICHEVER OCCURS FIRST, A COPY OF THE FRANCHISE DISCLOSURE DOCUMENT, TOGETHER WITH A COPY OF ALL PROPOSED AGREEMENTS RELATING TO THE SALE OF THE FRANCHISE.

THIS FRANCHISE DISCLOSURE DOCUMENT CONTAINS A SUMMARY ONLY OF CERTAIN MATERIAL PROVISIONS OF THE FRANCHISE AGREEMENT. THE CONTRACT OR AGREEMENT SHOULD BE REFERRED TO FOR A STATEMENT OF ALL RIGHTS, CONDITIONS, RESTRICTIONS AND OBLIGATIONS OF BOTH THE FRANCHISOR AND THE FRANCHISEE.

2. Section 482E-(3), Hawaii Revised Statutes, provides that franchisee may be entitled to certain compensation upon termination or refusal to renew the franchise. To the extent such Section is applicable, the franchisee shall have an interest in the franchise upon termination or refusal to renew as specified therein.

3. No release language set forth in the Franchise Agreement shall relieve Franchisor or any other person, directly or indirectly, from liability imposed by the laws concerning franchising in the State of Hawaii.

Each provision of this addendum is effective only to the extent that the jurisdictional requirements of the laws described above, with respect to each provision of the law, are met independent of this addendum. This addendum will have no force or effect if such jurisdictional requirements are not met.

ILLINOIS

1. Illinois law governs the agreements between the parties to this franchise.

2. Section 4 of the Illinois Franchise Disclosure Act provides that any provision in a franchise agreement that designates jurisdiction or venue outside the State of Illinois is void. However, a franchise agreement may provide for arbitration in a venue outside of Illinois.

3. Section 41 of the Illinois Franchise Disclosure Act provides that any condition, stipulation, or provision purporting to bind any person acquiring any franchise to waive compliance with the Illinois Franchise Disclosure Act or any other law or Illinois is void.

4. Franchisees' rights upon Termination and Non-Renewal are set forth in sections 19 and 20 of the Illinois Franchise Disclosure Act.

Each provision of this addendum is effective only to the extent that the jurisdictional requirements of the laws described above, with respect to each provision of the law, are met independent of this addendum. This addendum will have no force or effect if such jurisdictional requirements are not met.

MARYLAND

1. The Summary column for Item 17.v., "Choice of Forum," is amended as follows:

A franchisee may bring a lawsuit in Maryland for claims arising under the Maryland Franchise Registration and Disclosure Law ("Law"). Except for any rights a franchisee has under the Law to bring suit in Maryland for claims arising under the Law, mediation of disputes which are subject to mediation will be held at our corporate headquarters. Except as otherwise required by the Law, venue for all proceedings arising under the Franchise Agreement is the state, county, or judicial district where our principal place of business is located, unless otherwise brought by us.

2. Item 17.c., “Requirements for you to renew or extend” and Item 7.m. “Conditions for our approval of transfer” are amended by the addition of the following:

The Code of Maryland Regulations COMAR 02.02.08.16L., states that a general release required as a condition of renewal, sale, and/or assignment/transfer shall not apply to any liability under the Maryland Franchise Registration and Disclosure Law. This may affect the enforceability of certain provisions in the Franchise Agreement relating to renewal, sale, assignment, or transfer of the Franchise Agreements.

3. Item 17 is amended to add the following note at the end of that Item:

If the Franchise Agreement contains a limitations of claims provision, such provision will not act to reduce the three-year statute of limitations period afforded a franchisee under Section 14-227(e) of the Maryland Franchise Registration and Disclosure Law (“Law”) for claims arising under the Law.

4. The following is added as the last paragraph of Item 17:

A provision in the Franchise Agreement which terminates the agreement upon your bankruptcy may not be enforceable under Title 11, United States Code Section 101.

Each provision of this addendum is effective only to the extent that the jurisdictional requirements of the laws described above, with respect to each provision of the law, are met independent of this addendum. This addendum will have no force or effect if such jurisdictional requirements are not met.

MINNESOTA

1. The following is added to Item 13 of the disclosure document:

We will protect your right to use the trademarks, service marks, trade names, logos, or other commercial symbols or will indemnify you from any loss, costs, or expenses arising out of any claim, suit, or demand regarding the use of the marks to the extent required by Minnesota law.

2. The following is added to Item 17 of the disclosure document:

Under Minnesota law, and except in certain specified cases, we must give you 90 days notice of termination with 60 days to cure. To the extent that the Franchise Agreement or Development Agreement is inconsistent with the Minnesota law, the Minnesota law will control.

3. To the extent that any condition, stipulation, or provision contained in the Franchise Agreement or Development Agreement (including any choice of law provision) purports to bind any person who, at the time of acquiring a franchise is a resident of Minnesota, or, in the case of a partnership or corporation, organized or incorporated under the laws of Minnesota, or purporting to bind a person acquiring any franchise to be operated in Minnesota to waive compliance with the Minnesota Franchises Law, such condition, stipulation, or provision may be void and unenforceable under the non-waiver provision of the Minnesota Franchises Law.

Each provision of this addendum is effective only to the extent that the jurisdictional requirements of the laws described above, with respect to each provision of the law, are met independent of this addendum. This addendum will have no force or effect if such jurisdictional requirements are not met.

NEW YORK

1. Item 3, “Litigation” is hereby deleted in its entirety and is replaced by the following language:

- a. Neither we, any predecessor, any person identified in Item 2 above, nor any affiliate offering franchises under our principal trademark has pending any administrative, criminal or material civil action (or a significant number of civil actions irrespective of materiality) alleging a violation of any franchise, antitrust or securities law, fraud, embezzlement, fraudulent conversion, misappropriation of property, unfair or deceptive practices, or comparable allegations.
- b. Neither we, any predecessor, any person identified in Item 2 above, nor any affiliate offering franchises under our principal trademark has been convicted of a felony or pleaded *nolo contendere* to a felony charge or, within the ten-year period immediately preceding the date of this disclosure document, has been convicted of a misdemeanor or pleaded *nolo contendere* to a misdemeanor charge or been held liable in a civil action by final judgment or been the subject of a material complaint or other legal proceeding if such misdemeanor conviction or charge or civil

action, complaint or other legal proceeding involved a violation of any franchise, anti fraud or securities law, fraud, embezzlement, fraudulent conversion, misappropriation of property, unfair or deceptive practices, misappropriation of property or comparable allegations.

- c. Neither we, any predecessor any person identified in Item 2 above, nor any affiliate offering franchises under our principal trademark is subject to any currently effective injunctive or restrictive order or decree relating to franchises or under any Federal, State or Canadian franchise, securities, antitrust, trade regulation or trade practice law as a result of a concluded or pending action or proceeding brought by a public agency, is subject to any currently effective order of any national securities association or national securities exchange, as defined in the Securities and Exchange Act of 1934, suspending or expelling such person from membership in such association or exchange; or is subject to a currently effective injunctive or restrictive order relating to any other business activity as a result of an action brought by a public agency or department, including, without limitation, actions affecting a license as a real estate broker or sales agent.”
2. Item 4, “Bankruptcy” is hereby deleted in its entirety and is replaced by the following language:

Neither we, nor any affiliate or predecessor or current officer or general partner have during the 10 year period immediately before the date of this disclosure document (a) filed as a debtor (or had filed against it) a petition to start an action under the U.S. Bankruptcy Code; (b) obtained a discharge of its debts under the Bankruptcy Code; or (c) was a principal officer of a company or a general partner in a partnership that either filed as a debtor (or had filed against it) a petition to start an action under the U.S. Bankruptcy Code or that obtained a discharge of its debts under the U.S. Bankruptcy Code during or within one year after the officer or general partner of F45 Training Incorporated held this position with the company or partnership.
3. Item 17, “Renewal, Termination, Transfer, and Dispute Resolution” is amended as follows:
 - a. By adding the following in the “Summary” column opposite category d., “Termination by you”:

To the extent required by the New York General Business Law, you may terminate the Agreement on any grounds available by law.
 - b. By adding the following in the “Summary” column opposite category w., “Choice of law”:

The foregoing choice of law should not be considered a waiver of any right conferred upon you by the General Business Law of the State of New York, Article 33.
4. This Franchise Disclosure Document is amended by the addition of the following sentence:

Franchisor represents that this prospectus does not knowingly omit any material fact or contain any untrue statement of a material fact.

Each provision of this addendum is effective only to the extent that the jurisdictional requirements of the laws described above, with respect to each provision of the law, are met independent of this addendum. This addendum will have no force or effect if such jurisdictional requirements are not met.

NORTH DAKOTA

The State of North Dakota has determined that the following types of provisions are deemed to be contrary to North Dakota law:

- a. A provision requiring a North Dakota franchisee to sign a general release upon renewal of the franchise agreement;
- b. A provision requiring a North Dakota franchisee to consent to termination penalties or liquidated damages;
- c. A provision requiring a North Dakota franchisee to consent to the jurisdiction of courts outside the state of North Dakota;
- d. A provision requiring a North Dakota franchisee to consent that the Franchise Agreement be governed by a state, other than the State of North Dakota.

- e. A provision restricting the time in which a North Dakota franchisee may make a claim to less than the applicable North Dakota statute of limitations;
- f. A provision calling for the waiver by a North Dakota franchisee of the right to trial by jury;
- g. A provision requiring a North Dakota franchisee to consent to a waiver of exemplary and punitive damages.

The covenants not to compete contained within the Franchise Disclosure Document are subject to Section 9-08-06 and may be unenforceable under North Dakota law.

If the Franchise Agreement requires mediation or arbitration to be conducted in a forum other than the State of North Dakota, the requirement may be unenforceable under the North Dakota Franchise Investment Law. Mediation or arbitration involving a franchise purchased in the State of North Dakota must be held either in a location mutually agreed upon prior to the mediation or arbitration, or if the parties cannot agree on a location, the location will be determined by the mediator or the arbitrator.

Each provision of this addendum is effective only to the extent that the jurisdictional requirements of the laws described above, with respect to each provision of the law, are met independent of this addendum. This addendum will have no force or effect if such jurisdictional requirements are not met.

RHODE ISLAND

Item 17, "Renewal, Termination, Transfer, and Dispute Resolution" is amended by adding the following in the "Summary" column opposite category w., "Choice of law":

Section 19-28.1-14 of the Rhode Island Franchise Investment Act provides that "A provision in a franchise agreement restricting jurisdiction and venue to a forum outside this state or requiring the application of the laws of another state is void with respect to a claim otherwise enforceable under this Act."

Each provision of this addendum is effective only to the extent that the jurisdictional requirements of the laws described above, with respect to each provision of the law, are met independent of this addendum. This addendum will have no force or effect if such jurisdictional requirements are not met.

VIRGINIA

In recognition of the restrictions contained in Section 13.1-564 of the Virginia Retail Franchising Act, Item 17.h. is supplemented by the following:

Under Section 13.1-564 of the Virginia Retail Franchising Act, it is unlawful for a franchisor to cancel a franchise without reasonable cause. If any ground for default or termination stated in the franchise agreement does not constitute "reasonable cause," as that term may be defined in the Virginia Retail Franchising Act or the laws of Virginia, that provision may not be enforceable.

WASHINGTON

1. RCW 19.100.180 may supersede the franchise agreement in your relationship with the Franchisor including the areas of termination and renewal of your franchise. There may also be court decisions which may supersede the franchise agreement in your relationship with the franchisor including the areas of termination and renewal of your franchise.

2. In the event of a conflict of laws, the provisions of the Washington Franchise Investment Protection Act, Chapter 19.100 RCW will prevail

3. A release or waiver of rights executed by a franchisee may not include rights under the Washington Franchise Investment Protection Act or any rule or order thereunder except when executed pursuant to a negotiated settlement after the Agreement is in effect and where the parties are represented by independent counsel. Provisions such as those which unreasonably restrict or limit the statute of limitations period for claims under the Act, or rights or remedies under the Act such as a right to a jury trial, may not be enforceable.

4. Transfer fees are collectable to the extent that they reflect our reasonable estimated or actual costs in effecting a transfer.

5. In any arbitration or mediation involving a franchise purchased in Washington, the arbitration or mediation site will be either in the state of Washington, or in a place mutually agreed upon at the time of the arbitration or mediation, or as determined by the arbitrator or mediator at the time of arbitration or mediation. In addition, if litigation is not precluded by the franchise agreement, a franchisee may bring an action or proceeding arising out of or in connection with the sale of franchises, or a violation of the Washington Franchise Investment Protection Act, in Washington.

6. Pursuant to RCW 49.62.020, a noncompetition covenant is void and unenforceable against an employee, including an employee of a franchisee, unless the employee's earnings from the party seeking enforcement, when annualized, exceed \$100,000 per year (an amount that will be adjusted annually for inflation). In addition, a noncompetition covenant is void and unenforceable against an independent contractor of a franchisee under RCW 49.62.030 unless the independent contractor's earnings from the party seeking enforcement, when annualized, exceed \$250,000 per year (an amount that will be adjusted annually for inflation). As a result, any provisions contained in the franchise agreement or elsewhere that conflict with these limitations are void and unenforceable in Washington.

7. RCW 49.62.060 prohibits a franchisor from restricting, restraining, or prohibiting a franchisee from (i) soliciting or hiring any employee of a franchisee of the same franchisor or (ii) soliciting or hiring any employee of the franchisor. As a result, any such provisions contained in the franchise agreement or elsewhere are void and unenforceable in Washington.

8. The franchisor uses the services of franchise brokers to assist it in selling franchises. A franchise broker represents the franchisor and is paid a fee for referring prospects to the franchisor and/or selling the franchise. Do not rely only on the information provided by a franchise broker about a franchise. Do your own investigation by contacting the franchisor's current and former franchisees to ask them about their experience with the franchisor.

Each provision of this addendum is effective only to the extent that the jurisdictional requirements of the laws described above, with respect to each provision of the law, are met independent of this addendum. This addendum will have no force or effect if such jurisdictional requirements are not met.

EXHIBIT P
LIST OF STATE ADMINISTRATORS

LIST OF STATE ADMINISTRATORS

Listed below are the names, addresses and telephone numbers of the state agencies having responsibility for franchising disclosure/registration laws:

California

State of California
Department of Financial Protection and
Innovation
320 W. 4th Street, Suite 750
Los Angeles, California 90013-2344
(213) 576-7500
(866) 275-2677

Hawaii

Hawaii Commissioner of Securities
Department of Commerce and Consumer Affairs
Business Registration Division
State of Hawaii
335 Merchant Street, Room 203
Honolulu, Hawaii 96813
(808) 586-2722

Illinois

Franchise Bureau
Illinois Attorney General
500 South Second Street
Springfield, Illinois 62706
(217) 782-4465

Indiana

Franchise Section
Indiana Securities Division
302 West Washington Street
Room E-111
Indianapolis, Indiana 46204
(317) 232-6681

Maryland

Office of the Attorney General
Securities Division
200 St. Paul Place
Baltimore, Maryland 21202
(410) 576-6360

Michigan

Consumer Protection Division
Franchise Section
Michigan Department of Attorney General
G Mennen Williams Building
Franchise Section, 1st Floor
525 West Ottawa Street
Lansing, Michigan 48913
(517) 373-7117

Minnesota

Minnesota Department of Commerce
Franchise Section
85 7th Place East, Suite 280
Saint Paul, Minnesota 55101-2198
(651) 296-6328

New York

NYS Department of Law
Investor Protection Bureau
28 Liberty Street, 21st Floor
New York, New York 10005
(212) 416-8211

North Dakota

North Dakota Securities Department
State of North Dakota
600 East Boulevard Avenue
Fifth Floor
Bismarck, North Dakota 58505-0510
(701) 328-4712

Oregon

Oregon Division of Finance
And Corporate Securities
State of Oregon
Labor & Industries Bldg.
350 Winter Street, NE, #410
Salem, Oregon 97301-3881
(503) 378-4140

Rhode Island

Department of Business Regulation
Securities Division
John O. Pastore Complex
1511 Pontiac Avenue, Building 69-1
Cranston, Rhode Island 02920
(401) 222-3048

South Dakota

Franchise Administrator
South Dakota Department of Labor and
Regulations
Division of Insurance
Securities Regulation
124 S. Euclid, Suite 104
Pierre, South Dakota 57501
(605) 773-3563

Virginia

State Corporation Commission
Division of Securities and
Retail Franchising
1300 East Main Street, 9th floor
Richmond, Virginia 23219
(804) 371-9051

Washington

Department of Financial Institutions
Securities Division
State of Washington
150 Israel Rd. SW
Tumwater, Washington 98501
(360) 902-8738

Wisconsin

Division of Securities
Department of Financial Institutions
Wisconsin Commissioner of Securities
345 West Washington Avenue, 4th Floor
Madison, Wisconsin 53703
(608) 266-8559

EXHIBIT Q
STATE EFFECTIVE DATES

State Effective Dates

The following states have franchise laws that require that the Franchise Disclosure Document be registered or filed with the state, or be exempt from registration:

California, Hawaii, Illinois, Indiana, Maryland, Michigan, Minnesota, New York, North Dakota, Rhode Island, South Dakota, Virginia, Washington, and Wisconsin.

This document is effective and may be used in the following states, where the document is filed, registered or exempt from registration, as of the Effective Date stated below:

State	Effective Date
California	June 17, 2022
Hawaii	Pending
Illinois	June 17, 2022
Indiana	June 17, 2022
Maryland	Pending
Michigan	June 17, 2022
Minnesota	Pending
New York	June 17, 2022
North Dakota	Pending
Rhode Island	Pending
South Dakota	Pending
Virginia	Pending
Washington	Pending
Wisconsin	Pending

Other states may require registration, filing, or exemption of a franchise under other laws, such as those that regulate the offer and sale of business opportunities or seller-assisted marketing plans.

EXHIBIT R
RECEIPTS

ITEM 23 **RECEIPT**

This disclosure document summarizes certain provisions of the franchise agreement and other information in plain language. Read this disclosure document and all agreements carefully.

If Health Mart Systems offers you a franchise, it must provide this disclosure document to you 14 calendar days before you sign a binding agreement with, or make a payment to, the franchisor or an affiliate in connection with the proposed franchise sale, or sooner if required by applicable state law. Applicable state laws in (a) Connecticut and Michigan require us to provide you the disclosure document at least 10 business days before you sign a binding agreement with, or make a payment to, the franchisor or an affiliate in connection with the proposed franchise sale, (b) New York requires us to provide you the disclosure document at the earlier of the first personal meeting or 10 business days before you sign a binding agreement with, or make a payment to, the franchisor or an affiliate in connection with the proposed franchise sale, and (c) Iowa and Maine require us to provide you the disclosure document at the earlier of the first personal meeting or 14 days before you sign a binding agreement with, or make a payment to, the franchisor or an affiliate in connection with the proposed franchise sale.

If Health Mart Systems does not deliver this disclosure document on time or if it contains a false or misleading statement, or a material omission, a violation of federal law and state law may have occurred and should be reported to the Federal Trade Commission, Washington, D.C. 20580 and any applicable state agency (as listed in Exhibit P to this disclosure document).

The name, principal business address, and telephone number of the franchise seller offering the franchise is:

Health Mart Systems, Inc. 6535 State Hwy 161 Irving, TX 75039 415-983-8300	McKesson Corporation Name _____ Address 6535 State Hwy 161 Irving, Texas 75039 415-983-8300	_____ Name _____ _____ Address _____ Telephone Number	_____ Name _____ _____ Address _____ Telephone Number
---	--	--	--

Issuance Date: June 17, 2022

I received a disclosure document dated June 17, 2022. The disclosure document included the following Exhibits and Attachments:

- | | |
|-----------|--|
| Exhibit A | Agents for Service of Process |
| Exhibit B | Franchise Agreement, including attachments and state-amendments |
| Exhibit C | EQuIPP Services Agreement for Participating Pharmacy |
| Exhibit D | BULA Agreement (Optional) |
| Exhibit E | Pharmacy And Healthcare Solutions Master Services Agreement, Provider Participation Addendum, Providerpay Reconciliation Services Addendum, McKesson Reimbursement Advantage Addendum (Optional) |
| Exhibit F | McKesson Local Marketing Support Platform Agreement (Optional) |
| Exhibit G | Franchise Compliance Questionnaire |
| Exhibit H | Retail Vaccine Program Agreement (Optional) |
| Exhibit I | Health Mart Digital Portfolio ("HMDP") Program (Terms & Conditions, Privacy Notice, Business Associate Agreement) (Optional As To Premium Services) |

Exhibit J	Financing Documents
	J-1 - McKesson Corporation Short Term Financing Documents (Optional Financing) (Security Agreement, Guaranty, Note)
	J-2 - McKesson Corporation Long Term Financing Documents (Optional Financing) (Security Agreement, Guaranty, Forms Of Promissory Note, Certificate Of Insurance; Resolution Of Board Of Directors Of Corporate Franchisee, Resolution Of Members/Partners Of Partnership Or LLC Franchisee, Landlord Waiver, Life Insurance Assignment)
Exhibit K	Franchise Handbook Table of Contents
Exhibit L	Information About HMSI Franchisees
	L-1 - List Of Operational Franchisees As Of March 31, 2022
	L-2 - List Of Not Yet Operational Franchisees As Of March 31, 2022
	L-3 - List Of Franchisees Who Have Ceased To Do Business Under Their Agreement Or Who Otherwise Left The System During The Last Fiscal Year Ending March 31, 2022
Exhibit M	Financial Statements
Exhibit N	General Release
Exhibit O	State-Specific Addenda
Exhibit P	List of State Administrators
Exhibit Q	State Effective Dates
Exhibit R	Receipts

Dated: _____

 Signature if Franchise is an Individual

Dated: _____

 Individually and as an Officer of the company designated below or a
 company to be formed and designated below on formation

 Printed Name

of _____
 (a _____ Corporation)
 (a _____ Partnership)
 (a _____ Limited Liability
 Company)

(KEEP THIS COPY FOR YOUR RECORDS.)

ITEM 23
RECEIPT

This disclosure document summarizes certain provisions of the franchise agreement and other information in plain language. Read this disclosure document and all agreements carefully.

If Health Mart Systems offers you a franchise, it must provide this disclosure document to you 14 calendar days before you sign a binding agreement with, or make a payment to, the franchisor or an affiliate in connection with the proposed franchise sale, or sooner if required by applicable state law. Applicable state laws in (a) Connecticut and Michigan require us to provide you the disclosure document at least 10 business days before you sign a binding agreement with, or make a payment to, the franchisor or an affiliate in connection with the proposed franchise sale, (b) New York requires us to provide you the disclosure document at the earlier of the first personal meeting or 10 business days before you sign a binding agreement with, or make a payment to, the franchisor or an affiliate in connection with the proposed franchise sale, and (c) Iowa and Maine require us to provide you the disclosure document at the earlier of the first personal meeting or 14 days before you sign a binding agreement with, or make a payment to, the franchisor or an affiliate in connection with the proposed franchise sale.

If Health Mart Systems does not deliver this disclosure document on time or if it contains a false or misleading statement, or a material omission, a violation of federal law and state law may have occurred and should be reported to the Federal Trade Commission, Washington, D.C. 20580 and any applicable state agency (as listed in Exhibit P to this disclosure document).

The name, principal business address, and telephone number of the franchise seller offering the franchise is:

Health Mart Systems, Inc. 6535 State Hwy 161 Irving, TX 75039 415-983-8300	McKesson Corporation	_____	_____
	Name _____	Name _____	Name _____
	Address	Address	Address
	6535 State Hwy 161 Irving, Texas 75039 415-983-8300	_____	_____
		Telephone Number	Telephone Number

Issuance Date: June 17, 2022

I received a disclosure document dated June 17, 2022. The disclosure document included the following Exhibits and Attachments:

- | | |
|-----------|--|
| Exhibit A | Agents for Service of Process |
| Exhibit B | Franchise Agreement, including attachments and state-amendments |
| Exhibit C | EQuIPP Services Agreement for Participating Pharmacy |
| Exhibit D | BULA Agreement (Optional) |
| Exhibit E | Pharmacy And Healthcare Solutions Master Services Agreement, Provider Participation Addendum, Providerpay Reconciliation Services Addendum, McKesson Reimbursement Advantage Addendum (Optional) |
| Exhibit F | McKesson Local Marketing Support Platform Agreement (Optional) |
| Exhibit G | Franchise Compliance Questionnaire |
| Exhibit H | Retail Vaccine Program Agreement (Optional) |
| Exhibit I | Health Mart Digital Portfolio ("HMDP") Program (Terms & Conditions, Privacy Notice, Business Associate Agreement) (Optional As To Premium Services) |

Exhibit J	Financing Documents
	J-1 - McKesson Corporation Short Term Financing Documents (Optional Financing) (Security Agreement, Guaranty, Note)
	J-2 - McKesson Corporation Long Term Financing Documents (Optional Financing) (Security Agreement, Guaranty, Forms Of Promissory Note, Certificate Of Insurance; Resolution Of Board Of Directors Of Corporate Franchisee, Resolution Of Members/Partners Of Partnership Or LLC Franchisee, Landlord Waiver, Life Insurance Assignment)
Exhibit K	Franchise Handbook Table of Contents
Exhibit L	Information About HMSI Franchisees
	L-1 - List Of Operational Franchisees As Of March 31, 2022
	L-2 - List Of Not Yet Operational Franchisees As Of March 31, 2022
	L-3 - List Of Franchisees Who Have Ceased To Do Business Under Their Agreement Or Who Otherwise Left The System During The Last Fiscal Year Ending March 31, 2022
Exhibit M	Financial Statements
Exhibit N	General Release
Exhibit O	State-Specific Addenda
Exhibit P	List of State Administrators
Exhibit Q	State Effective Dates
Exhibit R	Receipts

Dated: _____

Signature if Franchise is an Individual

Dated: _____

Individually and as an Officer of the company designated below or a
company to be formed and designated below on formation

Printed Name

of _____

(a _____ Corporation)

(a _____ Partnership)

(a _____ Limited Liability
Company)

(RETURN THIS COPY TO US.)